US20170191064A1 - Oligonucleotides for inducing paternal ube3a expression - Google Patents

Oligonucleotides for inducing paternal ube3a expression Download PDF

Info

Publication number
US20170191064A1
US20170191064A1 US15/351,113 US201615351113A US2017191064A1 US 20170191064 A1 US20170191064 A1 US 20170191064A1 US 201615351113 A US201615351113 A US 201615351113A US 2017191064 A1 US2017191064 A1 US 2017191064A1
Authority
US
United States
Prior art keywords
oligonucleotide
nucleosides
nucleic acid
modified
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US15/351,113
Other versions
US10494633B2 (en
Inventor
Veronica Costa
Maj HEDTJÄRN
Marius Hoener
Ravi Jagasia
Mads Aaboe Jensen
Christoph Patsch
Lykke Pedersen
Søren Vestergaard Rasmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Roche Innovation Center Copenhagen AS
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Innovation Center Copenhagen AS, Hoffmann La Roche Inc filed Critical Roche Innovation Center Copenhagen AS
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COSTA, Veronica, HOENER, MARIUS, JAGASIA, RAVI, PATSCH, Christoph
Assigned to ROCHE INNOVATION CENTER COPENHAGEN A/S reassignment ROCHE INNOVATION CENTER COPENHAGEN A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Hedtjärn, Maj, PEDERSEN, Lykke, JENSEN, Mads Aaboe
Assigned to HOFFMAN-LA ROCHE INC. reassignment HOFFMAN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: F. HOFFMANN-LA ROCHE AG
Assigned to ROCHE INNOVATION CENTER COPENHAGEN A/S reassignment ROCHE INNOVATION CENTER COPENHAGEN A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Hedtjärn, Maj, JENSEN, Mads Aaboe, PEDERSEN, Lykke, RASMUSSEN, SOREN VESTERGAARD
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COSTA, Veronica, HOENER, MARIUS, JAGASIA, RAVI, PATSCH, Christoph
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: F. HOFFMANN-LA ROCHE AG
Publication of US20170191064A1 publication Critical patent/US20170191064A1/en
Priority to US16/388,714 priority Critical patent/US10739332B2/en
Priority to US16/663,024 priority patent/US10718753B2/en
Publication of US10494633B2 publication Critical patent/US10494633B2/en
Application granted granted Critical
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROCHE INNOVATION CENTER COPENHAGEN A/S
Priority to US16/933,445 priority patent/US11320421B2/en
Priority to US17/581,089 priority patent/US11852627B2/en
Priority to US18/172,707 priority patent/US20230296587A1/en
Priority to US18/491,513 priority patent/US20240085402A1/en
Assigned to ROCHE INNOVATION CENTER COPENHAGEN A/S reassignment ROCHE INNOVATION CENTER COPENHAGEN A/S CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND INVENTOR'S EXECUTION DATE PREVIOUSLY RECORDED AT REEL: 040327 FRAME: 0661. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Assignors: Hedtjärn, Maj, JENSEN, Mads Aaboe, PEDERSEN, Lykke
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0619Neurons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0623Stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0696Artificially induced pluripotent stem cells, e.g. iPS
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/341Gapmers, i.e. of the type ===---===
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/346Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/34Allele or polymorphism specific uses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/38Vitamins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/44Thiols, e.g. mercaptoethanol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/11Epidermal growth factor [EGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/115Basic fibroblast growth factor (bFGF, FGF-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/119Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/13Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40Regulators of development
    • C12N2501/41Hedgehog proteins; Cyclopamine (inhibitor)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60Transcription factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • C12N2501/72Transferases (EC 2.)
    • C12N2501/727Kinases (EC 2.7.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00Use of cells in diagnostics
    • C12N2503/02Drug screening
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/50Proteins
    • C12N2533/52Fibronectin; Laminin

Definitions

  • the present invention relates to oligonucleotides (oligomers) that are complementary to and hybridize to SNHG14 downstream of SNORD109B, leading to induction of paternal expression of Ubiquitin-protein ligase E3A (UBE3A) in an animal or human.
  • UBE3A Ubiquitin-protein ligase E3A
  • the present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
  • Angelman syndrome is neuro-genetic disorder caused by deletion or inactivation of the UBE3A genes on the maternally inherited chromosome 15q11.2.
  • the paternal copy of the UBE3A gene is subject to genomic imprinting and silencing in neurons by an endogenous antisense transcript of UBE3A, termed SNHG14 (also known as UBE3A-ATS) (Meng et al. 2012 Hum Mol Genet. Vol. 21 pp. 3001-12).
  • Other cell types than neurons seem to express the UBE3A gene from both the maternal and paternal allele.
  • Angelman syndrome is characterized by severe intellectual and developmental disability, sleep disturbance, seizures, jerky movements, EEG abnormalities, frequent laughter or smiling, and profound language impairments.
  • WO 2012/064806 discloses a method of inducing UBE3A expression in a cell by using a topoisomerase inhibitor. The method can be used to treat Angelman syndrome. There is no disclosure of antisense oligonucleotides.
  • WO 2014/004572 discloses oligonucleotides with 2′-O-methoxyethyl-RNA (MOE) modifications targeting mouse UBE3A-ATS.
  • MOE 2′-O-methoxyethyl-RNA
  • the oligonucleotides are only tested in mice related assays. In the region downstream of MBII-52 snoRNA (also known as SNORD115) and upstream of the UBE3A pre-mRNA there is no conservation between mouse and human. Oligonucleotides targeting mouse UBE 3A-ATS can therefore not be translated into oligonucleotides that will function in a human. There is no disclosure of oligonucleotides targeting human UBE3A-ATS.
  • the present invention identifies novel oligonucleotides which induce human paternal UBE3A expression in neuronal without affection expression of the paternal SNORD115, SNORD116 and SNRPN transcripts significantly.
  • the present invention relates to oligonucleotides targeting a nucleic acid capable of suppressing the expression of UBE3A and to treat or prevent diseases related to decreased activity of UBE3A, in particular in neuronal cells.
  • the invention provides oligonucleotides which comprise a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 98% complementarity to the part of human SNHG14 long non-coding RNA corresponding to position 25278410 to 25419462 on human chromosome 15 version GRCh38.p2. This region is also resembled by SEQ ID NO: 1.
  • the oligonucleotide can be an antisense oligonucleotide, preferably with a gapmer design.
  • the oligonucleotide is capable of inducing the expression of UBE3A, in particular paternal UBE3A expression in a neuron, by degradation, reduction or removal of the UBE3A suppressor, in particular by reduction of the SNHG14 long non-coding RNA transcript downstream of SNORD109B.
  • the UBE3A re-expression is achieved, without significantly affecting the expression of SNORD115.
  • the degradation of the target nucleic acid is preferably achieved via nuclease recruitment.
  • the invention provides pharmaceutical compositions comprising the oligonucleotides of the invention and pharmaceutically acceptable diluents, carriers, salts and/or adjuvants.
  • the invention provides methods for in vivo or in vitro induction of UBE3A expression in a target cell where expression of paternal UBE3A is suppressed, by administering an oligonucleotide or composition of the invention in an effective amount to said cell.
  • the invention provides methods for treating or preventing a disease, disorder or dysfunction associated with in vivo activity of UBE3A comprising administering a therapeutically or prophylactically effective amount of the oligonucleotide of the invention to a subject suffering from or susceptible to the disease, disorder or dysfunction.
  • oligonucleotide or composition of the invention is used for the treatment or prevention of Angelman syndrome.
  • FIG. 1 The upper strand illustrates the region of the SNHG14 transcript downstream of SNORD109B (UBE3A-ATS) where the black boxes indicate the location of the tested mouse oligonucleotides.
  • the lower strand illustrates the UBE3A coding region, where the black boxes indicate exons.
  • Exon 1 is located around 160 kb.
  • the oligonucleotides are placed in the antisense region of Exon 9 (positioned at ⁇ 97 kb), Exon 10 (positioned at ⁇ 92 kb), Exon 13 (positioned at ⁇ 77 kb) and the 5′ end of Exon 16 (positioned at ⁇ 60 kb).
  • FIG. 2 Representation of the ability of the oligonucleotides, tested in Example 2, to induce re-expression of UBE3A in human neuronal cell cultures.
  • Oligonucleotides complementary to the region of human SNHG14 long non-coding RNA between SNORD109B and the region upstream of the UBE3A coding region are indicated with ⁇ nonoverlap.
  • Oligonucleotides complementary to the region of human SNHG14 long non-coding RNA which is antisense to the UBE3A pre-mRNA (position 55319 to 141053 of SEQ ID NO: 1) are indicated with ⁇ overlap.
  • Oligonucleotides from Table 3 with conservation to human and rhesus monkey are indicated at the bottom of each plot as . Conservation between human:rhesus:mouse is indicated by . The oligonucleotide concentrations were 0.2, 1 and 5 microM as indicated in the right hand side each plot.
  • oligonucleotide as used herein is defined as it is generally understood by the skilled person as a molecule comprising two or more covalently linked nucleosides. Such covalently bound nucleosides may also be referred to as nucleic acid molecules or oligomers. Oligonucleotides are commonly made in the laboratory by solid-phase chemical synthesis followed by purification. When referring to a sequence of the oligonucleotide, reference is made to the sequence or order of nucleobase moieties, or modifications thereof, of the covalently linked nucleotides or nucleosides.
  • the oligonucleotide of the invention is man-made, and is chemically synthesized, and is typically purified or isolated.
  • the oligonucleotide of the invention may comprise one or more modified nucleosides or nucleotides.
  • Antisense oligonucleotide as used herein is defined as oligonucleotides capable of modulating expression of a target gene by hybridizing to a target nucleic acid, in particular to a contiguous sequence on a target nucleic acid.
  • the antisense oligonucleotides are not essentially double stranded and are therefore not siRNAs.
  • the antisense oligonucleotides of the present invention are single stranded.
  • oligonucleotide sequence refers to the region of the oligonucleotide which is complementary to the target nucleic acid.
  • the term is used interchangeably herein with the term “contiguous nucleobase sequence” and the term “oligonucleotide motif sequence”. In some embodiments all the nucleotides of the oligonucleotide are present in the contiguous nucleotide sequence.
  • the oligonucleotide comprises the contiguous nucleotide sequence and may, optionally comprise further nucleotide(s), for example a nucleotide linker region which may be used to attach a functional group to the contiguous nucleotide sequence. The nucleotide linker region may or may not be complementary to the target nucleic acid.
  • Nucleotides are the building blocks of oligonucleotides and polynucleotides, and for the purposes of the present invention include both naturally occurring and non-naturally occurring nucleotides.
  • nucleotides such as DNA and RNA nucleotides comprise a ribose sugar moiety, a nucleobase moiety and one or more phosphate groups (which is absent in nucleosides).
  • Nucleosides and nucleotides may also interchangeably be referred to as “units” or “monomers”.
  • modified nucleoside or “nucleoside modification” as used herein refers to nucleosides modified as compared to the equivalent DNA or RNA nucleoside by the introduction of one or more modifications of the sugar moiety or the (nucleo)base moiety.
  • the modified nucleoside comprises a modified sugar moiety.
  • modified nucleoside may also be used herein interchangeably with the term “nucleoside analogue” or modified “units” or modified “monomers”.
  • modified internucleoside linkage is defined as generally understood by the skilled person as linkages other than phosphodiester (PO) linkages, that covalently couples two nucleosides together. Nucleotides with modified internucleoside linkage are also termed “modified nucleotides”. In some embodiments, the modified internucleoside linkage increases the nuclease resistance of the oligonucleotide compared to a phosphodiester linkage. For naturally occurring oligonucleotides, the internucleoside linkage includes phosphate groups creating a phosphodiester bond between adjacent nucleosides.
  • Modified internucleoside linkages are particularly useful in stabilizing oligonucleotides for in vivo use, and may serve to protect against nuclease cleavage at regions of DNA or RNA nucleosides in the oligonucleotide of the invention, for example within the gap region of a gapmer oligonucleotide, as well as in regions of modified nucleosides.
  • the oligonucleotide comprises one or more internucleoside linkages modified from the natural phosphodiester to a linkage that is for example more resistant to nuclease attack.
  • Nuclease resistance may be determined by incubating the oligonucleotide in blood serum or by using a nuclease resistance assay (e.g. snake venom phosphodiesterase (SVPD)), both are well known in the art.
  • SVPD snake venom phosphodiesterase
  • Internucleoside linkages which are capable of enhancing the nuclease resistance of an oligonucleotide are referred to as nuclease resistant internucleoside linkages.
  • At least 50% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof are modified, such as at least 60%, such as at least 70%, such as at least 80 or such as at least 90% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are modified. In some embodiments all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are modified.
  • nucleosides which link the oligonucleotide of the invention to a non-nucleotide functional group, such as a conjugate may be phosphodiester.
  • all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are nuclease resistant internucleoside linkages.
  • Modified internucleoside linkages may be selected from the group comprising phosphorothioate, diphosphorothioate and boranophosphate.
  • the modified internucleoside linkages are compatible with the RNaseH recruitment of the oligonucleotide of the invention, for example phosphorothioate, diphosphorothioate or boranophosphate.
  • the internucleoside linkage comprises sulphur (S), such as a phosphorothioate internucleoside linkage.
  • a phosphorothioate internucleoside linkage is particularly useful due to nuclease resistance, beneficial pharmakokinetics and ease of manufacture.
  • at least 50% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof are phosphorothioate, such as at least 60%, such as at least 70%, such as at least 80 or such as at least 90% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate.
  • all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof are phosphorothioate.
  • the oligonucleotide comprises one or more neutral internucleoside linkage, particularly a internucleoside linkage selected from phosphotriester, methylphosphonate, MMI, amide-3, formacetal or thioformacetal.
  • internucleoside linkages are disclosed in WO2009/124238 (incorporated herein by reference).
  • the internucleoside linkage is selected from linkers disclosed in WO2007/031091 (incorporated herein by reference).
  • the internucleoside linkage may be selected from —O—P(O) 2 —O—, —O—P(O,S)—O—, —O—P(S) 2 —O—, —S—P(O,S)—O—, —S—P(O,S)—O—, —S—P(O) 2 —O—, —O—P(O) 2 —S—, —O—P(O,S)—S—, —O—PO(R H )—O—, 0-PO(OCH 3 )-0-, —O—PO(NR H )—O—, —O—PO(OCH 2 CH 2 S—R)—O—
  • Nuclease resistant linkages such as phosphothioate linkages, are particularly useful in oligonucleotide regions capable of recruiting nuclease when forming a duplex with the target nucleic acid, such as region G for gapmers, or the non-modified nucleoside region of headmers and tailmers.
  • Phosphorothioate linkages may, however, also be useful in non-nuclease recruiting regions and/or affinity enhancing regions such as regions F and F′ for gapmers, or the modified nucleoside region of headmers and tailmers.
  • Each of the design regions may however comprise internucleoside linkages other than phosphorothioate, such as phosphodiester linkages, in particularly in regions where modified nucleosides, such as LNA, protect the linkage against nuclease degradation.
  • phosphodiester linkages such as one or two linkages, particularly between or adjacent to modified nucleoside units (typically in the non-nuclease recruiting regions) can modify the bioavailability and/or bio-distribution of an oligonucleotide—see WO2008/113832, incorporated herein by reference.
  • all the internucleoside linkages in the oligonucleotide are phosphorothioate and/or boranophosphate linkages.
  • all the internucleoside linkages in the oligonucleotide are phosphorothioate linkages.
  • nucleobase includes the purine (e.g. adenine and guanine) and pyrimidine (e.g. uracil, thymine and cytosine) moiety present in nucleosides and nucleotides which form hydrogen bonds in nucleic acid hybridization.
  • pyrimidine e.g. uracil, thymine and cytosine
  • nucleobase also encompasses modified nucleobases which may differ from naturally occurring nucleobases, but are functional during nucleic acid hybridization.
  • nucleobase refers to both naturally occurring nucleobases such as adenine, guanine, cytosine, thymidine, uracil, xanthine and hypoxanthine, as well as non-naturally occurring variants. Such variants are for example described in Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1.
  • the nucleobase moiety is modified by changing the purine or pyrimidine into a modified purine or pyrimidine, such as substituted purine or substituted pyrimidine, such as a nucleobased selected from isocytosine, pseudoisocytosine, 5-methyl cytosine, 5-thiozolo-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil 5-thiazolo-uracil, 2-thio-uracil, 2′thio-thymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine and 2-chloro-6-aminopurine.
  • a nucleobased selected from isocytosine, pseudoisocytosine, 5-methyl cytosine, 5-thiozolo-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-brom
  • the nucleobase moieties may be indicated by the letter code for each corresponding nucleobase, e.g. A, T, G, C or U, wherein each letter may optionally include modified nucleobases of equivalent function.
  • the nucleobase moieties are selected from A, T, G, C, and 5-methyl cytosine.
  • 5-methyl cytosine LNA nucleosides may be used.
  • modified oligonucleotide describes an oligonucleotide comprising one or more sugar-modified nucleosides and/or modified internucleoside linkages.
  • chimeric oligonucleotide is a term that has been used in the literature to describe oligonucleotides with modified nucleosides.
  • complementarity describes the capacity for Watson-Crick base-pairing of nucleosides/nucleotides.
  • Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A)-thymine (T)/uracil (U).
  • G guanine
  • C cytosine
  • A adenine
  • T uracil
  • oligonucleotides may comprise nucleosides with modified nucleobases, for example 5-methyl cytosine is often used in place of cytosine, and as such the term complementarity encompasses Watson Crick base-paring between non-modified and modified nucleobases (see for example Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1).
  • % complementary refers to the number of nucleotides in percent of a contiguous nucleotide sequence in a nucleic acid molecule (e.g. oligonucleotide) which, at a given position, are complementary to (i.e. form Watson Crick base pairs with) a contiguous nucleotide sequence, at a given position of a separate nucleic acid molecule (e.g. the target nucleic acid).
  • the percentage is calculated by counting the number of aligned bases that form pairs between the two sequences, dividing by the total number of nucleotides in the oligonucleotide and multiplying by 100. In such a comparison a nucleobase/nucleotide which does not align (form a base pair) is termed a mismatch.
  • hybridizing or “hybridizes” as used herein is to be understood as two nucleic acid strands (e.g. an oligonucleotide and a target nucleic acid) forming hydrogen bonds between base pairs on opposite strands thereby forming a duplex.
  • the affinity of the binding between two nucleic acid strands is the strength of the hybridization. It is often described in terms of the melting temperature (T m ) defined as the temperature at which half of the oligonucleotides are duplexed with the target nucleic acid. At physiological conditions T m is not strictly proportional to the affinity (Mergny and Lacroix, 2003 , Oligonucleotides 13:515-537).
  • ⁇ G° is the energy associated with a reaction where aqueous concentrations are 1M, the pH is 7, and the temperature is 37° C.
  • ⁇ G° can be measured experimentally, for example, by use of the isothermal titration calorimetry (ITC) method as described in Hansen et al., 1965 , Chem. Comm. 36-38 and Holdgate et al., 2005 , Drug Discov Today .
  • ITC isothermal titration calorimetry
  • the skilled person will know that commercial equipment is available for ⁇ G° measurements.
  • ⁇ G° can also be estimated numerically by using the nearest neighbor model as described by SantaLucia, 1998 , Proc Natl Acad Sci USA.
  • oligonucleotides of the present invention hybridize to a target nucleic acid with estimated ⁇ G° values below ⁇ 10 kcal for oligonucleotides that are 10-30 nucleotides in length.
  • the degree or strength of hybridization is measured by the standard state Gibbs free energy ⁇ G°.
  • the oligonucleotides may hybridize to a target nucleic acid with estimated ⁇ G° values below the range of ⁇ 10 kcal, such as below ⁇ 15 kcal, such as below ⁇ 20 kcal and such as below ⁇ 25 kcal for oligonucleotides that are 8-30 nucleotides in length.
  • the oligonucleotides hybridize to a target nucleic acid with an estimated ⁇ G° value of ⁇ 10 to ⁇ 60 kcal, such as ⁇ 12 to ⁇ 40, such as from ⁇ 15 to ⁇ 30 kcal or ⁇ 16 to ⁇ 27 kcal such as ⁇ 18 to ⁇ 25 kcal.
  • the target refers to the protein which it is desired to modulate.
  • a target nucleic acid is the intended target which the oligonucleotide of the invention hybridizes to, and may for example be a gene, a RNA, a non-coding RNA, a long non-coding RNA, a mRNA, and pre-mRNA, a mature mRNA or a cDNA sequence.
  • the target nucleic acid is a non-coding RNA or a long non-coding RNA, or a subsequence thereof.
  • the oligonucleotide of the invention is capable of decreasing the level of the SNHG14 transcript downstream of SNORD109B of and thereby relieving the suppression of the paternal UBE3A transcript in the intended target cell.
  • the contiguous sequence of nucleobases of the oligonucleotide of the invention is complementary to the target nucleic acid, as measured across the length of the oligonucleotide, optionally with the exception of one or two mismatches, and optionally excluding nucleotide based linker regions which may link the oligonucleotide to an optional functional group such as a conjugate.
  • the oligonucleotide comprises a contiguous nucleotide sequence which is complementary to or hybridizes to a sub-sequence of the target nucleic acid molecule.
  • target sequence refers to a sequence of nucleotides present in the target nucleic acid which comprises the nucleobase sequence which is complementary to the oligonucleotide of the invention.
  • the target sequence consists of a region on the target nucleic acid which is complementary to the contiguous nucleotide sequence of the oligonucleotide of the invention.
  • the target sequence is longer than the complementary sequence of a single oligonucleotide, and may, for example represent a preferred region of the target nucleic acid which may be targeted by several oligonucleotides of the invention.
  • the oligonucleotide of the invention comprises a contiguous nucleotide sequence which is complementary to the target nucleic acid, such as a target sequence.
  • the oligonucleotide comprises a contiguous nucleotide sequence of at least 8 nucleotides which is complementary to or hybridizes to a target sequence present in the target nucleic acid molecule.
  • the contiguous nucleotide sequence (and therefore the target sequence) comprises of at least 8 contiguous nucleotides, such as 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleotides, such as from 12-25, such as from 14-18 contiguous nucleotides.
  • a target cell refers to a cell which is expressing the target nucleic acid.
  • the target cell may be in vivo or in vitro.
  • the target cell is a mammalian cell such as a rodent cell, such as a mouse cell or a rat cell, or a primate cell such as a monkey cell or a human cell.
  • the target cell is a neuronal cell.
  • naturally occurring variant refers to variants of SNHG14 transcript downstream of SNORD109B gene or transcripts which originate from the same genetic loci as the target nucleic acid, but may differ for example, by virtue of degeneracy of the genetic code causing a multiplicity of codons in the long non-coding RNA.
  • the oligonucleotide of the invention may therefore be designed to target the target nucleic acid and naturally occurring variants thereof.
  • modulation of expression is to be understood as an overall term for an oligonucleotide's ability to alter the amount of UBE3A protein when compared to the amount of UBE3A before administration of the oligonucleotide.
  • modulation of expression may be determined by reference to a control experiment where the oligonucleotide of the invention is not administered.
  • the modulation effected by the oligonucleotide is related to it's ability to reduce, remove, prevent, lessen, lower or terminate the suppression of the paternal UBE3A transcript, e.g.
  • the modulation can also be viewed as the oligonucleotide's ability to restore, increase or enhance expression of paternal UBE3A, e.g. by removal or blockage of inhibitory mechanisms affected by the non-coding SNHG14 transcript downstream of SNORD109B.
  • a high affinity modified nucleoside is a modified nucleotide which, when incorporated into the oligonucleotide enhances the affinity of the oligonucleotide for its complementary target, for example as measured by the melting temperature (T m ).
  • a high affinity modified nucleoside of the present invention preferably result in an increase in melting temperature between +0.5 to +12° C., more preferably between +1.5 to +10° C. and most preferably between +3 to +8° C. per modified nucleoside.
  • Numerous high affinity modified nucleosides are known in the art and include for example, many 2′ substituted nucleosides as well as locked nucleic acids (LNA) (see e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213).
  • the oligomer of the invention may comprise one or more nucleosides which have a modified sugar moiety, i.e. a modification of the sugar moiety when compared to the ribose sugar moiety found in DNA and RNA.
  • nucleosides with modification of the ribose sugar moiety have been made, primarily with the aim of improving certain properties of oligonucleotides, such as affinity and/or nuclease resistance.
  • Such modifications include those where the ribose ring structure is modified, e.g. by replacement with a hexose ring (HNA), or a bicyclic ring, which typically have a biradicle bridge between the C2 and C4 carbons on the ribose ring (LNA), or an unlinked ribose ring which typically lacks a bond between the C2 and C3 carbons (e.g. UNA).
  • HNA hexose ring
  • LNA ribose ring
  • UPA unlinked ribose ring which typically lacks a bond between the C2 and C3 carbons
  • Other sugar modified nucleosides include, for example, bicyclohexose nucleic acids (WO2011/017521) or tricyclic nucleic acids (WO2013/154798). Modified nucleosides also include nucleosides where the sugar moiety is replaced with a non-sugar moiety, for example in the case of
  • Sugar modifications also include modifications made via altering the substituent groups on the ribose ring to groups other than hydrogen, or the 2′-OH group naturally found in DNA and RNA nucleosides. Substituents may, for example be introduced at the 2′, 3′, 4′ or 5′ positions. Nucleosides with modified sugar moieties also include 2′ modified nucleosides, such as 2′ substituted nucleosides. Indeed, much focus has been spent on developing 2′ substituted nucleosides, and numerous 2′ substituted nucleosides have been found to have beneficial properties when incorporated into oligonucleotides, such as enhanced nucleoside resistance and enhanced affinity.
  • a 2′ sugar modified nucleoside is a nucleoside which has a substituent other than H or —OH at the 2′ position (2′ substituted nucleoside) or comprises a 2′ linked biradicle, and includes 2′ substituted nucleosides and LNA (2′-4′ biradicle bridged) nucleosides.
  • the 2′ modified sugar may provide enhanced binding affinity and/or increased nuclease resistance to the oligonucleotide.
  • 2′ substituted modified nucleosides are 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA (MOE), 2′-amino-DNA, 2′-Fluoro-RNA, and 2′-fluoro-ANA (F-ANA).
  • MOE 2′-O-methoxyethyl-RNA
  • F-ANA 2′-fluoro-ANA
  • F-ANA fluoro-ANA
  • LNA Locked Nucleic Acid Nucleosides
  • LNA nucleosides are modified nucleosides which comprise a linker group (referred to as a biradicle or a bridge) between C2′ and C4′ of the ribose sugar ring of a nucleotide. These nucleosides are also termed bridged nucleic acid or bicyclic nucleic acid (BNA) in the literature.
  • a linker group referred to as a biradicle or a bridge
  • the modified nucleoside or the LNA nucleosides of the oligomer of the invention has a general structure of the formula I or II:
  • W is selected from —O—, —S—, —N(R a )—, —C(R a R b )—, such as, in some embodiments —O—;
  • B designates a nucleobase or modified nucleobase moiety;
  • Z designates an internucleoside linkage to an adjacent nucleoside, or a 5′-terminal group;
  • Z* designates an internucleoside linkage to an adjacent nucleoside, or a 3′-terminal group;
  • X designates a group selected from the list consisting of —C(R a R b )—, —C(R a ) ⁇ C(R b )—, —C(R a ) ⁇ N—, —O—, —Si(R a ) 2 —, —S—, —SO 2 —, —N(R a )—, and >C ⁇ Z
  • the biradicle —X—Y— is —O—CH 2 —
  • W is O
  • all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • LNA nucleosides are disclosed in WO99/014226, WO00/66604, WO98/039352 and WO2004/046160 which are all hereby incorporated by reference, and include what are commonly known as beta-D-oxy LNA and alpha-L-oxy LNA nucleosides.
  • the biradicle —X—Y— is —S—CH 2 —
  • W is O
  • all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • Such thio LNA nucleosides are disclosed in WO99/014226 and WO2004/046160 which are hereby incorporated by reference.
  • the biradicle —X—Y— is —NH—CH 2 —
  • W is O
  • all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • amino LNA nucleosides are disclosed in WO99/014226 and WO2004/046160 which are hereby incorporated by reference.
  • the biradicle —X—Y— is —O—CH 2 —CH 2 — or —O—CH 2 —CH 2 —CH 2 —
  • W is O
  • all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • LNA nucleosides are disclosed in WO00/047599 and Morita et al, Bioorganic & Med. Chem. Lett. 12 73-76, which are hereby incorporated by reference, and include what are commonly known as 2′-O-4′C-ethylene bridged nucleic acids (ENA).
  • the biradicle —X—Y— is —O—CH 2 —
  • W is O
  • all of R 1 , R 2 , R 3 , and one of R 5 and R 5* are hydrogen
  • the other of R 5 and R 5* is other than hydrogen such as C 1-6 alkyl, such as methyl.
  • the biradicle —X—Y— is —O—CR a R b —, wherein one or both of R a and R b are other than hydrogen, such as methyl, W is O, and all of R 1 , R 2 , R 3 , and one of R 5 and R 5* are hydrogen, and the other of R 5 and R 5* is other than hydrogen such as C 1-6 alkyl, such as methyl.
  • R a and R b are other than hydrogen, such as methyl
  • W is O
  • all of R 1 , R 2 , R 3 , and one of R 5 and R 5* are hydrogen
  • the other of R 5 and R 5* is other than hydrogen such as C 1-6 alkyl, such as methyl.
  • the biradicle —X—Y— designate the bivalent linker group —O—CH(CH 2 OCH 3 )— (2′ O-methoxyethyl bicyclic nucleic acid—Seth at al., 2010, J. Org. Chem. Vol 75(5) pp. 1569-81).
  • the biradicle —X—Y— designate the bivalent linker group —O—CH(CH 2 CH 3 )-(2′O-ethyl bicyclic nucleic acid—Seth at al., 2010, J. Org. Chem. Vol 75(5) pp. 1569-81).
  • the biradicle —X—Y— is —O—CHR a —
  • W is O
  • all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • 6′ substituted LNA nucleosides are disclosed in WO10036698 and WO07090071 which are both hereby incorporated by reference.
  • the biradicle —X—Y— is —O—CH(CH 2 OCH 3 )—, W is O, and all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • LNA nucleosides are also known as cyclic MOEs in the art (cMOE) and are disclosed in WO07090071.
  • the biradicle —X—Y— designate the bivalent linker group —O—CH(CH 3 )—.—in either the R- or S-configuration. In some embodiments, the biradicle —X—Y— together designate the bivalent linker group —O—CH 2 —O—CH 2 — (Seth at al., 2010, J. Org. Chem). In some embodiments, the biradicle —X—Y— is —O—CH(CH 3 )—, W is O, and all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • Such 6′ methyl LNA nucleosides are also known as cET nucleosides in the art, and may be either (S)cET or (R)cET stereoisomers, as disclosed in WO07090071 (beta-D) and WO2010/036698 (alpha-L) which are both hereby incorporated by reference).
  • the biradicle —X—Y— is —O—CR a R b —, wherein in neither R a or R b is hydrogen, W is O, and all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • R a and R b are both methyl.
  • the biradicle —X—Y— is —S—CHR a —
  • W is O
  • all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • R a is methyl.
  • the biradicle —X—Y— is —C( ⁇ CH 2 )—C(R a R b )—, such as —C( ⁇ CH 2 )—CH 2 —, or —C( ⁇ CH 2 )—CH(CH 3 )—W is O, and all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • vinyl carbo LNA nucleosides are disclosed in WO08154401 and WO09067647 which are both hereby incorporated by reference.
  • the biradicle —X—Y— is —N(—OR a )—, W is O, and all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • R a is C 1-6 alkyl such as methyl.
  • LNA nucleosides are also known as N substituted LNAs and are disclosed in WO2008/150729 which is hereby incorporated by reference.
  • the biradicle —X—Y— together designate the bivalent linker group —O—NR a —CH 3 — (Seth at al., 2010, J. Org. Chem).
  • the biradicle —X—Y— is —N(R a )—, W is O, and all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • R a is C 1-6 alkyl such as methyl.
  • R 5 and R 5* is hydrogen and, when substituted the other of R 5 and R 5* is C 1-6 alkyl such as methyl.
  • R 1 , R 2 , R 3 may all be hydrogen, and the biradicle —X—Y— may be selected from —O—CH2- or —O—C(HCR a )—, such as —O—C(HCH3)-.
  • the biradicle is —CR a R b —O—CR a R b —, such as CH 2 —O—CH 2 —, W is O and all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • R a is C 1-6 alkyl such as methyl.
  • LNA nucleosides are also known as conformationally restricted nucleotides (CRNs) and are disclosed in WO2013036868 which is hereby incorporated by reference.
  • the biradicle is —O—CR a R b —O—CR a R b —, such as O—CH 2 —O—CH 2 —, W is O and all of R 1 , R 2 , R 3 , R 5 and R 5* are all hydrogen.
  • R a is C 1-6 alkyl such as methyl.
  • LNA nucleosides are also known as COC nucleotides and are disclosed in Mitsuoka et al., Nucleic Acids Research 2009 37(4), 1225-1238, which is hereby incorporated by reference.
  • the LNA nucleosides may be in the beta-D or alpha-L stereoisoform.
  • the LNA nucleosides in the oligonucleotides are beta-D-oxy-LNA nucleosides.
  • Nuclease mediated degradation refers to an oligonucleotide capable of mediating degradation of a complementary nucleotide sequence when forming a duplex with such a sequence.
  • the oligonucleotide may function via nuclease mediated degradation of the target nucleic acid, where the oligonucleotides of the invention are capable of recruiting a nuclease, particularly and endonuclease, preferably endoribonuclease (RNase), such as RNase H.
  • RNase endoribonuclease
  • oligonucleotide designs which operate via nuclease mediated mechanisms are oligonucleotides which typically comprise a region of at least 5 or 6 DNA nucleosides and are flanked on one side or both sides by affinity enhancing nucleosides, for example gapmers, headmers and tailmers.
  • the RNase H activity of an antisense oligonucleotide refers to its ability to recruit RNase H when in a duplex with a complementary RNA molecule.
  • WO01/23613 provides in vitro methods for determining RNaseH activity, which may be used to determine the ability to recruit RNaseH.
  • an oligonucleotide is deemed capable of recruiting RNase H if it, when provided with a complementary target nucleic acid sequence, has an initial rate, as measured in pmol/l/min, of at least 10% or more than 20% of the of the initial rate determined when using a oligonucleotide having the same base sequence as the modified oligonucleotide being tested, but containing only DNA monomers, with phosphorothioate linkages between all monomers in the oligonucleotide, and using the methodology provided by Example 91-95 of WO01/23613 (hereby incorporated by reference).
  • gapmer refers to an antisense oligonucleotide which comprises a region of RNase H recruiting oligonucleotides (gap) which is flanked 5′ and 3′ by one or more affinity enhancing modified nucleosides (flanks).
  • oligonucleotides capable of recruiting RNase H where one of the flanks is missing, i.e. only one of the ends of the oligonucleotide comprises affinity enhancing modified nucleosides.
  • the 3′ flank is missing (i.e. the 5′ flanc comprise affinity enhancing modified nucleosides) and for tailmers the 5′ flank is missing (i.e. the 3′ flank comprises affinity enhancing modified nucleosides).
  • LNA gapmer is a gapmer oligonucleotide wherein at least one of the affinity enhancing modified nucleosides is an LNA nucleoside.
  • mixed wing gapmer refers to a LNA gapmer wherein the flank regions comprise at least one LNA nucleoside and at least one non-LNA modified nucleoside, such as at least one 2′ substituted modified nucleoside, such as, for example, 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA (MOE), 2′-amino-DNA, 2′-Fluoro-RNA, and 2′-F-ANA nucleoside(s).
  • the mixed wing gapmer has one flank which comprises LNA nucleosides (e.g. 5′ or 3′) and the other flank (3′ or 5′ respectfully) comprises 2′ substituted modified nucleoside(s).
  • conjugate refers to an oligonucleotide which is covalently linked to a non-nucleotide moiety (conjugate moiety or region C or third region).
  • Conjugation of the oligonucleotide of the invention to one or more non-nucleotide moieties may improve the pharmacology of the oligonucleotide, e.g. by affecting the activity, cellular distribution, cellular uptake or stability of the oligonucleotide.
  • the conjugate moiety modify or enhance the pharmacokinetic properties of the oligonucleotide by improving cellular distribution, bioavailability, metabolism, excretion, permeability, and/or cellular uptake of the oligonucleotide.
  • the conjugate may target the oligonucleotide to a specific organ, tissue or cell type and thereby enhance the effectiveness of the oligonucleotide in that organ, tissue or cell type.
  • the conjugate may serve to reduce activity of the oligonucleotide in non-target cell types, tissues or organs, e.g. off target activity or activity in non-target cell types, tissues or organs.
  • WO 93/07883 and WO 2013/033230 provides suitable conjugate moieties, which are hereby incorporated by reference.
  • WO 2012/143379 provides a method of delivering a drug across the blood-brain-barrier by conjugation to an antibody fragment with affinity to the transferrin receptor, which are hereby incorporated by reference.
  • Oligonucleotide conjugates and their synthesis has also been reported in comprehensive reviews by Manoharan in Antisense Drug Technology, Principles, Strategies, and Applications, S. T. Crooke, ed., Ch. 16, Marcel Dekker, Inc., 2001 and Manoharan, Antisense and Nucleic Acid Drug Development, 2002, 12, 103, each of which is incorporated herein by reference in its entirety.
  • the non-nucleotide moiety is selected from the group consisting of carbohydrates, cell surface receptor ligands, drug substances, hormones, lipophilic substances, polymers, proteins, peptides, toxins (e.g. bacterial toxins), vitamins, viral proteins (e.g. capsids) or combinations thereof.
  • the non-nucleotide moiety an antibody or antibody fragment, such as an antibody or antibody fragment that facilitates delivery across the blood-brain-barrier, in particular an antibody or antibody fragment targeting the transferrin receptor.
  • a linkage or linker is a connection between two atoms that links one chemical group or segment of interest to another chemical group or segment of interest via one or more covalent bonds.
  • Conjugate moieties can be attached to the oligonucleotide directly or through a linking moiety (e.g. linker or tether).
  • Linkers serve to covalently connect a third region, e.g. a conjugate moiety (Region C), to a first region, e.g. an oligonucleotide (region A).
  • the conjugate or oligonucleotide conjugate of the invention may optionally, comprise a linker region (second region or region B and/or region Y) which is positioned between the oligonucleotide (region A or first region) and the conjugate moiety (region C or third region).
  • a linker region second region or region B and/or region Y
  • Region B refers to biocleavable linkers comprising or consisting of a physiologically labile bond that is cleavable under conditions normally encountered or analogous to those encountered within a mammalian body.
  • Conditions under which physiologically labile linkers undergo chemical transformation include chemical conditions such as pH, temperature, oxidative or reductive conditions or agents, and salt concentration found in or analogous to those encountered in mammalian cells.
  • Mammalian intracellular conditions also include the presence of enzymatic activity normally present in a mammalian cell such as from proteolytic enzymes or hydrolytic enzymes or nucleases.
  • the biocleavable linker is susceptible to S1 nuclease cleavage.
  • the nuclease susceptible linker comprises between 1 and 10 nucleosides, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleosides, more preferably between 2 and 6 nucleosides and most preferably between 2 and 4 linked nucleosides comprising at least two consecutive phosphodiester linkages, such as at least 3 or 4 or 5 consecutive phosphodiester linkages.
  • the nucleosides are DNA or RNA.
  • Phosphodiester containing biocleavable linkers are described in more detail in WO 2014/076195 (hereby incorporated by reference).
  • Region Y refers to linkers that are not necessarily biocleavable but primarily serve to covalently connect a conjugate moiety (region C or third region), to an oligonucleotide (region A or first region).
  • the region Y linkers may comprise a chain structure or an oligomer of repeating units such as ethylene glycol, amino acid units or amino alkyl groups
  • the oligonucleotide conjugates of the present invention can be constructed of the following regional elements A-C, A-B-C, A-B-Y-C, A-Y-B-C or A-Y-C.
  • the linker (region Y) is an amino alkyl, such as a C2-C36 amino alkyl group, including, for example C6 to C12 amino alkyl groups. In a preferred embodiment the linker (region Y) is a C6 amino alkyl group.
  • control when used in relation to measurements of the effect of an oligonucleotide it is generally understood that the control is an untreated individual or target cell or a individual or target cell treated with a non-targeting oligonucleotide (mock). It may however also be an individual treated with the standard of care.
  • treatment refers to both treatment of an existing disease (e.g. a disease or disorder as herein referred to), or prevention of a disease, i.e. prophylaxis. It will therefore be recognized that treatment as referred to herein may, in some embodiments, be prophylactic.
  • An aspect of the invention is to modulate the level of pig, primate or human UBE3A protein expression, in particular to increase the expression of paternal UBE3A expression in neuronal cells, in particular in human neuronal cells.
  • the human UBE3A protein exists in several isoforms which are listed under Uniprot nr. Q05086. Several mutations in the maternal UBE3A gene can results in Angelman syndrome.
  • the target nucleic acid for the oligonucleotides of the invention is RNA, in particular a long non-coding RNA.
  • the long non-coding RNA which is targeted by the oligonucleotides of the present invention is human SNHG14 (also known as UBE3A-ATS with Ensembl entry number ENSG00000224078, version GRCh38.p2).
  • the target nucleic acid is the region downstream of SNORD109B corresponding to position 25278410 to 25419462 on chromosome 15 (SEQ ID NO: 1).
  • the UBE3A suppressor is defined as region downstream of SNORD109A corresponding to position 4222848 to U.S. Pat. No. 4,373,084 (forward strand) on chromosome 7 using the Ensembl assembly MMUL 1.0 (SEQ ID NO: 2).
  • the target nucleic acid is SEQ ID NO: 1, or naturally occurring variants thereof.
  • target nucleic acid correspond to regions which are conserved between human (SEQ ID NO: 1) and Rhesus monkey (SEQ ID NO: 2). In certain embodiments target nucleic acid correspond to regions which are conserved between human (SEQ ID NO:1), Rhesus monkey (SEQ ID NO: 2) and mouse (SEQ ID NO: 3).
  • the target nucleic acid is the region that is antisense to the UBE3A pre-mRNA, this region corresponds to position 55319 to 141053 of SEQ ID NO: 1.
  • the target nucleic acid is the region that is downstream of SNORD109B and upstream of the region that is antisense to the UBE3A pre-mRNA, this region corresponds to position 1 to 55319 of SEQ ID NO: 1.
  • the target nucleic acid is present in a cell, such as a mammalian cell in particular a human cell in vitro or in vivo (the target cell).
  • the target cell is a neuron, preferably a human neuronal cell.
  • the target sequence may be a sub-sequence of the target nucleic acid.
  • the oligonucleotide targets sub-sequence selected from the group consisting of the antisense region of exon 9, exon10, exon13, exon14, intron 14, exon 15, intron15 and exon 16 of UBE3A.
  • the oligonucleotide or contiguous nucleotide sequence hybridize or is complementary to a single stranded nucleic acid molecule selected from the group consisting of positions: 55319-76274, 77483-77573, 92157-93403 and 97056-97354 of SEQ ID NO: 1.
  • the oligonucleotide or contiguous nucleotide sequence hybridize or is complementary to a single stranded nucleic acid molecule selected from the group consisting of positions: 60821-60849, 77567-77583, 92323-92339 and 97156-97172 of SEQ ID NO: 1.
  • the target nucleic acid is a region corresponding to positions 9200-9250 of SEQ ID NO: 1.
  • the target nucleic acid is a region corresponding to positions 11505-11555 of SEQ ID NO: 1.
  • the target nucleic acid is a region corresponding to positions 15100-15150 of SEQ ID NO: 1.
  • the target nucleic acid is a region corresponding to positions 30590-30740 of SEQ ID NO: 1.
  • the target nucleic acid is a region corresponding to positions 46380-46430 of SEQ ID NO: 1.
  • the invention relates to oligonucleotides capable of modulating expression of paternal UBE3A, in particular induction or up-regulation of paternally expressed UBE3A in neuronal cells.
  • the modulation is achieved by hybridizing to a target nucleic acid located on the long non-coding RNA SNHG14 transcript downstream of SNORD109B.
  • the oligonucleotide of the invention hybridizes to a sub-sequence of the target nucleic acid of SEQ ID NO: 1 with a ⁇ G° below ⁇ 10 kcal, such as with a ⁇ G° between ⁇ 10 to ⁇ 60 kcal, such as ⁇ 12 to ⁇ 40, such as from ⁇ 15 to ⁇ 30 kcal or ⁇ 16 to ⁇ 27 kcal such as ⁇ 18 to ⁇ 25 kcal.
  • the oligonucleotide of the invention is an antisense oligonucleotide which targets the pig, rhesus monkey and/or human SNHG14 transcript downstream of SNORD109B.
  • the antisense oligonucleotide of the invention is capable of modulating the expression of the target by removing, interfering with or decreasing the suppressor of the target.
  • the oligonucleotides of the invention induce UBE3A expression in a cell, in particular paternal UBE3A expression in a neuron, by degradation or removal of the SNHG14 transcript downstream of SNORD109B.
  • the oligonucleotides of the invention are capable of increasing the expression of UBE3A by least 20% compared to the expression level of UBE3A in a neuronal cell treated with saline or a non-targeting oligonucleotide, more preferably by at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 80%, 100%, 120%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240% or 250% compared to the expression level of UBE3A in a neuronal cell treated with saline or a non-targeting oligonucleotide.
  • the oligonucleotides of the invention are capable of decreasing the level of the SNHG14 transcript downstream of SNORD109B (in particular the part of the transcript that is antisense to the UBE3A pre-mRNA region) by at least 20% compared to the level of the SNHG14 transcript downstream of SNORD109B in a neuronal cell treated with saline or a non-targeting oligonucleotide, more preferably by at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% compared to the level of the SNHG14 transcript downstream of SNORD109B in a neuronal cell treated with saline or a non-targeting oligonucleotide, without reducing SNORD115 levels by more than 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25% or 30% compared to the level of SNORD115 in
  • SNRPN and SNORD116 transcripts are located upstream from the SNORD115 transcript consequently if the SNORD115 transcript is not reduced by the oligonucleotide it is highly likely that the SNRPN and SNORD116 transcripts are also not reduced.
  • SNRPN and SNORD116 transcripts levels are not reduced by more than 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25% or 30% compared to the level of SNRPN and SNORD116 in a cell treated with saline or a non-targeting oligonucleotide.
  • the target modulation is triggered by the hybridization between a contiguous nucleotide sequence of the oligonucleotide and the target nucleic acid.
  • the oligonucleotide of the invention comprises mismatches between the oligonucleotide and the target nucleic acid. Despite mismatches hybridization to the target nucleic acid may still be sufficient to show a desired modulation of UBE3A expression.
  • Reduced binding affinity resulting from mismatches may advantageously be compensated by increased number of nucleotides in the oligonucleotide and/or an increased number of modified nucleosides capable of increasing the binding affinity to the target, such as 2′ modified nucleosides, including LNA, present within the oligonucleotide sequence.
  • An aspect of the present invention relates to an antisense oligonucleotide which comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90%, such as 95%, such as 98% such as 100% complementarity to position 25278410 to 25419462 on human chromosome 15.
  • the oligonucleotide comprises a contiguous sequence which is at least 90% complementary, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98%, or 100% complementary with a region of the target nucleic acid shown as SEQ ID NO: 1, 2 or 3.
  • the oligonucleotide of the invention or contiguous nucleotide sequence thereof is fully complementary (100% complementary) to a region of the target nucleic acid shown as SEQ ID NO: 1, or in some embodiments may comprise one or two mismatches between the oligonucleotide and the target nucleic acid.
  • the oligonucleotide sequence is 100% complementary to a corresponding target nucleic acid region present in SEQ ID NO: 1 and SEQ ID NO: 2. In some embodiments the oligonucleotide sequence is 100% complementary to a corresponding target nucleic acid region present SEQ ID NO: 1, 2 and 3.
  • the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary, such as 100% complementarity, to a corresponding target nucleic acid region present in SEQ ID NO: 1, wherein the target nucleic acid region is selected from the group consisting of region A1 to A3649 in table 1
  • the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary, such as 100% complementarity, to a corresponding target nucleic acid region present in SEQ ID NO: 1, wherein the target nucleic acid region is selected from the group consisting of region B1 to B400 in table 2
  • the oligonucleotide or contiguous nucleotide sequence is complementary to a region (or sub-sequence)(or sub-sequence) of the target nucleic acid, wherein the target nucleic acid region is selected from the group consisting of position 1589-10889, 46089-53989 and 60789-62489 of SEQ ID NO: 1.
  • the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90%, such as 100% complementary to a target nucleic acid sequence of position 55319 to 141053 of SEQ ID NO: 1.
  • the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90%, such as 100% complementary to a target nucleic acid sequence of position 1 to 55318 of SEQ ID NO: 1.
  • the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid selected from the group corresponding to positions: 55319-76274, 77483-77573, 92157-93403 and 97056-97354 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid selected from the group corresponding to positions: 60821-60849, 77567-77583, 92323-92339 and 97156-97172 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions: 5218-5240 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions: 5782-5803 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions: 8113-8139 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions: 9200-9250 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions: 11505-11555 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions: 13223-13242 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions 15100-15150 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions 15113-15180 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions 29635-29705 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions 30590-30740 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions 39800-39855 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid to positions 44435-44460 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid to positions 45245-45270 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid to positions 46380-46430 of SEQ ID NO: 1.
  • the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid to positions 68915-68940 of SEQ ID NO: 1.
  • the oligonucleotide comprises or consists of 8 to 35 nucleotides in length, such as from 10 to 30, such as 11 to 22, such as from 12 to 18, such as from 13 to 17 or 14 to 16 contiguous nucleotides in length. In a preferred embodiment, the oligonucleotide comprises or consists of 15 to 20 nucleotides in length.
  • the oligonucleotide or contiguous nucleotide sequence thereof comprises or consists of 22 or less nucleotides, such as 20 or less nucleotides, such as 18 or less nucleotides, such as 14, 15, 16 or 17 nucleotides. It is to be understood that any range given herein includes the range endpoints. Accordingly, if an oligonucleotide is said to include from 10 to 30 nucleotides, both 10 and 30 nucleotides are included.
  • the contiguous nucleotide sequence comprises or consists of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleotides in length.
  • the oligonucleotide comprises or consists of 16, 17, 18 or 19 nucleotides in length.
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 4 to 150 (see motif sequences listed in table 3 in the Examples section).
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 4 to 818 (see motif sequences listed in table 3 in the Examples section).
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 4 to 678 (see motif sequences listed in table 3 in the Examples section).
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 166, 167, 167 or 169 (see motif sequences listed in table 3 in the Examples section).
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 570, 571, 572, 679, 680, 681, 682 and 683 (see motif sequences listed in table 3 in the Examples section).
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 34, 186, 187, 188, 573, 574, 575, 576, 572, 684, 685, 686, 687, 688, 689, 690, 691, 692, 963, 964, 965 and 696 (see motif sequences listed in table 3 in the Examples section).
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 35, 199, 200, 201, 202, 203, 204, 205, 206, 207, 209 and 210 or SEQ ID NO: 582, 583 and 584 (see motif sequences listed in table 3 in the Examples section).
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 221, 222, 223, 224, 225, 585, 586, 587, 588, 589, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717 and 718 (see motif sequences listed in table 3 in the Examples section).
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 236, 237, 238, 239, 240 and 590.
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 241, 591 and 719 (see motif sequences listed in table 3 in the Examples section).
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 46, 47, 48, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745,
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 331, 332, 638, 639, 640, 808, 809, 810, 811, 812, 813, 814 and 815 (see motif sequences listed in table 3 in the Examples section).
  • the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 409, 410, 411, 642, 643, 644, 645, 646, 816, 818 and 818 (see motif sequences listed in table 3 in the Examples section).
  • contiguous nucleobase sequences can be modified to for example increase nuclease resistance and/or binding affinity to the target nucleic acid. Modifications are described in the definitions and in the “Oligonucleotide design” section. Table 3 lists preferred designs of each motif sequence.
  • Oligonucleotide design refers to the pattern of nucleoside sugar modifications in the oligonucleotide sequence.
  • the oligonucleotides of the invention comprise sugar-modified nucleosides and may also comprise DNA or RNA nucleosides.
  • the oligonucleotide comprises sugar-modified nucleosides and DNA nucleosides. Incorporation of modified nucleosides into the oligonucleotide of the invention may enhance the affinity of the oligonucleotide for the target nucleic acid. In that case, the modified nucleosides can be referred to as affinity enhancing modified nucleotides.
  • the oligonucleotide comprises at least 1 modified nucleoside, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 modified nucleosides.
  • the oligonucleotide comprises from 1 to 10 modified nucleosides, such as from 2 to 9 modified nucleosides, such as from 3 to 8 modified nucleosides, such as from 4 to 7 modified nucleosides, such as 6 or 7 modified nucleosides.
  • At least 1 of the modified nucleosides is a locked nucleic acid (LNA), such as at least 2, such as at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 of the modified nucleosides are LNA. In a still further embodiment all the modified nucleosides are LNA.
  • LNA locked nucleic acid
  • the oligonucleotide of the invention may comprise modifications, which are independently selected from these three types of modifications (modified sugar, modified nucleobase and modified internucleoside linkage) or a combination thereof.
  • the oligonucleotide comprises one or more sugar modified nucleosides, such as 2′ sugar modified nucleosides.
  • the oligonucleotide of the invention comprise the one or more 2′ sugar modified nucleoside independently selected from the group consisting of 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA, 2′-amino-DNA, 2′-fluoro-DNA, arabino nucleic acid (ANA), 2′-fluoro-ANA and LNA nucleosides. Even more preferably the one or more modified nucleoside is LNA.
  • the oligonucleotide comprises at least one modified internucleoside linkage.
  • the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate or boranophosphate internucleoside linkages.
  • the oligonucleotide of the invention comprise at least one modified nucleoside which is a 2′-MOE-RNA, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 2′-MOE-RNA nucleoside units.
  • at least one of said modified nucleoside is 2′-fluoro DNA, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 2′-fluoro-DNA nucleoside units.
  • the oligonucleotide of the invention comprises at least one LNA unit, such as 1, 2, 3, 4, 5, 6, 7, or 8 LNA units, such as from 2 to 6 LNA units, such as from 3 to 7 LNA units, 4 to 8 LNA units or 3, 4, 5, 6 or 7 LNA units.
  • all the modified nucleosides are LNA nucleosides.
  • the oligonucleotide may comprise both beta-D-oxy-LNA, and one or more of the following LNA units: thio-LNA, amino-LNA, oxy-LNA, and/or ENA in either the beta-D or alpha-L configurations or combinations thereof.
  • all LNA cytosine units are 5-methyl-cytosine.
  • the oligonucleotide or contiguous nucleotide sequence has at least 1 LNA unit at the 5′ end and at least 2 LNA units at the 3′ end of the nucleotide sequence.
  • the oligonucleotide of the invention comprises at least one LNA unit and at least one 2′ substituted modified nucleoside.
  • the oligonucleotide comprise both 2′ sugar modified nucleosides and DNA units.
  • the oligonucleotide comprise both LNA and DNA units.
  • the combined total of LNA and DNA units is 8-30, such as 10-25, preferably 12-22, such as 12-18, even more preferably 11-16.
  • the nucleotide sequence of the oligonucleotide, such as the contiguous nucleotide sequence consists of at least one or two LNA units and the remaining nucleotide units are DNA units.
  • the oligonucleotide comprises only LNA nucleosides and naturally occurring nucleosides (such as RNA or DNA, most preferably DNA nucleosides), optionally with modified internucleoside linkages such as phosphorothioate.
  • the oligonucleotide of the invention is capable of recruiting RNase H.
  • the oligonucleotide of the invention has a gapmer design or structure also referred herein merely as “Gapmer”.
  • Gapmer the oligonucleotide comprises at least three distinct structural regions a 5′-flank, a gap and a 3′-flank, F-G-F′ in ′5->3′ orientation.
  • flanking regions F and F′ (also termed wing regions) comprise a contiguous stretch of modified nucleosides, which are complementary to the UBE3A target nucleic acid, while the gap region, G, comprises a contiguous stretch of nucleotides which are capable of recruiting a nuclease, preferably an endonuclease such as RNase, for example RNase H, when the oligonucleotide is in duplex with the target nucleic acid.
  • Nucleosides which are capable of recruiting a nuclease, in particular RNase H can be selected from the group consisting of DNA, alpha-L-oxy-LNA, 2′-Flouro-ANA and UNA.
  • Regions F and F′, flanking the 5′ and 3′ ends of region G preferably comprise non-nuclease recruiting nucleosides (nucleosides with a 3′ endo structure), more preferably one or more affinity enhancing modified nucleosides.
  • the 3′ flank comprises at least one LNA nucleoside, preferably at least 2 LNA nucleosides.
  • the 5′ flank comprises at least one LNA nucleoside.
  • both the 5′ and 3′ flanking regions comprise a LNA nucleoside.
  • all the nucleosides in the flanking regions are LNA nucleosides.
  • flanking regions may comprise both LNA nucleosides and other nucleosides (mixed flanks), such as DNA nucleosides and/or non-LNA modified nucleosides, such as 2′ substituted nucleosides.
  • the gap is defined as a contiguous sequence of at least 5 RNase H recruiting nucleosides (nucleosides with a 2′ endo structure, preferably DNA) flanked at the 5′ and 3′ end by an affinity enhancing modified nucleoside, preferably LNA, such as beta-D-oxy-LNA.
  • nucleosides of the 5′ flanking region and the 3′ flanking region which are adjacent to the gap region are modified nucleosides, preferably non-nuclease recruiting nucleosides.
  • the flanks comprise DNA the 5′ and 3′ nucleosides are modified nucleosides.
  • Region F (5′ flank or 5′ wing) attached to the ′5 end of region G comprises, contains or consists of at least one modified nucleoside such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 modified nucleosides.
  • region F comprises or consists of from 1 to 7 modified nucleosides, such as from 2 to 6 modified nucleosides, such as from 2 to 5 modified nucleosides, such as from 2 to 4 modified nucleosides, such as from 1 to 3 modified nucleosides, such as 1, 2, 3 or 4 modified nucleosides.
  • nucleosides may be attached to the ′5 end of region F, representing a region D preferably comprising 1, 2 or 3 nucleoside units, such as DNA nucleosides.
  • Region D can take the function of a biocleavable (B) linker described in the definition of “Linkers”.
  • the modified nucleosides in region F have a 3′ endo structure.
  • one or more of the modified nucleosides in region F are 2′ modified nucleosides.
  • one or more of the 2′ modified nucleosides in region F are selected from 2′-O-alkyl-RNA units, 2′-O-methyl-RNA, 2′-amino-DNA units, 2′-fluoro-DNA units, 2′-alkoxy-RNA, MOE units, LNA units, arabino nucleic acid (ANA) units and 2′-fluoro-ANA units.
  • all the modified nucleosides in region F are LNA nucleosides.
  • the LNA nucleosides in region F are independently selected from the group consisting of oxy-LNA, thio-LNA, amino-LNA, cET, and/or ENA, in either the beta-D or alpha-L configurations or combinations thereof.
  • region F has at least 1 beta-D-oxy LNA unit, at the 5′ end of the contiguous sequence.
  • Region G preferably comprise, contain or consist of at least 4, such as at least 5, such as at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 consecutive nucleosides capable of recruiting the aforementioned nuclease, in particular RNaseH.
  • region G comprise, contain or consist of from 5 to 12, or from 6 to 10 or from 7 to 9, such as 8 consecutive nucleotide units capable of recruiting aforementioned nuclease.
  • the nucleoside units in region G which are capable of recruiting nuclease are in an embodiment selected from the group consisting of DNA, alpha-L-LNA, C4′ alkylated DNA (as described in PCT/EP2009/050349 and Vester et al., Bioorg. Med. Chem. Lett. 18 (2008) 2296-2300, both incorporated herein by reference), arabinose derived nucleosides like ANA and 2′F-ANA (Mangos et al. 2003 J. AM. CHEM. SOC. 125, 654-661), UNA (unlocked nucleic acid) (as described in Fluiter et al., Mol. Biosyst., 2009, 10, 1039 incorporated herein by reference). UNA is unlocked nucleic acid, typically where the bond between C2 and C3 of the ribose has been removed, forming an unlocked “sugar” residue.
  • At least one nucleoside unit in region G is a DNA nucleoside unit, such as from 1 to 16 DNA units, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 DNA units, preferably from 2 to 13 DNA units, such as from 4 to 12 DNA units, more preferably from 5 to 11, or from 10 to 16, 11 to 15 or 12 to 14 DNA units.
  • region G consists of 100% DNA units.
  • G consists of, most preferably 10, 11, 12, 13, 14 or 15 DNA units.
  • region G may consist of a mixture of DNA and other nucleosides capable of mediating RNase H cleavage.
  • Region G may consist of at least 50% DNA, more preferably 60%, 70% or 80% DNA, and even more preferred 90% or 95% DNA.
  • At least one nucleoside unit in region G is an alpha-L-LNA nucleoside unit, such as at least one alpha-L-LNA unit, such as 2, 3, 4, 5, 6, 7, 8 or 9 alpha-L-LNA units.
  • region G comprises the least one alpha-L-LNA is alpha-L-oxy-LNA unit.
  • region G comprises a combination of DNA and alpha-L-LNA nucleoside units.
  • the size of the contiguous sequence in region G may be longer, such as 15, 16, 17, 18, 19 or 20 nucleoside units.
  • nucleosides in region G have a 2′ endo structure.
  • Region F′ (3′ flank or 3′ wing) attached to the ′3 end of region G comprises, contains or consists of at least one modified nucleoside such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 modified nucleosides.
  • region F′ comprise or consist of from 1 to 7 modified nucleosides, such as from 2 to 6 modified nucleoside, such as from 2 to 4 modified nucleosides, such as from 1 to 3 modified nucleosides, such as 1, 2, 3 or 4 modified nucleosides.
  • Region D′ can take the function of a biocleavable (B) linker described, in the section “Linkers”.
  • the modified nucleosides in region F′ have a 3′ endo structure.
  • modified nucleosides in region F′ is LNA.
  • modified nucleosides in region F′ are selected from 2′-O-alkyl-RNA units, 2′-O-methyl-RNA, 2′-amino-DNA units, 2′-fluoro-DNA units, 2′-alkoxy-RNA, MOE units, LNA units, arabino nucleic acid (ANA) units and 2′-fluoro-ANA units.
  • all the modified nucleosides in region F′ are LNA nucleosides.
  • the LNA nucleosides in region F′ are independently selected from the group consisting of oxy-LNA, thio-LNA, amino-LNA, cET and/or ENA, in either the beta-D or alpha-L configurations or combinations thereof.
  • region F′ has at least 2 beta-D-oxy LNA unit, at the 3′ end of the contiguous sequence.
  • Region D and D′ can be attached to the 5′ end of region F or the 3′ end of region F′, respectively.
  • Region D or D′ may independently comprise 1, 2, 3, 4 or 5 additional nucleotides, which may be complementary or non-complementary to the target nucleic acid.
  • the oligonucleotide of the invention may in some embodiments comprise a contiguous nucleotide sequence capable of modulating the target which is flanked at the 5′ and/or 3′ end by additional nucleotides.
  • additional nucleotides may serve as a nuclease susceptible biocleavable linker (see definition of linkers).
  • the additional 5′ and/or 3′ end nucleotides are linked with phosphodiester linkages, and may be DNA or RNA.
  • the additional 5′ and/or 3′ end nucleotides are modified nucleotides which may for example be included to enhance nuclease stability or for ease of synthesis.
  • the oligonucleotide of the invention comprises a region D and/or D′ in addition to the contiguous nucleotide sequence.
  • the gapmer oligonucleotide of the present invention can be represented by the following formulae:
  • F-G-F′ in particular F 1-7 -G 4-12 -F′ 1-7
  • D-F-G-F′ in particular D 1-3 -F 1-7 -G 4-12 -F′ 1-7
  • F-G-F′-D′ in particular F 1-7 -G 4-12 -F′ 1-7 -D′ 1-3
  • D-F-G-F′-D′ in particular D 1-3 -F 1-7 -G 4-12 -F′ 1-7 -D′ 1-3
  • nucleosides in regions F, G and F′, D and D′ have been described above.
  • the design of the individual oligonucleotide may also have profound impact on the properties of the oligonucleotide in its use for modulating expression of UBE3A.
  • the oligonucleotide is a gapmer consisting of 14, 15, 16, 17, 18, 19 or 20 nucleotides in length, wherein each of regions F and F′ independently consists of 2, 3 or 4 modified nucleoside units complementary to a part of the human SNHG14 long non-coding RNA which is antisense to the UBE3A pre-mRNA (the target nucleic acid) and region G consists of 10, 11, 12, 13, 14 or 15 nucleoside units, capable of recruiting nuclease when in duplex with the target nucleic acid.
  • the oligonucleotide is a gapmer wherein each of regions F and F′ independently consists of 2, 3, 4 or 5 modified nucleoside units, such as nucleoside units containing a 2′-O-methoxyethyl-ribose sugar (2′-MOE) or nucleoside units containing a 2′-fluoro-deoxyribose sugar and/or LNA units, and region G consists of 9, 10, 11, 12, 13, 14 or 15 nucleoside units, such as DNA units or other nuclease recruiting nucleosides such as alpha-L-LNA or a mixture of DNA and nuclease recruiting nucleosides.
  • 2′-MOE 2′-O-methoxyethyl-ribose sugar
  • region G consists of 9, 10, 11, 12, 13, 14 or 15 nucleoside units, such as DNA units or other nuclease recruiting nucleosides such as alpha-L-LNA or a mixture of DNA and nuclease
  • the oligonucleotide is a gapmer wherein each of regions F and F′ region consists of two LNA units each, and region G consists of 10, 11, 12, 13, 14 or 15 nucleoside units, preferably DNA units.
  • Specific gapmer designs of this nature include 2-10-2, 2-11-2, 2-12-2, 2-13-2, 2-14-2 and 2-15-2.
  • the oligonucleotide is a gapmer wherein each of regions F and F′ independently consists of three LNA units, and region G consists of 10, 11, 12, 13, 14 or 15 nucleoside units, preferably DNA units.
  • Specific gapmer designs of this nature include 3-10-3, 3-11-3, 3-12-3, 3-13-3, 3-14-3 and 3-15-3.
  • the oligonucleotide is a gapmer wherein each of regions F and F′ consists of four LNA units each, and region G consists of 10, 11, 12, 13, 14 or 15 nucleoside units, preferably DNA units.
  • Specific gapmer designs of this nature include 4-10-4, 4-11-4, 4-12-4, 4-13-4, 4-14-4 and 4-15-4.
  • gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 10 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-10-1, 2-10-1, 1-10-2, 1-10-3, 3-10-1, 1-10-4, 4-10-1, 2-10-2, 2-10-3, 3-10-2, 2-10-4, 4-10-2, 3-10-3, 3-10-4, 4-10-3 and 4-10-4 gapmers.
  • gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 11 nucleosides and independently 1 to 4 modified nucleosides in the wings including, 1-11-1, 2-11-1, 1-11-2, 1-11-3, 3-11-1, 1-11-4, 4-11-1, 2-11-2, 2-11-3, 3-11-2, 2-11-4, 4-11-2, 3-11-3, 3-11-4, 4-11-3 and 4-11-4 gapmers.
  • gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 12 nucleosides including, 1-12-1, 2-12-1, 1-12-2, 1-12-3, 3-12-1, 1-12-4, 4-12-1, 2-12-2, 2-12-3, 3-12-2, 2-12-4, 4-12-2, 3-12-3, 3-12-4, 4-12-3 and 4-12-4 gapmers.
  • gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 13 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-13-1, 1-13-2, 1-13-3, 3-13-1, 1-13-4, 4-13-1, 2-13-1, 2-13-2, 2-13-3, 3-13-2, 2-13-4, 4-13-2, 3-13-3, 3-13-4, 4-13-3, and 4-13-4 gapmers.
  • gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 14 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-14-1, 1-14-2, 2-14-1, 1-14-3, 3-14-1, 1-14-4, 4-14-1, 2-14-2, 2-14-3, 3-14-2 2-14-4, 4-14-2, 3-14-3, 3-14-4 and 4-14-3 gapmers.
  • gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 15 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-15-1, 1-15-2, 2-15-1, 1-15-3, 3-15-1, 1-15-4, 4-15-1, 2-15-2, 2-15-3, 3-15-2 2-15-4, 4-15-2, 3-15-3, 3-15-4 and 4-15-3 gapmers.
  • gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 16 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-16-1, 1-16-2, 2-16-1, 1-15-3, 3-16-1, 1-16-4, 4-16-1, 2-16-2, 2-16-3, 3-16-2 2-16-4, 4-16-2, 3-16-3, 3-16-4 and 4-16-3 gapmers.
  • the F-G-F′ design is selected from 2-10-4, 3-10-3 and 4-10-2.
  • the F-G-F′ design is selected from 2-11-4, 3-11-2, 3-11-3 and 4-11-2.
  • the F-G-F′ design is selected from 2-12-2, 2-12-3, 2-12-4, 3-12-2, 3-12-3, and 4-12-2.
  • the F-G-F′ design is selected from 2-13-2, 2-13-3, 2-13-4, 3-13-3 and 4-13-2.
  • the F-G-F′ design is selected from 2-14-2, 2-14-4, 3-14-3 and 4-14-2.
  • the F-G-F′ design is selected from 2-15-2 and 2-16-2.
  • the F-G-F′ design is selected from the designs indicated in table 3.
  • the F-G-F′ design may further include region D and/or D′, which may have 1, 2 or 3 nucleoside units, such as DNA units.
  • region D and/or D′ may have 1, 2 or 3 nucleoside units, such as DNA units.
  • the nucleosides in region F and F′ are modified nucleosides, while nucleotides in region G are preferably unmodified nucleosides.
  • the preferred modified nucleoside is LNA.
  • all the internucleoside linkages in the gap in a gapmer are phosphorothioate and/or boranophosphate linkages. In another embodiment all the internucleoside linkages in the flanks (F and F′ region) in a gapmer are phosphorothioate and/or boranophosphate linkages. In another preferred embodiment all the internucleoside linkages in the D and D′ region in a gapmer are phosphodiester linkages.
  • cytosine (C) residues are annotated as 5-methyl-cytosine
  • one or more of the C's present in the oligonucleotide may be unmodified C residues.
  • the oligonucleotide is selected from the group of oligonucleotide compounds in table 3.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 4_1 to 150_2.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 4_1 to 678_1.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 4_1 to 818_1 (see oligonucleotide sequences listed in table 3 in the Examples section).
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 155_1 or 165_1.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 169_52, 169_50 or 169_56.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 172_1, 272_1, 572_7, 572_6 or 572_5.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 175_1.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 178_1.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 573_8, 186_1 or 187_1.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 186_1.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 200_1, 204_1, 206_1, 35_2 or 209_1.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 585_1, 585_8, 586_9, 586_5, 586_8, 586_4 or 586_6.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 233_1.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 237_8 or 590_13.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 220_1.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 591_1, 592_2, 592_4 or 241_9.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 597_4, 598_4, 39_1 or 602_1.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 39_1.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 611_7.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 271_1 or 278_1.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 616_4, 621_2, 621_1, 622_3, 622_5, 622_4, 6243, 624_5, 287_1, 625_6, 626_7, 626_8, 626_9, 48_1, 631_6, 631_1, 303_1, 304_6 or 304_10.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 636_8.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 638_8, 639_5, 331_1 or 640_4.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 359_1, 361_1, 361_5, 362_1 or 641_5.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 378_1, 379_1, 399_1.
  • the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 403_1, 405_1, 642_12, 642_13, 644_3 or 646_16.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 85_1 or 425_5.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 116_1.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 123_1 or 124_1.
  • the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 126_2.
  • the invention provides methods for manufacturing the oligonucleotides of the invention comprising reacting nucleotide units and thereby forming covalently linked contiguous nucleotide units comprised in the oligonucleotide.
  • the method uses phophoramidite chemistry (see for example Caruthers et al, 1987, Methods in Enzymology vol. 154, pages 287-313).
  • the method further comprises reacting the contiguous nucleotide sequence with a conjugating moiety (ligand).
  • composition of the invention comprising mixing the oligonucleotide or conjugated oligonucleotide of the invention with a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
  • the invention provides pharmaceutical compositions comprising any of the aforementioned oligonucleotides and/or oligonucleotide conjugates and a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant.
  • a pharmaceutically acceptable diluent includes phosphate-buffered saline (PBS) and pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.
  • WO 2007/031091 provides suitable and preferred examples of pharmaceutically acceptable diluents, carriers and adjuvants (hereby incorporated by reference). Suitable dosages, formulations, administration routes, compositions, dosage forms, combinations with other therapeutic agents, pro-drug formulations are also provided in WO2007/031091.
  • Oligonucleotides or oligonucleotide conjugates of the invention may be mixed with pharmaceutically acceptable active or inert substances for the preparation of pharmaceutical compositions or formulations.
  • Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.
  • the oligonucleotide or oligonucleotide conjugate of the invention is a prodrug.
  • the conjugate moiety is cleaved of the oligonucleotide once the prodrug is delivered to the site of action, e.g. the target cell.
  • oligonucleotides of the invention may be utilized as research reagents for, for example, therapeutics and prophylaxis.
  • oligonucleotides may be used to specifically modulate the synthesis of UBE3A protein in cells (e.g. in vitro cell cultures) and experimental animals thereby facilitating functional analysis of the target or an appraisal of its usefulness as a target for therapeutic intervention.
  • the target modulation is achieved by degrading or inhibiting a modulator of the gene or mRNA producing the protein.
  • an animal or a human, suspected of having a disease or disorder which can be treated by modulating the expression of UBE3A.
  • the invention provides methods for treating or preventing a disease, comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide, an oligonucleotide conjugate or a pharmaceutical composition of the invention to a subject suffering from or susceptible to the disease.
  • the invention also relates to an oligonucleotide, a composition or a conjugate as defined herein for use as a medicament.
  • oligonucleotide, oligonucleotide conjugate or a pharmaceutical composition according to the invention is typically administered in an effective amount.
  • the invention also provides for the use of the oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament for the treatment of a disorder as referred to herein, or for a method of the treatment of as a disorder as referred to herein.
  • the disease or disorder is associated with expression of UBE3A.
  • the disease or disorder may be associated with a mutation in the maternal UBE3A gene.
  • the target nucleic acid is a regulator of the paternal UBE3A gene.
  • the methods of the invention are preferably employed for treatment or prophylaxis against diseases caused by abnormal levels and/or activity of UBE3A.
  • the disease may in particular be caused by reduced levels and/or activity of UBE3A protein.
  • the invention further relates to use of an oligonucleotide, oligonucleotide conjugate or a pharmaceutical composition as defined herein for the manufacture of a medicament for the treatment of abnormal levels and/or activity of UBE3A, in particular low levels and/or activity of UBE3A.
  • the invention relates to oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions for use in the treatment of Angelman syndrome.
  • oligonucleotides or pharmaceutical compositions of the present invention may be administered topical (such as, to the skin, inhalation, ophthalmic or otic) or enteral (such as, orally or through the gastrointestinal tract) or parenteral (such as, intravenous, subcutaneous, intra-muscular, intracerebral, intracerebroventricular or intrathecal).
  • topical such as, to the skin, inhalation, ophthalmic or otic
  • enteral such as, orally or through the gastrointestinal tract
  • parenteral such as, intravenous, subcutaneous, intra-muscular, intracerebral, intracerebroventricular or intrathecal.
  • the oligonucleotide or pharmaceutical compositions of the present invention are administered by a parenteral route including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, intrathecal or intracranial, e.g., intracerebral or intraventricular, administration.
  • a parenteral route including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, intrathecal or intracranial, e.g., intracerebral or intraventricular, administration.
  • the active oligonucleotide or oligonucleotide conjugate is administered intracerebral or intracerebroventricular.
  • the active oligonucleotide or oligonucleotide conjugate is administered intrathecal.
  • the invention also provides for the use of the oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament wherein the medicament is in a dosage form for intrathecal administration.
  • the invention also provides for the use of the oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament wherein the medicament is in a dosage form for intracerebral or intraventricular administration.
  • the invention also provides for the use of the oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament wherein the medicament is in a dosage form for intracerebroventricular administration.
  • the oligonucleotide, oligonucleotide conjugate or pharmaceutical composition of the invention is for use in a combination treatment with another therapeutic agent.
  • the therapeutic agent can for example be anticonvulsant medication.
  • An antisense oligonucleotide which comprises or consists of a contiguous nucleotide sequence of 10 to 30 nucleotides in length capable of inducing human paternal UBE3A expression, in particular in a neuronal cell.
  • oligonucleotide of embodiment 1 or 2 wherein the oligonucleotide is capable of hybridizing to a target nucleic acid of SEQ ID NO: 1 with a ⁇ G° below ⁇ 10 kcal.
  • oligonucleotide of embodiment 1-3 wherein the contiguous nucleotide sequence is at least 95%, such as 98%, such as 100% complementarity to region of the target nucleic acid of SEQ ID NO: 1 and/or 2.
  • oligonucleotide of embodiment 1-3 wherein the contiguous nucleotide sequence is 100% complementary to a region of the target nucleic acid of position 1 to 55318 of SEQ ID NO: 1.
  • oligonucleotide of embodiment 1-4 wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid, wherein the subsequence is selected from the group consisting of the regions indicated in table 1 or 2.
  • oligonucleotide of embodiment 1-4 wherein the contiguous nucleotide sequence is at least 98% complementarity to the part of human SNHG14 long non-coding RNA which is antisense to the UBE3A pre-mRNA.
  • oligonucleotide of embodiments 1-4 or 7-8 wherein the contiguous nucleotide sequence is 100% complementary to a target nucleic acid of position 55319 to 141053 of SEQ ID NO: 1.
  • RNA is a long non-coding RNA.
  • oligonucleotide of embodiment 1-11 wherein the contiguous nucleotide sequence comprises or consists of at least 10 contiguous nucleotides, particularly 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 contiguous nucleotides.
  • oligonucleotide of embodiment 1-12 wherein the contiguous nucleotide sequence comprises or consists of from 12 to 22 nucleotides.
  • oligonucleotide of embodiment 13 wherein the contiguous nucleotide sequence comprises or consists of from 15-20 nucleotides.
  • oligonucleotide of embodiment 1-14 wherein the oligonucleotide comprises or consists of 10 to 35 nucleotides in length.
  • oligonucleotide of embodiment 15 wherein the oligonucleotide comprises or consists of 15 to 24 nucleotides in length.
  • oligonucleotide of embodiment 1-18 wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid, selected from the group consisting of the regions indicated in table 1 or 2.
  • oligonucleotide of embodiment 1-18 wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid selected from the group consisting of position 1589-10889, 46089-53989 and 60789-62489 of SEQ ID NO: 1.
  • oligonucleotide of embodiment 1-18 wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions: 11505-11555 of SEQ ID NO: 1.
  • oligonucleotide of embodiment 1-18 wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 30590-30740 of SEQ ID NO: 1.
  • oligonucleotide of embodiment 1-18 wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 39800-39855 of SEQ ID NO: 1.
  • oligonucleotide of embodiment 1-18 wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid to positions 46380-46430 of SEQ ID NO: 1.
  • oligonucleotide of embodiment 1-18 wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 68915-68940 of SEQ ID NO: 1.
  • oligonucleotide of embodiment 1-36 wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 1819, 20, 21, 22, 23, 23, 24, 25, 26, 26, 27, 28, 29, 30, 31, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 44, 45, 45, 46, 47, 48, 49, 50, 51, 52, 53, 53, 54, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 79, 80, 81, 8283, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 95, 96, 96, 96
  • oligonucleotide of embodiment 1-36 wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 166, 167, 167 or 169 (see motif sequences listed in table 3 in the Examples section).
  • oligonucleotide of embodiment 1-36 wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 570, 571, 572, 679, 680, 681, 682 and 683 (see motif sequences listed in table 3 in the Examples section).
  • oligonucleotide of embodiment 1-36 wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 570, 571, 572, 679, 680, 681, 682 and 683 (see motif sequences listed in table 3 in the Examples section).
  • oligonucleotide of embodiment 1-36 wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 35, 199 to 210 or SEQ ID NO: 582 to 584 (see motif sequences listed in table 3 in the Examples section).
  • oligonucleotide of embodiment 1-36 wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 236, 237, 238, 239, 240 and 590 (see motif sequences listed in table 3 in the Examples section).
  • oligonucleotide of embodiment 1-36 wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 221 to 225 or SEQ ID NO: 585 to 589 (see motif sequences listed in table 3 in the Examples section).
  • oligonucleotide of embodiment 1-36 wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 241 or 591 (see motif sequences listed in table 3 in the Examples section).
  • oligonucleotide of embodiment 1-36 wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 46-48, 285 to 305 or SEQ ID NO: 613 to 632 or SEQ ID NO: 721 to 807 (see motif sequences listed in table 3 in the Examples section).
  • oligonucleotide of embodiment 1-36 wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 331, 332, 638, 639, 640, 808, 809, 810, 811, 812, 813, 814 and 815 (see motif sequences listed in table 3 in the Examples section).
  • oligonucleotide of embodiment 1-36 wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 409 to 411 or SEQ ID NO: 642 to 646 or SEQ ID NO: 816 to 818 (see motif sequences listed in table 3 in the Examples section).
  • oligonucleotide of embodiment 48 wherein the contiguous nucleotide sequence has two mismatches compared to the target nucleic acid.
  • oligonucleotide of embodiment 1-51 comprising one or more modified nucleosides.
  • oligonucleotide of embodiment 54 wherein the one or more 2′ sugar modified nucleoside is independently selected from the group consisting of 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA, 2′-amino-DNA, 2′-fluoro-DNA, 2′-fluoro-ANA and LNA nucleosides.
  • modified LNA nucleoside is selected from beta-D-oxy-LNA, alpha-L-oxy-LNA, beta-D-amino-LNA, alpha-L-amino-LNA, beta-D-thio-LNA, alpha-L-thio-LNA, (S)cET, (R)cET beta-D-ENA and alpha-L-ENA.
  • oligonucleotide of embodiment 65 or 66 wherein at least 50% of the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate internucleoside linkages or boranophosphate internucleoside linkages.
  • modified nucleoside is a 2′ sugar modified nucleoside independently selected from the group consisting of 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA, 2′-amino-DNA, 2′-fluoro-DNA, arabino nucleic acid (ANA), 2′-fluoro-ANA and LNA nucleosides.
  • oligonucleotide of embodiment 74, wherein region F and F′ consist of LNA nucleosides.
  • oligonucleotide of embodiment 73-77, wherein the RNaseH recruiting nucleosides in region G are independently selected from DNA, alpha-L-LNA, C4′ alkylated DNA, ANA and 2′F-ANA and UNA.
  • oligonucleotide of embodiment 78, wherein the nucleosides in region G is DNA and/or alpha-L-LNA nucleosides.
  • oligonucleotide of embodiment 1-80 wherein the oligonucleotide is capable of increasing the expression of UBE3A by at least 30% compared to a control.
  • oligonucleotide of embodiment 1-83 wherein the oligonucleotide is selected from CMP ID NO: 4_1 to 678_1.
  • oligonucleotide of embodiment 1-83 wherein the oligonucleotide is selected from the group consisting of CMP ID NO: 4_1, 4_2, 5_1, 5_2, 6_1, 6_2, 7_1, 7_2, 8_1, 9_1, 10_1, 11_1, 11_2, 12_1, 12_2, 13_1, 13_2, 14_1, 15_1, 16_1, 17_1, 17_2, 18_1, 18_2, 19_1, 19_2, 20_1, 21_1, 22_1, 23_1, 23_2, 24_1, 25_1, 26_1, 26_2, 27_1, 28_1, 28_2, 29_1, 29_2, 30_1, 31_1, 31_2, 32_1, 33_1, 34_1, 34_2, 34_3, 34_4, 34_5, 34_6, 34_7, 35_1, 35_2, 36_1, 37_1, 38_1, 38_2, 38_3, 38_4, 38_5, 38_6, 39_1, 39_2, 39_3, 39_4, 39_5, 40_1, 40_2, 40_3, 40_4, 40
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 155_1 or 165_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO 169_52, 169_50 or 169_56.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 172_1, 272_1, 572_7, 572_6 or 572_5.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 175_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 178_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 573_8, 186_1 or 187_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 200_1, 204_1, 206_1, 35_2 or 209_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 585_1, 585_8, 586_9, 586_5, 586_8, 586_4 or 586_6.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 233_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 237_8 or 590_13.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 220_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 591_1, 592_2, 592_4 or 241_9.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 597_4, 598_4, 39_1 or 602_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 39_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 611_7.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 271_1 or 278_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 616_4, 621_2, 621_1, 622_3, 622_5, 622_4, 624_3, 624_5, 287_1, 625_6, 626_7, 626_8, 626_9, 48_1, 631_6, 631_1, 303_1, 304_6 or 304_10.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 636_8.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 638_8, 639_5, 331_1 or 640_4.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 359_1, 361_1, 361_5, 362_1 or 641_5.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 378_1, 379_1 or 399_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 403_1, 405_1, 642_12, 642_13, 644_3 or 646_16.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 85_1 or 425_5.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 116_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 123_1 or 124_1.
  • oligonucleotide of embodiment 85 wherein the oligonucleotide is selected from CMP-ID-NO: 126_2.
  • a conjugate comprising the oligonucleotide according to any one of claims 1 - 112 , and at least one conjugate moiety covalently attached to said oligonucleotide.
  • oligonucleotide conjugate of embodiment 113 wherein the conjugate moiety is selected from carbohydrates, cell surface receptor ligands, drug substances, hormones, lipophilic substances, polymers, proteins, peptides, toxins, vitamins, viral proteins or combinations thereof.
  • oligonucleotide conjugate of embodiment 113 or 114, wherein the conjugate moiety is an antibody or antibody fragment.
  • oligonucleotide conjugate of embodiment 113-115 comprising a linker which is positioned between the oligonucleotide and the conjugate moiety.
  • oligonucleotide conjugate of embodiment 118 or 119 wherein the oligonucleotide has the formula D-F-G-F′ or F-G-F′-D′, wherein F, F′ and G are as defined in embodiments 73-80 and D or D′ comprises 1, 2 or 3 DNA nucleosides with phosphorothioate internucleoside linkages.
  • oligonucleotide conjugate of embodiment 113-120 which display improved uptake into the brain of the conjugate oligonucleotide as compared to an unconjugated oligonucleotide.
  • a pharmaceutical composition comprising the oligonucleotide of embodiment 1-112 or a conjugate of embodiment 113-121 and a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant.
  • a method for manufacturing the composition of embodiment 122 comprising mixing the oligonucleotide with a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant.
  • An in vivo or in vitro method for inducing UBE3A expression in a target cell where expression of paternal UBE3A is suppressed comprising administering an oligonucleotide of any one of embodiments 1-112 or a conjugate of embodiment 113-121 or the pharmaceutical composition of embodiment 122 in an effective amount to said cell.
  • a method for treating or preventing a disease comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide of embodiment 1-112 or a conjugate of embodiment 113-121 or the pharmaceutical composition of embodiment 122 to a subject suffering from or susceptible to the disease.
  • oligonucleotide of oligonucleotide of embodiment 1-112 or a conjugate of embodiment 113-121 for the preparation of a medicament for treatment or prevention of a disease in a subject.
  • flanks are mixed flanks, such flanks start and end with a 2′ modified nucleosides, in these cases the gap region is the number above 5 not located at the 5′ or 3′ terminal in of the design.
  • oligonucleotide compounds capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, and 5-methyl DNA cytosines are presented by “e”, all internucleoside linkages are phosphorothioate internucleoside linkages.
  • Oligonucleotides with an EX-EX indication as Start on SEQ ID NO: 1 are exon-exon spanning oligonucleotides designed to be complementary across exon-exon junctions of SNHG14-023 (ENST00000554726).
  • the oligonucleotides primarily span exon2 and exon3 (i.e. are complementary to a region in exon2 and a region in exon 3)
  • Oligonucleotide synthesis is generally known in the art. Below is a protocol which may be applied. The oligonucleotides of the present invention may have been produced by slightly varying methods in terms of apparatus, support and concentrations used.
  • Oligonucleotides are synthesized on uridine universal supports using the phosphoramidite approach on a MerMade12 or an Oligomaker DNA/RNA synthesizer at 1-4 ⁇ mol scale. At the end of the synthesis, the oligonucleotides are cleaved from the solid support using aqueous ammonia for 5-16 hours at 60° C. The oligonucleotides are purified by reverse phase HPLC (RP-HPLC) or by solid phase extractions and characterized by UPLC, and the molecular mass is further confirmed by ESI-MS.
  • RP-HPLC reverse phase HPLC
  • UPLC UPLC
  • the coupling of ⁇ -cyanoethyl-phosphoramidites (DNA-A(Bz), DNA-G(ibu), DNA-C(Bz), DNA-T, LNA-5-methyl-C(Bz), LNA-A(Bz), LNA-G(dmf), LNA-T or amino-C6 linker) is performed by using a solution of 0.1 M of the 5′-O-DMT-protected amidite in acetonitrile and DCI (4,5-dicyanoimidazole) in acetonitrile (0.25 M) as activator.
  • a phosphoramidite with desired modifications can be used, e.g.
  • a C6 linker for attaching a conjugate group or a conjugate group as such.
  • Thiolation for introduction of phosphorthioate linkages is carried out by using xanthane hydride (0.01 M in acetonitrile/pyridine 9:1).
  • Phosphordiester linkages can be introduced using 0.02 M iodine in THF/Pyridine/water 7:2:1.
  • the rest of the reagents are the ones typically used for oligonucleotide synthesis.
  • the crude compounds are purified by preparative RP-HPLC on a Phenomenex Jupiter C18 10 ⁇ 150 ⁇ 10 mm column. 0.1 M ammonium acetate pH 8 and acetonitrile is used as buffers at a flow rate of 5 mL/min. The collected fractions are lyophilized to give the purified compound typically as a white solid.
  • Oligonucleotide and RNA target duplexes are diluted to 3 mM in 500 ml RNase-free water and mixed with 500 ml 2 ⁇ T m -buffer (200 mM NaCl, 0.2 mM EDTA, 20 mM Naphosphate, pH 7.0). The solution is heated to 95° C. for 3 min and then allowed to anneal in room temperature for 30 min.
  • the duplex melting temperatures (T m ) is measured on a Lambda 40 UV/VIS Spectrophotometer equipped with a Peltier temperature programmer PTP6 using PE Templab software (Perkin Elmer). The temperature is ramped up from 20° C. to 95° C. and then down to 25° C., recording absorption at 260 nm. First derivative and the local maximums of both the melting and annealing are used to assess the duplex T m .
  • Primary cortical neuron cultures were prepared from mouse embryo brains of 15 days of age according to standard procedure. In brief, culture plates were coated with Poly-L-Lysine (50 ⁇ g/ml Poly-L-Lysine, 10 mM Na-tetraborate, pH 8 buffer) for 2-3 hrs at room temperature. The plates were washed with 1 ⁇ PBS before use. Harvested mouse embryo brains were dissected and homogenized by a razor blade and submerged into 38 ml dissection medium (HBSS, 0.01 M Hepes, Penicillin/Streptomycin). Then, 2 ml trypsin was added and cells were incubated for 30 min at 37° C. and centrifuged down.
  • HBSS HBSS, 0.01 M Hepes, Penicillin/Streptomycin
  • the cells were dissolved in 20 ml DMEM (+10% FBS) and passed through a syringe for further homogenization. This was followed by centrifugation at 500 rpm for 15 mins. The cells were dissolved in DMEM (+10% FBS) and seeded in 96 well plates (0.1 ⁇ 10 ⁇ 6 cells/well in 100 ⁇ l). The neuronal cell cultures were ready for use directly after seeding.
  • Any cell lines at any described time point was incubated at 37° C., 5% CO2 concentration and 95% relative humidity.
  • iPSC lines were generated by reprogramming erythroblast with CytoTune-iPS Sendai Reprogramming Kit (Thermo Fisher Scientific). Derived iPSC lines were maintained in feeder-free conditions using hESC-qualified Matrigel (Corning) in mTESR1 (STEMCELL Technologies) with daily medium replacement.
  • colonies Upon reaching confluence, colonies were dissociated into cell cluster of 50-200 ⁇ m in size using Gentle Cell Dissociation Reagent (STEMCELL Technologies) and subcultured at a ratio of 1:10-1:20 in the presence of 10 ⁇ M Y-27632 (Calbiochem).
  • NPC Neural Progenitor Cells
  • iPSC-derived cells Upon induction of neural differentiation iPSC-derived cells were maintained in basal medium composed of equal volumes of DMEM:F12 Glutamax medium and Neurobasal medium (Gibco, Invitrogen), supplemented with 1 ⁇ B27 (Gibco, Invitrogen), 1 ⁇ N2 (Gibco, Invitrogen), 0.1 mM beta-mercaptoethanol (Gibco, Invitrogen) and indicated supplements.
  • Neural progenitor cells were derived from hiPSCs by dual SMAD inhibition and according to published procedures with slight modifications (Chambers et al. 2009 Nat Biotechnol. Vol. 3 pp. 275-80, Boissart et al., 2013 Transl Psychiatry. 3:e294).
  • HiPSCs were dissociated with Accutase (Innovative Cell Technologies Inc.) into a single cell suspension and resuspended in basic medium further supplemented with 10 ⁇ M Y-27632 (Calbiochem), 5 ng/ml FGF (Peprotech), 10 ⁇ M SB-431542 (Calbiochem) and 100 nM LDN (Calbiochem).
  • Neural rosettes were selectively isolated using STEMdiffTM Neural Rosette Selection Reagent (STEMCELL Technologies), replated onto dishes coated with poly-L-ornithine and Laminin521 (BioLamina) and expanded in basic medium supplemented with 10 ng/ml FGF (Peprotech), 10 ng/ml EGF (RnD), and 20 ng/ml BDNF (Peprotech). When reaching confluency, cells were enzymatically dissociated with 0.05% Trypsin/EDTA (Gibco, Invitrogen) and sub-cultured.
  • NPC line neural progenitor cell line
  • a stable neural progenitor cell line is defined by its capacity to self-renew and by the expression of the developmental stage-specific markers Sox2 and Nestin.
  • MAP2+, Tau+, HuC/D+ neuronal
  • GFAP+ astroglial progenies
  • NPC neuronal differentiation
  • cells were dissociated with 0.05% Trypsin/EDTA (Gibco, Invitrogen) into single cell suspension and seeded onto Laminin521 (BioLamina) coated dishes at a density of 12.000 cells/cm2 and maintained in basic medium supplemented with 200 ng/ml Shh (Peprotech), 100 ng/ml FGF8 (Peprotech), and 100 ⁇ M ascorbic acid phosphate (Sigma) for a period of 7 days.
  • Trypsin/EDTA Gibco, Invitrogen
  • Y-27632 a cell-permeable, reversible, inhibitor of Rho kinases from Calbiochem
  • Neuronal cultures were further differentiated for additional 7 days in basal medium supplemented with 20 ng/ml BDNF (Peprotech), 10 ng/ml GDNF (Peprotech), 0.5 mM cAMP (BIOLOG Life Science), and 100 ⁇ M ascorbic acid phosphate (Sigma). Differentiation medium was exchanged twice per week. After a total differentiation period of 35 days neuronal cell cultures were ready for oligonucleotide treatment.
  • oligonucleotide stocks were pre-diluted to the indicated concentrations with water into 384 well microtiter plates (compound plate).
  • the plate layout served as a treatment template.
  • Two microliter oligonucleotide dilution from each well was transferred from the compound plate to a respective culture plate. All liquid handling was done under sterile conditions in a laminar flow using a semi-automated laboratory robotic system (Beckmancoulter). Neuronal cell cultures were incubated with oligonucleotides for 5 days without media change. Subsequently, neuronal cultures were lysed and processed for qPCR assay with RealTime ready Cell lysis and RNA Virus Master kit (Roche). Liquid handling was performed using a semi-automated laboratory robotic system (Beckmancoulter). Samples were analyzed by a Lightcycler480 real-time PCR system (Roche).
  • UBE3a-Sense Forward primer: (SEQ ID NO: 837) ATATGTGGAAGCCGGAATCT, Reverse primer: (SEQ ID NO: 838) TCCCAGAACTCCCTAATCAGAA, Internal probe labeled with dye FAM: (SEQ ID NO: 839) ATGACGGTGGCTATACCAGG
  • the RT-qPCR was multiplexed with PPIA (peptidylprolyl isomerase A) as housekeeping gene for normalization.
  • PPIA primers and probe labeled with the dye VIC were purchased from Thermo Fisher Scientific (assay ID Hs99999904_m1).
  • Each plate includes a non-targeting oligonucleotide (mock) as negative control (TTGaataagtggaTGT (SEQ ID NO: 846)) and a reference oligonucleotide CMP ID NO: 41_1, resulting in up-regulation of UBE3A mRNA.
  • SNORD115 transcript which is located upstream of SNORD109B on chromosome 15.
  • Expression of SNORD115 was monitored by qPCR using the following primers and probe
  • Forward primer (SEQ ID NO: 840) GGGTCAATGATGAGAACCTTAT, Reverse primer (SEQ ID NO: 841) GGGCCTCAGCGTAATCCTATT, Internal probe labeled with the dye FAM: (SEQ ID NO: 842) TTCTGAAGAGAGGTGATGACTTAAAA
  • RT-qPCR was multiplexed with PPIA (Thermo Fisher Scientific) upon oligonucleotide treatment.
  • Forward primer (SEQ ID NO: 843) ATCCGAGGCATGAATCTCAC, Reverse primer: (SEQ ID NO: 844) CAGGCCAAAACCCTTGATAA, Internal probe labeled with dye FAM: (SEQ ID NO: 845) TTGCTGAGCATTTTTGCATC
  • the RT-qPCR was multiplexed with PPIA (Thermo Fisher Scientific).
  • oligonucleotide stocks were pre-diluted to the indicated concentrations with water into 96 well microtiter plates (compound plate).
  • the plate layout served as a treatment template.
  • Two microliter oligonucleotide dilution from each well was transferred from the compound plate to a respective culture plate. All liquid handling was done under sterile conditions in a laminar flow using a semi-automated laboratory robotic system (Beckman Coulter).
  • Neuronal cell cultures were incubated with oligonucleotides for 5 days without media change. Subsequently, neuronal cultures were lysed and RNA purified using RNA purification kit Pure Link Pro96 (12173011A) LifeTechnologies.
  • qPCR UBE3a-Sense Forward primer: (SEQ ID NO: 697) ATATGTGGAAGCCGGAATCT, Reverse primer: (SEQ ID NO: 698) TCCCAGAACTCCCTAATCAGAA, Internal probe labeled with dye FAM: (SEQ ID NO: 699) ATGACGGTGGCTATACCAGG qPCR SNHG14 transcript downstream of SNORD109B (also termed the UBE3A suppressor): Commercially available primer and probe set from ThermoFisher: Hs01372957_m1. These primers amplifies a 87 bp exon-exon spanning sequence in the Genbank transcript AF400500.1
  • the RT-qPCR for both Ube3a and Ube3a-ATS was multiplexed with GAPDH as housekeeping gene for normalization.
  • Each plate includes a non-targeting oligonucleotide (mock) as negative control (TTGaataagtggaTGT (SEQ ID NO: 846)) and a reference oligonucleotide CMP ID NO: 21_1, resulting in up-regulation of UBE3A mRNA.
  • panel of oligos not targeting Ub3a or SNHG14 transcript downstream of SNORD109B also termed the UBE3A suppressor were included to monitor the assay noise and risk of detecting false positives. These were randomly distributed over the plates.
  • Oligonucleotides targeting the part of SNHG14 long non-coding RNA which is antisense to the UBE3A pre-mRNA were tested for their ability to reduce the SNHG14 long non-coding RNA transcript preventing UBE3A expression (also termed UBE3A suppressor or UBE3A-SUP in the data table) and their ability to induce UBE3A mRNA re-expression in mouse primary cortical neuron cell cultures, obtained as described in the “Materials and methods” section above.
  • the oligonucleotide concentration was 5 microM.
  • oligonucleotides were screened according to the protocol for screening in mouse cortical neuron cell cultures described in the section “Materials and methods”. The results are shown in table 4.
  • Oligonucleotides targeting human SNHG14 in the region downstream of SNORD109B corresponding to position 25278410 to 25419462 on chromosome 15 were tested in patient derived human neuronal cell cultures (see protocol in “Materials and methods” section).
  • the oligonucleotides ability to reduce the SNHG14 transcript in the region downstream of SNORD109B also termed UBE3A suppressor or UBE3A-SUP in the data table
  • UBE3A-SUP UBE3A suppressor
  • oligonucleotides were screened according to the protocol for screening oligonucleotides in human neuronal cell cultures described in the section “Materials and methods” above.
  • FIG. 2 plots the distribution of the oligonucleotides according to their position on chromosome 15 versus the UBE3A mRNA expression relative to the mock oligonucleotide.
  • Example 3 Activity of Oligonucleotides Targeting the SNHG14 Transcript in the Region Downstream of SNORD109B and Upstream of the Region Antisense to the UBE3A Pre-mRNA
  • Oligonucleotides targeting position 4806-54939 of SEQ ID NO: 1 were tested in patient derived human neuronal cell cultures (see protocol in “Materials and methods” section).
  • the oligonucleotides ability to reduce the SNHG14 transcript in the region downstream of SNORD109B also termed UBE3A suppressor or UBE3A-SUP in the data table.
  • UBE3A-SUP also termed UBE3A suppressor
  • oligonucleotides were screened according to the protocol for screening oligonucleotides in human neuronal cell cultures described in the section “Materials and methods”—“Screening oligonucleotides in human neuronal cell cultures—96 well system”
  • Oligonucleotides targeting position 55337-136214 of SEQ ID NO: 1 were tested in patient derived human neuronal cell cultures (see protocol in “Materials and methods” section).
  • the oligonucleotides ability to reduce the SNHG14 transcript in the region downstream of SNORD109B also termed UBE3A suppressor or UBE3A-SUP in the data table.
  • UBE3A-SUP UBE3A suppressor
  • oligonucleotides were screened according to the protocol for screening oligonucleotides in human neuronal cell cultures described in the section “Materials and methods”—“Screening oligonucleotides in human neuronal cell cultures—96 well system”.
  • Example 5 Activity of Oligonucleotides Targeting the SNHG14 Transcript in the Region Downstream of SNORD109B and Upstream of the Region Antisense to the UBE3A Pre-mRNA
  • Oligonucleotides targeting position 5224-51257 of SEQ ID NO: 1 were tested in patient derived human neuronal cell cultures (see protocol in “Materials and methods” section).
  • the oligonucleotides ability to reduce the SNHG14 transcript in the region downstream of SNORD109B also termed UBE3A suppressor or UBE3A-SUP in the data table.
  • UBE3A-SUP also termed UBE3A suppressor
  • oligonucleotides were screened according to the protocol for screening oligonucleotides in human neuronal cell cultures described in the section “Materials and methods” “Screening oligonucleotides in human neuronal cell cultures—96 well system” with the following modifications:
  • Each plate include PBS controls (instead on a non-targeting ologinucleotide) and a positive control oligonucleotide CMP ID NO: 271_1, resulting in up-regulation of UBE3A mRNA.
  • the additional control oligonucleotides were not included.
  • Oligonucleotides designed to be complementary across exon-exon junctions of SNHG14-023 were tested for their ability to reduce the SNHG14 transcript in the region downstream of SNORD109B (also termed UBE3A suppressor or UBE3A-SUP in the data table). Furthermore, the ability to induce UBE3A mRNA re-expression was analyzed. The oligonucleotides primarily span exon2 and exon3 (i.e. are complementary to a region in exon2 and a region in exon 3).
  • oligonucleotides were screened according to the protocol for screening oligonucleotides in human neuronal cell cultures described in the section Example 5.
  • oligonucleotides were selected for potency and efficacy testing.
  • oligonucleotides were screened in human AS patient derived cells as described in the Materials and Method section “Screening oligonucleotides in human neuronal cell cultures—96 well system” with the following modifications:
  • Each plate include PBS controls (instead on a non-targeting oligonucleotide) and the positive control oligonucleotides CMP ID NO: 186_1 and 39_1 identified in previous screens were included. The additional control oligonucleotides described in the materials and method section were not included. Oligonucleotide test concentrations were from 31.6 ⁇ M to 1 nM using a 10 point half-log dilution. All oligonucleotides were tested in 5 independent experiments in 5 different weeks. In the data QC process some plates were removed from the analysis if these were obvious outliers e.g. no PCR product detected. After this filtration there is a minimum of three independent experiments behind each the reported values.
  • the EC50 (UBE3A mRNA re-expression) and IC50 (reduction of the SNHG14 transcript in the region downstream of SNORD109B, also termed UBE3A suppressor or UBE3A-SUP in the data table) were determined after curve fitting using a 4 parameter sigmoidal dose-response model. Fitting was executed using the fit engine available inside the Biobook software by IDBS (XLfit). From the curve-fitting the maximum obtainable up-regulation of UBE3A (UBE3A Max Up) and the maximum obtainable knockdown of UBE3A-SUP (UBE3A-SUP max Kd) were determined. Both are shown as % of control (PBS treated cells). The results are shown in table 10, values are reported as geometric means of each biological replicate.

Abstract

The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

Description

    PRIORITY INFORMATION
  • This application is a continuation and claims priority to PCT/EP2016/077383, filed Nov. 11, 2016, which claims priority to EP15194367.7, filed Nov. 12, 2015 and EP161895024, filed Sep. 19, 2016. The contents of which are hereby incorporated by reference.
  • FIELD OF INVENTION
  • The present invention relates to oligonucleotides (oligomers) that are complementary to and hybridize to SNHG14 downstream of SNORD109B, leading to induction of paternal expression of Ubiquitin-protein ligase E3A (UBE3A) in an animal or human. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
  • BACKGROUND
  • Angelman syndrome is neuro-genetic disorder caused by deletion or inactivation of the UBE3A genes on the maternally inherited chromosome 15q11.2. The paternal copy of the UBE3A gene is subject to genomic imprinting and silencing in neurons by an endogenous antisense transcript of UBE3A, termed SNHG14 (also known as UBE3A-ATS) (Meng et al. 2012 Hum Mol Genet. Vol. 21 pp. 3001-12). Other cell types than neurons seem to express the UBE3A gene from both the maternal and paternal allele.
  • Angelman syndrome is characterized by severe intellectual and developmental disability, sleep disturbance, seizures, jerky movements, EEG abnormalities, frequent laughter or smiling, and profound language impairments.
  • WO 2012/064806 discloses a method of inducing UBE3A expression in a cell by using a topoisomerase inhibitor. The method can be used to treat Angelman syndrome. There is no disclosure of antisense oligonucleotides.
  • WO 2014/004572 discloses oligonucleotides with 2′-O-methoxyethyl-RNA (MOE) modifications targeting mouse UBE3A-ATS. The oligonucleotides are only tested in mice related assays. In the region downstream of MBII-52 snoRNA (also known as SNORD115) and upstream of the UBE3A pre-mRNA there is no conservation between mouse and human. Oligonucleotides targeting mouse UBE3A-ATS can therefore not be translated into oligonucleotides that will function in a human. There is no disclosure of oligonucleotides targeting human UBE3A-ATS.
  • OBJECTIVE OF THE INVENTION
  • The present invention identifies novel oligonucleotides which induce human paternal UBE3A expression in neuronal without affection expression of the paternal SNORD115, SNORD116 and SNRPN transcripts significantly.
  • SUMMARY OF INVENTION
  • The present invention relates to oligonucleotides targeting a nucleic acid capable of suppressing the expression of UBE3A and to treat or prevent diseases related to decreased activity of UBE3A, in particular in neuronal cells.
  • Accordingly, in a first aspect the invention provides oligonucleotides which comprise a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 98% complementarity to the part of human SNHG14 long non-coding RNA corresponding to position 25278410 to 25419462 on human chromosome 15 version GRCh38.p2. This region is also resembled by SEQ ID NO: 1. The oligonucleotide can be an antisense oligonucleotide, preferably with a gapmer design. Preferably, the oligonucleotide is capable of inducing the expression of UBE3A, in particular paternal UBE3A expression in a neuron, by degradation, reduction or removal of the UBE3A suppressor, in particular by reduction of the SNHG14 long non-coding RNA transcript downstream of SNORD109B. The UBE3A re-expression is achieved, without significantly affecting the expression of SNORD115. The degradation of the target nucleic acid is preferably achieved via nuclease recruitment.
  • In a further aspect, the invention provides pharmaceutical compositions comprising the oligonucleotides of the invention and pharmaceutically acceptable diluents, carriers, salts and/or adjuvants.
  • In a further aspect, the invention provides methods for in vivo or in vitro induction of UBE3A expression in a target cell where expression of paternal UBE3A is suppressed, by administering an oligonucleotide or composition of the invention in an effective amount to said cell.
  • In a further aspect the invention provides methods for treating or preventing a disease, disorder or dysfunction associated with in vivo activity of UBE3A comprising administering a therapeutically or prophylactically effective amount of the oligonucleotide of the invention to a subject suffering from or susceptible to the disease, disorder or dysfunction.
  • In a further aspect the oligonucleotide or composition of the invention is used for the treatment or prevention of Angelman syndrome.
  • BRIEF DESCRIPTION OF FIGURES
  • FIG. 1: The upper strand illustrates the region of the SNHG14 transcript downstream of SNORD109B (UBE3A-ATS) where the black boxes indicate the location of the tested mouse oligonucleotides. The lower strand illustrates the UBE3A coding region, where the black boxes indicate exons. Exon 1 is located around 160 kb. The oligonucleotides are placed in the antisense region of Exon 9 (positioned at ˜97 kb), Exon 10 (positioned at ˜92 kb), Exon 13 (positioned at ˜77 kb) and the 5′ end of Exon 16 (positioned at ˜60 kb).
  • FIG. 2: Representation of the ability of the oligonucleotides, tested in Example 2, to induce re-expression of UBE3A in human neuronal cell cultures. Oligonucleotides complementary to the region of human SNHG14 long non-coding RNA between SNORD109B and the region upstream of the UBE3A coding region (position 1 to 55318 of SEQ ID NO: 1) are indicated with  nonoverlap. Oligonucleotides complementary to the region of human SNHG14 long non-coding RNA which is antisense to the UBE3A pre-mRNA (position 55319 to 141053 of SEQ ID NO: 1) are indicated with ▴ overlap. Oligonucleotides from Table 3 with conservation to human and rhesus monkey are indicated at the bottom of each plot as
    Figure US20170191064A1-20170706-P00001
    . Conservation between human:rhesus:mouse is indicated by
    Figure US20170191064A1-20170706-P00002
    . The oligonucleotide concentrations were 0.2, 1 and 5 microM as indicated in the right hand side each plot.
  • DEFINITIONS Oligonucleotide
  • The term “oligonucleotide” as used herein is defined as it is generally understood by the skilled person as a molecule comprising two or more covalently linked nucleosides. Such covalently bound nucleosides may also be referred to as nucleic acid molecules or oligomers. Oligonucleotides are commonly made in the laboratory by solid-phase chemical synthesis followed by purification. When referring to a sequence of the oligonucleotide, reference is made to the sequence or order of nucleobase moieties, or modifications thereof, of the covalently linked nucleotides or nucleosides. The oligonucleotide of the invention is man-made, and is chemically synthesized, and is typically purified or isolated. The oligonucleotide of the invention may comprise one or more modified nucleosides or nucleotides.
  • Antisense Oligonucleotides
  • The term “Antisense oligonucleotide” as used herein is defined as oligonucleotides capable of modulating expression of a target gene by hybridizing to a target nucleic acid, in particular to a contiguous sequence on a target nucleic acid. The antisense oligonucleotides are not essentially double stranded and are therefore not siRNAs. Preferably, the antisense oligonucleotides of the present invention are single stranded.
  • Contiguous Nucleotide Sequence
  • The term “contiguous nucleotide sequence” refers to the region of the oligonucleotide which is complementary to the target nucleic acid. The term is used interchangeably herein with the term “contiguous nucleobase sequence” and the term “oligonucleotide motif sequence”. In some embodiments all the nucleotides of the oligonucleotide are present in the contiguous nucleotide sequence. In some embodiments the oligonucleotide comprises the contiguous nucleotide sequence and may, optionally comprise further nucleotide(s), for example a nucleotide linker region which may be used to attach a functional group to the contiguous nucleotide sequence. The nucleotide linker region may or may not be complementary to the target nucleic acid.
  • Nucleotides
  • Nucleotides are the building blocks of oligonucleotides and polynucleotides, and for the purposes of the present invention include both naturally occurring and non-naturally occurring nucleotides. In nature, nucleotides, such as DNA and RNA nucleotides comprise a ribose sugar moiety, a nucleobase moiety and one or more phosphate groups (which is absent in nucleosides). Nucleosides and nucleotides may also interchangeably be referred to as “units” or “monomers”.
  • Modified Nucleoside
  • The term “modified nucleoside” or “nucleoside modification” as used herein refers to nucleosides modified as compared to the equivalent DNA or RNA nucleoside by the introduction of one or more modifications of the sugar moiety or the (nucleo)base moiety. In a preferred embodiment the modified nucleoside comprises a modified sugar moiety. The term modified nucleoside may also be used herein interchangeably with the term “nucleoside analogue” or modified “units” or modified “monomers”.
  • Modified Internucleoside Linkage
  • The term “modified internucleoside linkage” is defined as generally understood by the skilled person as linkages other than phosphodiester (PO) linkages, that covalently couples two nucleosides together. Nucleotides with modified internucleoside linkage are also termed “modified nucleotides”. In some embodiments, the modified internucleoside linkage increases the nuclease resistance of the oligonucleotide compared to a phosphodiester linkage. For naturally occurring oligonucleotides, the internucleoside linkage includes phosphate groups creating a phosphodiester bond between adjacent nucleosides. Modified internucleoside linkages are particularly useful in stabilizing oligonucleotides for in vivo use, and may serve to protect against nuclease cleavage at regions of DNA or RNA nucleosides in the oligonucleotide of the invention, for example within the gap region of a gapmer oligonucleotide, as well as in regions of modified nucleosides.
  • In an embodiment, the oligonucleotide comprises one or more internucleoside linkages modified from the natural phosphodiester to a linkage that is for example more resistant to nuclease attack. Nuclease resistance may be determined by incubating the oligonucleotide in blood serum or by using a nuclease resistance assay (e.g. snake venom phosphodiesterase (SVPD)), both are well known in the art. Internucleoside linkages which are capable of enhancing the nuclease resistance of an oligonucleotide are referred to as nuclease resistant internucleoside linkages. In preferred embodiments at least 50% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are modified, such as at least 60%, such as at least 70%, such as at least 80 or such as at least 90% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are modified. In some embodiments all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are modified. It will be recognized that, in some embodiments the nucleosides which link the oligonucleotide of the invention to a non-nucleotide functional group, such as a conjugate, may be phosphodiester. In some embodiments all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are nuclease resistant internucleoside linkages.
  • Modified internucleoside linkages may be selected from the group comprising phosphorothioate, diphosphorothioate and boranophosphate. In preferred embodiments, the modified internucleoside linkages are compatible with the RNaseH recruitment of the oligonucleotide of the invention, for example phosphorothioate, diphosphorothioate or boranophosphate.
  • In some embodiments the internucleoside linkage comprises sulphur (S), such as a phosphorothioate internucleoside linkage.
  • A phosphorothioate internucleoside linkage is particularly useful due to nuclease resistance, beneficial pharmakokinetics and ease of manufacture. In preferred embodiments at least 50% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate, such as at least 60%, such as at least 70%, such as at least 80 or such as at least 90% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate. In some embodiments all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate.
  • In some embodiments, the oligonucleotide comprises one or more neutral internucleoside linkage, particularly a internucleoside linkage selected from phosphotriester, methylphosphonate, MMI, amide-3, formacetal or thioformacetal.
  • Further internucleoside linkages are disclosed in WO2009/124238 (incorporated herein by reference). In an embodiment the internucleoside linkage is selected from linkers disclosed in WO2007/031091 (incorporated herein by reference). Particularly, the internucleoside linkage may be selected from —O—P(O)2—O—, —O—P(O,S)—O—, —O—P(S)2—O—, —S—P(O)2—O—, —S—P(O,S)—O—, —S—P(S)2—O—, —O—P(O)2—S—, —O—P(O,S)—S—, —S—P(O)2—S—, —O—PO(RH)—O—, 0-PO(OCH3)-0-, —O—PO(NRH)—O—, —O—PO(OCH2CH2S—R)—O—, —O—PO(BH3)—O—, —O—PO(NHRH)—O—, —O—P(O)2—NRH—, —NRH—P(O)2—O—, —NRH—CO—O—, —NRH—CO—NRH—, and/or the internucleoside linker may be selected form the group consisting of: —O—CO—O—, —O—CO—NRH—, —NRH—CO—CH2—, —O—CH2—CO—NRH—, —O—CH2—CH2—NRH—, CO—NRH—CH2—, —CH2—NRHCO—, —O—CH2—CH2—S—, —S—CH2—CH2—O—, —S—CH2—CH2—S—, —CH2—SO2—CH2—, —CH2—CO—NRH—, —O—CH2—CH2—NRH—CO—, —CH2—NCH3—O—CH2—, where RH is selected from hydrogen and C1-4-alkyl.
  • Nuclease resistant linkages, such as phosphothioate linkages, are particularly useful in oligonucleotide regions capable of recruiting nuclease when forming a duplex with the target nucleic acid, such as region G for gapmers, or the non-modified nucleoside region of headmers and tailmers. Phosphorothioate linkages may, however, also be useful in non-nuclease recruiting regions and/or affinity enhancing regions such as regions F and F′ for gapmers, or the modified nucleoside region of headmers and tailmers.
  • Each of the design regions may however comprise internucleoside linkages other than phosphorothioate, such as phosphodiester linkages, in particularly in regions where modified nucleosides, such as LNA, protect the linkage against nuclease degradation. Inclusion of phosphodiester linkages, such as one or two linkages, particularly between or adjacent to modified nucleoside units (typically in the non-nuclease recruiting regions) can modify the bioavailability and/or bio-distribution of an oligonucleotide—see WO2008/113832, incorporated herein by reference.
  • In an embodiment all the internucleoside linkages in the oligonucleotide are phosphorothioate and/or boranophosphate linkages. Preferably, all the internucleoside linkages in the oligonucleotide are phosphorothioate linkages.
  • Nucleobase
  • The term nucleobase includes the purine (e.g. adenine and guanine) and pyrimidine (e.g. uracil, thymine and cytosine) moiety present in nucleosides and nucleotides which form hydrogen bonds in nucleic acid hybridization. In the context of the present invention the term nucleobase also encompasses modified nucleobases which may differ from naturally occurring nucleobases, but are functional during nucleic acid hybridization. In this context “nucleobase” refers to both naturally occurring nucleobases such as adenine, guanine, cytosine, thymidine, uracil, xanthine and hypoxanthine, as well as non-naturally occurring variants. Such variants are for example described in Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1.
  • In a some embodiments the nucleobase moiety is modified by changing the purine or pyrimidine into a modified purine or pyrimidine, such as substituted purine or substituted pyrimidine, such as a nucleobased selected from isocytosine, pseudoisocytosine, 5-methyl cytosine, 5-thiozolo-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil 5-thiazolo-uracil, 2-thio-uracil, 2′thio-thymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine and 2-chloro-6-aminopurine.
  • The nucleobase moieties may be indicated by the letter code for each corresponding nucleobase, e.g. A, T, G, C or U, wherein each letter may optionally include modified nucleobases of equivalent function. For example, in the exemplified oligonucleotides, the nucleobase moieties are selected from A, T, G, C, and 5-methyl cytosine. Optionally, for LNA gapmers, 5-methyl cytosine LNA nucleosides may be used.
  • Modified Oligonucleotide
  • The term modified oligonucleotide describes an oligonucleotide comprising one or more sugar-modified nucleosides and/or modified internucleoside linkages. The term chimeric” oligonucleotide is a term that has been used in the literature to describe oligonucleotides with modified nucleosides.
  • Complementarity
  • The term complementarity describes the capacity for Watson-Crick base-pairing of nucleosides/nucleotides. Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A)-thymine (T)/uracil (U). It will be understood that oligonucleotides may comprise nucleosides with modified nucleobases, for example 5-methyl cytosine is often used in place of cytosine, and as such the term complementarity encompasses Watson Crick base-paring between non-modified and modified nucleobases (see for example Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1).
  • The term “% complementary” as used herein, refers to the number of nucleotides in percent of a contiguous nucleotide sequence in a nucleic acid molecule (e.g. oligonucleotide) which, at a given position, are complementary to (i.e. form Watson Crick base pairs with) a contiguous nucleotide sequence, at a given position of a separate nucleic acid molecule (e.g. the target nucleic acid). The percentage is calculated by counting the number of aligned bases that form pairs between the two sequences, dividing by the total number of nucleotides in the oligonucleotide and multiplying by 100. In such a comparison a nucleobase/nucleotide which does not align (form a base pair) is termed a mismatch.
  • The term “fully complementary”, refers to 100% complementarity.
  • Hybridization
  • The term “hybridizing” or “hybridizes” as used herein is to be understood as two nucleic acid strands (e.g. an oligonucleotide and a target nucleic acid) forming hydrogen bonds between base pairs on opposite strands thereby forming a duplex. The affinity of the binding between two nucleic acid strands is the strength of the hybridization. It is often described in terms of the melting temperature (Tm) defined as the temperature at which half of the oligonucleotides are duplexed with the target nucleic acid. At physiological conditions Tm is not strictly proportional to the affinity (Mergny and Lacroix, 2003, Oligonucleotides 13:515-537). The standard state Gibbs free energy ΔG° is a more accurate representation of binding affinity and is related to the dissociation constant (Kd) of the reaction by ΔG°=−RTln(Kd), where R is the gas constant and T is the absolute temperature. Therefore, a very low ΔG° of the reaction between an oligonucleotide and the target nucleic acid reflects a strong hybridization between the oligonucleotide and target nucleic acid. ΔG° is the energy associated with a reaction where aqueous concentrations are 1M, the pH is 7, and the temperature is 37° C. The hybridization of oligonucleotides to a target nucleic acid is a spontaneous reaction and for spontaneous reactions ΔG° is less than zero. ΔG° can be measured experimentally, for example, by use of the isothermal titration calorimetry (ITC) method as described in Hansen et al., 1965, Chem. Comm. 36-38 and Holdgate et al., 2005, Drug Discov Today. The skilled person will know that commercial equipment is available for ΔG° measurements. ΔG° can also be estimated numerically by using the nearest neighbor model as described by SantaLucia, 1998, Proc Natl Acad Sci USA. 95: 1460-1465 using appropriately derived thermodynamic parameters described by Sugimoto et al., 1995, Biochemistry 34:11211-11216 and McTigue et al., 2004, Biochemistry 43:5388-5405. In order to have the possibility of modulating its intended nucleic acid target by hybridization, oligonucleotides of the present invention hybridize to a target nucleic acid with estimated ΔG° values below −10 kcal for oligonucleotides that are 10-30 nucleotides in length. In some embodiments the degree or strength of hybridization is measured by the standard state Gibbs free energy ΔG°. The oligonucleotides may hybridize to a target nucleic acid with estimated ΔG° values below the range of −10 kcal, such as below −15 kcal, such as below −20 kcal and such as below −25 kcal for oligonucleotides that are 8-30 nucleotides in length. In some embodiments the oligonucleotides hybridize to a target nucleic acid with an estimated ΔG° value of −10 to −60 kcal, such as −12 to −40, such as from −15 to −30 kcal or −16 to −27 kcal such as −18 to −25 kcal.
  • The Target
  • The target refers to the protein which it is desired to modulate.
  • Target Nucleic Acid
  • A target nucleic acid is the intended target which the oligonucleotide of the invention hybridizes to, and may for example be a gene, a RNA, a non-coding RNA, a long non-coding RNA, a mRNA, and pre-mRNA, a mature mRNA or a cDNA sequence. In some embodiments the target nucleic acid is a non-coding RNA or a long non-coding RNA, or a subsequence thereof. For in vivo or in vitro application, the oligonucleotide of the invention is capable of decreasing the level of the SNHG14 transcript downstream of SNORD109B of and thereby relieving the suppression of the paternal UBE3A transcript in the intended target cell. The contiguous sequence of nucleobases of the oligonucleotide of the invention is complementary to the target nucleic acid, as measured across the length of the oligonucleotide, optionally with the exception of one or two mismatches, and optionally excluding nucleotide based linker regions which may link the oligonucleotide to an optional functional group such as a conjugate.
  • Target Sequence
  • The oligonucleotide comprises a contiguous nucleotide sequence which is complementary to or hybridizes to a sub-sequence of the target nucleic acid molecule. The term “target sequence” as used herein refers to a sequence of nucleotides present in the target nucleic acid which comprises the nucleobase sequence which is complementary to the oligonucleotide of the invention. In some embodiments, the target sequence consists of a region on the target nucleic acid which is complementary to the contiguous nucleotide sequence of the oligonucleotide of the invention. In some embodiments the target sequence is longer than the complementary sequence of a single oligonucleotide, and may, for example represent a preferred region of the target nucleic acid which may be targeted by several oligonucleotides of the invention.
  • The oligonucleotide of the invention comprises a contiguous nucleotide sequence which is complementary to the target nucleic acid, such as a target sequence.
  • The oligonucleotide comprises a contiguous nucleotide sequence of at least 8 nucleotides which is complementary to or hybridizes to a target sequence present in the target nucleic acid molecule. The contiguous nucleotide sequence (and therefore the target sequence) comprises of at least 8 contiguous nucleotides, such as 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleotides, such as from 12-25, such as from 14-18 contiguous nucleotides.
  • Target Cell
  • The term a target cell as used herein refers to a cell which is expressing the target nucleic acid. In some embodiments the target cell may be in vivo or in vitro. In some embodiments the target cell is a mammalian cell such as a rodent cell, such as a mouse cell or a rat cell, or a primate cell such as a monkey cell or a human cell. In preferred embodiments the target cell is a neuronal cell.
  • Naturally Occurring Variant
  • The term “naturally occurring variant” refers to variants of SNHG14 transcript downstream of SNORD109B gene or transcripts which originate from the same genetic loci as the target nucleic acid, but may differ for example, by virtue of degeneracy of the genetic code causing a multiplicity of codons in the long non-coding RNA. The oligonucleotide of the invention may therefore be designed to target the target nucleic acid and naturally occurring variants thereof.
  • Modulation of Expression
  • The term “modulation of expression” as used herein is to be understood as an overall term for an oligonucleotide's ability to alter the amount of UBE3A protein when compared to the amount of UBE3A before administration of the oligonucleotide. Alternatively modulation of expression may be determined by reference to a control experiment where the oligonucleotide of the invention is not administered. The modulation effected by the oligonucleotide is related to it's ability to reduce, remove, prevent, lessen, lower or terminate the suppression of the paternal UBE3A transcript, e.g. by degradation or removal of the non-coding SNHG14 transcript downstream of SNORD109B or by blockage or prevention of polymerase activity associated with the SNHG14 transcript downstream of SNORD109B. The modulation can also be viewed as the oligonucleotide's ability to restore, increase or enhance expression of paternal UBE3A, e.g. by removal or blockage of inhibitory mechanisms affected by the non-coding SNHG14 transcript downstream of SNORD109B.
  • High Affinity Modified Nucleosides
  • A high affinity modified nucleoside is a modified nucleotide which, when incorporated into the oligonucleotide enhances the affinity of the oligonucleotide for its complementary target, for example as measured by the melting temperature (Tm). A high affinity modified nucleoside of the present invention preferably result in an increase in melting temperature between +0.5 to +12° C., more preferably between +1.5 to +10° C. and most preferably between +3 to +8° C. per modified nucleoside. Numerous high affinity modified nucleosides are known in the art and include for example, many 2′ substituted nucleosides as well as locked nucleic acids (LNA) (see e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213).
  • Sugar Modifications
  • The oligomer of the invention may comprise one or more nucleosides which have a modified sugar moiety, i.e. a modification of the sugar moiety when compared to the ribose sugar moiety found in DNA and RNA.
  • Numerous nucleosides with modification of the ribose sugar moiety have been made, primarily with the aim of improving certain properties of oligonucleotides, such as affinity and/or nuclease resistance.
  • Such modifications include those where the ribose ring structure is modified, e.g. by replacement with a hexose ring (HNA), or a bicyclic ring, which typically have a biradicle bridge between the C2 and C4 carbons on the ribose ring (LNA), or an unlinked ribose ring which typically lacks a bond between the C2 and C3 carbons (e.g. UNA). Other sugar modified nucleosides include, for example, bicyclohexose nucleic acids (WO2011/017521) or tricyclic nucleic acids (WO2013/154798). Modified nucleosides also include nucleosides where the sugar moiety is replaced with a non-sugar moiety, for example in the case of peptide nucleic acids (PNA), or morpholino nucleic acids.
  • Sugar modifications also include modifications made via altering the substituent groups on the ribose ring to groups other than hydrogen, or the 2′-OH group naturally found in DNA and RNA nucleosides. Substituents may, for example be introduced at the 2′, 3′, 4′ or 5′ positions. Nucleosides with modified sugar moieties also include 2′ modified nucleosides, such as 2′ substituted nucleosides. Indeed, much focus has been spent on developing 2′ substituted nucleosides, and numerous 2′ substituted nucleosides have been found to have beneficial properties when incorporated into oligonucleotides, such as enhanced nucleoside resistance and enhanced affinity.
  • 2′ Modified Nucleosides.
  • A 2′ sugar modified nucleoside is a nucleoside which has a substituent other than H or —OH at the 2′ position (2′ substituted nucleoside) or comprises a 2′ linked biradicle, and includes 2′ substituted nucleosides and LNA (2′-4′ biradicle bridged) nucleosides. For example, the 2′ modified sugar may provide enhanced binding affinity and/or increased nuclease resistance to the oligonucleotide. Examples of 2′ substituted modified nucleosides are 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA (MOE), 2′-amino-DNA, 2′-Fluoro-RNA, and 2′-fluoro-ANA (F-ANA). For further examples, please see e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213; and Deleavey and Damha, Chemistry and Biology 2012, 19, 937. Below are illustrations of some 2′ substituted modified nucleosides.
  • Figure US20170191064A1-20170706-C00001
  • Locked Nucleic Acid Nucleosides (LNA).
  • LNA nucleosides are modified nucleosides which comprise a linker group (referred to as a biradicle or a bridge) between C2′ and C4′ of the ribose sugar ring of a nucleotide. These nucleosides are also termed bridged nucleic acid or bicyclic nucleic acid (BNA) in the literature.
  • In some embodiments, the modified nucleoside or the LNA nucleosides of the oligomer of the invention has a general structure of the formula I or II:
  • Figure US20170191064A1-20170706-C00002
  • wherein W is selected from —O—, —S—, —N(Ra)—, —C(RaRb)—, such as, in some embodiments —O—;
    B designates a nucleobase or modified nucleobase moiety;
    Z designates an internucleoside linkage to an adjacent nucleoside, or a 5′-terminal group;
    Z* designates an internucleoside linkage to an adjacent nucleoside, or a 3′-terminal group;
    X designates a group selected from the list consisting of —C(RaRb)—, —C(Ra)═C(Rb)—, —C(Ra)═N—, —O—, —Si(Ra)2—, —S—, —SO2—, —N(Ra)—, and >C═Z
      • In some embodiments, X is selected from the group consisting of: —O—, —S—, NH—, NRaRb, —CH2—, CRaRb, —C(═CH2)—, and —C(═CRaRb)—
      • In some embodiments, X is —O—
        Y designates a group selected from the group consisting of —C(RaRb)—, —C(Ra)═C(Rb)—, —C(Ra)═N—, —O—, —Si(Ra)2—, —S—, —SO2—, —N(Ra)—, and >C═Z
      • In some embodiments, Y is selected from the group consisting of: —CH2—, —C(RaRb)—, —CH2CH2—, —C(RaRb)—C(RaRb)—, —CH2CH2CH2—, —C(RaRb)C(RaRb)C(RaRb)—, —C(Ra)═C(Rb)—, and —C(Ra)═N—
      • In some embodiments, Y is selected from the group consisting of: —CH2—, —CHRa—, —CHCH3—, CRaRb
        or —X—Y— together designate a bivalent linker group (also referred to as a radical) together designate a bivalent linker group consisting of 1, 2, 3 or 4 groups/atoms selected from the group consisting of —C(RaRb)—, —C(Ra)═C(Rb)—, —C(Ra)═N—, —O—, —Si(Ra)2—, —S—, —SO2—, —N(Ra)—, and >C═Z,
      • In some embodiments, —X—Y— designates a biradicle selected from the groups consisting of: —X—CH2—, —X—CRaRb—, —X—CHRa—, —X—C(HCH3)—, —O—Y—, —O—CH2—, —S—CH2—, —NH—CH2—, —O—CHCH3—, —CH2—O—CH2, —O—CH(CH3CH3)—, —O—CH2—CH2—, OCH2—CH2—CH2—, —O—CH2OCH2—, —O—NCH2—, —C(═CH2)—CH2—, —NRa—CH2—, N—O—CH2, —S—CRaRb— and —S—CHRa—.
      • In some embodiments —X—Y— designates —O—CH2— or —O—CH(CH3)—.
        wherein Z is selected from —O—, —S—, and —N(Ra)—,
        and Ra and, when present Rb, each is independently selected from hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, hydroxy, optionally substituted C1-6-alkoxy, C2-6-alkoxyalkyl, C2-6-alkenyloxy, carboxy, C1-6-alkoxycarbonyl, C1-6-alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C1-6-alkyl)amino, carbamoyl, mono- and di(C1-6-alkyl)-amino-carbonyl, amino-C1-6-alkyl-aminocarbonyl, mono- and di(C1-6-alkyl)amino-C1-6-alkyl-aminocarbonyl, C1-6-alkyl-carbonylamino, carbamido, C1-6-alkanoyloxy, sulphono, C1-6-alkylsulphonyloxy, nitro, azido, sulphanyl, C1-6-alkylthio, halogen, where aryl and heteroaryl may be optionally substituted and where two geminal substituents Ra and Rb together may designate optionally substituted methylene (═CH2), wherein for all chiral centers, asymmetric groups may be found in either R or S orientation.
        wherein R1, R2, R3, R5 and R5* are independently selected from the group consisting of: hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, hydroxy, C1-6-alkoxy, C2-6-alkoxyalkyl, C2-6-alkenyloxy, carboxy, C1-6-alkoxycarbonyl, C1-6-alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C1-6-alkyl)amino, carbamoyl, mono- and di(C1-6-alkyl)-amino-carbonyl, amino-C1-6-alkyl-aminocarbonyl, mono- and di(C1-6-alkyl)amino-C1-6-alkyl-aminocarbonyl, C1-6-alkyl-carbonylamino, carbamido, C1-6-alkanoyloxy, sulphono, C1-6-alkylsulphonyloxy, nitro, azido, sulphanyl, C1-6-alkylthio, halogen, where aryl and heteroaryl may be optionally substituted, and where two geminal substituents together may designate oxo, thioxo, imino, or optionally substituted methylene.
      • In some embodiments R1, R2, R3, R5 and R5* are independently selected from C1-6 alkyl, such as methyl, and hydrogen.
      • In some embodiments R1, R2, R3, R5 and R5* are all hydrogen.
      • In some embodiments R1, R2, R3, are all hydrogen, and either R5 and R5* is also hydrogen and the other of R5 and R5* is other than hydrogen, such as C1-6 alkyl such as methyl.
      • In some embodiments, Ra is either hydrogen or methyl. In some embodiments, when present, Rb is either hydrogen or methyl.
      • In some embodiments, one or both of Ra and Rb is hydrogen
      • In some embodiments, one of Ra and Rb is hydrogen and the other is other than hydrogen
      • In some embodiments, one of Ra and Rb is methyl and the other is hydrogen
      • In some embodiments, both of Ra and Rb are methyl.
  • In some embodiments, the biradicle —X—Y— is —O—CH2—, W is O, and all of R1, R2, R3, R5 and R5* are all hydrogen. Such LNA nucleosides are disclosed in WO99/014226, WO00/66604, WO98/039352 and WO2004/046160 which are all hereby incorporated by reference, and include what are commonly known as beta-D-oxy LNA and alpha-L-oxy LNA nucleosides.
  • In some embodiments, the biradicle —X—Y— is —S—CH2—, W is O, and all of R1, R2, R3, R5 and R5* are all hydrogen. Such thio LNA nucleosides are disclosed in WO99/014226 and WO2004/046160 which are hereby incorporated by reference.
  • In some embodiments, the biradicle —X—Y— is —NH—CH2—, W is O, and all of R1, R2, R3, R5 and R5* are all hydrogen. Such amino LNA nucleosides are disclosed in WO99/014226 and WO2004/046160 which are hereby incorporated by reference.
  • In some embodiments, the biradicle —X—Y— is —O—CH2—CH2— or —O—CH2—CH2—CH2—, W is O, and all of R1, R2, R3, R5 and R5* are all hydrogen. Such LNA nucleosides are disclosed in WO00/047599 and Morita et al, Bioorganic & Med. Chem. Lett. 12 73-76, which are hereby incorporated by reference, and include what are commonly known as 2′-O-4′C-ethylene bridged nucleic acids (ENA).
  • In some embodiments, the biradicle —X—Y— is —O—CH2—, W is O, and all of R1, R2, R3, and one of R5 and R5* are hydrogen, and the other of R5 and R5* is other than hydrogen such as C1-6 alkyl, such as methyl. Such 5′ substituted LNA nucleosides are disclosed in WO2007/134181 which is hereby incorporated by reference.
  • In some embodiments, the biradicle —X—Y— is —O—CRaRb—, wherein one or both of Ra and Rb are other than hydrogen, such as methyl, W is O, and all of R1, R2, R3, and one of R5 and R5* are hydrogen, and the other of R5 and R5* is other than hydrogen such as C1-6 alkyl, such as methyl. Such bis modified LNA nucleosides are disclosed in WO2010/077578 which is hereby incorporated by reference.
  • In some embodiments, the biradicle —X—Y— designate the bivalent linker group —O—CH(CH2OCH3)— (2′ O-methoxyethyl bicyclic nucleic acid—Seth at al., 2010, J. Org. Chem. Vol 75(5) pp. 1569-81). In some embodiments, the biradicle —X—Y— designate the bivalent linker group —O—CH(CH2CH3)-(2′O-ethyl bicyclic nucleic acid—Seth at al., 2010, J. Org. Chem. Vol 75(5) pp. 1569-81). In some embodiments, the biradicle —X—Y— is —O—CHRa—, W is O, and all of R1, R2, R3, R5 and R5* are all hydrogen. Such 6′ substituted LNA nucleosides are disclosed in WO10036698 and WO07090071 which are both hereby incorporated by reference.
  • In some embodiments, the biradicle —X—Y— is —O—CH(CH2OCH3)—, W is O, and all of R1, R2, R3, R5 and R5* are all hydrogen. Such LNA nucleosides are also known as cyclic MOEs in the art (cMOE) and are disclosed in WO07090071.
  • In some embodiments, the biradicle —X—Y— designate the bivalent linker group —O—CH(CH3)—.—in either the R- or S-configuration. In some embodiments, the biradicle —X—Y— together designate the bivalent linker group —O—CH2—O—CH2— (Seth at al., 2010, J. Org. Chem). In some embodiments, the biradicle —X—Y— is —O—CH(CH3)—, W is O, and all of R1, R2, R3, R5 and R5* are all hydrogen. Such 6′ methyl LNA nucleosides are also known as cET nucleosides in the art, and may be either (S)cET or (R)cET stereoisomers, as disclosed in WO07090071 (beta-D) and WO2010/036698 (alpha-L) which are both hereby incorporated by reference).
  • In some embodiments, the biradicle —X—Y— is —O—CRaRb—, wherein in neither Ra or Rb is hydrogen, W is O, and all of R1, R2, R3, R5 and R5* are all hydrogen. In some embodiments, Ra and Rb are both methyl. Such 6′ di-substituted LNA nucleosides are disclosed in WO 2009006478 which is hereby incorporated by reference.
  • In some embodiments, the biradicle —X—Y— is —S—CHRa—, W is O, and all of R1, R2, R3, R5 and R5* are all hydrogen. Such 6′ substituted thio LNA nucleosides are disclosed in WO11156202 which is hereby incorporated by reference. In some 6′ substituted thio LNA embodiments Ra is methyl.
  • In some embodiments, the biradicle —X—Y— is —C(═CH2)—C(RaRb)—, such as —C(═CH2)—CH2—, or —C(═CH2)—CH(CH3)—W is O, and all of R1, R2, R3, R5 and R5* are all hydrogen. Such vinyl carbo LNA nucleosides are disclosed in WO08154401 and WO09067647 which are both hereby incorporated by reference.
  • In some embodiments the biradicle —X—Y— is —N(—ORa)—, W is O, and all of R1, R2, R3, R5 and R5* are all hydrogen. In some embodiments Ra is C1-6 alkyl such as methyl. Such LNA nucleosides are also known as N substituted LNAs and are disclosed in WO2008/150729 which is hereby incorporated by reference. In some embodiments, the biradicle —X—Y— together designate the bivalent linker group —O—NRa—CH3— (Seth at al., 2010, J. Org. Chem). In some embodiments the biradicle —X—Y— is —N(Ra)—, W is O, and all of R1, R2, R3, R5 and R5* are all hydrogen. In some embodiments Ra is C1-6 alkyl such as methyl.
  • In some embodiments, one or both of R5 and R5* is hydrogen and, when substituted the other of R5 and R5* is C1-6 alkyl such as methyl. In such an embodiment, R1, R2, R3, may all be hydrogen, and the biradicle —X—Y— may be selected from —O—CH2- or —O—C(HCRa)—, such as —O—C(HCH3)-.
  • In some embodiments, the biradicle is —CRaRb—O—CRaRb—, such as CH2—O—CH2—, W is O and all of R1, R2, R3, R5 and R5* are all hydrogen. In some embodiments Ra is C1-6 alkyl such as methyl. Such LNA nucleosides are also known as conformationally restricted nucleotides (CRNs) and are disclosed in WO2013036868 which is hereby incorporated by reference.
  • In some embodiments, the biradicle is —O—CRaRb—O—CRaRb—, such as O—CH2—O—CH2—, W is O and all of R1, R2, R3, R5 and R5* are all hydrogen. In some embodiments Ra is C1-6 alkyl such as methyl. Such LNA nucleosides are also known as COC nucleotides and are disclosed in Mitsuoka et al., Nucleic Acids Research 2009 37(4), 1225-1238, which is hereby incorporated by reference.
  • It will be recognized than, unless specified, the LNA nucleosides may be in the beta-D or alpha-L stereoisoform.
  • Certain examples of LNA nucleosides are presented in Scheme 1.
  • Figure US20170191064A1-20170706-C00003
  • As illustrated in the examples, in preferred embodiments of the invention the LNA nucleosides in the oligonucleotides are beta-D-oxy-LNA nucleosides.
  • Nuclease Mediated Degradation
  • Nuclease mediated degradation refers to an oligonucleotide capable of mediating degradation of a complementary nucleotide sequence when forming a duplex with such a sequence.
  • In some embodiments, the oligonucleotide may function via nuclease mediated degradation of the target nucleic acid, where the oligonucleotides of the invention are capable of recruiting a nuclease, particularly and endonuclease, preferably endoribonuclease (RNase), such as RNase H. Examples of oligonucleotide designs which operate via nuclease mediated mechanisms are oligonucleotides which typically comprise a region of at least 5 or 6 DNA nucleosides and are flanked on one side or both sides by affinity enhancing nucleosides, for example gapmers, headmers and tailmers.
  • RNase H Activity and Recruitment
  • The RNase H activity of an antisense oligonucleotide refers to its ability to recruit RNase H when in a duplex with a complementary RNA molecule. WO01/23613 provides in vitro methods for determining RNaseH activity, which may be used to determine the ability to recruit RNaseH. Typically an oligonucleotide is deemed capable of recruiting RNase H if it, when provided with a complementary target nucleic acid sequence, has an initial rate, as measured in pmol/l/min, of at least 10% or more than 20% of the of the initial rate determined when using a oligonucleotide having the same base sequence as the modified oligonucleotide being tested, but containing only DNA monomers, with phosphorothioate linkages between all monomers in the oligonucleotide, and using the methodology provided by Example 91-95 of WO01/23613 (hereby incorporated by reference).
  • Gapmer
  • The term gapmer as used herein refers to an antisense oligonucleotide which comprises a region of RNase H recruiting oligonucleotides (gap) which is flanked 5′ and 3′ by one or more affinity enhancing modified nucleosides (flanks). Various gapmer designs are described herein. Headmers and tailmers are oligonucleotides capable of recruiting RNase H where one of the flanks is missing, i.e. only one of the ends of the oligonucleotide comprises affinity enhancing modified nucleosides. For headmers the 3′ flank is missing (i.e. the 5′ flanc comprise affinity enhancing modified nucleosides) and for tailmers the 5′ flank is missing (i.e. the 3′ flank comprises affinity enhancing modified nucleosides).
  • LNA Gapmer
  • The term LNA gapmer is a gapmer oligonucleotide wherein at least one of the affinity enhancing modified nucleosides is an LNA nucleoside.
  • Mixed Wing Gapmer
  • The term mixed wing gapmer refers to a LNA gapmer wherein the flank regions comprise at least one LNA nucleoside and at least one non-LNA modified nucleoside, such as at least one 2′ substituted modified nucleoside, such as, for example, 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA (MOE), 2′-amino-DNA, 2′-Fluoro-RNA, and 2′-F-ANA nucleoside(s). In some embodiments the mixed wing gapmer has one flank which comprises LNA nucleosides (e.g. 5′ or 3′) and the other flank (3′ or 5′ respectfully) comprises 2′ substituted modified nucleoside(s).
  • Conjugate
  • The term conjugate as used herein refers to an oligonucleotide which is covalently linked to a non-nucleotide moiety (conjugate moiety or region C or third region).
  • Conjugation of the oligonucleotide of the invention to one or more non-nucleotide moieties may improve the pharmacology of the oligonucleotide, e.g. by affecting the activity, cellular distribution, cellular uptake or stability of the oligonucleotide. In some embodiments the conjugate moiety modify or enhance the pharmacokinetic properties of the oligonucleotide by improving cellular distribution, bioavailability, metabolism, excretion, permeability, and/or cellular uptake of the oligonucleotide. In particular the conjugate may target the oligonucleotide to a specific organ, tissue or cell type and thereby enhance the effectiveness of the oligonucleotide in that organ, tissue or cell type. A the same time the conjugate may serve to reduce activity of the oligonucleotide in non-target cell types, tissues or organs, e.g. off target activity or activity in non-target cell types, tissues or organs. WO 93/07883 and WO 2013/033230 provides suitable conjugate moieties, which are hereby incorporated by reference. WO 2012/143379 provides a method of delivering a drug across the blood-brain-barrier by conjugation to an antibody fragment with affinity to the transferrin receptor, which are hereby incorporated by reference.
  • Oligonucleotide conjugates and their synthesis has also been reported in comprehensive reviews by Manoharan in Antisense Drug Technology, Principles, Strategies, and Applications, S. T. Crooke, ed., Ch. 16, Marcel Dekker, Inc., 2001 and Manoharan, Antisense and Nucleic Acid Drug Development, 2002, 12, 103, each of which is incorporated herein by reference in its entirety.
  • In an embodiment, the non-nucleotide moiety (conjugate moiety) is selected from the group consisting of carbohydrates, cell surface receptor ligands, drug substances, hormones, lipophilic substances, polymers, proteins, peptides, toxins (e.g. bacterial toxins), vitamins, viral proteins (e.g. capsids) or combinations thereof. In some embodiments the non-nucleotide moiety an antibody or antibody fragment, such as an antibody or antibody fragment that facilitates delivery across the blood-brain-barrier, in particular an antibody or antibody fragment targeting the transferrin receptor.
  • Linkers
  • A linkage or linker is a connection between two atoms that links one chemical group or segment of interest to another chemical group or segment of interest via one or more covalent bonds. Conjugate moieties can be attached to the oligonucleotide directly or through a linking moiety (e.g. linker or tether). Linkers serve to covalently connect a third region, e.g. a conjugate moiety (Region C), to a first region, e.g. an oligonucleotide (region A).
  • In some embodiments of the invention the conjugate or oligonucleotide conjugate of the invention may optionally, comprise a linker region (second region or region B and/or region Y) which is positioned between the oligonucleotide (region A or first region) and the conjugate moiety (region C or third region).
  • Region B refers to biocleavable linkers comprising or consisting of a physiologically labile bond that is cleavable under conditions normally encountered or analogous to those encountered within a mammalian body. Conditions under which physiologically labile linkers undergo chemical transformation (e.g., cleavage) include chemical conditions such as pH, temperature, oxidative or reductive conditions or agents, and salt concentration found in or analogous to those encountered in mammalian cells. Mammalian intracellular conditions also include the presence of enzymatic activity normally present in a mammalian cell such as from proteolytic enzymes or hydrolytic enzymes or nucleases. In one embodiment the biocleavable linker is susceptible to S1 nuclease cleavage. In a preferred embodiment the nuclease susceptible linker comprises between 1 and 10 nucleosides, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleosides, more preferably between 2 and 6 nucleosides and most preferably between 2 and 4 linked nucleosides comprising at least two consecutive phosphodiester linkages, such as at least 3 or 4 or 5 consecutive phosphodiester linkages. Preferably the nucleosides are DNA or RNA. Phosphodiester containing biocleavable linkers are described in more detail in WO 2014/076195 (hereby incorporated by reference).
  • Region Y refers to linkers that are not necessarily biocleavable but primarily serve to covalently connect a conjugate moiety (region C or third region), to an oligonucleotide (region A or first region). The region Y linkers may comprise a chain structure or an oligomer of repeating units such as ethylene glycol, amino acid units or amino alkyl groups The oligonucleotide conjugates of the present invention can be constructed of the following regional elements A-C, A-B-C, A-B-Y-C, A-Y-B-C or A-Y-C. In some embodiments the linker (region Y) is an amino alkyl, such as a C2-C36 amino alkyl group, including, for example C6 to C12 amino alkyl groups. In a preferred embodiment the linker (region Y) is a C6 amino alkyl group.
  • Control
  • By the term “control” when used in relation to measurements of the effect of an oligonucleotide it is generally understood that the control is an untreated individual or target cell or a individual or target cell treated with a non-targeting oligonucleotide (mock). It may however also be an individual treated with the standard of care.
  • Treatment
  • The term ‘treatment’ as used herein refers to both treatment of an existing disease (e.g. a disease or disorder as herein referred to), or prevention of a disease, i.e. prophylaxis. It will therefore be recognized that treatment as referred to herein may, in some embodiments, be prophylactic.
  • DETAILED DESCRIPTION OF THE INVENTION The Target
  • An aspect of the invention is to modulate the level of pig, primate or human UBE3A protein expression, in particular to increase the expression of paternal UBE3A expression in neuronal cells, in particular in human neuronal cells. The human UBE3A protein exists in several isoforms which are listed under Uniprot nr. Q05086. Several mutations in the maternal UBE3A gene can results in Angelman syndrome.
  • The target nucleic acid for the oligonucleotides of the invention is RNA, in particular a long non-coding RNA. The long non-coding RNA which is targeted by the oligonucleotides of the present invention is human SNHG14 (also known as UBE3A-ATS with Ensembl entry number ENSG00000224078, version GRCh38.p2). In particular the target nucleic acid is the region downstream of SNORD109B corresponding to position 25278410 to 25419462 on chromosome 15 (SEQ ID NO: 1). In Rhesus monkey (Macaca mulatta) the UBE3A suppressor is defined as region downstream of SNORD109A corresponding to position 4222848 to U.S. Pat. No. 4,373,084 (forward strand) on chromosome 7 using the Ensembl assembly MMUL 1.0 (SEQ ID NO: 2).
  • In some embodiments, the target nucleic acid is SEQ ID NO: 1, or naturally occurring variants thereof.
  • In certain embodiments the target nucleic acid correspond to regions which are conserved between human (SEQ ID NO: 1) and Rhesus monkey (SEQ ID NO: 2). In certain embodiments target nucleic acid correspond to regions which are conserved between human (SEQ ID NO:1), Rhesus monkey (SEQ ID NO: 2) and mouse (SEQ ID NO: 3).
  • In certain embodiments the target nucleic acid is the region that is antisense to the UBE3A pre-mRNA, this region corresponds to position 55319 to 141053 of SEQ ID NO: 1.
  • In certain embodiments the target nucleic acid is the region that is downstream of SNORD109B and upstream of the region that is antisense to the UBE3A pre-mRNA, this region corresponds to position 1 to 55319 of SEQ ID NO: 1.
  • In some embodiments, the target nucleic acid is present in a cell, such as a mammalian cell in particular a human cell in vitro or in vivo (the target cell). In certain embodiments the target cell is a neuron, preferably a human neuronal cell.
  • The target sequence may be a sub-sequence of the target nucleic acid. In some embodiments the oligonucleotide targets sub-sequence selected from the group consisting of the antisense region of exon 9, exon10, exon13, exon14, intron 14, exon 15, intron15 and exon 16 of UBE3A. In some embodiments the oligonucleotide or contiguous nucleotide sequence hybridize or is complementary to a single stranded nucleic acid molecule selected from the group consisting of positions: 55319-76274, 77483-77573, 92157-93403 and 97056-97354 of SEQ ID NO: 1. In some embodiments the oligonucleotide or contiguous nucleotide sequence hybridize or is complementary to a single stranded nucleic acid molecule selected from the group consisting of positions: 60821-60849, 77567-77583, 92323-92339 and 97156-97172 of SEQ ID NO: 1.
  • In some embodiments the target nucleic acid is a region corresponding to positions 9200-9250 of SEQ ID NO: 1.
  • In some embodiments the target nucleic acid is a region corresponding to positions 11505-11555 of SEQ ID NO: 1.
  • In some embodiments the target nucleic acid is a region corresponding to positions 15100-15150 of SEQ ID NO: 1.
  • In some embodiments the target nucleic acid is a region corresponding to positions 30590-30740 of SEQ ID NO: 1.
  • In some embodiments the target nucleic acid is a region corresponding to positions 46380-46430 of SEQ ID NO: 1.
  • The Oligonucleotides of the Invention
  • The invention relates to oligonucleotides capable of modulating expression of paternal UBE3A, in particular induction or up-regulation of paternally expressed UBE3A in neuronal cells. The modulation is achieved by hybridizing to a target nucleic acid located on the long non-coding RNA SNHG14 transcript downstream of SNORD109B. In certain embodiments the oligonucleotide of the invention hybridizes to a sub-sequence of the target nucleic acid of SEQ ID NO: 1 with a ΔG° below −10 kcal, such as with a ΔG° between −10 to −60 kcal, such as −12 to −40, such as from −15 to −30 kcal or −16 to −27 kcal such as −18 to −25 kcal.
  • The oligonucleotide of the invention is an antisense oligonucleotide which targets the pig, rhesus monkey and/or human SNHG14 transcript downstream of SNORD109B.
  • In some embodiments the antisense oligonucleotide of the invention is capable of modulating the expression of the target by removing, interfering with or decreasing the suppressor of the target. Preferably, the oligonucleotides of the invention induce UBE3A expression in a cell, in particular paternal UBE3A expression in a neuron, by degradation or removal of the SNHG14 transcript downstream of SNORD109B. In some embodiments the oligonucleotides of the invention are capable of increasing the expression of UBE3A by least 20% compared to the expression level of UBE3A in a neuronal cell treated with saline or a non-targeting oligonucleotide, more preferably by at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 80%, 100%, 120%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240% or 250% compared to the expression level of UBE3A in a neuronal cell treated with saline or a non-targeting oligonucleotide. In additional embodiments the oligonucleotides of the invention are capable of decreasing the level of the SNHG14 transcript downstream of SNORD109B (in particular the part of the transcript that is antisense to the UBE3A pre-mRNA region) by at least 20% compared to the level of the SNHG14 transcript downstream of SNORD109B in a neuronal cell treated with saline or a non-targeting oligonucleotide, more preferably by at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% compared to the level of the SNHG14 transcript downstream of SNORD109B in a neuronal cell treated with saline or a non-targeting oligonucleotide, without reducing SNORD115 levels by more than 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25% or 30% compared to the level of SNORD115 in a cell treated with saline or a non-targeting oligonucleotide. SNRPN and SNORD116 transcripts are located upstream from the SNORD115 transcript consequently if the SNORD115 transcript is not reduced by the oligonucleotide it is highly likely that the SNRPN and SNORD116 transcripts are also not reduced. In a further embodiment SNRPN and SNORD116 transcripts levels are not reduced by more than 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25% or 30% compared to the level of SNRPN and SNORD116 in a cell treated with saline or a non-targeting oligonucleotide.
  • The target modulation is triggered by the hybridization between a contiguous nucleotide sequence of the oligonucleotide and the target nucleic acid. In some embodiments the oligonucleotide of the invention comprises mismatches between the oligonucleotide and the target nucleic acid. Despite mismatches hybridization to the target nucleic acid may still be sufficient to show a desired modulation of UBE3A expression. Reduced binding affinity resulting from mismatches may advantageously be compensated by increased number of nucleotides in the oligonucleotide and/or an increased number of modified nucleosides capable of increasing the binding affinity to the target, such as 2′ modified nucleosides, including LNA, present within the oligonucleotide sequence.
  • An aspect of the present invention relates to an antisense oligonucleotide which comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90%, such as 95%, such as 98% such as 100% complementarity to position 25278410 to 25419462 on human chromosome 15.
  • In some embodiments, the oligonucleotide comprises a contiguous sequence which is at least 90% complementary, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98%, or 100% complementary with a region of the target nucleic acid shown as SEQ ID NO: 1, 2 or 3.
  • In a preferred embodiment the oligonucleotide of the invention, or contiguous nucleotide sequence thereof is fully complementary (100% complementary) to a region of the target nucleic acid shown as SEQ ID NO: 1, or in some embodiments may comprise one or two mismatches between the oligonucleotide and the target nucleic acid.
  • In some embodiments the oligonucleotide sequence is 100% complementary to a corresponding target nucleic acid region present in SEQ ID NO: 1 and SEQ ID NO: 2. In some embodiments the oligonucleotide sequence is 100% complementary to a corresponding target nucleic acid region present SEQ ID NO: 1, 2 and 3.
  • In some embodiments, the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary, such as 100% complementarity, to a corresponding target nucleic acid region present in SEQ ID NO: 1, wherein the target nucleic acid region is selected from the group consisting of region A1 to A3649 in table 1
  • TABLE 1
    Regions of SEQ ID NO 1 which may be targeted
    using oligonucleotide of the invention
    Position in
    SEQ ID NO 1
    Reg. A from to Length
    1 10 75 66
    2 77 91 15
    3 93 108 16
    4 168 213 46
    5 217 282 66
    6 284 299 16
    7 301 328 28
    8 330 344 15
    9 361 400 40
    10 415 447 33
    11 449 470 22
    12 472 487 16
    13 489 521 33
    14 523 540 18
    15 551 570 20
    16 590 638 49
    17 652 670 19
    18 672 733 62
    19 735 756 22
    20 758 773 16
    21 781 829 49
    22 831 870 40
    23 882 903 22
    24 918 949 32
    25 961 990 30
    26 1007 1021 15
    27 1019 1050 32
    28 1052 1090 39
    29 1092 1139 48
    30 1147 1179 33
    31 1175 1212 38
    32 1220 1242 23
    33 1245 1259 15
    34 1265 1278 14
    35 1285 1323 39
    36 1317 1330 14
    37 1337 1355 19
    38 1357 1403 47
    39 1405 1421 17
    40 1423 1481 59
    41 1486 1515 30
    42 1521 1581 61
    43 1611 1633 23
    44 1631 1644 14
    45 1635 1663 29
    46 1669 1684 16
    47 1685 1709 25
    48 1711 1724 14
    49 1726 1746 21
    50 1754 1808 55
    51 1819 1860 42
    52 1862 1878 17
    53 1896 1910 15
    54 1923 1944 22
    55 1946 1987 42
    56 1985 2051 67
    57 2053 2082 30
    58 2088 2104 17
    59 2106 2125 20
    60 2132 2207 76
    61 2209 2234 26
    62 2247 2261 15
    63 2263 2286 24
    64 2290 2306 17
    65 2308 2329 22
    66 2347 2391 45
    67 2398 2431 34
    68 2447 2468 22
    69 2470 2555 86
    70 2565 2579 15
    71 2579 2592 14
    72 2589 2605 17
    73 2594 2657 64
    74 2672 2687 16
    75 2692 2705 14
    76 2703 2721 19
    77 2770 2824 55
    78 2826 2841 16
    79 2838 2851 14
    80 2843 2889 47
    81 2896 2930 35
    82 2930 2967 38
    83 2965 2988 24
    84 2984 3028 45
    85 3024 3080 57
    86 3081 3135 55
    87 3140 3176 37
    88 3168 3189 22
    89 3197 3222 26
    90 3212 3226 15
    91 3221 3248 28
    92 3243 3256 14
    93 3250 3264 15
    94 3266 3292 27
    95 3326 3343 18
    96 3345 3391 47
    97 3400 3422 23
    98 3424 3441 18
    99 3434 3447 14
    100 3443 3503 61
    101 3495 3508 14
    102 3505 3558 54
    103 3589 3609 21
    104 3611 3641 31
    105 3662 3696 35
    106 3698 3719 22
    107 3723 3790 68
    108 3810 3854 45
    109 3858 3873 16
    110 3902 3968 67
    111 3971 4009 39
    112 4005 4018 14
    113 4011 4030 20
    114 4032 4077 46
    115 4082 4114 33
    116 4123 4140 18
    117 4150 4164 15
    118 4166 4183 18
    119 4185 4243 59
    120 4248 4268 21
    121 4284 4313 30
    122 4317 4348 32
    123 4364 4471 108
    124 4473 4491 19
    125 4494 4519 26
    126 4521 4535 15
    127 4545 4560 16
    128 4567 4606 40
    129 4616 4714 99
    130 4725 4755 31
    131 4757 4786 30
    132 4788 4852 65
    133 4856 4910 55
    134 4912 4935 24
    135 4937 4970 34
    136 4972 5010 39
    137 5058 5078 21
    138 5080 5116 37
    139 5110 5124 15
    140 5135 5166 32
    141 5168 5201 34
    142 5203 5247 45
    143 5261 5276 16
    144 5278 5293 16
    145 5314 5330 17
    146 5332 5382 51
    147 5398 5414 17
    148 5427 5456 30
    149 5458 5471 14
    150 5487 5500 14
    151 5506 5545 40
    152 5561 5577 17
    153 5580 5617 38
    154 5607 5620 14
    155 5619 5642 24
    156 5644 5683 40
    157 5685 5698 14
    158 5713 5759 47
    159 5756 5769 14
    160 5784 5803 20
    161 5801 5865 65
    162 5873 5905 33
    163 5907 5937 31
    164 5939 5985 47
    165 5987 6017 31
    166 6016 6039 24
    167 6028 6092 65
    168 6102 6127 26
    169 6127 6152 26
    170 6151 6171 21
    171 6178 6206 29
    172 6217 6234 18
    173 6224 6270 47
    174 6272 6289 18
    175 6291 6310 20
    176 6312 6357 46
    177 6367 6389 23
    178 6396 6422 27
    179 6440 6454 15
    180 6456 6482 27
    181 6484 6513 30
    182 6505 6519 15
    183 6518 6553 36
    184 6552 6565 14
    185 6557 6590 34
    186 6596 6628 33
    187 6640 6675 36
    188 6686 6711 26
    189 6714 6746 33
    190 6781 6818 38
    191 6832 6885 54
    192 6889 6912 24
    193 6920 6938 19
    194 6940 6960 21
    195 6954 6976 23
    196 6998 7033 36
    197 7035 7061 27
    198 7071 7143 73
    199 7159 7214 56
    200 7253 7266 14
    201 7268 7281 14
    202 7283 7328 46
    203 7329 7343 15
    204 7338 7355 18
    205 7345 7374 30
    206 7374 7387 14
    207 7383 7396 14
    208 7389 7405 17
    209 7399 7413 15
    210 7420 7437 18
    211 7427 7448 22
    212 7450 7503 54
    213 7495 7565 71
    214 7561 7616 56
    215 7618 7703 86
    216 7717 7772 56
    217 7776 7838 63
    218 7852 7869 18
    219 7882 7910 29
    220 7919 7942 24
    221 7944 7957 14
    222 7959 7977 19
    223 7979 7996 18
    224 7998 8014 17
    225 8030 8046 17
    226 8059 8092 34
    227 8100 8113 14
    228 8115 8141 27
    229 8143 8175 33
    230 8179 8192 14
    231 8187 8208 22
    232 8205 8219 15
    233 8210 8229 20
    234 8231 8252 22
    235 8254 8298 45
    236 8302 8316 15
    237 8306 8329 24
    238 8331 8357 27
    239 8400 8443 44
    240 8443 8456 14
    241 8445 8460 16
    242 8472 8505 34
    243 8494 8507 14
    244 8554 8569 16
    245 8571 8653 83
    246 8659 8673 15
    247 8675 8694 20
    248 8696 8713 18
    249 8736 8844 109
    250 8847 8909 63
    251 8915 8959 45
    252 8961 8975 15
    253 8993 9009 17
    254 9024 9048 25
    255 9050 9063 14
    256 9089 9120 32
    257 9127 9166 40
    258 9191 9249 59
    259 9257 9285 29
    260 9288 9302 15
    261 9331 9397 67
    262 9399 9438 40
    263 9437 9455 19
    264 9483 9505 23
    265 9507 9526 20
    266 9583 9598 16
    267 9600 9613 14
    268 9628 9641 14
    269 9653 9674 22
    270 9676 9690 15
    271 9745 9758 14
    272 9752 9780 29
    273 9796 9809 14
    274 9811 9825 15
    275 9832 9853 22
    276 9877 9899 23
    277 9901 9932 32
    278 10000 10016 17
    279 10029 10049 21
    280 10051 10071 21
    281 10089 10120 32
    282 10111 10127 17
    283 10122 10203 82
    284 10211 10237 27
    285 10239 10256 18
    286 10258 10285 28
    287 10287 10304 18
    288 10306 10350 45
    289 10352 10375 24
    290 10381 10402 22
    291 10412 10470 59
    292 10474 10488 15
    293 10508 10557 50
    294 10565 10630 66
    295 10632 10674 43
    296 10698 10711 14
    297 10701 10714 14
    298 10704 10718 15
    299 10720 10740 21
    300 10742 10785 44
    301 10786 10809 24
    302 10811 10829 19
    303 10832 10867 36
    304 10869 10930 62
    305 10932 10950 19
    306 10959 10996 38
    307 10998 11028 31
    308 11037 11077 41
    309 11079 11105 27
    310 11115 11132 18
    311 11134 11154 21
    312 11156 11196 41
    313 11206 11239 34
    314 11241 11255 15
    315 11266 11287 22
    316 11299 11329 31
    317 11331 11352 22
    318 11358 11403 46
    319 11405 11432 28
    320 11434 11480 47
    321 11482 11535 54
    322 11539 11573 35
    323 11584 11732 149
    324 11731 11763 33
    325 11765 11782 18
    326 11784 11813 30
    327 11815 11829 15
    328 11831 11852 22
    329 11854 11871 18
    330 11866 11895 30
    331 11930 11943 14
    332 11975 12007 33
    333 11996 12012 17
    334 12017 12040 24
    335 12050 12083 34
    336 12088 12111 24
    337 12133 12151 19
    338 12161 12174 14
    339 12179 12225 47
    340 12238 12256 19
    341 12265 12278 14
    342 12296 12360 65
    343 12362 12381 20
    344 12384 12399 16
    345 12400 12475 76
    346 12487 12502 16
    347 12504 12531 28
    348 12533 12562 30
    349 12564 12602 39
    350 12627 12646 20
    351 12655 12679 25
    352 12681 12698 18
    353 12700 12812 113
    354 12828 12876 49
    355 12877 12913 37
    356 12932 12945 14
    357 12936 12967 32
    358 12988 13002 15
    359 12996 13009 14
    360 13018 13035 18
    361 13031 13049 19
    362 13056 13093 38
    363 13096 13126 31
    364 13128 13142 15
    365 13144 13193 50
    366 13201 13221 21
    367 13223 13280 58
    368 13282 13298 17
    369 13300 13315 16
    370 13307 13320 14
    371 13315 13331 17
    372 13351 13411 61
    373 13422 13437 16
    374 13439 13456 18
    375 13461 13483 23
    376 13485 13541 57
    377 13543 13560 18
    378 13574 13606 33
    379 13618 13646 29
    380 13778 13801 24
    381 13994 14009 16
    382 14508 14521 14
    383 15049 15067 19
    384 15069 15090 22
    385 15102 15139 38
    386 15142 15180 39
    387 15182 15205 24
    388 15238 15252 15
    389 15254 15277 24
    390 15292 15320 29
    391 15322 15348 27
    392 15343 15358 16
    393 15362 15387 26
    394 15399 15414 16
    395 15416 15445 30
    396 15459 15528 70
    397 15537 15592 56
    398 15610 15638 29
    399 15640 15653 14
    400 15655 15717 63
    401 15719 15738 20
    402 15757 15778 22
    403 15783 15801 19
    404 15818 15838 21
    405 15835 15849 15
    406 15840 15857 18
    407 15856 15898 43
    408 15900 15916 17
    409 15931 15972 42
    410 15988 16028 41
    411 16030 16075 46
    412 16103 16164 62
    413 16207 16243 37
    414 16233 16246 14
    415 16255 16329 75
    416 16349 16376 28
    417 16378 16404 27
    418 16399 16419 21
    419 16421 16461 41
    420 16463 16479 17
    421 16481 16503 23
    422 16506 16579 74
    423 16582 16620 39
    424 16622 16698 77
    425 16700 16716 17
    426 16723 16771 49
    427 16786 16816 31
    428 16835 16864 30
    429 16865 16878 14
    430 16872 16888 17
    431 16890 16906 17
    432 16904 16938 35
    433 16965 17052 88
    434 17054 17069 16
    435 17071 17085 15
    436 17083 17098 16
    437 17088 17111 24
    438 17124 17138 15
    439 17140 17159 20
    440 17181 17202 22
    441 17202 17218 17
    442 17229 17248 20
    443 17250 17268 19
    444 17332 17349 18
    445 17363 17387 25
    446 17389 17429 41
    447 17450 17464 15
    448 17482 17497 16
    449 18104 18117 14
    450 18418 18431 14
    451 18613 18626 14
    452 18620 18634 15
    453 18707 18721 15
    454 18841 18855 15
    455 18875 18889 15
    456 19282 19295 14
    457 19310 19323 14
    458 19454 19467 14
    459 19774 19792 19
    460 19794 19864 71
    461 19862 19890 29
    462 19892 19918 27
    463 19907 19931 25
    464 19927 19942 16
    465 19932 19971 40
    466 19973 20011 39
    467 20022 20063 42
    468 20080 20093 14
    469 20131 20144 14
    470 20240 20253 14
    471 20448 20463 16
    472 20495 20508 14
    473 20532 20545 14
    474 20600 20613 14
    475 20617 20630 14
    476 20960 20977 18
    477 21412 21428 17
    478 21465 21479 15
    479 21489 21508 20
    480 21797 21812 16
    481 22015 22030 16
    482 22144 22157 14
    483 22153 22167 15
    484 22265 22278 14
    485 23110 23123 14
    486 23114 23133 20
    487 23286 23303 18
    488 23364 23379 16
    489 23478 23498 21
    490 23544 23587 44
    491 23589 23630 42
    492 23658 23676 19
    493 23678 23702 25
    494 23704 23729 26
    495 23731 23748 18
    496 23740 23755 16
    497 23744 23757 14
    498 23750 23764 15
    499 23767 23795 29
    500 23802 23816 15
    501 23818 23831 14
    502 23855 23869 15
    503 23906 23926 21
    504 23928 23942 15
    505 23994 24007 14
    506 24005 24018 14
    507 24023 24056 34
    508 24074 24088 15
    509 24088 24104 17
    510 24112 24163 52
    511 24199 24212 14
    512 24231 24244 14
    513 24237 24252 16
    514 24254 24267 14
    515 24281 24325 45
    516 24327 24353 27
    517 24355 24374 20
    518 24376 24399 24
    519 24401 24416 16
    520 24442 24489 48
    521 24492 24506 15
    522 24498 24511 14
    523 24538 24556 19
    524 24546 24562 17
    525 24591 24618 28
    526 24620 24633 14
    527 24635 24650 16
    528 24665 24681 17
    529 24687 24706 20
    530 24709 24729 21
    531 24731 24752 22
    532 24756 24771 16
    533 24773 24788 16
    534 24793 24821 29
    535 24823 24854 32
    536 24856 24870 15
    537 24873 24922 50
    538 24933 24954 22
    539 24965 24984 20
    540 25019 25052 34
    541 25054 25099 46
    542 25112 25125 14
    543 25133 25169 37
    544 25171 25184 14
    545 25186 25221 36
    546 25236 25253 18
    547 25246 25296 51
    548 25298 25336 39
    549 25332 25348 17
    550 25349 25363 15
    551 25388 25432 45
    552 25439 25462 24
    553 25509 25523 15
    554 25525 25547 23
    555 25578 25593 16
    556 25587 25601 15
    557 25604 25617 14
    558 25633 25655 23
    559 25672 25716 45
    560 25725 25738 14
    561 25764 25800 37
    562 25802 25828 27
    563 25831 25846 16
    564 25851 25872 22
    565 25877 25904 28
    566 25921 25946 26
    567 25943 25970 28
    568 25972 25986 15
    569 26051 26064 14
    570 26068 26086 19
    571 26113 26137 25
    572 26139 26159 21
    573 26182 26197 16
    574 26243 26296 54
    575 26298 26313 16
    576 26327 26350 24
    577 26366 26385 20
    578 26387 26404 18
    579 26397 26415 19
    580 26416 26453 38
    581 26447 26461 15
    582 26457 26471 15
    583 26481 26498 18
    584 26502 26525 24
    585 26528 26562 35
    586 26564 26590 27
    587 26590 26622 33
    588 26624 26638 15
    589 26687 26702 16
    590 26706 26719 14
    591 26717 26730 14
    592 26729 26743 15
    593 26767 26797 31
    594 26796 26816 21
    595 26831 26847 17
    596 26837 26850 14
    597 26877 26890 14
    598 26900 26922 23
    599 26911 26933 23
    600 26933 26946 14
    601 26938 26977 40
    602 26979 26992 14
    603 26981 27017 37
    604 27023 27041 19
    605 27039 27055 17
    606 27075 27121 47
    607 27138 27153 16
    608 27163 27266 104
    609 27270 27293 24
    610 27325 27358 34
    611 27363 27408 46
    612 27419 27448 30
    613 27450 27469 20
    614 27471 27498 28
    615 27510 27523 14
    616 27535 27562 28
    617 28098 28119 22
    618 28136 28155 20
    619 28169 28197 29
    620 28199 28212 14
    621 28221 28244 24
    622 28271 28285 15
    623 28400 28414 15
    624 28441 28476 36
    625 28490 28533 44
    626 28535 28562 28
    627 28575 28600 26
    628 28621 28634 14
    629 28650 28663 14
    630 28674 28687 14
    631 28681 28699 19
    632 28713 28730 18
    633 28736 28761 26
    634 28763 28811 49
    635 28821 28854 34
    636 28856 28881 26
    637 28883 28920 38
    638 28922 28947 26
    639 28979 29006 28
    640 29008 29056 49
    641 29078 29095 18
    642 29098 29129 32
    643 29122 29135 14
    644 29131 29144 14
    645 29144 29158 15
    646 29160 29207 48
    647 29209 29230 22
    648 29234 29266 33
    649 29268 29286 19
    650 29301 29315 15
    651 29304 29323 20
    652 29330 29352 23
    653 29344 29358 15
    654 29347 29365 19
    655 29377 29402 26
    656 29402 29422 21
    657 29424 29445 22
    658 29443 29457 15
    659 29447 29460 14
    660 29462 29475 14
    661 29491 29512 22
    662 29514 29551 38
    663 29547 29560 14
    664 29553 29620 68
    665 29625 29700 76
    666 29714 29745 32
    667 29774 29805 32
    668 29816 29847 32
    669 29875 29892 18
    670 29894 29908 15
    671 29897 29910 14
    672 29917 29938 22
    673 29939 29952 14
    674 29961 29976 16
    675 29974 29987 14
    676 29978 30001 24
    677 30006 30023 18
    678 30025 30039 15
    679 30043 30107 65
    680 30145 30158 14
    681 30149 30166 18
    682 30173 30228 56
    683 30230 30250 21
    684 30251 30309 59
    685 30321 30358 38
    686 30359 30380 22
    687 30382 30422 41
    688 30428 30442 15
    689 30455 30482 28
    690 30484 30498 15
    691 30516 30531 16
    692 30533 30646 114
    693 30654 30745 92
    694 30745 30760 16
    695 30752 30766 15
    696 30788 30843 56
    697 30845 30867 23
    698 30869 30912 44
    699 30906 30920 15
    700 30934 30951 18
    701 30962 30984 23
    702 30989 31002 14
    703 31010 31033 24
    704 31036 31062 27
    705 31092 31106 15
    706 31128 31166 39
    707 31168 31182 15
    708 31189 31203 15
    709 31205 31218 14
    710 31224 31253 30
    711 31256 31272 17
    712 31274 31292 19
    713 31294 31322 29
    714 31324 31353 30
    715 31357 31370 14
    716 31373 31399 27
    717 31403 31426 24
    718 31445 31460 16
    719 31463 31483 21
    720 31485 31501 17
    721 31494 31508 15
    722 31507 31529 23
    723 31531 31565 35
    724 31567 31615 49
    725 31630 31665 36
    726 31675 31691 17
    727 31703 31721 19
    728 31729 31769 41
    729 31770 31790 21
    730 31795 31813 19
    731 31815 31835 21
    732 31837 31865 29
    733 31876 31889 14
    734 31920 31945 26
    735 31962 31978 17
    736 31983 32014 32
    737 32029 32050 22
    738 32058 32110 53
    739 32129 32147 19
    740 32166 32242 77
    741 32244 32279 36
    742 32296 32315 20
    743 32334 32396 63
    744 32398 32425 28
    745 32427 32453 27
    746 32459 32481 23
    747 32475 32498 24
    748 32490 32523 34
    749 32519 32534 16
    750 32525 32547 23
    751 32542 32555 14
    752 32559 32572 14
    753 32574 32587 14
    754 32595 32618 24
    755 32613 32626 14
    756 32627 32649 23
    757 32651 32664 14
    758 32655 32689 35
    759 32693 32719 27
    760 32721 32750 30
    761 32752 32778 27
    762 32780 32795 16
    763 32797 32847 51
    764 32881 32894 14
    765 32891 32904 14
    766 32896 32911 16
    767 32927 32972 46
    768 32986 33017 32
    769 33019 33036 18
    770 33038 33096 59
    771 33102 33123 22
    772 33132 33145 14
    773 33150 33163 14
    774 33166 33199 34
    775 33214 33260 47
    776 33262 33292 31
    777 33294 33307 14
    778 33316 33351 36
    779 33360 33402 43
    780 33412 33425 14
    781 33427 33442 16
    782 33439 33452 14
    783 33443 33456 14
    784 33460 33501 42
    785 33503 33535 33
    786 33542 33557 16
    787 34168 34181 14
    788 34370 34385 16
    789 35422 35435 14
    790 35627 35641 15
    791 35685 35700 16
    792 35837 35851 15
    793 35849 35864 16
    794 35866 35879 14
    795 35974 35987 14
    796 36009 36042 34
    797 36044 36079 36
    798 36081 36097 17
    799 36099 36120 22
    800 36119 36133 15
    801 36147 36163 17
    802 36171 36200 30
    803 36216 36241 26
    804 36245 36274 30
    805 36265 36283 19
    806 36295 36348 54
    807 36352 36389 38
    808 36383 36400 18
    809 36402 36419 18
    810 36475 36520 46
    811 36522 36539 18
    812 36541 36626 86
    813 36652 36672 21
    814 36675 36705 31
    815 36707 36746 40
    816 36780 36808 29
    817 36810 36823 14
    818 36825 36901 77
    819 36903 36922 20
    820 36924 36982 59
    821 36999 37030 32
    822 37056 37083 28
    823 37091 37135 45
    824 37194 37221 28
    825 37238 37277 40
    826 37280 37294 15
    827 37298 37315 18
    828 37325 37350 26
    829 37363 37383 21
    830 37377 37394 18
    831 37384 37397 14
    832 37390 37438 49
    833 37456 37481 26
    834 37478 37491 14
    835 37481 37503 23
    836 37506 37524 19
    837 37526 37545 20
    838 37540 37572 33
    839 37574 37590 17
    840 37601 37616 16
    841 37621 37658 38
    842 37673 37690 18
    843 37703 37738 36
    844 37740 37753 14
    845 37764 37790 27
    846 37800 37818 19
    847 37820 37850 31
    848 37888 37909 22
    849 37911 37972 62
    850 37986 38014 29
    851 38016 38032 17
    852 38034 38053 20
    853 38055 38073 19
    854 38075 38090 16
    855 38092 38128 37
    856 38141 38167 27
    857 38171 38194 24
    858 38213 38240 28
    859 38264 38286 23
    860 38288 38370 83
    861 38394 38420 27
    862 38452 38467 16
    863 38471 38487 17
    864 38477 38490 14
    865 38494 38507 14
    866 38536 38556 21
    867 38580 38593 14
    868 38602 38618 17
    869 38628 38654 27
    870 38693 38709 17
    871 38709 38722 14
    872 38711 38725 15
    873 38740 38756 17
    874 38749 38769 21
    875 38772 38797 26
    876 38827 38846 20
    877 38860 38883 24
    878 38885 38905 21
    879 38911 38931 21
    880 38933 38949 17
    881 38962 39032 71
    882 39034 39047 14
    883 39049 39070 22
    884 39075 39115 41
    885 39127 39143 17
    886 39148 39162 15
    887 39164 39222 59
    888 39218 39231 14
    889 39224 39256 33
    890 39265 39306 42
    891 39297 39311 15
    892 39308 39343 36
    893 39345 39359 15
    894 39361 39381 21
    895 39370 39383 14
    896 39383 39399 17
    897 39417 39469 53
    898 39490 39503 14
    899 39500 39522 23
    900 39535 39549 15
    901 39551 39611 61
    902 39628 39647 20
    903 39649 39690 42
    904 39707 39759 53
    905 39773 39797 25
    906 39799 39858 60
    907 39872 39928 57
    908 39930 39969 40
    909 39973 39997 25
    910 39998 40013 16
    911 40015 40064 50
    912 40067 40108 42
    913 40110 40140 31
    914 40147 40163 17
    915 40154 40179 26
    916 40181 40196 16
    917 40232 40282 51
    918 40284 40307 24
    919 40309 40368 60
    920 40381 40399 19
    921 40431 40471 41
    922 40479 40493 15
    923 40484 40522 39
    924 40524 40544 21
    925 40547 40561 15
    926 40577 40594 18
    927 40586 40599 14
    928 40616 40631 16
    929 40634 40647 14
    930 40674 40727 54
    931 40738 40755 18
    932 40749 40771 23
    933 40780 40802 23
    934 40811 40834 24
    935 40847 40865 19
    936 40861 40875 15
    937 40869 40897 29
    938 40899 40919 21
    939 40921 40939 19
    940 40942 40962 21
    941 40967 40980 14
    942 41008 41097 90
    943 41099 41131 33
    944 41133 41200 68
    945 41202 41223 22
    946 41225 41242 18
    947 41266 41279 14
    948 41275 41298 24
    949 41300 41321 22
    950 41325 41360 36
    951 41367 41388 22
    952 41403 41421 19
    953 41439 41462 24
    954 41481 41496 16
    955 41508 41523 16
    956 41531 41550 20
    957 41552 41590 39
    958 41590 41603 14
    959 41612 41662 51
    960 41664 41688 25
    961 41685 41698 14
    962 41691 41716 26
    963 41718 41764 47
    964 41761 41776 16
    965 41778 41809 32
    966 41798 41811 14
    967 41838 41866 29
    968 41872 41893 22
    969 41885 41898 14
    970 41912 41925 14
    971 41914 41930 17
    972 41923 41942 20
    973 41933 41956 24
    974 41962 41978 17
    975 41997 42012 16
    976 42026 42042 17
    977 42035 42048 14
    978 42037 42050 14
    979 42048 42064 17
    980 42056 42079 24
    981 42081 42095 15
    982 42096 42139 44
    983 42141 42187 47
    984 42190 42226 37
    985 42232 42253 22
    986 42255 42305 51
    987 42307 42320 14
    988 42347 42375 29
    989 42389 42425 37
    990 42427 42442 16
    991 42452 42474 23
    992 42482 42496 15
    993 42495 42509 15
    994 42536 42550 15
    995 42566 42580 15
    996 42590 42612 23
    997 42646 42678 33
    998 42683 42723 41
    999 42735 42750 16
    1000 42752 42817 66
    1001 42843 42873 31
    1002 42890 42939 50
    1003 42938 42989 52
    1004 42991 43005 15
    1005 43007 43020 14
    1006 43036 43055 20
    1007 43057 43102 46
    1008 43113 43145 33
    1009 43147 43180 34
    1010 43204 43221 18
    1011 43221 43265 45
    1012 43267 43296 30
    1013 43311 43334 24
    1014 43336 43361 26
    1015 43371 43395 25
    1016 43399 43423 25
    1017 43425 43453 29
    1018 43452 43468 17
    1019 43470 43488 19
    1020 43495 43522 28
    1021 43525 43559 35
    1022 43561 43584 24
    1023 43590 43611 22
    1024 43618 43650 33
    1025 43670 43685 16
    1026 43722 43774 53
    1027 43776 43791 16
    1028 43808 43835 28
    1029 43835 43851 17
    1030 43853 43868 16
    1031 43923 43937 15
    1032 43952 43987 36
    1033 44011 44029 19
    1034 44028 44070 43
    1035 44072 44094 23
    1036 44101 44130 30
    1037 44137 44205 69
    1038 44224 44244 21
    1039 44246 44265 20
    1040 44267 44318 52
    1041 44316 44336 21
    1042 44338 44359 22
    1043 44361 44424 64
    1044 44439 44474 36
    1045 44476 44500 25
    1046 44502 44519 18
    1047 44539 44553 15
    1048 44563 44578 16
    1049 44585 44599 15
    1050 44601 44617 17
    1051 44640 44701 62
    1052 44704 44723 20
    1053 44741 44763 23
    1054 44766 44846 81
    1055 44870 44889 20
    1056 44887 44905 19
    1057 44920 44947 28
    1058 44949 44966 18
    1059 44994 45022 29
    1060 45042 45059 18
    1061 45061 45087 27
    1062 45116 45154 39
    1063 45156 45182 27
    1064 45183 45198 16
    1065 45210 45243 34
    1066 45245 45320 76
    1067 45331 45367 37
    1068 45380 45399 20
    1069 45415 45428 14
    1070 45421 45486 66
    1071 45488 45545 58
    1072 45556 45576 21
    1073 45578 45597 20
    1074 45603 45650 48
    1075 45652 45665 14
    1076 45675 45715 41
    1077 45749 45763 15
    1078 45804 45826 23
    1079 45839 45861 23
    1080 45878 45910 33
    1081 45926 45954 29
    1082 45956 45975 20
    1083 45977 45997 21
    1084 45999 46020 22
    1085 46046 46063 18
    1086 46065 46088 24
    1087 46097 46118 22
    1088 46120 46142 23
    1089 46144 46160 17
    1090 46162 46185 24
    1091 46204 46280 77
    1092 46302 46326 25
    1093 46328 46355 28
    1094 46358 46377 20
    1095 46379 46436 58
    1096 46457 46471 15
    1097 46473 46492 20
    1098 46501 46541 41
    1099 46543 46572 30
    1100 46584 46626 43
    1101 46655 46683 29
    1102 46685 46702 18
    1103 46704 46722 19
    1104 46724 46763 40
    1105 46784 46800 17
    1106 46802 46827 26
    1107 46830 46867 38
    1108 46869 46887 19
    1109 46889 46920 32
    1110 46922 46947 26
    1111 46976 47009 34
    1112 47011 47030 20
    1113 47032 47064 33
    1114 47066 47092 27
    1115 47108 47130 23
    1116 47132 47168 37
    1117 47170 47199 30
    1118 47201 47222 22
    1119 47238 47277 40
    1120 47296 47350 55
    1121 47352 47391 40
    1122 47416 47440 25
    1123 47452 47466 15
    1124 47468 47523 56
    1125 47522 47546 25
    1126 47548 47567 20
    1127 47569 47595 27
    1128 47597 47634 38
    1129 47657 47693 37
    1130 47712 47731 20
    1131 47749 47762 14
    1132 47771 47825 55
    1133 47827 47846 20
    1134 47848 47872 25
    1135 47874 47888 15
    1136 47890 47909 20
    1137 47911 47925 15
    1138 47927 47952 26
    1139 47961 47993 33
    1140 48001 48016 16
    1141 48051 48083 33
    1142 48096 48158 63
    1143 48158 48176 19
    1144 48186 48201 16
    1145 48213 48239 27
    1146 48241 48256 16
    1147 48258 48278 21
    1148 48280 48339 60
    1149 48341 48357 17
    1150 48359 48377 19
    1151 48379 48393 15
    1152 48395 48488 94
    1153 48492 48510 19
    1154 48528 48549 22
    1155 48550 48589 40
    1156 48636 48658 23
    1157 48683 48697 15
    1158 48699 48762 64
    1159 48762 48775 14
    1160 48773 48832 60
    1161 48873 48886 14
    1162 48888 48914 27
    1163 48916 48944 29
    1164 48969 49008 40
    1165 49010 49024 15
    1166 49051 49110 60
    1167 49116 49150 35
    1168 49151 49184 34
    1169 49187 49200 14
    1170 49213 49230 18
    1171 49233 49247 15
    1172 49267 49284 18
    1173 49297 49310 14
    1174 49317 49369 53
    1175 49371 49435 65
    1176 49444 49458 15
    1177 49467 49500 34
    1178 49510 49538 29
    1179 49540 49559 20
    1180 49561 49584 24
    1181 49591 49626 36
    1182 49628 49646 19
    1183 49653 49737 85
    1184 49787 49802 16
    1185 49817 49835 19
    1186 49841 49860 20
    1187 49862 49883 22
    1188 49885 49905 21
    1189 49921 49950 30
    1190 49961 49979 19
    1191 49995 50051 57
    1192 50053 50071 19
    1193 50073 50088 16
    1194 50132 50158 27
    1195 50167 50183 17
    1196 50201 50226 26
    1197 50226 50239 14
    1198 50259 50313 55
    1199 50323 50341 19
    1200 50343 50396 54
    1201 50390 50403 14
    1202 50398 50448 51
    1203 50451 50483 33
    1204 50489 50507 19
    1205 50526 50548 23
    1206 50550 50569 20
    1207 50575 50602 28
    1208 50606 50621 16
    1209 50617 50630 14
    1210 50623 50641 19
    1211 50634 50647 14
    1212 50644 50663 20
    1213 50665 50684 20
    1214 50705 50730 26
    1215 50732 50763 32
    1216 50766 50799 34
    1217 50797 50823 27
    1218 50838 50864 27
    1219 50870 50884 15
    1220 50885 50911 27
    1221 50924 50937 14
    1222 50939 50974 36
    1223 50980 51008 29
    1224 51015 51030 16
    1225 51034 51047 14
    1226 51075 51089 15
    1227 51109 51123 15
    1228 51135 51172 38
    1229 51189 51216 28
    1230 51241 51260 20
    1231 51273 51294 22
    1232 51296 51312 17
    1233 51337 51357 21
    1234 51356 51381 26
    1235 51393 51465 73
    1236 51476 51494 19
    1237 51496 51515 20
    1238 51530 51544 15
    1239 51546 51572 27
    1240 51586 51600 15
    1241 51602 51617 16
    1242 51619 51677 59
    1243 51679 51700 22
    1244 51727 51741 15
    1245 51743 51821 79
    1246 51826 51859 34
    1247 51884 51912 29
    1248 51918 51936 19
    1249 51947 51979 33
    1250 52004 52017 14
    1251 52023 52048 26
    1252 52141 52167 27
    1253 52169 52188 20
    1254 52204 52225 22
    1255 52246 52262 17
    1256 52289 52306 18
    1257 52321 52339 19
    1258 52341 52360 20
    1259 52360 52428 69
    1260 52430 52504 75
    1261 52506 52567 62
    1262 52579 52594 16
    1263 52591 52610 20
    1264 52612 52642 31
    1265 52644 52667 24
    1266 52672 52686 15
    1267 52688 52702 15
    1268 52715 52753 39
    1269 52770 52783 14
    1270 52779 52792 14
    1271 52814 52845 32
    1272 52834 52857 24
    1273 52858 52885 28
    1274 52887 52943 57
    1275 52945 52962 18
    1276 52971 53019 49
    1277 53011 53036 26
    1278 53053 53066 14
    1279 53092 53112 21
    1280 53124 53151 28
    1281 53161 53175 15
    1282 53184 53220 37
    1283 53222 53243 22
    1284 53245 53260 16
    1285 53278 53304 27
    1286 53311 53346 36
    1287 53364 53386 23
    1288 53388 53404 17
    1289 53417 53431 15
    1290 53449 53463 15
    1291 53465 53484 20
    1292 53514 53527 14
    1293 53552 53567 16
    1294 53570 53591 22
    1295 53618 53644 27
    1296 53645 53667 23
    1297 53669 53684 16
    1298 53714 53742 29
    1299 53744 53764 21
    1300 53818 53843 26
    1301 53845 53860 16
    1302 53875 53889 15
    1303 53961 53991 31
    1304 53991 54013 23
    1305 54015 54055 41
    1306 54057 54081 25
    1307 54114 54135 22
    1308 54163 54178 16
    1309 54180 54193 14
    1310 54195 54254 60
    1311 54261 54290 30
    1312 54292 54307 16
    1313 54309 54327 19
    1314 54357 54372 16
    1315 54404 54420 17
    1316 54418 54439 22
    1317 54441 54466 26
    1318 54468 54512 45
    1319 54519 54532 14
    1320 54555 54572 18
    1321 54588 54601 14
    1322 54609 54633 25
    1323 54644 54688 45
    1324 54690 54721 32
    1325 54723 54761 39
    1326 54786 54802 17
    1327 54819 54835 17
    1328 54837 54912 76
    1329 54924 54941 18
    1330 54999 55017 19
    1331 55019 55035 17
    1332 55060 55073 14
    1333 55075 55100 26
    1334 55129 55171 43
    1335 55173 55188 16
    1336 55190 55203 14
    1337 55210 55230 21
    1338 55233 55281 49
    1339 55276 55289 14
    1340 55283 55320 38
    1341 55330 55379 50
    1342 55381 55423 43
    1343 55420 55441 22
    1344 55486 55502 17
    1345 55515 55533 19
    1346 55535 55553 19
    1347 55555 55569 15
    1348 55569 55588 20
    1349 55590 55611 22
    1350 55615 55663 49
    1351 55665 55678 14
    1352 55696 55713 18
    1353 55715 55738 24
    1354 55744 55774 31
    1355 55776 55794 19
    1356 55801 55823 23
    1357 55862 55906 45
    1358 55920 55933 14
    1359 55922 55947 26
    1360 55974 55993 20
    1361 55990 56031 42
    1362 56045 56073 29
    1363 56082 56114 33
    1364 56117 56140 24
    1365 56183 56214 32
    1366 56218 56236 19
    1367 56261 56282 22
    1368 56311 56336 26
    1369 56331 56345 15
    1370 56338 56358 21
    1371 56369 56390 22
    1372 56391 56431 41
    1373 56433 56451 19
    1374 56453 56473 21
    1375 56475 56498 24
    1376 56500 56546 47
    1377 56558 56581 24
    1378 56584 56597 14
    1379 56611 56647 37
    1380 56643 56657 15
    1381 56667 56691 25
    1382 56732 56759 28
    1383 56788 56805 18
    1384 56821 56845 25
    1385 56850 56882 33
    1386 56885 56906 22
    1387 56928 56942 15
    1388 56944 56959 16
    1389 56961 56975 15
    1390 56984 57002 19
    1391 57004 57041 38
    1392 57057 57082 26
    1393 57084 57122 39
    1394 57162 57222 61
    1395 57224 57246 23
    1396 57259 57284 26
    1397 57317 57332 16
    1398 57346 57369 24
    1399 57388 57423 36
    1400 57425 57440 16
    1401 57442 57455 14
    1402 57475 57492 18
    1403 57508 57522 15
    1404 57522 57546 25
    1405 57548 57576 29
    1406 57593 57634 42
    1407 57658 57675 18
    1408 57687 57771 85
    1409 57786 57803 18
    1410 57801 57819 19
    1411 57830 57858 29
    1412 57889 57911 23
    1413 57926 57945 20
    1414 57947 57972 26
    1415 58009 58028 20
    1416 58030 58060 31
    1417 58063 58091 29
    1418 58124 58146 23
    1419 58147 58162 16
    1420 58163 58198 36
    1421 58214 58292 79
    1422 58292 58309 18
    1423 58336 58429 94
    1424 58436 58457 22
    1425 58453 58501 49
    1426 58525 58553 29
    1427 58566 58579 14
    1428 58571 58584 14
    1429 58586 58601 16
    1430 58604 58630 27
    1431 58656 58682 27
    1432 58696 58713 18
    1433 58722 58744 23
    1434 58757 58771 15
    1435 58805 58979 175
    1436 58987 59073 87
    1437 59072 59123 52
    1438 59124 59150 27
    1439 59154 59234 81
    1440 59231 59276 46
    1441 59291 59413 123
    1442 59413 59458 46
    1443 59466 59511 46
    1444 59513 59533 21
    1445 59549 59764 216
    1446 59762 59825 64
    1447 59824 59907 84
    1448 59916 60004 89
    1449 60006 60030 25
    1450 60027 60040 14
    1451 60032 60100 69
    1452 60119 60188 70
    1453 60191 60227 37
    1454 60220 60287 68
    1455 60289 60314 26
    1456 60316 60554 239
    1457 60556 60575 20
    1458 60579 60593 15
    1459 60595 60638 44
    1460 60651 60690 40
    1461 60692 60724 33
    1462 60716 60799 84
    1463 60801 60872 72
    1464 60868 60881 14
    1465 60885 60912 28
    1466 60961 61009 49
    1467 61014 61042 29
    1468 61046 61059 14
    1469 61053 61066 14
    1470 61061 61084 24
    1471 61134 61164 31
    1472 61178 61199 22
    1473 61201 61229 29
    1474 61258 61284 27
    1475 61286 61304 19
    1476 61316 61332 17
    1477 61341 61354 14
    1478 61356 61383 28
    1479 61407 61440 34
    1480 61451 61468 18
    1481 61470 61497 28
    1482 61493 61506 14
    1483 61499 61529 31
    1484 61531 61558 28
    1485 61590 61615 26
    1486 61623 61640 18
    1487 61673 61877 205
    1488 61879 61898 20
    1489 61900 61941 42
    1490 61943 61962 20
    1491 61964 61983 20
    1492 62003 62017 15
    1493 62015 62080 66
    1494 62100 62124 25
    1495 62133 62146 14
    1496 62139 62175 37
    1497 62191 62237 47
    1498 62250 62270 21
    1499 62283 62316 34
    1500 62310 62358 49
    1501 62357 62397 41
    1502 62399 62413 15
    1503 62415 62470 56
    1504 62472 62501 30
    1505 62503 62541 39
    1506 62553 62609 57
    1507 62611 62656 46
    1508 62663 62690 28
    1509 62703 62735 33
    1510 62737 62759 23
    1511 62765 62789 25
    1512 62802 62816 15
    1513 62810 62824 15
    1514 62853 62868 16
    1515 62864 62878 15
    1516 62878 62907 30
    1517 62905 62937 33
    1518 62937 62951 15
    1519 62943 62956 14
    1520 62946 62960 15
    1521 62961 62988 28
    1522 62993 63006 14
    1523 63005 63019 15
    1524 63030 63049 20
    1525 63057 63076 20
    1526 63073 63088 16
    1527 63078 63125 48
    1528 63128 63152 25
    1529 63154 63170 17
    1530 63172 63196 25
    1531 63185 63223 39
    1532 63225 63245 21
    1533 63236 63254 19
    1534 63245 63261 17
    1535 63263 63276 14
    1536 63280 63295 16
    1537 63292 63336 45
    1538 63344 63368 25
    1539 63369 63396 28
    1540 63385 63398 14
    1541 63395 63417 23
    1542 63433 63451 19
    1543 63440 63453 14
    1544 63454 63470 17
    1545 63472 63511 40
    1546 63513 63539 27
    1547 63547 63603 57
    1548 63625 63651 27
    1549 63676 63692 17
    1550 63730 63746 17
    1551 63759 63775 17
    1552 63779 63833 55
    1553 63844 63883 40
    1554 63889 63907 19
    1555 63910 63938 29
    1556 63943 63962 20
    1557 64004 64033 30
    1558 64056 64087 32
    1559 64112 64132 21
    1560 64142 64158 17
    1561 64160 64191 32
    1562 64193 64209 17
    1563 64214 64227 14
    1564 64228 64241 14
    1565 64254 64278 25
    1566 64280 64298 19
    1567 64300 64338 39
    1568 64340 64355 16
    1569 64357 64380 24
    1570 64412 64434 23
    1571 64438 64456 19
    1572 64458 64488 31
    1573 64490 64517 28
    1574 64519 64538 20
    1575 64552 64572 21
    1576 64585 64608 24
    1577 64625 64642 18
    1578 64631 64644 14
    1579 64644 64683 40
    1580 64703 64716 14
    1581 64736 64751 16
    1582 64759 64773 15
    1583 64775 64806 32
    1584 64815 64831 17
    1585 64845 64878 34
    1586 64880 64904 25
    1587 64915 64937 23
    1588 64948 64971 24
    1589 64973 64994 22
    1590 64996 65017 22
    1591 65019 65055 37
    1592 65062 65109 48
    1593 65111 65138 28
    1594 65140 65179 40
    1595 65181 65195 15
    1596 65210 65230 21
    1597 65232 65248 17
    1598 65271 65296 26
    1599 65298 65319 22
    1600 65321 65371 51
    1601 65391 65413 23
    1602 65415 65436 22
    1603 65436 65454 19
    1604 65477 65490 14
    1605 65492 65520 29
    1606 65522 65552 31
    1607 65554 65579 26
    1608 65581 65594 14
    1609 65591 65606 16
    1610 65595 65616 22
    1611 65618 65632 15
    1612 65634 65657 24
    1613 65661 65716 56
    1614 65730 65747 18
    1615 65748 65807 60
    1616 65809 65829 21
    1617 65831 65844 14
    1618 65846 65859 14
    1619 65861 65891 31
    1620 65898 65920 23
    1621 65930 65963 34
    1622 65980 66060 81
    1623 66069 66085 17
    1624 66095 66108 14
    1625 66110 66126 17
    1626 66139 66173 35
    1627 66175 66191 17
    1628 66204 66226 23
    1629 66224 66263 40
    1630 66265 66278 14
    1631 66280 66320 41
    1632 66322 66345 24
    1633 66355 66371 17
    1634 66375 66407 33
    1635 66411 66424 14
    1636 66421 66441 21
    1637 66440 66460 21
    1638 66463 66482 20
    1639 66484 66501 18
    1640 66509 66527 19
    1641 66534 66548 15
    1642 66556 66569 14
    1643 66562 66593 32
    1644 66606 66637 32
    1645 66639 66665 27
    1646 66674 66690 17
    1647 66692 66720 29
    1648 66722 66742 21
    1649 66758 66786 29
    1650 66787 66802 16
    1651 66812 66862 51
    1652 66864 66885 22
    1653 66940 66953 14
    1654 66982 66997 16
    1655 67024 67084 61
    1656 67103 67118 16
    1657 67156 67185 30
    1658 67181 67195 15
    1659 67193 67206 14
    1660 67215 67229 15
    1661 67231 67271 41
    1662 67288 67301 14
    1663 67294 67345 52
    1664 67362 67379 18
    1665 67381 67397 17
    1666 67409 67448 40
    1667 67468 67481 14
    1668 67483 67510 28
    1669 67540 67561 22
    1670 67620 67640 21
    1671 67656 67672 17
    1672 67674 67749 76
    1673 67751 67764 14
    1674 67783 67801 19
    1675 67803 67828 26
    1676 67830 67848 19
    1677 67850 67868 19
    1678 67877 67918 42
    1679 67933 67961 29
    1680 67963 67978 16
    1681 67998 68026 29
    1682 68028 68046 19
    1683 68048 68082 35
    1684 68084 68112 29
    1685 68114 68130 17
    1686 68129 68155 27
    1687 68170 68192 23
    1688 68194 68237 44
    1689 68239 68261 23
    1690 68272 68286 15
    1691 68290 68373 84
    1692 68375 68419 45
    1693 68442 68487 46
    1694 68489 68547 59
    1695 68549 68592 44
    1696 68599 68614 16
    1697 68617 68657 41
    1698 68659 68686 28
    1699 68688 68735 48
    1700 68732 68747 16
    1701 68749 68786 38
    1702 68788 68830 43
    1703 68837 68879 43
    1704 68882 68899 18
    1705 68918 68942 25
    1706 68944 68968 25
    1707 68983 69007 25
    1708 69012 69027 16
    1709 69020 69064 45
    1710 69064 69077 14
    1711 69079 69114 36
    1712 69116 69196 81
    1713 69185 69198 14
    1714 69202 69219 18
    1715 69228 69246 19
    1716 69240 69282 43
    1717 69294 69317 24
    1718 69306 69324 19
    1719 69333 69346 14
    1720 69352 69366 15
    1721 69387 69431 45
    1722 69433 69447 15
    1723 69452 69480 29
    1724 69482 69497 16
    1725 69491 69504 14
    1726 69511 69564 54
    1727 69566 69628 63
    1728 69628 69642 15
    1729 69659 69681 23
    1730 69684 69697 14
    1731 69719 69744 26
    1732 69746 69763 18
    1733 69765 69792 28
    1734 69801 69828 28
    1735 69853 69901 49
    1736 69933 69949 17
    1737 69951 69966 16
    1738 69968 69983 16
    1739 69988 70061 74
    1740 70083 70100 18
    1741 70110 70154 45
    1742 70161 70199 39
    1743 70202 70225 24
    1744 70231 70246 16
    1745 70269 70295 27
    1746 70292 70327 36
    1747 70331 70349 19
    1748 70351 70371 21
    1749 70381 70403 23
    1750 70405 70420 16
    1751 70422 70483 62
    1752 70496 70533 38
    1753 70535 70578 44
    1754 70577 70639 63
    1755 70653 70667 15
    1756 70661 70674 14
    1757 70669 70695 27
    1758 70687 70705 19
    1759 70708 70744 37
    1760 70746 70764 19
    1761 70766 70779 14
    1762 70781 70832 52
    1763 70834 70851 18
    1764 70858 70887 30
    1765 70889 70902 14
    1766 70920 70933 14
    1767 70935 70964 30
    1768 70974 70987 14
    1769 71008 71028 21
    1770 71030 71046 17
    1771 71048 71073 26
    1772 71075 71106 32
    1773 71108 71133 26
    1774 71137 71152 16
    1775 71153 71170 18
    1776 71179 71192 14
    1777 71197 71224 28
    1778 71235 71251 17
    1779 71253 71311 59
    1780 71310 71329 20
    1781 71330 71364 35
    1782 71366 71386 21
    1783 71388 71410 23
    1784 71412 71433 22
    1785 71448 71472 25
    1786 71475 71491 17
    1787 71491 71553 63
    1788 71555 71581 27
    1789 71583 71624 42
    1790 71634 71700 67
    1791 71706 71725 20
    1792 71732 71747 16
    1793 71789 71804 16
    1794 71810 71824 15
    1795 71819 71834 16
    1796 71839 71872 34
    1797 71876 71889 14
    1798 71886 71908 23
    1799 71910 71924 15
    1800 71985 71999 15
    1801 72000 72021 22
    1802 72023 72047 25
    1803 72071 72158 88
    1804 72165 72192 28
    1805 72194 72234 41
    1806 72236 72255 20
    1807 72257 72281 25
    1808 72283 72299 17
    1809 72312 72329 18
    1810 72323 72336 14
    1811 72348 72395 48
    1812 72398 72411 14
    1813 72413 72455 43
    1814 72470 72503 34
    1815 72506 72541 36
    1816 72545 72558 14
    1817 72560 72586 27
    1818 72583 72597 15
    1819 72588 72602 15
    1820 72611 72636 26
    1821 72638 72688 51
    1822 72696 72736 41
    1823 72738 72761 24
    1824 72774 72799 26
    1825 72801 72886 86
    1826 72888 72903 16
    1827 72928 72958 31
    1828 72962 72990 29
    1829 73001 73014 14
    1830 73017 73053 37
    1831 73055 73078 24
    1832 73077 73090 14
    1833 73088 73121 34
    1834 73124 73153 30
    1835 73147 73172 26
    1836 73164 73203 40
    1837 73218 73257 40
    1838 73260 73273 14
    1839 73268 73281 14
    1840 73278 73291 14
    1841 73298 73313 16
    1842 73451 73465 15
    1843 73459 73472 14
    1844 73512 73567 56
    1845 73569 73611 43
    1846 73614 73645 32
    1847 73661 73713 53
    1848 73712 73727 16
    1849 73716 73731 16
    1850 73735 73748 14
    1851 73741 73760 20
    1852 73764 73782 19
    1853 73783 73801 19
    1854 73795 73829 35
    1855 73860 73873 14
    1856 73885 73904 20
    1857 73906 73919 14
    1858 73916 73945 30
    1859 73947 73961 15
    1860 73978 74018 41
    1861 74020 74046 27
    1862 74061 74082 22
    1863 74092 74158 67
    1864 74160 74177 18
    1865 74179 74209 31
    1866 74216 74245 30
    1867 74270 74287 18
    1868 74289 74305 17
    1869 74307 74368 62
    1870 74369 74411 43
    1871 74416 74461 46
    1872 74463 74479 17
    1873 74506 74541 36
    1874 74543 74636 94
    1875 74647 74704 58
    1876 74745 74770 26
    1877 74789 74813 25
    1878 74815 74838 24
    1879 74850 74877 28
    1880 74891 74923 33
    1881 74925 74940 16
    1882 74952 74969 18
    1883 74979 75001 23
    1884 75037 75066 30
    1885 75068 75088 21
    1886 75097 75123 27
    1887 75131 75149 19
    1888 75152 75189 38
    1889 75210 75252 43
    1890 75254 75276 23
    1891 75288 75310 23
    1892 75338 75357 20
    1893 75359 75372 14
    1894 75376 75397 22
    1895 75405 75432 28
    1896 75440 75470 31
    1897 75482 75501 20
    1898 75503 75540 38
    1899 75544 75560 17
    1900 75562 75576 15
    1901 75589 75610 22
    1902 75633 75646 14
    1903 75648 75679 32
    1904 75691 75709 19
    1905 75711 75724 14
    1906 75740 75764 25
    1907 75763 75776 14
    1908 75767 75790 24
    1909 75780 75794 15
    1910 75792 75808 17
    1911 75810 75829 20
    1912 75831 75863 33
    1913 75865 75880 16
    1914 75882 75922 41
    1915 75932 75998 67
    1916 76000 76026 27
    1917 76028 76045 18
    1918 76046 76082 37
    1919 76098 76413 316
    1920 76420 76442 23
    1921 76456 76477 22
    1922 76484 76558 75
    1923 76573 76592 20
    1924 76608 76622 15
    1925 76627 76663 37
    1926 76665 76683 19
    1927 76685 76698 14
    1928 76702 76716 15
    1929 76725 76744 20
    1930 76745 76761 17
    1931 76780 76796 17
    1932 76798 76812 15
    1933 76814 76832 19
    1934 76834 76859 26
    1935 76871 76934 64
    1936 77012 77034 23
    1937 77039 77055 17
    1938 77081 77094 14
    1939 77121 77184 64
    1940 77186 77200 15
    1941 77202 77225 24
    1942 77227 77247 21
    1943 77261 77317 57
    1944 77327 77340 14
    1945 77342 77366 25
    1946 77377 77394 18
    1947 77396 77439 44
    1948 77453 77468 16
    1949 77462 77593 132
    1950 77586 77599 14
    1951 77595 77641 47
    1952 77643 77728 86
    1953 77730 77768 39
    1954 77778 77816 39
    1955 77818 77835 18
    1956 77837 77855 19
    1957 77861 77876 16
    1958 77882 77898 17
    1959 77900 77924 25
    1960 77923 77936 14
    1961 77957 77970 14
    1962 77962 77985 24
    1963 77994 78022 29
    1964 78024 78056 33
    1965 78079 78128 50
    1966 78132 78158 27
    1967 78173 78213 41
    1968 78224 78265 42
    1969 78275 78332 58
    1970 78334 78440 107
    1971 78442 78489 48
    1972 78491 78505 15
    1973 78501 78514 14
    1974 78507 78537 31
    1975 78557 78570 14
    1976 78562 78623 62
    1977 78625 78665 41
    1978 78668 78684 17
    1979 78686 78759 74
    1980 78761 78787 27
    1981 78793 78814 22
    1982 78816 78854 39
    1983 78847 78860 14
    1984 78874 78909 36
    1985 78917 78944 28
    1986 78956 78978 23
    1987 78991 79008 18
    1988 79003 79032 30
    1989 79026 79040 15
    1990 79044 79072 29
    1991 79098 79158 61
    1992 79162 79182 21
    1993 79184 79228 45
    1994 79221 79235 15
    1995 79230 79262 33
    1996 79287 79333 47
    1997 79356 79392 37
    1998 79441 79476 36
    1999 79488 79522 35
    2000 79522 79539 18
    2001 79568 79583 16
    2002 79574 79601 28
    2003 79603 79618 16
    2004 79617 79639 23
    2005 79651 79683 33
    2006 79685 79724 40
    2007 79721 79736 16
    2008 79727 79782 56
    2009 79784 79812 29
    2010 79809 79834 26
    2011 79841 79861 21
    2012 79873 79923 51
    2013 79928 79948 21
    2014 79950 79986 37
    2015 79993 80019 27
    2016 80019 80063 45
    2017 80071 80088 18
    2018 80114 80160 47
    2019 80154 80183 30
    2020 80185 80212 28
    2021 80214 80232 19
    2022 80240 80266 27
    2023 80293 80312 20
    2024 80344 80380 37
    2025 80382 80420 39
    2026 80410 80423 14
    2027 80417 80438 22
    2028 80440 80456 17
    2029 80467 80499 33
    2030 80501 80527 27
    2031 80532 80561 30
    2032 80563 80599 37
    2033 80604 80692 89
    2034 80702 80737 36
    2035 80739 80795 57
    2036 80796 80871 76
    2037 80873 80891 19
    2038 80925 80961 37
    2039 80963 80992 30
    2040 81009 81068 60
    2041 81070 81150 81
    2042 81156 81199 44
    2043 81201 81225 25
    2044 81237 81253 17
    2045 81255 81271 17
    2046 81292 81351 60
    2047 81353 81371 19
    2048 81392 81422 31
    2049 81438 81483 46
    2050 81485 81503 19
    2051 81512 81526 15
    2052 81532 81554 23
    2053 81556 81593 38
    2054 81606 81664 59
    2055 81666 81698 33
    2056 81701 81720 20
    2057 81728 81776 49
    2058 81781 81810 30
    2059 81812 81847 36
    2060 81849 81893 45
    2061 81908 81934 27
    2062 81943 81964 22
    2063 81967 82034 68
    2064 82036 82134 99
    2065 82136 82154 19
    2066 82176 82197 22
    2067 82199 82250 52
    2068 82252 82269 18
    2069 82271 82293 23
    2070 82300 82314 15
    2071 82329 82343 15
    2072 82344 82357 14
    2073 82378 82407 30
    2074 82406 82422 17
    2075 82421 82443 23
    2076 82446 82469 24
    2077 82490 82507 18
    2078 82502 82523 22
    2079 82547 82576 30
    2080 82590 82603 14
    2081 82628 82647 20
    2082 82650 82666 17
    2083 82669 82683 15
    2084 82685 82716 32
    2085 82715 82736 22
    2086 82760 82785 26
    2087 82778 82791 14
    2088 82780 82818 39
    2089 82811 82825 15
    2090 82821 82864 44
    2091 82883 82915 33
    2092 82919 82935 17
    2093 82930 82946 17
    2094 82937 82957 21
    2095 82959 82972 14
    2096 82974 83000 27
    2097 83020 83036 17
    2098 83038 83088 51
    2099 83090 83115 26
    2100 83120 83140 21
    2101 83142 83155 14
    2102 83160 83186 27
    2103 83198 83215 18
    2104 83227 83246 20
    2105 83273 83339 67
    2106 83341 83385 45
    2107 83387 83400 14
    2108 83413 83426 14
    2109 83417 83449 33
    2110 83486 83520 35
    2111 83522 83565 44
    2112 83567 83581 15
    2113 83576 83670 95
    2114 83681 83701 21
    2115 83703 83716 14
    2116 83733 83817 85
    2117 83817 83830 14
    2118 83832 83853 22
    2119 83855 83871 17
    2120 83886 83926 41
    2121 83958 83974 17
    2122 83976 83991 16
    2123 83993 84031 39
    2124 84033 84067 35
    2125 84069 84102 34
    2126 84104 84121 18
    2127 84143 84233 91
    2128 84249 84281 33
    2129 84283 84403 121
    2130 84404 84432 29
    2131 84431 84444 14
    2132 84434 84490 57
    2133 84503 84520 18
    2134 84522 84555 34
    2135 84557 84572 16
    2136 84574 84597 24
    2137 84607 84626 20
    2138 84650 84675 26
    2139 84677 84700 24
    2140 84721 84753 33
    2141 84755 84807 53
    2142 84809 84826 18
    2143 84831 84849 19
    2144 84879 84893 15
    2145 84895 84915 21
    2146 84917 84961 45
    2147 85234 85247 14
    2148 85253 85267 15
    2149 85256 85351 96
    2150 85359 85374 16
    2151 85363 85376 14
    2152 85365 85381 17
    2153 85380 85414 35
    2154 85416 85454 39
    2155 85456 85484 29
    2156 85509 85545 37
    2157 85535 85550 16
    2158 85566 85584 19
    2159 85586 85610 25
    2160 85604 85627 24
    2161 85628 85665 38
    2162 85698 85723 26
    2163 85713 85728 16
    2164 85722 85735 14
    2165 85770 85785 16
    2166 85800 85813 14
    2167 85875 85888 14
    2168 85950 85963 14
    2169 86097 86125 29
    2170 86127 86142 16
    2171 86175 86198 24
    2172 86226 86242 17
    2173 86237 86302 66
    2174 86308 86327 20
    2175 86321 86334 14
    2176 86329 86382 54
    2177 86384 86400 17
    2178 86403 86417 15
    2179 86414 86437 24
    2180 86439 86455 17
    2181 86461 86478 18
    2182 86473 86487 15
    2183 86480 86517 38
    2184 86517 86531 15
    2185 86565 86583 19
    2186 86600 86632 33
    2187 86634 86651 18
    2188 86653 86678 26
    2189 86697 86756 60
    2190 86782 86796 15
    2191 86786 86809 24
    2192 86811 86855 45
    2193 86857 86891 35
    2194 86894 86908 15
    2195 86916 86933 18
    2196 86945 86959 15
    2197 86951 86965 15
    2198 86969 86990 22
    2199 87017 87057 41
    2200 87059 87073 15
    2201 87062 87076 15
    2202 87066 87089 24
    2203 87097 87121 25
    2204 87110 87134 25
    2205 87130 87155 26
    2206 87160 87194 35
    2207 87185 87198 14
    2208 87209 87260 52
    2209 87257 87270 14
    2210 87274 87287 14
    2211 87276 87294 19
    2212 87294 87328 35
    2213 87317 87333 17
    2214 87336 87360 25
    2215 87368 87418 51
    2216 87441 87460 20
    2217 87462 87487 26
    2218 87489 87518 30
    2219 87520 87539 20
    2220 87542 87570 29
    2221 87572 87601 30
    2222 87603 87644 42
    2223 87642 87750 109
    2224 87756 87776 21
    2225 87778 87803 26
    2226 87803 87837 35
    2227 87872 87888 17
    2228 87890 87917 28
    2229 87949 87964 16
    2230 87963 88008 46
    2231 88010 88027 18
    2232 88029 88046 18
    2233 88048 88089 42
    2234 88091 88108 18
    2235 88110 88177 68
    2236 88179 88192 14
    2237 88194 88229 36
    2238 88234 88259 26
    2239 88261 88291 31
    2240 88303 88328 26
    2241 88328 88341 14
    2242 88340 88354 15
    2243 88356 88372 17
    2244 88411 88446 36
    2245 88448 88465 18
    2246 88469 88511 43
    2247 88518 88533 16
    2248 88531 88557 27
    2249 88547 88560 14
    2250 88573 88593 21
    2251 88597 88618 22
    2252 88620 88690 71
    2253 88692 88745 54
    2254 88954 88973 20
    2255 88988 89047 60
    2256 89066 89091 26
    2257 89098 89119 22
    2258 89135 89149 15
    2259 89151 89181 31
    2260 89177 89193 17
    2261 89223 89273 51
    2262 89285 89300 16
    2263 89315 89383 69
    2264 89404 89442 39
    2265 89444 89541 98
    2266 89579 89639 61
    2267 89660 89692 33
    2268 89694 89741 48
    2269 89773 89787 15
    2270 89789 89817 29
    2271 89826 89888 63
    2272 89904 89922 19
    2273 89937 89950 14
    2274 89945 89958 14
    2275 89956 89974 19
    2276 89971 89985 15
    2277 89979 89992 14
    2278 89984 90000 17
    2279 89999 90014 16
    2280 90017 90041 25
    2281 90036 90049 14
    2282 90077 90093 17
    2283 90099 90128 30
    2284 90130 90155 26
    2285 90157 90200 44
    2286 90225 90256 32
    2287 90258 90293 36
    2288 90305 90318 14
    2289 90320 90352 33
    2290 90356 90370 15
    2291 90400 90421 22
    2292 90423 90461 39
    2293 90464 90507 44
    2294 90509 90530 22
    2295 90529 90542 14
    2296 90531 90567 37
    2297 90569 90612 44
    2298 90614 90730 117
    2299 90732 90758 27
    2300 90760 90885 126
    2301 90887 90918 32
    2302 90920 90946 27
    2303 90938 90955 18
    2304 90960 90973 14
    2305 90965 90981 17
    2306 90973 91000 28
    2307 90997 91011 15
    2308 91002 91019 18
    2309 91059 91140 82
    2310 91142 91157 16
    2311 91157 91194 38
    2312 91196 91231 36
    2313 91233 91251 19
    2314 91253 91274 22
    2315 91296 91310 15
    2316 91335 91367 33
    2317 91406 91442 37
    2318 91447 91477 31
    2319 91489 91509 21
    2320 91520 91621 102
    2321 91623 91674 52
    2322 91680 91703 24
    2323 91715 91731 17
    2324 91733 91771 39
    2325 91773 91788 16
    2326 91790 91805 16
    2327 91807 91823 17
    2328 91825 91859 35
    2329 91861 91900 40
    2330 91907 91926 20
    2331 91928 91943 16
    2332 91950 91980 31
    2333 91982 91996 15
    2334 91998 92011 14
    2335 92010 92027 18
    2336 92027 92067 41
    2337 92069 92126 58
    2338 92128 92321 194
    2339 92323 92540 218
    2340 92542 92558 17
    2341 92566 92684 119
    2342 92686 92726 41
    2343 92728 92837 110
    2344 92839 93032 194
    2345 93034 93094 61
    2346 93100 93209 110
    2347 93211 93254 44
    2348 93256 93323 68
    2349 93325 93448 124
    2350 93459 93477 19
    2351 93475 93497 23
    2352 93509 93530 22
    2353 93532 93566 35
    2354 93568 93601 34
    2355 93606 93646 41
    2356 93668 93716 49
    2357 93718 93742 25
    2358 93744 93788 45
    2359 93790 93808 19
    2360 93811 93832 22
    2361 93874 93901 28
    2362 93904 93986 83
    2363 94021 94036 16
    2364 94038 94079 42
    2365 94073 94086 14
    2366 94097 94116 20
    2367 94118 94141 24
    2368 94140 94219 80
    2369 94242 94257 16
    2370 94264 94335 72
    2371 94337 94356 20
    2372 94358 94378 21
    2373 94373 94386 14
    2374 94384 94403 20
    2375 94405 94422 18
    2376 94453 94497 45
    2377 94497 94558 62
    2378 94560 94605 46
    2379 94630 94724 95
    2380 94739 94752 14
    2381 94755 94786 32
    2382 94800 94815 16
    2383 94872 94901 30
    2384 94903 94953 51
    2385 94955 95060 106
    2386 95070 95085 16
    2387 95093 95110 18
    2388 95135 95149 15
    2389 95154 95168 15
    2390 95170 95210 41
    2391 95227 95257 31
    2392 95302 95318 17
    2393 95311 95356 46
    2394 95359 95401 43
    2395 95403 95453 51
    2396 95450 95463 14
    2397 95475 95491 17
    2398 95503 95553 51
    2399 95555 95569 15
    2400 95583 95609 27
    2401 95634 95668 35
    2402 95718 95738 21
    2403 95727 95740 14
    2404 95836 95849 14
    2405 95851 95872 22
    2406 95874 95888 15
    2407 95890 95910 21
    2408 95912 95925 14
    2409 95938 95969 32
    2410 95973 95990 18
    2411 95992 96066 75
    2412 96073 96087 15
    2413 96103 96120 18
    2414 96122 96167 46
    2415 96169 96182 14
    2416 96183 96211 29
    2417 96213 96234 22
    2418 96246 96279 34
    2419 96300 96334 35
    2420 96358 96375 18
    2421 96377 96398 22
    2422 96424 96467 44
    2423 96496 96518 23
    2424 96520 96535 16
    2425 96540 96566 27
    2426 96572 96592 21
    2427 96604 96646 43
    2428 96642 96655 14
    2429 96648 96667 20
    2430 96681 96728 48
    2431 96730 96781 52
    2432 96804 96829 26
    2433 96831 96879 49
    2434 96887 96916 17
    2435 96928 96944 30
    2436 96946 96959 14
    2437 96970 96990 21
    2438 96992 97021 30
    2439 97023 97037 15
    2440 97039 97073 35
    2441 97075 97366 292
    2442 97368 97393 26
    2443 97420 97466 47
    2444 97469 97507 39
    2445 97513 97529 17
    2446 97531 97583 53
    2447 97585 97600 16
    2448 97602 97631 30
    2449 97633 97683 51
    2450 97685 97703 19
    2451 97705 97742 38
    2452 97787 97803 17
    2453 97805 97822 18
    2454 97824 97876 53
    2455 97878 97921 44
    2456 97923 97943 21
    2457 97945 97963 19
    2458 97965 97994 30
    2459 97995 98011 17
    2460 98014 98044 31
    2461 98039 98061 23
    2462 98055 98076 22
    2463 98077 98090 14
    2464 98079 98092 14
    2465 98085 98098 14
    2466 98100 98115 16
    2467 98113 98145 33
    2468 98142 98160 19
    2469 98162 98180 19
    2470 98188 98219 32
    2471 98215 98237 23
    2472 98227 98240 14
    2473 98232 98255 24
    2474 98255 98268 14
    2475 98264 98287 24
    2476 98292 98326 35
    2477 98373 98397 25
    2478 98399 98428 30
    2479 98442 98461 20
    2480 98480 98501 22
    2481 98499 98520 22
    2482 98524 98538 15
    2483 98537 98550 14
    2484 98545 98585 41
    2485 98595 98610 16
    2486 98599 98624 26
    2487 98644 98668 25
    2488 98678 98704 27
    2489 98703 98718 16
    2490 98736 98754 19
    2491 98778 98794 17
    2492 98802 98821 20
    2493 98845 98876 32
    2494 98878 98900 23
    2495 98900 98972 73
    2496 98961 98976 16
    2497 98974 98998 25
    2498 99011 99029 19
    2499 99033 99065 33
    2500 99067 99107 41
    2501 99151 99186 36
    2502 99188 99219 32
    2503 99222 99245 24
    2504 99254 99276 23
    2505 99288 99312 25
    2506 99314 99338 25
    2507 99367 99430 64
    2508 99444 99491 48
    2509 99496 99554 59
    2510 99570 99585 16
    2511 99587 99618 32
    2512 99620 99669 50
    2513 99679 99710 32
    2514 99720 99748 29
    2515 99750 99763 14
    2516 99768 99805 38
    2517 99818 99841 24
    2518 99855 99879 25
    2519 99881 99900 20
    2520 99902 99932 31
    2521 99934 99954 21
    2522 99959 100011 53
    2523 100011 100037 27
    2524 100057 100071 15
    2525 100073 100102 30
    2526 100104 100118 15
    2527 100131 100186 56
    2528 100188 100201 14
    2529 100194 100212 19
    2530 100214 100277 64
    2531 100279 100303 25
    2532 100309 100355 47
    2533 100349 100386 38
    2534 100379 100393 15
    2535 100388 100401 14
    2536 100403 100423 21
    2537 100452 100473 22
    2538 100508 100542 35
    2539 100548 100580 33
    2540 100582 100612 31
    2541 100614 100652 39
    2542 100695 100714 20
    2543 100736 100749 14
    2544 100751 100790 40
    2545 100808 100842 35
    2546 100844 100860 17
    2547 100862 100930 69
    2548 100939 100953 15
    2549 100955 100971 17
    2550 100973 101003 31
    2551 101021 101048 28
    2552 101057 101093 37
    2553 101109 101148 40
    2554 101145 101189 45
    2555 101194 101208 15
    2556 101210 101244 35
    2557 101256 101271 16
    2558 101277 101300 24
    2559 101310 101327 18
    2560 101329 101345 17
    2561 101374 101397 24
    2562 101409 101426 18
    2563 101453 101466 14
    2564 101474 101487 14
    2565 101481 101515 35
    2566 101518 101541 24
    2567 101542 101560 19
    2568 101554 101591 38
    2569 101593 101609 17
    2570 101635 101695 61
    2571 101707 101746 40
    2572 101748 101763 16
    2573 101774 101810 37
    2574 101812 101828 17
    2575 101819 101835 17
    2576 101829 101842 14
    2577 101842 101855 14
    2578 101857 101878 22
    2579 101880 101943 64
    2580 101947 101981 35
    2581 101988 102009 22
    2582 102022 102066 45
    2583 102068 102084 17
    2584 102100 102113 14
    2585 102115 102130 16
    2586 102132 102145 14
    2587 102192 102241 50
    2588 102269 102285 17
    2589 102312 102327 16
    2590 102357 102392 36
    2591 102407 102428 22
    2592 102430 102444 15
    2593 102460 102485 26
    2594 102487 102508 22
    2595 102532 102573 42
    2596 102595 102642 48
    2597 102653 102694 42
    2598 102701 102718 18
    2599 102720 102734 15
    2600 102736 102757 22
    2601 102799 102836 38
    2602 102847 102882 36
    2603 102890 102927 38
    2604 102938 102971 34
    2605 102982 103019 38
    2606 103014 103027 14
    2607 103027 103054 28
    2608 103065 103088 24
    2609 103090 103108 19
    2610 103098 103112 15
    2611 103117 103138 22
    2612 103152 103170 19
    2613 103174 103204 31
    2614 103206 103234 29
    2615 103240 103268 29
    2616 103286 103325 40
    2617 103327 103347 21
    2618 103349 103384 36
    2619 103386 103405 20
    2620 103422 103449 28
    2621 103451 103493 43
    2622 103495 103509 15
    2623 103511 103560 50
    2624 103565 103582 18
    2625 103585 103607 23
    2626 103631 103645 15
    2627 103653 103684 32
    2628 103683 103696 14
    2629 103691 103733 43
    2630 103738 103762 25
    2631 103752 103765 14
    2632 103755 103768 14
    2633 103758 103771 14
    2634 103790 103814 25
    2635 103803 103816 14
    2636 103830 103865 36
    2637 103900 103923 24
    2638 103912 103933 22
    2639 103945 103964 20
    2640 103990 104005 16
    2641 104024 104055 32
    2642 104058 104077 20
    2643 104086 104099 14
    2644 104095 104122 28
    2645 104124 104146 23
    2646 104148 104168 21
    2647 104162 104176 15
    2648 104173 104187 15
    2649 104201 104241 41
    2650 104234 104266 33
    2651 104268 104286 19
    2652 104288 104302 15
    2653 104304 104335 32
    2654 104340 104354 15
    2655 104356 104373 18
    2656 104375 104391 17
    2657 104393 104417 25
    2658 104426 104439 14
    2659 104448 104478 31
    2660 104480 104504 25
    2661 104519 104546 28
    2662 104549 104580 32
    2663 104604 104620 17
    2664 104620 104646 27
    2665 104654 104673 20
    2666 104675 104691 17
    2667 104689 104776 88
    2668 104829 104842 14
    2669 104838 104852 15
    2670 104934 104952 19
    2671 104956 104987 32
    2672 104993 105045 53
    2673 105041 105055 15
    2674 105047 105078 32
    2675 105090 105107 18
    2676 105101 105115 15
    2677 105109 105137 29
    2678 105149 105167 19
    2679 105163 105176 14
    2680 105185 105237 53
    2681 105230 105243 14
    2682 105233 105250 18
    2683 105260 105286 27
    2684 105288 105340 53
    2685 105345 105370 26
    2686 105372 105402 31
    2687 105441 105458 18
    2688 105460 105521 62
    2689 105526 105541 16
    2690 105543 105560 18
    2691 105562 105575 14
    2692 105582 105606 25
    2693 105616 105671 56
    2694 105677 105704 28
    2695 105703 105725 23
    2696 105746 105759 14
    2697 105750 105765 16
    2698 105776 105796 21
    2699 105798 105824 27
    2700 105827 105907 81
    2701 105924 105939 16
    2702 105941 105963 23
    2703 105990 106014 25
    2704 106017 106048 32
    2705 106039 106072 34
    2706 106061 106074 14
    2707 106073 106102 30
    2708 106092 106107 16
    2709 106114 106159 46
    2710 106161 106180 20
    2711 106197 106243 47
    2712 106237 106250 14
    2713 106243 106256 14
    2714 106247 106267 21
    2715 106273 106333 61
    2716 106335 106367 33
    2717 106369 106417 49
    2718 106419 106471 53
    2719 106486 106523 38
    2720 106525 106538 14
    2721 106552 106572 21
    2722 106584 106598 15
    2723 106609 106696 88
    2724 106698 106723 26
    2725 106725 106740 16
    2726 106743 106781 39
    2727 106783 106811 29
    2728 106826 106866 41
    2729 106875 106902 28
    2730 106916 106935 20
    2731 106942 106960 19
    2732 106991 107010 20
    2733 107019 107038 20
    2734 107040 107072 33
    2735 107079 107094 16
    2736 107087 107101 15
    2737 107090 107109 20
    2738 107113 107127 15
    2739 107129 107143 15
    2740 107154 107172 19
    2741 107174 107198 25
    2742 107210 107226 17
    2743 107226 107239 14
    2744 107237 107274 38
    2745 107296 107356 61
    2746 107358 107381 24
    2747 107383 107415 33
    2748 107417 107433 17
    2749 107435 107455 21
    2750 107457 107508 52
    2751 107510 107525 16
    2752 107527 107546 20
    2753 107559 107573 15
    2754 107586 107617 32
    2755 107643 107689 47
    2756 107694 107716 23
    2757 107744 107792 49
    2758 107790 107832 43
    2759 107834 107860 27
    2760 107864 107896 33
    2761 107898 107912 15
    2762 107914 107953 40
    2763 107967 107992 26
    2764 107994 108008 15
    2765 108010 108038 29
    2766 108065 108084 20
    2767 108113 108215 103
    2768 108220 108249 30
    2769 108253 108281 29
    2770 108283 108304 22
    2771 108317 108359 43
    2772 108361 108375 15
    2773 108386 108402 17
    2774 108421 108440 20
    2775 108538 108551 14
    2776 108561 108575 15
    2777 108577 108616 40
    2778 108618 108665 48
    2779 108677 108707 31
    2780 108735 108768 34
    2781 108762 108777 16
    2782 108780 108824 45
    2783 108842 108885 44
    2784 108907 108970 64
    2785 108983 109019 37
    2786 109021 109053 33
    2787 109055 109068 14
    2788 109070 109099 30
    2789 109097 109122 26
    2790 109113 109132 20
    2791 109125 109165 41
    2792 109167 109181 15
    2793 109183 109200 18
    2794 109214 109248 35
    2795 109256 109277 22
    2796 109281 109298 18
    2797 109298 109311 14
    2798 109300 109318 19
    2799 109324 109374 51
    2800 109377 109397 21
    2801 109399 109437 39
    2802 109446 109461 16
    2803 109463 109476 14
    2804 109472 109485 14
    2805 109478 109514 37
    2806 109516 109540 25
    2807 109556 109588 33
    2808 109601 109644 44
    2809 109661 109681 21
    2810 109683 109709 27
    2811 109707 109737 31
    2812 109739 109754 16
    2813 109754 109768 15
    2814 109770 109798 29
    2815 109810 109829 20
    2816 109859 109877 19
    2817 109879 109934 56
    2818 109955 109975 21
    2819 109975 109988 14
    2820 109994 110096 103
    2821 110103 110129 27
    2822 110131 110152 22
    2823 110153 110173 21
    2824 110175 110195 21
    2825 110192 110226 35
    2826 110297 110312 16
    2827 110301 110314 14
    2828 110308 110333 26
    2829 110335 110351 17
    2830 110353 110368 16
    2831 110376 110401 26
    2832 110418 110462 45
    2833 110464 110481 18
    2834 110531 110558 28
    2835 110571 110590 20
    2836 110599 110639 41
    2837 110630 110643 14
    2838 110641 110661 21
    2839 110668 110681 14
    2840 110683 110709 27
    2841 110717 110798 82
    2842 110804 110849 46
    2843 110853 110890 38
    2844 110928 110966 39
    2845 110971 111003 33
    2846 111000 111013 14
    2847 111015 111033 19
    2848 111035 111050 16
    2849 111062 111094 33
    2850 111092 111105 14
    2851 111107 111140 34
    2852 111161 111203 43
    2853 111209 111223 15
    2854 111224 111280 57
    2855 111275 111290 16
    2856 111283 111303 21
    2857 111305 111320 16
    2858 111311 111347 37
    2859 111355 111368 14
    2860 111357 111371 15
    2861 111360 111381 22
    2862 111373 111421 49
    2863 111412 111426 15
    2864 111451 111468 18
    2865 111467 111480 14
    2866 111482 111496 15
    2867 111486 111500 15
    2868 111497 111510 14
    2869 111531 111564 34
    2870 111580 111606 27
    2871 111616 111637 22
    2872 111658 111671 14
    2873 111674 111688 15
    2874 111692 111710 19
    2875 111712 111725 14
    2876 111727 111761 35
    2877 111781 111804 24
    2878 111811 111828 18
    2879 111831 111849 19
    2880 111856 111871 16
    2881 111901 111917 17
    2882 111919 111940 22
    2883 111942 111987 46
    2884 111984 112002 19
    2885 112004 112069 66
    2886 112070 112091 22
    2887 112093 112116 24
    2888 112118 112132 15
    2889 112139 112170 32
    2890 112180 112196 17
    2891 112204 112223 20
    2892 112236 112283 48
    2893 112329 112343 15
    2894 112345 112383 39
    2895 112385 112401 17
    2896 112404 112423 20
    2897 112463 112477 15
    2898 112485 112547 63
    2899 112563 112581 19
    2900 112583 112597 15
    2901 112607 112638 32
    2902 112640 112664 25
    2903 112683 112721 39
    2904 112730 112759 30
    2905 112773 112811 39
    2906 112811 112825 15
    2907 112828 112862 35
    2908 112882 112912 31
    2909 112914 112967 54
    2910 112968 112982 15
    2911 112984 113016 33
    2912 113044 113064 21
    2913 113074 113097 24
    2914 113111 113153 43
    2915 113169 113194 26
    2916 113198 113212 15
    2917 113214 113230 17
    2918 113232 113263 32
    2919 113265 113284 20
    2920 113306 113328 23
    2921 113330 113355 26
    2922 113357 113371 15
    2923 113404 113422 19
    2924 113421 113489 69
    2925 113533 113559 27
    2926 113561 113574 14
    2927 113595 113616 22
    2928 113648 113700 53
    2929 113702 113739 38
    2930 113762 113823 62
    2931 113825 113960 136
    2932 113962 114015 54
    2933 114017 114048 32
    2934 114045 114124 80
    2935 114151 114170 20
    2936 114182 114218 37
    2937 114230 114270 41
    2938 114272 114292 21
    2939 114296 114339 44
    2940 114354 114433 80
    2941 114440 114457 18
    2942 114459 114484 26
    2943 114478 114536 59
    2944 114538 114559 22
    2945 114567 114592 26
    2946 114594 114610 17
    2947 114612 114652 41
    2948 114681 114752 72
    2949 114775 114805 31
    2950 114803 114816 14
    2951 114807 114821 15
    2952 114823 114847 25
    2953 114868 114912 45
    2954 114947 114961 15
    2955 114974 114997 24
    2956 115001 115015 15
    2957 115004 115017 14
    2958 115019 115069 51
    2959 115060 115073 14
    2960 115072 115085 14
    2961 115087 115100 14
    2962 115102 115124 23
    2963 115132 115151 20
    2964 115154 115168 15
    2965 115188 115208 21
    2966 115219 115256 38
    2967 115258 115283 26
    2968 115285 115300 16
    2969 115331 115353 23
    2970 115355 115372 18
    2971 115380 115397 18
    2972 115399 115412 14
    2973 115426 115475 50
    2974 115496 115510 15
    2975 115521 115545 25
    2976 115555 115580 26
    2977 115582 115600 19
    2978 115602 115621 20
    2979 115653 115677 25
    2980 115692 115720 29
    2981 115722 115738 17
    2982 115769 115783 15
    2983 115792 115808 17
    2984 115819 115837 19
    2985 115846 115878 33
    2986 115888 115901 14
    2987 115916 115932 17
    2988 115943 115956 14
    2989 115967 115993 27
    2990 115996 116014 19
    2991 116027 116045 19
    2992 116105 116127 23
    2993 116126 116139 14
    2994 116141 116158 18
    2995 116171 116186 16
    2996 116194 116208 15
    2997 116257 116279 23
    2998 116318 116373 56
    2999 116375 116437 63
    3000 116439 116454 16
    3001 116456 116496 41
    3002 116500 116532 33
    3003 116534 116554 21
    3004 116556 116573 18
    3005 116575 116592 18
    3006 116596 116615 20
    3007 116617 116650 34
    3008 116650 116664 15
    3009 116666 116694 29
    3010 116775 116792 18
    3011 116794 116811 18
    3012 116813 116838 26
    3013 116840 116872 33
    3014 116890 116911 22
    3015 116921 116948 28
    3016 116952 116988 37
    3017 116990 117006 17
    3018 117008 117036 29
    3019 117059 117133 75
    3020 117187 117207 21
    3021 117204 117217 14
    3022 117209 117237 29
    3023 117239 117252 14
    3024 117255 117275 21
    3025 117277 117300 24
    3026 117337 117371 35
    3027 117373 117416 44
    3028 117418 117450 33
    3029 117456 117507 52
    3030 117518 117532 15
    3031 117534 117590 57
    3032 117582 117604 23
    3033 117593 117617 25
    3034 117621 117648 28
    3035 117640 117662 23
    3036 117664 117688 25
    3037 117690 117711 22
    3038 117728 117743 16
    3039 117747 117781 35
    3040 117784 117801 18
    3041 117792 117822 31
    3042 117824 117842 19
    3043 117850 117869 20
    3044 117890 117940 51
    3045 117936 117968 33
    3046 117970 117990 21
    3047 117989 118034 46
    3048 118034 118057 24
    3049 118061 118083 23
    3050 118086 118122 37
    3051 118122 118182 61
    3052 118172 118186 15
    3053 118197 118211 15
    3054 118216 118275 60
    3055 118291 118316 26
    3056 118318 118354 37
    3057 118373 118388 16
    3058 118391 118405 15
    3059 118407 118423 17
    3060 118425 118456 32
    3061 118465 118492 28
    3062 118498 118521 24
    3063 118533 118551 19
    3064 118553 118581 29
    3065 118587 118617 31
    3066 118620 118679 60
    3067 118687 118716 30
    3068 118731 118771 41
    3069 118779 118805 27
    3070 118816 118830 15
    3071 118832 118895 64
    3072 118910 119065 156
    3073 119067 119081 15
    3074 119095 119140 46
    3075 119170 119205 36
    3076 119210 119232 23
    3077 119230 119246 17
    3078 119236 119252 17
    3079 119255 119274 20
    3080 119271 119284 14
    3081 119290 119307 18
    3082 119320 119335 16
    3083 119357 119463 107
    3084 119465 119483 19
    3085 119485 119535 51
    3086 119550 119571 22
    3087 119577 119608 32
    3088 119610 119646 37
    3089 119648 119688 41
    3090 119713 119752 40
    3091 119743 119784 42
    3092 119786 119800 15
    3093 119822 119836 15
    3094 119830 119847 18
    3095 119849 119900 52
    3096 119912 119925 14
    3097 119960 119982 23
    3098 119984 120013 30
    3099 120038 120054 17
    3100 120057 120090 34
    3101 120092 120134 43
    3102 120138 120154 17
    3103 120157 120189 33
    3104 120187 120200 14
    3105 120191 120211 21
    3106 120225 120239 15
    3107 120242 120267 26
    3108 120271 120301 31
    3109 120320 120340 21
    3110 120363 120406 44
    3111 120406 120421 16
    3112 120414 120468 55
    3113 120457 120470 14
    3114 120487 120518 32
    3115 120545 120563 19
    3116 120567 120587 21
    3117 120589 120625 37
    3118 120619 120633 15
    3119 120650 120663 14
    3120 120676 120694 19
    3121 120703 120717 15
    3122 120721 120737 17
    3123 120755 120812 58
    3124 120816 120838 23
    3125 120843 120871 29
    3126 120873 120899 27
    3127 120903 120922 20
    3128 120933 120946 14
    3129 120936 120981 46
    3130 120983 121004 22
    3131 121006 121021 16
    3132 121023 121036 14
    3133 121035 121061 27
    3134 121063 121079 17
    3135 121081 121097 17
    3136 121105 121134 30
    3137 121138 121156 19
    3138 121155 121168 14
    3139 121158 121174 17
    3140 121166 121189 24
    3141 121194 121208 15
    3142 121201 121218 18
    3143 121213 121237 25
    3144 121246 121271 26
    3145 121298 121314 17
    3146 121311 121324 14
    3147 121327 121351 25
    3148 121359 121388 30
    3149 121390 121419 30
    3150 121446 121462 17
    3151 121468 121487 20
    3152 121499 121515 17
    3153 121517 121543 27
    3154 121545 121564 20
    3155 121575 121597 23
    3156 121599 121617 19
    3157 121619 121662 44
    3158 121664 121681 18
    3159 121683 121700 18
    3160 121702 121751 50
    3161 121773 121788 16
    3162 121790 121805 16
    3163 121807 121834 28
    3164 121836 121857 22
    3165 121859 121874 16
    3166 121877 121925 49
    3167 121923 121936 14
    3168 121928 121943 16
    3169 121962 121976 15
    3170 121978 121992 15
    3171 122004 122028 25
    3172 122030 122056 27
    3173 122046 122059 14
    3174 122052 122072 21
    3175 122080 122095 16
    3176 122099 122122 24
    3177 122143 122163 21
    3178 122169 122189 21
    3179 122258 122274 17
    3180 122289 122309 21
    3181 122311 122346 36
    3182 122357 122395 39
    3183 122446 122468 23
    3184 122471 122489 19
    3185 122491 122512 22
    3186 122526 122541 16
    3187 122543 122557 15
    3188 122579 122592 14
    3189 122606 122653 48
    3190 122663 122690 28
    3191 122728 122742 15
    3192 122757 122770 14
    3193 122779 122840 62
    3194 122842 122857 16
    3195 122900 122923 24
    3196 122933 122955 23
    3197 122968 123042 75
    3198 123055 123076 22
    3199 123094 123108 15
    3200 123114 123134 21
    3201 123143 123160 18
    3202 123162 123180 19
    3203 123184 123198 15
    3204 123200 123235 36
    3205 123237 123321 85
    3206 123314 123329 16
    3207 123342 123360 19
    3208 123356 123389 34
    3209 123391 123410 20
    3210 123412 123453 42
    3211 123455 123485 31
    3212 123488 123503 16
    3213 123506 123524 19
    3214 123526 123543 18
    3215 123545 123578 34
    3216 123598 123634 37
    3217 123654 123683 30
    3218 123685 123706 22
    3219 123710 123774 65
    3220 123803 123816 14
    3221 123818 123831 14
    3222 123896 123939 44
    3223 123941 123974 34
    3224 123976 124021 46
    3225 124026 124040 15
    3226 124042 124079 38
    3227 124091 124109 19
    3228 124158 124185 28
    3229 124238 124274 37
    3230 124319 124332 14
    3231 124335 124373 39
    3232 124394 124412 19
    3233 124419 124445 27
    3234 124450 124470 21
    3235 124472 124493 22
    3236 124499 124520 22
    3237 124522 124561 40
    3238 124564 124595 32
    3239 124607 124649 43
    3240 124662 124729 68
    3241 124750 124767 18
    3242 124769 124793 25
    3243 124812 124828 17
    3244 124853 124906 54
    3245 124923 124948 26
    3246 124958 124986 29
    3247 125023 125042 20
    3248 125032 125046 15
    3249 125065 125083 19
    3250 125073 125091 19
    3251 125093 125107 15
    3252 125132 125149 18
    3253 125139 125154 16
    3254 125151 125200 50
    3255 125201 125274 74
    3256 125314 125329 16
    3257 125331 125370 40
    3258 125372 125386 15
    3259 125411 125431 21
    3260 125433 125462 30
    3261 125475 125562 88
    3262 125564 125589 26
    3263 125605 125639 35
    3264 125641 125699 59
    3265 125719 125732 14
    3266 125737 125769 33
    3267 125815 125829 15
    3268 125834 125848 15
    3269 125850 125884 35
    3270 125899 125966 68
    3271 125967 125999 33
    3272 126026 126080 55
    3273 126097 126115 19
    3274 126130 126149 20
    3275 126151 126179 29
    3276 126186 126238 53
    3277 126241 126279 39
    3278 126275 126295 21
    3279 126297 126312 16
    3280 126320 126363 44
    3281 126376 126395 20
    3282 126406 126419 14
    3283 126420 126442 23
    3284 126467 126501 35
    3285 126503 126538 36
    3286 126566 126580 15
    3287 126584 126597 14
    3288 126620 126653 34
    3289 126654 126694 41
    3290 126697 126715 19
    3291 126764 126777 14
    3292 126792 126828 37
    3293 126842 126862 21
    3294 126866 126879 14
    3295 126881 126897 17
    3296 126906 126925 20
    3297 126956 126987 32
    3298 126989 127023 35
    3299 127026 127135 110
    3300 127142 127174 33
    3301 127176 127191 16
    3302 127193 127217 25
    3303 127229 127253 25
    3304 127255 127280 26
    3305 127294 127394 101
    3306 127396 127415 20
    3307 127417 127478 62
    3308 127491 127504 14
    3309 127506 127530 25
    3310 127542 127566 25
    3311 127582 127628 47
    3312 127654 127675 22
    3313 127681 127706 26
    3314 127706 127739 34
    3315 127769 127792 24
    3316 127808 127829 22
    3317 127839 127888 50
    3318 127900 127932 33
    3319 127943 127975 33
    3320 127988 128046 59
    3321 128048 128069 22
    3322 128068 128106 39
    3323 128105 128118 14
    3324 128121 128157 37
    3325 128159 128188 30
    3326 128190 128268 79
    3327 128279 128317 39
    3328 128321 128335 15
    3329 128342 128368 27
    3330 128374 128446 73
    3331 128444 128540 97
    3332 128546 128586 41
    3333 128588 128640 53
    3334 128642 128674 33
    3335 128675 128879 205
    3336 128881 128936 56
    3337 128934 129000 67
    3338 129002 129060 59
    3339 129074 129100 27
    3340 129107 129123 17
    3341 129125 129163 39
    3342 129168 129230 63
    3343 129264 129277 14
    3344 129284 129318 35
    3345 129320 129346 27
    3346 129357 129391 35
    3347 129393 129420 28
    3348 129447 129485 39
    3349 129489 129504 16
    3350 129514 129540 27
    3351 129550 129563 14
    3352 129559 129595 37
    3353 129606 129627 22
    3354 129633 129681 49
    3355 129683 129697 15
    3356 129699 129716 18
    3357 129706 129738 33
    3358 129757 129790 34
    3359 129792 129820 29
    3360 129812 129846 35
    3361 129851 129867 17
    3362 129869 129883 15
    3363 129885 129915 31
    3364 129917 129955 39
    3365 129957 130046 90
    3366 130042 130070 29
    3367 130110 130156 47
    3368 130158 130309 152
    3369 130311 130373 63
    3370 130375 130391 17
    3371 130407 130429 23
    3372 130439 130461 23
    3373 130475 130507 33
    3374 130512 130550 39
    3375 130552 130582 31
    3376 130584 130614 31
    3377 130616 130764 149
    3378 130766 130869 104
    3379 130871 131021 151
    3380 131033 131051 19
    3381 131092 131105 14
    3382 131112 131188 77
    3383 131194 131237 44
    3384 131233 131247 15
    3385 131236 131287 52
    3386 131292 131307 16
    3387 131314 131333 20
    3388 131373 131386 14
    3389 131396 131417 22
    3390 131419 131439 21
    3391 131429 131458 30
    3392 131481 131499 19
    3393 131676 131689 14
    3394 131729 131743 15
    3395 131745 131764 20
    3396 131785 131807 23
    3397 131809 131875 67
    3398 131877 131953 77
    3399 131955 131980 26
    3400 132020 132068 49
    3401 132086 132108 23
    3402 132118 132138 21
    3403 132152 132183 32
    3404 132185 132205 21
    3405 132219 132232 14
    3406 132234 132252 19
    3407 132261 132291 31
    3408 132319 132337 19
    3409 132345 132363 19
    3410 132365 132378 14
    3411 132414 132483 70
    3412 132504 132547 44
    3413 132549 132582 34
    3414 132584 132602 19
    3415 132616 132642 27
    3416 132643 132681 39
    3417 132685 132714 30
    3418 132736 132769 34
    3419 132771 132793 23
    3420 132809 132825 17
    3421 132827 132841 15
    3422 132861 132884 24
    3423 132882 132900 19
    3424 132899 132915 17
    3425 132917 132951 35
    3426 132940 132954 15
    3427 132958 132983 26
    3428 132985 133031 47
    3429 133032 133051 20
    3430 133042 133060 19
    3431 133051 133071 21
    3432 133073 133087 15
    3433 133083 133104 22
    3434 133097 133110 14
    3435 133131 133199 69
    3436 133198 133222 25
    3437 133233 133249 17
    3438 133251 133284 34
    3439 133327 133429 103
    3440 133431 133596 166
    3441 133588 133602 15
    3442 133598 133611 14
    3443 133613 133628 16
    3444 133628 133646 19
    3445 133651 133670 20
    3446 133666 133707 42
    3447 133718 133742 25
    3448 133743 133777 35
    3449 133779 133794 16
    3450 133821 133851 31
    3451 133859 133880 22
    3452 133890 133921 32
    3453 133923 133974 52
    3454 133982 133998 17
    3455 134000 134036 37
    3456 134065 134107 43
    3457 134120 134173 54
    3458 134165 134179 15
    3459 134187 134200 14
    3460 134207 134242 36
    3461 134244 134258 15
    3462 134260 134273 14
    3463 134275 134299 25
    3464 134314 134346 33
    3465 134356 134371 16
    3466 134365 134380 16
    3467 134374 134420 47
    3468 134445 134477 33
    3469 134508 134523 16
    3470 134531 134548 18
    3471 134542 134555 14
    3472 134568 134621 54
    3473 134647 134667 21
    3474 134679 134719 41
    3475 134721 134824 104
    3476 134826 134849 24
    3477 134856 134869 14
    3478 134877 134910 34
    3479 134912 134966 55
    3480 134960 134980 21
    3481 134989 135012 24
    3482 135014 135066 53
    3483 135074 135093 20
    3484 135108 135125 18
    3485 135151 135260 110
    3486 135264 135277 14
    3487 135273 135310 38
    3488 135321 135337 17
    3489 135340 135365 26
    3490 135360 135374 15
    3491 135364 135386 23
    3492 135388 135430 43
    3493 135432 135447 16
    3494 135498 135521 24
    3495 135519 135545 27
    3496 135559 135622 64
    3497 135624 135647 24
    3498 135656 135673 18
    3499 135675 135704 30
    3500 135721 135742 22
    3501 135753 135796 44
    3502 135815 135858 44
    3503 135860 135880 21
    3504 135883 135915 33
    3505 135922 135965 44
    3506 135979 135993 15
    3507 135995 136036 42
    3508 136051 136065 15
    3509 136108 136165 58
    3510 136173 136190 18
    3511 136192 136287 96
    3512 136289 136303 15
    3513 136317 136346 30
    3514 136375 136415 41
    3515 136429 136470 42
    3516 136472 136496 25
    3517 136498 136532 35
    3518 136542 136565 24
    3519 136643 136657 15
    3520 136674 136701 28
    3521 136704 136719 16
    3522 136715 136728 14
    3523 136721 136737 17
    3524 136737 136750 14
    3525 136783 136810 28
    3526 136824 136849 26
    3527 136859 136896 38
    3528 136898 136927 30
    3529 136949 136983 35
    3530 136985 137000 16
    3531 137053 137071 19
    3532 137077 137097 21
    3533 137108 137164 57
    3534 137166 137196 31
    3535 137198 137221 24
    3536 137223 137267 45
    3537 137276 137359 84
    3538 137360 137385 26
    3539 137393 137440 48
    3540 137438 137496 59
    3541 137498 137518 21
    3542 137523 137536 14
    3543 137539 137572 34
    3544 137584 137612 29
    3545 137614 137628 15
    3546 137630 137644 15
    3547 137646 137669 24
    3548 137702 137727 26
    3549 137731 137745 15
    3550 137759 137772 14
    3551 137784 137819 36
    3552 137832 137858 27
    3553 137861 137876 16
    3554 137878 137900 23
    3555 137909 137925 17
    3556 137924 137961 38
    3557 137968 137981 14
    3558 138011 138033 23
    3559 138035 138077 43
    3560 138079 138097 19
    3561 138224 138238 15
    3562 138232 138252 21
    3563 138242 138256 15
    3564 138255 138284 30
    3565 138295 138326 32
    3566 138328 138357 30
    3567 138359 138389 31
    3568 138403 138449 47
    3569 138451 138492 42
    3570 138500 138515 16
    3571 138524 138548 25
    3572 138555 138568 14
    3573 138571 138589 19
    3574 138589 138629 41
    3575 138644 138680 37
    3576 138697 138710 14
    3577 138712 138729 18
    3578 138744 138761 18
    3579 138776 138801 26
    3580 138860 138896 37
    3581 138898 138923 26
    3582 138925 138965 41
    3583 138967 139008 42
    3584 139010 139031 22
    3585 139029 139043 15
    3586 139034 139048 15
    3587 139041 139056 16
    3588 139055 139074 20
    3589 139078 139094 17
    3590 139084 139098 15
    3591 139092 139116 25
    3592 139133 139147 15
    3593 139154 139173 20
    3594 139175 139192 18
    3595 139204 139229 26
    3596 139231 139255 25
    3597 139257 139270 14
    3598 139272 139303 32
    3599 139315 139335 21
    3600 139337 139372 36
    3601 139383 139397 15
    3602 139399 139419 21
    3603 139423 139437 15
    3604 139435 139492 58
    3605 139501 139518 18
    3606 139508 139521 14
    3607 139571 139586 16
    3608 139588 139622 35
    3609 139636 139655 20
    3610 139657 139673 17
    3611 139685 139699 15
    3612 139724 139795 72
    3613 139796 139811 16
    3614 139818 139834 17
    3615 139836 139857 22
    3616 139856 139869 14
    3617 139859 139882 24
    3618 139891 139920 30
    3619 139930 139952 23
    3620 139965 139980 16
    3621 139982 140011 30
    3622 140013 140031 19
    3623 140047 140072 26
    3624 140074 140099 26
    3625 140101 140119 19
    3626 140121 140135 15
    3627 140144 140158 15
    3628 140157 140183 27
    3629 140185 140210 26
    3630 140231 140262 32
    3631 140258 140272 15
    3632 140264 140288 25
    3633 140290 140325 36
    3634 140339 140364 26
    3635 140369 140402 34
    3636 140428 140451 24
    3637 140453 140510 58
    3638 140512 140541 30
    3639 140556 140621 66
    3640 140626 140651 26
    3641 140653 140724 72
    3642 140726 140789 64
    3643 140802 140825 24
    3644 140837 140861 25
    3645 140863 140896 34
    3646 140903 140927 25
    3647 140958 140993 36
    3648 141001 141014 14
    3649 141022 141053 32
  • In some embodiments, the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary, such as 100% complementarity, to a corresponding target nucleic acid region present in SEQ ID NO: 1, wherein the target nucleic acid region is selected from the group consisting of region B1 to B400 in table 2
  • TABLE 2
    Regions of SEQ ID NO 1 which may be targeted
    using oligonucleotide of the invention
    Position in
    SEQ ID NO 1
    Reg. To From Length
    B1 225 238 14
    B2 1163 1178 16
    B3 2526 2539 14
    B4 2805 2820 16
    B5 3027 3040 14
    B6 3208 3222 15
    B7 3212 3225 14
    B8 3228 3241 14
    B9 3243 3256 14
    B10 3810 3854 45
    B11 4664 4680 17
    B12 5516 5529 14
    B13 5657 5671 15
    B14 5661 5676 16
    B15 5964 5977 14
    B16 6217 6234 18
    B17 6224 6237 14
    B18 6408 6422 15
    B19 7300 7313 14
    B20 7399 7412 14
    B21 7541 7564 24
    B22 7626 7640 15
    B23 7662 7694 33
    B24 7791 7806 16
    B25 7853 7868 16
    B26 8206 8219 14
    B27 8443 8456 14
    B28 8739 8752 14
    B29 9197 9212 16
    B30 10189 10203 15
    B31 10754 10768 15
    B32 10758 10771 14
    B33 11790 11803 14
    B34 11870 11883 14
    B35 11993 12007 15
    B36 B11996 12011 16
    B37 12017 12040 24
    B38 12095 12108 14
    B39 12345 12358 14
    B40 12721 12734 14
    B41 13372 13386 15
    B42 13489 13505 17
    B43 15576 15590 15
    B44 15617 15632 16
    B45 15840 15853 14
    B46 16041 16054 14
    B47 16207 16222 16
    B48 16308 16321 14
    B49 16349 16362 14
    B50 16463 16479 17
    B51 16528 16542 15
    B52 16543 16556 14
    B53 20495 20508 14
    B54 20617 20630 14
    B55 20960 20977 18
    B56 21465 21479 15
    B57 21491 21508 18
    B58 23479 23496 18
    B59 23741 23755 15
    B60 25236 25249 14
    B61 25323 25336 14
    B62 25447 25462 16
    B63 25588 25601 14
    B64 25853 25867 15
    B65 25885 25898 14
    B66 26280 26293 14
    B67 26388 26404 17
    B68 26416 26450 35
    B69 26687 26702 16
    B70 26706 26719 14
    B71 26783 26796 14
    B72 27039 27052 14
    B73 27251 27265 15
    B74 28683 28698 16
    B75 29302 29315 14
    B76 29304 29317 14
    B77 29308 29321 14
    B78 29532 29545 14
    B79 29974 29987 14
    B80 30054 30068 15
    B81 30267 30281 15
    B82 30623 30638 16
    B83 30628 30641 14
    B84 30814 30827 14
    B85 30881 30894 14
    B86 32459 32478 20
    B87 37299 37315 17
    B88 39083 39096 14
    B89 39370 39383 14
    B90 39659 39672 14
    B91 40814 40831 18
    B92 40851 40864 14
    B93 41782 41795 14
    B94 41873 41886 14
    B95 42037 42050 14
    B96 42048 42063 16
    B97 42096 42116 21
    B98 42959 42973 15
    B99 43165 43178 14
    B100 45926 45939 14
    B101 48163 48176 14
    B102 52732 52745 14
    B103 52984 53015 32
    B104 54404 54420 17
    B105 55294 55320 27
    B106 55337 55350 14
    B107 55420 55434 15
    B108 55487 55501 15
    B109 55623 55638 16
    B110 56195 56214 20
    B111 56584 56597 14
    B112 57267 57282 16
    B113 58126 58139 14
    B114 58170 58183 14
    B115 58295 58309 15
    B116 58658 58671 14
    B117 58906 58921 16
    B118 58988 59005 18
    B119 59024 59045 22
    B120 59191 59207 17
    B121 59236 59251 16
    B122 59298 59312 15
    B123 59358 59378 21
    B124 59400 59413 14
    B125 59434 59447 14
    B126 59589 59602 14
    B127 59620 59642 23
    B128 59718 59743 26
    B129 59826 59841 16
    B130 59843 59864 22
    B131 59882 59906 25
    B132 59930 59958 29
    B133 59959 60004 46
    B134 60006 60029 24
    B135 60033 60071 39
    B136 60139 60171 33
    B137 60193 60215 23
    B138 60212 60225 14
    B139 60231 60244 14
    B140 60246 60265 20
    B141 60267 60282 16
    B142 60292 60309 18
    B143 60348 60361 14
    B144 60358 60429 72
    B145 60427 60517 91
    B146 60519 60545 27
    B147 60557 60575 19
    B148 60580 60593 14
    B149 60595 60622 28
    B150 60675 60690 16
    B151 60697 60713 17
    B152 60727 60754 28
    B153 60756 60799 44
    B154 60801 60817 17
    B155 60819 60855 37
    B156 61423 61436 14
    B157 61592 61605 14
    B158 61624 61637 14
    B159 61673 61713 41
    B160 61715 61731 17
    B161 61733 61752 20
    B162 61769 61794 26
    B163 61805 61825 21
    B164 62101 62114 14
    B165 62302 62315 14
    B166 62436 62449 14
    B167 62664 62679 16
    B168 62993 63006 14
    B169 63098 63111 14
    B170 63347 63367 21
    B171 63371 63396 26
    B172 63385 63398 14
    B173 63526 63539 14
    B174 65032 65045 14
    B175 66556 66569 14
    B176 67158 67183 26
    B177 67181 67194 14
    B178 68007 68021 15
    B179 68644 68657 14
    B180 69294 69317 24
    B181 69306 69323 18
    B182 69353 69366 14
    B183 70497 70511 15
    B184 71600 71613 14
    B185 71887 71905 19
    B186 72259 72272 14
    B187 72589 72602 14
    B188 72783 72796 14
    B189 73528 73541 14
    B190 73783 73800 18
    B191 74907 74920 14
    B192 75965 75981 17
    B193 75983 75998 16
    B194 76004 76020 17
    B195 76110 76166 57
    B196 76186 76205 20
    B197 76234 76253 20
    B198 76261 76280 20
    B199 76369 76382 14
    B200 77139 77152 14
    B201 77409 77422 14
    B202 77478 77524 47
    B203 77526 77590 65
    B204 77628 77641 14
    B205 77688 77701 14
    B206 78275 78308 34
    B207 78310 78332 23
    B208 78340 78356 17
    B209 78358 78371 14
    B210 78373 78395 23
    B211 78397 78440 44
    B212 78442 78455 14
    B213 78475 78489 15
    B214 78696 78709 14
    B215 78847 78860 14
    B216 79493 79516 24
    B217 79705 79718 14
    B218 81009 81054 46
    B219 81353 81367 15
    B220 81970 81986 17
    B221 81991 82006 16
    B222 82042 82106 65
    B223 82278 82291 14
    B224 82716 82735 20
    B225 84314 84328 15
    B226 85628 85665 38
    B227 86226 86239 14
    B228 86237 86253 17
    B229 86566 86579 14
    B230 86945 86959 15
    B231 87337 87358 22
    B232 87662 87675 14
    B233 89424 89439 16
    B234 89972 89985 14
    B235 90782 90795 14
    B236 90939 90953 15
    B237 90942 90955 14
    B238 90965 90981 17
    B239 91101 91115 15
    B240 92083 92096 14
    B241 92164 92177 14
    B242 92179 92192 14
    B243 92194 92210 17
    B244 92212 92236 25
    B245 92245 92260 16
    B246 92262 92302 41
    B247 92304 92321 18
    B248 92323 92366 44
    B249 92375 92389 15
    B250 92392 92405 14
    B251 92407 92426 20
    B252 92442 92459 18
    B253 92497 92516 20
    B254 92578 92591 14
    B255 92599 92612 14
    B256 92614 92651 38
    B257 92659 92684 26
    B258 92686 92699 14
    B259 92704 92726 23
    B260 92731 92750 20
    B261 92752 92774 23
    B262 92780 92795 16
    B263 92800 92813 14
    B264 92839 92858 20
    B265 92860 92891 32
    B266 92893 92906 14
    B267 92908 92921 14
    B268 92923 92941 19
    B269 92965 92986 22
    B270 92988 93002 15
    B271 93044 93059 16
    B272 93061 93076 16
    B273 93105 93122 18
    B274 93142 93209 68
    B275 93227 93241 15
    B276 93288 93305 18
    B277 93325 93344 20
    B278 93398 93412 15
    B279 93572 93586 15
    B280 94509 94522 14
    B281 95720 95738 19
    B282 97050 97065 16
    B283 97079 97098 20
    B284 97127 97194 68
    B285 97208 97230 23
    B286 97232 97284 53
    B287 97286 97311 26
    B288 97313 97362 50
    B289 97368 97383 16
    B290 97426 97439 14
    B291 98077 98090 14
    B292 98227 98240 14
    B293 98232 98255 24
    B294 99151 99164 14
    B295 99405 99418 14
    B296 99570 99583 14
    B297 99733 99748 16
    B298 101829 101842 14
    B299 101882 101895 14
    B300 101955 101968 14
    B301 102202 102215 14
    B302 103310 103325 16
    B303 103653 103666 14
    B304 103908 103923 16
    B305 103912 103928 17
    B306 103917 103933 17
    B307 104971 104984 14
    B308 105217 105230 14
    B309 105233 105250 18
    B310 105443 105457 15
    B311 105544 105559 16
    B312 106047 106071 25
    B313 106061 106074 14
    B314 106093 106107 15
    B315 106114 106130 17
    B316 106243 106256 14
    B317 106251 106264 14
    B318 106840 106855 16
    B319 108113 108130 18
    B320 108325 108338 14
    B321 108856 108869 14
    B322 109109 109122 14
    B323 109113 109127 15
    B324 109116 109132 17
    B325 110301 110314 14
    B326 110315 110328 14
    B327 110317 110330 14
    B328 112528 112546 19
    B329 112607 112620 14
    B330 114775 114788 14
    B331 116322 116335 14
    B332 116968 116981 14
    B333 117788 117801 14
    B334 118034 118057 24
    B335 118230 118246 17
    B336 118235 118248 14
    B337 118870 118883 14
    B338 119755 119784 30
    B339 119786 119800 15
    B340 120363 120406 44
    B341 120504 120517 14
    B342 121161 121174 14
    B343 121330 121347 18
    B344 121338 121351 14
    B345 123417 123430 14
    B346 123464 123481 18
    B347 125026 125042 17
    B348 127046 127071 26
    B349 127090 127103 14
    B350 127311 127324 14
    B351 127354 127367 14
    B352 127363 127379 17
    B353 127399 127412 14
    B354 127863 127876 14
    B355 128134 128148 15
    B356 128280 128310 31
    B357 128343 128368 26
    B358 128444 128457 14
    B359 128446 128469 24
    B360 128498 128511 14
    B361 128511 128524 14
    B362 129892 129905 14
    B363 130261 130283 23
    B364 130375 130388 14
    B365 130415 130428 14
    B366 130634 130650 17
    B367 130667 130717 51
    B368 130719 130764 46
    B369 130783 130796 14
    B370 130798 130820 23
    B371 130840 130861 22
    B372 130975 130994 20
    B373 131112 131132 21
    B374 131142 131161 20
    B375 131233 131246 14
    B376 131729 131743 15
    B377 132754 132767 14
    B378 132924 132937 14
    B379 133174 133190 17
    B380 133198 133212 15
    B381 133207 133222 16
    B382 133476 133489 14
    B383 133479 133492 14
    B384 133491 133531 41
    B385 133533 133550 18
    B386 133555 133594 40
    B387 134160 134173 14
    B388 134165 134178 14
    B389 134533 134546 14
    B390 136724 136737 14
    B391 137438 137463 26
    B392 137878 137891 14
    B393 138082 138097 16
    B394 138233 138252 20
    B395 138930 138943 14
    B396 138947 138960 14
    B397 138950 138963 14
    B398 139502 139518 17
    B399 139508 139521 14
    B400 140978 140991 14
  • In certain embodiments the oligonucleotide or contiguous nucleotide sequence is complementary to a region (or sub-sequence)(or sub-sequence) of the target nucleic acid, wherein the target nucleic acid region is selected from the group consisting of position 1589-10889, 46089-53989 and 60789-62489 of SEQ ID NO: 1.
  • In one embodiment the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90%, such as 100% complementary to a target nucleic acid sequence of position 55319 to 141053 of SEQ ID NO: 1.
  • In one embodiment the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90%, such as 100% complementary to a target nucleic acid sequence of position 1 to 55318 of SEQ ID NO: 1.
  • In some embodiments, the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid selected from the group corresponding to positions: 55319-76274, 77483-77573, 92157-93403 and 97056-97354 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid selected from the group corresponding to positions: 60821-60849, 77567-77583, 92323-92339 and 97156-97172 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions: 5218-5240 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions: 5782-5803 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions: 8113-8139 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions: 9200-9250 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions: 11505-11555 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions: 13223-13242 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions 15100-15150 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions 15113-15180 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions 29635-29705 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions 30590-30740 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid corresponding to positions 39800-39855 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid to positions 44435-44460 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid to positions 45245-45270 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid to positions 46380-46430 of SEQ ID NO: 1.
  • In some embodiments the oligonucleotide a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary to a sub-sequence of the target nucleic acid to positions 68915-68940 of SEQ ID NO: 1.
  • In some embodiments, the oligonucleotide comprises or consists of 8 to 35 nucleotides in length, such as from 10 to 30, such as 11 to 22, such as from 12 to 18, such as from 13 to 17 or 14 to 16 contiguous nucleotides in length. In a preferred embodiment, the oligonucleotide comprises or consists of 15 to 20 nucleotides in length.
  • In some embodiments, the oligonucleotide or contiguous nucleotide sequence thereof comprises or consists of 22 or less nucleotides, such as 20 or less nucleotides, such as 18 or less nucleotides, such as 14, 15, 16 or 17 nucleotides. It is to be understood that any range given herein includes the range endpoints. Accordingly, if an oligonucleotide is said to include from 10 to 30 nucleotides, both 10 and 30 nucleotides are included.
  • In some embodiments, the contiguous nucleotide sequence comprises or consists of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleotides in length. In a preferred embodiment, the oligonucleotide comprises or consists of 16, 17, 18 or 19 nucleotides in length.
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 4 to 150 (see motif sequences listed in table 3 in the Examples section).
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 4 to 818 (see motif sequences listed in table 3 in the Examples section).
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 4 to 678 (see motif sequences listed in table 3 in the Examples section).
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 166, 167, 167 or 169 (see motif sequences listed in table 3 in the Examples section).
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 570, 571, 572, 679, 680, 681, 682 and 683 (see motif sequences listed in table 3 in the Examples section).
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 34, 186, 187, 188, 573, 574, 575, 576, 572, 684, 685, 686, 687, 688, 689, 690, 691, 692, 963, 964, 965 and 696 (see motif sequences listed in table 3 in the Examples section).
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 35, 199, 200, 201, 202, 203, 204, 205, 206, 207, 209 and 210 or SEQ ID NO: 582, 583 and 584 (see motif sequences listed in table 3 in the Examples section).
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 221, 222, 223, 224, 225, 585, 586, 587, 588, 589, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717 and 718 (see motif sequences listed in table 3 in the Examples section).
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 236, 237, 238, 239, 240 and 590.
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 241, 591 and 719 (see motif sequences listed in table 3 in the Examples section).
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 46, 47, 48, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 800, 800, 800, 800, 801, 801, 802, 803, 804, 805, 806 and 807 (see motif sequences listed in table 3 in the Examples section).
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 331, 332, 638, 639, 640, 808, 809, 810, 811, 812, 813, 814 and 815 (see motif sequences listed in table 3 in the Examples section).
  • In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity to a sequence selected from the group consisting of SEQ ID NO: 409, 410, 411, 642, 643, 644, 645, 646, 816, 818 and 818 (see motif sequences listed in table 3 in the Examples section).
  • It is understood that the contiguous nucleobase sequences (motif sequence) can be modified to for example increase nuclease resistance and/or binding affinity to the target nucleic acid. Modifications are described in the definitions and in the “Oligonucleotide design” section. Table 3 lists preferred designs of each motif sequence.
  • Oligonucleotide Design
  • Oligonucleotide design refers to the pattern of nucleoside sugar modifications in the oligonucleotide sequence. The oligonucleotides of the invention comprise sugar-modified nucleosides and may also comprise DNA or RNA nucleosides. In some embodiments, the oligonucleotide comprises sugar-modified nucleosides and DNA nucleosides. Incorporation of modified nucleosides into the oligonucleotide of the invention may enhance the affinity of the oligonucleotide for the target nucleic acid. In that case, the modified nucleosides can be referred to as affinity enhancing modified nucleotides.
  • In an embodiment, the oligonucleotide comprises at least 1 modified nucleoside, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 modified nucleosides. In an embodiment the oligonucleotide comprises from 1 to 10 modified nucleosides, such as from 2 to 9 modified nucleosides, such as from 3 to 8 modified nucleosides, such as from 4 to 7 modified nucleosides, such as 6 or 7 modified nucleosides. In some embodiments, at least 1 of the modified nucleosides is a locked nucleic acid (LNA), such as at least 2, such as at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 of the modified nucleosides are LNA. In a still further embodiment all the modified nucleosides are LNA.
  • In an embodiment, the oligonucleotide of the invention may comprise modifications, which are independently selected from these three types of modifications (modified sugar, modified nucleobase and modified internucleoside linkage) or a combination thereof. Preferably the oligonucleotide comprises one or more sugar modified nucleosides, such as 2′ sugar modified nucleosides. Preferably the oligonucleotide of the invention comprise the one or more 2′ sugar modified nucleoside independently selected from the group consisting of 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA, 2′-amino-DNA, 2′-fluoro-DNA, arabino nucleic acid (ANA), 2′-fluoro-ANA and LNA nucleosides. Even more preferably the one or more modified nucleoside is LNA.
  • In a further embodiment the oligonucleotide comprises at least one modified internucleoside linkage. In a preferred embodiment the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate or boranophosphate internucleoside linkages.
  • In some embodiments, the oligonucleotide of the invention comprise at least one modified nucleoside which is a 2′-MOE-RNA, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 2′-MOE-RNA nucleoside units. In some embodiments, at least one of said modified nucleoside is 2′-fluoro DNA, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 2′-fluoro-DNA nucleoside units.
  • In some embodiments, the oligonucleotide of the invention comprises at least one LNA unit, such as 1, 2, 3, 4, 5, 6, 7, or 8 LNA units, such as from 2 to 6 LNA units, such as from 3 to 7 LNA units, 4 to 8 LNA units or 3, 4, 5, 6 or 7 LNA units. In some embodiments, all the modified nucleosides are LNA nucleosides. In a further embodiment, the oligonucleotide may comprise both beta-D-oxy-LNA, and one or more of the following LNA units: thio-LNA, amino-LNA, oxy-LNA, and/or ENA in either the beta-D or alpha-L configurations or combinations thereof. In a further embodiment, all LNA cytosine units are 5-methyl-cytosine. In a preferred embodiment the oligonucleotide or contiguous nucleotide sequence has at least 1 LNA unit at the 5′ end and at least 2 LNA units at the 3′ end of the nucleotide sequence.
  • In some embodiments, the oligonucleotide of the invention comprises at least one LNA unit and at least one 2′ substituted modified nucleoside.
  • In some embodiments of the invention, the oligonucleotide comprise both 2′ sugar modified nucleosides and DNA units. Preferably the oligonucleotide comprise both LNA and DNA units. Preferably, the combined total of LNA and DNA units is 8-30, such as 10-25, preferably 12-22, such as 12-18, even more preferably 11-16. In some embodiments of the invention, the nucleotide sequence of the oligonucleotide, such as the contiguous nucleotide sequence consists of at least one or two LNA units and the remaining nucleotide units are DNA units. In some embodiments the oligonucleotide comprises only LNA nucleosides and naturally occurring nucleosides (such as RNA or DNA, most preferably DNA nucleosides), optionally with modified internucleoside linkages such as phosphorothioate.
  • In an embodiment of the invention the oligonucleotide of the invention is capable of recruiting RNase H.
  • Gapmer Design
  • In a preferred embodiment the oligonucleotide of the invention has a gapmer design or structure also referred herein merely as “Gapmer”. In a gapmer structure the oligonucleotide comprises at least three distinct structural regions a 5′-flank, a gap and a 3′-flank, F-G-F′ in ′5->3′ orientation. In this design, flanking regions F and F′ (also termed wing regions) comprise a contiguous stretch of modified nucleosides, which are complementary to the UBE3A target nucleic acid, while the gap region, G, comprises a contiguous stretch of nucleotides which are capable of recruiting a nuclease, preferably an endonuclease such as RNase, for example RNase H, when the oligonucleotide is in duplex with the target nucleic acid. Nucleosides which are capable of recruiting a nuclease, in particular RNase H, can be selected from the group consisting of DNA, alpha-L-oxy-LNA, 2′-Flouro-ANA and UNA. Regions F and F′, flanking the 5′ and 3′ ends of region G, preferably comprise non-nuclease recruiting nucleosides (nucleosides with a 3′ endo structure), more preferably one or more affinity enhancing modified nucleosides. In some embodiments, the 3′ flank comprises at least one LNA nucleoside, preferably at least 2 LNA nucleosides. In some embodiments, the 5′ flank comprises at least one LNA nucleoside. In some embodiments both the 5′ and 3′ flanking regions comprise a LNA nucleoside. In some embodiments all the nucleosides in the flanking regions are LNA nucleosides. In other embodiments, the flanking regions may comprise both LNA nucleosides and other nucleosides (mixed flanks), such as DNA nucleosides and/or non-LNA modified nucleosides, such as 2′ substituted nucleosides. In this case the gap is defined as a contiguous sequence of at least 5 RNase H recruiting nucleosides (nucleosides with a 2′ endo structure, preferably DNA) flanked at the 5′ and 3′ end by an affinity enhancing modified nucleoside, preferably LNA, such as beta-D-oxy-LNA. Consequently, the nucleosides of the 5′ flanking region and the 3′ flanking region which are adjacent to the gap region are modified nucleosides, preferably non-nuclease recruiting nucleosides. In oligonucleotides with mixed flanks where the flanks comprise DNA the 5′ and 3′ nucleosides are modified nucleosides.
  • Region F
  • Region F (5′ flank or 5′ wing) attached to the ′5 end of region G comprises, contains or consists of at least one modified nucleoside such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 modified nucleosides. In an embodiment region F comprises or consists of from 1 to 7 modified nucleosides, such as from 2 to 6 modified nucleosides, such as from 2 to 5 modified nucleosides, such as from 2 to 4 modified nucleosides, such as from 1 to 3 modified nucleosides, such as 1, 2, 3 or 4 modified nucleosides. In a further embodiment further additional nucleosides may be attached to the ′5 end of region F, representing a region D preferably comprising 1, 2 or 3 nucleoside units, such as DNA nucleosides. Region D can take the function of a biocleavable (B) linker described in the definition of “Linkers”.
  • In some embodiments, the modified nucleosides in region F have a 3′ endo structure.
  • In an embodiment, one or more of the modified nucleosides in region F are 2′ modified nucleosides.
  • In a further embodiment one or more of the 2′ modified nucleosides in region F are selected from 2′-O-alkyl-RNA units, 2′-O-methyl-RNA, 2′-amino-DNA units, 2′-fluoro-DNA units, 2′-alkoxy-RNA, MOE units, LNA units, arabino nucleic acid (ANA) units and 2′-fluoro-ANA units.
  • In one embodiment of the invention all the modified nucleosides in region F are LNA nucleosides. In a further embodiment the LNA nucleosides in region F are independently selected from the group consisting of oxy-LNA, thio-LNA, amino-LNA, cET, and/or ENA, in either the beta-D or alpha-L configurations or combinations thereof. In a preferred embodiment region F has at least 1 beta-D-oxy LNA unit, at the 5′ end of the contiguous sequence.
  • Region G
  • Region G (gap region) preferably comprise, contain or consist of at least 4, such as at least 5, such as at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 consecutive nucleosides capable of recruiting the aforementioned nuclease, in particular RNaseH. In a further embodiment region G comprise, contain or consist of from 5 to 12, or from 6 to 10 or from 7 to 9, such as 8 consecutive nucleotide units capable of recruiting aforementioned nuclease.
  • The nucleoside units in region G, which are capable of recruiting nuclease are in an embodiment selected from the group consisting of DNA, alpha-L-LNA, C4′ alkylated DNA (as described in PCT/EP2009/050349 and Vester et al., Bioorg. Med. Chem. Lett. 18 (2008) 2296-2300, both incorporated herein by reference), arabinose derived nucleosides like ANA and 2′F-ANA (Mangos et al. 2003 J. AM. CHEM. SOC. 125, 654-661), UNA (unlocked nucleic acid) (as described in Fluiter et al., Mol. Biosyst., 2009, 10, 1039 incorporated herein by reference). UNA is unlocked nucleic acid, typically where the bond between C2 and C3 of the ribose has been removed, forming an unlocked “sugar” residue.
  • In a still further embodiment at least one nucleoside unit in region G is a DNA nucleoside unit, such as from 1 to 16 DNA units, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 DNA units, preferably from 2 to 13 DNA units, such as from 4 to 12 DNA units, more preferably from 5 to 11, or from 10 to 16, 11 to 15 or 12 to 14 DNA units. In some embodiments, region G consists of 100% DNA units. In a preferred embodiment G consists of, most preferably 10, 11, 12, 13, 14 or 15 DNA units.
  • In further embodiments the region G may consist of a mixture of DNA and other nucleosides capable of mediating RNase H cleavage. Region G may consist of at least 50% DNA, more preferably 60%, 70% or 80% DNA, and even more preferred 90% or 95% DNA.
  • In a still further embodiment at least one nucleoside unit in region G is an alpha-L-LNA nucleoside unit, such as at least one alpha-L-LNA unit, such as 2, 3, 4, 5, 6, 7, 8 or 9 alpha-L-LNA units. In a further embodiment, region G comprises the least one alpha-L-LNA is alpha-L-oxy-LNA unit. In a further embodiment region G comprises a combination of DNA and alpha-L-LNA nucleoside units.
  • In some embodiments the size of the contiguous sequence in region G may be longer, such as 15, 16, 17, 18, 19 or 20 nucleoside units.
  • In some embodiments, nucleosides in region G have a 2′ endo structure.
  • Region F′
  • Region F′ (3′ flank or 3′ wing) attached to the ′3 end of region G comprises, contains or consists of at least one modified nucleoside such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 modified nucleosides. In an embodiment region F′ comprise or consist of from 1 to 7 modified nucleosides, such as from 2 to 6 modified nucleoside, such as from 2 to 4 modified nucleosides, such as from 1 to 3 modified nucleosides, such as 1, 2, 3 or 4 modified nucleosides. In a further embodiment further additional nucleosides attached to the ′3 end of region F′, representing a region D′, preferably comprising 1, 2 or 3 nucleoside units, such as DNA nucleosides. Region D′ can take the function of a biocleavable (B) linker described, in the section “Linkers”.
  • In some embodiments, the modified nucleosides in region F′ have a 3′ endo structure.
  • In a preferred embodiment, modified nucleosides in region F′ is LNA.
  • In a further embodiment modified nucleosides in region F′ are selected from 2′-O-alkyl-RNA units, 2′-O-methyl-RNA, 2′-amino-DNA units, 2′-fluoro-DNA units, 2′-alkoxy-RNA, MOE units, LNA units, arabino nucleic acid (ANA) units and 2′-fluoro-ANA units.
  • In one embodiment of the invention all the modified nucleosides in region F′ are LNA nucleosides. In a further embodiment the LNA nucleosides in region F′ are independently selected from the group consisting of oxy-LNA, thio-LNA, amino-LNA, cET and/or ENA, in either the beta-D or alpha-L configurations or combinations thereof. In a preferred embodiment region F′ has at least 2 beta-D-oxy LNA unit, at the 3′ end of the contiguous sequence.
  • Region D and D′
  • Region D and D′ can be attached to the 5′ end of region F or the 3′ end of region F′, respectively.
  • Region D or D′ may independently comprise 1, 2, 3, 4 or 5 additional nucleotides, which may be complementary or non-complementary to the target nucleic acid. In this respect the oligonucleotide of the invention, may in some embodiments comprise a contiguous nucleotide sequence capable of modulating the target which is flanked at the 5′ and/or 3′ end by additional nucleotides. Such additional nucleotides may serve as a nuclease susceptible biocleavable linker (see definition of linkers). In some embodiments the additional 5′ and/or 3′ end nucleotides are linked with phosphodiester linkages, and may be DNA or RNA. In another embodiment, the additional 5′ and/or 3′ end nucleotides are modified nucleotides which may for example be included to enhance nuclease stability or for ease of synthesis. In an embodiment of the oligonucleotide of the invention, comprises a region D and/or D′ in addition to the contiguous nucleotide sequence.
  • The gapmer oligonucleotide of the present invention can be represented by the following formulae:

  • F-G-F′; in particular F1-7-G4-12-F′1-7

  • D-F-G-F′, in particular D1-3-F1-7-G4-12-F′1-7

  • F-G-F′-D′, in particular F1-7-G4-12-F′1-7-D′1-3

  • D-F-G-F′-D′, in particular D1-3-F1-7-G4-12-F′1-7-D′1-3
  • The preferred number and types of nucleosides in regions F, G and F′, D and D′ have been described above. The design of the individual oligonucleotide may also have profound impact on the properties of the oligonucleotide in its use for modulating expression of UBE3A.
  • In some embodiments the oligonucleotide is a gapmer consisting of 14, 15, 16, 17, 18, 19 or 20 nucleotides in length, wherein each of regions F and F′ independently consists of 2, 3 or 4 modified nucleoside units complementary to a part of the human SNHG14 long non-coding RNA which is antisense to the UBE3A pre-mRNA (the target nucleic acid) and region G consists of 10, 11, 12, 13, 14 or 15 nucleoside units, capable of recruiting nuclease when in duplex with the target nucleic acid.
  • In a further embodiments, the oligonucleotide is a gapmer wherein each of regions F and F′ independently consists of 2, 3, 4 or 5 modified nucleoside units, such as nucleoside units containing a 2′-O-methoxyethyl-ribose sugar (2′-MOE) or nucleoside units containing a 2′-fluoro-deoxyribose sugar and/or LNA units, and region G consists of 9, 10, 11, 12, 13, 14 or 15 nucleoside units, such as DNA units or other nuclease recruiting nucleosides such as alpha-L-LNA or a mixture of DNA and nuclease recruiting nucleosides.
  • In a further specific embodiment, the oligonucleotide is a gapmer wherein each of regions F and F′ region consists of two LNA units each, and region G consists of 10, 11, 12, 13, 14 or 15 nucleoside units, preferably DNA units. Specific gapmer designs of this nature include 2-10-2, 2-11-2, 2-12-2, 2-13-2, 2-14-2 and 2-15-2.
  • In a further specific embodiment, the oligonucleotide is a gapmer wherein each of regions F and F′ independently consists of three LNA units, and region G consists of 10, 11, 12, 13, 14 or 15 nucleoside units, preferably DNA units. Specific gapmer designs of this nature include 3-10-3, 3-11-3, 3-12-3, 3-13-3, 3-14-3 and 3-15-3.
  • In a further specific embodiment, the oligonucleotide is a gapmer wherein each of regions F and F′ consists of four LNA units each, and region G consists of 10, 11, 12, 13, 14 or 15 nucleoside units, preferably DNA units. Specific gapmer designs of this nature include 4-10-4, 4-11-4, 4-12-4, 4-13-4, 4-14-4 and 4-15-4.
  • Specific gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 10 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-10-1, 2-10-1, 1-10-2, 1-10-3, 3-10-1, 1-10-4, 4-10-1, 2-10-2, 2-10-3, 3-10-2, 2-10-4, 4-10-2, 3-10-3, 3-10-4, 4-10-3 and 4-10-4 gapmers.
  • Specific gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 11 nucleosides and independently 1 to 4 modified nucleosides in the wings including, 1-11-1, 2-11-1, 1-11-2, 1-11-3, 3-11-1, 1-11-4, 4-11-1, 2-11-2, 2-11-3, 3-11-2, 2-11-4, 4-11-2, 3-11-3, 3-11-4, 4-11-3 and 4-11-4 gapmers.
  • Specific gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 12 nucleosides including, 1-12-1, 2-12-1, 1-12-2, 1-12-3, 3-12-1, 1-12-4, 4-12-1, 2-12-2, 2-12-3, 3-12-2, 2-12-4, 4-12-2, 3-12-3, 3-12-4, 4-12-3 and 4-12-4 gapmers.
  • Specific gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 13 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-13-1, 1-13-2, 1-13-3, 3-13-1, 1-13-4, 4-13-1, 2-13-1, 2-13-2, 2-13-3, 3-13-2, 2-13-4, 4-13-2, 3-13-3, 3-13-4, 4-13-3, and 4-13-4 gapmers.
  • Specific gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 14 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-14-1, 1-14-2, 2-14-1, 1-14-3, 3-14-1, 1-14-4, 4-14-1, 2-14-2, 2-14-3, 3-14-2 2-14-4, 4-14-2, 3-14-3, 3-14-4 and 4-14-3 gapmers.
  • Specific gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 15 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-15-1, 1-15-2, 2-15-1, 1-15-3, 3-15-1, 1-15-4, 4-15-1, 2-15-2, 2-15-3, 3-15-2 2-15-4, 4-15-2, 3-15-3, 3-15-4 and 4-15-3 gapmers.
  • Specific gapmer designs of this nature include F-G-F′ designs selected from a group consisting of a gap with 16 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-16-1, 1-16-2, 2-16-1, 1-15-3, 3-16-1, 1-16-4, 4-16-1, 2-16-2, 2-16-3, 3-16-2 2-16-4, 4-16-2, 3-16-3, 3-16-4 and 4-16-3 gapmers.
  • In some embodiments the F-G-F′ design is selected from 2-10-4, 3-10-3 and 4-10-2.
  • In some embodiments the F-G-F′ design is selected from 2-11-4, 3-11-2, 3-11-3 and 4-11-2.
  • In some embodiments the F-G-F′ design is selected from 2-12-2, 2-12-3, 2-12-4, 3-12-2, 3-12-3, and 4-12-2.
  • In some embodiments the F-G-F′ design is selected from 2-13-2, 2-13-3, 2-13-4, 3-13-3 and 4-13-2.
  • In some embodiments the F-G-F′ design is selected from 2-14-2, 2-14-4, 3-14-3 and 4-14-2.
  • In some embodiments the F-G-F′ design is selected from 2-15-2 and 2-16-2.
  • In some embodiments the F-G-F′ design is selected from the designs indicated in table 3.
  • In all instances the F-G-F′ design may further include region D and/or D′, which may have 1, 2 or 3 nucleoside units, such as DNA units. Preferably, the nucleosides in region F and F′ are modified nucleosides, while nucleotides in region G are preferably unmodified nucleosides.
  • In each design, the preferred modified nucleoside is LNA.
  • In another embodiment all the internucleoside linkages in the gap in a gapmer are phosphorothioate and/or boranophosphate linkages. In another embodiment all the internucleoside linkages in the flanks (F and F′ region) in a gapmer are phosphorothioate and/or boranophosphate linkages. In another preferred embodiment all the internucleoside linkages in the D and D′ region in a gapmer are phosphodiester linkages.
  • For specific gapmers as disclosed herein, when the cytosine (C) residues are annotated as 5-methyl-cytosine, in various embodiments, one or more of the C's present in the oligonucleotide may be unmodified C residues.
  • Further gapmer designs are disclosed in WO2004/046160, WO2007/146511 and incorporated by reference.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds in table 3.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 4_1 to 150_2.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 4_1 to 678_1.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 4_1 to 818_1 (see oligonucleotide sequences listed in table 3 in the Examples section).
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 155_1 or 165_1.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 169_52, 169_50 or 169_56.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 172_1, 272_1, 572_7, 572_6 or 572_5.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 175_1.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 178_1.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 573_8, 186_1 or 187_1.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 186_1.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 200_1, 204_1, 206_1, 35_2 or 209_1.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 585_1, 585_8, 586_9, 586_5, 586_8, 586_4 or 586_6.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 233_1.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 237_8 or 590_13.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 220_1.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 591_1, 592_2, 592_4 or 241_9.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 597_4, 598_4, 39_1 or 602_1.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 39_1.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 611_7.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 271_1 or 278_1.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 616_4, 621_2, 621_1, 622_3, 622_5, 622_4, 6243, 624_5, 287_1, 625_6, 626_7, 626_8, 626_9, 48_1, 631_6, 631_1, 303_1, 304_6 or 304_10.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 636_8.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 638_8, 639_5, 331_1 or 640_4.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 359_1, 361_1, 361_5, 362_1 or 641_5.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 378_1, 379_1, 399_1.
  • For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 403_1, 405_1, 642_12, 642_13, 644_3 or 646_16.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 85_1 or 425_5.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 116_1.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 123_1 or 124_1.
  • For certain embodiments of the invention, the oligonucleotide is an oligonucleotide compound with CMP-ID-NO: 126_2.
  • Method of Manufacture
  • In a further aspect, the invention provides methods for manufacturing the oligonucleotides of the invention comprising reacting nucleotide units and thereby forming covalently linked contiguous nucleotide units comprised in the oligonucleotide. Preferably, the method uses phophoramidite chemistry (see for example Caruthers et al, 1987, Methods in Enzymology vol. 154, pages 287-313). In a further embodiment the method further comprises reacting the contiguous nucleotide sequence with a conjugating moiety (ligand). In a further aspect a method is provided for manufacturing the composition of the invention, comprising mixing the oligonucleotide or conjugated oligonucleotide of the invention with a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
  • Pharmaceutical Composition
  • In a further aspect, the invention provides pharmaceutical compositions comprising any of the aforementioned oligonucleotides and/or oligonucleotide conjugates and a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant. A pharmaceutically acceptable diluent includes phosphate-buffered saline (PBS) and pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.
  • WO 2007/031091 provides suitable and preferred examples of pharmaceutically acceptable diluents, carriers and adjuvants (hereby incorporated by reference). Suitable dosages, formulations, administration routes, compositions, dosage forms, combinations with other therapeutic agents, pro-drug formulations are also provided in WO2007/031091.
  • Oligonucleotides or oligonucleotide conjugates of the invention may be mixed with pharmaceutically acceptable active or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.
  • In some embodiments, the oligonucleotide or oligonucleotide conjugate of the invention is a prodrug. In particular with respect to oligonucleotide conjugates the conjugate moiety is cleaved of the oligonucleotide once the prodrug is delivered to the site of action, e.g. the target cell.
  • Applications
  • The oligonucleotides of the invention may be utilized as research reagents for, for example, therapeutics and prophylaxis.
  • In research, such oligonucleotides may be used to specifically modulate the synthesis of UBE3A protein in cells (e.g. in vitro cell cultures) and experimental animals thereby facilitating functional analysis of the target or an appraisal of its usefulness as a target for therapeutic intervention. The target modulation is achieved by degrading or inhibiting a modulator of the gene or mRNA producing the protein.
  • For therapeutics, an animal or a human, suspected of having a disease or disorder, which can be treated by modulating the expression of UBE3A.
  • The invention provides methods for treating or preventing a disease, comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide, an oligonucleotide conjugate or a pharmaceutical composition of the invention to a subject suffering from or susceptible to the disease.
  • The invention also relates to an oligonucleotide, a composition or a conjugate as defined herein for use as a medicament.
  • The oligonucleotide, oligonucleotide conjugate or a pharmaceutical composition according to the invention is typically administered in an effective amount.
  • The invention also provides for the use of the oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament for the treatment of a disorder as referred to herein, or for a method of the treatment of as a disorder as referred to herein.
  • The disease or disorder, as referred to herein, is associated with expression of UBE3A. In some embodiments the disease or disorder may be associated with a mutation in the maternal UBE3A gene. In some embodiments, the target nucleic acid is a regulator of the paternal UBE3A gene.
  • The methods of the invention are preferably employed for treatment or prophylaxis against diseases caused by abnormal levels and/or activity of UBE3A. The disease may in particular be caused by reduced levels and/or activity of UBE3A protein.
  • The invention further relates to use of an oligonucleotide, oligonucleotide conjugate or a pharmaceutical composition as defined herein for the manufacture of a medicament for the treatment of abnormal levels and/or activity of UBE3A, in particular low levels and/or activity of UBE3A.
  • In one embodiment, the invention relates to oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions for use in the treatment of Angelman syndrome.
  • Administration
  • The oligonucleotides or pharmaceutical compositions of the present invention may be administered topical (such as, to the skin, inhalation, ophthalmic or otic) or enteral (such as, orally or through the gastrointestinal tract) or parenteral (such as, intravenous, subcutaneous, intra-muscular, intracerebral, intracerebroventricular or intrathecal).
  • In a preferred embodiment the oligonucleotide or pharmaceutical compositions of the present invention are administered by a parenteral route including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, intrathecal or intracranial, e.g., intracerebral or intraventricular, administration. In one embodiment the active oligonucleotide or oligonucleotide conjugate is administered intracerebral or intracerebroventricular. In another embodiment the active oligonucleotide or oligonucleotide conjugate is administered intrathecal.
  • The invention also provides for the use of the oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament wherein the medicament is in a dosage form for intrathecal administration.
  • The invention also provides for the use of the oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament wherein the medicament is in a dosage form for intracerebral or intraventricular administration.
  • The invention also provides for the use of the oligonucleotide or oligonucleotide conjugate of the invention as described for the manufacture of a medicament wherein the medicament is in a dosage form for intracerebroventricular administration.
  • Combination Therapies
  • In some embodiments the oligonucleotide, oligonucleotide conjugate or pharmaceutical composition of the invention is for use in a combination treatment with another therapeutic agent. The therapeutic agent can for example be anticonvulsant medication.
  • EMBODIMENTS
  • The following embodiments of the present invention may be used in combination with any other embodiments described herein.
  • 1. An antisense oligonucleotide which comprises or consists of a contiguous nucleotide sequence of 10 to 30 nucleotides in length capable of inducing human paternal UBE3A expression, in particular in a neuronal cell.
  • 2. The oligonucleotide of embodiment 1, wherein the contiguous nucleotide sequence is at least 95% complementarity to the part of human SNHG14 long non-coding RNA which is downstream of SNORD109B corresponding to position 25278410 to 25419462 on chromosome 15.
  • 3. The oligonucleotide of embodiment 1 or 2, wherein the oligonucleotide is capable of hybridizing to a target nucleic acid of SEQ ID NO: 1 with a ΔG° below −10 kcal.
  • 4. The oligonucleotide of embodiment 1-3, wherein the contiguous nucleotide sequence is at least 95%, such as 98%, such as 100% complementarity to region of the target nucleic acid of SEQ ID NO: 1 and/or 2.
  • 5. The oligonucleotide of embodiment 1-3, wherein the contiguous nucleotide sequence is 100% complementary to a region of the target nucleic acid of position 1 to 55318 of SEQ ID NO: 1.
  • 6. The oligonucleotide of embodiment 1-4, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid, wherein the subsequence is selected from the group consisting of the regions indicated in table 1 or 2.
  • 7. The oligonucleotide of embodiment 1-4, wherein the contiguous nucleotide sequence is at least 98% complementarity to the part of human SNHG14 long non-coding RNA which is antisense to the UBE3A pre-mRNA.
  • 8. The oligonucleotide of embodiments 1-4 or 7, wherein the oligonucleotide is capable of hybridizing to a target nucleic acid corresponding to position 55319 to 141053 of SEQ ID NO: 1, with a ΔG° below −10 kcal.
  • 9. The oligonucleotide of embodiments 1-4 or 7-8, wherein the contiguous nucleotide sequence is 100% complementary to a target nucleic acid of position 55319 to 141053 of SEQ ID NO: 1.
  • 10. The oligonucleotide of embodiment 1-8, wherein the target nucleic acid is RNA.
  • 11. The oligonucleotide of embodiment 10, wherein the RNA is a long non-coding RNA.
  • 12. The oligonucleotide of embodiment 1-11, wherein the contiguous nucleotide sequence comprises or consists of at least 10 contiguous nucleotides, particularly 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 contiguous nucleotides.
  • 13. The oligonucleotide of embodiment 1-12, wherein the contiguous nucleotide sequence comprises or consists of from 12 to 22 nucleotides.
  • 14. The oligonucleotide of embodiment 13, wherein the contiguous nucleotide sequence comprises or consists of from 15-20 nucleotides.
  • 15. The oligonucleotide of embodiment 1-14, wherein the oligonucleotide comprises or consists of 10 to 35 nucleotides in length.
  • 16. The oligonucleotide of embodiment 15, wherein the oligonucleotide comprises or consists of 15 to 24 nucleotides in length.
  • 17. The oligonucleotide of embodiment 15 or 17, wherein the oligonucleotide comprises or consists of 17 to 22 nucleotides in length.
  • 18. The oligonucleotide of embodiment 1-17, wherein the oligonucleotide or contiguous nucleotide sequence is single stranded.
  • 19. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid, selected from the group consisting of the regions indicated in table 1 or 2.
  • 20. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid selected from the group consisting of position 1589-10889, 46089-53989 and 60789-62489 of SEQ ID NO: 1.
  • 21. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 5218-5240 of SEQ ID NO: 1.
  • 22. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 5782-5803 of SEQ ID NO: 1.
  • 23. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 8113-8139 of SEQ ID NO: 1.
  • 24. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions: 9200-9250 of SEQ ID NO: 1.
  • 25. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions: 11505-11555 of SEQ ID NO: 1.
  • 26. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 13223-13242 of SEQ ID NO: 1.
  • 27. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 15100-15150 of SEQ ID NO: 1.
  • 28. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 15113-15180 of SEQ ID NO: 1.
  • 29. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 29635-29705 of SEQ ID NO: 1.
  • 30. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 30590-30740 of SEQ ID NO: 1.
  • 31. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 39800-39855 of SEQ ID NO: 1.
  • 32. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 44435-44460 of SEQ ID NO: 1.
  • 33. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 45245-45270 of SEQ ID NO: 1
  • 34. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid to positions 46380-46430 of SEQ ID NO: 1.
  • 35. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid corresponding to positions 68915-68940 of SEQ ID NO: 1.
  • 36. The oligonucleotide of embodiment 1-35, wherein the oligonucleotide is neither siRNA nor self-complementary.
  • 37. The oligonucleotide of embodiment 1-36, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 1819, 20, 21, 22, 23, 23, 24, 25, 26, 26, 27, 28, 29, 30, 31, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 44, 45, 45, 46, 47, 48, 49, 50, 51, 52, 53, 53, 54, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 79, 80, 81, 8283, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 95, 96, 96, 96, 97, 98, 99, 100, 101, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817 and 818.
  • 38. The oligonucleotide of embodiment 1-36, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 166, 167, 167 or 169 (see motif sequences listed in table 3 in the Examples section).
  • 39. The oligonucleotide of embodiment 1-36, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 570, 571, 572, 679, 680, 681, 682 and 683 (see motif sequences listed in table 3 in the Examples section).
  • 40. The oligonucleotide of embodiment 1-36, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 570, 571, 572, 679, 680, 681, 682 and 683 (see motif sequences listed in table 3 in the Examples section).
  • 41. The oligonucleotide of embodiment 1-36, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 35, 199 to 210 or SEQ ID NO: 582 to 584 (see motif sequences listed in table 3 in the Examples section).
  • 42. The oligonucleotide of embodiment 1-36, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 236, 237, 238, 239, 240 and 590 (see motif sequences listed in table 3 in the Examples section).
  • 43. The oligonucleotide of embodiment 1-36, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 221 to 225 or SEQ ID NO: 585 to 589 (see motif sequences listed in table 3 in the Examples section).
  • 44. The oligonucleotide of embodiment 1-36, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 241 or 591 (see motif sequences listed in table 3 in the Examples section).
  • 45. The oligonucleotide of embodiment 1-36, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 46-48, 285 to 305 or SEQ ID NO: 613 to 632 or SEQ ID NO: 721 to 807 (see motif sequences listed in table 3 in the Examples section).
  • 46. The oligonucleotide of embodiment 1-36, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 331, 332, 638, 639, 640, 808, 809, 810, 811, 812, 813, 814 and 815 (see motif sequences listed in table 3 in the Examples section).
  • 47. The oligonucleotide of embodiment 1-36, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of SEQ ID NO: 409 to 411 or SEQ ID NO: 642 to 646 or SEQ ID NO: 816 to 818 (see motif sequences listed in table 3 in the Examples section).
  • 48. The oligonucleotide of embodiment 1-47, wherein the contiguous nucleotide sequence has zero to three mismatches compared to the target nucleic acid it is complementary to.
  • 49. The oligonucleotide of embodiment 48, wherein the contiguous nucleotide sequence has one mismatch compared to the target nucleic acid.
  • 50. The oligonucleotide of embodiment 48, wherein the contiguous nucleotide sequence has two mismatches compared to the target nucleic acid.
  • 51. The oligonucleotide of embodiment 48, wherein the contiguous nucleotide sequence is fully complementary to the target nucleic acid sequence.
  • 52. The oligonucleotide of embodiment 1-51, comprising one or more modified nucleosides.
  • 53. The oligonucleotide of embodiment 52, wherein the one or more modified nucleoside is a high-affinity modified nucleosides.
  • 54. The oligonucleotide of embodiment 52 or 53, wherein the one or more modified nucleoside is a 2′ sugar modified nucleoside.
  • 55. The oligonucleotide of embodiment 54, wherein the one or more 2′ sugar modified nucleoside is independently selected from the group consisting of 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA, 2′-amino-DNA, 2′-fluoro-DNA, 2′-fluoro-ANA and LNA nucleosides.
  • 56. The oligonucleotide of embodiment 54, wherein the one or more modified nucleoside is a LNA nucleoside.
  • 57. The oligonucleotide of embodiment 56, wherein the modified LNA nucleoside is oxy-LNA.
  • 58. The oligonucleotide of embodiment 57, wherein the modified nucleoside is beta-D-oxy-LNA.
  • 59. The oligonucleotide of embodiment 57, wherein the modified nucleoside is alpha-L-oxy-LNA
  • 60. The oligonucleotide of embodiment 56, wherein the modified nucleoside is thio-LNA.
  • 61. The oligonucleotide of embodiment 56, wherein the modified nucleoside is amino-LNA.
  • 62. The oligonucleotide of embodiment 56, wherein the modified nucleoside is cET.
  • 63. The oligonucleotide of embodiment 56, wherein the modified nucleoside is ENA.
  • 64. The oligonucleotide of embodiment 56, wherein the modified LNA nucleoside is selected from beta-D-oxy-LNA, alpha-L-oxy-LNA, beta-D-amino-LNA, alpha-L-amino-LNA, beta-D-thio-LNA, alpha-L-thio-LNA, (S)cET, (R)cET beta-D-ENA and alpha-L-ENA.
  • 65. The oligonucleotide of any one of embodiments 1-64, wherein the oligonucleotide comprises at least one modified internucleoside linkage.
  • 66. The oligonucleotide of embodiment 65, wherein the modified internucleoside linkage is nuclease resistant.
  • 67. The oligonucleotide of embodiment 65 or 66, wherein at least 50% of the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate internucleoside linkages or boranophosphate internucleoside linkages.
  • 68. The oligonucleotide of embodiment 65 or 66, wherein all the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate internucleoside linkages.
  • 69. The oligonucleotide of embodiment 1-68, wherein the oligonucleotide is capable of recruiting RNase H.
  • 70. The oligonucleotide of embodiment 69, wherein the oligonucleotide is a gapmer.
  • 71. The oligonucleotide of embodiment 69 or 70, wherein the oligonucleotide is a gapmer of formula 5′-F-G-F′-3′, where region F and F′ independently comprise or consist of 1-7 modified nucleosides and G is a region between 6 and 16 nucleosides which are capable of recruiting RNaseH.
  • 72. The oligonucleotide of embodiment 71, wherein the modified nucleoside is a 2′ sugar modified nucleoside independently selected from the group consisting of 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA, 2′-amino-DNA, 2′-fluoro-DNA, arabino nucleic acid (ANA), 2′-fluoro-ANA and LNA nucleosides.
  • 73. The oligonucleotide of embodiment 71 or 72, wherein one or more of the modified nucleosides in region F and F′ is a LNA nucleoside.
  • 74. The oligonucleotide of embodiment 73, wherein all the modified nucleosides in region F and F′ are LNA nucleosides.
  • 75. The oligonucleotide of embodiment 74, wherein region F and F′ consist of LNA nucleosides.
  • 76. The oligonucleotide of embodiment 73-75, wherein all the modified nucleosides in region F and F′ are oxy-LNA nucleosides.
  • 77. The oligonucleotide of embodiment 73, wherein at least one of region F or F′ further comprises at least one 2′ substituted modified nucleoside independently selected from the group consisting of 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA, 2′-amino-DNA and 2′-fluoro-DNA.
  • 78. The oligonucleotide of embodiment 73-77, wherein the RNaseH recruiting nucleosides in region G are independently selected from DNA, alpha-L-LNA, C4′ alkylated DNA, ANA and 2′F-ANA and UNA.
  • 79. The oligonucleotide of embodiment 78, wherein the nucleosides in region G is DNA and/or alpha-L-LNA nucleosides.
  • 80. The oligonucleotide of embodiment 78 or 79, wherein region G consists of at least 75% DNA nucleosides.
  • 81. The oligonucleotide of embodiment 1-80, wherein the oligonucleotide is capable of increasing the expression of UBE3A by at least 30% compared to a control.
  • 82. The oligonucleotide of embodiment 1-81, wherein the level of the SNHG14 transcript downstream of SNORD109B is reduced by at least 20% compared to a control.
  • 83. The oligonucleotide of embodiment 1-82, wherein the expression of SNORD115 is not significantly affected compared to a control.
  • 84. The oligonucleotide of embodiment 1-83, wherein the oligonucleotide is selected from CMP ID NO: 4_1 to 678_1.
  • 85. The oligonucleotide of embodiment 1-83, wherein the oligonucleotide is selected from the group consisting of CMP ID NO: 4_1, 4_2, 5_1, 5_2, 6_1, 6_2, 7_1, 7_2, 8_1, 9_1, 10_1, 11_1, 11_2, 12_1, 12_2, 13_1, 13_2, 14_1, 15_1, 16_1, 17_1, 17_2, 18_1, 18_2, 19_1, 19_2, 20_1, 21_1, 22_1, 23_1, 23_2, 24_1, 25_1, 26_1, 26_2, 27_1, 28_1, 28_2, 29_1, 29_2, 30_1, 31_1, 31_2, 32_1, 33_1, 34_1, 34_2, 34_3, 34_4, 34_5, 34_6, 34_7, 35_1, 35_2, 36_1, 37_1, 38_1, 38_2, 38_3, 38_4, 38_5, 38_6, 39_1, 39_2, 39_3, 39_4, 39_5, 40_1, 40_2, 40_3, 40_4, 40_5, 40_6, 40_7, 40_8, 41_1, 42_1, 43_1, 44_1, 44_2, 45_1, 45_2, 46_1, 47_1, 48_1, 48_2, 48_3, 48_4, 48_5, 48_6, 48_7, 49_1, 50_1, 51_1, 52_1, 53_1, 53_2, 54_1, 54_2, 54_3, 55_1, 55_2, 56_1, 57_1, 58_1, 58_2, 58_3, 59_1, 59_2, 60_1, 60_2, 60_3, 61_1, 62_1, 63_1, 64_1, 64_2, 65_1, 66_1, 67_1, 68_1, 69_1, 69_2, 69_3, 70_1, 70_2, 70_3, 71_1, 72_1, 72_2, 73_1, 73_2, 73_3, 74_1, 74_2, 75_1, 75_2, 76_1, 77_1, 77_2, 77_3, 78_1, 79_1, 79_2, 79_3, 80_1, 80_2, 80_3, 81_1, 82_1, 82_2, 83_1, 83_2, 84_1, 84_2, 85_1, 85_2, 86_1, 87_1, 88_1, 88_2, 89_1, 90_1, 91_1, 92_1, 93_1, 94_1, 95_1, 95_2, 96_1, 96_2, 96_3, 97_1, 97_2, 97_3, 97_4, 98_1, 98_2, 98_3, 99_1, 99_2, 99_3, 99_4, 100_1, 100_2, 100_3, 101_1, 101_2, 101_3, 101_4, 102_1, 102_2, 102_3, 102_4, 103_1, 103_2, 103_3, 103_4, 104_1, 104_2, 104_3, 105_1, 105_2, 105_3, 105_4, 106_1, 106_2, 106_3, 106_4, 107_1, 107_2, 107_3, 107_4, 108_1, 108_2, 108_3, 108_4, 109_1, 109_2, 109_3, 109_4, 110_1, 110_2, 111_1, 111_2, 111_3, 112_1, 112_2, 113_1, 114_1, 115_1, 116_1, 117_1, 118_1, 119_1, 120_1, 120_2, 121_1, 122_1, 123_1, 124_1, 125_1, 126_1, 126_2, 127_1, 128_1, 128_2, 128_3, 128_4, 129_1, 129_2, 130_1, 131_1, 132_1, 132_2, 132_3, 133_1, 133_2, 133_3, 133_4, 134_1, 134_2, 135_1, 135_2, 136_1, 137_1, 138_1, 139_1, 140_1, 141_1, 142_1, 143_1, 144_1, 145_1, 145_2, 146_1, 146_2, 147_1, 148_1, 149_1, 150_1, 150_2, 151_1, 152_1, 153_1, 154_1, 155_1, 156_1, 157_1, 158_1, 159_1, 160_1, 161_1, 162_1, 163_1, 164_1, 165_1, 166_1, 167_1, 168_1, 169_1, 169_10, 169_11, 169_12, 169_13, 169_14, 169_15, 169_16, 169_17, 169_18, 169_19, 169_2, 169_20, 169_21, 169_22, 169_23, 169_24, 169_25, 169_26, 169_27, 169_28, 169_29, 169_3, 169_30, 169_31, 169_32, 169_33, 169_34, 169_35, 169_36, 169_37, 169_38, 169_39, 169_4, 169_40, 169_41, 169_42, 169_43, 169_44, 169_45, 169_46, 169_47, 169_48, 169_49, 169_5, 169_50, 169_51, 169_52, 169_53, 169_54, 169_55, 169_56, 169_57, 169_6, 169_7, 169_8, 169_9, 169_58, 169_59, 169_60, 169_61, 169_62, 170_1, 171_1, 172_1, 173_1, 174_1, 175_1, 176_1, 177_1, 178_1, 179_1, 180_1, 181_1, 182_1, 183_1, 184_1, 185_1, 186_1, 187_1, 188_1, 189_1, 190_1, 191_1, 192_1, 193_1, 194_1, 195_1, 196_1, 197_1, 198_1, 199_1, 200_1, 201_1, 202_1, 203_1, 204_1, 205_1, 206_1, 207_1, 208_1, 208_2, 208_3, 208_4, 208_5, 208_6, 208_7, 209_1, 209_10, 209_2, 209_3, 209_4, 209_5, 209_6, 209_7, 209_8, 209_9, 210_1, 211_1, 212_1, 213_1, 214_1, 215_1, 216_1, 217_1, 218_1, 219_1, 220_1, 221_1, 222_1, 223_1, 224_1, 225_1, 226_1, 227_1, 228_1, 229_1, 230_1, 231_1, 232_1, 233_1, 234_1, 235_1, 236_1, 236_10, 236_11, 236_12, 236_13, 236_14, 236_15, 236_16, 236_2, 236_3, 236_4, 236_5, 236_6, 236_7, 236_8, 236_9, 236_17, 236_18, 236_19, 236_20, 236_21, 237_1, 237_10, 237_11, 237_12, 237_13, 237_14, 237_15, 237_16, 237_2, 237_3, 237_4, 237_5, 237_6, 237_7, 237_8, 237_9, 237_17, 237_18, 237_19, 237_20, 237_21, 238_1, 239_1, 239_10, 239_11, 239_12, 239_13, 239_14, 239_15, 239_16, 239_2, 239_3, 239_4, 239_5, 239_6, 239_7, 239_8, 239_9, 239_17, 239_18, 239_19, 239_20, 239_21, 240_1, 241_1, 241_10, 241_2, 241_3, 241_4, 241_5, 241_6, 241_7, 241_8, 241_9, 241_11, 241_12, 241_13, 241_14, 241_15, 242_1, 243_1, 244_1, 244_2, 244_3, 244_4, 244_5, 245_1, 246_1, 247_1, 248_1, 249_1, 250_1, 251_1, 252_1, 253_1, 254_1, 255_1, 256_1, 257_1, 258_1, 259_1, 260_1, 261_1, 262_1, 263_1, 264_1, 265_1, 266_1, 267_1, 268_1, 269_1, 270_1, 271_1, 272_1, 273_1, 274_1, 275_1, 276_1, 277_1, 278_1, 279_1, 280_1, 281_1, 282_1, 283_1, 284_1, 285_1, 285_2, 285_3, 285_4, 285_5, 285_6, 285_7, 285_8, 285_9, 285_10, 285_11, 286_1, 287_1, 288_1, 289_1, 290_1, 291_1, 292_1, 293_1, 294_1, 295_1, 296_1, 297_1, 298_1, 299_1, 300_1, 301_1, 302_1, 303_1, 304_1, 304_10, 304_2, 304_3, 304_4, 304_5, 304_6, 304_7, 304_8, 304_9, 304_11, 304_12, 304_13, 304_14, 304_15, 305_1, 306_1, 307_1, 308_1, 309_1, 310_1, 311_1, 312_1, 313_1, 314_1, 315_1, 316_1, 317_1, 318_1, 319_1, 320_1, 321_1, 322_1, 323_1, 324_1, 325_1, 326_1, 327_1, 328_1, 329_1, 330_1, 331_1, 332_1, 333_1, 334_1, 335_1, 336_1, 337_1, 338_1, 339_1, 340_1, 341_1, 342_1, 343_1, 344_1, 345_1, 346_1, 347_1, 348_1, 349_1, 350_1, 351_1, 352_1, 353_1, 354_1, 355_1, 356_1, 357_1, 358_1, 359_1, 360_1, 361_1, 361_10, 361_2, 361_3, 361_4, 361_5, 361_6, 361_7, 361_8, 361_9, 362_1, 362_10, 362_2, 362_3, 362_4, 362_5, 362_6, 362_7, 362_8, 362_9, 363_1, 364_1, 365_1, 366_1, 367_1, 368_1, 369_1, 370_1, 371_1, 372_1, 373_1, 374_1, 375_1, 376_1, 377_1, 378_1, 379_1, 380_1, 381_1, 382_1, 383_1, 384_1, 385_1, 386_1, 387_1, 388_1, 389_1, 390_1, 391_1, 392_1, 393_1, 394_1, 395_1, 396_1, 397_1, 398_1, 399_1, 400_1, 401_1, 402_1, 403_1, 404_1, 405_1, 406_1, 407_1, 408_1, 409_1, 410_1, 411_1, 412_1, 413_1, 414_1, 415_1, 416_1, 417_1, 418_1, 419_1, 420_1, 421_1, 422_1, 423_1, 424_1, 425_1, 425_10, 425_2, 425_3, 425_4, 425_5, 425_6, 425_7, 425_8, 425_9, 426_1, 427_1, 428_1, 429_1, 430_1, 431_1, 432_1, 433_1, 434_1, 435_1, 436_1, 437_1, 438_1, 439_1, 440_1, 441_1, 442_1, 443_1, 444_1, 445_1, 446_1, 447_1, 448_1, 449_1, 450_1, 451_1, 452_1, 453_1, 454_1, 455_1, 456_1, 457_1, 458_1, 459_1, 460_1, 461_1, 462_1, 463_1, 464_1, 465_1, 466_1, 467_1, 468_1, 469_1, 470_1, 471_1, 472_1, 473_1, 474_1, 475_1, 476_1, 477_1, 478_1, 479_1, 480_1, 481_1, 482_1, 483_1, 484_1, 485_1, 486_1, 487_1, 488_1, 489_1, 490_1, 491_1, 492_1, 493_1, 494_1, 495_1, 496_1, 497_1, 498_1, 499_1, 500_1, 501_1, 502_1, 503_1, 504_1, 505_1, 506_1, 507_1, 508_1, 509_1, 510_1, 511_1, 512_1, 513_1, 514_1, 515_1, 516_1, 517_1, 518_1, 519_1, 520_1, 521_1, 522_1, 523_1, 524_1, 525_1, 526_1, 527_1, 528_1, 529_1, 530_1, 531_1, 532_1, 533_1, 534_1, 535_1, 536_1, 537_1, 538_1, 539_1, 540_1, 541_1, 542_1, 543_1, 544_1, 545_1, 546_1, 547_1, 548_1, 549_1, 550_1, 551_1, 552_1, 553_1, 554_1, 555_1, 556_1, 557_1, 558_1, 559_1, 560_1, 561_1, 562_1, 563_1, 564_1, 565_1, 566_1, 567_1, 568_1, 569_1, 570_1, 570_2, 570_3, 570_4, 570_5, 570_6, 570_7, 570_8, 570_9, 570_10, 570_11, 570_12, 570_13, 570_14, 571_1, 571_2, 571_3, 571_4, 571_5, 571_6, 571_7, 571_8, 571_9, 571_10, 571_11, 571_12, 571_13, 571_14, 572_1, 572_2, 572_3, 572_4, 572_5, 572_6, 572_7, 572_8, 572_9, 572_10, 572_11, 572_12, 572_13, 572_14, 573_1, 573_2, 573_3, 573_4, 573_5, 573_6, 573_7, 573_8, 573_9, 573_10, 573_11, 573_12, 573_13, 573_14, 574_1, 574_2, 574_3, 574_4, 574_5, 574_6, 574_7, 574_8, 574_9, 574_10, 574_11, 574_12, 574_13, 574_14, 575_1, 575_2, 575_3, 575_4, 575_5, 575_6, 575_7, 575_8, 575_9, 575_10, 575_11, 575_12, 575_13, 575_14, 576_1, 576_2, 576_3, 576_4, 576_5, 576_6, 576_7, 576_8, 576_9, 576_10, 576_11, 576_12, 576_13, 576_14, 577_1, 577_2, 577_3, 577_4, 577_5, 577_6, 577_7, 577_8, 577_9, 577_10, 577_11, 577_12, 577_13, 577_14, 578_1, 578_2, 578_3, 578_4, 578_5, 578_6, 578_7, 578_8, 578_9, 579_1, 579_2, 579_3, 579_4, 579_5, 579_6, 579_7, 579_8, 579_9, 580_1, 580_2, 580_3, 580_4, 580_5, 580_6, 580_7, 580_8, 580_9, 581_1, 581_2, 581_3, 581_4, 581_5, 581_6, 581_7, 581_8, 581_9, 582_1, 582_2, 582_3, 582_4, 582_5, 582_6, 582_7, 582_8, 582_9, 583_1, 583_2, 583_3, 583_4, 583_5, 583_6, 583_7, 583_8, 583_9, 584_1, 584_2, 584_3, 584_4, 584_5, 584_6, 584_7, 584_8, 585_1, 585_2, 585_3, 585_4, 585_5, 585_6, 585_7, 585_8, 585_9, 585_10, 585_11, 585_12, 585_13, 585_14, 586_1, 586_2, 586_3, 586_4, 586_5, 586_6, 586_7, 586_8, 586_9, 586_10, 586_11, 586_12, 586_13, 586_14, 587_1, 587_2, 587_3, 587_4, 587_5, 587_6, 587_7, 587_8, 587_9, 587_10, 587_11, 587_12, 587_13, 587_14, 588_1, 588_2, 588_3, 588_4, 588_5, 588_6, 588_7, 588_8, 588_9, 588_10, 588_11, 588_12, 588_13, 588_14, 589_1, 589_2, 589_3, 589_4, 589_5, 589_6, 589_7, 589_8, 589_9, 589_10, 589_11, 589_12, 589_13, 589_14, 590_1, 590_10, 590_11, 590_12, 590_13, 590_14, 590_15, 590_2, 590_3, 590_4, 590_5, 590_6, 590_7, 590_8, 590_9, 590_16, 590_17, 590_18, 590_19, 590_20, 591_1, 591_2, 592_1, 592_2, 592_3, 592_4, 592_5, 592_6, 592_7, 592_8, 592_9, 592_10, 592_11, 592_12, 592_13, 592_14, 593_1, 593_2, 593_3, 593_4, 594_1, 594_2, 594_3, 594_4, 595_1, 595_2, 595_3, 595_4, 596_1, 596_2, 596_3, 596_4, 597_1, 597_2, 597_3, 597_4, 598_1, 598_2, 598_3, 598_4, 599_1, 599_2, 599_3, 599_4, 600_1, 600_2, 600_3, 600_4, 601_1, 601_2, 601_3, 601_4, 602_1, 602_2, 602_3, 602_4, 603_1, 603_2, 603_3, 603_4, 604_1, 604_2, 604_3, 604_4, 605_1, 605_2, 605_3, 605_4, 606_1, 606_2, 606_3, 606_4, 607_1, 607_2, 607_3, 607_4, 608_1, 608_2, 608_3, 608_4, 608_5, 608_6, 608_7, 608_8, 608_9, 609_1, 609_2, 609_3, 609_4, 609_5, 609_6, 609_7, 609_8, 609_9, 610_1, 610_2, 610_3, 610_4, 610_5, 610_6, 610_7, 610_8, 610_9, 611_1, 611_2, 611_3, 611_4, 611_5, 611_6, 611_7, 611_8, 611_9, 612_1, 612_2, 612_3, 612_4, 612_5, 612_6, 612_7, 612_8, 612_9, 613_1, 613_2, 613_3, 613_4, 613_5, 613_6, 613_7, 613_8, 613_9, 613_10, 614_1, 614_2, 614_3, 614_4, 614_5, 614_6, 614_7, 614_8, 614_9, 614_10, 615_1, 615_2, 615_3, 615_4, 615_5, 615_6, 615_7, 615_8, 615_9, 615_10, 616_1, 616_2, 616_3, 616_4, 616_5, 616_6, 616_7, 616_8, 616_9, 616_10, 617_1, 617_2, 617_3, 617_4, 617_5, 617_6, 617_7, 617_8, 617_9, 617_10, 618_1, 618_2, 618_3, 618_4, 618_5, 618_6, 618_7, 618_8, 618_9, 618_10, 619_1, 619_2, 619_3, 619_4, 619_5, 619_6, 619_7, 619_8, 619_9, 619_10, 620_1, 620_2, 620_3, 620_4, 620_5, 620_6, 620_7, 620_8, 620_9, 620_10, 621_1, 621_2, 621_3, 621_4, 621_5, 621_6, 621_7, 621_8, 621_9, 621_10, 621_11, 622_1, 622_2, 622_3, 622_4, 622_5, 622_6, 622_7, 622_8, 622_9, 622_10, 623_1, 623_2, 623_3, 623_4, 623_5, 623_6, 623_7, 623_8, 623_9, 623_10, 624_1, 624_2, 624_3, 624_4, 624_5, 624_6, 624_7, 624_8, 624_9, 624_10, 625_1, 625_2, 625_3, 625_4, 625_5, 625_6, 625_7, 625_8, 625_9, 625_10, 625_11, 625_12, 625_13, 625_14, 626_1, 626_2, 626_3, 626_4, 626_5, 626_6, 626_7, 626_8, 626_9, 626_10, 626_11, 626_12, 626_13, 626_14, 627_1, 627_2, 627_3, 627_4, 627_5, 627_6, 627_7, 627_8, 627_9, 627_10, 627_11, 627_12, 627_13, 627_14, 628_1, 628_2, 628_3, 628_4, 628_5, 628_6, 628_7, 628_8, 628_9, 628_10, 628_11, 628_12, 628_13, 628_14, 629_1, 629_10, 629_11, 629_2, 629_3, 629_4, 629_5, 629_6, 629_7, 629_8, 629_9, 629_12, 629_13, 629_14, 629_15, 629_16, 630_1, 630_2, 630_3, 631_1, 631_10, 631_2, 631_3, 631_4, 631_5, 631_6, 631_7, 631_8, 631_9, 631_11, 631_12, 631_13, 631_14, 631_15, 632_1, 632_2, 632_3, 632_4, 632_5, 632_6, 632_7, 632_8, 632_9, 632_10, 632_11, 632_12, 632_13, 632_14, 633_1, 633_2, 633_3, 633_4, 633_5, 633_6, 633_7, 633_8, 633_9, 634_1, 634_2, 634_3, 634_4, 634_5, 634_6, 634_7, 634_8, 634_9, 635_1, 635_2, 635_3, 635_4, 635_5, 635_6, 635_7, 635_8, 635_9, 636_1, 636_2, 636_3, 636_4, 636_5, 636_6, 636_7, 636_8, 636_9, 637_1, 637_2, 637_3, 637_4, 637_5, 637_6, 637_7, 637_8, 637_9, 638_1, 638_2, 638_3, 638_4, 638_5, 638_6, 638_7, 638_8, 638_9, 638_10, 638_11, 638_12, 638_13, 638_14, 639_1, 639_2, 639_3, 639_4, 639_5, 639_6, 639_7, 639_8, 639_9, 639_10, 639_11, 639_12, 639_13, 639_14, 640_1, 640_2, 640_3, 640_4, 640_5, 640_6, 640_7, 640_8, 640_9, 640_10, 640_11, 640_12, 640_13, 640_14, 641_1, 641_2, 641_3, 641_4, 641_5, 641_6, 641_7, 641_8, 641_9, 642_1, 642_10, 642_11, 642_12, 642_13, 642_14, 642_15, 642_16, 642_17, 642_2, 642_3, 642_4, 642_5, 642_6, 642_7, 642_8, 642_9, 642_18, 642_19, 642_20, 642_21, 642_22, 643_1, 644_1, 644_2, 644_3, 644_4, 644_5, 644_6, 645_1, 645_2, 645_3, 645_4, 645_5, 645_6, 645_7, 645_8, 645_9, 645_10, 646_1, 646_10, 646_11, 646_12, 646_13, 646_14, 646_15, 646_16, 646_17, 646_18, 646_19, 646_2, 646_3, 646_4, 646_5, 646_6, 646_7, 646_8, 646_9, 646_20, 646_21, 646_22, 646_23, 646_24, 647_1, 648_1, 649_1, 650_1, 651_1, 652_1, 653_1, 654_1, 655_1, 656_1, 657_1, 658_1, 659_1, 660_1, 661_1, 662_1, 663_1, 664_1, 665_1, 666_1, 667_1, 668_1, 669_1, 670_1, 671_1, 672_1, 673_1, 674_1, 675_1, 676_1, 677_1, 678_1, 679_1, 679_2, 679_3, 679_4, 679_5, 680_1, 680_2, 680_3, 680_4, 680_5, 681_1, 681_2, 681_3, 681_4, 681_5, 682_1, 682_2, 682_3, 682_4, 682_5, 683_1, 683_2, 683_3, 683_4, 683_5, 684_1, 684_2, 684_3, 684_4, 684_5, 685_1, 685_2, 685_3, 685_4, 685_5, 686_1, 686_2, 686_3, 686_4, 686_5, 687_1, 687_2, 687_3, 687_4, 687_5, 688_1, 688_2, 688_3, 688_4, 688_5, 689_1, 689_2, 689_3, 689_4, 689_5, 690_1, 690_2, 690_3, 690_4, 690_5, 691_1, 691_2, 692_1, 692_2, 692_3, 692_4, 692_5, 693_1, 693_2, 693_3, 693_4, 693_5, 694_1, 694_2, 694_3, 694_4, 694_5, 695_1, 695_2, 695_3, 695_4, 695_5, 696_1, 696_2, 696_3, 696_4, 696_5, 697_1, 697_2, 697_3, 697_4, 697_5, 698_1, 698_2, 698_3, 698_4, 698_5, 699_1, 699_2, 699_3, 699_4, 699_5, 700_1, 700_2, 700_3, 700_4, 700_5, 701_1, 701_2, 701_3, 701_4, 701_5, 702_1, 702_2, 702_3, 702_4, 702_5, 703_1, 703_2, 703_3, 703_4, 703_5, 704_1, 704_2, 704_3, 704_4, 704_5, 705_1, 705_2, 705_3, 705_4, 705_5, 706_1, 706_2, 706_3, 706_4, 706_5, 707_1, 707_2, 707_3, 707_4, 707_5, 708_1, 708_2, 708_3, 708_4, 708_5, 709_1, 709_2, 709_3, 709_4, 709_5, 710_1, 710_2, 710_3, 710_4, 710_5, 711_1, 711_2, 711_3, 711_4, 711_5, 712_1, 712_2, 712_3, 712_4, 712_5, 713_1, 713_2, 713_3, 713_4, 713_5, 714_1, 714_2, 714_3, 714_4, 714_5, 715_1, 715_2, 715_3, 715_4, 715_5, 716_1, 716_2, 716_3, 716_4, 716_5, 717_1, 717_2, 717_3, 717_4, 717_5, 718_1, 718_2, 719_1, 719_2, 719_3, 719_4, 719_5, 720_1, 720_2, 720_3, 720_4, 720_5, 721_1, 721_2, 721_3, 721_4, 721_5, 722_1, 722_2, 722_3, 722_4, 722_5, 723_1, 723_2, 723_3, 723_4, 723_5, 724_1, 724_2, 724_3, 724_4, 724_5, 725_1, 725_2, 725_3, 725_4, 725_5, 726_1, 726_2, 726_3, 726_4, 726_5, 727_1, 727_2, 727_3, 727_4, 727_5, 728_1, 728_2, 728_3, 728_4, 728_5, 729_1, 729_2, 729_3, 729_4, 729_5, 730_1, 730_2, 730_3, 730_4, 730_5, 731_1, 731_2, 731_3, 731_4, 731_5, 732_1, 732_2, 732_3, 732_4, 732_5, 733_1, 733_2, 733_3, 733_4, 733_5, 734_1, 734_2, 734_3, 734_4, 734_5, 735_1, 735_2, 735_3, 735_4, 735_5, 736_1, 736_2, 736_3, 736_4, 736_5, 737_1, 737_2, 737_3, 737_4, 737_5, 738_1, 738_2, 738_3, 738_4, 738_5, 738_6, 739_1, 739_2, 739_3, 739_4, 739_5, 740_1, 740_2, 740_3, 740_4, 740_5, 741_1, 741_2, 741_3, 741_4, 741_5, 742_1, 742_2, 742_3, 743_1, 743_2, 743_3, 743_4, 743_5, 744_1, 744_2, 744_3, 744_4, 744_5, 745_1, 745_2, 745_3, 745_4, 745_5, 746_1, 746_2, 746_3, 747_1, 747_2, 747_3, 747_4, 747_5, 748_1, 748_2, 748_3, 748_4, 748_5, 749_1, 749_2, 749_3, 749_4, 749_5, 750_1, 750_2, 750_3, 750_4, 751_1, 751_2, 751_3, 751_4, 751_5, 752_1, 752_2, 752_3, 752_4, 752_5, 753_1, 753_2, 753_3, 753_4, 753_5, 754_1, 754_2, 754_3, 754_4, 754_5, 755_1, 755_2, 755_3, 755_4, 755_5, 756_1, 756_2, 756_3, 756_4, 756_5, 757_1, 757_2, 757_3, 757_4, 757_5, 758_1, 758_2, 758_3, 758_4, 758_5, 759_1, 759_2, 759_3, 759_4, 759_5, 760_1, 760_2, 760_3, 760_4, 760_5, 761_1, 761_2, 761_3, 761_4, 761_5, 762_1, 762_2, 762_3, 762_4, 762_5, 763_1, 763_2, 763_3, 763_4, 763_5, 764_1, 764_2, 764_3, 764_4, 764_5, 765_1, 765_2, 765_3, 765_4, 765_5, 766_1, 766_2, 766_3, 766_4, 766_5, 767_1, 767_2, 767_3, 767_4, 767_5, 768_1, 768_2, 768_3, 768_4, 768_5, 769_1, 769_2, 769_3, 769_4, 769_5, 770_1, 770_2, 770_3, 770_4, 770_5, 771_1, 771_2, 771_3, 771_4, 771_5, 772_1, 772_2, 772_3, 772_4, 772_5, 773_1, 773_2, 773_3, 773_4, 773_5, 774_1, 774_2, 774_3, 774_4, 774_5, 775_1, 775_2, 775_3, 775_4, 775_5, 776_1, 776_2, 776_3, 776_4, 776_5, 777_1, 777_2, 777_3, 777_4, 777_5, 778_1, 778_2, 778_3, 778_4, 778_5, 779_1, 779_2, 779_3, 779_4, 779_5, 780_1, 780_2, 780_3, 780_4, 780_5, 781_1, 782_1, 782_2, 782_3, 782_4, 782_5, 783_1, 783_2, 783_3, 783_4, 783_5, 784_1, 784_2, 784_3, 784_4, 784_5, 785_1, 786_1, 786_2, 786_3, 786_4, 786_5, 787_1, 787_2, 787_3, 787_4, 787_5, 788_1, 788_2, 788_3, 788_4, 788_5, 789_1, 789_2, 789_3, 789_4, 789_5, 790_1, 790_2, 790_3, 790_4, 790_5, 791_1, 791_2, 791_3, 791_4, 791_5, 792_1, 792_2, 792_3, 792_4, 792_5, 793_1, 793_2, 793_3, 793_4, 793_5, 794_1, 794_2, 794_3, 794_4, 794_5, 795_1, 795_2, 795_3, 795_4, 795_5, 796_1, 796_2, 796_3, 796_4, 796_5, 797_1, 797_2, 797_3, 797_4, 797_5, 798_1, 798_2, 798_3, 798_4, 798_5, 799_1, 799_2, 799_3, 799_4, 799_5, 800_1, 800_2, 800_3, 800_4, 800_5, 801_1, 801_2, 801_3, 801_4, 801_5, 802_1, 802_2, 802_3, 802_4, 802_5, 803_1, 803_2, 803_3, 803_4, 803_5, 804_1, 804_2, 804_3, 804_4, 804_5, 805_1, 805_2, 805_3, 805_4, 805_5, 806_1, 806_2, 806_3, 806_4, 806_5, 807_1, 807_2, 807_3, 807_4, 807_5, 808_1, 808_2, 808_3, 808_4, 808_5, 809_1, 809_2, 809_3, 809_4, 809_5, 810_1, 810_2, 810_3, 810_4, 810_5, 811_1, 811_2, 811_3, 811_4, 811_5, 812_1, 812_2, 812_3, 812_4, 812_5, 813_1, 813_2, 813_3, 813_4, 813_5, 814_1, 814_2, 814_3, 814_4, 814_5, 815_1, 815_2, 815_3, 815_4, 815_5, 816_1, 816_2, 816_3, 816_4, 816_5, 816_6, 817_1 and 818_1.
  • 86. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 155_1 or 165_1.
  • 87. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO 169_52, 169_50 or 169_56.
  • 88. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 172_1, 272_1, 572_7, 572_6 or 572_5.
  • 89. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 175_1.
  • 90. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 178_1.
  • 91. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 573_8, 186_1 or 187_1.
  • 92. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 186_1.
  • 93. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 200_1, 204_1, 206_1, 35_2 or 209_1.
  • 94. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 585_1, 585_8, 586_9, 586_5, 586_8, 586_4 or 586_6.
  • 95. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 233_1.
  • 96. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 237_8 or 590_13.
  • 97. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 220_1.
  • 98. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 591_1, 592_2, 592_4 or 241_9.
  • 99. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 597_4, 598_4, 39_1 or 602_1.
  • 100. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 39_1.
  • 101. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 611_7.
  • 102. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 271_1 or 278_1.
  • 103. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 616_4, 621_2, 621_1, 622_3, 622_5, 622_4, 624_3, 624_5, 287_1, 625_6, 626_7, 626_8, 626_9, 48_1, 631_6, 631_1, 303_1, 304_6 or 304_10.
  • 104. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 636_8.
  • 105. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 638_8, 639_5, 331_1 or 640_4.
  • 106. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 359_1, 361_1, 361_5, 362_1 or 641_5.
  • 107. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 378_1, 379_1 or 399_1.
  • 108. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from the group consisting of CMP-ID-NO: 403_1, 405_1, 642_12, 642_13, 644_3 or 646_16.
  • 109. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 85_1 or 425_5.
  • 110. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 116_1.
  • 111. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 123_1 or 124_1.
  • 112. The oligonucleotide of embodiment 85, wherein the oligonucleotide is selected from CMP-ID-NO: 126_2.
  • 113. A conjugate comprising the oligonucleotide according to any one of claims 1-112, and at least one conjugate moiety covalently attached to said oligonucleotide.
  • 114. The oligonucleotide conjugate of embodiment 113, wherein the conjugate moiety is selected from carbohydrates, cell surface receptor ligands, drug substances, hormones, lipophilic substances, polymers, proteins, peptides, toxins, vitamins, viral proteins or combinations thereof.
  • 115. The oligonucleotide conjugate of embodiment 113 or 114, wherein the conjugate moiety is an antibody or antibody fragment.
  • 116. The oligonucleotide conjugate of embodiment 115, wherein the antibody or antibody fragment has affinity to the transferrin receptor.
  • 117. The oligonucleotide conjugate of embodiment 113-115, comprising a linker which is positioned between the oligonucleotide and the conjugate moiety.
  • 118. The oligonucleotide conjugate of embodiment 117, wherein the linker is a physiologically labile linker.
  • 119. The oligonucleotide conjugate of embodiment 118, wherein the physiologically labile linker is nuclease susceptible linker.
  • 120. The oligonucleotide conjugate of embodiment 118 or 119, wherein the oligonucleotide has the formula D-F-G-F′ or F-G-F′-D′, wherein F, F′ and G are as defined in embodiments 73-80 and D or D′ comprises 1, 2 or 3 DNA nucleosides with phosphorothioate internucleoside linkages.
  • 121. The oligonucleotide conjugate of embodiment 113-120, which display improved uptake into the brain of the conjugate oligonucleotide as compared to an unconjugated oligonucleotide.
  • 122. A pharmaceutical composition comprising the oligonucleotide of embodiment 1-112 or a conjugate of embodiment 113-121 and a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant.
  • 123. A method for manufacturing the oligonucleotide of embodiment 1-112, comprising reacting nucleotide units thereby forming covalently linked contiguous nucleotide units comprised in the oligonucleotide.
  • 124. The method of embodiment 123, further comprising reacting the contiguous nucleotide sequence with a non-nucleotide conjugation moiety.
  • 125. A method for manufacturing the composition of embodiment 122, comprising mixing the oligonucleotide with a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant.
  • 126. An in vivo or in vitro method for inducing UBE3A expression in a target cell where expression of paternal UBE3A is suppressed, said method comprising administering an oligonucleotide of any one of embodiments 1-112 or a conjugate of embodiment 113-121 or the pharmaceutical composition of embodiment 122 in an effective amount to said cell.
  • 127. The method of embodiment 126, wherein the expression of UBE3A is increased by at least 40% compared to a control.
  • 128. The method of embodiment 126 or 127, wherein the level of the SNHG14 transcript downstream of SNORD109B is reduced by at least 30% compared to a control.
  • 129. The method of embodiment 126-128, wherein the target cell is a neuronal cell.
  • 130. The method of embodiment 126-129, wherein the expression of SNORD115 is not significantly affected compared to a control.
  • 131. A method for treating or preventing a disease comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide of embodiment 1-112 or a conjugate of embodiment 113-121 or the pharmaceutical composition of embodiment 122 to a subject suffering from or susceptible to the disease.
  • 132. The oligonucleotide of embodiment 1-112 or a conjugate of embodiment 113-121 or the pharmaceutical composition of embodiment 122, for use as a medicament for treatment or prevention of a disease in a subject.
  • 133. Use of the oligonucleotide of oligonucleotide of embodiment 1-112 or a conjugate of embodiment 113-121 for the preparation of a medicament for treatment or prevention of a disease in a subject.
  • 134. The method, the oligonucleotide or the use of embodiments 131-133, wherein the disease is associated with in vivo activity of UBE3A.
  • 135. The method, the oligonucleotide or the use of embodiments 131-134, wherein the disease is associated with reduced expression of UBE3A and/or reduced activity of UBE3A in neuronal cells.
  • 136. The method, the oligonucleotide or the use of embodiment 135, wherein the reduced expression of UBE3A and/or reduced activity of UBE3A is due to mutations in the maternal allele of the UBE3A gene.
  • 137. The method, the oligonucleotide or the use of embodiments 134-136, wherein the UBE3A expression is increased by at least 30%, or at least 50%, or at least 70%, or at least 90%, or at least 100%, or at least 150% or at least 200%, compared to the expression without the oligonucleotide of embodiment 1-112 or a conjugate of embodiment 113-121 or the pharmaceutical composition of embodiment 122.
  • 138. The method, the oligonucleotide or the use of embodiments 131-137, wherein the disease is Angelman syndrome.
  • 139. The method, the oligonucleotide or the use of embodiments 131-138, wherein the subject is a mammal.
  • 140. The method, the oligonucleotide or the use of embodiment 139, wherein the mammal is human.
  • 141. The method, the oligonucleotide or the use of embodiment 139 or 140, wherein the subject is an infant or a juvenile.
  • EXAMPLES
  • Materials and methods
  • TABLE 3
    List of oligonucleotides or contiguous nucleobase sequences complementary to SEQ
    ID NO: 1 (motif sequences indicated by SEQ ID NO), oligonucleotide designs made from these,
    as well as specific oligonucleotide compounds (indicated by CMP ID NO) designed based on
    the motif sequence.
    Start
    Seq CMP SEQ ID
    ID NO Motif Design Compound ID NO ΔG° NO 1
    4 AACTTCATCAATATTTCCC 3-13-3 AACttcatcaatatttCCC 4_1 -23.36 1677
    4 AACTTCATCAATATTTCCC 2-15-2 AActtcatcaatatttcCC 4_2 -19.60 1677
    5 ACTTCATCAATATTTCCC 3-12-3 ACTtcatcaatatttCCC 5_1 -23.80 1677
    5 ACTTCATCAATATTTCCC 2-14-2 ACttcatcaatatttcCC 5_2 -20.24 1677
    6 CAACTTCATCAATATTTCCC 2-14-4 CAacttcatcaatattTCCC 6_1 -25.64 1677
    6 CAACTTCATCAATATTTCCC 2-16-2 CAacttcatcaatatttcCC 6_2 -22.28 1677
    7 CAACTTCATCAATATTTCC 4-13-2 CAACttcatcaatatttCC 7_1 -21.47 1678
    7 CAACTTCATCAATATTTCC 2-15-2 CAacttcatcaatatttCC 7_2 -19.46 1678
    8 CCAACTTCATCAATATTTCC 3-14-3 CCAacttcatcaatattTCC 8_1 -25.64 1678
    9 CCCAACTTCATCAATATTTC 4-14-2 CCCAacttcatcaatattTC 9_1 -25.64 1679
    10 ACCCAACTTCATCAATATTT 2-16-2 ACccaacttcatcaatatTT 10_1 -20.05 1680
    11 CCCAACTTCATCAATATTT 4-13-2 CCCAacttcatcaatatTT 11_1 -23.96 1680
    11 CCCAACTTCATCAATATTT 2-15-2 CCcaacttcatcaatatTT 11_2 -20.28 1680
    12 ACCCAACTTCATCAATATT 4-13-2 ACCCaacttcatcaataTT 12_1 -23.64 1681
    12 ACCCAACTTCATCAATATT 2-15-2 ACccaacttcatcaataTT 12_2 -19.18 1681
    13 CCCAACTTCATCAATATT 4-12-2 CCCAacttcatcaataTT 13_1 -23.09 1681
    13 CCCAACTTCATCAATATT 2-14-2 CCcaacttcatcaataTT 13_2 -19.41 1681
    14 TACCCAACTTCATCAATAT 2-15-2 TAcccaacttcatcaatAT 14_1 -19.31 1682
    15 TACCCAACTTCATCAATA 2-14-2 TAcccaacttcatcaaTA 15_1 -19.14 1683
    16 TTACCCAACTTCATCAATA 2-15-2 TTacccaacttcatcaaTA 16_1 -19.74 1683
    17 TTTACCCAACTTCATCAAT 4-13-2 TTTAcccaacttcatcaAT 17_1 -21.68 1684
    17 TTTACCCAACTTCATCAAT 2-15-2 TTtacccaacttcatcaAT 17_2 -19.22 1684
    18 ATACTTTACCCAACTTCAT 3-13-3 ATActttacccaacttCAT 18_1 -23.44 1688
    18 ATACTTTACCCAACTTCAT 2-15-2 ATactttacccaacttcAT 18_2 -20.13 1688
    19 TACTTTACCCAACTTCAT 3-12-3 TACtttacccaacttCAT 19_1 -22.78 1688
    19 TACTTTACCCAACTTCAT 2-14-2 TActttacccaacttcAT 19_2 -19.30 1688
    20 TTATACTTTACCCAACTTCA 2-16-2 TTatactttacccaacttCA 20_1 -21.40 1689
    21 TCACTGTTCTGACTTT 3-10-3 TCActgttctgacTTT 21_1 -19.11 1712
    22 TTCAATCTCTATCTCATCAT 2-16-2 TTcaatctctatctcatcAT 22_1 -19.42 4169
    23 CTTCAATCTCTATCTCATCA 4-14-2 CTTCaatctctatctcatCA 23_1 -24.21 4170
    23 CTTCAATCTCTATCTCATCA 2-16-2 CTtcaatctctatctcatCA 23_2 -22.04 4170
    24 TTCAATCTCTATCTCATCA 2-15-2 TTcaatctctatctcatCA 24_1 -19.44 4170
    25 CTTCAATCTCTATCTCATC 2-15-2 CTtcaatctctatctcaTC 25_1 -19.87 4171
    26 ACTTCAATCTCTATCTCAT 3-13-3 ACTtcaatctctatctCAT 26_1 -22.36 4172
    26 ACTTCAATCTCTATCTCAT 2-15-2 ACttcaatctctatctcAT 26_2 -19.08 4172
    27 CACTTCAATCTCTATCTCAT 2-16-2 CActtcaatctctatctcAT 27_1 -20.98 4172
    28 ACTTCAATCTCTATCTCA 2-12-4 ACttcaatctctatCTCA 28_1 -21.96 4173
    28 ACTTCAATCTCTATCTCA 2-14-2 ACttcaatctctatctCA 28_2 -19.10 4173
    29 CACTTCAATCTCTATCTCA 2-13-4 CActtcaatctctatCTCA 29_1 -23.86 4173
    29 CACTTCAATCTCTATCTCA 2-15-2 CActtcaatctctatctCA 29_2 -21.00 4173
    30 ACACTTCAATCTCTATCTC 2-15-2 ACacttcaatctctatcTC 30_1 -19.38 4174
    31 TACACTTCAATCTCTATCTC 2-14-4 TAcacttcaatctctaTCTC 31_1 -23.31 4174
    31 TACACTTCAATCTCTATCTC 2-16-2 TAcacttcaatctctatcTC 31_2 -20.53 4174
    32 TACACTTCAATCTCTATCT 4-13-2 TACActtcaatctctatCT 32_1 -22.34 4175
    33 CTTTGTCTCTCTTTACT 2-13-2 CTttgtctctctttaCT 33_1 -19.36 4374
    34 TATACCTTTCTTTAACCC 3-12-3 TATacctttctttaaCCC 34_1 -24.89 8118
    34 TATACCTTTCTTTAACCC 2-14-2 TAtacctttctttaacCC 34_2 -20.83 8118
    34 TATACCTTTCTTTAACCC 1-3-1-7-1-1-1-1-2 TataCctttcttTaAcCC 34_3 -21.63 8116
    34 TATACCTTTCTTTAACCC 1-4-1-6-1-3-2 TatacCtttcttTaacCC 34_4 -21.31 8116
    34 TATACCTTTCTTTAACCC 1-2-1-1-1-7-2-1-2 TatAcCtttctttAAcCC 34_5 -21.51 8116
    34 TATACCTTTCTTTAACCC 2-3-1-7-1-2-2 TAtacCtttctttAacCC 34_6 -21.84 8116
    34 TATACCTTTCTTTAACCC 2-13-3 TAtacctttctttaaCCC 34_7 -23.21 8116
    35 TGTTTATACCCTTTCC 2-12-2 TGtttataccctttCC 35_1 -20.33 9212
    35 TGTTTATACCCTTTCC 4-10-2 TGTTtataccctttCC 35_2 -22.69 9212
    36 TCTCCTTTATGACTCC 2-10-4 TCtcctttatgaCTCC 36_1 -23.29 10839
    37 CTTCTCCTTTATGACTC 2-13-2 CTtctcctttatgacTC 37_1 -19.26 10840
    38 CCATTTATTTCCATTTATT 4-13-2 CCATttatttccatttaTT 38_1 -22.32 15567
    38 CCATTTATTTCCATTTATT 2-15-2 CCatttatttccatttaTT 38_2 -19.61 15567
    38 CCATTTATTTCCATTTATT 1-2-1-9-2-1-3 CcaTttatttccaTTtATT 38_3 -20.02 15567
    38 CCATTTATTTCCATTTATT 1-1-1-1-1-8-1-1-1-1-2 CcAtTtatttccaTtTaTT 38_4 -18.95 15567
    38 CCATTTATTTCCATTTATT 2-2-1-8-1-3-2 CCatTtatttccaTttaTT 38_5 -20.35 15567
    38 CCATTTATTTCCATTTATT 1-2-3-6-1-3-3 CcaTTTatttccAtttATT 38_6 -20.87 15567
    39 CTTTCCATTTATTTCCATTT 2-14-4 CTttccatttatttccATTT 39_1 -23.14 15570
    39 CTTTCCATTTATTTCCATTT 1-13-1-1-1-1-2 CtttccatttatttCcAtTT 39_2 -20.96 15570
    39 CTTTCCATTTATTTCCATTT 1-13-1-3-2 CtttccatttatttCcatTT 39_3 -20.91 15570
    39 CTTTCCATTTATTTCCATTT 1-3-1-1-1-11-2 CtttCcAtttatttccatTT 39_4 -20.96 15570
    39 CTTTCCATTTATTTCCATTT 1-1-1-3-1-9-1-1-2 CtTtccAtttatttccAtTT 39_5 -20.54 15570
    40 TCTTTCCATTTATTTCCATT 2-14-4 TCtttccatttatttcCATT 40_1 -24.62 15571
    40 TCTTTCCATTTATTTCCATT 2-13-1-1-3 TCtttccatttatttCcATT 40_2 -23.39 15571
    40 TCTTTCCATTTATTTCCATT 2-13-1-2-2 TCtttccatttatttCcaTT 40_3 -22.53 15571
    40 TCTTTCCATTTATTTCCATT 2-14-1-1-2 TCtttccatttatttcCaTT 40_4 -22.34 15571
    40 TCTTTCCATTTATTTCCATT 2-3-1-11-3 TCtttCcatttatttccATT 40_5 -23.39 15571
    40 TCTTTCCATTTATTTCCATT 2-4-1-10-3 TCtttcCatttatttccATT 40_6 -23.20 15571
    40 TCTTTCCATTTATTTCCATT 2-3-1-12-2 TCtttCcatttatttccaTT 40_7 -22.53 15571
    40 TCTTTCCATTTATTTCCATT 2-4-1-11-2 TCtttcCatttatttccaTT 40_8 -22.34 15571
    41 ATTACCCATCCGTTCT 2-12-2 ATtacccatccgttCT 41_1 -21.15 21965
    42 GCATTAGGCACATTACAT 3-12-3 GCAttaggcacattaCAT 42_1 -23.96 22211
    43 ATTATTATTTAACCTTCCTA 2-16-2 ATtattatttaaccttccTA 43_1 -19.28 30451
    44 ACATTATTATTTAACCTTCC 4-14-2 ACATtattatttaaccttCC 44_1 -22.84 30453
    44 ACATTATTATTTAACCTTCC 2-16-2 ACattattatttaaccttCC 44_2 -20.13 30453
    45 CATTATTATTTAACCTTCC 4-13-2 CATTattatttaaccttCC 45_1 -22.04 30453
    45 CATTATTATTTAACCTTCC 2-15-2 CAttattatttaaccttCC 45_2 -19.55 30453
    46 CCTCTGCTTATAACTTT 2-13-2 CCtctgcttataactTT 46_1 -19.15 30699
    47 CTACTATACTTTCCTCT 2-11-4 CTactatactttcCTCT 47_1 -22.32 30711
    48 GTTCTACTATACTTTCC 4-11-2 GTTCtactatactttCC 48_1 -21.69 30714
    48 GTTCTACTATACTTTCC 2-13-2 GTtctactatactttCC 48_2 -19.21 30714
    48 GTTCTACTATACTTTCC 1-2-1-7-2-2-2 GttCtactataCTttCC 48_3 -20.83 30712
    48 GTTCTACTATACTTTCC 2-9-1-3-2 GTtctactataCtttCC 48_4 -20.20 30712
    48 GTTCTACTATACTTTCC 1-2-1-9-1-1-2 GttCtactatactTtCC 48_5 -18.95 30712
    48 GTTCTACTATACTTTCC 2-1-1-10-3 GTtCtactatacttTCC 48_6 -21.18 30712
    48 GTTCTACTATACTTTCC 1-3-1-10-2 GttcTactatactttCC 48_7 -18.61 30712
    49 CACCTGATAACAGACCCT 3-12-3 CACctgataacagacCCT 49_1 -26.38 36068
    50 CACCTGATAACAGACC 3-10-3 CACctgataacagACC 50_1 -21.10 36070
    51 CCCACCAAAGGATATATT 3-12-3 CCCaccaaaggatatATT 51_1 -23.47 37208
    52 ACCAGCTACAGGAACCTC 3-12-3 ACCagctacaggaacCTC 52_1 -26.57 46132
    53 CTATATCTCACTCCTATTT 4-13-2 CTATatctcactcctatTT 53_1 -23.07 48143
    53 CTATATCTCACTCCTATTT 2-13-4 CTatatctcactcctATTT 53_2 -22.12 48143
    54 CTATATCTCACTCCTATT 2-14-2 CTatatctcactcctaTT 54_1 -19.40 48144
    54 CTATATCTCACTCCTATT 2-12-4 CTatatctcactccTATT 54_2 -22.28 48144
    54 CTATATCTCACTCCTATT 3-12-3 CTAtatctcactcctATT 54_3 -21.44 48144
    55 CTACTATATCTCACTCCTAT 2-16-2 CTactatatctcactcctAT 55_1 -22.00 48145
    55 CTACTATATCTCACTCCTAT 2-14-4 CTactatatctcactcCTAT 55_2 -25.54 48145
    56 TACTATATCTCACTCCTAT 2-13-4 TActatatctcactcCTAT 56_1 -23.29 48145
    57 CTACTATATCTCACTCCTA 2-15-2 CTactatatctcactccTA 57_1 -21.91 48146
    58 TACTATATCTCACTCCTA 2-14-2 TActatatctcactccTA 58_1 -19.66 48146
    58 TACTATATCTCACTCCTA 2-12-4 TActatatctcactCCTA 58_2 -23.59 48146
    58 TACTATATCTCACTCCTA 3-12-3 TACtatatctcactcCTA 58_3 -22.62 48146
    59 CTACTATATCTCACTCCT 2-14-2 CTactatatctcactcCT 59_1 -21.25 48147
    59 CTACTATATCTCACTCCT 4-12-2 CTACtatatctcactcCT 59_2 -23.87 48147
    60 CTACTATATCTCACTCC 2-13-2 CTactatatctcactCC 60_1 -20.13 48148
    60 CTACTATATCTCACTCC 2-11-4 CTactatatctcaCTCC 60_2 -23.00 48148
    60 CTACTATATCTCACTCC 3-11-3 CTActatatctcacTCC 60_3 -22.56 48148
    61 CCTACTATATCTCACTC 2-11-4 CCtactatatctcACTC 61_1 -21.93 48149
    62 CTCCTACTATATCTCACTC 4-13-2 CTCCtactatatctcacTC 62_1 -25.69 48149
    63 TCCTACTATATCTCACTC 3-12-3 TCCtactatatctcaCTC 63_1 -23.88 48149
    64 CTCCTACTATATCTCACT 4-12-2 CTCCtactatatctcaCT 64_1 -24.87 48150
    64 CTCCTACTATATCTCACT 3-12-3 CTCctactatatctcACT 64_2 -22.93 48150
    65 TTTCCTCTCCTACTATATC 2-15-2 TTtcctctcctactataTC 65_1 -21.23 48155
    66 ATCCATATCCTTTCCT 3-10-3 ATCcatatcctttCCT 66_1 -24.02 48168
    67 CATCCATATCCTTTCCT 4-11-2 CATCcatatcctttcCT 67_1 -24.94 48168
    68 ATCATCCATATCCTTTCC 4-12-2 ATCAtccatatcctttCC 68_1 -25.69 48169
    69 CATCATCCATATCCTTTC 4-12-2 CATCatccatatccttTC 69_1 -23.32 48170
    69 CATCATCCATATCCTTTC 2-14-2 CAtcatccatatccttTC 69_2 -20.72 48170
    69 CATCATCCATATCCTTTC 2-12-4 CAtcatccatatccTTTC 69_3 -22.56 48170
    70 TACATCATCCATATCCTTTC 2-16-2 TAcatcatccatatccttTC 70_1 -22.45 48170
    70 TACATCATCCATATCCTTTC 4-14-2 TACAtcatccatatccttTC 70_2 -25.00 48170
    70 TACATCATCCATATCCTTTC 2-14-4 TAcatcatccatatccTTTC 70_3 -24.29 48170
    71 ACATCATCCATATCCTTT 3-12-3 ACAtcatccatatccTTT 71_1 -22.11 48171
    72 CATCATCCATATCCTTT 2-13-2 CAtcatccatatcctTT 72_1 -19.04 48171
    72 CATCATCCATATCCTTT 4-11-2 CATCatccatatcctTT 72_2 -21.64 48171
    73 TACATCATCCATATCCTTT 2-15-2 TAcatcatccatatcctTT 73_1 -20.76 48171
    73 TACATCATCCATATCCTTT 2-13-4 TAcatcatccatatcCTTT 73_2 -23.36 48171
    73 TACATCATCCATATCCTTT 3-13-3 TACatcatccatatccTTT 73_3 -22.88 48171
    74 ATACATCATCCATATCCTT 2-15-2 ATacatcatccatatccTT 74_1 -20.80 48172
    74 ATACATCATCCATATCCTT 4-13-2 ATACatcatccatatccTT 74_2 -23.12 48172
    75 TACATCATCCATATCCTT 2-14-2 TAcatcatccatatccTT 75_1 -19.97 48172
    75 TACATCATCCATATCCTT 4-12-2 TACAtcatccatatccTT 75_2 -22.52 48172
    76 TATACATCATCCATATCCTT 2-16-2 TAtacatcatccatatccTT 76_1 -21.36 48172
    77 ATACATCATCCATATCCT 3-12-3 ATAcatcatccatatCCT 77_1 -24.15 48173
    77 ATACATCATCCATATCCT 2-14-2 ATacatcatccatatcCT 77_2 -20.55 48173
    77 ATACATCATCCATATCCT 2-13-3 ATacatcatccatatCCT 77_3 -22.92 48173
    78 ATATACATCATCCATATCCT 2-16-2 ATatacatcatccatatcCT 78_1 -22.04 48173
    79 TACATCATCCATATCCT 2-11-4 TAcatcatccataTCCT 79_1 -23.21 48173
    79 TACATCATCCATATCCT 2-13-2 TAcatcatccatatcCT 79_2 -19.71 48173
    79 TACATCATCCATATCCT 4-11-2 TACAtcatccatatcCT 79_3 -22.27 48173
    80 TATACATCATCCATATCCT 2-15-2 TAtacatcatccatatcCT 80_1 -21.11 48173
    80 TATACATCATCCATATCCT 3-13-3 TATacatcatccatatCCT 80_2 -25.15 48173
    80 TATACATCATCCATATCCT 4-13-2 TATAcatcatccatatcCT 80_3 -24.01 48173
    81 ATACATCATCCATATCC 3-11-3 ATAcatcatccataTCC 81_1 -21.79 48174
    82 ATATACATCATCCATATCC 4-13-2 ATATacatcatccatatCC 82_1 -23.73 48174
    82 ATATACATCATCCATATCC 2-15-2 ATatacatcatccatatCC 82_2 -20.93 48174
    83 TATACATCATCCATATCC 2-14-2 TAtacatcatccatatCC 83_1 -20.00 48174
    83 TATACATCATCCATATCC 4-12-2 TATAcatcatccatatCC 83_2 -22.90 48174
    84 TATATACATCATCCATATCC 2-16-2 TAtatacatcatccatatCC 84_1 -21.49 48174
    84 TATATACATCATCCATATCC 4-14-2 TATAtacatcatccatatCC 84_2 -24.29 48174
    85 GCTTCATATTTCTCCA 2-12-2 GCttcatatttctcCA 85_1 -20.44 49345
    85 GCTTCATATTTCTCCA 2-11-3 GCttcatatttctCCA 85_2 -22.81 49345
    86 CATCTTGTTCTTTACCT 2-13-2 CAtcttgttctttacCT 86_1 -19.67 49581
    87 TATATTCACCATTGCC 2-10-4 TAtattcaccatTGCC 87_1 -22.70 49724
    88 CCTTATATTCACCATTG 2-13-2 CCttatattcaccatTG 88_1 -19.44 49726
    88 CCTTATATTCACCATTG 2-11-4 CCttatattcaccATTG 88_2 -21.25 49726
    89 CCTCCTTATATTCACC 4-10-2 CCTCcttatattcaCC 89_1 -24.64 49730
    go CCCTTCCTTTATTCAA 3-10-3 CCCttcctttattCAA 90_1 -23.86 50189
    gi CCTTACTGTTAAATCCT 2-13-2 CCttactgttaaatcCT 91_1 -19.81 50475
    92 CAGGCAGATAACCTCCAA 3-12-3 CAGgcagataacctcCAA 92_1 -25.31 52419
    93 CAGCAGGCAGATAACCTC 3-12-3 CAGcaggcagataacCTC 93_1 -25.88 52422
    94 CGAATCTTGACATACAGG 3-12-3 CGAatcttgacatacAGG 94_1 -21.47 53955
    95 CTCATACTTGCTTTAAT 4-11-2 CTCAtacttgctttaAT 95_1 -19.10 60821
    95 CTCATACTTGCTTTAAT 2-13-2 CTcatacttgctttaAT 95_2 -16.35 60821
    96 ACATCTCATACTTGCTT 2-11-4 ACatctcatacttGCTT 96_1 -21.31 60825
    96 ACATCTCATACTTGCTT 2-13-2 ACatctcatacttgcTT 96_2 -17.66 60825
    96 ACATCTCATACTTGCTT 2-12-3 ACatctcatacttgCTT 96_3 -19.52 60825
    97 ACATCTCATACTTGCT 2-10-4 ACatctcatactTGCT 97_1 -21.18 60826
    97 ACATCTCATACTTGCT 2-12-2 ACatctcatacttgCT 97_2 -17.70 60826
    97 ACATCTCATACTTGCT 2-11-3 ACatctcatacttGCT 97_3 -19.49 60826
    97 ACATCTCATACTTGCT 4-10-2 ACATctcatacttgCT 97_4 -20.48 60826
    98 TACATCTCATACTTGCT 2-11-4 TAcatctcatactTGCT 98_1 -22.33 60826
    98 TACATCTCATACTTGCT 2-13-2 TAcatctcatacttgCT 98_2 -18.85 60826
    98 TACATCTCATACTTGCT 4-11-2 TACAtctcatacttgCT 98_3 -21.40 60826
    gg CCTACATCTCATACTTGC 3-12-3 CCTacatctcatactTGC gg_1 -26.29 60827
    gg CCTACATCTCATACTTGC 2-14-2 CCtacatctcatacttGC 99_2 -22.98 60827
    gg CCTACATCTCATACTTGC 2-13-3 CCtacatctcatactTGC 99_3 -24.67 60827
    gg CCTACATCTCATACTTGC 2-12-4 CCtacatctcatacTTGC 99_4 -25.70 60827
    100 CTACATCTCATACTTGC 3-11-3 CTAcatctcatactTGC 100_1 -22.33 60827
    100 CTACATCTCATACTTGC 2-13-2 CTacatctcatacttGC 100_2 -19.41 60827
    100 CTACATCTCATACTTGC 2-12-3 CTacatctcatactTGC 100_3 -21.10 60827
    101 TACATCTCATACTTGC 3-10-3 TACatctcatactTGC 101_1 -19.94 60827
    101 TACATCTCATACTTGC 2-12-2 TAcatctcatacttGC 101_2 -17.15 60827
    101 TACATCTCATACTTGC 2-11-3 TAcatctcatactTGC 101_3 -18.85 60827
    101 TACATCTCATACTTGC 4-10-2 TACAtctcatacttGC 101_4 -19.71 60827
    102 CCTACATCTCATACTTG 4-11-2 CCTAcatctcatactTG 102_1 -22.52 60828
    102 CCTACATCTCATACTTG 2-13-2 CCtacatctcatactTG 102_2 -19.67 60828
    102 CCTACATCTCATACTTG 3-12-2 CCTacatctcatactTG 102_3 -21.29 60828
    102 CCTACATCTCATACTTG 3-11-3 CCTacatctcatacTTG 102_4 -22.31 60828
    103 ACCTACATCTCATACTT 3-11-3 ACCtacatctcataCTT 103_1 -21.93 60829
    103 ACCTACATCTCATACTT 2-13-2 ACctacatctcatacTT 103_2 -17.76 60829
    103 ACCTACATCTCATACTT 2-11-4 ACctacatctcatACTT 103_3 -20.03 60829
    103 ACCTACATCTCATACTT 3-12-2 ACCtacatctcatacTT 103_4 -20.26 60829
    104 CCTACATCTCATACTT 3-10-3 CCTacatctcataCTT 104_1 -21.50 60829
    104 CCTACATCTCATACTT 2-12-2 CCtacatctcatacTT 104_2 -18.21 60829
    104 CCTACATCTCATACTT 2-10-4 CCtacatctcatACTT 104_3 -20.48 60829
    105 TACCTACATCTCATACTT 4-12-2 TACCtacatctcatacTT 105_1 -22.49 60829
    105 TACCTACATCTCATACTT 2-14-2 TAcctacatctcatacTT 105_2 -18.81 60829
    105 TACCTACATCTCATACTT 2-13-3 TAcctacatctcataCTT 105_3 -20.48 60829
    105 TACCTACATCTCATACTT 2-12-4 TAcctacatctcatACTT 105_4 -21.08 60829
    106 TTACCTACATCTCATACTT 3-13-3 TTAcctacatctcataCTT 106_1 -22.30 60829
    106 TTACCTACATCTCATACTT 2-15-2 TTacctacatctcatacTT 106_2 -19.40 60829
    106 TTACCTACATCTCATACTT 2-14-3 TTacctacatctcataCTT 106_3 -21.08 60829
    106 TTACCTACATCTCATACTT 2-13-4 TTacctacatctcatACTT 106_4 -21.67 60829
    107 ACCTACATCTCATACT 4-10-2 ACCTacatctcataCT 107_1 -21.72 60830
    107 ACCTACATCTCATACT 2-12-2 ACctacatctcataCT 107_2 -17.61 60830
    107 ACCTACATCTCATACT 3-11-2 ACCtacatctcataCT 107_3 -20.10 60830
    107 ACCTACATCTCATACT 2-10-4 ACctacatctcaTACT 107_4 -20.11 60830
    108 TACCTACATCTCATACT 4-11-2 TACCtacatctcataCT 108_1 -22.34 60830
    108 TACCTACATCTCATACT 2-13-2 TAcctacatctcataCT 108_2 -18.66 60830
    108 TACCTACATCTCATACT 3-12-2 TACctacatctcataCT 108_3 -19.85 60830
    108 TACCTACATCTCATACT 3-11-3 TACctacatctcatACT 108_4 -20.44 60830
    109 TTACCTACATCTCATACT 2-12-4 TTacctacatctcaTACT 109_1 -21.75 60830
    109 TTACCTACATCTCATACT 2-14-2 TTacctacatctcataCT 109_2 -19.25 60830
    109 TTACCTACATCTCATACT 3-13-2 TTAcctacatctcataCT 109_3 -20.48 60830
    109 TTACCTACATCTCATACT 3-12-3 TTAcctacatctcatACT 109_4 -21.08 60830
    110 TTACCTACATCTCATAC 3-11-3 TTAcctacatctcaTAC 110_1 -19.50 60831
    110 TTACCTACATCTCATAC 2-13-2 TTacctacatctcatAC 110_2 -16.37 60831
    111 GTTACCTACATCTCATA 2-11-4 GTtacctacatctCATA 111_1 -21.69 60832
    111 GTTACCTACATCTCATA 2-13-2 GTtacctacatctcaTA 111_2 -18.74 60832
    111 GTTACCTACATCTCATA 3-12-2 GTTacctacatctcaTA 111_3 -19.98 60832
    112 GTTACCTACATCTCAT 3-10-3 GTTacctacatctCAT 112_1 -20.69 60833
    112 GTTACCTACATCTCAT 2-12-2 GTtacctacatctcAT 112_2 -17.37 60833
    113 ATATACCCAAAGGCACCT 3-12-3 ATAtacccaaaggcaCCT 113_1 -25.99 62200
    114 TCTACTCATCCTTTAACTCA 2-14-4 TCtactcatcctttaaCTCA 114_1 -25.63 62251
    115 CCTTAATCTGTATCACT 2-13-2 CCttaatctgtatcaCT 115_1 -19.58 62286
    116 CCATACACAGCACATA 2-12-2 CCatacacagcacaTA 116_1 -19.04 62424
    117 CTCCATACACAGCACAT 2-13-2 CTccatacacagcacAT 117_1 -20.08 62425
    118 CAGAATAATTCTCCTCC 2-13-2 CAgaataattctcctCC 118_1 -19.86 62441
    119 GTCCTACATATATACC 4-10-2 GTCCtacatatataCC 119_1 -22.09 66380
    120 TGCTTCCTTACTAACC 4-10-2 TGCTtccttactaaCC 120_1 -23.93 66701
    120 TGCTTCCTTACTAACC 2-12-2 TGcttccttactaaCC 120_2 -20.10 66701
    121 CCCTTTGTAATCATCT 4-10-2 CCCTttgtaatcatCT 121_1 -23.44 66838
    122 TCCCTTTGTAATCATCT 2-13-2 TCcctttgtaatcatCT 122_1 -19.97 66838
    123 CTGCCATCAATACCAT 2-12-2 CTgccatcaataccAT 123_1 -19.14 68918
    124 TCACTGCCATCAATACC 2-13-2 TCactgccatcaataCC 124_1 -21.35 68920
    125 ATTCTTACTTTATTCCTCA 2-15-2 ATtcttactttattcctCA 125_1 -20.16 70033
    126 TCACTTTCCAGATATCA 4-11-2 TCACtttccagatatCA 126_1 -21.61 77567
    126 TCACTTTCCAGATATCA 2-13-2 TCactttccagatatCA 126_2 -18.65 77567
    127 TCCTTCAAATTCCACATAC 3-13-3 TCCttcaaattccacaTAC 127_1 -24.09 82053
    128 ACATGTCCCTTTATATT 4-11-2 ACATgtccctttataTT 128_1 -20.87 92323
    128 ACATGTCCCTTTATATT 2-13-2 ACatgtccctttataTT 128_2 -17.66 92323
    128 ACATGTCCCTTTATATT 3-12-2 ACAtgtccctttataTT 128_3 -19.13 92323
    128 ACATGTCCCTTTATATT 3-11-3 ACAtgtccctttatATT 128_4 -20.03 92323
    129 ACATGTCCCTTTATAT 3-10-3 ACAtgtccctttaTAT 129_1 -20.11 92324
    129 ACATGTCCCTTTATAT 2-12-2 ACatgtccctttatAT 129_2 -16.74 92324
    130 CCAAGAAAGGAGCAAGCT 3-12-3 CCAagaaaggagcaaGCT 130_1 -25.26 97146
    131 TCCAAGAAAGGAGCAAGC 3-12-3 TCCaagaaaggagcaAGC 131_1 -24.12 97147
    132 CTCATCCCTCCAAGAAA 4-11-2 CTCAtccctccaagaAA 132_1 -22.58 97156
    132 CTCATCCCTCCAAGAAA 2-13-2 CTcatccctccaagaAA 132_2 -19.83 97156
    132 CTCATCCCTCCAAGAAA 3-12-2 CTCatccctccaagaAA 132_3 -21.11 97156
    133 TCATCCCTCCAAGAAA 4-10-2 TCATccctccaagaAA 133_1 -20.41 97156
    133 TCATCCCTCCAAGAAA 2-12-2 TCatccctccaagaAA 133_2 -17.63 97156
    133 TCATCCCTCCAAGAAA 3-11-2 TCAtccctccaagaAA 133_3 -19.09 97156
    133 TCATCCCTCCAAGAAA 3-10-3 TCAtccctccaagAAA 133_4 -19.81 97156
    134 CACCTCCCTATTACATAAA 4-13-2 CACCtccctattacataAA 134_1 -24.18 100018
    134 CACCTCCCTATTACATAAA 2-15-2 CAcctccctattacataAA 134_2 -20.51 100018
    135 CACCTCCCTATTACATAA 4-12-2 CACCtccctattacatAA 135_1 -23.75 100019
    135 CACCTCCCTATTACATAA 2-14-2 CAcctccctattacatAA 135_2 -20.07 100019
    136 CCTCCCTATTACATAA 2-12-2 CCtccctattacatAA 136_1 -18.40 100019
    137 CTAAATCTTCCAATTCATA 2-15-2 CTaaatcttccaattcaTA 137_1 -18.12 106139
    138 TATCCCTTGATTATCCT 2-13-2 TAtcccttgattatcCT 138_1 -20.68 109406
    139 CCTCTTTGTCAAATACT 2-13-2 CCtctttgtcaaataCT 139_1 -19.30 110768
    140 CAGCTTATTTACCTCTT 2-13-2 CAgcttatttacctcTT 140_1 -19.30 114828
    141 ACTCTTTACCTCTAACACT 4-13-2 ACTCtttacctctaacaCT 141_1 -24.26 117468
    142 TTACTCTTTACCTCTAACAC 3-14-3 TTActctttacctctaaCAC 142_1 -23.23 117469
    143 CCAACCTAATACCTTAATA 2-15-2 CCaacctaataccttaaTA 143_1 -20.27 118639
    144 TACCAACCTAATACCTTAA 2-15-2 TAccaacctaataccttAA 144_1 -18.32 118641
    145 CCAATACCCACAAACC 3-10-3 CCAatacccacaaACC 145_1 -23.17 124162
    145 CCAATACCCACAAACC 2-12-2 CCaatacccacaaaCC 145_2 -20.85 124162
    146 CCATTATTCTACTTTGT 3-11-3 CCAttattctacttTGT 146_1 -21.79 125501
    146 CCATTATTCTACTTTGT 2-13-2 CCattattctactttGT 146_2 -18.63 125501
    147 CATTTCCTTATCTTCACA 2-14-2 CAtttccttatcttcaCA 147_1 -20.39 125529
    148 TCATTTCCTTATCTTCACA 4-13-2 TCATttccttatcttcaCA 148_1 -24.13 125529
    149 AATAATTCCTCATTTCCT 2-14-2 AAtaattcctcatttcCT 149_1 -18.01 125539
    150 ACAATAATTCCTCATTTCC 3-13-3 ACAataattcctcattTCC 150_1 -22.71 125540
    150 ACAATAATTCCTCATTTCC 2-15-2 ACaataattcctcatttCC 150_2 -20.23 125540
    151 TATTGAACCAATTCTA 3-10-3 TATtgaaccaattCTA 151_1 -16.93 4806
    152 CATATTGAACCAATTC 4-10-2 CATAttgaaccaatTC 152_1 -16.32 4808
    153 TCATATTGAACCAATT 4-10-2 TCATattgaaccaaTT 153_1 -16.14 4809
    154 CATCATATTGAACCAA 2-10-4 CAtcatattgaaCCAA 154_1 -17.65 4811
    155 TCATCATATTGAACCA 3-10-3 TCAtcatattgaaCCA 155_1 -19.40 4812
    156 CACAATCAACAACAAATA 4-12-2 CACAatcaacaacaaaTA 156_1 -16.16 4972
    157 TACACAATCAACAACAAAT 4-13-2 TACAcaatcaacaacaaAT 157_1 -16.76 4973
    158 CTGTACACAATCAACA 4-10-2 CTGTacacaatcaaCA 158_1 -19.05 4979
    159 CACTAATAATTCACTTT 4-11-2 CACTaataattcactTT 159_1 -16.39 5058
    160 CAACATTATTGACACT 2-10-4 CAacattattgaCACT 160_1 -17.17 5071
    161 AAACTTTCCCAACATTAT 2-12-4 AAactttcccaacaTTAT 161_1 -18.69 5078
    162 TCCTATATTCTCTTAAA 4-11-2 TCCTatattctcttaAA 162_1 -18.58 5094
    163 TTTCCTATATTCTCTTA 4-11-2 TTTCctatattctctTA 163_1 -18.69 5096
    164 CAAGTTTCCTATATTCT 4-11-2 CAAGtttcctatattCT 164_1 -19.97 5100
    165 CAAGTTTCCTATATTC 4-10-2 CAAGtttcctatatTC 165_1 -17.47 5101
    166 CATTCTATCTGCCAAA 2-10-4 CAttctatctgcCAAA 166_1 -18.36 5218
    167 CCATTCTATCTGCCAAA 2-11-4 CCattctatctgcCAAA 167_1 -22.08 5218
    168 TATAGCCATTCTATCT 4-10-2 TATAgccattctatCT 168_1 -20.63 5224
    169 TTATAGCCATTCTATCT 4-11-2 TTATagccattctatCT 169_1 -20.82 5224
    169 TTATAGCCATTCTATCT 1-10-3-1-2 TtatagccattCTAtCT 169_2 -20.51 5224
    169 TTATAGCCATTCTATCT 2-9-1-2-3 TTatagccattCtaTCT 169_3 -20.12 5224
    169 TTATAGCCATTCTATCT 1-1-1-8-2-1-3 TtAtagccattCTaTCT 169_4 -20.59 5224
    169 TTATAGCCATTCTATCT 1-3-1-6-2-2-2 TtatAgccattCTatCT 169_5 -19.97 5224
    169 TTATAGCCATTCTATCT 3-8-1-3-2 TTAtagccattCtatCT 169_6 -20.13 5224
    169 TTATAGCCATTCTATCT 1-10-2-2-2 TtatagccattCTatCT 169_7 -19.37 5224
    169 TTATAGCCATTCTATCT 2-9-1-1-4 TTatagccattCtATCT 169_8 -21.02 5224
    169 TTATAGCCATTCTATCT 1-1-1-8-1-1-4 TtAtagccattCtATCT 169_9 -19.88 5224
    169 TTATAGCCATTCTATCT 1-2-1-7-1-1-4 TtaTagccattCtATCT 169_10 -20.65 5224
    169 TTATAGCCATTCTATCT 1-3-1-6-1-1-4 TtatAgccattCtATCT 169_11 -20.38 5224
    169 TTATAGCCATTCTATCT 1-10-1-1-4 TtatagccattCtATCT 169_12 -19.78 5224
    169 TTATAGCCATTCTATCT 3-8-1-1-1-1-2 TTAtagccattCtAtCT 169_13 -20.22 5224
    169 TTATAGCCATTCTATCT 2-1-1-7-1-1-1-1-2 TTaTagccattCtAtCT 169_14 -19.96 5224
    169 TTATAGCCATTCTATCT 2-2-1-6-1-1-1-1-2 TTatAgccattCtAtCT 169_15 -19.69 5224
    169 TTATAGCCATTCTATCT 2-9-1-1-1-1-2 TTatagccattCtAtCT 169_16 -19.09 5224
    169 TTATAGCCATTCTATCT 1-2-2-6-1-1-1-1-2 TtaTAgccattCtAtCT 169_17 -20.35 5224
    169 TTATAGCCATTCTATCT 1-2-1-7-1-1-1-1-2 TtaTagccattCtAtCT 169_18 -18.72 5224
    169 TTATAGCCATTCTATCT 1-3-1-6-1-1-1-1-2 TtatAgccattCtAtCT 169_19 -18.45 5224
    169 TTATAGCCATTCTATCT 2-2-1-6-1-2-3 TTatAgccattCtaTCT 169_20 -20.71 5224
    169 TTATAGCCATTCTATCT 1-1-2-7-1-2-3 TtATagccattCtaTCT 169_21 -20.65 5224
    169 TTATAGCCATTCTATCT 1-1-1-1-1-6-1-2-3 TtAtAgccattCtaTCT 169_22 -19.57 5224
    169 TTATAGCCATTCTATCT 1-1-1-8-1-2-3 TtAtagccattCtaTCT 169_23 -18.98 5224
    169 TTATAGCCATTCTATCT 4-7-1-3-2 TTATagccattCtatCT 169_24 -21.80 5224
    169 TTATAGCCATTCTATCT 3-1-1-6-1-3-2 TTAtAgccattCtatCT 169_25 -20.72 5224
    169 TTATAGCCATTCTATCT 2-1-1-7-1-3-2 TTaTagccattCtatCT 169_26 -19.86 5224
    169 TTATAGCCATTCTATCT 2-2-1-6-1-3-2 TTatAgccattCtatCT 169_27 -19.59 5224
    169 TTATAGCCATTCTATCT 2-9-1-3-2 TTatagccattCtatCT 169_28 -18.99 5224
    169 TTATAGCCATTCTATCT 1-1-3-6-1-3-2 TtATAgccattCtatCT 169_29 -21.16 5224
    169 TTATAGCCATTCTATCT 1-1-2-7-1-3-2 TtATagccattCtatCT 169_30 -19.53 5224
    169 TTATAGCCATTCTATCT 1-1-1-1-1-6-1-3-2 TtAtAgccattCtatCT 169_31 -18.45 5224
    169 TTATAGCCATTCTATCT 1-2-2-6-1-3-2 TtaTAgccattCtatCT 169_32 -20.25 5224
    169 TTATAGCCATTCTATCT 1-2-1-7-1-3-2 TtaTagccattCtatCT 169_33 -18.62 5224
    169 TTATAGCCATTCTATCT 1-3-1-6-1-3-2 TtatAgccattCtatCT 169_34 -18.35 5224
    169 TTATAGCCATTCTATCT 1-1-1-9-5 TtAtagccattcTATCT 169_35 -20.88 5224
    169 TTATAGCCATTCTATCT 2-10-2-1-2 TTatagccattcTAtCT 169_36 -20.09 5224
    169 TTATAGCCATTCTATCT 1-1-1-9-2-1-2 TtAtagccattcTAtCT 169_37 -18.95 5224
    169 TTATAGCCATTCTATCT 1-2-1-8-2-1-2 TtaTagccattcTAtCT 169_38 -19.72 5224
    169 TTATAGCCATTCTATCT 1-3-1-7-2-1-2 TtatAgccattcTAtCT 169_39 -19.44 5224
    169 TTATAGCCATTCTATCT 1-11-2-1-2 TtatagccattcTAtCT 169_40 -18.85 5224
    169 TTATAGCCATTCTATCT 3-9-1-1-3 TTAtagccattcTaTCT 169_41 -21.21 5224
    169 TTATAGCCATTCTATCT 1-1-1-9-1-1-3 TtAtagccattcTaTCT 169_42 -18.94 5224
    169 TTATAGCCATTCTATCT 3-9-1-2-2 TTAtagccattcTatCT 169_43 -20.09 5224
    169 TTATAGCCATTCTATCT 1-2-1-8-1-2-2 TtaTagccattcTatCT 169_44 -18.58 5224
    169 TTATAGCCATTCTATCT 1-3-1-7-1-2-2 TtatAgccattcTatCT 169_45 -18.31 5224
    169 TTATAGCCATTCTATCT 1-1-1-10-4 TtAtagccattctATCT 169_46 -18.90 5224
    169 TTATAGCCATTCTATCT 3-10-1-1-2 TTAtagccattctAtCT 169_47 -19.24 5224
    169 TTATAGCCATTCTATCT 2-11-1-1-2 TTatagccattctAtCT 169_48 -18.11 5224
    169 TTATAGCCATTCTATCT 1-2-2-8-1-1-2 TtaTAgccattctAtCT 169_49 -19.37 5224
    169 TTATAGCCATTCTATCT 3-1-1-10-2 TTAtAgccattctatCT 169_50 -19.74 5224
    169 TTATAGCCATTCTATCT 3-12-2 TTAtagccattctatCT 169_51 -19.15 5224
    169 TTATAGCCATTCTATCT 2-1-2-10-2 TTaTAgccattctatCT 169_52 -20.51 5224
    169 TTATAGCCATTCTATCT 2-1-1-11-2 TTaTagccattctatCT 169_53 -18.88 5224
    169 TTATAGCCATTCTATCT 2-2-1-10-2 TTatAgccattctatCT 169_54 -18.61 5224
    169 TTATAGCCATTCTATCT 2-13-2 TTatagccattctatCT 169_55 -18.02 5224
    169 TTATAGCCATTCTATCT 1-1-3-10-2 TtATAgccattctatCT 169_56 -20.18 5224
    169 TTATAGCCATTCTATCT 1-1-2-11-2 TtATagccattctatCT 169_57 -18.55 5224
    169 TTATAGCCATTCTATCT 2-9-3-1-2 TTatagccattCTAtCT 169_58 -21.75 5224
    169 TTATAGCCATTCTATCT 1-1-1-8-2-2-2 TtAtagccattCTatCT 169_59 -19.47 5224
    169 TTATAGCCATTCTATCT 1-2-2-6-2-2-2 TtaTAgccattCTatCT 169_60 -21.87 5224
    169 TTATAGCCATTCTATCT 1-1-3-6-1-1-1-1-2 TtATAgccattCtAtCT 169_61 -21.25 5224
    169 TTATAGCCATTCTATCT 3-8-1-2-3 TTAtagccattCtaTCT 169_62 -21.25 5224
    170 ATTTAAATTTCCAAACATT 2-13-4 ATttaaatttccaaaCATT 170_1 -16.82 5427
    171 GCTAATTTAAATTTCC 4-10-2 GCTAatttaaatttCC 171_1 -18.50 5434
    172 ATCAATATCTTCTCAC 3-10-3 ATCaatatcttctCAC 172_1 -17.10 5785
    173 TATCAATATCTTCTCA 2-10-4 TAtcaatatcttCTCA 173_1 -17.55 5786
    174 CTACAAATTCAATTTACT 2-12-4 CTacaaattcaattTACT 174_1 -17.38 6341
    175 TCTTACTCTGACTTTCCA 2-14-2 TCttactctgactttcCA 175_1 -21.47 6694
    176 TCTTACTCTGACTTTCC 2-12-3 TCttactctgacttTCC 176_1 -21.53 6695
    177 AAATTTCCAAACCTTTC 2-11-4 AAatttccaaaccTTTC 177_1 -16.30 6958
    178 CTTCTTGTTTATCCCAA 2-11-4 CTtcttgtttatcCCAA 178_1 -22.77 7159
    179 TTCTTGTTTATCCCAA 2-10-4 TTcttgtttatcCCAA 179_1 -20.17 7159
    180 ATGCTTCTAACTAACA 4-10-2 ATGCttctaactaaCA 180_1 -19.21 7720
    181 CTTTAATGCTTCTAACT 4-11-2 CTTTaatgcttctaaCT 181_1 -18.49 7724
    182 CCTTTAATGCTTCTAAC 2-11-4 CCtttaatgcttcTAAC 182_1 -20.06 7725
    183 CTTTAATGCTTCTAAC 2-10-4 CTttaatgcttcTAAC 183_1 -16.07 7725
    184 TTCCTTTAATGCTTCTA 4-11-2 TTCCtttaatgcttcTA 184_1 -21.59 7727
    185 TATACCTTTCTTTAACCCT 2-15-2 TAtacctttctttaaccCT 185_1 -22.03 8117
    186 ATACCTTTCTTTAACCC 4-11-2 ATACctttctttaacCC 186_1 -22.68 8118
    187 TTATACCTTTCTTTAACC 4-12-2 TTATacctttctttaaCC 187_1 -21.52 8119
    188 TTTATACCTTTCTTTAAC 2-12-4 TTtatacctttcttTAAC 188_1 -17.01 8120
    189 TCAAGAATTCTCTCCTT 2-11-4 TCaagaattctctCCTT 189_1 -21.29 8571
    190 TTCAAGAATTCTCTCC 2-10-4 TTcaagaattctCTCC 190_1 -19.38 8573
    191 CTTCAAGAATTCTCTC 2-10-4 CTtcaagaattcTCTC 191_1 -18.00 8574
    192 TCTTCAAGAATTCTCT 2-10-4 TCttcaagaattCTCT 192_1 -18.46 8575
    193 ATCTTCAAGAATTCTC 3-10-3 ATCttcaagaattCTC 193_1 -17.04 8576
    194 TTTCTTACTATCTTCA 4-10-2 TTTCttactatcttCA 194_1 -17.47 8585
    195 CCTTTAGCATTTCTATT 2-11-4 CCtttagcatttcTATT 195_1 -21.72 8819
    196 TCCTTTAGCATTTCTAT 3-11-3 TCCtttagcatttcTAT 196_1 -22.39 8820
    197 GTTCTCTTTATTTCTTCT 2-12-4 GTtctctttatttcTTCT 197_1 -21.76 8887
    198 TTTACTGTCAACTCCT 2-10-4 TTtactgtcaacTCCT 198_1 -20.83 9150
    199 TTTCCAATGAATCTAT 2-10-4 TTtccaatgaatCTAT 199_1 -16.61 9201
    200 CCTTTCCAATGAATCTA 2-11-4 CCtttccaatgaaTCTA 200_1 -22.34 9202
    201 CTTTCCAATGAATCTA 2-10-4 CTttccaatgaaTCTA 201_1 -18.34 9202
    202 CCTTTCCAATGAATCT 3-10-3 CCTttccaatgaaTCT 202_1 -21.30 9203
    203 TTATACCCTTTCCAAT 2-10-4 TTataccctttcCAAT 203_1 -19.61 9209
    204 GTTTATACCCTTTCCAA 3-11-3 GTTtataccctttcCAA 204_1 -21.88 9210
    205 TTTATACCCTTTCCAA 2-10-4 TTtataccctttCCAA 205_1 -20.50 9210
    206 GTTTATACCCTTTCCA 2-11-3 GTttataccctttCCA 206_1 -22.69 9211
    207 TGTTTATACCCTTTCCA 3-12-2 TGTttataccctttcCA 207_1 -22.80 9211
    208 ACTGTTTATACCCTTTCC 2-14-2 ACtgtttataccctttCC 208_1 -22.96 9212
    208 ACTGTTTATACCCTTTCC 1-11-1-3-2 ActgtttataccCtttCC 208_2 -22.45 9212
    208 ACTGTTTATACCCTTTCC 1-2-1-10-1-1-2 ActGtttataccctTtCC 208_3 -22.17 9212
    208 ACTGTTTATACCCTTTCC 1-2-1-1-1-10-2 ActGtTtataccctttCC 208_4 -22.17 9212
    208 ACTGTTTATACCCTTTCC 1-2-1-12-2 ActGtttataccctttCC 208_5 -21.87 9212
    208 ACTGTTTATACCCTTTCC 1-3-1-11-2 ActgTttataccctttCC 208_6 -22.22 9212
    208 ACTGTTTATACCCTTTCC 1-15-2 ActgtttataccctttCC 208_7 -21.56 9212
    209 ACTGTTTATACCCTTTC 4-11-2 ACTGtttatacccttTC 209_1 -21.65 9213
    209 ACTGTTTATACCCTTTC 1-11-1-2-2 ActgtttataccCttTC 209_2 -18.25 9213
    209 ACTGTTTATACCCTTTC 1-1-1-8-1-1-1-1-2 AcTgtttatacCcTtTC 209_3 -19.56 9213
    209 ACTGTTTATACCCTTTC 1-2-1-9-4 ActGtttatacccTTTC 209_4 -19.51 9213
    209 ACTGTTTATACCCTTTC 1-3-1-6-1-2-3 ActgTttatacCctTTC 209_5 -19.51 9213
    209 ACTGTTTATACCCTTTC 2-9-1-3-2 ACtgtttatacCcttTC 209_6 -19.43 9213
    209 ACTGTTTATACCCTTTC 1-2-1-7-1-3-2 ActGtttatacCcttTC 209_7 -18.35 9213
    209 ACTGTTTATACCCTTTC 1-3-1-8-1-1-2 ActgTttatacccTtTC 209_8 -18.53 9213
    209 ACTGTTTATACCCTTTC 1-11-1-1-3 ActgtttataccCtTTC 209_9 -19.06 9213
    209 ACTGTTTATACCCTTTC 2-10-1-2-2 ACtgtttataccCttTC 209_10 -19.64 9213
    210 AACTGTTTATACCCTTT 4-11-2 AACTgtttataccctTT 210_1 -19.51 9214
    211 TATGACTCCAATAATC 3-10-3 TATgactccaataATC 211_1 -16.57 10832
    212 CTCCTTTATGACTCCAA 4-11-2 CTCCtttatgactccAA 212_1 -22.74 10837
    213 CTCCTTTATGACTCCA 3-11-2 CTCctttatgactcCA 213_1 -21.50 10838
    214 CCATTATTTCTTAAATA 4-11-2 CCATtatttcttaaaTA 214_1 -17.56 10877
    215 ATTTCATATTACTAACTA 2-12-4 ATttcatattactaACTA 215_1 -16.64 11434
    216 CATTTCATATTACTAACT 3-12-3 CATttcatattactaACT 216_1 -17.70 11435
    217 TCATTTCATATTACTAAC 4-12-2 TCATttcatattactaAC 217_1 -16.72 11436
    218 ATCATTTCATATTACTA 3-11-3 ATCatttcatattaCTA 218_1 -17.23 11438
    219 TTATCATTTCATATTACT 4-12-2 TTATcatttcatattaCT 219_1 -17.77 11439
    220 TGTACTTTCCTTTACCA 2-13-2 TGtactttcctttacCA 220_1 -20.37 11464
    221 TATACACCATCATTATA 4-11-2 TATAcaccatcattaTA 221_1 -18.48 11507
    222 TTATACACCATCATTAT 3-11-3 TTAtacaccatcatTAT 222_1 -17.83 11508
    223 TATTTATACACCATCAT 3-11-3 TATttatacaccatCAT 223_1 -18.54 11511
    224 TTATTTATACACCATC 2-10-4 TTatttatacacCATC 224_1 -16.60 11513
    225 AATTATTTATACACCAT 2-11-4 AAttatttatacaCCAT 225_1 -16.82 11514
    226 CATGACACTTACATAA 3-10-3 CATgacacttacaTAA 226_1 -16.26 11736
    227 AGTTCACTACTATTAC 3-10-3 AGTtcactactatTAC 227_1 -17.55 12361
    228 ATAAGCTTACCTCATA 2-10-4 ATaagcttacctCATA 228_1 -19.32 12794
    229 TATAAGCTTACCTCAT 3-10-3 TATaagcttacctCAT 229_1 -19.32 12795
    230 ATATAAGCTTACCTCA 4-10-2 ATATaagcttacctCA 230_1 -19.32 12796
    231 CTTCCCTTTGATAACAT 3-11-3 CTTccctttgataaCAT 231_1 -21.19 12894
    232 TTCCCTTTGATAACAT 4-10-2 TTCCctttgataacAT 232_1 -19.27 12894
    233 CCTTCCCTTTGATAACA 2-12-3 CCttccctttgataACA 233_1 -23.06 12895
    234 CTTCCCTTTGATAACA 4-10-2 CTTCcctttgataaCA 234_1 -20.51 12895
    235 CCTTCCCTTTGATAAC 3-11-2 CCTtccctttgataAC 235_1 -20.96 12896
    236 TTGATTCAATTCCCTTA 2-11-4 TTgattcaattccCTTA 236_1 -20.48 13223
    236 TTGATTCAATTCCCTTA 2-9-1-1-1-1-2 TTgattcaattCcCtTA 236_2 -19.54 13223
    236 TTGATTCAATTCCCTTA 2-10-1-1-3 TTgattcaattcCcTTA 236_3 -19.59 13223
    236 TTGATTCAATTCCCTTA 2-1-1-8-1-2-2 TTgAttcaattcCctTA 236_4 -19.06 13223
    236 TTGATTCAATTCCCTTA 2-2-1-7-1-2-2 TTgaTtcaattcCctTA 236_5 -19.00 13223
    236 TTGATTCAATTCCCTTA 2-9-1-3-2 TTgattcaattCcctTA 236_6 -18.65 13223
    236 TTGATTCAATTCCCTTA 1-2-2-6-2-2-2 TtgATtcaattCCctTA 236_7 -21.37 13223
    236 TTGATTCAATTCCCTTA 2-1-1-7-1-1-1-1-2 TTgAttcaattCcCtTA 236_8 -20.04 13223
    236 TTGATTCAATTCCCTTA 1-1-2-7-1-1-1-1-2 TtGAttcaattCcCtTA 236_9 -20.10 13223
    236 TTGATTCAATTCCCTTA 1-2-1-9-4 TtgAttcaattccCTTA 236_10 -19.67 13223
    236 TTGATTCAATTCCCTTA 1-3-1-6-1-1-1-1-2 TtgaTtcaattCcCtTA 236_11 -18.67 13223
    236 TTGATTCAATTCCCTTA 2-10-1-2-2 TTgattcaattcCctTA 236_12 -18.56 13223
    236 TTGATTCAATTCCCTTA 1-2-2-7-2-1-2 TtgATtcaattcCCtTA 236_13 -21.49 13223
    236 TTGATTCAATTCCCTTA 1-1-2-8-1-2-2 TtGAttcaattcCctTA 236_14 -19.13 13223
    236 TTGATTCAATTCCCTTA 2-11-1-1-2 TTgattcaattccCtTA 236_15 -18.77 13223
    236 TTGATTCAATTCCCTTA 1-1-1-1-1-8-1-1-2 TtGaTtcaattccCtTA 236_16 -18.07 13223
    236 TTGATTCAATTCCCTTA 1-1-2-7-2-2-2 TtGAttcaattCCctTA 236_17 -21.50 13223
    236 TTGATTCAATTCCCTTA 1-2-1-7-1-1-4 TtgAttcaattCcCTTA 236_18 -20.44 13223
    236 TTGATTCAATTCCCTTA 3-8-1-1-1-1-2 TTGattcaattCcCtTA 236_19 -20.60 13223
    236 TTGATTCAATTCCCTTA 2-2-1-6-1-3-2 TTgaTtcaattCcctTA 236_20 -19.09 13223
    236 TTGATTCAATTCCCTTA 2-2-1-7-2-1-2 TTgaTtcaattcCCtTA 236_21 -21.49 13223
    237 ATTGATTCAATTCCCTT 2-11-4 ATtgattcaattcCCTT 237_1 -21.28 13224
    237 ATTGATTCAATTCCCTT 3-8-3-1-2 ATTgattcaatTCCcTT 237_2 -22.78 13224
    237 ATTGATTCAATTCCCTT 1-1-1-8-3-1-2 AtTgattcaatTCCcTT 237_3 -21.02 13224
    237 ATTGATTCAATTCCCTT 1-2-1-8-2-1-2 AttGattcaattCCcTT 237_4 -19.40 13224
    237 ATTGATTCAATTCCCTT 1-3-1-7-2-1-2 AttgAttcaattCCcTT 237_5 -19.74 13224
    237 ATTGATTCAATTCCCTT 1-2-1-7-2-1-3 AttGattcaatTCcCTT 237_6 -19.67 13224
    237 ATTGATTCAATTCCCTT 2-2-1-7-1-1-3 ATtgAttcaattCcCTT 237_7 -20.27 13224
    237 ATTGATTCAATTCCCTT 1-1-1-9-1-1-3 AtTgattcaattCcCTT 237_8 -19.32 13224
    237 ATTGATTCAATTCCCTT 1-3-1-7-1-1-3 AttgAttcaattCcCTT 237_9 -19.02 13224
    237 ATTGATTCAATTCCCTT 1-1-1-1-1-7-2-1-2 AtTgAttcaattCCcTT 237_10 -20.53 13224
    237 ATTGATTCAATTCCCTT 1-2-2-7-2-1-2 AttGAttcaattCCcTT 237_11 -21.11 13224
    237 ATTGATTCAATTCCCTT 1-2-1-8-1-1-3 AttGattcaattCcCTT 237_12 -18.68 13224
    237 ATTGATTCAATTCCCTT 1-1-2-8-1-2-2 AtTGattcaattCccTT 237_13 -18.81 13224
    237 ATTGATTCAATTCCCTT 3-10-1-1-2 ATTgattcaattcCcTT 237_14 -19.42 13224
    237 ATTGATTCAATTCCCTT 1-1-2-9-4 AtTGattcaattcCCTT 237_15 -21.89 13224
    237 ATTGATTCAATTCCCTT 2-2-1-8-1-1-2 ATtgAttcaattcCcTT 237_16 -18.61 13224
    237 ATTGATTCAATTCCCTT 1-2-2-6-3-1-2 AttGAttcaatTCCcTT 237_17 -22.09 13224
    237 ATTGATTCAATTCCCTT 1-1-1-8-2-1-3 AtTgattcaatTCcCTT 237_18 -20.30 13224
    237 ATTGATTCAATTCCCTT 1-1-1-9-2-1-2 AtTgattcaattCCcTT 237_19 -20.03 13224
    237 ATTGATTCAATTCCCTT 1-1-1-1-1-7-1-1-3 AtTgAttcaattCcCTT 237_20 -19.82 13224
    237 ATTGATTCAATTCCCTT 3-1-1-8-1-1-2 ATTgAttcaattcCcTT 237_21 -19.92 13224
    238 TTGATTCAATTCCCTT 2-10-4 TTgattcaattcCCTT 238_1 -20.52 13224
    239 TATTGATTCAATTCCCT 2-11-4 TAttgattcaattCCCT 239_1 -22.82 13225
    239 TATTGATTCAATTCCCT 3-9-2-1-2 TATtgattcaatTCcCT 239_2 -21.17 13225
    239 TATTGATTCAATTCCCT 2-9-1-1-1-1-2 TAttgattcaaTtCcCT 239_3 -19.37 13225
    239 TATTGATTCAATTCCCT 1-1-2-7-3-1-2 TaTTgattcaaTTCcCT 239_4 -21.49 13225
    239 TATTGATTCAATTCCCT 1-3-1-6-3-1-2 TattGattcaaTTCcCT 239_5 -19.90 13225
    239 TATTGATTCAATTCCCT 2-9-1-2-3 TAttgattcaaTtcCCT 239_6 -20.89 13225
    239 TATTGATTCAATTCCCT 1-10-1-2-3 TattgattcaaTtcCCT 239_7 -19.76 13225
    239 TATTGATTCAATTCCCT 1-1-1-1-1-8-1-1-2 TaTtGattcaattCcCT 239_8 -18.41 13225
    239 TATTGATTCAATTCCCT 1-2-2-8-1-1-2 TatTGattcaattCcCT 239_9 -19.66 13225
    239 TATTGATTCAATTCCCT 1-2-1-9-1-1-2 TatTgattcaattCcCT 239_10 -18.60 13225
    239 TATTGATTCAATTCCCT 2-2-1-10-2 TAttGattcaattccCT 239_11 -18.33 13225
    239 TATTGATTCAATTCCCT 1-12-4 TattgattcaattCCCT 239_12 -21.69 13225
    239 TATTGATTCAATTCCCT 2-1-1-9-1-1-2 TAtTgattcaattCcCT 239_13 -19.73 13225
    239 TATTGATTCAATTCCCT 2-12-3 TAttgattcaattcCCT 239_14 -20.45 13225
    239 TATTGATTCAATTCCCT 1-2-1-10-3 TatTgattcaattcCCT 239_15 -20.11 13225
    239 TATTGATTCAATTCCCT 1-1-3-10-2 TaTTGattcaattccCT 239_16 -19.84 13225
    239 TATTGATTCAATTCCCT 1-1-1-1-1-6-3-1-2 TaTtGattcaaTTCcCT 239_17 -20.34 13225
    239 TATTGATTCAATTCCCT 2-2-1-6-1-1-1-1-2 TAttGattcaaTtCcCT 239_18 -19.54 13225
    239 TATTGATTCAATTCCCT 2-1-1-8-2-1-2 TAtTgattcaatTCcCT 239_19 -20.72 13225
    239 TATTGATTCAATTCCCT 1-1-2-9-1-1-2 TaTTgattcaattCcCT 239_20 -19.55 13225
    239 TATTGATTCAATTCCCT 2-1-1-10-3 TAtTgattcaattcCCT 239_21 -21.24 13225
    240 TATTGATTCAATTCCC 3-10-3 TATtgattcaattCCC 240_1 -20.58 13226
    241 GCACATTCTTTCTATAC 3-11-3 GCAcattctttctaTAC 241_1 -21.17 15115
    241 GCACATTCTTTCTATAC 1-1-3-6-2-2-2 GcACAttctttCTatAC 241_2 -20.68 15115
    241 GCACATTCTTTCTATAC 1-1-1-1-1-6-1-2-3 GcAcAttctttCtaTAC 241_3 -18.46 15115
    241 GCACATTCTTTCTATAC 1-1-2-7-1-2-3 GcACattctttCtaTAC 241_4 -19.49 15115
    241 GCACATTCTTTCTATAC 2-9-1-3-2 GCacattctttCtatAC 241_5 -18.68 15115
    241 GCACATTCTTTCTATAC 1-1-3-8-4 GcACAttctttctATAC 241_6 -20.89 15115
    241 GCACATTCTTTCTATAC 2-2-1-9-3 GCacAttctttctaTAC 241_7 -19.66 15115
    241 GCACATTCTTTCTATAC 2-1-1-11-2 GCaCattctttctatAC 241_8 -18.39 15115
    241 GCACATTCTTTCTATAC 1-1-3-9-3 GcACAttctttctaTAC 241_9 -19.98 15115
    241 GCACATTCTTTCTATAC 3-12-2 GCAcattctttctatAC 241_10 -19.27 15115
    241 GCACATTCTTTCTATAC 1-1-1-1-1-6-1-1-4 GcAcAttctttCtATAC 241_11 -19.36 15115
    241 GCACATTCTTTCTATAC 3-8-1-1-1-1-2 GCAcattctttCtAtAC 241_12 -20.34 15115
    241 GCACATTCTTTCTATAC 2-1-1-7-1-2-3 GCaCattctttCtaTAC 241_13 -21.27 15115
    241 GCACATTCTTTCTATAC 1-2-2-8-4 GcaCAttctttctATAC 241_14 -20.33 15115
    241 GCACATTCTTTCTATAC 1-1-3-10-2 GcACAttctttctatAC 241_15 -18.08 15115
    242 GAATTTCAACTACTAT 2-10-4 GAatttcaactaCTAT 242_1 -16.13 15258
    243 CCATTTATTTCCATTTAT 3-12-3 CCAtttatttccattTAT 243_1 -21.92 15568
    244 TTTCCATTTATTTCCATTT 4-13-2 TTTCcatttatttccatTT 244_1 -20.93 15570
    244 TTTCCATTTATTTCCATTT 1-4-1-7-1-1-4 TttccAtttatttCcATTT 244_2 -20.48 15570
    244 TTTCCATTTATTTCCATTT 2-1-1-10-2-1-2 TTtCcatttatttcCAtTT 244_3 -21.47 15570
    244 TTTCCATTTATTTCCATTT 1-2-1-1-1-7-1-3-2 TttCcAtttatttCcatTT 244_4 -19.43 15570
    244 TTTCCATTTATTTCCATTT 2-2-2-11-2 TTtcCAtttatttccatTT 244_5 -20.70 15570
    245 CTTTCCATTTATTTCCAT 3-12-3 CTTtccatttatttcCAT 245_1 -22.31 15572
    246 TCTTTCCATTTATTTCCA 4-12-2 TCTTtccatttatttcCA 246_1 -22.74 15573
    247 ATCTTTCCATTTATTTCC 3-12-3 ATCtttccatttattTCC 247_1 -22.85 15574
    248 TTCCATGCAAACTTTA 4-10-2 TTCCatgcaaacttTA 248_1 -19.01 15722
    249 CAGTTTAAATTCACAC 3-10-3 CAGtttaaattcaCAC 249_1 -16.68 16597
    250 CTATTCCAGTTTAAAT 4-10-2 CTATtccagtttaaAT 250_1 -16.86 16603
    251 TGCAAATACCTCTTCA 4-10-2 TGCAaatacctcttCA 251_1 -21.49 16730
    252 CTAAATAGATTCCACT 2-10-4 CTaaatagattcCACT 252_1 -17.95 16849
    253 TATTGATATTTACTCT 2-10-4 TAttgatatttaCTCT 253_1 -16.32 17089
    254 CCTTAGTATTACAATT 4-10-2 CCTTagtattacaaTT 254_1 -17.43 17401
    255 CTATTCAATAAACTAAACA 4-13-2 CTATtcaataaactaaaCA 255_1 -16.45 24290
    256 CAGCTATTCAATAAAC 4-10-2 CAGCtattcaataaAC 256_1 -16.94 24296
    257 TATAGACCCAAACTAT 3-10-3 TATagacccaaacTAT 257_1 -18.15 24811
    258 TAATCCCATACATCTAT 2-11-4 TAatcccatacatCTAT 258_1 -20.45 25032
    259 ATAATCCCATACATCTA 3-11-3 ATAatcccatacatCTA 259_1 -20.45 25033
    260 ATCTCAACTACCATTT 4-10-2 ATCTcaactaccatTT 260_1 -18.14 25250
    261 AATCTCAACTACCATT 4-10-2 AATCtcaactaccaTT 261_1 -16.76 25251
    262 ACAACTTCTATCATAC 3-10-3 ACAacttctatcaTAC 262_1 -16.33 25718
    263 GAACAACTTCTATCAT 2-10-4 GAacaacttctaTCAT 263_1 -16.94 25720
    264 TGAACAACTTCTATCA 3-10-3 TGAacaacttctaTCA 264_1 -17.36 25721
    265 TACACAAATACTTAAATCA 4-13-2 TACAcaaatacttaaatCA 265_1 -16.93 26331
    266 TTAAGCTTTCACCTAT 2-10-4 TTaagctttcacCTAT 266_1 -19.36 27165
    267 AAACTCTTGCATCTACT 2-13-2 AAactcttgcatctaCT 267_1 -16.65 27248
    268 AAATTTCTCAACCTAAATTT 2-14-4 AAatttctcaacctaaATTT 268_1 -16.78 29330
    269 CCAACATAGATCCTCT 2-10-4 CCaacatagatcCTCT 269_1 -22.49 29635
    270 TCCAACATAGATCCTCT 2-11-4 TCcaacatagatcCTCT 270_1 -22.81 29635
    271 CTCCAACATAGATCCTC 3-11-3 CTCcaacatagatcCTC 271_1 -22.81 29636
    272 TCCAACATAGATCCTC 2-10-4 TCcaacatagatCCTC 272_1 -21.69 29636
    273 CTCCAACATAGATCCT 3-10-3 CTCcaacatagatCCT 273_1 -22.68 29637
    274 TCTCCAACATAGATCCT 4-11-2 TCTCcaacatagatcCT 274_1 -22.81 29637
    275 ATTCTCAATTGCACTT 4-10-2 ATTCtcaattgcacTT 275_1 -17.90 29661
    276 TATTCTCAATTGCACTT 4-11-2 TATTctcaattgcacTT 276_1 -18.54 29661
    277 TCACCTAATAGCACCA 2-10-4 TCacctaatagcACCA 277_1 -21.99 29684
    278 TTCACCTAATAGCACCA 2-11-4 TTcacctaatagcACCA 278_1 -22.53 29684
    279 CATTATTATTTAACCTT 2-11-4 CAttattatttaaCCTT 279_1 -17.83 30455
    280 ACATTATTATTTAACCT 3-11-3 ACAttattatttaaCCT 280_1 -18.05 30456
    281 TACATTATTATTTAACC 4-11-2 TACAttattatttaaCC 281_1 -16.80 30457
    282 CATTTACATTATTATTTAAC 2-14-4 CAtttacattattattTAAC 282_1 -16.44 30458
    283 CTCATTTACATTATTATT 4-12-2 CTCAtttacattattaTT 283_1 -17.33 30462
    284 TATCTCATTTACATTATT 4-12-2 TATCtcatttacattaTT 284_1 -17.62 30465
    285 ATCATTCTCAACAATTA 4-11-2 ATCAttctcaacaatTA 285_1 -17.04 30601
    285 ATCATTCTCAACAATTA 4-7-6 ATCAttctcaaCAATTA 285_2 -21.48 30601
    285 ATCATTCTCAACAATTA 1-1-3-6-6 AtCATtctcaaCAATTA 285_3 -20.80 30601
    285 ATCATTCTCAACAATTA 5-6-2-2-2 ATCATtctcaaCAatTA 285_4 -20.46 30601
    285 ATCATTCTCAACAATTA 4-7-1-1-4 ATCAttctcaaCaATTA 285_5 -19.80 30601
    285 ATCATTCTCAACAATTA 5-7-1-1-3 ATCATtctcaacAaTTA 285_6 -19.31 30601
    285 ATCATTCTCAACAATTA 5-6-3-1-2 ATCATtctcaaCAAtTA 285_7 -20.97 30601
    285 ATCATTCTCAACAATTA 4-7-2-1-3 ATCAttctcaaCAaTTA 285_8 -20.16 30601
    285 ATCATTCTCAACAATTA 5-6-1-1-4 ATCATtctcaaCaATTA 285_9 -21.05 30601
    285 ATCATTCTCAACAATTA 5-6-1-1-1-1-2 ATCATtctcaaCaAtTA 285_10 -19.29 30601
    285 ATCATTCTCAACAATTA 1-1-3-7-5 AtCATtctcaacAATTA 285_11 -18.70 30601
    286 AAGATCATTCTCAACA 4-10-2 AAGAtcattctcaaCA 286_1 -17.15 30605
    287 TCTCAAAGATCATTCTC 3-11-3 TCTcaaagatcattCTC 287_1 -19.02 30609
    288 TCTCAAAGATCATTCT 4-10-2 TCTCaaagatcattCT 288_1 -17.81 30610
    289 ACTTAATTATACTTCC 4-10-2 ACTTaattatacttCC 289_1 -17.28 30667
    290 TACACTTAATTATACTTC 2-12-4 TAcacttaattataCTTC 290_1 -16.87 30668
    291 TTACACTTAATTATACTT 3-12-3 TTAcacttaattataCTT 291_1 -16.20 30669
    292 TTTACACTTAATTATACT 2-12-4 TTtacacttaattaTACT 292_1 -16.23 30670
    293 CTATTTAATTTACACTT 3-11-3 CTAtttaatttacaCTT 293_1 -16.26 30679
    294 TATCTATTTAATTTACAC 3-12-3 TATctatttaatttaCAC 294_1 -16.06 30681
    295 TTTATCTATTTAATTTACA 4-13-2 TTTAtctatttaatttaCA 295_1 -16.34 30682
    296 CTCTGCTTATAACTTT 4-10-2 CTCTgcttataactTT 296_1 -18.51 30699
    297 CCTCTGCTTATAACTT 3-10-3 CCTctgcttataaCTT 297_1 -21.29 30700
    298 TCCTCTGCTTATAACTT 3-12-2 TCCtctgcttataacTT 298_1 -20.86 30700
    299 TCCTCTGCTTATAACT 3-11-2 TCCtctgcttataaCT 299_1 -20.70 30701
    300 TTCCTCTGCTTATAACT 3-12-2 TTCctctgcttataaCT 300_1 -20.03 30701
    301 TTTCCTCTGCTTATAAC 4-11-2 TTTCctctgcttataAC 301_1 -19.20 30702
    302 TACTATACTTTCCTCT 2-10-4 TActatactttcCTCT 302_1 -20.07 30711
    303 TTCTACTATACTTTCC 4-10-2 TTCTactatactttCC 303_1 -19.55 30714
    304 AGTTCTACTATACTTTC 4-11-2 AGTTctactatacttTC 304_1 -18.49 30715
    304 AGTTCTACTATACTTTC 1-10-6 AgttctactatACTTTC 304_2 -18.76 30715
    304 AGTTCTACTATACTTTC 1-1-2-7-1-1-4 AgTTctactatAcTTTC 304_3 -18.23 30715
    304 AGTTCTACTATACTTTC 3-8-2-2-2 AGTtctactatACttTC 304_4 -19.19 30715
    304 AGTTCTACTATACTTTC 2-2-1-6-1-1-4 AGttCtactatAcTTTC 304_5 -19.07 30715
    304 AGTTCTACTATACTTTC 1-2-2-8-4 AgtTCtactatacTTTC 304_6 -18.46 30715
    304 AGTTCTACTATACTTTC 3-10-1-1-2 AGTtctactatacTtTC 304_7 -18.12 30715
    304 AGTTCTACTATACTTTC 3-11-3 AGTtctactatactTTC 304_8 -18.42 30715
    304 AGTTCTACTATACTTTC 3-1-1-10-2 AGTtCtactatacttTC 304_9 -18.58 30715
    304 AGTTCTACTATACTTTC 2-1-2-10-2 AGtTCtactatacttTC 304_10 -18.02 30715
    304 AGTTCTACTATACTTTC 1-2-2-6-2-1-3 AgtTCtactatACtTTC 304_11 -19.02 30715
    304 AGTTCTACTATACTTTC 2-1-2-6-1-3-2 AGtTCtactatActtTC 304_12 -18.22 30715
    304 AGTTCTACTATACTTTC 2-2-1-7-2-1-2 AGttCtactataCTtTC 304_13 -19.22 30715
    304 AGTTCTACTATACTTTC 3-1-1-7-1-1-3 AGTtCtactataCtTTC 304_14 -20.39 30715
    304 AGTTCTACTATACTTTC 1-1-1-1-1-8-4 AgTtCtactatacTTTC 304_15 -18.13 30715
    305 GTTCTACTATACTTTC 4-10-2 GTTCtactatacttTC 305_1 -17.48 30715
    306 CATTATATTTAAACTATCA 4-13-2 CATTatatttaaactatCA 306_1 -16.93 31630
    307 CACATTATATTTAAACTAT 2-13-4 CAcattatatttaaaCTAT 307_1 -17.11 31632
    308 ACACATTATATTTAAACTA 3-13-3 ACAcattatatttaaaCTA 308_1 -17.09 31633
    309 ACCACCTAAGACCTCAA 2-11-4 ACcacctaagaccTCAA 309_1 -22.49 32755
    310 CCACCTAAGACCTCAA 2-10-4 CCacctaagaccTCAA 310_1 -22.63 32755
    311 ACCACCTAAGACCTCA 2-11-3 ACcacctaagaccTCA 311_1 -21.74 32756
    312 ACCTTAAGTAACATTT 4-10-2 ACCTtaagtaacatTT 312_1 -16.82 33366
    313 CACCTTAAGTAACATT 4-10-2 CACCttaagtaacaTT 313_1 -18.05 33367
    314 CCACCTTAAGTAACAT 3-10-3 CCAccttaagtaaCAT 314_1 -20.70 33368
    315 ACCACCTTAAGTAACA 4-10-2 ACCAccttaagtaaCA 315_1 -20.68 33369
    316 TTATTAACCACCTTAA 3-10-3 TTAttaaccacctTAA 316_1 -16.19 33375
    317 CATTATTAACCACCTT 2-10-4 CAttattaaccaCCTT 317_1 -19.92 33377
    318 ACATTATTAACCACCT 3-10-3 ACAttattaaccaCCT 318_1 -20.14 33378
    319 ACCAATTATACTTACAA 3-11-3 ACCaattatacttaCAA 319_1 -17.16 36606
    320 AACCAATTATACTTACA 4-11-2 AACCaattatacttaCA 320_1 -17.16 36607
    321 CAAATACAGATTATCC 2-10-4 CAaatacagattATCC 321_1 -16.44 38092
    322 TTTACATTCCCATCATC 2-11-4 TTtacattcccatCATC 322_1 -21.08 38297
    323 CACACCTATTATATAAT 4-11-2 CACAcctattatataAT 323_1 -17.02 39173
    324 TCACACCTATTATATAA 3-11-3 TCAcacctattataTAA 324_1 -17.02 39174
    325 CTTCACACCTATTATATA 2-12-4 CTtcacacctattaTATA 325_1 -20.65 39175
    326 ACTTCACACCTATTATAT 3-12-3 ACTtcacacctattaTAT 326_1 -20.46 39176
    327 GCTCACACTAATTATT 2-10-4 GCtcacactaatTATT 327_1 -18.72 39228
    328 ATGCTCACACTAATTA 4-10-2 ATGCtcacactaatTA 328_1 -19.38 39230
    329 AATGCTCACACTAATT 4-10-2 AATGctcacactaaTT 329_1 -16.21 39231
    330 AAACTGTACACCTACT 2-10-4 AAactgtacaccTACT 330_1 -17.99 39563
    331 GTTTCCATCTACTATTA 2-11-4 GTttccatctactATTA 331_1 -19.78 39808
    332 TTTCCATCTACTATTA 4-10-2 TTTCcatctactatTA 332_1 -17.25 39808
    333 TGACATAACCATATAC 3-10-3 TGAcataaccataTAC 333_1 -16.63 39931
    334 GCTCCCAAACAACTAA 2-12-2 GCtcccaaacaactAA 334_1 -17.55 41114
    335 CCTCAATACTCTACTT 4-10-2 CCTCaatactctacTT 335_1 -20.30 41444
    336 GACCTCAATACTCTACT 3-11-3 GACctcaatactctACT 336_1 -21.01 41445
    337 GACCTCAATACTCTAC 4-10-2 GACCtcaatactctAC 337_1 -20.02 41446
    338 TACTAAACATACACATA 4-11-2 TACTaaacatacacaTA 338_1 -16.12 41725
    339 CTACTAAACATACACAT 3-11-3 CTActaaacatacaCAT 339_1 -17.31 41726
    340 TTCTACTAAACATACAC 3-11-3 TTCtactaaacataCAC 340_1 -16.07 41728
    341 TACCAATAGTTACCTT 2-10-4 TAccaatagttaCCTT 341_1 -20.03 42167
    342 CTTACCAATAGTTACCT 3-11-3 CTTaccaatagttaCCT 342_1 -22.29 42168
    343 TTACCAATAGTTACCT 3-10-3 TTAccaatagttaCCT 343_1 -20.03 42168
    344 CTTACCAATAGTTACC 4-10-2 CTTAccaatagttaCC 344_1 -20.03 42169
    345 TCTTACCAATAGTTACC 4-11-2 TCTTaccaatagttaCC 345_1 -21.30 42169
    346 TCAAAGCACACCACCAC 2-12-3 TCaaagcacaccacCAC 346_1 -21.69 42287
    347 ATTCAAAGCACACCACC 2-12-3 ATtcaaagcacaccACC 347_1 -21.00 42289
    348 AGACTAATCCTCTTAA 3-10-3 AGActaatcctctTAA 348_1 -17.72 43452
    349 TAGACTAATCCTCTTA 4-10-2 TAGActaatcctctTA 349_1 -19.20 43453
    350 CCCATTTCTAACATTTAC 3-12-3 CCCatttctaacattTAC 350_1 -22.93 43562
    351 ACCCATTTCTAACATT 4-10-2 ACCCatttctaacaTT 351_1 -20.64 43565
    352 AACCCATTTCTAACAT 4-10-2 AACCcatttctaacAT 352_1 -18.25 43566
    353 CCTCAACTTCACCAAT 2-10-4 CCtcaacttcacCAAT 353_1 -21.73 43634
    354 ACTGATTTCCTTAAAC 4-10-2 ACTGatttccttaaAC 354_1 -16.67 44180
    355 CACTGATTTCCTTAAAC 4-11-2 CACTgatttccttaaAC 355_1 -18.91 44180
    356 CCACTGATTTCCTTAAA 4-11-2 CCACtgatttccttaAA 356_1 -20.91 44181
    357 ACCACTGATTTCCTTA 2-10-4 ACcactgatttcCTTA 357_1 -20.98 44183
    358 CACCACTGATTTCCTT 3-10-3 CACcactgatttcCTT 358_1 -22.04 44184
    359 CTCTGCAATACACCAA 2-10-4 CTctgcaatacaCCAA 359_1 -20.90 44439
    360 ACTCTGCAATACACCA 3-10-3 ACTctgcaatacaCCA 360_1 -22.19 44440
    361 TACTCTGCAATACACCA 2-11-4 TActctgcaatacACCA 361_1 -22.32 44440
    361 TACTCTGCAATACACCA 1-1-1-10-1-1-2 TaCtctgcaatacAcCA 361_2 -19.29 44440
    361 TACTCTGCAATACACCA 1-3-1-8-1-1-2 TactCtgcaatacAcCA 361_3 -19.28 44440
    361 TACTCTGCAATACACCA 1-10-1-3-2 TactctgcaatAcacCA 361_4 -18.35 44440
    361 TACTCTGCAATACACCA 2-10-2-1-2 TActctgcaataCAcCA 361_5 -21.63 44440
    361 TACTCTGCAATACACCA 1-13-3 TactctgcaatacaCCA 361_6 -20.54 44440
    361 TACTCTGCAATACACCA 2-10-1-2-2 TActctgcaataCacCA 361_7 -20.06 44440
    361 TACTCTGCAATACACCA 1-1-1-12-2 TaCtctgcaatacacCA 361_8 -19.14 44440
    361 TACTCTGCAATACACCA 1-2-2-10-2 TacTCtgcaatacacCA 361_9 -20.33 44440
    361 TACTCTGCAATACACCA 1-3-1-10-2 TactCtgcaatacacCA 361_10 -19.13 44440
    362 TACTCTGCAATACACC 2-10-4 TActctgcaataCACC 362_1 -21.12 44441
    362 TACTCTGCAATACACC 1-1-1-11-2 TaCtctgcaatacaCC 362_2 -18.23 44441
    362 TACTCTGCAATACACC 1-1-1-10-3 TaCtctgcaatacACC 362_3 -18.78 44441
    362 TACTCTGCAATACACC 1-3-1-7-4 TactCtgcaataCACC 362_4 -20.87 44441
    362 TACTCTGCAATACACC 3-11-2 TACtctgcaatacaCC 362_5 -19.86 44441
    362 TACTCTGCAATACACC 2-2-1-9-2 TActCtgcaatacaCC 362_6 -19.44 44441
    362 TACTCTGCAATACACC 2-12-2 TActctgcaatacaCC 362_7 -18.47 44441
    362 TACTCTGCAATACACC 1-2-2-9-2 TacTCtgcaatacaCC 362_8 -19.42 44441
    362 TACTCTGCAATACACC 2-1-2-9-2 TAcTCtgcaatacaCC 362_9 -20.64 44441
    362 TACTCTGCAATACACC 1-3-1-9-2 TactCtgcaatacaCC 362_10 -18.22 44441
    363 TTACTCTGCAATACACC 2-11-4 TTactctgcaataCACC 363_1 -21.71 44441
    364 TTACTCTGCAATACAC 3-10-3 TTActctgcaataCAC 364_1 -17.75 44442
    365 TTTACTCTGCAATACAC 3-11-3 TTTactctgcaataCAC 365_1 -18.34 44442
    366 CTTTACTCTGCAATACA 2-11-4 CTttactctgcaaTACA 366_1 -20.23 44443
    367 TTTACTCTGCAATACA 2-10-4 TTtactctgcaaTACA 367_1 -17.56 44443
    368 GACCACACTTTCTACCA 2-13-2 GAccacactttctacCA 368_1 -21.72 44477
    369 GACCACACTTTCTACC 2-12-2 GAccacactttctaCC 369_1 -20.81 44478
    370 AAGAAACACCCTTCCA 2-10-4 AAgaaacaccctTCCA 370_1 -21.48 44776
    371 ATCTGCTACATATTCTT 4-11-2 ATCTgctacatattcTT 371_1 -19.88 45216
    372 ATCTGCTACATATTCT 4-10-2 ATCTgctacatattCT 372_1 -19.71 45217
    373 CATCTGCTACATATTCT 4-11-2 CATCtgctacatattCT 373_1 -21.32 45217
    374 CATCTGCTACATATTC 4-10-2 CATCtgctacatatTC 374_1 -18.82 45218
    375 TTCAACCCTAATCACT 4-10-2 TTCAaccctaatcaCT 375_1 -19.99 45246
    376 ATTCAACCCTAATCAC 2-10-4 ATtcaaccctaaTCAC 376_1 -18.67 45247
    377 CATTCAACCCTAATCA 3-10-3 CATtcaaccctaaTCA 377_1 -19.93 45248
    378 GCATTCAACCCTAATCA 3-12-2 GCAttcaaccctaatCA 378_1 -22.56 45248
    379 AGCATTCAACCCTAATC 4-11-2 AGCAttcaaccctaaTC 379_1 -22.98 45249
    380 GCATTCAACCCTAATC 4-10-2 GCATtcaaccctaaTC 380_1 -21.63 45249
    381 AGCATTCAACCCTAAT 4-10-2 AGCAttcaaccctaAT 381_1 -21.62 45250
    382 CAGCATTCAACCCTAAT 3-12-2 CAGcattcaaccctaAT 382_1 -21.12 45250
    383 TTAAATCCAGCATTCA 3-10-3 TTAaatccagcatTCA 383_1 -18.08 45258
    384 CTCCATATTTAAATCC 4-10-2 CTCCatatttaaatCC 384_1 -20.02 45266
    385 GCTCCATATTTAAATCC 4-11-2 GCTCcatatttaaatCC 385_1 -22.84 45266
    386 GCTCCATATTTAAATC 4-10-2 GCTCcatatttaaaTC 386_1 -18.78 45267
    387 AGCTCCATATTTAAAT 4-10-2 AGCTccatatttaaAT 387_1 -18.62 45268
    388 TAAGCTCCATATTTAA 3-10-3 TAAgctccatattTAA 388_1 -16.08 45270
    389 CCTAAGCTCCATATTTA 3-11-3 CCTaagctccatatTTA 389_1 -22.65 45271
    390 CTAAGCTCCATATTTA 4-10-2 CTAAgctccatattTA 390_1 -18.81 45271
    391 CCTAAGCTCCATATTT 4-10-2 CCTAagctccatatTT 391_1 -21.57 45272
    392 TCTACCCTAAATTCCC 2-11-3 TCtaccctaaattCCC 392_1 -23.00 45560
    393 CACATCTTGTATACAA 3-10-3 CACatcttgtataCAA 393_1 -16.65 45627
    394 ACACATCTTGTATACA 4-10-2 ACACatcttgtataCA 394_1 -17.95 45628
    395 CTACACATCTTGTATAC 3-11-3 CTAcacatcttgtaTAC 395_1 -19.13 45629
    396 TACACATCTTGTATAC 3-10-3 TACacatcttgtaTAC 396_1 -16.73 45629
    397 CTTGACTACACATCTT 3-10-3 CTTgactacacatCTT 397_1 -18.89 45635
    398 CTCTACAACAGTCCCA 3-11-2 CTCtacaacagtccCA 398_1 -22.06 45709
    399 TCTCTACAACAGTCCCA 2-13-2 TCtctacaacagtccCA 399_1 -21.70 45709
    400 ATAACATTACTCTTAACA 3-12-3 ATAacattactcttaACA 400_1 -17.03 46215
    401 TTTGACATTCCATCTCC 2-12-3 TTtgacattccatcTCC 401_1 -21.62 46256
    402 CTTTGACATTCCATCTC 2-11-4 CTttgacattccaTCTC 402_1 -21.88 46257
    403 TCTTTGACATTCCATCTC 4-12-2 TCTTtgacattccatcTC 403_1 -22.41 46257
    404 TTTGACATTCCATCTC 3-10-3 TTTgacattccatCTC 404_1 -19.40 46257
    405 ATCTTTGACATTCCATC 2-11-4 ATctttgacattcCATC 405_1 -20.53 46259
    406 TATCTTTGACATTCCAT 2-11-4 TAtctttgacattCCAT 406_1 -21.32 46260
    407 TACTATCTTTGACATTC 4-11-2 TACTatctttgacatTC 407_1 -18.39 46263
    408 TACTATCTTTGACATT 4-10-2 TACTatctttgacaTT 408_1 -16.84 46264
    409 CTGTATACACCATCCC 2-12-2 CTgtatacaccatcCC 409_1 -21.84 46392
    410 TCTGTATACACCATCC 4-10-2 TCTGtatacaccatCC 410_1 -22.73 46393
    411 TTTCTGACTCCCTATCC 2-13-2 TTtctgactccctatCC 411_1 -22.48 46420
    412 CCTATGTTAATACTTTC 4-11-2 CCTAtgttaatacttTC 412_1 -19.53 46505
    413 CTATGTTAATACTTTC 4-10-2 CTATgttaatacttTC 413_1 -16.09 46505
    414 CCTATGTTAATACTTT 4-10-2 CCTAtgttaatactTT 414_1 -17.85 46506
    415 TCCTATGTTAATACTT 3-10-3 TCCtatgttaataCTT 415_1 -18.47 46507
    416 ATCCTATGTTAATACT 4-10-2 ATCCtatgttaataCT 416_1 -18.71 46508
    417 ATTTCATTAAGTCACCC 3-11-3 ATTtcattaagtcaCCC 417_1 -22.16 47364
    418 ATTTCATTAAGTCACC 2-10-4 ATttcattaagtCACC 418_1 -18.79 47365
    419 CTCTCCTCAAGATCAAC 3-11-3 CTCtcctcaagatcAAC 419_1 -20.29 48110
    420 CTCTCCTCAAGATCAA 3-10-3 CTCtcctcaagatCAA 420_1 -20.33 48111
    421 CCATACAGTATATACA 4-10-2 CCATacagtatataCA 421_1 -19.53 48186
    422 CAACTATTATCTTCTT 2-10-4 CAactattatctTCTT 422_1 -16.38 48221
    423 ACAACTATTATCTTCT 3-10-3 ACAactattatctTCT 423_1 -16.60 48222
    424 TTGCTTCCAATTTATTT 4-11-2 TTGCttccaatttatTT 424_1 -19.93 50282
    425 ATCTCATGACCACCTAA 3-11-3 ATCtcatgaccaccTAA 425_1 -21.74 51241
    425 ATCTCATGACCACCTAA 1-1-1-9-2-1-2 AtCtcatgaccaCCTAA 425_2 -21.11 51241
    425 ATCTCATGACCACCTAA 1-1-1-8-1-2-3 AtCtcatgaccAccTAA 425_3 -19.96 51241
    425 ATCTCATGACCACCTAA 1-12-4 AtctcatgaccacCTAA 425_4 -20.40 51241
    425 ATCTCATGACCACCTAA 3-10-1-1-2 ATCtcatgaccacCTAA 425_5 -20.66 51241
    425 ATCTCATGACCACCTAA 1-1-1-10-1-1-2 AtCtcatgaccacCTAA 425_6 -18.72 51241
    425 ATCTCATGACCACCTAA 1-1-1-9-1-1-3 AtCtcatgaccaCcTAA 425_7 -20.59 51241
    425 ATCTCATGACCACCTAA 1-2-2-7-1-1-3 AtcTCatgaccaCcTAA 425_8 -21.48 51241
    425 ATCTCATGACCACCTAA 1-3-1-8-4 AtctCatgaccacCTAA 425_9 -21.07 51241
    425 ATCTCATGACCACCTAA 1-1-3-8-1-1-2 AtCTCatgaccacCtAA 425_10 -21.27 51241
    426 TCTCATGACCACCTAA 2-10-4 TCtcatgaccacCTAA 426_1 -21.25 51241
    427 ATCTCATGACCACCTA 3-10-3 ATCtcatgaccacCTA 427_1 -22.56 51242
    428 TATCTCATGACCACCTA 2-12-3 TAtctcatgaccacCTA 428_1 -21.88 51242
    429 TTTATCTCATGACCACC 2-11-4 TTtatctcatgacCACC 429_1 -22.37 51244
    430 TTTATCTCATGACCAC 2-10-4 TTtatctcatgaCCAC 430_1 -19.56 51245
    431 ATTCTTACCGTCTTTA 4-10-2 ATTCttaccgtcttTA 431_1 -19.52 51358
    432 TATTCTTACCGTCTTTA 3-11-3 TATtcttaccgtctTTA 432_1 -20.10 51358
    433 TATTCTTACCGTCTTT 2-10-4 TAttcttaccgtCTTT 433_1 -19.30 51359
    434 TTATTCTTACCGTCTTT 2-11-4 TTattcttaccgtCTTT 434_1 -19.99 51359
    435 ATCTGATCTCACACAT 3-10-3 ATCtgatctcacaCAT 435_1 -19.62 51438
    436 CATCTGATCTCACACAT 4-11-2 CATCtgatctcacacAT 436_1 -20.82 51438
    437 ACTTCCAGATTTCTACA 2-11-4 ACttccagatttcTACA 437_1 -21.44 51953
    438 TTTATGTTTACTTCAT 3-10-3 TTTatgtttacttCAT 438_1 -16.05 52150
    439 TAAAGATCCCATCACTC 3-11-3 TAAagatcccatcaCTC 439_1 -20.31 52549
    440 TAAAGATCCCATCACT 4-10-2 TAAAgatcccatcaCT 440_1 -18.82 52550
    441 CCTAAAGATCCCATCAC 2-12-3 CCtaaagatcccatCAC 441_1 -22.32 52551
    442 ATCATCAGTTACATCA 4-10-2 ATCAtcagttacatCA 442_1 -18.64 52579
    443 ACTCTCACTGTAACTTT 4-11-2 ACTCtcactgtaactTT 443_1 -19.76 53012
    444 AACTCTCACTGTAACTT 3-11-3 AACtctcactgtaaCTT 444_1 -18.53 53013
    445 ACTCTCACTGTAACTT 3-10-3 ACTctcactgtaaCTT 445_1 -19.04 53013
    446 AACTCTCACTGTAACT 4-10-2 AACTctcactgtaaCT 446_1 -17.97 53014
    447 CAACTCTCACTGTAACT 4-11-2 CAACtctcactgtaaCT 447_1 -20.01 53014
    448 CCTTTCATTAACATTTA 3-11-3 CCTttcattaacatTTA 448_1 -19.03 54198
    449 TTCCTTTCATTAACATTT 4-12-2 TTCCtttcattaacatTT 449_1 -19.92 54199
    450 TAATCCTATTCCAACT 3-10-3 TAAtcctattccaACT 450_1 -18.05 54232
    451 CTAATCCTATTCCAAC 2-10-4 CTaatcctattcCAAC 451_1 -18.65 54233
    452 CTCTAATCCTATTCCA 3-10-3 CTCtaatcctattCCA 452_1 -22.58 54235
    453 TCTCTAATCCTATTCC 4-10-2 TCTCtaatcctattCC 453_1 -21.78 54236
    454 TTGTCTCTAATCCTATT 2-11-4 TTgtctctaatccTATT 454_1 -19.70 54238
    455 TTGTCTCTAATCCTAT 2-10-4 TTgtctctaatcCTAT 455_1 -19.45 54239
    456 TCTTTAAGCTTCCCAC 2-10-4 TCtttaagcttcCCAC 456_1 -22.96 54609
    457 AAACTACCCTGCACAA 3-10-3 AAActaccctgcaCAA 457_1 -18.41 54924
    458 CCATGCTACATAAACC 4-10-2 CCATgctacataaaCC 458_1 -22.25 55337
    459 TCCATGCTACATAAAC 4-10-2 TCCAtgctacataaAC 459_1 -18.64 55338
    460 ACTCCTAAGAATTACA 4-10-2 ACTCctaagaattaCA 460_1 -17.62 59565
    461 GAAACTATTACTCCTA 2-10-4 GAaactattactCCTA 461_1 -19.06 59574
    462 TGAAACTATTACTCCT 3-10-3 TGAaactattactCCT 462_1 -19.30 59575
    463 ATGAAACTATTACTCC 2-10-4 ATgaaactattaCTCC 463_1 -17.96 59576
    464 AACAACTCATGCCACA 2-10-4 AAcaactcatgcCACA 464_1 -19.72 60012
    465 AAATATTGCCACCATT 2-10-4 AAatattgccacCATT 465_1 -17.78 60298
    466 GTTACATATTCTTTCAC 3-11-3 GTTacatattctttCAC 466_1 -18.76 60448
    467 TCATACTTGCTTTAAT 4-10-2 TCATacttgctttaAT 467_1 -17.29 60821
    468 ATCCTGATAATTAACT 4-10-2 ATCCtgataattaaCT 468_1 -17.73 61925
    469 CCTTAATCTGTATCAC 3-10-3 CCTtaatctgtatCAC 469_1 -19.92 62287
    470 ATACACAGCACATATT 2-10-4 ATacacagcacaTATT 470_1 -17.58 62422
    471 TCAGAATAATTCTCCT 3-10-3 TCAgaataattctCCT 471_1 -19.81 62443
    472 TCTTCAGCTTTCTAAAT 4-11-2 TCTTcagctttctaaAT 472_1 -18.58 64113
    473 AGTCCTTCCTTTAACCA 2-13-2 AGtccttcctttaacCA 473_1 -22.20 64461
    474 TAGTCCTTCCTTTAACC 2-13-2 TAgtccttcctttaaCC 474_1 -22.12 64462
    475 TTTAACCTTGCTTATA 2-10-4 TTtaaccttgctTATA 475_1 -17.50 65272
    476 ATCCCTTTGTAATCAT 4-10-2 ATCCctttgtaatcAT 476_1 -20.31 66840
    477 CTTGCATTTCTAATTAC 3-11-3 CTTgcatttctaatTAC 477_1 -18.09 67426
    478 CTTGTCAAATCATTTCT 4-11-2 CTTGtcaaatcatttCT 478_1 -19.10 68194
    479 CCATCTAATGATTATT 4-10-2 CCATctaatgattaTT 479_1 -17.28 68328
    480 TATCAGTTATCCAATA 4-10-2 TATCagttatccaaTA 480_1 -17.39 68805
    481 TCACTGCCATCAATAC 4-10-2 TCACtgccatcaatAC 481_1 -19.71 68921
    482 TGTCATCTACAAATCA 4-10-2 TGTCatctacaaatCA 482_1 -18.01 70133
    483 CTCTTTAGATTCATCC 4-10-2 CTCTttagattcatCC 483_1 -20.94 72377
    484 ACTCTTTAGATTCATC 2-10-4 ACtctttagattCATC 484_1 -17.81 72378
    485 CAACTCTATGACTACC 2-10-4 CAactctatgacTACC 485_1 -20.07 72826
    486 ACCTGTAATACTTCTT 4-10-2 ACCTgtaatacttcTT 486_1 -19.67 72861
    487 GAATTCTTTATTCCTCC 2-11-4 GAattctttattcCTCC 487_1 -22.53 72887
    488 ATCTGAATCAAACCTT 2-10-4 ATctgaatcaaaCCTT 488_1 -17.97 73474
    489 ACTTTACTGCCATAATC 3-11-3 ACTttactgccataATC 489_1 -19.60 73992
    490 TTACTCTTAGCAACCT 4-10-2 TTACtcttagcaacCT 490_1 -20.19 74791
    491 CACCAGTATTTCTTCTT 4-11-2 CACCagtatttcttcTT 491_1 -22.15 74851
    492 TTCACCAGTATTTCTTC 4-11-2 TTCAccagtatttctTC 492_1 -20.43 74853
    493 CCAAATAAGCAAACTC 3-10-3 CCAaataagcaaaCTC 493_1 -17.54 75840
    494 CCCAAATAAGCAAACT 4-10-2 CCCAaataagcaaaCT 494_1 -20.23 75841
    495 GACTACATTCTCAATA 3-10-3 GACtacattctcaATA 495_1 -17.49 76238
    496 TTGTCAATCTTTATTCT 4-11-2 TTGTcaatctttattCT 496_1 -18.85 76254
    497 AGCTTACCAAATATTC 4-10-2 AGCTtaccaaatatTC 497_1 -18.68 76811
    498 TTACACATGTATATCC 3-10-3 TTAcacatgtataTCC 498_1 -18.23 77114
    499 ATCCTGTTAATACCAT 2-10-4 ATcctgttaataCCAT 499_1 -20.41 80468
    500 TTCTTAGTCACACACA 4-10-2 TTCTtagtcacacaCA 500_1 -19.37 81047
    501 TTCTGTTTCCATTTACA 4-11-2 TTCTgtttccatttaCA 501_1 -21.31 82233
    502 TCTATATCAAGTTCCTT 2-11-4 TCtatatcaagttCCTT 502_1 -20.95 84166
    503 ATTCAGTTACCAACTA 3-10-3 ATTcagttaccaaCTA 503_1 -18.37 85392
    504 GCTTCTACTTAAATAT 3-10-3 GCTtctacttaaaTAT 504_1 -17.58 86974
    505 CCCTCAAAGTAATTTC 4-10-2 CCCTcaaagtaattTC 505_1 -20.53 87728
    506 AACATGTAATTTCCAT 2-10-4 AAcatgtaatttCCAT 506_1 -17.21 87810
    507 CCAGACTCCAATATTT 4-10-2 CCAGactccaatatTT 507_1 -20.78 88417
    508 CTTAGACTTCACCTTTC 2-11-4 CTtagacttcaccTTTC 508_1 -20.56 88991
    509 CTGCTTAATTATATCA 4-10-2 CTGCttaattatatCA 509_1 -18.85 90228
    510 AAATTGTCTACCTTCCT 2-12-3 AAattgtctaccttCCT 510_1 -20.62 90474
    511 CACTTAGAATATCCCT 2-10-4 CActtagaatatCCCT 511_1 -22.28 91625
    512 ATCCAAAGTTTCTTTC 4-10-2 ATCCaaagtttcttTC 512_1 -18.64 91885
    513 ATATTTGTCACCTAAC 4-10-2 ATATttgtcacctaAC 513_1 -17.12 92976
    514 CTATTCTCAGTATTAT 3-10-3 CTAttctcagtatTAT 514_1 -17.42 94304
    515 CCATTCAATGATCACT 2-10-4 CCattcaatgatCACT 515_1 -20.55 94528
    516 CACTAGTACTCTTATT 4-10-2 CACTagtactcttaTT 516_1 -18.01 95653
    517 GCCACAACATCTATTT 4-10-2 GCCAcaacatctatTT 517_1 -21.53 96751
    518 AGCACATATACCATCA 4-10-2 AGCAcatataccatCA 518_1 -21.98 97636
    519 GTCATCTAACTTCTTAC 3-11-3 GTCatctaacttctTAC 519_1 -19.25 98480
    520 TGTCATCTAACTTCTTA 4-11-2 TGTCatctaacttctTA 520_1 -19.69 98481
    521 CCCTTATAGTTATTAA 3-10-3 CCCttatagttatTAA 521_1 -19.32 99646
    522 TCCATAGAATTCTTCA 4-10-2 TCCAtagaattcttCA 522_1 -19.92 100334
    523 TTGATTCCACCATTAA 3-10-3 TTGattccaccatTAA 523_1 -18.05 101110
    524 CAGCCATAAACTATAT 4-10-2 CAGCcataaactatAT 524_1 -18.60 101898
    525 TATGACTTATTCCATA 2-10-4 TAtgacttattcCATA 525_1 -17.88 102558
    526 GTTAACCTATATTTCA 4-10-2 GTTAacctatatttCA 526_1 -17.69 103589
    527 TGTCTATTCTCTTCATT 4-11-2 TGTCtattctcttcaTT 527_1 -20.62 104309
    528 TTACTCTTTGATTTCAT 3-11-3 TTActctttgatttCAT 528_1 -18.39 105686
    529 GATAATTCCAAATCCC 2-10-4 GAtaattccaaaTCCC 529_1 -20.99 107972
    530 TCTTATCCTTGAATTTC 4-11-2 TCTTatccttgaattTC 530_1 -18.85 108257
    531 ATATCCCTTGATTATCC 3-11-3 ATAtcccttgattaTCC 531_1 -22.75 109407
    532 TTAGTATACCCTTTAT 3-10-3 TTAgtatacccttTAT 532_1 -18.67 110210
    533 CTCTTTGTCAAATACT 4-10-2 CTCTttgtcaaataCT 533_1 -18.16 110768
    534 CCAAACTGTCTTCTAAT 2-11-4 CCaaactgtcttcTAAT 534_1 -19.87 111811
    535 TCCAAACTGTCTTCTAA 3-12-2 TCCaaactgtcttctAA 535_1 -18.33 111812
    536 CCAGCATATTATATAC 3-10-3 CCAgcatattataTAC 536_1 -18.96 112149
    537 TCCAGCATATTATATA 4-10-2 TCCAgcatattataTA 537_1 -19.41 112150
    538 TCATTGAACAACTCTTC 4-11-2 TCATtgaacaactctTC 538_1 -18.01 112945
    539 CTGCCATCTTTATTTAT 4-11-2 CTGCcatctttatttAT 539_1 -21.89 113533
    540 TGAAACATTCTTCCCAC 2-12-3 TGaaacattcttccCAC 540_1 -19.76 114274
    541 TTTATTAGATTACTCC 2-10-4 TTtattagattaCTCC 541_1 -17.38 114495
    542 TTCCAGCTTATTTACCT 3-12-2 TTCcagcttatttacCT 542_1 -21.28 114831
    543 AGCATCATATAAACCT 3-10-3 AGCatcatataaaCCT 543_1 -20.62 115355
    544 GTACTTACACATCTAT 2-10-4 GTacttacacatCTAT 544_1 -18.96 116105
    545 TGTACTTACACATCTA 3-10-3 TGTacttacacatCTA 545_1 -19.38 116106
    546 ATTTCTCTATGTCACAT 3-11-3 ATTtctctatgtcaCAT 546_1 -19.28 117096
    547 CAAACCTACGTCTCTC 2-10-4 CAaacctacgtcTCTC 547_1 -20.87 117189
    548 GTATTTACTCTTTACCT 3-11-3 GTAtttactctttaCCT 548_1 -22.15 117476
    549 CTAATGCAATAACCCA 2-10-4 CTaatgcaataaCCCA 549_1 -21.79 118293
    550 ACTAATGCAATAACCC 3-10-3 ACTaatgcaataaCCC 550_1 -20.53 118294
    551 AGCTCTAAACCTTCAA 3-10-3 AGCtctaaaccttCAA 551_1 -20.51 118756
    552 TATTTGTCACCAAACC 3-10-3 TATttgtcaccaaACC 552_1 -19.63 119621
    553 CTCAGACATCTCAATA 4-10-2 CTCAgacatctcaaTA 553_1 -19.25 120655
    554 TCTCAGCTTCTTCAAAT 2-12-3 TCtcagcttcttcaAAT 554_1 -18.33 123733
    555 GCCAATACCCACAAAC 3-10-3 GCCaatacccacaAAC 555_1 -22.03 124163
    556 CCTCTGACAACCATTA 4-10-2 CCTCtgacaaccatTA 556_1 -22.57 125512
    557 CAGATAACTCTAAACC 4-10-2 CAGAtaactctaaaCC 557_1 -18.43 126882
    558 CTAACTGTTTCTCAATT 3-11-3 CTAactgtttctcaATT 558_1 -18.10 127105
    559 CCAAGATAATCATCAT 3-10-3 CCAagataatcatCAT 559_1 -18.37 127809
    560 TACATATTGTACTTCT 4-10-2 TACAtattgtacttCT 560_1 -17.48 129020
    561 TAGCCTACTTTAATAT 4-10-2 TAGCctactttaatAT 561_1 -18.67 129205
    562 CATTTACAAGCACATA 2-10-4 CAtttacaagcaCATA 562_1 -17.81 129928
    563 TTATTCTGACACACTT 3-10-3 TTAttctgacacaCTT 563_1 -17.49 130020
    564 TACATTGACACCTAAT 4-10-2 TACAttgacacctaAT 564_1 -17.37 130884
    565 TTTACATTGACACCTA 2-10-4 TTtacattgacaCCTA 565_1 -19.42 130886
    566 TGTATATAACTATTCC 4-10-2 TGTAtataactattCC 566_1 -17.79 131404
    567 GAATCTTCTAATTCCAC 2-11-4 GAatcttctaattCCAC 567_1 -20.40 132514
    568 TGCTCACTAACTACAC 3-10-3 TGCtcactaactaCAC 568_1 -20.66 133367
    569 TGCTACCATCATTACCT 2-13-2 TGctaccatcattacCT 569_1 -21.32 136198
    570 TTTATCAATATCTTCTCACT 1-13-1-1-1-1-2 TttatcaatatcttCtCaCT 570_1 -19.69 5784
    570 TTTATCAATATCTTCTCACT 1-2-1-10-1-2-3 TttAtcaatatcttCtcACT 570_2 -19.67 5784
    570 TTTATCAATATCTTCTCACT 1-5-1-7-1-2-3 TttatcAatatcttCtcACT 570_3 -19.65 5784
    570 TTTATCAATATCTTCTCACT 1-1-1-11-1-3-2 TtTatcaatatcttCtcaCT 570_4 -19.75 5784
    570 TTTATCAATATCTTCTCACT 1-2-1-2-1-11-2 TttAtcAatatcttctcaCT 570_5 -18.21 5784
    570 TTTATCAATATCTTCTCACT 1-4-1-8-1-3-2 TttatCaatatcttCtcaCT 570_6 -19.69 5784
    570 TTTATCAATATCTTCTCACT 1-2-1-2-1-9-1-1-2 TttAtcAatatcttctCaCT 570_7 -18.88 5784
    570 TTTATCAATATCTTCTCACT 1-2-1-1-1-11-3 TttAtCaatatcttctcACT 570_8 -19.36 5784
    570 TTTATCAATATCTTCTCACT 1-4-1-10-1-1-2 TttatCaatatcttctCaCT 570_9 -19.38 5784
    570 TTTATCAATATCTTCTCACT 2-1-1-10-1-1-1-1-2 TTTAtcaatatcttCtCaCT 570_10 -20.60 5784
    570 TTTATCAATATCTTCTCACT 1-4-1-8-1-1-1-1-2 TttatCaatatcttCtCaCT 570_11 -20.36 5784
    570 TTTATCAATATCTTCTCACT 1-2-1-1-1-8-1-2-3 TttAtCaatatcttCtcACT 570_12 -20.34 5784
    570 TTTATCAATATCTTCTCACT 1-2-1-2-1-7-1-3-2 TttAtcAatatcttCtcaCT 570_13 -19.19 5784
    570 TTTATCAATATCTTCTCACT 1-1-2-1-1-10-1-1-2 TtTAtCaatatcttctCaCT 570_14 -21.24 5784
    571 TTTATCAATATCTTCTCAC 1-12-2-1-3 TttatcaatatctTCtCAC 571_1 -19.16 5785
    571 TTTATCAATATCTTCTCAC 2-1-1-1-1-6-2-2-3 TTrAtCaatatcTTctCAC 571_2 -20.17 5785
    571 TTTATCAATATCTTCTCAC 3-2-1-7-2-2-2 TTTatCaatatctTCtcAC 571_3 -19.79 5785
    571 TTTATCAATATCTTCTCAC 1-2-3-8-1-2-2 TttATCaatatcttCtcAC 571_4 -18.78 5785
    571 TTTATCAATATCTTCTCAC 1-4-1-9-4 TttatCaatatcttcTCAC 571_5 -19.06 5785
    571 TTTATCAATATCTTCTCAC 2-1-1-1-1-8-1-1-3 TTrAtCaatatcttCtCAC 571_6 -19.75 5785
    571 TTTATCAATATCTTCTCAC 1-1-1-2-1-6-1-3-3 TtTatCaatatcTtctCAC 571_7 -19.11 5785
    571 TTTATCAATATCTTCTCAC 2-1-3-6-1-4-2 TTTATCaatatcTtctcAC 571_8 -19.13 5785
    571 TTTATCAATATCTTCTCAC 4-12-3 TTTAtcaatatcttctCAC 571_9 -20.38 5785
    571 TTTATCAATATCTTCTCAC 1-1-2-1-1-6-1-3-3 TtTAtCaatatoTtctCAC 571_10 -20.24 5785
    571 TTTATCAATATCTTCTCAC 2-1-1-1-1-7-2-2-2 TTrAtCaatatctTCtcAC 571_11 -18.65 5785
    571 TTTATCAATATCTTCTCAC 3-2-1-8-1-1-3 TTTatCaatatottCtCAC 571_12 -20.89 5785
    571 TTTATCAATATCTTCTCAC 1-3-2-8-1-1-3 TttaTCaatatottCtCAC 571_13 -19.96 5785
    571 TTTATCAATATCTTCTCAC 1-2-1-1-1-9-4 TttAtCaatatottcTCAC 571_14 -19.16 5785
    572 TTTATCAATATCTTCTCA 2-1-1-1-1-7-2-1-2 TTrAtCaatatctTCtCA 572_1 -18.69 5786
    572 TTTATCAATATCTTCTCA 3-2-1-6-1-1-1-1-2 TTTatCaatatoTtCtCA 572_2 -19.36 5786
    572 TTTATCAATATCTTCTCA 1-4-1-6-1-1-4 TttatCaatatoTtCTCA 572_3 -19.19 5786
    572 TTTATCAATATCTTCTCA 1-2-3-6-1-2-3 TttATCaatatoTtcTCA 572_4 -19.56 5786
    572 TTTATCAATATCTTCTCA 4-1-1-7-1-2-2 TTTAtCaatatotTctCA 572_5 -19.37 5786
    572 TTTATCAATATCTTCTCA 1-2-3-8-1-1-2 TttATCaatatottCtCA 572_6 -18.83 5786
    572 TTTATCAATATCTTCTCA 3-2-1-9-3 TTTatCaatatottcTCA 572_7 -19.07 5786
    572 TTTATCAATATCTTCTCA 1-2-1-10-4 TttAtcaatatottCTCA 572_8 -18.10 5786
    572 TTTATCAATATCTTCTCA 4-10-1-1-2 TTTAtcaatatottCtCA 572_9 -19.31 5786
    572 TTTATCAATATCTTCTCA 2-1-3-6-1-1-1-1-2 TTTATCaatatoTtCtCA 572_10 -20.15 5786
    572 TTTATCAATATCTTCTCA 3-2-1-6-1-2-3 TTTatCaatatoTtcTCA 572_11 -19.59 5786
    572 TTTATCAATATCTTCTCA 1-1-2-1-1-7-2-1-2 TtTAtCaatatotTCtCA 572_12 -19.64 5786
    572 TTTATCAATATCTTCTCA 4-9-1-1-3 TTTAtcaatatotTcTCA 572_13 -19.90 5786
    572 TTTATCAATATCTTCTCA 1-3-2-8-4 TttaTCaatatcttCTCA 572_14 -19.80 5786
    573 TATACCTTTCTTTAACCCTT 1-4-1-10-1-1-2 TatacCtttctttaacCcTT 573_1 -22.72 8116
    573 TATACCTTTCTTTAACCCTT 2-4-1-11-2 TAtaccTttctttaacccTT 573_2 -22.80 8116
    573 TATACCTTTCTTTAACCCTT 1-3-1-10-1-2-2 TataCctttctttaaCccTT 573_3 -22.72 8116
    573 TATACCTTTCTTTAACCCTT 1-4-1-9-1-2-2 TatacCtttctttaaCccTT 573_4 -22.82 8116
    573 TATACCTTTCTTTAACCCTT 1-5-1-9-1-1-2 TataccTttctttaacCcTT 573_5 -22.35 8116
    573 TATACCTTTCTTTAACCCTT 1-5-1-1-1-2 TatacctttctttaacCcTT 573_6 -21.83 8116
    573 TATACCTTTCTTTAACCCTT 1-2-1-1-1-10-1-1-2 TatAcCtttctttaacCcTT 573_7 -22.91 8116
    573 TATACCTTTCTTTAACCCTT 2-2-1-1-1-11-2 TAtaCcTttctttaacccTT 573_8 -23.58 8116
    573 TATACCTTTCTTTAACCCTT 2-3-1-12-2 TAtacCtttctttaacccTT 573_9 -23.17 8116
    573 TATACCTTTCTTTAACCCTT 1-3-1-8-2-1-1-1-2 TataCctttctttAAcCcTT 573_10 -23.35 8116
    573 TATACCTTTCTTTAACCCTT 2-2-1-1-1-7-1-1-1-1-2 TAtaCcTttctttaAcCcTT 573_11 -24.68 8116
    573 TATACCTTTCTTTAACCCTT 2-4-1-8-2-1-2 TAtaccTttctttaaCCcTT 573_12 -25.86 8116
    573 TATACCTTTCTTTAACCCTT 2-3-1-9-1-2-2 TAtacCtttctttaaCccTT 573_13 -23.96 8116
    573 TATACCTTTCTTTAACCCTT 2-3-1-10-1-1-2 TAtacCtttctttaacCcTT 573_14 -23.85 8116
    574 TTATACCTTTCTTTAACCCT 1-1-1-10-1-4-2 TtAtacctttcttTaaccCT 574_1 -22.31 8117
    574 TTATACCTTTCTTTAACCCT 1-13-1-1-1-1-2 TtatacctttctttAaCcCT 574_2 -22.38 8117
    574 TTATACCTTTCTTTAACCCT 1-1-1-3-1-11-2 TtAtacCtttctttaaccCT 574_3 -22.47 8117
    574 TTATACCTTTCTTTAACCCT 1-3-1-1-1-7-1-3-2 TtatAcCtttctttAaccCT 574_4 -22.68 8117
    574 TTATACCTTTCTTTAACCCT 1-4-1-8-1-3-2 TtataCctttctttAaccCT 574_5 -22.38 8117
    574 TTATACCTTTCTTTAACCCT 1-1-1-13-1-1-2 TtAtacctttctttaaCcCT 574_6 -22.36 8117
    574 TTATACCTTTCTTTAACCCT 1-3-1-11-1-1-2 TtatAcctttctttaaCcCT 574_7 -22.46 8117
    574 TTATACCTTTCTTTAACCCT 1-1-1-2-1-12-2 TtAtaCctttctttaaccCT 574_8 -22.36 8117
    574 TTATACCTTTCTTTAACCCT 1-5-1-11-2 TtatacCtttctttaaccCT 574_9 -22.37 8117
    574 TTATACCTTTCTTTAACCCT 1-1-1-2-1-10-1-1-2 TtAtaCctttctttaaCcCT 574_10 -23.14 8117
    574 TTATACCTTTCTTTAACCCT 1-1-1-3-1-9-1-1-2 TtAtacCtttctttaaCcCT 574_11 -23.25 8117
    574 TTATACCTTTCTTTAACCCT 1-1-1-3-1-10-3 TtAtacCtttctttaacCCT 574_12 -24.75 8117
    574 TTATACCTTTCTTTAACCCT 1-1-1-2-2-11-2 TtAtaCCtttctttaaccCT 574_13 -24.85 8117
    574 TTATACCTTTCTTTAACCCT 1-3-1-1-1-11-2 TtatAcCtttctttaaccCT 574_14 -22.56 8117
    575 TTTATACCTTTCTTTAACCC 1-2-1-9-1-4-2 TttAtacctttctTtaacCC 575_1 -21.69 8118
    575 TTTATACCTTTCTTTAACCC 1-12-1-4-2 TttatacctttctTtaacCC 575_2 -21.59 8118
    575 TTTATACCTTTCTTTAACCC 1-12-1-1-1-2-2 TttatacctttctTtAacCC 575_3 -21.71 8118
    575 TTTATACCTTTCTTTAACCC 1-4-1-10-1-1-2 TttatAcctttctttaAcCC 575_4 -21.90 8118
    575 TTTATACCTTTCTTTAACCC 1-13-1-3-2 TttatacctttcttTaacCC 575_5 -22.01 8118
    575 TTTATACCTTTCTTTAACCC 2-1-1-14-2 TTTAtacctttctttaacCC 575_6 -22.20 8118
    575 TTTATACCTTTCTTTAACCC 1-14-2-1-2 TttatacctttctttAAcCC 575_7 -22.02 8118
    575 TTTATACCTTTCTTTAACCC 1-14-1-2-2 TttatacctttctttAacCC 575_8 -21.41 8118
    575 TTTATACCTTTCTTTAACCC 1-15-1-1-2 TttatacctttctttaAcCC 575_9 -21.71 8118
    575 TTTATACCTTTCTTTAACCC 2-1-1-9-1-4-2 TTTAtacctttctTtaacCC 575_10 -22.50 8118
    575 TTTATACCTTTCTTTAACCC 1-2-1-10-1-3-2 TttAtacctttcttTaacCC 575_11 -22.11 8118
    575 TTTATACCTTTCTTTAACCC 1-4-2-8-2-1-2 TttatACctttctttAAcCC 575_12 -23.40 8118
    575 TTTATACCTTTCTTTAACCC 1-2-1-2-1-9-1-1-2 TttAtaCctttctttaAcCC 575_13 -22.59 8118
    575 TTTATACCTTTCTTTAACCC 1-1-2-14-2 TtTAtacctttctttaacCC 575_14 -23.15 8118
    576 TTTTATACCTTTCTTTAACC 1-1-1-10-2-3-2 TtTtatacctttcTTtaaCC 576_1 -21.12 8119
    576 TTTTATACCTTTCTTTAACC 1-3-1-8-1-4-2 TtttAtacctttcTttaaCC 576_2 -20.10 8119
    576 TTTTATACCTTTCTTTAACC 1-1-1-10-1-2-4 TtTtatacctttcTttAACC 576_3 -21.45 8119
    576 TTTTATACCTTTCTTTAACC 3-11-1-1-1-1-2 TTTtatacctttctTtAaCC 576_4 -21.54 8119
    576 TTTTATACCTTTCTTTAACC 2-4-1-7-1-3-2 TTttatAcctttctTtaaCC 576_5 -20.80 8119
    576 TTTTATACCTTTCTTTAACC 1-14-1-2-2 TtttatacctttcttTaaCC 576_6 -20.22 8119
    576 TTTTATACCTTTCTTTAACC 1-15-1-1-2 TtttatacctttctttAaCC 576_7 -19.61 8119
    576 TTTTATACCTTTCTTTAACC 1-5-1-10-3 TtttatAcctttctttaACC 576_8 -20.51 8119
    576 TTTTATACCTTTCTTTAACC 1-1-2-14-2 TtTTatacctttctttaaCC 576_9 -21.03 8119
    576 TTTTATACCTTTCTTTAACC 1-1-2-10-1-1-1-1-2 TtTTatacctttctTtAaCC 576_10 -21.46 8119
    576 TTTTATACCTTTCTTTAACC 2-2-1-9-1-3-2 TTttAtacctttctTtaaCC 576_11 -20.70 8119
    576 TTTTATACCTTTCTTTAACC 1-5-1-7-1-3-2 TtttatAcctttctTtaaCC 576_12 -19.99 8119
    576 TTTTATACCTTTCTTTAACC 1-1-1-12-2-1-2 TtTtatacctttcttTAaCC 576_13 -21.68 8119
    576 TTTTATACCTTTCTTTAACC 1-1-1-1-1-13-2 TtTtAtacctttctttaaCC 576_14 -19.89 8119
    577 TTTTTATACCTTTCTTTAAC 1-12-1-2-4 TttttatacctttCttTAAC 577_1 -19.19 8120
    577 TTTTTATACCTTTCTTTAAC 1-2-1-9-1-1-2-1-2 TttTtatacctttCtTTaAC 577_2 -18.96 8120
    577 TTTTTATACCTTTCTTTAAC 2-12-3-1-2 TTtttatacctttcTTTaAC 577_3 -19.52 8120
    577 TTTTTATACCTTTCTTTAAC 1-1-1-2-1-7-2-3-2 TtTttAtacctttCTttaAC 577_4 -18.71 8120
    577 TTTTTATACCTTTCTTTAAC 4-9-1-1-1-2-2 TTTTtatacctttCtTtaAC 577_5 -19.85 8120
    577 TTTTTATACCTTTCTTTAAC 3-1-1-8-1-1-1-1-3 TTTtTatacctttCtTtAAC 577_6 -20.08 8120
    577 TTTTTATACCTTTCTTTAAC 2-1-2-8-2-2-3 TTtTTatacctttCTttAAC 577_7 -20.97 8120
    577 TTTTTATACCTTTCTTTAAC 1-1-2-10-2-1-3 TtTTtatacctttcTTTAAC 577_8 -18.89 8120
    577 TTTTTATACCTTTCTTTAAC 1-3-2-7-1-4-2 TtttTAtacctttCtttaAC 577_9 -18.97 8120
    577 TTTTTATACCTTTCTTTAAC 1-2-1-9-2-1-1-1-2 TttTtatacctttCTtTaAC 577_10 -19.34 8120
    577 TTTTTATACCTTTCTTTAAC 2-3-1-7-2-2-3 TTtttAtacctttCTttAAC 577_11 -19.53 8120
    577 TTTTTATACCTTTCTTTAAC 1-1-2-9-1-1-1-1-3 TtTTtatacctttCtTtAAC 577_12 -18.84 8120
    577 TTTTTATACCTTTCTTTAAC 1-3-2-7-1-1-1-2-2 TtttTAtacctttCtTtaAC 577_13 -19.27 8120
    577 TTTTTATACCTTTCTTTAAC 3-1-1-8-1-2-1-1-2 TTTtTatacctttCttTaAC 577_14 -20.20 8120
    578 TTTTTTCTTACTATCTTCAA 1-5-1-7-2-2-2 TtttttCttactatCTtcAA 578_1 -19.02 8584
    578 TTTTTTCTTACTATCTTCAA 2-2-1-1-1-7-1-1-1-1-2 TTttTtCttactatCtTcAA 578_2 -19.31 8584
    578 TTTTTTCTTACTATCTTCAA 1-2-2-9-1-2-3 TttTTtcttactatCttCAA 578_3 -20.05 8584
    578 TTTTTTCTTACTATCTTCAA 1-1-1-1-1-1-1-7-1-3-2 TtTtTtCttactatCttcAA 578_4 -18.43 8584
    578 TTTTTTCTTACTATCTTCAA 3-3-1-8-1-2-2 TTTtttCttactatcTtcAA 578_5 -18.99 8584
    578 TTTTTTCTTACTATCTTCAA 2-1-2-1-1-8-1-2-2 TTtTTtCttactatcttcAA 578_6 -19.29 8584
    578 TTTTTTCTTACTATCTTCAA 1-1-3-1-1-9-1-1-2 TtTTTtCttactatctTcAA 578_7 -19.15 8584
    578 TTTTTTCTTACTATCTTCAA 2-1-1-11-1-1-3 TTtTttcttactatcTtCAA 578_8 -19.58 8584
    578 TTTTTTCTTACTATCTTCAA 1-4-1-10-4 TttttTcttactatctTCAA 578_9 -19.31 8584
    579 TTTTTTTCTTACTATCTTCA 1-12-1-1-1-2-2 TttttttcttactAtCttCA 579_1 -19.29 8585
    579 TTTTTTTCTTACTATCTTCA 2-1-1-9-1-4-2 TTtTtttcttactAtcttCA 579_2 -19.42 8585
    579 TTTTTTTCTTACTATCTTCA 1-1-1-2-1-7-1-4-2 TtTttTtcttactAtcttCA 579_3 -18.91 8585
    579 TTTTTTTCTTACTATCTTCA 1-1-2-9-1-2-1-1-2 TtTTtttcttactAtcTtCA 579_4 -19.94 8585
    579 TTTTTTTCTTACTATCTTCA 1-3-2-10-1-1-2 TttttTtcttactatcTtCA 579_5 -19.84 8585
    579 TTTTTTTCTTACTATCTTCA 2-3-1-12-2 TTtttTtcttactatcttCA 579_6 -19.33 8585
    579 TTTTTTTCTTACTATCTTCA 3-15-2 TTTttttcttactatcttCA 579_7 -19.84 8585
    579 TTTTTTTCTTACTATCTTCA 1-2-2-13-2 TttTTttcttactatcttCA 579_8 -19.33 8585
    579 TTTTTTTCTTACTATCTTCA 1-14-1-2-2 TttttttcttactatCttCA 579_9 -19.19 8585
    580 ATTTTTTTCTTACTATCTTC 1-4-1-8-1-1-1-1-2 AttttTttcttactAtCtTC 580_1 -18.09 8586
    580 ATTTTTTTCTTACTATCTTC 2-1-1-10-1-2-3 ATtTttttcttactAtcTTC 580_2 -19.39 8586
    580 ATTTTTTTCTTACTATCTTC 1-3-2-8-1-2-3 AtttTTttcttactAtcTTC 580_3 -18.95 8586
    580 ATTTTTTTCTTACTATCTTC 1-5-1-6-1-3-3 AtttttTtcttacTatcTTC 580_4 -18.98 8586
    580 ATTTTTTTCTTACTATCTTC 2-2-1-1-1-7-1-3-2 ATttTtTtcttactAtctTC 580_5 -18.66 8586
    580 ATTTTTTTCTTACTATCTTC 1-1-3-8-1-4-2 AtTTTtttcttacTatctTC 580_6 -19.58 8586
    580 ATTTTTTTCTTACTATCTTC 2-1-1-12-1-1-2 ATtTttttcttactatCtTC 580_7 -19.24 8586
    580 ATTTTTTTCTTACTATCTTC 1-1-1-2-1-11-3 AtTttTttcttactatcTTC 580_8 -18.34 8586
    580 ATTTTTTTCTTACTATCTTC 1-1-2-1-2-11-2 AtTTtTTtcttactatctTC 580_9 -18.94 8586
    581 AATTTTTTTCTTACTATCTT 1-4-1-7-1-1-1-1-3 AatttTtttcttaCtAtCTT 581_1 -18.53 8587
    581 AATTTTTTTCTTACTATCTT 1-3-1-1-1-6-2-3-2 AattTtTttcttaCTatcTT 581_2 -18.69 8587
    581 AATTTTTTTCTTACTATCTT 1-1-2-10-2-2-2 AaTTtttttcttacTAtcTT 581_3 -18.80 8587
    581 AATTTTTTTCTTACTATCTT 2-1-1-1-1-8-1-2-3 AAtTtTtttcttacTatCTT 581_4 -19.20 8587
    581 AATTTTTTTCTTACTATCTT 4-2-1-7-1-3-2 AATTtttttcttacTatcTT 581_5 -19.30 8587
    581 AATTTTTTTCTTACTATCTT 2-2-2-7-1-1-2-1-2 AAtttTtttcttaCtATcTT 581_6 -19.52 8587
    581 AATTTTTTTCTTACTATCTT 1-12-1-2-4 AatttttttcttaCtaTCTT 581_7 -19.25 8587
    581 AATTTTTTTCTTACTATCTT 1-1-4-7-1-4-2 AaTTTTtttcttaCtatcTT 581_8 -19.35 8587
    581 AATTTTTTTCTTACTATCTT 2-1-3-9-1-1-3 AAtTTTtttcttactAtCTT 581_9 -19.68 8587
    582 GTTTATACCCTTTCCAAT 1-1-1-1-1-7-2-2-2 GtTtAtacccttTCcaAT 582_1 -21.48 9209
    582 GTTTATACCCTTTCCAAT 1-12-2-1-2 GtttataccctttCCaAT 582_2 -22.28 9209
    582 GTTTATACCCTTTCCAAT 1-3-1-8-1-1-3 GtttAtaccctttCcAAT 582_3 -20.46 9209
    582 GTTTATACCCTTTCCAAT 1-1-1-1-1-9-1-1-2 GtTtAtaccctttcCaAT 582_4 -20.30 9209
    582 GTTTATACCCTTTCCAAT 2-11-1-2-2 GTttataccctttCcaAT 582_5 -21.64 9209
    582 GTTTATACCCTTTCCAAT 1-1-2-9-1-1-3 GtTTataccctttCcAAT 582_6 -21.90 9209
    582 GTTTATACCCTTTCCAAT 1-1-1-13-2 GtTtataccctttccaAT 582_7 -19.63 9209
    582 GTTTATACCCTTTCCAAT 1-2-1-12-2 GttTataccctttccaAT 582_8 -20.05 9209
    582 GTTTATACCCTTTCCAAT 1-13-4 GtttataccctttcCAAT 582_9 -21.59 9209
    583 TGTTTATACCCTTTCCAA 2-1-1-10-1-1-2 TGtTtataccctttCcAA 583_1 -21.08 9210
    583 TGTTTATACCCTTTCCAA 1-4-1-6-1-1-1-1-2 TgtttAtaccctTtCcAA 583_2 -19.97 9210
    583 TGTTTATACCCTTTCCAA 1-3-1-9-1-1-2 TgttTataccctttCcAA 583_3 -20.30 9210
    583 TGTTTATACCCTTTCCAA 2-1-1-1-1-6-1-3-2 TGtTtAtaccctTtccAA 583_4 -20.71 9210
    583 TGTTTATACCCTTTCCAA 1-2-1-8-1-2-3 TgtTtataccctTtcCAA 583_5 -21.40 9210
    583 TGTTTATACCCTTTCCAA 1-4-1-9-3 TgtttAtaccctttcCAA 583_6 -20.89 9210
    583 TGTTTATACCCTTTCCAA 1-1-2-12-2 TgTTtataccctttccAA 583_7 -20.27 9210
    583 TGTTTATACCCTTTCCAA 1-12-2-1-2 TgtttatacccttTCcAA 583_8 -20.56 9210
    583 TGTTTATACCCTTTCCAA 2-2-1-11-2 TGttTataccctttccAA 583_9 -20.74 9210
    584 CTGTTTATACCCTTTCCA 1-1-1-10-1-2-2 CtGtttataccctTtcCA 584_1 -22.45 9211
    584 CTGTTTATACCCTTTCCA 1-12-1-2-2 CtgtttataccctTtcCA 584_2 -22.14 9211
    584 CTGTTTATACCCTTTCCA 1-1-1-1-1-11-2 CtGtTtataccctttcCA 584_3 -22.45 9211
    584 CTGTTTATACCCTTTCCA 1-1-1-13-2 CtGtttataccctttcCA 584_4 -22.15 9211
    584 CTGTTTATACCCTTTCCA 1-2-1-12-2 CtgTttataccctttcCA 584_5 -22.50 9211
    584 CTGTTTATACCCTTTCCA 1-3-1-11-2 CtgtTtataccctttcCA 584_6 -22.14 9211
    584 CTGTTTATACCCTTTCCA 1-4-1-10-2 CtgttTataccctttcCA 584_7 -22.57 9211
    584 CTGTTTATACCCTTTCCA 1-15-2 CtgtttataccctttcCA 584_8 -21.84 9211
    585 AATTATTTATACACCATCAT 2-1-1-1-1-8-3-1-2 AAtTaTttatacacCATcAT 585_1 -20.76 11511
    585 AATTATTTATACACCATCAT 3-2-2-6-1-1-2-1-2 AATtaTTtatacaCcATcAT 585_2 -20.88 11511
    585 AATTATTTATACACCATCAT 1-4-1-7-2-1-1-1-2 AattaTttatacaCCaTcAT 585_3 -19.62 11511
    585 AATTATTTATACACCATCAT 1-3-1-1-1-6-1-3-3 AattAtTtatacaCcatCAT 585_4 -18.98 11511
    585 AATTATTTATACACCATCAT 1-2-3-7-1-1-1-2-2 AatTATttatacaCcAtcAT 585_5 -19.65 11511
    585 AATTATTTATACACCATCAT 1-1-2-11-1-1-3 AaTTatttatacaccAtCAT 585_6 -19.53 11511
    585 AATTATTTATACACCATCAT 2-2-1-9-1-1-4 AAttAtttatacacCaTCAT 585_7 -20.11 11511
    585 AATTATTTATACACCATCAT 3-1-2-8-1-2-3 AATTATttatacacCatCAT 585_8 -21.48 11511
    585 AATTATTTATACACCATCAT 4-2-1-7-1-3-2 AATTatTtatacacCatcAT 585_9 -19.60 11511
    585 AATTATTTATACACCATCAT 2-1-1-2-1-6-3-2-2 AAtTatTtatacaCCAtcAT 585_10 -21.69 11511
    585 AATTATTTATACACCATCAT 1-3-2-7-1-1-1-1-3 AattATttatacaCcAtCAT 585_11 -19.97 11511
    585 AATTATTTATACACCATCAT 2-1-3-8-1-1-1-1-2 AAtTATttatacacCaTcAT 585_12 -20.42 11511
    585 AATTATTTATACACCATCAT 1-1-2-1-1-8-1-2-3 AaTTaTttatacacCatCAT 585_13 -20.49 11511
    585 AATTATTTATACACCATCAT 2-1-1-2-1-9-4 AAtTatTtatacaccaTCAT 585_14 -20.47 11511
    586 AAATTATTTATACACCATCA 1-12-3-1-3 AaattatttatacACCaTCA 586_1 -20.58 11512
    586 AAATTATTTATACACCATCA 1-1-1-2-1-7-1-1-2-1-2 AaAttAtttatacAcCAtCA 586_2 -18.56 11512
    586 AAATTATTTATACACCATCA 3-2-2-6-2-3-2 AAAttATttatacACcatCA 586_3 -19.68 11512
    586 AAATTATTTATACACCATCA 4-10-1-2-3 AAATtatttatacaCcaTCA 586_4 -20.15 11512
    586 AAATTATTTATACACCATCA 1-1-4-8-1-1-1-1-2 AaATTAtttatacaCcAtCA 586_5 -20.72 11512
    586 AAATTATTTATACACCATCA 2-1-2-1-1-7-1-3-2 AAaTTaTttatacaCcatCA 586_6 -19.39 11512
    586 AAATTATTTATACACCATCA 1-3-2-7-1-1-1-1-3 AaatTAtttatacAcCaTCA 586_7 -19.65 11512
    586 AAATTATTTATACACCATCA 1-1-3-8-1-2-4 AaATTatttatacAccATCA 586_8 -20.88 11512
    586 AAATTATTTATACACCATCA 2-2-1-1-1-9-4 AAatTaTttatacaccATCA 586_9 -19.63 11512
    586 AAATTATTTATACACCATCA 1-1-1-1-1-1-1-6-3-2-2 AaAtTaTttatacACCatCA 586_10 -20.95 11512
    586 AAATTATTTATACACCATCA 1-3-2-7-1-1-2-1-2 AaatTAtttatacAcCAtCA 586_11 -20.00 11512
    586 AAATTATTTATACACCATCA 2-1-2-1-1-7-1-1-1-1-2 AAaTTaTttatacaCcAtCA 586_12 -19.44 11512
    586 AAATTATTTATACACCATCA 3-2-1-8-1-2-3 AAAttAtttatacaCcaTCA 586_13 -19.00 11512
    586 AAATTATTTATACACCATCA 1-1-4-9-1-1-3 AaATTAtttatacacCaTCA 586_14 -21.59 11512
    587 AAAATTATTTATACACCATC 2-3-1-7-1-1-5 AAaatTatttataCaCCATC 587_1 -21.17 11513
    587 AAAATTATTTATACACCATC 1-2-2-9-6 AaaATtatttatacACCATC 587_2 -21.34 11513
    587 AAAATTATTTATACACCATC 2-3-2-6-3-1-3 AAaatTAtttataCACcATC 587_3 -20.67 11513
    587 AAAATTATTTATACACCATC 3-1-1-1-1-7-3-1-2 AAAaTtAtttatacACCaTC 587_4 -19.11 11513
    587 AAAATTATTTATACACCATC 7-6-1-1-1-2-2 AAAATTAtttataCaCcaTC 587_5 -20.66 11513
    587 AAAATTATTTATACACCATC 1-1-1-1-2-8-2-1-3 AaAaTTatttatacACcATC 587_6 -18.20 11513
    587 AAAATTATTTATACACCATC 1-1-5-6-2-3-2 AaAATTAtttataCAccaTC 587_7 -20.71 11513
    587 AAAATTATTTATACACCATC 2-1-3-7-1-2-4 AAaATTatttataCacCATC 587_8 -20.87 11513
    587 AAAATTATTTATACACCATC 4-1-1-8-1-1-4 AAAAtTatttatacAcCATC 587_9 -19.30 11513
    587 AAAATTATTTATACACCATC 1-1-2-1-2-6-3-2-2 AaAAtTAtttataCACcaTC 587_10 -20.13 11513
    587 AAAATTATTTATACACCATC 1-2-3-7-1-1-2-1-2 AaaATTatttataCaCCaTC 587_11 -20.44 11513
    587 AAAATTATTTATACACCATC 3-1-2-7-1-2-4 AAAaTTatttataCacCATC 587_12 -20.27 11513
    587 AAAATTATTTATACACCATC 3-2-1-8-3-1-2 AAAatTatttatacACCaTC 587_13 -19.30 11513
    587 AAAATTATTTATACACCATC 2-1-3-8-2-1-3 AAaATTatttatacACcATC 587_14 -19.52 11513
    588 TAAAATTATTTATACACCAT 2-3-1-7-1-1-5 TAaaaTtatttatAcACCAT 588_1 -20.14 11514
    588 TAAAATTATTTATACACCAT 1-2-1-2-1-6-2-1-4 TaaAatTatttatACaCCAT 588_2 -20.15 11514
    588 TAAAATTATTTATACACCAT 1-1-1-1-2-8-1-1-4 TaAaATtatttataCaCCAT 588_3 -20.40 11514
    588 TAAAATTATTTATACACCAT 4-1-2-6-4-1-2 TAAAaTTatttatACACcAT 588_4 -21.36 11514
    588 TAAAATTATTTATACACCAT 1-3-3-6-3-1-3 TaaaATTatttatACAcCAT 588_5 -21.07 11514
    588 TAAAATTATTTATACACCAT 2-1-4-7-3-1-2 TAaAATTatttataCACcAT 588_6 -21.36 11514
    588 TAAAATTATTTATACACCAT 3-1-1-1-1-7-2-1-3 TAAaAtTatttataCAcCAT 588_7 -20.41 11514
    588 TAAAATTATTTATACACCAT 7-6-1-3-3 TAAAATTatttatAcacCAT 588_8 -20.85 11514
    588 TAAAATTATTTATACACCAT 2-1-2-11-4 TAaAAttatttatacaCCAT 588_9 -19.82 11514
    588 TAAAATTATTTATACACCAT 2-2-3-6-4-1-2 TAaaATTatttatACACcAT 588_10 -21.41 11514
    588 TAAAATTATTTATACACCAT 1-1-1-1-3-6-1-2-4 TaAaATTatttatAcaCCAT 588_11 -21.15 11514
    588 TAAAATTATTTATACACCAT 2-1-2-1-1-7-2-1-3 TAaAAtTatttataCAcCAT 588_12 -20.41 11514
    588 TAAAATTATTTATACACCAT 3-2-2-7-1-1-4 TAAaaTTatttataCaCCAT 588_13 -21.86 11514
    588 TAAAATTATTTATACACCAT 1-1-2-1-1-9-5 TaAAaTtatttatacACCAT 588_14 -19.68 11514
    589 TAAAATTATTTATACACCA 1-1-2-1-1-7-6 TaAAaTtatttatACACCA 589_1 -20.31 11515
    589 TAAAATTATTTATACACCA 1-2-3-6-1-1-5 TaaAATtatttaTaCACCA 589_2 -21.36 11515
    589 TAAAATTATTTATACACCA 2-3-1-7-6 TAaaaTtatttatACACCA 589_3 -20.58 11515
    589 TAAAATTATTTATACACCA 3-1-2-6-4-1-2 TAAaATtatttaTACAcCA 589_4 -21.36 11515
    589 TAAAATTATTTATACACCA 4-1-1-6-2-2-3 TAAAaTtatttaTAcaCCA 589_5 -20.51 11515
    589 TAAAATTATTTATACACCA 2-1-2-7-1-1-1-1-3 TAaAAttatttaTaCaCCA 589_6 -19.30 11515
    589 TAAAATTATTTATACACCA 1-3-2-6-2-2-3 TaaaATtatttaTAcaCCA 589_7 -19.40 11515
    589 TAAAATTATTTATACACCA 5-8-2-1-3 TAAAAttatttatACaCCA 589_8 -19.77 11515
    589 TAAAATTATTTATACACCA 3-1-2-9-4 TAAaATtatttatacACCA 589_9 -19.55 11515
    589 TAAAATTATTTATACACCA 2-1-3-6-4-1-2 TAaAATtatttaTACAcCA 589_10 -21.36 11515
    589 TAAAATTATTTATACACCA 3-1-2-6-3-1-3 TAAaATtatttaTACaCCA 589_11 -22.18 11515
    589 TAAAATTATTTATACACCA 1-1-3-7-2-1-4 TaAAAttatttaTAcACCA 589_12 -19.78 11515
    589 TAAAATTATTTATACACCA 2-2-1-7-1-1-1-1-3 TAaaAttatttaTaCaCCA 589_13 -18.76 11515
    589 TAAAATTATTTATACACCA 4-1-1-8-5 TAAAaTtatttataCACCA 589_14 -21.06 11515
    590 ATATTGATTCAATTCCC 2-9-2-1-3 ATattgattcaATtCCC 590_1 -21.84 13226
    590 ATATTGATTCAATTCCC 1-2-1-7-6 AtaTtgattcaATTCCC 590_2 -22.10 13226
    590 ATATTGATTCAATTCCC 2-9-1-1-1-1-2 ATattgattcaAtTcCC 590_3 -18.59 13226
    590 ATATTGATTCAATTCCC 1-1-2-8-5 AtATtgattcaaTTCCC 590_4 -21.87 13226
    590 ATATTGATTCAATTCCC 1-2-2-7-2-1-2 AtaTTgattcaaTTcCC 590_5 -19.29 13226
    590 ATATTGATTCAATTCCC 1-3-1-6-2-2-2 AtatTgattcaATtcCC 590_6 -18.59 13226
    590 ATATTGATTCAATTCCC 1-2-2-6-1-2-3 AtaTTgattcaAttCCC 590_7 -20.66 13226
    590 ATATTGATTCAATTCCC 1-1-1-1-1-7-1-1-3 AtAtTgattcaaTtCCC 590_8 -19.92 13226
    590 ATATTGATTCAATTCCC 1-1-1-8-1-2-3 AtAttgattcaAttCCC 590_9 -19.01 13226
    590 ATATTGATTCAATTCCC 4-7-1-3-2 ATATtgattcaAttcCC 590_10 -20.60 13226
    590 ATATTGATTCAATTCCC 3-1-1-7-1-2-2 ATAtTgattcaaTtcCC 590_11 -20.26 13226
    590 ATATTGATTCAATTCCC 1-3-1-8-4 AtatTgattcaatTCCC 590_12 -20.37 13226
    590 ATATTGATTCAATTCCC 2-1-1-10-3 ATaTtgattcaattCCC 590_13 -20.71 13226
    590 ATATTGATTCAATTCCC 2-2-1-9-3 ATatTgattcaattCCC 590_14 -21.06 13226
    590 ATATTGATTCAATTCCC 1-1-3-10-2 AtATTgattcaattcCC 590_15 -18.87 13226
    590 ATATTGATTCAATTCCC 2-2-1-6-2-2-2 ATatTgattcaATtcCC 590_16 -20.26 13226
    590 ATATTGATTCAATTCCC 3-8-1-1-4 ATAttgattcaAtTCCC 590_17 -22.71 13226
    590 ATATTGATTCAATTCCC 1-1-3-6-1-2-3 AtATTgattcaAttCCC 590_18 -21.57 13226
    590 ATATTGATTCAATTCCC 1-1-1-1-1-7-5 AtAtTgattcaaTTCCC 590_19 -21.42 13226
    590 ATATTGATTCAATTCCC 2-1-1-8-1-1-3 ATaTtgattcaaTtCCC 590_20 -21.15 13226
    591 GCACATTCTTTCTATACCT 1-1-1-1-1-12-2 GcAcAttctttctatacCT 591_1 -21.27 15113
    591 GCACATTCTTTCTATACCT 1-3-1-12-2 GcacAttctttctatacCT 591_2 -21.12 15113
    592 GCACATTCTTTCTATACC 1-12-1-2-2 GcacattctttctAtaCC 592_1 -20.07 15114
    592 GCACATTCTTTCTATACC 1-1-1-1-1-11-2 GcAcAttctttctataCC 592_2 -20.17 15114
    592 GCACATTCTTTCTATACC 1-3-1-11-2 GcacAttctttctataCC 592_3 -20.02 15114
    592 GCACATTCTTTCTATACC 1-1-2-11-3 GcACattctttctatACC 592_4 -21.80 15114
    592 GCACATTCTTTCTATACC 1-1-1-1-2-7-1-1-3 GcAcATtctttctAtACC 592_5 -22.11 15114
    592 GCACATTCTTTCTATACC 1-1-1-1-2-7-1-2-2 GcAcATtctttctAtaCC 592_6 -21.51 15114
    592 GCACATTCTTTCTATACC 1-15-2 GcacattctttctataCC 592_7 -19.97 15114
    592 GCACATTCTTTCTATACC 1-4-1-9-3 GcacaTtctttctatACC 592_8 -21.01 15114
    592 GCACATTCTTTCTATACC 1-4-1-10-2 GcacaTtctttctataCC 592_9 -20.41 15114
    592 GCACATTCTTTCTATACC 2-11-1-2-2 GCacattctttctAtaCC 592_10 -22.39 15114
    592 GCACATTCTTTCTATACC 1-1-1-1-1-8-1-2-2 GcAcAttctttctAtaCC 592_11 -20.27 15114
    592 GCACATTCTTTCTATACC 1-3-1-9-1-1-2 GcacAttctttctaTaCC 592_12 -20.89 15114
    592 GCACATTCTTTCTATACC 1-1-1-1-1-10-3 GcAcAttctttctatACC 592_13 -20.77 15114
    592 GCACATTCTTTCTATACC 1-1-1-2-1-10-2 GcAcaTtctttctataCC 592_14 -20.56 15114
    593 TTATTTCCATTTATTTTCA 1-1-1-1-1-8-3-1-2 TtAtTtccatttaTTTtCA 593_1 -19.10 15563
    593 TTATTTCCATTTATTTTCA 1-2-2-7-1-1-1-1-3 TtaTTtccatttAtTtTCA 593_2 -19.27 15563
    593 TTATTTCCATTTATTTTCA 2-2-1-8-1-1-1-1-2 TTatTtccatttaTtTtCA 593_3 -18.92 15563
    593 TTATTTCCATTTATTTTCA 1-1-2-9-1-2-3 TtATttccatttaTttTCA 593_4 -19.41 15563
    594 TTTATTTCCATTTATTTTCA 1-1-1-11-1-2-3 TtTatttccatttaTttTCA 594_1 -19.80 15563
    594 TTTATTTCCATTTATTTTCA 1-4-1-7-1-1-1-2-2 TttatTtccatttAtTttCA 594_2 -18.34 15563
    594 TTTATTTCCATTTATTTTCA 1-3-2-9-2-1-2 TttaTTtccatttatTTtCA 594_3 -20.01 15563
    594 TTTATTTCCATTTATTTTCA 2-1-1-1-1-8-1-1-1-1-2 TTTAtTtccatttaTtTtCA 594_4 -19.60 15563
    595 ATTTATTTCCATTTATTTTC 1-1-1-2-1-8-3-1-2 AtTtaTttccatttATTtTC 595_1 -19.05 15564
    595 ATTTATTTCCATTTATTTTC 1-3-2-7-1-3-3 AtttATttccattTattTTC 595_2 -19.03 15564
    595 ATTTATTTCCATTTATTTTC 1-1-2-10-1-2-3 AtTTatttccatttAttTTC 595_3 -18.60 15564
    595 ATTTATTTCCATTTATTTTC 2-1-1-1-1-8-1-1-1-1-2 ATtTaTttccatttAtTtTC 595_4 -18.96 15564
    596 TTTATTTCCATTTATTTTC 1-1-1-1-1-8-2-1-3 TtTaTttccatttATtTTC 596_1 -18.66 15564
    596 TTTATTTCCATTTATTTTC 3-2-1-7-3-1-2 TTTatTtccatttATTtTC 596_2 -19.84 15564
    596 TTTATTTCCATTTATTTTC 2-2-2-7-1-1-4 TTtaTTtccatttAtTTTC 596_3 -19.12 15564
    596 TTTATTTCCATTTATTTTC 5-7-1-3-3 TTTATttccattTattTTC 596_4 -21.30 15564
    597 CCATTTATTTCCATTTATTT 1-1-1-11-2-2-2 CcAtttatttccatTTatTT 597_1 -19.89 15566
    597 CCATTTATTTCCATTTATTT 1-3-1-9-1-1-1-1-2 CcatTtatttccatTtAtTT 597_2 -19.00 15566
    597 CCATTTATTTCCATTTATTT 1-1-1-2-1-8-1-2-3 CcAttTatttccatTtaTTT 597_3 -20.33 15566
    597 CCATTTATTTCCATTTATTT 1-2-2-1-1-11-2 CcaTTTAtttccatttatTT 597_4 -19.64 15566
    598 TCCATTTATTTCCATTTATT 2-11-2-3-2 TCcatttatttccATttaTT 598_1 -21.22 15567
    598 TCCATTTATTTCCATTTATT 2-2-1-8-1-1-1-2-2 TCcaTttatttccAtTtaTT 598_2 -20.71 15567
    598 TCCATTTATTTCCATTTATT 1-1-2-9-1-4-2 TcCAtttatttccAtttaTT 598_3 -20.63 15567
    598 TCCATTTATTTCCATTTATT 2-1-1-1-1-11-3 TCcAtTtatttccatttATT 598_4 -21.18 15567
    599 TCCATTTATTTCCATTTAT 2-11-2-2-2 TCcatttatttccATttAT 599_1 -20.30 15568
    599 TCCATTTATTTCCATTTAT 2-2-1-8-1-1-1-1-2 TCcaTttatttccAtTTAT 599_2 -19.80 15568
    599 TCCATTTATTTCCATTTAT 1-1-2-9-1-3-2 TcCAtttatttccAtttAT 599_3 -19.72 15568
    599 TCCATTTATTTCCATTTAT 1-1-1-1-2-7-1-3-2 TcCaTTtatttccAtttAT 599_4 -19.50 15568
    600 TTCCATTTATTTCCATTTAT 1-1-1-2-1-8-1-1-1-1-2 TtCcaTttatttccAtTtAT 600_1 -20.12 15568
    600 TTCCATTTATTTCCATTTAT 1-3-1-10-2-1-2 TtccAtttatttccaTTTAT 600_2 -19.86 15568
    600 TTCCATTTATTTCCATTTAT 1-1-1-3-1-7-1-3-2 TtCcatTtatttccAtttAT 600_3 -19.68 15568
    600 TTCCATTTATTTCCATTTAT 1-1-1-1-2-8-1-3-2 TtCcATttatttccAtttAT 600_4 -20.68 15568
    601 TTTCCATTTATTTCCATTTA 1-4-1-7-1-2-1-1-2 TttccAtttatttCcaTtTA 601_1 -20.53 15569
    601 TTTCCATTTATTTCCATTTA 2-2-1-12-3 TTtcCatttatttccatTTA 601_2 -21.47 15569
    601 TTTCCATTTATTTCCATTTA 1-2-1-2-1-8-1-2-2 TttCcaTttatttccAttTA 601_3 -20.53 15569
    601 TTTCCATTTATTTCCATTTA 1-4-1-9-1-2-2 TttccAtttatttccAttTA 601_4 -19.37 15569
    602 CTTTCCATTTATTTCCATT 1-11-1-1-1-1-3 CtttccatttatTtCcATT 602_1 -21.20 15571
    602 CTTTCCATTTATTTCCATT 2-2-1-9-1-2-2 CTttCcatttatttCcaTT 602_2 -22.00 15571
    602 CTTTCCATTTATTTCCATT 1-4-1-9-1-1-2 CtttcCatttatttcCaTT 602_3 -20.42 15571
    602 CTTTCCATTTATTTCCATT 1-3-1-11-3 CtttCcatttatttccATT 602_4 -20.89 15571
    603 ATCTTTCCATTTATTTCCAT 1-2-1-12-1-1-2 AtcTttccatttatttCcAT 603_1 -21.24 15572
    603 ATCTTTCCATTTATTTCCAT 1-3-1-1-1-7-1-3-2 AtctTtCcatttatTtccAT 603_2 -21.33 15572
    603 ATCTTTCCATTTATTTCCAT 1-5-1-6-1-4-2 AtctttCcatttaTttccAT 603_3 -21.16 15572
    603 ATCTTTCCATTTATTTCCAT 1-16-3 AtctttccatttatttcCAT 603_4 -21.95 15572
    604 TCTTTCCATTTATTTCCAT 2-13-1-1-2 TCtttccatttatttCcAT 604_1 -21.57 15572
    604 TCTTTCCATTTATTTCCAT 1-2-1-1-1-7-1-1-1-1-2 TctTtCcatttatTtCcAT 604_2 -21.35 15572
    604 TCTTTCCATTTATTTCCAT 2-14-3 TCtttccatttatttcCAT 604_3 -22.80 15572
    604 TCTTTCCATTTATTTCCAT 2-3-1-11-2 TCtttCcatttatttccAT 604_4 -21.57 15572
    605 ATCTTTCCATTTATTTCCA 1-2-1-10-1-2-2 AtcTttccatttatTtcCA 605_1 -20.70 15573
    605 ATCTTTCCATTTATTTCCA 1-3-1-8-1-3-2 AtctTtccatttaTttcCA 605_2 -20.63 15573
    605 ATCTTTCCATTTATTTCCA 1-1-1-14-2 AtCtttccatttatttcCA 605_3 -20.86 15573
    605 ATCTTTCCATTTATTTCCA 1-4-1-9-1-1-2 AtcttTccatttattTcCA 605_4 -20.63 15573
    606 TATCTTTCCATTTATTTCCA 1-4-1-8-2-2-2 TatctTtccatttaTTtcCA 606_1 -22.54 15573
    606 TATCTTTCCATTTATTTCCA 2-16-2 TAtctttccatttatttcCA 606_2 -22.12 15573
    606 TATCTTTCCATTTATTTCCA 1-2-1-14-2 TatCtttccatttatttcCA 606_3 -21.97 15573
    606 TATCTTTCCATTTATTTCCA 1-17-2 TatctttccatttatttcCA 606_4 -20.99 15573
    607 TATCTTTCCATTTATTTCC 2-12-1-2-2 TAtctttccatttaTttCC 607_1 -21.63 15574
    607 TATCTTTCCATTTATTTCC 1-2-1-13-2 TatCtttccatttatttCC 607_2 -21.04 15574
    607 TATCTTTCCATTTATTTCC 1-2-2-12-2 TatCTttccatttatttCC 607_3 -22.23 15574
    607 TATCTTTCCATTTATTTCC 1-4-1-9-1-1-2 TatctTtccatttatTtCC 607_4 -20.66 15574
    608 AAATCTCAACTACCATTTTT 1-1-1-3-1-7-3-1-2 AaAtctCaactaccATTtTT 608_1 -19.53 25248
    608 AAATCTCAACTACCATTTTT 3-1-1-9-2-1-3 AAAtCtcaactaccATtTTT 608_2 -20.58 25248
    608 AAATCTCAACTACCATTTTT 1-3-1-8-1-1-5 AaatCtcaactacCaTTTTT 608_3 -20.56 25248
    608 AAATCTCAACTACCATTTTT 1-1-1-2-1-7-2-2-3 AaAtcTcaactacCAttTTT 608_4 -20.20 25248
    608 AAATCTCAACTACCATTTTT 1-3-1-1-1-6-1-1-1-2-2 AaatCtCaactacCaTttTT 608_5 -19.10 25248
    608 AAATCTCAACTACCATTTTT 2-3-2-6-1-2-4 AAatcTCaactacCatTTTT 608_6 -21.04 25248
    608 AAATCTCAACTACCATTTTT 2-1-2-1-1-7-1-3-2 AAaTCtCaactaccAtttTT 608_7 -19.79 25248
    608 AAATCTCAACTACCATTTTT 1-1-3-11-1-1-2 AaATCtcaactaccatTtTT 608_8 -19.97 25248
    608 AAATCTCAACTACCATTTTT 3-1-1-1-1-10-3 AAAtCtCaactaccattTTT 608_9 -19.95 25248
    609 AAAATCTCAACTACCATTTT 1-12-4-1-2 AaaatctcaactaCCATtTT 609_1 -21.31 25249
    609 AAAATCTCAACTACCATTTT 3-11-2-1-3 AAAatctcaactacCAtTTT 609_2 -19.57 25249
    609 AAAATCTCAACTACCATTTT 2-1-1-1-1-8-2-1-3 AAaAtCtcaactacCAtTTT 609_3 -20.33 25249
    609 AAAATCTCAACTACCATTTT 1-1-4-9-1-2-2 AaAATCtcaactaccAttTT 609_4 -19.46 25249
    609 AAAATCTCAACTACCATTTT 1-1-2-2-1-7-2-2-2 AaAAtcTcaactacCAttTT 609_5 -19.13 25249
    609 AAAATCTCAACTACCATTTT 4-1-1-7-1-2-4 AAAAtCtcaactaCcaTTTT 609_6 -20.75 25249
    609 AAAATCTCAACTACCATTTT 1-1-1-2-1-8-1-1-4 AaAatCtcaactacCaTTTT 609_7 -19.30 25249
    609 AAAATCTCAACTACCATTTT 1-2-3-7-1-1-1-1-3 AaaATCtcaactaCcAtTTT 609_8 -20.51 25249
    609 AAAATCTCAACTACCATTTT 2-2-2-10-1-1-2 AAaaTCtcaactaccaTtTT 609_9 -18.72 25249
    610 AAAATCTCAACTACCATTT 1-4-1-6-4-1-2 AaaatCtcaactACCAtTT 610_1 -20.63 25250
    610 AAAATCTCAACTACCATTT 3-10-6 AAAatctcaactaCCATTT 610_2 -21.90 25250
    610 AAAATCTCAACTACCATTT 6-6-2-2-3 AAAATCtcaactACcaTTT 610_3 -21.46 25250
    610 AAAATCTCAACTACCATTT 2-2-2-7-2-1-3 AAaaTCtcaactaCCaTTT 610_4 -21.18 25250
    610 AAAATCTCAACTACCATTT 6-7-2-2-2 AAAATCtcaactaCCatTT 610_5 -22.10 25250
    610 AAAATCTCAACTACCATTT 2-1-1-1-1-8-5 AAaAtCtcaactacCATTT 610_6 -20.27 25250
    610 AAAATCTCAACTACCATTT 1-1-1-1-2-8-5 AaAaTCtcaactacCATTT 610_7 -20.88 25250
    610 AAAATCTCAACTACCATTT 1-1-2-1-1-8-2-1-2 AaAAtCtcaactacCAtTT 610_8 -18.51 25250
    610 AAAATCTCAACTACCATTT 6-9-4 AAAATCtcaactaccATTT 610_9 -20.94 25250
    611 GAAAATCTCAACTACCATT 1-1-3-7-1-2-4 GaAAAtctcaacTacCATT 611_1 -20.48 25251
    611 GAAAATCTCAACTACCATT 1-1-2-8-1-1-1-1-3 GaAAatctcaacTaCcATT 611_2 -18.75 25251
    611 GAAAATCTCAACTACCATT 3-1-1-10-4 GAAaAtctcaactacCATT 611_3 -20.73 25251
    611 GAAAATCTCAACTACCATT 2-1-2-10-4 GAaAAtctcaactacCATT 611_4 -20.73 25251
    611 GAAAATCTCAACTACCATT 2-2-1-7-1-4-2 GAaaAtctcaacTaccaTT 611_5 -18.28 25251
    611 GAAAATCTCAACTACCATT 2-12-5 GAaaatctcaactaCCATT 611_6 -22.25 25251
    611 GAAAATCTCAACTACCATT 4-10-2-1-2 GAAAatctcaactaCCaTT 611_7 -21.06 25251
    611 GAAAATCTCAACTACCATT 4-10-1-1-3 GAAAatctcaactaCcATT 611_8 -19.73 25251
    611 GAAAATCTCAACTACCATT 5-12-2 GAAAAtctcaactaccaTT 611_9 -18.61 25251
    612 TGAAAATCTCAACTACCAT 1-4-1-6-1-1-2-1-2 TgaaaAtctcaaCtACcAT 612_1 -18.43 25252
    612 TGAAAATCTCAACTACCAT 2-1-2-7-1-2-1-1-2 TGaAAatctcaaCtaCcAT 612_2 -19.46 25252
    612 TGAAAATCTCAACTACCAT 1-1-2-8-1-2-1-1-2 TgAAaatctcaaCtaCcAT 612_3 -18.58 25252
    612 TGAAAATCTCAACTACCAT 1-2-1-1-1-6-1-3-3 TgaAaAtctcaaCtacCAT 612_4 -19.40 25252
    612 TGAAAATCTCAACTACCAT 1-3-2-10-3 TgaaAAtctcaactacCAT 612_5 -18.60 25252
    612 TGAAAATCTCAACTACCAT 1-11-1-2-4 TgaaaatctcaaCtaCCAT 612_6 -21.11 25252
    612 TGAAAATCTCAACTACCAT 3-1-2-6-1-4-2 TGAaAAtctcaaCtaccAT 612_7 -20.39 25252
    612 TGAAAATCTCAACTACCAT 1-1-1-1-1-7-1-3-3 TgAaAatctcaaCtacCAT 612_8 -19.60 25252
    612 TGAAAATCTCAACTACCAT 4-12-3 TGAAaatctcaactacCAT 612_9 -21.07 25252
    613 ATCATTCTCAACAATTAAA 4-8-7 ATCAttctcaacAATTAAA 613_1 -20.89 30599
    613 ATCATTCTCAACAATTAAA 1-1-4-6-7 AtCATTctcaacAATTAAA 613_2 -21.09 30599
    613 ATCATTCTCAACAATTAAA 5-7-2-1-1-1-2 ATCATtctcaacAAtTaAA 613_3 -19.03 30599
    613 ATCATTCTCAACAATTAAA 5-8-2-2-2 ATCATtctcaacaATtaAA 613_4 -19.28 30599
    613 ATCATTCTCAACAATTAAA 4-1-1-8-5 ATCAtTctcaacaaTTAAA 613_5 -19.86 30599
    613 ATCATTCTCAACAATTAAA 5-7-4-1-2 ATCATtctcaacAATTaAA 613_6 -20.79 30599
    613 ATCATTCTCAACAATTAAA 4-8-1-1-5 ATCAttctcaacAaTTAAA 613_7 -19.56 30599
    613 ATCATTCTCAACAATTAAA 1-1-4-6-1-1-5 AtCATTctcaacAaTTAAA 613_8 -19.76 30599
    613 ATCATTCTCAACAATTAAA 4-1-1-7-3-1-2 ATCAtTctcaacaATTaAA 613_9 -19.64 30599
    613 ATCATTCTCAACAATTAAA 5-8-1-1-4 ATCATtctcaacaAtTAAA 613_10 -20.11 30599
    614 ATCATTCTCAACAATTAA 4-8-6 ATCAttctcaacAATTAA 614_1 -20.14 30600
    614 ATCATTCTCAACAATTAA 1-1-4-6-6 AtCATTctcaacAATTAA 614_2 -20.34 30600
    614 ATCATTCTCAACAATTAA 5-8-1-1-3 ATCATtctcaacaAtTAA 614_3 -19.36 30600
    614 ATCATTCTCAACAATTAA 4-8-1-1-4 ATCAttctcaacAaTTAA 614_4 -18.81 30600
    614 ATCATTCTCAACAATTAA 5-8-5 ATCATtctcaacaATTAA 614_5 -21.12 30600
    614 ATCATTCTCAACAATTAA 5-7-1-2-3 ATCATtctcaacAatTAA 614_6 -19.11 30600
    614 ATCATTCTCAACAATTAA 3-10-5 ATCattctcaacaATTAA 614_7 -18.40 30600
    614 ATCATTCTCAACAATTAA 4-9-1-1-3 ATCAttctcaacaAtTAA 614_8 -18.11 30600
    614 ATCATTCTCAACAATTAA 4-1-1-8-4 ATCAtTctcaacaaTTAA 614_9 -19.11 30600
    614 ATCATTCTCAACAATTAA 1-1-3-9-4 AtCATtctcaacaaTTAA 614_10 -18.05 30600
    615 GATCATTCTCAACAATTAA 2-3-1-6-2-1-4 GAtcaTtctcaaCAaTTAA 615_1 -20.54 30600
    615 GATCATTCTCAACAATTAA 1-2-2-7-1-2-4 GatCAttctcaaCaaTTAA 615_2 -19.04 30600
    615 GATCATTCTCAACAATTAA 2-1-3-6-3-2-2 GAtCATtctcaaCAAttAA 615_3 -21.29 30600
    615 GATCATTCTCAACAATTAA 2-1-2-8-2-1-3 GAtCAttctcaacAAtTAA 615_4 -19.70 30600
    615 GATCATTCTCAACAATTAA 5-8-1-1-1-1-2 GATCAttctcaacAaTtAA 615_5 -19.79 30600
    615 GATCATTCTCAACAATTAA 4-8-3-2-2 GATCattctcaaCAAttAA 615_6 -20.50 30600
    615 GATCATTCTCAACAATTAA 1-2-3-6-2-2-3 GatCATtctcaaCAatTAA 615_7 -20.82 30600
    615 GATCATTCTCAACAATTAA 2-2-2-6-1-1-5 GAtcATtctcaaCaATTAA 615_8 -21.04 30600
    615 GATCATTCTCAACAATTAA 2-1-1-8-1-2-4 GAtCattctcaaCaaTTAA 615_9 -19.28 30600
    615 GATCATTCTCAACAATTAA 1-1-3-9-1-1-3 GaTCAttctcaacaAtTAA 615_10 -18.85 30600
    616 AGATCATTCTCAACAATTA 1-1-1-2-1-7-3-1-2 AgAtcAttctcaaCAAtTA 616_1 -19.10 30601
    616 AGATCATTCTCAACAATTA 1-3-1-8-2-1-3 AgatCattctcaaCAaTTA 616_2 -19.65 30601
    616 AGATCATTCTCAACAATTA 1-3-2-6-1-1-1-2-2 AgatCAttctcaAcAatTA 616_3 -18.49 30601
    616 AGATCATTCTCAACAATTA 1-1-1-1-2-11-2 AgAtCAttctcaacaatTA 616_4 -18.49 30601
    616 AGATCATTCTCAACAATTA 1-1-1-2-1-9-4 AgAtcAttctcaacaATTA 616_5 -18.49 30601
    616 AGATCATTCTCAACAATTA 1-3-2-6-1-1-5 AgatCAttctcaAcAATTA 616_6 -20.76 30601
    616 AGATCATTCTCAACAATTA 2-2-1-8-3-1-2 AGatCattctcaaCAAtTA 616_7 -20.47 30601
    616 AGATCATTCTCAACAATTA 3-2-1-7-1-2-3 AGAtcAttctcaaCaaTTA 616_8 -20.51 30601
    616 AGATCATTCTCAACAATTA 1-2-3-7-1-3-2 AgaTCAttctcaaCaatTA 616_9 -19.80 30601
    616 AGATCATTCTCAACAATTA 1-1-1-1-2-8-2-1-2 AgAtCAttctcaacAAtTA 616_10 -19.08 30601
    617 GATCATTCTCAACAATTA 2-3-1-6-6 GAtcaTtctcaaCAATTA 617_1 -21.11 30601
    617 GATCATTCTCAACAATTA 2-1-2-8-5 GAtCAttctcaacAATTA 617_2 -20.71 30601
    617 GATCATTCTCAACAATTA 2-2-2-6-2-2-2 GAtcATtctcaaCAatTA 617_3 -19.70 30601
    617 GATCATTCTCAACAATTA 1-1-3-7-1-1-1-1-2 GaTCAttctcaaCaAtTA 617_4 -18.78 30601
    617 GATCATTCTCAACAATTA 2-1-2-10-3 GAtCAttctcaacaaTTA 617_5 -19.31 30601
    617 GATCATTCTCAACAATTA 2-1-1-1-1-6-3-1-2 GAtCaTtctcaaCAAtTA 617_6 -20.02 30601
    617 GATCATTCTCAACAATTA 2-1-2-7-2-2-2 GAtCAttctcaaCAatTA 617_7 -20.53 30601
    617 GATCATTCTCAACAATTA 2-1-3-6-1-2-3 GAtCATtctcaaCaaTTA 617_8 -21.24 30601
    617 GATCATTCTCAACAATTA 2-2-1-8-5 GAtcAttctcaacAATTA 617_9 -18.63 30601
    617 GATCATTCTCAACAATTA 1-1-3-9-1-1-2 GaTCAttctcaacaAtTA 617_10 -18.10 30601
    618 AGATCATTCTCAACAATT 1-3-2-6-6 AgatCAttctcaACAATT 618_1 -21.03 30602
    618 AGATCATTCTCAACAATT 1-1-1-1-2-7-5 AgAtCAttctcaaCAATT 618_2 -20.70 30602
    618 AGATCATTCTCAACAATT 1-1-4-6-1-3-2 AgATCAttctcaAcaaTT 618_3 -19.56 30602
    618 AGATCATTCTCAACAATT 3-1-1-9-4 AGAtCattctcaacAATT 618_4 -19.61 30602
    618 AGATCATTCTCAACAATT 2-1-3-10-2 AGaTCAttctcaacaaTT 618_5 -19.09 30602
    618 AGATCATTCTCAACAATT 1-2-3-6-1-3-2 AgaTCAttctcaAcaaTT 618_6 -18.25 30602
    618 AGATCATTCTCAACAATT 2-2-2-7-2-1-2 AGatCAttctcaaCAaTT 618_7 -20.14 30602
    618 AGATCATTCTCAACAATT 1-1-1-1-2-7-1-1-3 AgAtCAttctcaaCaATT 618_8 -19.02 30602
    618 AGATCATTCTCAACAATT 1-2-3-8-4 AgaTCAttctcaacAATT 618_9 -19.23 30602
    618 AGATCATTCTCAACAATT 3-1-1-10-3 AGAtCattctcaacaATT 618_10 -19.34 30602
    619 GATCATTCTCAACAATT 2-1-2-6-6 GAtCAttctcaACAATT 619_1 -21.40 30602
    619 GATCATTCTCAACAATT 1-1-3-7-5 GaTCAttctcaaCAATT 619_2 -19.99 30602
    619 GATCATTCTCAACAATT 5-7-1-2-2 GATCAttctcaaCaaTT 619_3 -19.69 30602
    619 GATCATTCTCAACAATT 5-6-1-1-4 GATCAttctcaAcAATT 619_4 -20.83 30602
    619 GATCATTCTCAACAATT 2-1-2-7-5 GAtCAttctcaaCAATT 619_5 -20.57 30602
    619 GATCATTCTCAACAATT 5-6-1-3-2 GATCAttctcaAcaaTT 619_6 -19.43 30602
    619 GATCATTCTCAACAATT 4-8-5 GATCattctcaaCAATT 619_7 -21.04 30602
    619 GATCATTCTCAACAATT 1-1-3-7-2-1-2 GaTCAttctcaaCAaTT 619_8 -18.67 30602
    619 GATCATTCTCAACAATT 5-7-1-1-3 GATCAttctcaaCaATT 619_9 -20.82 30602
    619 GATCATTCTCAACAATT 2-1-2-8-4 GAtCAttctcaacAATT 619_10 -18.48 30602
    620 AAGATCATTCTCAACAAT 4-1-1-6-1-1-4 AAGAtCattctcAaCAAT 620_1 -20.71 30603
    620 AAGATCATTCTCAACAAT 4-9-5 AAGAtcattctcaACAAT 620_2 -20.79 30603
    620 AAGATCATTCTCAACAAT 2-2-2-6-6 AAgaTCattctcAACAAT 620_3 -19.88 30603
    620 AAGATCATTCTCAACAAT 4-1-1-7-2-1-2 AAGAtCattctcaACaAT 620_4 -19.77 30603
    620 AAGATCATTCTCAACAAT 2-1-3-8-4 AAgATCattctcaaCAAT 620_5 -20.10 30603
    620 AAGATCATTCTCAACAAT 4-1-1-6-2-2-2 AAGAtCattctcAAcaAT 620_6 -18.96 30603
    620 AAGATCATTCTCAACAAT 3-1-2-6-1-1-4 AAGaTCattctcAaCAAT 620_7 -20.12 30603
    620 AAGATCATTCTCAACAAT 2-1-3-6-1-1-4 AAgATCattctcAaCAAT 620_8 -20.17 30603
    620 AAGATCATTCTCAACAAT 1-1-1-2-1-7-5 AaGatCattctcaACAAT 620_9 -18.21 30603
    620 AAGATCATTCTCAACAAT 4-1-1-8-4 AAGAtCattctcaaCAAT 620_10 -20.63 30603
    621 AAAGATCATTCTCAACAA 1-1-1-9-6 AaAgatcattctCAACAA 621_1 -18.13 30604
    621 AAAGATCATTCTCAACAA 1-1-3-7-2-1-3 AaAGAtcattctCAaCAA 621_2 -20.08 30604
    621 AAAGATCATTCTCAACAA 1-3-2-6-2-1-3 AaagATcattctCAaCAA 621_3 -18.11 30604
    621 AAAGATCATTCTCAACAA 1-2-2-7-1-1-4 AaaGAtcattctCaACAA 621_4 -18.07 30604
    621 AAAGATCATTCTCAACAA 5-10-3 AAAGAtcattctcaaCAA 621_5 -18.65 30604
    621 AAAGATCATTCTCAACAA 1-1-3-7-3-1-2 AaAGAtcattctCAAcAA 621_6 -18.59 30604
    621 AAAGATCATTCTCAACAA 4-8-2-1-3 AAAGatcattctCAaCAA 621_7 -19.10 30604
    621 AAAGATCATTCTCAACAA 3-1-1-7-2-1-3 AAAgAtcattctCAaCAA 621_8 -18.35 30604
    621 AAAGATCATTCTCAACAA 1-1-2-8-2-1-3 AaAGatcattctCAaCAA 621_9 -18.37 30604
    621 AAAGATCATTCTCAACAA 1-2-2-7-2-1-3 AaaGAtcattctCAaCAA 621_10 -18.74 30604
    621 AAAGATCATTCTCAACAA 5-7-1-2-3 AAAGAtcattctCaaCAA 621_11 -19.32 30604
    622 CAAAGATCATTCTCAACA 1-1-2-8-6 CaAAgatcattcTCAACA 622_1 -20.93 30605
    622 CAAAGATCATTCTCAACA 2-1-1-9-5 CAaAgatcattctCAACA 622_2 -20.68 30605
    622 CAAAGATCATTCTCAACA 1-4-1-7-5 CaaagAtcattctCAACA 622_3 -18.86 30605
    622 CAAAGATCATTCTCAACA 4-1-1-7-1-2-2 CAAAgAtcattctCaaCA 622_4 -19.40 30605
    622 CAAAGATCATTCTCAACA 3-1-2-10-2 CAAaGAtcattctcaaCA 622_5 -19.67 30605
    622 CAAAGATCATTCTCAACA 4-8-2-2-2 CAAAgatcattcTCaaCA 622_6 -20.10 30605
    622 CAAAGATCATTCTCAACA 1-1-2-1-1-7-5 CaAAgAtcattctCAACA 622_7 -20.23 30605
    622 CAAAGATCATTCTCAACA 2-1-1-9-2-1-2 CAaAgatcattctCAaCA 622_8 -19.66 30605
    622 CAAAGATCATTCTCAACA 3-2-1-7-1-1-3 CAAagAtcattctCaACA 622_9 -19.21 30605
    622 CAAAGATCATTCTCAACA 1-3-2-7-1-2-2 CaaaGAtcattctCaaCA 622_10 -18.30 30605
    623 CAAAGATCATTCTCAAC 3-8-6 CAAagatcattCTCAAC 623_1 -19.95 30606
    623 CAAAGATCATTCTCAAC 2-1-1-7-6 CAaAgatcattCTCAAC 623_2 -20.23 30606
    623 CAAAGATCATTCTCAAC 2-2-1-6-6 CAaaGatcattCTCAAC 623_3 -20.15 30606
    623 CAAAGATCATTCTCAAC 1-2-2-6-6 CaaAGatcattCTCAAC 623_4 -20.00 30606
    623 CAAAGATCATTCTCAAC 5-6-1-1-4 CAAAGatcattCtCAAC 623_5 -20.35 30606
    623 CAAAGATCATTCTCAAC 4-7-3-1-2 CAAAgatcattCTCaAC 623_6 -19.28 30606
    623 CAAAGATCATTCTCAAC 3-1-1-6-1-1-4 CAAaGatcattCtCAAC 623_7 -18.81 30606
    623 CAAAGATCATTCTCAAC 2-1-1-7-1-1-4 CAaAgatcattCtCAAC 623_8 -18.36 30606
    623 CAAAGATCATTCTCAAC 1-2-2-6-1-1-4 CaaAGatcattCtCAAC 623_9 -18.12 30606
    623 CAAAGATCATTCTCAAC 4-8-5 CAAAgatcattcTCAAC 623_10 -19.31 30606
    624 CTCAAAGATCATTCTCA 1-2-1-7-6 CtcAaagatcaTTCTCA 624_1 -20.57 30608
    624 CTCAAAGATCATTCTCA 1-1-1-1-1-7-2-1-2 CtCaAagatcatTCtCA 624_2 -18.69 30608
    624 CTCAAAGATCATTCTCA 1-1-2-7-1-2-3 CtCAaagatcaTtcTCA 624_3 -19.51 30608
    624 CTCAAAGATCATTCTCA 3-10-1-1-2 CTCaaagatcattCtCA 624_4 -19.23 30608
    624 CTCAAAGATCATTCTCA 1-1-3-8-4 CtCAAagatcattCTCA 624_5 -21.26 30608
    624 CTCAAAGATCATTCTCA 1-1-3-6-1-1-1-1-2 CtCAAagatcaTtCtCA 624_6 -19.82 30608
    624 CTCAAAGATCATTCTCA 4-7-1-3-2 CTCAaagatcaTtctCA 624_7 -20.18 30608
    624 CTCAAAGATCATTCTCA 1-2-2-7-5 CtcAAagatcatTCTCA 624_8 -20.16 30608
    624 CTCAAAGATCATTCTCA 1-1-2-8-2-1-2 CtCAaagatcatTCtCA 624_9 -19.83 30608
    624 CTCAAAGATCATTCTCA 3-10-4 CTCaaagatcattCTCA 624_10 -21.11 30608
    625 TACACTTAATTATACTTCCA 1-2-1-1-1-7-2-3-2 TacAcTtaattatACttcCA 625_1 -20.33 30666
    625 TACACTTAATTATACTTCCA 1-2-1-2-1-6-1-4-2 TacActTaattatActtcCA 625_2 -19.15 30666
    625 TACACTTAATTATACTTCCA 1-4-1-7-1-1-1-2-2 TacacTtaattatAcTtcCA 625_3 -19.30 30666
    625 TACACTTAATTATACTTCCA 1-1-1-2-2-6-1-4-2 TaCacTTaattatActtcCA 625_4 -20.71 30666
    625 TACACTTAATTATACTTCCA 1-1-1-3-1-8-1-2-2 TaCactTaattatacTtcCA 625_5 -20.00 30666
    625 TACACTTAATTATACTTCCA 1-2-1-1-2-8-1-2-2 TacAcTTaattatacTtcCA 625_6 -20.50 30666
    625 TACACTTAATTATACTTCCA 1-2-1-13-3 TacActtaattatacttCCA 625_7 -20.60 30666
    625 TACACTTAATTATACTTCCA 1-4-1-11-3 TacacTtaattatacttCCA 625_8 -20.96 30666
    625 TACACTTAATTATACTTCCA 2-1-1-1-1-12-2 TAcAcTtaattatacttcCA 625_9 -19.97 30666
    625 TACACTTAATTATACTTCCA 1-1-1-2-1-7-2-3-2 TaCacTtaattatACttcCA 625_10 -20.87 30666
    625 TACACTTAATTATACTTCCA 1-2-1-1-2-6-1-1-1-2-2 TacAcTTaattatAcTtcCA 625_11 -20.69 30666
    625 TACACTTAATTATACTTCCA 1-2-1-1-1-9-1-1-3 TacAcTtaattatacTtCCA 625_12 -21.63 30666
    625 TACACTTAATTATACTTCCA 1-1-1-3-1-10-3 TaCactTaattatacttCCA 625_13 -21.86 30666
    625 TACACTTAATTATACTTCCA 2-1-2-1-1-11-2 TAcACtTaattatacttcCA 625_14 -21.58 30666
    626 TTACACTTAATTATACTTCC 1-3-1-1-1-7-2-2-2 TtacAcTtaattatACttCC 626_1 -19.98 30667
    626 TTACACTTAATTATACTTCC 1-5-1-7-1-1-1-1-2 TtacacTtaattatAcTtCC 626_2 -18.96 30667
    626 TTACACTTAATTATACTTCC 2-4-1-11-2 TTacacTtaattatacttCC 626_3 -19.49 30667
    626 TTACACTTAATTATACTTCC 1-5-1-9-4 TtacacTtaattatacTTCC 626_4 -20.26 30667
    626 TTACACTTAATTATACTTCC 1-1-1-3-1-8-1-2-2 TtAcacTtaattataCttCC 626_5 -19.43 30667
    626 TTACACTTAATTATACTTCC 1-1-2-2-1-7-1-3-2 TtACacTtaattatActtCC 626_6 -19.72 30667
    626 TTACACTTAATTATACTTCC 3-1-1-12-3 TTAcActtaattatactTCC 626_7 -21.33 30667
    626 TTACACTTAATTATACTTCC 1-1-1-1-1-1-1-9-1-1-2 TtAcAcTtaattatacTtCC 626_8 -19.10 30667
    626 TTACACTTAATTATACTTCC 1-2-2-1-1-11-2 TtaCAcTtaattatacttCC 626_9 -20.49 30667
    626 TTACACTTAATTATACTTCC 1-5-1-7-2-1-3 TtacacTtaattatACtTCC 626_10 -20.82 30667
    626 TTACACTTAATTATACTTCC 4-2-1-7-1-3-2 TTACacTtaattatActtCC 626_11 -21.99 30667
    626 TTACACTTAATTATACTTCC 1-1-1-1-3-8-1-2-2 TtAcACTtaattataCttCC 626_12 -21.65 30667
    626 TTACACTTAATTATACTTCC 2-1-2-11-4 TTaCActtaattatacTTCC 626_13 -23.23 30667
    626 TTACACTTAATTATACTTCC 2-2-1-1-1-9-1-1-2 TTacAcTtaattatacTtCC 626_14 -20.15 30667
    627 TTTACACTTAATTATACTTC 2-1-2-8-1-1-5 TTTACacttaattAtACTTC 627_1 -20.02 30668
    627 TTTACACTTAATTATACTTC 2-3-1-7-4-1-2 TTtacActtaattATACtTC 627_2 -19.89 30668
    627 TTTACACTTAATTATACTTC 1-2-1-1-1-7-2-1-4 TttAcActtaattATaCTTC 627_3 -19.35 30668
    627 TTTACACTTAATTATACTTC 1-1-3-8-3-2-2 TtTACacttaattATActTC 627_4 -20.58 30668
    627 TTTACACTTAATTATACTTC 3-2-1-7-3-1-3 TTTacActtaattATAcTTC 627_5 -20.76 30668
    627 TTTACACTTAATTATACTTC 1-3-2-7-2-2-3 TttaCActtaattATacTTC 627_6 -19.58 30668
    627 TTTACACTTAATTATACTTC 3-2-1-7-2-1-4 TTTacActtaattATaCTTC 627_7 -21.21 30668
    627 TTTACACTTAATTATACTTC 3-1-1-8-1-2-4 TTTaCacttaattAtaCTTC 627_8 -20.07 30668
    627 TTTACACTTAATTATACTTC 6-7-1-4-2 TTTACActtaattAtactTC 627_9 -20.56 30668
    627 TTTACACTTAATTATACTTC 4-1-1-7-4-1-2 TTTAcActtaattATACtTC 627_10 -22.36 30668
    627 TTTACACTTAATTATACTTC 3-1-1-1-1-6-3-1-3 TTTaCaCttaattATAcTTC 627_11 -22.29 30668
    627 TTTACACTTAATTATACTTC 2-1-3-7-3-2-2 TTTACActtaattATActTC 627_12 -21.19 30668
    627 TTTACACTTAATTATACTTC 3-1-2-7-2-1-4 TTTaCActtaattATaCTTC 627_13 -23.30 30668
    627 TTTACACTTAATTATACTTC 1-1-4-7-1-2-4 TtTACActtaattAtaCTTC 627_14 -21.94 30668
    628 ATTTACACTTAATTATACTT 2-1-1-2-1-6-3-1-3 ATtTacActtaatTATaCTT 628_1 -21.21 30669
    628 ATTTACACTTAATTATACTT 3-1-1-8-2-1-4 ATTtAcacttaatTAtACTT 628_2 -20.27 30669
    628 ATTTACACTTAATTATACTT 1-1-2-2-1-6-4-1-2 AtTTacActtaatTATAcTT 628_3 -20.33 30669
    628 ATTTACACTTAATTATACTT 1-3-1-1-1-7-6 AtttAcActtaattATACTT 628_4 -19.30 30669
    628 ATTTACACTTAATTATACTT 2-2-2-7-3-2-2 ATttACacttaatTATacTT 628_5 -19.94 30669
    628 ATTTACACTTAATTATACTT 4-1-2-6-2-3-2 ATTTaCActtaatTAtacTT 628_6 -21.29 30669
    628 ATTTACACTTAATTATACTT 1-1-4-7-1-1-1-2-2 AtTTACacttaatTaTacTT 628_7 -19.33 30669
    628 ATTTACACTTAATTATACTT 2-2-3-6-1-2-4 ATttACActtaatTatACTT 628_8 -20.97 30669
    628 ATTTACACTTAATTATACTT 4-2-1-6-1-3-3 ATTTacActtaatTataCTT 628_9 -19.73 30669
    628 ATTTACACTTAATTATACTT 1-1-2-1-2-6-4-1-2 AtTTaCActtaatTATAcTT 628_10 -22.43 30669
    628 ATTTACACTTAATTATACTT 3-2-2-6-2-2-3 ATTtaCActtaatTAtaCTT 628_11 -21.72 30669
    628 ATTTACACTTAATTATACTT 1-2-4-6-2-2-3 AttTACActtaatTAtaCTT 628_12 -22.02 30669
    628 ATTTACACTTAATTATACTT 2-1-1-1-2-6-1-1-5 ATtTaCActtaatTaTACTT 628_13 -23.00 30669
    628 ATTTACACTTAATTATACTT 5-8-1-1-1-1-3 ATTTAcacttaatTaTaCTT 628_14 -21.68 30669
    629 TTCTACTATACTTTCCTCT 1-3-1-7-1-1-1-2-2 TtctActatactTtCctCT 629_1 -21.04 30711
    629 TTCTACTATACTTTCCTCT 1-11-1-1-1-2-2 TtctactatactTtCctCT 629_2 -20.85 30711
    629 TTCTACTATACTTTCCTCT 1-11-1-2-1-1-2 TtctactatactTtcCtCT 629_3 -20.97 30711
    629 TTCTACTATACTTTCCTCT 1-1-1-9-1-4-2 TtCtactatactTtcctCT 629_4 -21.06 30711
    629 TTCTACTATACTTTCCTCT 1-1-1-11-1-2-2 TtCtactatactttCctCT 629_5 -21.53 30711
    629 TTCTACTATACTTTCCTCT 1-3-1-9-1-2-2 TtctActatactttCctCT 629_6 -20.74 30711
    629 TTCTACTATACTTTCCTCT 1-4-1-8-1-2-2 TtctaCtatactttCctCT 629_7 -21.54 30711
    629 TTCTACTATACTTTCCTCT 1-13-1-2-2 TtctactatactttCctCT 629_8 -20.55 30711
    629 TTCTACTATACTTTCCTCT 1-1-1-12-1-1-2 TtCtactatactttcCtCT 629_9 -21.65 30711
    629 TTCTACTATACTTTCCTCT 1-3-1-10-1-1-2 TtctActatactttcCtCT 629_10 -20.86 30711
    629 TTCTACTATACTTTCCTCT 1-14-1-1-2 TtctactatactttcCtCT 629_11 -20.67 30711
    629 TTCTACTATACTTTCCTCT 1-1-1-1-1-7-1-1-1-2-2 TtCtActatactTtCctCT 629_12 -22.02 30711
    629 TTCTACTATACTTTCCTCT 1-1-1-2-1-8-1-2-2 TtCtaCtatactttCctCT 629_13 -22.52 30711
    629 TTCTACTATACTTTCCTCT 1-3-2-8-1-2-2 TtctACtatactttCctCT 629_14 -22.14 30711
    629 TTCTACTATACTTTCCTCT 1-1-1-1-1-10-1-1-2 TtCtActatactttcCtCT 629_15 -21.84 30711
    629 TTCTACTATACTTTCCTCT 1-1-1-2-1-9-1-1-2 TtCtaCtatactttcCtCT 629_16 -22.64 30711
    630 GTTCTACTATACTTTCCTC 1-12-1-1-1-1-2 GttctactatactTtCcTC 630_1 -20.78 30712
    630 GTTCTACTATACTTTCCTC 1-4-1-9-1-1-2 GttctActatactttCcTC 630_2 -20.67 30712
    630 GTTCTACTATACTTTCCTC 1-14-1-1-2 GttctactatactttCcTC 630_3 -20.48 30712
    631 GTTCTACTATACTTTCCT 1-2-1-1-1-7-1-2-2 GttCtActatactTtcCT 631_1 -20.25 30713
    631 GTTCTACTATACTTTCCT 1-2-1-9-1-2-2 GttCtactatactTtcCT 631_2 -20.06 30713
    631 GTTCTACTATACTTTCCT 1-2-1-11-3 GttCtactatactttCCT 631_3 -22.13 30713
    631 GTTCTACTATACTTTCCT 1-4-1-9-3 GttctActatactttCCT 631_4 -21.34 30713
    631 GTTCTACTATACTTTCCT 1-14-3 GttctactatactttCCT 631_5 -21.15 30713
    631 GTTCTACTATACTTTCCT 2-1-1-1-1-10-2 GTtCtActatactttcCT 631_6 -21.50 30713
    631 GTTCTACTATACTTTCCT 2-1-1-12-2 GTtCtactatactttcCT 631_7 -21.30 30713
    631 GTTCTACTATACTTTCCT 1-2-1-1-1-10-2 GttCtActatactttcCT 631_8 -19.95 30713
    631 GTTCTACTATACTTTCCT 1-2-1-12-2 GttCtactatactttcCT 631_9 -19.76 30713
    631 GTTCTACTATACTTTCCT 1-15-2 GttctactatactttcCT 631_10 -18.78 30713
    631 GTTCTACTATACTTTCCT 1-2-1-9-1-1-3 GttCtactatactTtCCT 631_11 -22.43 30713
    631 GTTCTACTATACTTTCCT 2-1-1-1-1-7-1-2-2 GTtCtActatactTtcCT 631_12 -21.80 30713
    631 GTTCTACTATACTTTCCT 1-2-2-8-1-2-2 GttCTactatactTtcCT 631_13 -21.68 30713
    631 GTTCTACTATACTTTCCT 1-2-1-1-1-9-3 GttCtActatactttCCT 631_14 -22.32 30713
    631 GTTCTACTATACTTTCCT 1-2-3-10-2 GttCTActatactttcCT 631_15 -22.60 30713
    632 AGTTCTACTATACTTTCC 1-12-1-2-2 AgttctactatacTttCC 632_1 -19.37 30714
    632 AGTTCTACTATACTTTCC 1-13-1-1-2 AgttctactatactTtCC 632_2 -19.16 30714
    632 AGTTCTACTATACTTTCC 1-1-1-13-2 AgTtctactatactttCC 632_3 -19.51 30714
    632 AGTTCTACTATACTTTCC 1-15-2 AgttctactatactttCC 632_4 -18.86 30714
    632 AGTTCTACTATACTTTCC 1-1-1-10-1-2-2 AgTtctactatacTttCC 632_5 -20.03 30714
    632 AGTTCTACTATACTTTCC 1-4-1-7-1-2-2 AgttcTactatacTttCC 632_6 -20.31 30714
    632 AGTTCTACTATACTTTCC 2-14-2 AGttctactatactttCC 632_7 -20.26 30714
    632 AGTTCTACTATACTTTCC 1-2-1-12-2 AgtTctactatactttCC 632_8 -19.23 30714
    632 AGTTCTACTATACTTTCC 1-4-1-10-2 AgttcTactatactttCC 632_9 -19.80 30714
    632 AGTTCTACTATACTTTCC 2-10-1-3-2 AGttctactataCtttCC 632_10 -21.25 30714
    632 AGTTCTACTATACTTTCC 1-4-1-6-1-3-2 AgttcTactataCtttCC 632_11 -20.79 30714
    632 AGTTCTACTATACTTTCC 1-4-1-7-2-1-2 AgttcTactatacTTtCC 632_12 -21.13 30714
    632 AGTTCTACTATACTTTCC 1-1-1-11-1-1-2 AgTtctactatactTtCC 632_13 -19.82 30714
    632 AGTTCTACTATACTTTCC 1-3-1-11-2 AgttCtactatactttCC 632_14 -19.83 30714
    633 CAACATTATTAACCACCTTA 1-13-3-1-2 CaacattattaaccACCtTA 633_1 -22.44 33376
    633 CAACATTATTAACCACCTTA 4-10-1-2-3 CAACattattaaccAccTTA 633_2 -22.98 33376
    633 CAACATTATTAACCACCTTA 2-2-1-10-1-1-3 CAacAttattaaccaCcTTA 633_3 -21.97 33376
    633 CAACATTATTAACCACCTTA 1-4-2-8-1-2-2 CaacaTTattaaccaCctTA 633_4 -21.08 33376
    633 CAACATTATTAACCACCTTA 1-1-2-11-1-2-2 CaACattattaaccaCctTA 633_5 -20.90 33376
    633 CAACATTATTAACCACCTTA 1-2-2-13-2 CaaCAttattaaccacctTA 633_6 -20.76 33376
    633 CAACATTATTAACCACCTTA 1-1-1-1-1-11-1-1-2 CaAcAttattaaccacCtTA 633_7 -19.97 33376
    633 CAACATTATTAACCACCTTA 1-15-4 CaacattattaaccacCTTA 633_8 -21.21 33376
    633 CAACATTATTAACCACCTTA 2-4-1-11-2 CAacatTattaaccacctTA 633_9 -20.83 33376
    634 CAACATTATTAACCACCTT 2-10-2-3-2 CAacattattaaCCaccTT 634_1 -21.86 33377
    634 CAACATTATTAACCACCTT 1-14-4 CaacattattaaccaCCTT 634_2 -21.36 33377
    634 CAACATTATTAACCACCTT 1-1-1-11-1-1-3 CaAcattattaaccAcCTT 634_3 -19.54 33377
    634 CAACATTATTAACCACCTT 3-1-1-11-3 CAAcAttattaaccacCTT 634_4 -21.13 33377
    634 CAACATTATTAACCACCTT 3-11-2-1-2 CAAcattattaaccACcTT 634_5 -20.84 33377
    634 CAACATTATTAACCACCTT 2-1-2-9-1-1-3 CAaCAttattaaccAcCTT 634_6 -22.76 33377
    634 CAACATTATTAACCACCTT 2-1-2-10-1-1-2 CAaCAttattaaccaCcTT 634_7 -21.83 33377
    634 CAACATTATTAACCACCTT 1-1-2-11-1-1-2 CaACattattaaccaCcTT 634_8 -19.70 33377
    634 CAACATTATTAACCACCTT 1-2-1-12-3 CaaCattattaaccacCTT 634_9 -19.66 33377
    635 GCAACATTATTAACCACCT 1-1-1-2-1-6-2-3-2 GcAacAttattaACcacCT 635_1 -21.56 33378
    635 GCAACATTATTAACCACCT 1-1-2-1-1-6-1-2-1-1-2 GcAAcAttattaAccAcCT 635_2 -21.14 33378
    635 GCAACATTATTAACCACCT 1-11-2-1-1-1-2 GcaacattattaACcAcCT 635_3 -21.59 33378
    635 GCAACATTATTAACCACCT 1-4-1-6-1-3-3 GcaacAttattaAccaCCT 635_4 -22.69 33378
    635 GCAACATTATTAACCACCT 1-1-1-1-1-7-1-4-2 GcAaCattattaAccacCT 635_5 -21.01 33378
    635 GCAACATTATTAACCACCT 1-11-1-1-1-2-2 GcaacattattaAcCacCT 635_6 -20.83 33378
    635 GCAACATTATTAACCACCT 2-3-1-6-1-4-2 GCaacAttattaAccacCT 635_7 -22.63 33378
    635 GCAACATTATTAACCACCT 1-1-1-12-1-1-2 GcAacattattaaccAcCT 635_8 -20.05 33378
    635 GCAACATTATTAACCACCT 1-2-1-1-1-11-2 GcaAcAttattaaccacCT 635_9 -20.30 33378
    636 AGCAACATTATTAACCACC 1-2-1-9-2-1-3 AgcAacattattaACcACC 636_1 -22.13 33379
    636 AGCAACATTATTAACCACC 1-11-1-1-1-2-2 AgcaacattattAaCcaCC 636_2 -20.80 33379
    636 AGCAACATTATTAACCACC 1-4-1-6-2-3-2 AgcaaCattattAAccaCC 636_3 -21.32 33379
    636 AGCAACATTATTAACCACC 1-2-2-7-1-2-1-1-2 AgcAAcattattAacCaCC 636_4 -21.29 33379
    636 AGCAACATTATTAACCACC 2-11-1-3-2 AGcaacattattaAccaCC 636_5 -21.75 33379
    636 AGCAACATTATTAACCACC 1-1-1-1-1-8-1-2-3 AgCaAcattattaAccACC 636_6 -22.16 33379
    636 AGCAACATTATTAACCACC 1-2-1-1-1-6-1-3-3 AgcAaCattattAaccACC 636_7 -21.33 33379
    636 AGCAACATTATTAACCACC 2-1-2-12-2 AGcAAcattattaaccaCC 636_8 -22.02 33379
    636 AGCAACATTATTAACCACC 1-15-3 AgcaacattattaaccACC 636_9 -20.45 33379
    637 AGCAACATTATTAACCAC 2-1-1-9-5 AGcAacattattaACCAC 637_1 -21.97 33380
    637 AGCAACATTATTAACCAC 1-3-1-7-6 AgcaAcattattAACCAC 637_2 -21.20 33380
    637 AGCAACATTATTAACCAC 2-10-2-1-3 AGcaacattattAAcCAC 637_3 -19.42 33380
    637 AGCAACATTATTAACCAC 1-2-1-8-1-1-4 AgcAacattattAaCCAC 637_4 -19.84 33380
    637 AGCAACATTATTAACCAC 3-9-3-1-2 AGCaacattattAACcAC 637_5 -20.94 33380
    637 AGCAACATTATTAACCAC 1-1-3-7-3-1-2 AgCAAcattattAACcAC 637_6 -20.15 33380
    637 AGCAACATTATTAACCAC 1-1-3-7-2-1-3 AgCAAcattattAAcCAC 637_7 -20.96 33380
    637 AGCAACATTATTAACCAC 5-7-1-3-2 AGCAAcattattAaccAC 637_8 -21.24 33380
    637 AGCAACATTATTAACCAC 3-1-1-8-1-2-2 AGCaAcattattaAccAC 637_9 -19.86 33380
    638 GTTTCCATCTACTATTAAT 1-3-1-7-1-1-1-1-3 GtttCcatctacTaTtAAT 638_1 -19.59 39806
    638 GTTTCCATCTACTATTAAT 1-1-1-9-2-3-2 GtTtccatctacTAttaAT 638_2 -19.50 39806
    638 GTTTCCATCTACTATTAAT 1-4-1-6-2-2-3 GtttcCatctacTAttAAT 638_3 -20.09 39806
    638 GTTTCCATCTACTATTAAT 1-3-1-8-1-2-3 GtttCcatctactAttAAT 638_4 -18.30 39806
    638 GTTTCCATCTACTATTAAT 3-1-1-8-1-3-2 GTTtCcatctactAttaAT 638_5 -20.35 39806
    638 GTTTCCATCTACTATTAAT 1-2-2-12-2 GttTCcatctactattaAT 638_6 -18.88 39806
    638 GTTTCCATCTACTATTAAT 1-1-1-11-1-1-3 GtTtccatctactaTtAAT 638_7 -18.18 39806
    638 GTTTCCATCTACTATTAAT 2-2-1-10-1-1-2 GTttCcatctactatTaAT 638_8 -20.16 39806
    638 GTTTCCATCTACTATTAAT 1-1-1-1-2-10-3 GtTtCCatctactattAAT 638_9 -20.69 39806
    638 GTTTCCATCTACTATTAAT 2-2-1-7-1-3-3 GTttCcatctacTattAAT 638_10 -20.69 39806
    638 GTTTCCATCTACTATTAAT 1-1-1-10-2-1-3 GtTtccatctactATTAAT 638_11 -19.08 39806
    638 GTTTCCATCTACTATTAAT 1-3-1-8-1-1-1-1-2 GtttCcatctactAtTaAT 638_12 -18.72 39806
    638 GTTTCCATCTACTATTAAT 1-2-3-7-1-2-3 GttTCCatctactAttAAT 638_13 -21.47 39806
    638 GTTTCCATCTACTATTAAT 1-1-1-1-2-11-2 GtTtCCatctactattaAT 638_14 -20.37 39806
    639 GTTTCCATCTACTATTAA 1-11-2-1-3 GtttccatctacTAtTAA 639_1 -19.21 39807
    639 GTTTCCATCTACTATTAA 1-3-1-7-1-1-4 GtttCcatctacTaTTAA 639_2 -19.80 39807
    639 GTTTCCATCTACTATTAA 3-1-1-7-2-2-2 GTTtCcatctacTAttAA 639_3 -20.57 39807
    639 GTTTCCATCTACTATTAA 2-2-1-7-1-1-1-1-2 GTttCcatctacTaTtAA 639_4 -19.07 39807
    639 GTTTCCATCTACTATTAA 1-3-2-7-2-1-2 GtttCCatctactATTAA 639_5 -19.67 39807
    639 GTTTCCATCTACTATTAA 3-2-1-6-1-3-2 GTTtcCatctacTattAA 639_6 -19.25 39807
    639 GTTTCCATCTACTATTAA 1-1-3-8-1-2-2 GtTTCcatctactAttAA 639_7 -18.04 39807
    639 GTTTCCATCTACTATTAA 1-1-1-1-2-10-2 GtTtCCatctactattAA 639_8 -18.62 39807
    639 GTTTCCATCTACTATTAA 3-1-1-9-4 GTTtCcatctactaTTAA 639_9 -21.21 39807
    639 GTTTCCATCTACTATTAA 1-3-2-6-2-2-2 GtttCCatctacTAttAA 639_10 -20.39 39807
    639 GTTTCCATCTACTATTAA 1-1-3-7-1-1-1-1-2 GtTTCcatctacTaTtAA 639_11 -19.32 39807
    639 GTTTCCATCTACTATTAA 2-2-1-7-1-2-3 GTttCcatctacTatTAA 639_12 -20.39 39807
    639 GTTTCCATCTACTATTAA 2-2-1-8-2-1-2 GTttCcatctactATTAA 639_13 -19.03 39807
    639 GTTTCCATCTACTATTAA 1-1-1-1-2-8-4 GtTtCCatctactaTTAA 639_14 -21.34 39807
    640 TGTTTCCATCTACTATTA 1-1-1-11-1-1-2 TgTttccatctactAtTA 640_1 -18.41 39808
    640 TGTTTCCATCTACTATTA 1-2-1-9-2-1-2 TgtTtccatctacTAtTA 640_2 -20.03 39808
    640 TGTTTCCATCTACTATTA 1-4-1-7-1-2-2 TgtttCcatctacTatTA 640_3 -19.37 39808
    640 TGTTTCCATCTACTATTA 1-4-1-8-4 TgtttCcatctactATTA 640_4 -20.28 39808
    640 TGTTTCCATCTACTATTA 1-4-1-8-1-1-2 TgtttCcatctactAtTA 640_5 -18.52 39808
    640 TGTTTCCATCTACTATTA 1-1-2-1-1-10-2 TgTTtCcatctactatTA 640_6 -19.89 39808
    640 TGTTTCCATCTACTATTA 1-4-1-9-3 TgtttCcatctactaTTA 640_7 -19.37 39808
    640 TGTTTCCATCTACTATTA 1-2-1-1-1-10-2 TgtTtCcatctactatTA 640_8 -18.73 39808
    640 TGTTTCCATCTACTATTA 1-4-1-10-2 TgtttCcatctactatTA 640_9 -18.42 39808
    640 TGTTTCCATCTACTATTA 1-4-1-6-1-1-4 TgtttCcatctaCtATTA 640_10 -21.27 39808
    640 TGTTTCCATCTACTATTA 2-1-1-9-2-1-2 TGtTtccatctacTAtTA 640_11 -21.24 39808
    640 TGTTTCCATCTACTATTA 1-3-2-8-1-1-2 TgttTCcatctactAtTA 640_12 -19.51 39808
    640 TGTTTCCATCTACTATTA 2-1-1-1-1-10-2 TGtTtCcatctactatTA 640_13 -19.94 39808
    640 TGTTTCCATCTACTATTA 1-1-1-2-1-10-2 TgTttCcatctactatTA 640_14 -19.08 39808
    641 ACTCTGCAATACACCAA 2-1-1-8-2-1-2 ACtCtgcaatacACcAA 641_1 -19.61 44439
    641 ACTCTGCAATACACCAA 2-2-1-6-1-1-1-1-2 ACtcTgcaataCaCcAA 641_2 -19.77 44439
    641 ACTCTGCAATACACCAA 1-2-1-7-1-1-1-1-2 ActCtgcaataCaCcAA 641_3 -18.35 44439
    641 ACTCTGCAATACACCAA 2-1-2-6-2-2-2 ACtCTgcaataCAccAA 641_4 -22.21 44439
    641 ACTCTGCAATACACCAA 1-3-1-7-1-1-3 ActcTgcaatacAcCAA 641_5 -19.05 44439
    641 ACTCTGCAATACACCAA 4-8-1-2-2 ACTCtgcaatacAccAA 641_6 -20.30 44439
    641 ACTCTGCAATACACCAA 2-1-2-9-3 ACtCTgcaatacacCAA 641_7 -21.96 44439
    641 ACTCTGCAATACACCAA 2-11-4 ACtctgcaatacaCCAA 641_8 -21.68 44439
    641 ACTCTGCAATACACCAA 1-1-2-10-3 AcTCtgcaatacacCAA 641_9 -20.07 44439
    642 CTGTATACACCATCCCA 1-10-1-1-1-1-2 CtgtatacaccAtCcCA 642_1 -21.99 46391
    642 CTGTATACACCATCCCA 1-10-1-3-2 CtgtatacaccAtccCA 642_2 -21.22 46391
    642 CTGTATACACCATCCCA 1-1-1-8-1-3-2 CtGtatacaccAtccCA 642_3 -21.53 46391
    642 CTGTATACACCATCCCA 1-2-1-7-1-3-2 CtgTatacaccAtccCA 642_4 -22.31 46391
    642 CTGTATACACCATCCCA 1-3-1-6-1-3-2 CtgtAtacaccAtccCA 642_5 -21.32 46391
    642 CTGTATACACCATCCCA 1-11-2-1-2 CtgtatacaccaTCcCA 642_6 -23.06 46391
    642 CTGTATACACCATCCCA 1-1-1-1-1-8-1-1-2 CtGtAtacaccatCcCA 642_7 -22.35 46391
    642 CTGTATACACCATCCCA 1-1-1-10-1-1-2 CtGtatacaccatCcCA 642_8 -22.25 46391
    642 CTGTATACACCATCCCA 1-2-1-9-1-1-2 CtgTatacaccatCcCA 642_9 -23.02 46391
    642 CTGTATACACCATCCCA 1-3-1-8-1-1-2 CtgtAtacaccatCcCA 642_10 -22.04 46391
    642 CTGTATACACCATCCCA 1-12-1-1-2 CtgtatacaccatCcCA 642_11 -21.94 46391
    642 CTGTATACACCATCCCA 2-2-1-10-2 CTgtAtacaccatccCA 642_12 -22.95 46391
    642 CTGTATACACCATCCCA 1-1-1-1-1-10-2 CtGtAtacaccatccCA 642_13 -21.58 46391
    642 CTGTATACACCATCCCA 1-1-1-12-2 CtGtatacaccatccCA 642_14 -21.48 46391
    642 CTGTATACACCATCCCA 1-2-2-10-2 CtgTAtacaccatccCA 642_15 -23.39 46391
    642 CTGTATACACCATCCCA 1-3-1-10-2 CtgtAtacaccatccCA 642_16 -21.27 46391
    642 CTGTATACACCATCCCA 1-14-2 CtgtatacaccatccCA 642_17 -21.17 46391
    642 CTGTATACACCATCCCA 1-3-1-6-3-1-2 CtgtAtacaccATCcCA 642_18 -24.02 46391
    642 CTGTATACACCATCCCA 1-1-1-8-1-1-1-1-2 CtGtatacaccAtCcCA 642_19 -22.30 46391
    642 CTGTATACACCATCCCA 1-1-3-6-1-3-2 CtGTAtacaccAtccCA 642_20 -24.64 46391
    642 CTGTATACACCATCCCA 2-2-1-8-1-1-2 CTgtAtacaccatCcCA 642_21 -23.72 46391
    642 CTGTATACACCATCCCA 1-3-1-9-3 CtgtAtacaccatcCCA 642_22 -23.55 46391
    643 TCTGTATACACCATCCCA 1-4-1-8-1-1-2 TctgtAtacaccatCcCA 643_1 -22.94 46391
    644 TCTGTATACACCATCCC 2-10-1-2-2 TCtgtatacaccAtcCC 644_1 -22.70 46392
    644 TCTGTATACACCATCCC 1-11-1-2-2 TctgtatacaccAtcCC 644_2 -21.11 46392
    644 TCTGTATACACCATCCC 2-1-1-11-2 TCtGtatacaccatcCC 644_3 -22.96 46392
    644 TCTGTATACACCATCCC 2-13-2 TCtgtatacaccatcCC 644_4 -22.65 46392
    644 TCTGTATACACCATCCC 3-9-1-2-2 TCTgtatacaccAtcCC 644_5 -24.39 46392
    644 TCTGTATACACCATCCC 2-1-1-8-1-2-2 TCtGtatacaccAtcCC 644_6 -23.01 46392
    645 TTCTGTATACACCATCCC 1-11-1-3-2 TtctgtatacacCatcCC 645_1 -22.57 46392
    645 TTCTGTATACACCATCCC 1-1-1-10-1-2-2 TtCtgtatacaccAtcCC 645_2 -23.02 46392
    645 TTCTGTATACACCATCCC 1-3-1-8-1-2-2 TtctGtatacaccAtcCC 645_3 -22.36 46392
    645 TTCTGTATACACCATCCC 1-12-1-2-2 TtctgtatacaccAtcCC 645_4 -22.05 46392
    645 TTCTGTATACACCATCCC 1-15-2 TtctgtatacaccatcCC 645_5 -22.00 46392
    645 TTCTGTATACACCATCCC 1-4-1-6-2-2-2 TtctgTatacacCAtcCC 645_6 -25.12 46392
    645 TTCTGTATACACCATCCC 1-3-1-8-1-1-3 TtctGtatacaccAtCCC 645_7 -24.73 46392
    645 TTCTGTATACACCATCCC 3-10-1-2-2 TTCtgtatacaccAtcCC 645_8 -24.52 46392
    645 TTCTGTATACACCATCCC 1-1-2-9-1-2-2 TtCTgtatacaccAtcCC 645_9 -24.71 46392
    645 TTCTGTATACACCATCCC 1-1-1-1-1-8-1-2-2 TtCtGtatacaccAtcCC 645_10 -23.34 46392
    646 TTCTGTATACACCATCC 1-10-1-3-2 TtctgtatacaCcatCC 646_1 -19.96 46393
    646 TTCTGTATACACCATCC 1-12-4 TtctgtatacaccATCC 646_2 -21.16 46393
    646 TTCTGTATACACCATCC 2-11-1-1-2 TTctgtatacaccAtCC 646_3 -20.11 46393
    646 TTCTGTATACACCATCC 1-2-1-9-1-1-2 TtcTgtatacaccAtCC 646_4 -20.24 46393
    646 TTCTGTATACACCATCC 1-3-1-8-1-1-2 TtctGtatacaccAtCC 646_5 -19.54 46393
    646 TTCTGTATACACCATCC 1-2-1-8-1-2-2 TtcTgtatacacCatCC 646_6 -20.77 46393
    646 TTCTGTATACACCATCC 1-12-1-1-2 TtctgtatacaccAtCC 646_7 -19.23 46393
    646 TTCTGTATACACCATCC 1-3-1-7-1-1-3 TtctGtatacacCaTCC 646_8 -21.19 46393
    646 TTCTGTATACACCATCC 1-1-1-1-1-10-2 TtCtGtatacaccatCC 646_9 -20.47 46393
    646 TTCTGTATACACCATCC 1-1-1-12-2 TtCtgtatacaccatCC 646_10 -20.16 46393
    646 TTCTGTATACACCATCC 1-1-1-11-3 TtCtgtatacaccaTCC 646_11 -21.28 46393
    646 TTCTGTATACACCATCC 1-3-1-9-3 TtctGtatacaccaTCC 646_12 -20.61 46393
    646 TTCTGTATACACCATCC 1-13-3 TtctgtatacaccaTCC 646_13 -20.30 46393
    646 TTCTGTATACACCATCC 3-1-1-10-2 TTCtGtatacaccatCC 646_14 -21.96 46393
    646 TTCTGTATACACCATCC 3-12-2 TTCtgtatacaccatCC 646_15 -21.65 46393
    646 TTCTGTATACACCATCC 1-1-2-11-2 TtCTgtatacaccatCC 646_16 -21.84 46393
    646 TTCTGTATACACCATCC 1-2-1-11-2 TtcTgtatacaccatCC 646_17 -20.19 46393
    646 TTCTGTATACACCATCC 1-3-1-10-2 TtctGtatacaccatCC 646_18 -19.49 46393
    646 TTCTGTATACACCATCC 1-14-2 TtctgtatacaccatCC 646_19 -19.18 46393
    646 TTCTGTATACACCATCC 3-8-1-3-2 TTCtgtatacaCcatCC 646_20 -22.44 46393
    646 TTCTGTATACACCATCC 1-3-1-6-1-3-2 TtctGtatacaCcatCC 646_21 -20.27 46393
    646 TTCTGTATACACCATCC 1-3-1-7-2-1-2 TtctGtatacacCAtCC 646_22 -21.53 46393
    646 TTCTGTATACACCATCC 1-1-1-9-1-2-2 TtCtgtatacacCatCC 646_23 -20.74 46393
    646 TTCTGTATACACCATCC 1-1-1-10-1-1-2 TtCtgtatacaccAtCC 646_24 -20.21 46393
    647 AGCTTTTAACCAGAGT 2-10-4 AGcttttaaccaGAGT 647_1 -21.73 EX-EX
    648 AGCTTTTAACCAGAGTG 2-11-4 AGcttttaaccagAGTG 648_1 -22.27 EX-EX
    649 AGCTTTTAACCAGAGTGG 1-14-3 AgcttttaaccagagTGG 649_1 -21.63 EX-EX
    650 AGCTTTTAACCAGAGTGGC 1-16-2 AgcttttaaccagagtgGC 650_1 -23.20 EX-EX
    651 AGCTTTTAACCAGAGTGGCA 1-17-2 AgcttttaaccagagtggCA 651_1 -24.11 EX-EX
    652 CAGCTTTTAACCAGAGT 2-12-3 CAgcttttaaccagAGT 652_1 -21.65 EX-EX
    653 CAGCTTTTAACCAGAGTG 3-13-2 CAGcttttaaccagagTG 653_1 -22.27 EX-EX
    654 CAGCTTTTAACCAGAGTGG 1-15-3 CagcttttaaccagagTGG 654_1 -22.97 EX-EX
    655 CAGCTTTTAACCAGAGTGGC 1-17-2 CagcttttaaccagagtgGC 655_1 -24.53 EX-EX
    656 CTTTTAACCAGAGTG 4-7-4 CTTTtaaccagAGTG 656_1 -20.12 EX-EX
    657 CTTTTAACCAGAGTGG 4-9-3 CTTTtaaccagagTGG 657_1 -20.92 EX-EX
    658 CTTTTAACCAGAGTGGC 4-11-2 CTTTtaaccagagtgGC 658_1 -22.48 EX-EX
    659 CTTTTAACCAGAGTGGCA 1-14-3 CttttaaccagagtgGCA 659_1 -22.96 EX-EX
    660 CTTTTAACCAGAGTGGCAT 3-13-3 CTTttaaccagagtggCAT 660_1 -24.65 EX-EX
    661 CTTTTAACCAGAGTGGCATC 2-16-2 CTtttaaccagagtggcaTC 661_1 -23.19 EX-EX
    662 GCTTTTAACCAGAGT 3-9-3 GCTtttaaccagAGT 662_1 -21.02 EX-EX
    663 GCTTTTAACCAGAGTG 4-10-2 GCTTttaaccagagTG 663_1 -21.02 EX-EX
    664 GCTTTTAACCAGAGTGG 1-12-4 GcttttaaccagaGTGG 664_1 -22.24 EX-EX
    665 GCTTTTAACCAGAGTGGC 1-14-3 GcttttaaccagagtGGC 665_1 -23.42 EX-EX
    666 GCTTTTAACCAGAGTGGCA 1-16-2 GcttttaaccagagtggCA 666_1 -22.94 EX-EX
    667 GCTTTTAACCAGAGTGGCAT 1-16-3 GcttttaaccagagtggCAT 667_1 -25.01 EX-EX
    668 TCAGCTTTTAACCAGAGT 2-13-3 TCagcttttaaccagAGT 668_1 -22.18 EX-EX
    669 TCAGCTTTTAACCAGAGTG 2-14-3 TCagcttttaaccagaGTG 669_1 -23.15 EX-EX
    670 TCAGCTTTTAACCAGAGTGG 2-16-2 TCagcttttaaccagagtGG 670_1 -23.41 EX-EX
    671 TTCAGCTTTTAACCAGAGT 2-14-3 TTcagcttttaaccagAGT 671_1 -22.72 EX-EX
    672 TTCAGCTTTTAACCAGAGTG 2-15-3 TTcagcttttaaccagaGTG 672_1 -23.69 EX-EX
    673 TTTCAGCTTTTAACCAGAGT 2-15-3 TTtcagcttttaaccagAGT 673_1 -23.66 EX-EX
    674 TTTTAACCAGAGTGGC 1-11-4 TtttaaccagagTGGC 674_1 -20.81 EX-EX
    675 TTTTAACCAGAGTGGCA 3-11-3 TTTtaaccagagtgGCA 675_1 -22.30 EX-EX
    676 TTTTAACCAGAGTGGCAT 4-11-3 TTTTaaccagagtggCAT 676_1 -23.21 EX-EX
    677 TTTTAACCAGAGTGGCATC 4-13-2 TTTTaaccagagtggcaTC 677_1 -22.57 EX-EX
    678 TTTTAACCAGAGTGGCATCC 2-16-2 TTttaaccagagtggcatCC 678_1 -24.58 EX-EX
    679 ATCAATATCTTCTCACT 1-1-2-7-1-1-1-1-2 AtCAatatcttCtCaCT 679_1 -19.16 5782
    679 ATCAATATCTTCTCACT 5-6-1-2-3 ATCAAtatcttCtcACT 679_2 -21.49 5782
    679 ATCAATATCTTCTCACT 1-1-1-1-1-7-5 AtCaAtatcttcTCACT 679_3 -20.18 5782
    679 ATCAATATCTTCTCACT 1-1-3-8-4 AtCAAtatcttctCACT 679_4 -20.66 5782
    679 ATCAATATCTTCTCACT 3-10-1-1-2 ATCaatatcttctCaCT 679_5 -18.62 5782
    680 TATCAATATCTTCTCACT 2-2-1-7-1-1-1-1-2 TAtcAatatcttCtCaCT 680_1 -19.31 5782
    680 TATCAATATCTTCTCACT 1-1-2-8-1-1-1-1-2 TaTCaatatcttCtCaCT 680_2 -19.89 5782
    680 TATCAATATCTTCTCACT 1-2-3-6-1-2-3 TatCAAtatcttCtcACT 680_3 -20.66 5782
    680 TATCAATATCTTCTCACT 1-2-3-7-2-1-2 TatCAAtatcttcTCaCT 680_4 -20.99 5782
    680 TATCAATATCTTCTCACT 2-1-1-10-4 TAtCaatatcttctCACT 680_5 -20.89 5782
    681 TATCAATATCTTCTCAC 4-7-2-1-3 TATCaatatctTCtCAC 681_1 -21.30 5783
    681 TATCAATATCTTCTCAC 1-2-2-6-2-1-3 TatCAatatctTCtCAC 681_2 -19.73 5783
    681 TATCAATATCTTCTCAC 2-1-1-8-5 TAtCaatatcttCTCAC 681_3 -20.26 5783
    681 TATCAATATCTTCTCAC 1-1-3-7-5 TaTCAatatcttCTCAC 681_4 -21.74 5783
    681 TATCAATATCTTCTCAC 5-9-3 TATCAatatcttctCAC 681_5 -20.83 5783
    682 TTATCAATATCTTCTCAC 1-1-1-1-2-6-2-2-2 TtAtCAatatctTCtcAC 682_1 -18.32 5783
    682 TTATCAATATCTTCTCAC 1-3-1-8-5 TtatCaatatcttCTCAC 682_2 -19.71 5783
    682 TTATCAATATCTTCTCAC 3-10-1-1-3 TTAtcaatatcttCtCAC 682_3 -19.53 5783
    682 TTATCAATATCTTCTCAC 2-1-2-8-1-1-3 TTaTCaatatcttCtCAC 682_4 -20.20 5783
    682 TTATCAATATCTTCTCAC 1-2-3-9-3 TtaTCAatatcttctCAC 682_5 -19.47 5783
    683 TTATCAATATCTTCTCACT 1-1-1-1-1-8-1-1-1-1-2 TtAtCaatatcttCtCaCT 683_1 -19.45 5782
    683 TTATCAATATCTTCTCACT 1-3-1-8-1-1-1-1-2 TtatCaatatcttCtCaCT 683_2 -19.35 5782
    683 TTATCAATATCTTCTCACT 1-1-1-1-1-8-1-2-3 TtAtCaatatcttCtcACT 683_3 -19.33 5782
    683 TTATCAATATCTTCTCACT 1-1-1-2-1-7-1-3-2 TtAtcAatatcttCtcaCT 683_4 -18.18 5782
    683 TTATCAATATCTTCTCACT 1-1-1-2-1-9-4 TtAtcAatatcttctCACT 683_5 -19.84 5782
    684 ACCTTTCTTTAACCCTTT 2-1-1-8-2-1-3 ACcTttctttaaCCcTTT 684_1 -25.24 8113
    684 ACCTTTCTTTAACCCTTT 2-10-1-1-1-1-2 ACctttctttaaCcCtTT 684_2 -22.31 8113
    684 ACCTTTCTTTAACCCTTT 1-1-1-9-1-1-1-1-2 AcCtttctttaaCcCtTT 684_3 -22.01 8113
    684 ACCTTTCTTTAACCCTTT 1-1-1-1-1-9-1-1-2 AcCtTtctttaaccCtTT 684_4 -21.53 8113
    684 ACCTTTCTTTAACCCTTT 1-1-1-11-1-1-2 AcCtttctttaaccCtTT 684_5 -21.23 8113
    685 TACCTTTCTTTAACCCTTT 1-2-1-8-1-1-1-2-2 TacCtttctttaAcCctTT 685_1 -22.44 8113
    685 TACCTTTCTTTAACCCTTT 1-2-1-1-1-7-1-1-1-1-2 TacCtTtctttaaCcCtTT 685_2 -23.32 8113
    685 TACCTTTCTTTAACCCTTT 2-1-1-10-1-1-3 TAcCtttctttaacCcTTT 685_3 -24.28 8113
    685 TACCTTTCTTTAACCCTTT 1-1-1-12-1-1-2 TaCctttctttaaccCtTT 685_4 -22.13 8113
    685 TACCTTTCTTTAACCCTTT 1-2-1-11-1-1-2 TacCtttctttaaccCtTT 685_5 -22.23 8113
    686 ATACCTTTCTTTAACCC 1-2-1-7-1-1-1-1-2 AtaCctttcttTaAcCC 686_1 -20.53 8116
    686 ATACCTTTCTTTAACCC 1-3-1-6-1-3-2 AtacCtttcttTaacCC 686_2 -20.21 8116
    686 ATACCTTTCTTTAACCC 2-2-1-7-2-1-2 ATacCtttctttAAcCC 686_3 -21.89 8116
    686 ATACCTTTCTTTAACCC 1-1-1-1-1-8-1-1-2 AtAcCtttctttaAcCC 686_4 -20.10 8116
    686 ATACCTTTCTTTAACCC 1-2-1-10-3 AtaCctttctttaaCCC 686_5 -21.76 8116
    687 ATACCTTTCTTTAACCCTT 1-3-2-6-1-2-4 AtacCTttctttAacCCTT 687_1 -26.10 8114
    687 ATACCTTTCTTTAACCCTT 1-1-1-1-1-8-1-1-1-1-2 AtAcCtttctttaAcCcTT 687_2 -22.23 8114
    687 ATACCTTTCTTTAACCCTT 1-2-1-9-1-1-1-1-2 AtaCctttctttaAcCcTT 687_3 -21.93 8114
    687 ATACCTTTCTTTAACCCTT 1-2-1-1-1-8-2-1-2 AtaCcTttctttaaCCcTT 687_4 -24.41 8114
    687 ATACCTTTCTTTAACCCTT 1-3-1-11-3 AtacCtttctttaaccCTT 687_5 -22.51 8114
    688 ATACCTTTCTTTAACCCTTT 1-3-1-8-1-1-1-2-2 AtacCtttctttaAcCctTT 688_1 -22.83 8113
    688 ATACCTTTCTTTAACCCTTT 1-3-1-9-1-1-1-1-2 AtacCtttctttaaCcCtTT 688_2 -23.41 8113
    688 ATACCTTTCTTTAACCCTTT 1-4-2-7-1-2-3 AtaccTTtctttaaCccTTT 688_3 -23.98 8113
    688 ATACCTTTCTTTAACCCTTT 1-1-1-1-1-10-1-1-3 AtAcCtttctttaacCcTTT 688_4 -23.63 8113
    688 ATACCTTTCTTTAACCCTTT 1-2-1-12-1-1-2 AtaCctttctttaaccCtTT 688_5 -22.52 8113
    689 ATACCTTTCTTTAACCCT 1-3-2-6-2-2-2 AtacCTttctttAAccCT 689_1 -22.61 8115
    689 ATACCTTTCTTTAACCCT 1-1-1-1-2-8-1-1-2 AtAcCTttctttaaCcCT 689_2 -22.85 8115
    689 ATACCTTTCTTTAACCCT 1-2-1-10-1-1-2 AtaCctttctttaaCcCT 689_3 -21.36 8115
    689 ATACCTTTCTTTAACCCT 1-2-3-10-2 AtaCCTttctttaaccCT 689_4 -24.26 8115
    689 ATACCTTTCTTTAACCCT 1-3-1-11-2 AtacCtttctttaaccCT 689_5 -20.69 8115
    690 TATACCTTTCTTTAACCCT 2-2-1-10-1-1-2 TAtaCctttctttaaCcCT 690_1 -23.60 8115
    690 TATACCTTTCTTTAACCCT 1-4-1-9-1-1-2 TatacCtttctttaaCcCT 690_2 -22.57 8115
    690 TATACCTTTCTTTAACCCT 2-3-1-11-2 TAtacCtttctttaaccCT 690_3 -22.92 8115
    690 TATACCTTTCTTTAACCCT 1-3-1-12-2 TataCctttctttaaccCT 690_4 -21.68 8115
    690 TATACCTTTCTTTAACCCT 1-4-1-11-2 TatacCtttctttaaccCT 690_5 -21.79 8115
    691 TTATACCTTTCTTTAAC 4-7-2-2-2 TTATacctttcTTtaAC 691_1 -18.49 8118
    691 TTATACCTTTCTTTAAC 3-8-1-1-4 TTAtacctttcTtTAAC 691_2 -18.07 8118
    692 TTATACCTTTCTTTAACCC 2-10-1-1-1-2-2 TTatacctttctTtAacCC 692_1 -21.94 8116
    692 TTATACCTTTCTTTAACCC 1-1-1-9-1-4-2 TtAtacctttctTtaacCC 692_2 -20.68 8116
    692 TTATACCTTTCTTTAACCC 1-4-1-7-1-3-2 TtataCctttcttTaacCC 692_3 -21.79 8116
    692 TTATACCTTTCTTTAACCC 1-3-2-8-2-1-2 TtatACctttctttAAcCC 692_4 -22.39 8116
    692 TTATACCTTTCTTTAACCC 1-1-1-2-1-9-1-1-2 TtAtaCctttctttaAcCC 692_5 -21.58 8116
    693 TTATACCTTTCTTTAACC 2-3-1-6-1-3-2 TTataCctttctTtaaCC 693_1 -19.80 8117
    693 TTATACCTTTCTTTAACC 1-1-1-1-2-6-1-3-2 TtAtACctttctTtaaCC 693_2 -19.25 8117
    693 TTATACCTTTCTTTAACC 1-3-2-7-2-1-2 TtatACctttcttTAaCC 693_3 -20.74 8117
    693 TTATACCTTTCTTTAACC 1-1-1-2-1-7-1-2-2 TtAtaCctttcttTaaCC 693_4 -19.08 8117
    693 TTATACCTTTCTTTAACC 1-2-1-1-1-8-4 TtaTaCctttctttAACC 693_5 -20.26 8117
    694 TTTATACCTTTCTTTAACC 2-1-1-8-2-3-2 TTTAtacctttcTTtaaCC 694_1 -20.72 8117
    694 TTTATACCTTTCTTTAACC 1-4-1-6-1-2-4 TttatAcctttcTttAACC 694_2 -20.33 8117
    694 TTTATACCTTTCTTTAACC 2-11-1-1-1-1-2 TTtatacctttctTtAaCC 694_3 -19.72 8117
    694 TTTATACCTTTCTTTAACC 1-1-2-9-1-3-2 TtTAtacctttctTtaaCC 694_4 -20.65 8117
    694 TTTATACCTTTCTTTAACC 1-3-2-7-1-3-2 TttaTAcctttctTtaaCC 694_5 -20.88 8117
    695 TTTATACCTTTCTTTAAC 3-9-3-1-2 TTTatacctttcTTTaAC 695_1 -18.74 8118
    695 TTTATACCTTTCTTTAAC 5-7-2-2-2 TTTATacctttcTTtaAC 695_2 -20.31 8118
    695 TTTATACCTTTCTTTAAC 1-1-3-7-2-2-2 TtTATacctttcTTtaAC 695_3 -18.98 8118
    695 TTTATACCTTTCTTTAAC 4-8-1-1-4 TTTAtacctttcTtTAAC 695_4 -19.89 8118
    695 TTTATACCTTTCTTTAAC 2-3-1-7-5 TTtatAcctttctTTAAC 695_5 -18.02 8118
    696 TTTTATACCTTTCTTTAAC 2-3-1-6-3-2-2 TTttaTacctttCTTtaAC 696_1 -19.79 8118
    696 TTTTATACCTTTCTTTAAC 1-1-2-8-2-1-1-1-2 TtTTatacctttCTtTaAC 696_2 -19.57 8118
    696 TTTTATACCTTTCTTTAAC 2-1-2-7-2-2-3 TTtTAtacctttCTttAAC 696_3 -20.28 8118
    696 TTTTATACCTTTCTTTAAC 3-9-1-1-5 TTTtatacctttCtTTAAC 696_4 -20.62 8118
    696 TTTTATACCTTTCTTTAAC 1-1-3-7-1-1-1-2-2 TtTTAtacctttCtTtaAC 696_5 -19.08 8118
    697 TGTACTTTCCTTTACCA 2-9-1-3-2 TGtactttcctTtacCA 697_1 -20.68 11462
    697 TGTACTTTCCTTTACCA 1-2-1-7-1-3-2 TgtActttcctTtacCA 697_2 -19.66 11462
    697 TGTACTTTCCTTTACCA 1-3-1-6-1-3-2 TgtaCtttcctTtacCA 697_3 -20.46 11462
    697 TGTACTTTCCTTTACCA 2-2-1-8-1-1-2 TGtaCtttcctttAcCA 697_4 -21.56 11462
    697 TGTACTTTCCTTTACCA 1-3-1-9-3 TgtaCtttcctttaCCA 697_5 -22.54 11462
    698 TTATACACCATCATTAT 4-7-3-1-2 TTATacaccatCATTAT 698_1 -21.13 11506
    698 TTATACACCATCATTAT 4-7-2-1-3 TTATacaccatCAtTAT 698_2 -21.64 11506
    698 TTATACACCATCATTAT 3-8-1-1-4 TTAtacaccatCaTTAT 698_3 -19.45 11506
    698 TTATACACCATCATTAT 2-1-2-7-5 TTaTAcaccatcATTAT 698_4 -20.61 11506
    698 TTATACACCATCATTAT 5-9-3 TTATAcaccatcatTAT 698_5 -20.74 11506
    699 TTATACACCATCATTATA 3-2-1-6-2-2-2 TTAtaCaccatcATtaTA 699_1 -19.38 11505
    699 TTATACACCATCATTATA 1-2-3-6-1-1-4 TtaTACaccatcAtTATA 699_2 -20.93 11505
    699 TTATACACCATCATTATA 4-1-1-7-2-1-2 TTATaCaccatcaTTaTA 699_3 -21.44 11505
    699 TTATACACCATCATTATA 2-1-2-8-1-1-3 TTaTAcaccatcaTtATA 699_4 -19.71 11505
    699 TTATACACCATCATTATA 3-2-1-8-4 TTAtaCaccatcatTATA 699_5 -20.75 11505
    700 TTTATACACCATCATTAT 2-1-2-7-3-1-2 TTtATacaccatCATtAT 700_1 -20.67 11506
    700 TTTATACACCATCATTAT 3-1-1-7-2-1-3 TTTaTacaccatCAtTAT 700_2 -21.52 11506
    700 TTTATACACCATCATTAT 1-3-2-6-2-1-3 TttaTAcaccatCAtTAT 700_3 -20.70 11506
    700 TTTATACACCATCATTAT 1-1-3-8-1-1-3 TtTATacaccatcAtTAT 700_4 -20.05 11506
    700 TTTATACACCATCATTAT 3-1-1-9-4 TTTaTacaccatcaTTAT 700_5 -20.34 11506
    701 TTTATACACCATCATTATA 4-8-1-1-2-1-2 TTTAtacaccatCaTTaTA 701_1 -21.57 11505
    701 TTTATACACCATCATTATA 2-2-1-7-1-2-4 TTtaTacaccatCatTATA 701_2 -21.05 11505
    701 TTTATACACCATCATTATA 1-1-1-1-1-8-2-1-3 TtTaTacaccatcATtATA 701_3 -19.83 11505
    701 TTTATACACCATCATTATA 2-2-2-7-2-2-2 TTtaTAcaccatcATtaTA 701_4 -20.24 11505
    701 TTTATACACCATCATTATA 1-1-3-10-1-1-2 TtTATacaccatcatTaTA 701_5 -20.30 11505
    702 ATTTATACACCATCATTAT 1-1-1-2-1-7-3-1-2 AtTtaTacaccatCATtAT 702_1 -20.07 11506
    702 ATTTATACACCATCATTAT 1-1-2-1-1-7-2-2-2 AtTTaTacaccatCAttAT 702_2 -20.07 11506
    702 ATTTATACACCATCATTAT 2-1-2-8-1-1-1-1-2 ATtTAtacaccatCaTtAT 702_3 -19.74 11506
    702 ATTTATACACCATCATTAT 2-3-1-7-1-2-3 ATttaTacaccatCatTAT 702_4 -20.07 11506
    702 ATTTATACACCATCATTAT 1-1-1-1-1-10-4 AtTtAtacaccatcaTTAT 702_5 -18.64 11506
    703 ATTTATACACCATCATTATA 1-4-1-7-1-2-4 AtttaTacaccatCatTATA 703_1 -21.05 11505
    703 ATTTATACACCATCATTATA 2-1-1-2-1-7-2-2-2 ATtTatAcaccatcATtaTA 703_2 -20.32 11505
    703 ATTTATACACCATCATTATA 1-1-1-2-1-8-1-1-1-1-2 AtTtaTacaccatcAtTaTA 703_3 -18.80 11505
    703 ATTTATACACCATCATTATA 1-2-3-8-1-1-1-1-2 AttTATacaccatcAtTaTA 703_4 -21.17 11505
    703 ATTTATACACCATCATTATA 3-1-1-9-1-2-3 ATTTAtacaccatcAttATA 703_5 -19.97 11505
    704 TATTTATACACCATCATTA 1-2-3-6-2-3-2 TatTTAtacaccATcatTA 704_1 -20.37 11507
    704 TATTTATACACCATCATTA 4-8-1-1-2-1-2 TATTtatacaccAtCAtTA 704_2 -21.70 11507
    704 TATTTATACACCATCATTA 1-1-1-1-1-7-1-1-1-1-3 TaTtTatacaccAtCaTTA 704_3 -19.16 11507
    704 TATTTATACACCATCATTA 2-2-1-8-2-2-2 TAttTatacaccaTCatTA 704_4 -19.98 11507
    704 TATTTATACACCATCATTA 2-2-1-10-4 TAttTatacaccatcATTA 704_5 -19.99 11507
    705 TATTTATACACCATCATTAT 2-2-1-1-1-7-2-2-2 TAttTaTacaccatCAttAT 705_1 -21.49 11506
    705 TATTTATACACCATCATTAT 2-1-1-10-1-1-4 TAtTtatacaccatCaTTAT 705_2 -21.44 11506
    705 TATTTATACACCATCATTAT 1-1-1-2-1-8-1-1-1-1-2 TaTttAtacaccatCaTtAT 705_3 -18.27 11506
    705 TATTTATACACCATCATTAT 2-1-2-9-1-3-2 TAtTTatacaccatCattAT 705_4 -19.97 11506
    705 TATTTATACACCATCATTAT 1-2-3-9-1-1-3 TatTTAtacaccatcAtTAT 705_5 -21.11 11506
    706 TTATTTATACACCATCATTA 2-3-1-7-1-1-1-1-3 TTattTatacaccAtCaTTA 706_1 -20.54 11507
    706 TTATTTATACACCATCATTA 1-1-2-1-1-7-1-2-4 TtATtTatacaccAtcATTA 706_2 -20.84 11507
    706 TTATTTATACACCATCATTA 1-1-1-2-1-8-2-2-2 TtAttTatacaccaTCatTA 706_3 -19.52 11507
    706 TTATTTATACACCATCATTA 1-2-3-8-1-1-1-1-2 TtaTTTatacaccaTcAtTA 706_4 -19.96 11507
    706 TTATTTATACACCATCATTA 3-1-1-11-1-1-2 TTAtTtatacaccatcAtTA 706_5 -19.63 11507
    707 ATTATTTATACACCATCAT 2-2-2-6-3-2-2 ATtaTTtatacaCCAtcAT 707_1 -22.41 11509
    707 ATTATTTATACACCATCAT 2-3-1-6-1-2-4 ATtatTtatacaCcaTCAT 707_2 -21.02 11509
    707 ATTATTTATACACCATCAT 1-1-1-1-1-8-3-1-2 AtTaTttatacacCATcAT 707_3 -20.01 11509
    707 ATTATTTATACACCATCAT 1-1-2-1-1-7-1-2-3 AtTAtTtatacacCatCAT 707_4 -20.30 11509
    707 ATTATTTATACACCATCAT 2-1-2-9-1-1-3 ATtATttatacaccAtCAT 707_5 -20.20 11509
    708 ATTATTTATACACCATCA 2-2-2-6-2-2-2 ATtaTTtatacaCCatCA 708_1 -20.96 11510
    708 ATTATTTATACACCATCA 3-1-1-7-1-1-4 ATTaTttatacaCcATCA 708_2 -21.19 11510
    708 ATTATTTATACACCATCA 1-1-3-7-1-3-2 AtTATttatacaCcatCA 708_3 -19.39 11510
    708 ATTATTTATACACCATCA 1-1-1-2-1-7-2-1-2 AtTatTtatacacCAtCA 708_4 -18.57 11510
    708 ATTATTTATACACCATCA 2-1-2-8-1-1-3 ATTATttatacacCaTCA 708_5 -19.79 11510
    709 ATTATTTATACACCATCATT 1-2-3-7-1-1-2-1-2 AttATTtatacacCaTCaTT 709_1 -20.97 11508
    709 ATTATTTATACACCATCATT 1-1-1-2-2-6-1-4-2 AtTatTTatacacCatcaTT 709_2 -19.29 11508
    709 ATTATTTATACACCATCATT 1-1-1-2-1-8-2-1-3 AtTatTtatacaccATcATT 709_3 -19.70 11508
    709 ATTATTTATACACCATCATT 3-1-1-9-1-1-1-1-2 ATTaTttatacaccAtCaTT 709_4 -20.09 11508
    709 ATTATTTATACACCATCATT 2-1-2-1-1-7-1-2-3 ATtATtTatacaccAtcATT 709_5 -20.67 11508
    710 ATTATTTATACACCATC 5-6-3-1-2 ATTATttatacACCaTC 710_1 -21.70 11511
    710 ATTATTTATACACCATC 5-6-2-1-3 ATTATttatacACcATC 710_2 -20.38 11511
    710 ATTATTTATACACCATC 2-2-1-7-5 ATtaTttatacaCCATC 710_3 -20.25 11511
    710 ATTATTTATACACCATC 1-1-2-8-5 AtTAtttatacaCCATC 710_4 -20.42 11511
    710 ATTATTTATACACCATC 5-8-4 ATTATttatacacCATC 710_5 -21.04 11511
    711 AATTATTTATACACCATC 2-2-2-6-3-1-2 AAttATttatacACCaTC 711_1 -18.93 11511
    711 AATTATTTATACACCATC 2-1-3-6-1-1-4 AAtTATttatacAcCATC 711_2 -20.18 11511
    711 AATTATTTATACACCATC 4-1-1-7-5 AATTaTttatacaCCATC 711_3 -22.24 11511
    711 AATTATTTATACACCATC 2-1-2-8-5 AAtTAtttatacaCCATC 711_4 -21.17 11511
    711 AATTATTTATACACCATC 1-1-4-7-2-1-2 AaTTATttatacaCCaTC 711_5 -20.58 11511
    712 AATTATTTATACACCATCA 1-2-1-1-1-6-3-2-2 AatTaTttatacACCatCA 712_1 -20.42 11510
    712 AATTATTTATACACCATCA 2-2-1-7-1-1-2-1-2 AAttAtttatacAcCAtCA 712_2 -18.54 11510
    712 AATTATTTATACACCATCA 1-1-3-7-1-2-4 AaTTAtttatacAccATCA 712_3 -20.67 11510
    712 AATTATTTATACACCATCA 2-1-2-8-2-1-3 AAtTAtttatacaCCaTCA 712_4 -22.20 11510
    712 AATTATTTATACACCATCA 3-1-1-8-1-2-3 AATtAtttatacaCcaTCA 712_5 -19.50 11510
    713 AAATTATTTATACACCATC 3-2-1-6-3-1-3 AAAttAtttataCACcATC 713_1 -19.21 11511
    713 AAATTATTTATACACCATC 1-2-3-6-3-2-2 AaaTTAtttataCACcaTC 713_2 -20.01 11511
    713 AAATTATTTATACACCATC 1-1-3-7-2-1-4 AaATTatttataCAcCATC 713_3 -21.68 11511
    713 AAATTATTTATACACCATC 2-1-2-7-1-1-2-1-2 AAaTTatttataCaCCaTC 713_4 -19.63 11511
    713 AAATTATTTATACACCATC 1-1-2-1-1-8-5 AaATtAtttatacaCCATC 713_5 -20.67 11511
    714 AAATTATTTATACACCAT 1-1-4-6-2-1-3 AaATTAtttataCAcCAT 714_1 -20.31 11512
    714 AAATTATTTATACACCAT 2-2-2-6-1-1-4 AAatTAtttataCaCCAT 714_2 -19.59 11512
    714 AAATTATTTATACACCAT 1-1-3-7-1-1-4 AaATTatttataCaCCAT 714_3 -20.00 11512
    714 AAATTATTTATACACCAT 4-9-5 AAATtatttatacACCAT 714_4 -19.36 11512
    714 AAATTATTTATACACCAT 3-1-2-7-5 AAAtTAtttatacACCAT 714_5 -19.98 11512
    715 AAAATTATTTATACACCAT 2-1-2-7-3-1-3 AAaATtatttatACAcCAT 715_1 -19.29 11512
    715 AAAATTATTTATACACCAT 1-3-2-6-2-1-4 AaaaTTatttatACaCCAT 715_2 -19.68 11512
    715 AAAATTATTTATACACCAT 3-2-1-6-1-1-5 AAAatTatttatAcACCAT 715_3 -19.27 11512
    715 AAAATTATTTATACACCAT 1-1-4-7-1-1-4 AaAATTatttataCaCCAT 715_4 -20.75 11512
    715 AAAATTATTTATACACCAT 2-1-2-9-5 AAaATtatttatacACCAT 715_5 -19.38 11512
    716 TAAAATTATTTATACACC 2-1-3-6-3-1-2 TAaAATtatttaTACaCC 716_1 -18.88 11514
    716 TAAAATTATTTATACACC 3-1-2-7-5 TAAaATtatttatACACC 716_2 -18.95 11514
    716 TAAAATTATTTATACACC 1-1-4-7-5 TaAAATtatttatACACC 716_3 -18.33 11514
    716 TAAAATTATTTATACACC 3-1-2-8-4 TAAaATtatttataCACC 716_4 -18.35 11514
    716 TAAAATTATTTATACACC 2-1-3-8-4 TAaAATtatttataCACC 716_5 -18.35 11514
    717 GTAAAATTATTTATACACC 2-1-3-6-4-1-2 GTaAAAttatttATACaCC 717_1 -21.68 11514
    717 GTAAAATTATTTATACACC 3-2-1-6-2-2-3 GTAaaAttatttATacACC 717_2 -20.00 11514
    717 GTAAAATTATTTATACACC 3-1-2-7-2-1-3 GTAaAAttatttaTAcACC 717_3 -20.86 11514
    717 GTAAAATTATTTATACACC 2-1-3-7-1-1-4 GTaAAAttatttaTaCACC 717_4 -21.11 11514
    717 GTAAAATTATTTATACACC 4-1-1-8-5 GTAAaAttatttatACACC 717_5 -21.46 11514
    718 GTAAAATTATTTATACAC 4-1-1-7-5 GTAAaAttatttaTACAC 718_1 -18.17 11515
    718 GTAAAATTATTTATACAC 3-1-2-7-5 GTAaAAttatttaTACAC 718_2 -18.17 11515
    719 GAGTATATTACCTCCA 3-10-3 GAGtatattacctCCA 719_1 -22.56 15162
    719 GAGTATATTACCTCCA 2-1-1-9-3 GAgTatattacctCCA 719_2 -22.24 15162
    719 GAGTATATTACCTCCA 2-11-3 GAgtatattacctCCA 719_3 -21.15 15162
    719 GAGTATATTACCTCCA 1-1-3-8-3 GaGTAtattacctCCA 719_4 -22.93 15162
    719 GAGTATATTACCTCCA 5-9-2 GAGTAtattacctcCA 719_5 -23.29 15162
    720 CTTTTCTATAATCTCAC 2-2-1-6-3-1-2 CTttTctataaTCTcAC 720_1 -18.54 30553
    720 CTTTTCTATAATCTCAC 3-8-2-1-3 CTTttctataaTCtCAC 720_2 -19.80 30553
    720 CTTTTCTATAATCTCAC 1-1-3-6-1-1-4 CtTTTctataaTcTCAC 720_3 -19.40 30553
    720 CTTTTCTATAATCTCAC 4-8-5 CTTTtctataatCTCAC 720_4 -21.37 30553
    720 CTTTTCTATAATCTCAC 1-3-1-7-5 CtttTctataatCTCAC 720_5 -18.92 30553
    721 CTTTTCTATAATCTCACA 2-3-1-6-1-1-1-1-2 CTtttCtataatCtCaCA 721_1 -20.17 30552
    721 CTTTTCTATAATCTCACA 1-1-1-1-2-6-1-2-3 CtTtTCtataatCtcACA 721_2 -20.15 30552
    721 CTTTTCTATAATCTCACA 1-2-1-1-1-7-2-1-2 CttTtCtataatcTCaCA 721_3 -19.50 30552
    721 CTTTTCTATAATCTCACA 1-1-3-8-1-1-3 CtTTTctataatcTcACA 721_4 -19.49 30552
    721 CTTTTCTATAATCTCACA 3-2-1-8-4 CTTttCtataatctCACA 721_5 -21.97 30552
    722 TCTTTTCTATAATCTCACA 1-1-3-7-1-1-1-1-3 TcTTTtctataaTcTcACA 722_1 -21.04 30552
    722 TCTTTTCTATAATCTCACA 1-4-1-6-1-2-1-1-2 TctttTctataaTctCaCA 722_2 -18.81 30552
    722 TCTTTTCTATAATCTCACA 2-2-1-8-1-2-3 TCttTtctataatCtcACA 722_3 -20.68 30552
    722 TCTTTTCTATAATCTCACA 2-1-1-9-1-3-2 TCtTttctataatCtcaCA 722_4 -20.13 30552
    722 TCTTTTCTATAATCTCACA 2-13-1-1-2 TCttttctataatctCaCA 722_5 -19.52 30552
    723 TCTTTTCTATAATCTCAC 2-1-1-8-2-2-2 TCtTttctataaTCtcAC 723_1 -18.51 30553
    723 TCTTTTCTATAATCTCAC 3-10-1-1-3 TCTtttctataatCtCAC 723_2 -20.36 30553
    723 TCTTTTCTATAATCTCAC 1-2-3-7-1-1-3 TctTTTctataatCtCAC 723_3 -19.57 30553
    723 TCTTTTCTATAATCTCAC 2-2-2-8-4 TCttTTctataatcTCAC 723_4 -20.57 30553
    723 TCTTTTCTATAATCTCAC 1-1-4-8-4 TcTTTTctataatcTCAC 723_5 -20.82 30553
    724 ATCTTTTCTATAATCTCACA 1-1-1-1-1-9-1-1-1-1-2 AtCtTttctataatCtCaCA 724_1 -20.93 30552
    724 ATCTTTTCTATAATCTCACA 1-1-1-11-1-2-3 AtCttttctataatCtcACA 724_2 -20.51 30552
    724 ATCTTTTCTATAATCTCACA 1-2-1-1-1-8-1-2-3 AtcttTtctataatCtcACA 724_3 -20.35 30552
    724 ATCTTTTCTATAATCTCACA 1-3-2-8-1-3-2 AtctTTtctataatCtcaCA 724_4 -20.10 30552
    724 ATCTTTTCTATAATCTCACA 1-1-1-2-1-10-1-1-2 AtCttTtctataatctCaCA 724_5 -19.95 30552
    725 ATCTTTTCTATAATCTCAC 1-1-1-9-1-1-1-1-3 AtCttttctataAtCtCAC 725_1 -19.62 30553
    725 ATCTTTTCTATAATCTCAC 1-2-2-7-1-1-1-1-3 AtcttttctataAtCtCAC 725_2 -19.97 30553
    725 ATCTTTTCTATAATCTCAC 1-1-2-1-1-7-2-2-2 AtCTtTtctataaTCtcAC 725_3 -19.83 30553
    725 ATCTTTTCTATAATCTCAC 1-2-1-1-1-9-4 AtcttTtctataatcTCAC 725_4 -19.36 30553
    725 ATCTTTTCTATAATCTCAC 3-13-3 ATCttttctataatctCAC 725_5 -20.25 30553
    726 ATCTTTTCTATAATCTCA 1-1-2-8-1-1-1-1-2 AtCTtttctataAtCtCA 726_1 -18.77 30554
    726 ATCTTTTCTATAATCTCA 3-1-1-7-1-2-3 ATCtTttctataAtcTCA 726_2 -20.03 30554
    726 ATCTTTTCTATAATCTCA 3-10-2-1-2 ATCttttctataaTCtCA 726_3 -20.31 30554
    726 ATCTTTTCTATAATCTCA 1-1-1-1-2-7-2-1-2 AtCtTTtctataaTCtCA 726_4 -19.49 30554
    726 ATCTTTTCTATAATCTCA 1-1-3-9-4 AtCTTttctataatCTCA 726_5 -21.14 30554
    727 CATCTTTTCTATAATCTCAC 2-11-1-1-1-2-2 CAtcttttctataAtCtcAC 727_1 -19.86 30553
    727 CATCTTTTCTATAATCTCAC 1-1-2-9-1-1-1-2-2 CaTCttttctataAtCtcAC 727_2 -20.49 30553
    727 CATCTTTTCTATAATCTCAC 1-3-1-1-1-8-1-1-3 CatcTtTtctataatCtCAC 727_3 -20.97 30553
    727 CATCTTTTCTATAATCTCAC 1-2-1-1-1-9-1-2-2 CatCtTttctataatCtcAC 727_4 -19.35 30553
    727 CATCTTTTCTATAATCTCAC 2-1-1-2-1-10-3 CAtCttTtctataatctCAC 727_5 -21.92 30553
    728 CATCTTTTCTATAATCTCA 1-3-1-7-2-1-1-1-2 CatcTtttctatAAtCtCA 728_1 -19.26 30554
    728 CATCTTTTCTATAATCTCA 2-3-1-6-2-2-3 CAtctTttctatAAtcTCA 728_2 -20.74 30554
    728 CATCTTTTCTATAATCTCA 1-2-1-8-1-2-1-1-2 CatCttttctatAatCtCA 728_3 -19.21 30554
    728 CATCTTTTCTATAATCTCA 2-1-1-1-1-9-1-1-2 CAtCtTttctataatCtCA 728_4 -20.86 30554
    728 CATCTTTTCTATAATCTCA 1-1-2-13-2 CaTCttttctataatctCA 728_5 -19.23 30554
    729 TCATCTTTTCTATAATCTCA 1-1-1-2-1-7-2-1-1-1-2 TcAtcTtttctatAAtCtCA 729_1 -20.53 30554
    729 TCATCTTTTCTATAATCTCA 2-4-1-6-2-3-2 TCatctTttctatAAtctCA 729_2 -20.57 30554
    729 TCATCTTTTCTATAATCTCA 2-2-1-8-1-2-1-1-2 TCatCttttctatAatCtCA 729_3 -21.70 30554
    729 TCATCTTTTCTATAATCTCA 3-13-1-1-2 TCAtcttttctataatCtCA 729_4 -22.07 30554
    729 TCATCTTTTCTATAATCTCA 3-1-1-13-2 TCAtCttttctataatctCA 729_5 -22.07 30554
    730 TCATCTTTTCTATAATCTC 3-2-1-7-2-2-2 TCAtcTtttctatAAtcTC 730_1 -20.15 30555
    730 TCATCTTTTCTATAATCTC 3-1-1-8-1-3-2 TCAtCttttctatAatcTC 730_2 -20.09 30555
    730 TCATCTTTTCTATAATCTC 2-2-1-9-1-2-2 TCatCttttctataAtcTC 730_3 -18.83 30555
    730 TCATCTTTTCTATAATCTC 3-13-3 TCAtcttttctataatCTC 730_4 -20.65 30555
    730 TCATCTTTTCTATAATCTC 2-2-2-10-3 TCatCTtttctataatCTC 730_5 -21.35 30555
    731 GTCATCTTTTCTATAATC 1-1-1-2-1-6-3-1-2 GtCatCttttctATAaTC 731_1 -19.76 30557
    731 GTCATCTTTTCTATAATC 1-1-1-1-2-6-1-2-3 GtCaTCttttctAtaATC 731_2 -19.19 30557
    731 GTCATCTTTTCTATAATC 4-9-1-2-2 GTCAtcttttctaTaaTC 731_3 -20.42 30557
    731 GTCATCTTTTCTATAATC 3-2-1-8-4 GTCatCttttctatAATC 731_4 -20.51 30557
    731 GTCATCTTTTCTATAATC 1-1-4-10-2 GtCATCttttctataaTC 731_5 -20.23 30557
    732 TGTCATCTTTTCTATAAT 2-1-1-8-2-1-3 TGtCatcttttcTAtAAT 732_1 -19.36 30558
    732 TGTCATCTTTTCTATAAT 2-1-2-7-2-2-2 TGtCAtcttttcTAtaAT 732_2 -20.51 30558
    732 TGTCATCTTTTCTATAAT 1-1-3-7-1-3-2 TgTCAtcttttcTataAT 732_3 -19.51 30558
    732 TGTCATCTTTTCTATAAT 4-10-4 TGTCatcttttctaTAAT 732_4 -21.42 30558
    732 TGTCATCTTTTCTATAAT 2-2-1-9-4 TGtcAtcttttctaTAAT 732_5 -18.57 30558
    733 ACTTAATTATACTTCCA 5-6-2-2-2 ACTTAattataCTtcCA 733_1 -21.55 30664
    733 ACTTAATTATACTTCCA 2-1-2-6-1-2-3 ACtTAattataCttCCA 733_2 -21.02 30664
    733 ACTTAATTATACTTCCA 1-2-2-7-5 ActTAattatacTTCCA 733_3 -20.65 30664
    733 ACTTAATTATACTTCCA 4-8-1-1-3 ACTTaattatacTtCCA 733_4 -21.09 30664
    733 ACTTAATTATACTTCCA 1-1-1-1-1-8-4 AcTtAattatactTCCA 733_5 -18.37 30664
    734 CACTTAATTATACTTCC 2-1-2-6-2-2-2 CAcTTaattatACttCC 734_1 -20.10 30665
    734 CACTTAATTATACTTCC 5-6-1-2-3 CACTTaattatActTCC 734_2 -21.76 30665
    734 CACTTAATTATACTTCC 1-1-1-1-1-7-2-1-2 CaCtTaattataCTtCC 734_3 -19.09 30665
    734 CACTTAATTATACTTCC 1-1-3-7-1-1-3 CaCTTaattataCtTCC 734_4 -20.59 30665
    734 CACTTAATTATACTTCC 2-1-2-8-4 CAcTTaattatacTTCC 734_5 -20.52 30665
    735 CACTTAATTATACTTCCA 2-2-1-7-2-1-3 CActTaattataCTtCCA 735_1 -22.96 30664
    735 CACTTAATTATACTTCCA 2-1-1-1-1-6-1-3-2 CAcTtAattataCttcCA 735_2 -19.31 30664
    735 CACTTAATTATACTTCCA 1-1-3-8-1-1-3 CaCTTaattatacTtCCA 735_3 -22.43 30664
    735 CACTTAATTATACTTCCA 1-1-1-1-2-7-1-2-2 CaCtTAattatacTtcCA 735_4 -19.51 30664
    735 CACTTAATTATACTTCCA 2-2-1-9-4 CActTaattatactTCCA 735_5 -21.76 30664
    736 ACACTTAATTATACTTCCA 1-1-2-1-1-6-2-3-2 AcACtTaattatACttcCA 736_1 -20.93 30664
    736 ACACTTAATTATACTTCCA 2-2-1-7-1-1-1-2-2 ACacTtaattatAcTtcCA 736_2 -19.38 30664
    736 ACACTTAATTATACTTCCA 1-1-1-1-1-8-1-2-3 AcAcTtaattataCttCCA 736_3 -21.10 30664
    736 ACACTTAATTATACTTCCA 1-1-1-2-1-9-4 AcActTaattatactTCCA 736_4 -21.31 30664
    736 ACACTTAATTATACTTCCA 2-2-2-11-2 ACacTTaattatacttcCA 736_5 -19.91 30664
    737 ACACTTAATTATACTTCC 1-3-1-7-2-1-3 AcacTtaattatACtTCC 737_1 -19.24 30665
    737 ACACTTAATTATACTTCC 1-1-1-1-2-6-2-2-2 AcAcTTaattatACttCC 737_2 -19.64 30665
    737 ACACTTAATTATACTTCC 2-1-2-7-1-1-1-1-2 ACaCTtaattatAcTtCC 737_3 -20.12 30665
    737 ACACTTAATTATACTTCC 3-2-1-8-4 ACActTaattatacTTCC 737_4 -21.53 30665
    737 ACACTTAATTATACTTCC 1-1-2-1-1-9-3 AcACtTaattatactTCC 737_5 -19.40 30665
    738 ACACTTAATTATACTTC 5-7-5 ACACTtaattatACTTC 738_1 -20.47 30666
    738 ACACTTAATTATACTTC 3-1-1-7-5 ACAcTtaattatACTTC 738_2 -18.40 30666
    738 ACACTTAATTATACTTC 2-1-2-7-5 ACaCTtaattatACTTC 738_3 -18.51 30666
    738 ACACTTAATTATACTTC 5-7-2-1-2 ACACTtaattatACtTC 738_4 -18.77 30666
    738 ACACTTAATTATACTTC 5-7-1-1-3 ACACTtaattatAcTTC 738_5 -18.40 30666
    738 ACACTTAATTATACTTC 5-8-4 ACACTtaattataCTTC 738_6 -19.88 30666
    739 TACACTTAATTATACTTCC 3-2-1-7-2-2-2 TACacTtaattatACttCC 739_1 -21.57 30665
    739 TACACTTAATTATACTTCC 1-4-1-7-1-1-4 TacacTtaattatAcTTCC 739_2 -19.87 30665
    739 TACACTTAATTATACTTCC 1-2-3-8-1-2-2 TacACTtaattataCttCC 739_3 -20.88 30665
    739 TACACTTAATTATACTTCC 4-11-4 TACActtaattatacTTCC 739_4 -23.04 30665
    739 TACACTTAATTATACTTCC 2-1-1-1-1-10-3 TAcAcTtaattatactTCC 739_5 -20.03 30665
    740 TACACTTAATTATACTTC 4-1-1-7-5 TACAcTtaattatACTTC 740_1 -20.63 30666
    740 TACACTTAATTATACTTC 3-1-2-7-5 TACaCTtaattatACTTC 740_2 -20.74 30666
    740 TACACTTAATTATACTTC 2-1-3-7-5 TAcACTtaattatACTTC 740_3 -20.21 30666
    740 TACACTTAATTATACTTC 3-1-2-8-4 TACaCTtaattataCTTC 740_4 -20.14 30666
    740 TACACTTAATTATACTTC 1-1-4-8-4 TaCACTtaattataCTTC 740_5 -20.48 30666
    741 TTACACTTAATTATACTTC 2-1-2-7-4-1-2 TTaCActtaattATACtTC 741_1 -21.41 30666
    741 TTACACTTAATTATACTTC 5-7-3-1-3 TTACActtaattATAcTTC 741_2 -22.67 30666
    741 TTACACTTAATTATACTTC 4-1-1-6-2-1-4 TTACaCttaattATaCTTC 741_3 -22.54 30666
    741 TTACACTTAATTATACTTC 2-1-2-7-2-1-4 TTaCActtaattATaCTTC 741_4 -21.48 30666
    741 TTACACTTAATTATACTTC 5-7-1-1-5 TTACActtaattAtACTTC 741_5 -22.04 30666
    742 TTACACTTAATTATACTT 5-7-3-1-2 TTACActtaattATAcTT 742_1 -20.18 30667
    742 TTACACTTAATTATACTT 5-7-2-1-3 TTACActtaattATaCTT 742_2 -20.62 30667
    742 TTACACTTAATTATACTT 5-7-1-1-4 TTACActtaattAtACTT 742_3 -19.54 30667
    743 TTTACACTTAATTATACTT 4-1-1-6-4-1-2 TTTAcActtaatTATAcTT 743_1 -21.26 30667
    743 TTTACACTTAATTATACTT 3-1-2-6-3-1-3 TTTaCActtaatTATaCTT 743_2 -22.57 30667
    743 TTTACACTTAATTATACTT 4-8-2-1-4 TTTAcacttaatTAtACTT 743_3 -20.48 30667
    743 TTTACACTTAATTATACTT 1-1-4-6-2-2-3 TtTACActtaatTAtaCTT 743_4 -21.20 30667
    743 TTTACACTTAATTATACTT 2-2-2-6-1-1-5 TTtaCActtaatTaTACTT 743_5 -21.02 30667
    744 TTTACACTTAATTATACT 3-1-2-6-3-1-2 TTTaCActtaatTATaCT 744_1 -20.75 30668
    744 TTTACACTTAATTATACT 1-1-4-6-3-1-2 TtTACActtaatTATaCT 744_2 -21.06 30668
    744 TTTACACTTAATTATACT 2-1-3-6-2-1-3 TTtACActtaatTAtACT 744_3 -19.03 30668
    744 TTTACACTTAATTATACT 4-8-1-1-4 TTTAcacttaatTaTACT 744_4 -19.42 30668
    744 TTTACACTTAATTATACT 1-1-1-1-2-6-1-1-4 TtTaCActtaatTaTACT 744_5 -19.12 30668
    745 ATTTACACTTAATTATACT 4-1-1-6-4-1-2 ATTTaCacttaaTTATaCT 745_1 -22.20 30668
    745 ATTTACACTTAATTATACT 2-1-3-6-3-1-3 ATtTACacttaaTTAtACT 745_2 -21.43 30668
    745 ATTTACACTTAATTATACT 5-7-2-1-4 ATTTAcacttaaTTaTACT 745_3 -22.44 30668
    745 ATTTACACTTAATTATACT 1-2-3-6-2-1-4 AttTACacttaaTTaTACT 745_4 -20.95 30668
    745 ATTTACACTTAATTATACT 3-1-2-6-1-1-5 ATTTACacttaaTtATACT 745_5 -20.92 30668
    746 ATTTACACTTAATTATAC 5-8-5 ATTTAcacttaatTATAC 746_1 -19.94 30669
    746 ATTTACACTTAATTATAC 4-1-1-7-5 ATTTaCacttaatTATAC 746_2 -19.40 30669
    746 ATTTACACTTAATTATAC 2-1-3-7-5 ATtTACacttaatTATAC 746_3 -19.70 30669
    747 AATTTACACTTAATTATAC 3-1-2-6-3-1-3 AATtTAcacttaATTaTAC 747_1 -19.51 30669
    747 AATTTACACTTAATTATAC 1-1-4-6-3-1-3 AaTTTAcacttaATTaTAC 747_2 -19.51 30669
    747 AATTTACACTTAATTATAC 4-8-2-1-4 AATTtacacttaATTATAC 747_3 -18.04 30669
    747 AATTTACACTTAATTATAC 5-7-1-1-5 AATTTacacttaAtTATAC 747_4 -19.79 30669
    747 AATTTACACTTAATTATAC 2-1-3-6-1-1-5 AAtTTAcacttaAtTATAC 747_5 -19.26 30669
    748 AATTTACACTTAATTATACT 3-2-2-6-4-1-2 AATttACacttaaTTATaCT 748_1 -21.50 30668
    748 AATTTACACTTAATTATACT 5-1-1-6-3-1-3 AATTTaCacttaaTTAtACT 748_2 -21.87 30668
    748 AATTTACACTTAATTATACT 3-1-3-6-2-1-4 AATtTACacttaaTTaTACT 748_3 -22.95 30668
    748 AATTTACACTTAATTATACT 1-1-4-7-2-1-1-1-2 AaTTTAcacttaaTTaTaCT 748_4 -20.23 30668
    748 AATTTACACTTAATTATACT 2-1-2-1-1-6-1-1-5 AAtTTaCacttaaTtATACT 748_5 -20.55 30668
    749 TAATTTACACTTAATTATAC 2-1-4-6-4-1-2 TAaTTTAcacttaATTAtAC 749_1 -20.98 30669
    749 TAATTTACACTTAATTATAC 5-8-3-1-3 TAATTtacacttaATTaTAC 749_2 -20.60 30669
    749 TAATTTACACTTAATTATAC 2-2-3-6-3-1-3 TAatTTAcacttaATTaTAC 749_3 -20.80 30669
    749 TAATTTACACTTAATTATAC 4-1-2-6-2-1-4 TAATtTAcacttaATTATAC 749_4 -21.41 30669
    749 TAATTTACACTTAATTATAC 1-1-1-1-2-7-1-1-5 TaAtTTacacttaAtTATAC 749_5 -18.92 30669
    750 TAATTTACACTTAATTAT 5-8-5 TAATTtacacttaATTAT 750_1 -18.27 30671
    750 TAATTTACACTTAATTAT 4-1-1-7-5 TAATtTacacttaATTAT 750_2 -18.18 30671
    750 TAATTTACACTTAATTAT 2-1-3-7-5 TAaTTTacacttaATTAT 750_3 -18.18 30671
    750 TAATTTACACTTAATTAT 1-1-4-7-5 TaATTTacacttaATTAT 750_4 -18.16 30671
    751 TAATTTACACTTAATTATA 5-7-4-1-2 TAATTtacacttAATTaTA 751_1 -18.87 30670
    751 TAATTTACACTTAATTATA 5-7-2-1-4 TAATTtacacttAAtTATA 751_2 -19.05 30670
    751 TAATTTACACTTAATTATA 3-1-2-6-2-1-4 TAAtTTacacttAAtTATA 751_3 -18.54 30670
    751 TAATTTACACTTAATTATA 4-1-1-6-1-1-5 TAATtTacacttAaTTATA 751_4 -19.40 30670
    751 TAATTTACACTTAATTATA 2-1-3-6-1-1-5 TAaTTTacacttAaTTATA 751_5 -19.41 30670
    752 TTAATTTACACTTAATTATA 3-1-3-6-4-1-2 TTAaTTTacacttAATTaTA 752_1 -20.61 30670
    752 TTAATTTACACTTAATTATA 5-1-1-6-3-1-3 TTAATtTacacttAATtATA 752_2 -20.28 30670
    752 TTAATTTACACTTAATTATA 2-1-4-6-2-1-4 TTaATTTacacttAAtTATA 752_3 -20.77 30670
    752 TTAATTTACACTTAATTATA 3-2-2-6-1-1-5 TTAatTTacacttAaTTATA 752_4 -20.28 30670
    752 TTAATTTACACTTAATTATA 4-1-1-8-1-1-4 TTAAtTtacacttaAtTATA 752_5 -18.80 30670
    753 TTAATTTACACTTAATTAT 4-1-1-6-3-1-3 TTAAtTtacactTAAtTAT 753_1 -18.65 30671
    753 TTAATTTACACTTAATTAT 3-1-2-6-2-1-4 TTAaTTtacactTAaTTAT 753_2 -19.52 30671
    753 TTAATTTACACTTAATTAT 2-1-2-7-2-1-4 TTaATttacactTAaTTAT 753_3 -18.68 30671
    753 TTAATTTACACTTAATTAT 5-7-1-1-5 TTAATttacactTaATTAT 753_4 -20.00 30671
    753 TTAATTTACACTTAATTAT 2-1-3-6-1-1-5 TTaATTtacactTaATTAT 753_5 -19.47 30671
    754 TTTAATTTACACTTAATTA 3-1-2-6-3-1-3 TTTaATttacacTTAaTTA 754_1 -19.46 30672
    754 TTTAATTTACACTTAATTA 5-7-2-1-4 TTTAAtttacacTTaATTA 754_2 -19.54 30672
    754 TTTAATTTACACTTAATTA 4-1-1-6-2-1-4 TTTAaTttacacTTaATTA 754_3 -19.46 30672
    754 TTTAATTTACACTTAATTA 1-1-1-1-2-6-2-1-4 TtTaATttacacTTaATTA 754_4 -18.11 30672
    754 TTTAATTTACACTTAATTA 1-1-4-7-3-1-2 TtTAATttacactTAAtTA 754_5 -18.02 30672
    755 TTTAATTTACACTTAATTAT 4-1-2-6-3-1-3 TTTAaTTtacactTAAtTAT 755_1 -20.90 30671
    755 TTTAATTTACACTTAATTAT 3-1-2-7-2-1-4 TTTaATttacactTAaTTAT 755_2 -20.50 30671
    755 TTTAATTTACACTTAATTAT 1-1-5-6-2-1-4 TtTAATTtacactTAaTTAT 755_3 -21.34 30671
    755 TTTAATTTACACTTAATTAT 5-8-1-1-5 TTTAAtttacactTaATTAT 755_4 -20.58 30671
    755 TTTAATTTACACTTAATTAT 2-2-3-6-1-1-5 TTtaATTtacactTaATTAT 755_5 -20.05 30671
    756 ATTTAATTTACACTTAATTA 5-1-1-6-4-1-2 ATTTAaTttacacTTAAtTA 756_1 -21.11 30672
    756 ATTTAATTTACACTTAATTA 3-2-2-6-3-1-3 ATTtaATttacacTTAaTTA 756_2 -20.29 30672
    756 ATTTAATTTACACTTAATTA 4-1-2-6-2-1-4 ATTTaATttacacTTaATTA 756_3 -21.50 30672
    756 ATTTAATTTACACTTAATTA 2-1-4-6-2-2-3 ATtTAATttacacTTaaTTA 756_4 -20.39 30672
    756 ATTTAATTTACACTTAATTA 2-1-4-8-5 ATtTAATttacacttAATTA 756_5 -20.08 30672
    757 ATTTAATTTACACTTAATT 5-7-3-1-3 ATTTAatttacaCTTaATT 757_1 -20.52 30673
    757 ATTTAATTTACACTTAATT 4-1-1-7-2-1-3 ATTTaAtttacacTTaATT 757_2 -18.02 30673
    757 ATTTAATTTACACTTAATT 2-1-3-7-2-1-3 ATtTAAtttacacTTaATT 757_3 -18.04 30673
    757 ATTTAATTTACACTTAATT 4-1-1-8-5 ATTTaAtttacactTAATT 757_4 -18.34 30673
    757 ATTTAATTTACACTTAATT 2-1-3-8-5 ATtTAAtttacactTAATT 757_5 -18.37 30673
    758 TATTTAATTTACACTTAAT 3-1-2-6-4-1-2 TATtTAatttacACTTaAT 758_1 -20.16 30674
    758 TATTTAATTTACACTTAAT 2-1-3-6-2-1-4 TAtTTAatttacACtTAAT 758_2 -19.37 30674
    758 TATTTAATTTACACTTAAT 1-1-4-6-2-1-4 TaTTTAatttacACtTAAT 758_3 -19.19 30674
    758 TATTTAATTTACACTTAAT 3-1-2-6-1-1-5 TATtTAatttacAcTTAAT 758_4 -19.44 30674
    758 TATTTAATTTACACTTAAT 2-1-3-6-1-1-5 TAtTTAatttacAcTTAAT 758_5 -19.00 30674
    759 TATTTAATTTACACTTAATT 2-1-4-6-4-1-2 TAtTTAAtttacaCTTAaTT 759_1 -21.54 30673
    759 TATTTAATTTACACTTAATT 5-1-1-6-3-1-3 TATTTaAtttacaCTTaATT 759_2 -21.92 30673
    759 TATTTAATTTACACTTAATT 4-1-2-7-3-1-2 TATTTAAtttacacTTAaTT 759_3 -19.35 30673
    759 TATTTAATTTACACTTAATT 3-1-3-7-2-1-3 TATtTAAtttacacTTaATT 759_4 -20.28 30673
    759 TATTTAATTTACACTTAATT 2-1-4-8-5 TAtTTAAtttacactTAATT 759_5 -20.16 30673
    760 CTATTTAATTTACACTT 5-6-1-1-4 CTATTtaatttAcACTT 760_1 -19.07 30677
    760 CTATTTAATTTACACTT 5-7-5 CTATTtaatttaCACTT 760_2 -20.97 30677
    760 CTATTTAATTTACACTT 2-2-1-7-5 CTatTtaatttaCACTT 760_3 -18.08 30677
    760 CTATTTAATTTACACTT 5-7-2-1-2 CTATTtaatttaCAcTT 760_4 -18.90 30677
    760 CTATTTAATTTACACTT 5-7-1-1-3 CTATTtaatttaCaCTT 760_5 -19.01 30677
    761 CTATTTAATTTACACTTAA 2-1-3-6-4-1-2 CTaTTTaatttaCACTTAA 761_1 -20.98 30675
    761 CTATTTAATTTACACTTAA 3-1-2-6-3-1-3 CTAtTTaatttaCACtTAA 761_2 -21.73 30675
    761 CTATTTAATTTACACTTAA 4-1-1-6-2-1-4 CTATtTaatttaCAcTTAA 761_3 -21.80 30675
    761 CTATTTAATTTACACTTAA 5-7-2-2-3 CTATTtaatttaCActTAA 761_4 -20.86 30675
    761 CTATTTAATTTACACTTAA 2-1-3-6-1-1-5 CTaTTTaatttaCaCTTAA 761_5 -21.29 30675
    762 CTATTTAATTTACACTTA 5-7-3-1-2 CTATTtaatttaCACtTA 762_1 -21.50 30676
    762 CTATTTAATTTACACTTA 3-2-1-6-3-1-2 CTAttTaatttaCACtTA 762_2 -20.17 30676
    762 CTATTTAATTTACACTTA 3-1-1-7-2-1-3 CTAtTtaatttaCAcTTA 762_3 -19.37 30676
    762 CTATTTAATTTACACTTA 2-1-3-6-2-1-3 CTaTTTaatttaCAcTTA 762_4 -20.43 30676
    762 CTATTTAATTTACACTTA 2-1-3-6-1-1-4 CTaTTTaatttaCaCTTA 762_5 -20.54 30676
    763 CTATTTAATTTACACTTAAT 2-1-4-6-3-2-2 CTaTTTAatttacACTtaAT 763_1 -21.79 30674
    763 CTATTTAATTTACACTTAAT 4-1-2-6-2-1-4 CTATtTAatttacACtTAAT 763_2 -23.29 30674
    763 CTATTTAATTTACACTTAAT 1-2-4-6-1-1-5 CtaTTTAatttacAcTTAAT 763_3 -20.68 30674
    763 CTATTTAATTTACACTTAAT 3-1-3-6-1-1-2-1-2 CTAtTTAatttacAcTTaAT 763_4 -21.14 30674
    763 CTATTTAATTTACACTTAAT 5-1-1-7-3-1-2 CTATTtAatttacaCTTaAT 763_5 -22.14 30674
    764 TCTATTTAATTTACACTTA 2-1-3-6-4-1-2 TCtATTtaatttACACtTA 764_1 -21.94 30676
    764 TCTATTTAATTTACACTTA 4-1-1-6-3-1-3 TCTAtTtaatttACAcTTA 764_2 -22.47 30676
    764 TCTATTTAATTTACACTTA 3-1-2-7-2-1-3 TCTaTTtaatttaCAcTTA 764_3 -21.69 30676
    764 TCTATTTAATTTACACTTA 1-1-4-7-2-2-2 TcTATTtaatttaCActTA 764_4 -20.33 30676
    764 TCTATTTAATTTACACTTA 3-2-1-7-1-1-4 TCTatTtaatttaCaCTTA 764_5 -20.85 30676
    765 TCTATTTAATTTACACTT 3-2-1-6-2-1-3 TCTatTtaatttACaCTT 765_1 -19.21 30677
    765 TCTATTTAATTTACACTT 3-1-2-7-5 TCTaTTtaatttaCACTT 765_2 -21.53 30677
    765 TCTATTTAATTTACACTT 2-1-3-7-5 TCtATTtaatttaCACTT 765_3 -20.81 30677
    765 TCTATTTAATTTACACTT 4-1-1-7-2-1-2 TCTAtTtaatttaCAcTT 765_4 -19.64 30677
    765 TCTATTTAATTTACACTT 1-1-4-7-2-1-2 TcTATTtaatttaCAcTT 765_5 -19.12 30677
    766 TCTATTTAATTTACACTTAA 2-1-2-1-1-6-3-2-2 TCtATtTaatttaCACttAA 766_1 -20.25 30675
    766 TCTATTTAATTTACACTTAA 4-1-1-7-2-1-4 TCTAtTtaatttaCAcTTAA 766_2 -22.62 30675
    766 TCTATTTAATTTACACTTAA 1-1-1-1-3-6-2-2-3 TcTaTTTaatttaCActTAA 766_3 -20.38 30675
    766 TCTATTTAATTTACACTTAA 3-1-2-7-1-1-2-1-2 TCTaTTtaatttaCaCTTAA 766_4 -20.27 30675
    766 TCTATTTAATTTACACTTAA 2-3-2-6-1-1-1-1-3 TCtatTTaatttaCaCtTAA 766_5 -19.51 30675
    767 ATCTATTTAATTTACACTT 2-1-2-7-4-1-2 ATcTAtttaattTACAcTT 767_1 -21.49 30677
    767 ATCTATTTAATTTACACTT 1-1-4-6-3-1-3 AtCTATttaattTACaCTT 767_2 -23.18 30677
    767 ATCTATTTAATTTACACTT 4-1-1-6-2-1-4 ATCTaTttaattTAcACTT 767_3 -22.64 30677
    767 ATCTATTTAATTTACACTT 5-7-2-2-3 ATCTAtttaattTAcaCTT 767_4 -22.78 30677
    767 ATCTATTTAATTTACACTT 1-1-4-6-1-1-5 AtCTATttaattTaCACTT 767_5 -23.52 30677
    768 ATCTATTTAATTTACACTTA 1-2-4-6-2-1-1-1-2 AtcTATTtaatttACaCtTA 768_1 -21.10 30676
    768 ATCTATTTAATTTACACTTA 1-1-3-1-1-6-1-1-5 AtCTAtTtaatttAcACTTA 768_2 -22.17 30676
    768 ATCTATTTAATTTACACTTA 3-2-2-6-1-1-2-1-2 ATCtaTTtaatttAcACtTA 768_3 -20.60 30676
    768 ATCTATTTAATTTACACTTA 1-1-2-1-2-7-2-2-2 AtCTaTTtaatttaCActTA 768_4 -20.80 30676
    768 ATCTATTTAATTTACACTTA 3-1-1-1-1-7-1-2-3 ATCtAtTtaatttaCacTTA 768_5 -19.72 30676
    769 TATCTATTTAATTTACACTT 1-1-2-1-2-6-4-1-2 TaTCTATttaattTACAcTT 769_1 -22.65 30677
    769 TATCTATTTAATTTACACTT 2-1-1-1-2-6-2-1-4 TAtCtATttaattTAcACTT 769_2 -22.23 30677
    769 TATCTATTTAATTTACACTT 2-1-4-6-2-3-2 TAtCTATttaattTAcacTT 769_3 -22.66 30677
    769 TATCTATTTAATTTACACTT 1-3-3-6-1-1-5 TatcTATttaattTaCACTT 769_4 -22.96 30677
    769 TATCTATTTAATTTACACTT 1-1-3-1-1-6-1-3-3 TaTCTaTttaattTacaCTT 769_5 -21.15 30677
    770 TATCTATTTAATTTACACT 2-1-3-6-3-1-3 TAtCTAtttaatTTAcACT 770_1 -22.62 30678
    770 TATCTATTTAATTTACACT 1-1-4-6-3-1-3 TaTCTAtttaatTTAcACT 770_2 -22.62 30678
    770 TATCTATTTAATTTACACT 2-2-2-6-2-1-4 TAtcTAtttaatTTaCACT 770_3 -21.84 30678
    770 TATCTATTTAATTTACACT 1-2-3-6-1-1-5 TatCTAtttaatTtACACT 770_4 -21.72 30678
    770 TATCTATTTAATTTACACT 4-1-1-7-2-1-3 TATCtAtttaattTAcACT 770_5 -21.09 30678
    771 TTATCTATTTAATTTACACT 2-4-1-6-4-1-2 TTatctAtttaatTTACaCT 771_1 -20.22 30678
    771 TTATCTATTTAATTTACACT 2-2-3-6-3-2-2 TTatCTAtttaatTTAcaCT 771_2 -22.76 30678
    771 TTATCTATTTAATTTACACT 1-1-5-6-2-2-3 TtATCTAtttaatTTacACT 771_3 -22.87 30678
    771 TTATCTATTTAATTTACACT 2-2-3-6-1-2-4 TTatCTAtttaatTtaCACT 771_4 -22.94 30678
    771 TTATCTATTTAATTTACACT 5-1-1-7-1-2-3 TTATCtAtttaattTacACT 771_5 -21.68 30678
    772 TTTATCTATTTAATTTACA 1-1-3-7-4-1-2 TtTATctatttaATTTaCA 772_1 -19.96 30680
    772 TTTATCTATTTAATTTACA 4-1-1-6-3-2-2 TTTAtCtatttaATTtaCA 772_2 -19.70 30680
    772 TTTATCTATTTAATTTACA 3-1-2-6-2-1-4 TTTaTCtatttaATtTACA 772_3 -21.24 30680
    772 TTTATCTATTTAATTTACA 5-7-2-2-3 TTTATctatttaATttACA 772_4 -19.82 30680
    772 TTTATCTATTTAATTTACA 1-1-4-6-1-1-5 TtTATCtatttaAtTTACA 772_5 -21.42 30680
    773 TTTTATCTATTTAATTTAC 2-1-3-6-3-1-3 TTtTATctatttAATtTAC 773_1 -19.10 30681
    773 TTTTATCTATTTAATTTAC 1-1-4-6-2-1-4 TtTTATctatttAAtTTAC 773_2 -18.66 30681
    773 TTTTATCTATTTAATTTAC 3-1-2-6-1-1-5 TTTTATctatttAaTTTAC 773_3 -18.15 30681
    773 TTTTATCTATTTAATTTAC 1-2-3-6-1-1-5 TttTATctatttAaTTTAC 773_4 -18.29 30681
    773 TTTTATCTATTTAATTTAC 2-1-3-6-1-2-4 TTtTATctatttAatTTAC 773_5 -18.15 30681
    774 TTTTATCTATTTAATTTACA 1-1-2-1-1-7-4-1-2 TtTTaTctatttaATTTaCA 774_1 -19.84 30680
    774 TTTTATCTATTTAATTTACA 2-1-1-1-2-6-3-1-3 TTtTaTCtatttaATTTACA 774_2 -20.79 30680
    774 TTTTATCTATTTAATTTACA 4-2-1-6-2-1-4 TTTTatCtatttaATtTACA 774_3 -21.94 30680
    774 TTTTATCTATTTAATTTACA 1-1-5-6-2-3-2 TtTTATCtatttaATttaCA 774_4 -21.32 30680
    774 TTTTATCTATTTAATTTACA 2-2-3-6-1-2-4 TTttATCtatttaAttTACA 774_5 -20.67 30680
    775 CTTTTATCTATTTAATTTA 5-7-4-1-2 CTTTTatctattTAATtTA 775_1 -21.18 30682
    775 CTTTTATCTATTTAATTTA 5-7-2-1-4 CTTTTatctattTAaTTTA 775_2 -21.18 30682
    775 CTTTTATCTATTTAATTTA 5-7-2-2-3 CTTTTatctattTAatTTA 775_3 -20.23 30682
    775 CTTTTATCTATTTAATTTA 3-1-1-7-1-1-5 CTTtTatctattTaATTTA 775_4 -19.83 30682
    775 CTTTTATCTATTTAATTTA 2-1-2-7-1-1-1-1-3 CTtTTatctattTaAtTTA 775_5 -18.07 30682
    776 CTTTTATCTATTTAATTTAC 1-1-5-6-4-1-2 CtTTTATctatttAATTTAC 776_1 -21.25 30681
    776 CTTTTATCTATTTAATTTAC 3-1-1-8-3-1-3 CTTtTatctatttAATtTAC 776_2 -20.13 30681
    776 CTTTTATCTATTTAATTTAC 5-8-2-1-4 CTTTTatctatttAAtTTAC 776_3 -21.02 30681
    776 CTTTTATCTATTTAATTTAC 1-1-2-1-2-6-2-1-4 CtTTTATctatttAAtTTAC 776_4 -19.49 30681
    776 CTTTTATCTATTTAATTTAC 2-1-4-6-2-2-3 CTtTTATctatttAAttTAC 776_5 -21.33 30681
    777 ACTTTTATCTATTTAATTT 4-1-1-6-4-1-2 ACTTtTatctatTTAAtTT 777_1 -20.04 30683
    777 ACTTTTATCTATTTAATTT 3-1-2-6-3-1-3 ACTtTTatctatTTAaTTT 777_2 -20.48 30683
    777 ACTTTTATCTATTTAATTT 5-7-2-1-4 ACTTTtatctatTTaATTT 777_3 -20.54 30683
    777 ACTTTTATCTATTTAATTT 2-2-2-6-2-1-4 ACttTTatctatTTaATTT 777_4 -19.26 30683
    777 ACTTTTATCTATTTAATTT 4-1-1-6-1-2-4 ACTTtTatctatTtaATTT 777_5 -19.21 30683
    778 ACTTTTATCTATTTAATTTA 2-3-1-7-4-1-2 ACtttTatctattTAATtTA 778_1 -19.89 30682
    778 ACTTTTATCTATTTAATTTA 1-1-4-7-2-1-1-1-2 AcTTTTatctattTAaTtTA 778_2 -19.82 30682
    778 ACTTTTATCTATTTAATTTA 3-2-1-7-2-2-3 ACTttTatctattTAatTTA 778_3 -20.13 30682
    778 ACTTTTATCTATTTAATTTA 4-9-1-1-5 ACTTttatctattTaATTTA 778_4 -21.14 30682
    778 ACTTTTATCTATTTAATTTA 2-1-3-7-1-1-5 ACtTTTatctattTaATTTA 778_5 -21.49 30682
    779 ACTTTTATCTATTTAATT 2-1-3-6-2-1-3 ACtTTTatctatTTaATT 779_1 -18.25 30684
    779 ACTTTTATCTATTTAATT 4-1-1-7-5 ACTTtTatctattTAATT 779_2 -19.17 30684
    779 ACTTTTATCTATTTAATT 3-1-2-7-5 ACTtTTatctattTAATT 779_3 -19.17 30684
    779 ACTTTTATCTATTTAATT 2-1-3-7-5 ACtTTTatctattTAATT 779_4 -18.79 30684
    779 ACTTTTATCTATTTAATT 1-1-4-7-5 AcTTTTatctattTAATT 779_5 -18.42 30684
    780 AACTTTTATCTATTTAATT 5-7-3-1-3 AACTTttatctaTTTaATT 780_1 -19.61 30684
    780 AACTTTTATCTATTTAATT 5-8-3-1-2 AACTTttatctatTTAaTT 780_2 -18.68 30684
    780 AACTTTTATCTATTTAATT 4-1-1-7-3-1-2 AACTtTtatctatTTAaTT 780_3 -18.17 30684
    780 AACTTTTATCTATTTAATT 1-1-4-7-2-1-3 AaCTTTtatctatTTaATT 780_4 -18.45 30684
    780 AACTTTTATCTATTTAATT 5-9-5 AACTTttatctattTAATT 780_5 -19.19 30684
    781 AACTTTTATCTATTTAAT 5-8-5 AACTTttatctatTTAAT 781_1 -18.18 30685
    782 AACTTTTATCTATTTAATTT 1-1-1-1-3-6-4-1-2 AaCtTTTatctatTTAAtTT 782_1 -19.40 30683
    782 AACTTTTATCTATTTAATTT 4-2-1-6-3-1-3 AACTttTatctatTTAaTTT 782_2 -20.41 30683
    782 AACTTTTATCTATTTAATTT 5-1-1-6-2-1-4 AACTTtTatctatTTaATTT 782_3 -21.20 30683
    782 AACTTTTATCTATTTAATTT 2-1-4-6-1-2-4 AAcTTTTatctatTtaATTT 782_4 -19.21 30683
    782 AACTTTTATCTATTTAATTT 1-1-2-1-2-7-2-1-3 AaCTtTTatctattTAaTTT 782_5 -19.40 30683
    783 TAACTTTTATCTATTTAAT 2-1-3-6-4-1-2 TAaCTTttatctATTTaAT 783_1 -19.91 30685
    783 TAACTTTTATCTATTTAAT 2-1-3-6-2-1-4 TAaCTTttatctATtTAAT 783_2 -19.93 30685
    783 TAACTTTTATCTATTTAAT 5-7-2-1-1-1-2 TAACTtttatctATtTaAT 783_3 -18.79 30685
    783 TAACTTTTATCTATTTAAT 1-1-4-6-1-1-5 TaACTTttatctAtTTAAT 783_4 -19.16 30685
    783 TAACTTTTATCTATTTAAT 5-9-5 TAACTtttatctatTTAAT 783_5 -19.60 30685
    784 TAACTTTTATCTATTTAATT 4-1-1-7-1-1-2-1-2 TAACtTttatctaTtTAaTT 784_1 -18.83 30684
    784 TAACTTTTATCTATTTAATT 2-1-4-7-3-1-2 TAaCTTTtatctatTTAaTT 784_2 -20.71 30684
    784 TAACTTTTATCTATTTAATT 2-1-3-8-2-1-3 TAaCTTttatctatTTaATT 784_3 -19.87 30684
    784 TAACTTTTATCTATTTAATT 1-1-5-7-2-1-3 TaACTTTtatctatTTaATT 784_4 -20.35 30684
    784 TAACTTTTATCTATTTAATT 5-10-5 TAACTtttatctattTAATT 784_5 -20.61 30684
    785 TAACTTTTATCTATTTAA 5-7-2-1-3 TAACTtttatctATtTAA 785_1 -18.07 30686
    786 ATAACTTTTATCTATTTAA 3-1-2-6-4-1-2 ATAaCTtttatcTATTtAA 786_1 -20.14 30686
    786 ATAACTTTTATCTATTTAA 4-1-1-6-3-1-3 ATAAcTtttatcTATtTAA 786_2 -20.03 30686
    786 ATAACTTTTATCTATTTAA 2-1-3-6-2-1-4 ATaACTtttatcTAtTTAA 786_3 -20.33 30686
    786 ATAACTTTTATCTATTTAA 3-1-2-6-2-2-3 ATAaCTtttatcTAttTAA 786_4 -19.84 30686
    786 ATAACTTTTATCTATTTAA 5-7-1-1-5 ATAACttttatcTaTTTAA 786_5 -20.30 30686
    787 ATAACTTTTATCTATTTAAT 3-1-3-6-3-2-2 ATAaCTTttatctATTtaAT 787_1 -20.73 30685
    787 ATAACTTTTATCTATTTAAT 2-1-4-6-2-1-4 ATaACTTttatctATtTAAT 787_2 -21.66 30685
    787 ATAACTTTTATCTATTTAAT 3-1-2-7-1-2-4 ATAaCTtttatctAttTAAT 787_3 -19.93 30685
    787 ATAACTTTTATCTATTTAAT 4-2-1-7-3-1-2 ATAActTttatctaTTTaAT 787_4 -18.98 30685
    787 ATAACTTTTATCTATTTAAT 2-1-4-8-5 ATaACTTttatctatTTAAT 787_5 -21.13 30685
    788 TATAACTTTTATCTATTTA 1-1-2-1-1-6-4-1-2 TaTAaCttttatCTATtTA 788_1 -21.10 30687
    788 TATAACTTTTATCTATTTA 2-2-2-6-3-1-3 TAtaACttttatCTAtTTA 788_2 -20.60 30687
    788 TATAACTTTTATCTATTTA 3-1-2-6-2-1-4 TATaACttttatCTaTTTA 788_3 -22.09 30687
    788 TATAACTTTTATCTATTTA 5-7-1-1-5 TATAActtttatCtATTTA 788_4 -21.33 30687
    788 TATAACTTTTATCTATTTA 4-1-1-7-2-2-2 TATAaCttttatcTAttTA 788_5 -20.13 30687
    789 TATAACTTTTATCTATTTAA 4-1-1-7-4-1-2 TATAaCttttatcTATTTAA 789_1 -21.18 30686
    789 TATAACTTTTATCTATTTAA 2-2-3-6-3-1-3 TAtaACTtttatcTATtTAA 789_2 -21.32 30686
    789 TATAACTTTTATCTATTTAA 1-1-5-6-2-1-4 TaTAACTtttatcTAtTTAA 789_3 -21.97 30686
    789 TATAACTTTTATCTATTTAA 3-1-2-7-1-1-1-1-3 TATaACttttatcTaTtTAA 789_4 -19.86 30686
    789 TATAACTTTTATCTATTTAA 4-2-1-6-1-2-4 TATAacTtttatcTatTTAA 789_5 -20.09 30686
    790 TTATAACTTTTATCTATTT 2-1-3-6-4-1-2 TTaTAActtttaTCTAtTT 790_1 -21.00 30688
    790 TTATAACTTTTATCTATTT 5-7-2-2-3 TTATAacttttaTCtaTTT 790_2 -20.52 30688
    790 TTATAACTTTTATCTATTT 4-1-1-6-1-1-5 TTATaActtttaTcTATTT 790_3 -21.08 30688
    790 TTATAACTTTTATCTATTT 4-1-1-7-3-1-2 TTATaActtttatCTAtTT 790_4 -20.46 30688
    790 TTATAACTTTTATCTATTT 2-1-3-8-5 TTaTAActtttatcTATTT 790_5 -19.98 30688
    791 TTATAACTTTTATCTATT 5-7-3-1-2 TTATAacttttaTCTaTT 791_1 -20.32 30689
    791 TTATAACTTTTATCTATT 5-7-1-1-4 TTATAacttttaTcTATT 791_2 -19.99 30689
    791 TTATAACTTTTATCTATT 4-1-1-7-5 TTATaActtttatCTATT 791_3 -20.40 30689
    791 TTATAACTTTTATCTATT 4-9-5 TTATaacttttatCTATT 791_4 -19.98 30689
    791 TTATAACTTTTATCTATT 2-1-3-7-5 TTaTAActtttatCTATT 791_5 -19.81 30689
    792 TTATAACTTTTATCTATTTA 1-2-1-1-2-6-3-2-2 TtaTaACttttatCTAttTA 792_1 -20.10 30687
    792 TTATAACTTTTATCTATTTA 3-2-1-7-1-1-2-1-2 TTAtaActtttatCtATtTA 792_2 -18.80 30687
    792 TTATAACTTTTATCTATTTA 4-1-2-6-1-3-3 TTATaACttttatCtatTTA 792_3 -21.34 30687
    792 TTATAACTTTTATCTATTTA 2-1-2-1-1-7-2-1-3 TTaTAaCttttatcTAtTTA 792_4 -20.83 30687
    792 TTATAACTTTTATCTATTTA 1-1-4-8-1-1-4 TtATAActtttatcTaTTTA 792_5 -19.94 30687
    793 CTTATAACTTTTATCTATT 1-1-1-1-2-6-3-2-2 CtTaTAacttttATCtaTT 793_1 -19.45 30689
    793 CTTATAACTTTTATCTATT 1-2-3-6-1-1-5 CttATAacttttAtCTATT 793_2 -21.25 30689
    793 CTTATAACTTTTATCTATT 3-2-1-8-5 CTTatAacttttatCTATT 793_3 -20.78 30689
    793 CTTATAACTTTTATCTATT 1-1-3-9-2-1-2 CtTATaacttttatCTaTT 793_4 -19.82 30689
    793 CTTATAACTTTTATCTATT 5-9-1-1-3 CTTATaacttttatCtATT 793_5 -20.81 30689
    794 CTTATAACTTTTATCTAT 5-7-3-1-2 CTTATaacttttATCtAT 794_1 -21.02 30690
    794 CTTATAACTTTTATCTAT 1-1-3-7-1-1-4 CtTATaacttttAtCTAT 794_2 -20.04 30690
    794 CTTATAACTTTTATCTAT 2-2-1-8-5 CTtaTaacttttaTCTAT 794_3 -19.59 30690
    794 CTTATAACTTTTATCTAT 3-1-2-8-4 CTTaTAacttttatCTAT 794_4 -20.86 30690
    794 CTTATAACTTTTATCTAT 5-10-3 CTTATaacttttatcTAT 794_5 -19.99 30690
    795 CTTATAACTTTTATCTATTT 1-1-1-2-2-6-2-1-1-1-2 CtTatAActtttaTCtAtTT 795_1 -18.22 30688
    795 CTTATAACTTTTATCTATTT 1-1-1-1-2-8-2-1-3 CtTaTAacttttatCTaTTT 795_2 -20.86 30688
    795 CTTATAACTTTTATCTATTT 2-1-2-1-1-7-2-2-2 CTtATaActtttatCTatTT 795_3 -20.54 30688
    795 CTTATAACTTTTATCTATTT 3-2-1-8-1-1-1-1-2 CTTatAacttttatCtAtTT 795_4 -18.19 30688
    795 CTTATAACTTTTATCTATTT 1-2-2-1-1-9-4 CttATaActtttatctATTT 795_5 -18.61 30688
    796 CTTATAACTTTTATCTA 5-6-2-1-3 CTTATaactttTAtCTA 796_1 -21.44 30691
    796 CTTATAACTTTTATCTA 5-6-1-2-3 CTTATaactttTatCTA 796_2 -20.31 30691
    796 CTTATAACTTTTATCTA 1-1-3-7-5 CtTATaacttttATCTA 796_3 -19.90 30691
    796 CTTATAACTTTTATCTA 3-1-1-8-4 CTTaTaacttttaTCTA 796_4 -18.77 30691
    796 CTTATAACTTTTATCTA 2-1-2-8-4 CTtATaacttttaTCTA 796_5 -18.43 30691
    797 GCTTATAACTTTTATCTA 2-2-2-6-2-2-2 GCttATaactttTAtcTA 797_1 -21.32 30691
    797 GCTTATAACTTTTATCTA 4-9-1-1-3 GCTTataacttttAtCTA 797_2 -21.88 30691
    797 GCTTATAACTTTTATCTA 2-12-4 GCttataacttttaTCTA 797_3 -20.47 30691
    797 GCTTATAACTTTTATCTA 2-1-1-1-1-9-3 GCtTaTaacttttatCTA 797_4 -20.94 30691
    797 GCTTATAACTTTTATCTA 1-1-4-10-2 GcTTATaacttttatcTA 797_5 -19.62 30691
    798 GCTTATAACTTTTATCT 2-9-1-2-3 GCttataacttTtaTCT 798_1 -18.54 30692
    798 GCTTATAACTTTTATCT 2-10-5 GCttataactttTATCT 798_2 -20.90 30692
    798 GCTTATAACTTTTATCT 4-8-1-1-3 GCTTataactttTaTCT 798_3 -21.40 30692
    798 GCTTATAACTTTTATCT 2-1-2-8-4 GCtTAtaacttttATCT 798_4 -21.00 30692
    798 GCTTATAACTTTTATCT 5-10-2 GCTTAtaacttttatCT 798_5 -20.68 30692
    799 TGCTTATAACTTTTATC 3-8-3-1-2 TGCttataactTTTaTC 799_1 -19.59 30693
    799 TGCTTATAACTTTTATC 3-8-2-1-3 TGCttataactTTTATC 799_2 -19.26 30693
    799 TGCTTATAACTTTTATC 2-10-5 TGcttataacttTTATC 799_3 -18.08 30693
    799 TGCTTATAACTTTTATC 5-8-4 TGCTTataactttTATC 799_4 -22.34 30693
    799 TGCTTATAACTTTTATC 3-10-4 TGCttataactttTATC 799_5 -19.90 30693
    800 TGCTTATAACTTTTATCT 3-9-3-1-2 TGCttataacttTTAtCT 800_1 -22.27 30692
    800 TGCTTATAACTTTTATCT 2-2-2-7-5 TGctTAtaactttTATCT 800_2 -22.61 30692
    800 TGCTTATAACTTTTATCT 3-10-1-1-3 TGCttataactttTaTCT 800_3 -21.45 30692
    800 TGCTTATAACTTTTATCT 1-1-1-1-2-8-4 TgCtTAtaacttttATCT 800_4 -20.79 30692
    800 TGCTTATAACTTTTATCT 4-1-1-10-2 TGCTtAtaacttttatCT 800_5 -20.89 30692
    801 CTGCTTATAACTTTTATC 2-1-1-8-2-1-3 CTgCttataactTTtATC 801_1 -20.05 30693
    801 CTGCTTATAACTTTTATC 4-8-1-3-2 CTGCttataactTttaTC 801_2 -21.02 30693
    801 CTGCTTATAACTTTTATC 2-1-1-10-4 CTgCttataactttTATC 801_3 -20.69 30693
    801 CTGCTTATAACTTTTATC 1-1-2-10-1-1-2 CtGCttataactttTaTC 801_4 -18.86 30693
    801 CTGCTTATAACTTTTATC 1-1-4-9-3 CtGCTTataacttttATC 801_5 -21.47 30693
    802 CTCTGCTTATAACTTTT 1-1-1-1-1-6-2-1-3 CtCtGcttataACtTTT 802_1 -18.92 30696
    802 CTCTGCTTATAACTTTT 1-1-1-1-1-7-2-1-2 CtCtGcttataaCTtTT 802_2 -18.47 30696
    802 CTCTGCTTATAACTTTT 1-1-2-8-1-1-3 CtCTgcttataaCtTTT 802_3 -19.44 30696
    802 CTCTGCTTATAACTTTT 1-2-2-7-1-1-3 CtcTGcttataaCtTTT 802_4 -19.02 30696
    802 CTCTGCTTATAACTTTT 3-1-1-10-2 CTCtGcttataacttTT 802_5 -18.16 30696
    803 CCTCTGCTTATAACTTT 1-1-2-7-2-1-3 CcTCtgcttatAAcTTT 803_1 -20.60 30697
    803 CCTCTGCTTATAACTTT 2-9-1-3-2 CCtctgcttatAactTT 803_2 -19.28 30697
    803 CCTCTGCTTATAACTTT 2-2-1-7-1-2-2 CCtcTgcttataActTT 803_3 -20.58 30697
    803 CCTCTGCTTATAACTTT 1-2-1-8-1-2-2 CctCtgcttataActTT 803_4 -18.06 30697
    803 CCTCTGCTTATAACTTT 2-1-1-9-1-1-2 CCtCtgcttataaCtTT 803_5 -21.12 30697
    804 CTACTATACTTTCCTCT 3-8-2-2-2 CTActatacttTCctCT 804_1 -22.54 30709
    804 CTACTATACTTTCCTCT 1-1-1-9-2-1-2 CtActatactttCCtCT 804_2 -21.39 30709
    804 CTACTATACTTTCCTCT 1-2-1-8-1-2-2 CtaCtatactttCctCT 804_3 -19.70 30709
    804 CTACTATACTTTCCTCT 2-11-1-1-2 CTactatactttcCtCT 804_4 -20.45 30709
    804 CTACTATACTTTCCTCT 1-3-1-8-1-1-2 CtacTatactttcCtCT 804_5 -19.77 30709
    805 TCTACTATACTTTCCTCT 2-1-1-9-1-2-2 TCtActatactttCctCT 805_1 -21.40 30709
    805 TCTACTATACTTTCCTCT 2-2-1-8-1-2-2 TCtaCtatactttCctCT 805_2 -22.20 30709
    805 TCTACTATACTTTCCTCT 2-11-1-2-2 TCtactatactttCctCT 805_3 -21.20 30709
    805 TCTACTATACTTTCCTCT 2-1-1-10-1-1-2 TCtActatactttcCtCT 805_4 -21.52 30709
    805 TCTACTATACTTTCCTCT 2-2-1-9-1-1-2 TCtaCtatactttcCtCT 805_5 -22.32 30709
    806 TTCTACTATACTTTCCT 1-1-1-8-1-3-2 TtCtactatacTttcCT 806_1 -18.06 30711
    806 TTCTACTATACTTTCCT 1-2-1-7-1-3-2 TtcTactatacTttcCT 806_2 -18.02 30711
    806 TTCTACTATACTTTCCT 1-1-1-1-1-7-1-1-3 TtCtActatactTtCCT 806_3 -20.41 30711
    806 TTCTACTATACTTTCCT 1-1-1-10-4 TtCtactatacttTCCT 806_4 -20.90 30711
    806 TTCTACTATACTTTCCT 1-1-1-1-1-9-3 TtCtActatactttCCT 806_5 -20.11 30711
    807 TTCTACTATACTTTCCTC 1-2-1-8-1-1-1-1-2 TtcTactatactTtCcTC 807_1 -19.51 30710
    807 TTCTACTATACTTTCCTC 1-1-1-2-1-6-1-3-2 TtCtaCtatactTtccTC 807_2 -19.77 30710
    807 TTCTACTATACTTTCCTC 1-1-1-1-1-9-1-1-2 TtCtActatactttCcTC 807_3 -19.44 30710
    807 TTCTACTATACTTTCCTC 1-1-1-12-3 TtCtactatactttcCTC 807_4 -20.04 30710
    807 TTCTACTATACTTTCCTC 1-2-1-1-1-10-2 TtcTaCtatactttccTC 807_5 -19.43 30710
    808 TTTCCATCTACTATTAAT 1-1-3-7-3-1-2 TtTCCatctactATTaAT 808_1 -21.43 39804
    808 TTTCCATCTACTATTAAT 2-1-2-7-1-1-1-1-2 TTtCCatctactAtTaAT 808_2 -19.50 39804
    808 TTTCCATCTACTATTAAT 1-1-4-6-1-2-3 TtTCCAtctactAttAAT 808_3 -20.72 39804
    808 TTTCCATCTACTATTAAT 2-1-2-8-1-1-3 TTtCCatctactaTtAAT 808_4 -19.43 39804
    808 TTTCCATCTACTATTAAT 4-1-1-8-4 TTTCcAtctactatTAAT 808_5 -20.12 39804
    809 TTTCCATCTACTATTAA 5-6-3-1-2 TTTCCatctacTATtAA 809_1 -21.74 39805
    809 TTTCCATCTACTATTAA 2-1-2-6-2-1-3 TTtCCatctacTAtTAA 809_2 -20.76 39805
    809 TTTCCATCTACTATTAA 1-1-3-6-1-1-4 TtTCCatctacTaTTAA 809_3 -20.75 39805
    809 TTTCCATCTACTATTAA 2-1-2-7-5 TTtCCatctactATTAA 809_4 -20.54 39805
    809 TTTCCATCTACTATTAA 5-9-3 TTTCCatctactatTAA 809_5 -20.18 39805
    810 GTTTCCATCTACTATTA 3-9-2-1-2 GTTtccatctacTAtTA 810_1 -20.81 39806
    810 GTTTCCATCTACTATTA 1-1-1-1-1-7-1-1-3 GtTtCcatctacTaTTA 810_2 -19.35 39806
    810 GTTTCCATCTACTATTA 2-2-1-7-1-2-2 GTttCcatctacTatTA 810_3 -19.64 39806
    810 GTTTCCATCTACTATTA 3-1-1-8-4 GTTtCcatctactATTA 810_4 -21.37 39806
    810 GTTTCCATCTACTATTA 1-2-2-10-2 GttTCcatctactatTA 810_5 -18.14 39806
    811 AATACAAAATCATCTTAC 3-1-2-6-1-1-4 AATaCAaaatcaTcTTAC 811_1 -18.05 39836
    811 AATACAAAATCATCTTAC 4-9-5 AATAcaaaatcatCTTAC 811_2 -18.25 39836
    811 AATACAAAATCATCTTAC 3-1-2-7-5 AATaCAaaatcatCTTAC 811_3 -19.20 39836
    811 AATACAAAATCATCTTAC 2-1-3-7-5 AAtACAaaatcatCTTAC 811_4 -18.12 39836
    811 AATACAAAATCATCTTAC 1-1-4-7-5 AaTACAaaatcatCTTAC 811_5 -19.50 39836
    812 AATACAAAATCATCTTACA 2-2-2-6-4-1-2 AAtaCAaaatcaTCTTaCA 812_1 -20.31 39835
    812 AATACAAAATCATCTTACA 4-8-3-2-2 AATAcaaaatcaTCTtaCA 812_2 -19.80 39835
    812 AATACAAAATCATCTTACA 3-1-2-6-2-1-4 AATaCAaaatcaTCtTACA 812_3 -21.91 39835
    812 AATACAAAATCATCTTACA 1-1-4-7-2-2-2 AaTACAaaatcatCTtaCA 812_4 -19.93 39835
    812 AATACAAAATCATCTTACA 5-8-1-1-4 AATACaaaatcatCtTACA 812_5 -20.93 39835
    813 TAATACAAAATCATCTTA 1-1-4-6-3-1-2 TaATACaaaatcATCtTA 813_1 -18.46 39837
    813 TAATACAAAATCATCTTA 5-8-5 TAATAcaaaatcaTCTTA 813_2 -19.57 39837
    813 TAATACAAAATCATCTTA 5-9-4 TAATAcaaaatcatCTTA 813_3 -18.44 39837
    813 TAATACAAAATCATCTTA 2-1-3-8-4 TAaTACaaaatcatCTTA 813_4 -18.20 39837
    813 TAATACAAAATCATCTTA 1-1-4-8-4 TaATACaaaatcatCTTA 813_5 -18.18 39837
    814 TAATACAAAATCATCTTAC 2-1-3-6-4-1-2 TAaTACaaaatcATCTtAC 814_1 -19.95 39836
    814 TAATACAAAATCATCTTAC 4-1-1-6-3-1-3 TAATaCaaaatcATCtTAC 814_2 -20.22 39836
    814 TAATACAAAATCATCTTAC 1-2-3-6-1-1-5 TaaTACaaaatcAtCTTAC 814_3 -19.14 39836
    814 TAATACAAAATCATCTTAC 5-8-2-1-3 TAATAcaaaatcaTCtTAC 814_4 -19.90 39836
    814 TAATACAAAATCATCTTAC 4-1-1-8-5 TAATaCaaaatcatCTTAC 814_5 -19.94 39836
    815 TAATACAAAATCATCTTACA 3-2-2-6-2-1-1-1-2 TAAtaCAaaatcaTCtTaCA 815_1 -20.84 39835
    815 TAATACAAAATCATCTTACA 2-3-1-8-2-1-3 TAataCaaaatcatCTtACA 815_2 -18.77 39835
    815 TAATACAAAATCATCTTACA 2-1-2-1-1-7-2-2-2 TAaTAcAaaatcatCTtaCA 815_3 -19.66 39835
    815 TAATACAAAATCATCTTACA 1-1-1-1-2-8-1-1-4 TaAtACaaaatcatCtTACA 815_4 -19.11 39835
    815 TAATACAAAATCATCTTACA 4-10-1-1-1-1-2 TAATacaaaatcatCtTaCA 815_5 -19.22 39835
    816 TCTGTATACACCATCCCA 2-10-1-1-1-1-2 TCtgtatacaccAtCcCA 816_1 -24.49 46389
    816 TCTGTATACACCATCCCA 2-3-1-6-1-3-2 TCtgtAtacaccAtccCA 816_2 -23.81 46389
    816 TCTGTATACACCATCCCA 2-10-1-3-2 TCtgtatacaccAtccCA 816_3 -23.72 46389
    816 TCTGTATACACCATCCCA 2-1-1-10-1-1-2 TCtGtatacaccatCcCA 816_4 -24.75 46389
    816 TCTGTATACACCATCCCA 2-3-1-8-1-1-2 TCtgtAtacaccatCcCA 816_5 -24.53 46389
    816 TCTGTATACACCATCCCA 2-3-1-10-2 TCtgtAtacaccatccCA 816_6 -23.76 46389
    817 TTCTGACTCCCTATCCA 1-1-1-12-2 TtCtgactccctatcCA 817_1 -22.56 46417
    818 TTTCTGACTCCCTATCC 1-2-1-11-2 TttCtgactccctatCC 818_1 -22.64 46418
  • Designs refer to the gapmer design, F-G-F′, where each number represents the number of consecutive modified nucleosides, e.g 2′ modified nucleosides (first number=5′ flank), followed by the number of DNA nucleosides (second number=gap region), followed by the number of modified nucleosides, e.g 2′ modified nucleosides (third number=3′ flank), optionally preceded by or followed by further repeated regions of DNA and LNA, which are not necessarily part of the contiguous sequence that is complementary to the target nucleic acid. For some oligonucleotides in table 3 the flanks are mixed flanks, such flanks start and end with a 2′ modified nucleosides, in these cases the gap region is the number above 5 not located at the 5′ or 3′ terminal in of the design.
  • For the oligonucleotide compounds capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, and 5-methyl DNA cytosines are presented by “e”, all internucleoside linkages are phosphorothioate internucleoside linkages.
  • Oligonucleotides with an EX-EX indication as Start on SEQ ID NO: 1 are exon-exon spanning oligonucleotides designed to be complementary across exon-exon junctions of SNHG14-023 (ENST00000554726). The oligonucleotides primarily span exon2 and exon3 (i.e. are complementary to a region in exon2 and a region in exon 3)
  • Oligonucleotide Synthesis
  • Oligonucleotide synthesis is generally known in the art. Below is a protocol which may be applied. The oligonucleotides of the present invention may have been produced by slightly varying methods in terms of apparatus, support and concentrations used.
  • Oligonucleotides are synthesized on uridine universal supports using the phosphoramidite approach on a MerMade12 or an Oligomaker DNA/RNA synthesizer at 1-4 μmol scale. At the end of the synthesis, the oligonucleotides are cleaved from the solid support using aqueous ammonia for 5-16 hours at 60° C. The oligonucleotides are purified by reverse phase HPLC (RP-HPLC) or by solid phase extractions and characterized by UPLC, and the molecular mass is further confirmed by ESI-MS.
  • Elongation of the Oligonucleotide:
  • The coupling of β-cyanoethyl-phosphoramidites (DNA-A(Bz), DNA-G(ibu), DNA-C(Bz), DNA-T, LNA-5-methyl-C(Bz), LNA-A(Bz), LNA-G(dmf), LNA-T or amino-C6 linker) is performed by using a solution of 0.1 M of the 5′-O-DMT-protected amidite in acetonitrile and DCI (4,5-dicyanoimidazole) in acetonitrile (0.25 M) as activator. For the final cycle a phosphoramidite with desired modifications can be used, e.g. a C6 linker for attaching a conjugate group or a conjugate group as such. Thiolation for introduction of phosphorthioate linkages is carried out by using xanthane hydride (0.01 M in acetonitrile/pyridine 9:1). Phosphordiester linkages can be introduced using 0.02 M iodine in THF/Pyridine/water 7:2:1. The rest of the reagents are the ones typically used for oligonucleotide synthesis.
  • Purification by RP-HPLC:
  • The crude compounds are purified by preparative RP-HPLC on a Phenomenex Jupiter C18 10μ 150×10 mm column. 0.1 M ammonium acetate pH 8 and acetonitrile is used as buffers at a flow rate of 5 mL/min. The collected fractions are lyophilized to give the purified compound typically as a white solid.
  • Abbreviations DCI: 4,5-Dicyanoimidazole DCM: Dichloromethane DMF: Dimethylformamide DMT: 4,4′-Dimethoxytrityl THF: Tetrahydrofurane Bz: Benzoyl Ibu: Isobutyryl
  • RP-HPLC: Reverse phase high performance liquid chromatography
  • Tm Assay
  • Oligonucleotide and RNA target duplexes are diluted to 3 mM in 500 ml RNase-free water and mixed with 500 ml 2×Tm-buffer (200 mM NaCl, 0.2 mM EDTA, 20 mM Naphosphate, pH 7.0). The solution is heated to 95° C. for 3 min and then allowed to anneal in room temperature for 30 min. The duplex melting temperatures (Tm) is measured on a Lambda 40 UV/VIS Spectrophotometer equipped with a Peltier temperature programmer PTP6 using PE Templab software (Perkin Elmer). The temperature is ramped up from 20° C. to 95° C. and then down to 25° C., recording absorption at 260 nm. First derivative and the local maximums of both the melting and annealing are used to assess the duplex Tm.
  • Preparation of Mouse Primary Cortical Neuron Cell Cultures
  • Primary cortical neuron cultures were prepared from mouse embryo brains of 15 days of age according to standard procedure. In brief, culture plates were coated with Poly-L-Lysine (50 μg/ml Poly-L-Lysine, 10 mM Na-tetraborate, pH 8 buffer) for 2-3 hrs at room temperature. The plates were washed with 1×PBS before use. Harvested mouse embryo brains were dissected and homogenized by a razor blade and submerged into 38 ml dissection medium (HBSS, 0.01 M Hepes, Penicillin/Streptomycin). Then, 2 ml trypsin was added and cells were incubated for 30 min at 37° C. and centrifuged down. The cells were dissolved in 20 ml DMEM (+10% FBS) and passed through a syringe for further homogenization. This was followed by centrifugation at 500 rpm for 15 mins. The cells were dissolved in DMEM (+10% FBS) and seeded in 96 well plates (0.1× 10̂6 cells/well in 100 μl). The neuronal cell cultures were ready for use directly after seeding.
  • Screening Oligonucleotides in Mouse Primary Cortical Neuron Cell Cultures
  • Cells were cultured in growth medium (Gibco Neurobasal medium, B27 supplement, Glutamax, Pencillin-streptomycin) in 96-well plates and incubated with oligonucleotides for 3 days at the desired concentrations. Total RNA was isolated from the cells and the knock-down efficacy was measured by qPCR analysis using the qScript™ XLT One-Step RT-qPCR ToughMix®, Low ROX™ kit from Quanta Bioscience (95134-500). A commercial taqman assays from Thermo Fisher Scientific was used to measure Ube3a_ATS including GAPDH for normalization.
  • Generation of Human Primary Neuronal Cell Cultures
  • Any cell lines at any described time point was incubated at 37° C., 5% CO2 concentration and 95% relative humidity.
  • Human Induced Pluripotent Stem Cells (hiPSC) Culture
  • Whole human blood samples were obtained from patients diagnosed with Angelman syndrome. The subsequent cultures of primary Peripheral Blood Mononuclear Cells (PMCSs) were enriched for erythroblasts. Patient-specific iPSC lines were generated by reprogramming erythroblast with CytoTune-iPS Sendai Reprogramming Kit (Thermo Fisher Scientific). Derived iPSC lines were maintained in feeder-free conditions using hESC-qualified Matrigel (Corning) in mTESR1 (STEMCELL Technologies) with daily medium replacement. Upon reaching confluence, colonies were dissociated into cell cluster of 50-200 μm in size using Gentle Cell Dissociation Reagent (STEMCELL Technologies) and subcultured at a ratio of 1:10-1:20 in the presence of 10 μM Y-27632 (Calbiochem).
  • Differentiation into Neural Progenitor Cells (NPC)
  • Upon induction of neural differentiation iPSC-derived cells were maintained in basal medium composed of equal volumes of DMEM:F12 Glutamax medium and Neurobasal medium (Gibco, Invitrogen), supplemented with 1×B27 (Gibco, Invitrogen), 1×N2 (Gibco, Invitrogen), 0.1 mM beta-mercaptoethanol (Gibco, Invitrogen) and indicated supplements.
  • Neural progenitor cells (NPCs) were derived from hiPSCs by dual SMAD inhibition and according to published procedures with slight modifications (Chambers et al. 2009 Nat Biotechnol. Vol. 3 pp. 275-80, Boissart et al., 2013 Transl Psychiatry. 3:e294). HiPSCs were dissociated with Accutase (Innovative Cell Technologies Inc.) into a single cell suspension and resuspended in basic medium further supplemented with 10 μM Y-27632 (Calbiochem), 5 ng/ml FGF (Peprotech), 10 μM SB-431542 (Calbiochem) and 100 nM LDN (Calbiochem). Single cell suspension was transferred to AggreWell800 plates (STEMCELL Technologies) enabling the formation of aggregates consisting of 8000 cells. After 5 days neural aggregates were transferred onto plates coated with poly-L-ornithine (Sigma) and laminin (Roche) and allowed to form neural rosettes under continued dual SMAD inhibition (SB-431542 and LDN) in basic medium supplemented with FGF. Neural rosettes were selectively isolated using STEMdiff™ Neural Rosette Selection Reagent (STEMCELL Technologies), replated onto dishes coated with poly-L-ornithine and Laminin521 (BioLamina) and expanded in basic medium supplemented with 10 ng/ml FGF (Peprotech), 10 ng/ml EGF (RnD), and 20 ng/ml BDNF (Peprotech). When reaching confluency, cells were enzymatically dissociated with 0.05% Trypsin/EDTA (Gibco, Invitrogen) and sub-cultured. Continued passaging in basic medium supplemented with FGF, EGF and BDNF leads to a stable neural progenitor cell line (NPC line) within 10 to 20 passages. A stable neural progenitor cell line is defined by its capacity to self-renew and by the expression of the developmental stage-specific markers Sox2 and Nestin. Upon specific stimuli, NPCs differentiate into neuronal (MAP2+, Tau+, HuC/D+) and astroglial (GFAP+) progenies (Dunkley et al., 2015 Proteomics Clin Appl. Vol. 7-8 pp. 684-94).
  • NPC Culture
  • Conditions for NPC culture have been described previously and were used with slight modifications (Boissart et al., 2013 Transl Psychiatry. 3:e294). In brief, cells were maintained in dishes coated with Laminin521 (BioLamina) and cultured in basic medium [composed of equal volumes of DMEM:F12 Glutamax medium and Neurobasal medium (Gibco, Invitrogen), supplemented with 1×B27 (Gibco, Invitrogen), 1×N2 (Gibco, Invitrogen), 0.1 mM beta-mercaptoethanol (Gibco, Invitrogen)] and supplemented with 10 ng/ml FGF (Peprotech), 10 ng/ml EGF (RnD), and 20 ng/ml BDNF (Peprotech).
  • Differentiation into Neuronal Cell Culture
  • To induce neuronal differentiation of NPC, cells were dissociated with 0.05% Trypsin/EDTA (Gibco, Invitrogen) into single cell suspension and seeded onto Laminin521 (BioLamina) coated dishes at a density of 12.000 cells/cm2 and maintained in basic medium supplemented with 200 ng/ml Shh (Peprotech), 100 ng/ml FGF8 (Peprotech), and 100 μM ascorbic acid phosphate (Sigma) for a period of 7 days. Subsequently, cells were replated in basal medium supplemented with 20 ng/ml BDNF (Peprotech), 10 ng/ml GDNF (Peprotech), 0.5 mM cAMP (BIOLOG Life Science), and 100 μM ascorbic acid phosphate (Sigma) at a density of 45000 cells/cm2 and differentiated for a period of 21 days. At day 21 of differentiation, differentiated neuronal cultures were replated onto the screening-compatible plate format. Replating was performed by dissociating the cultures with Accutase (Innovative Cell Technologies Inc.) into a single cell suspension. Cells were seeded at a density of 200.000 cells/cm2 in presence of 10 μM Y-27632 (a cell-permeable, reversible, inhibitor of Rho kinases from Calbiochem) into the 384 well microtiter plates for final oligonucleotides screening assay. Neuronal cultures were further differentiated for additional 7 days in basal medium supplemented with 20 ng/ml BDNF (Peprotech), 10 ng/ml GDNF (Peprotech), 0.5 mM cAMP (BIOLOG Life Science), and 100 μM ascorbic acid phosphate (Sigma). Differentiation medium was exchanged twice per week. After a total differentiation period of 35 days neuronal cell cultures were ready for oligonucleotide treatment.
  • Screening Oligonucleotides in Human Neuronal Cell Cultures—384 Well System
  • For screening, oligonucleotide stocks were pre-diluted to the indicated concentrations with water into 384 well microtiter plates (compound plate). The plate layout served as a treatment template. Two microliter oligonucleotide dilution from each well was transferred from the compound plate to a respective culture plate. All liquid handling was done under sterile conditions in a laminar flow using a semi-automated laboratory robotic system (Beckmancoulter). Neuronal cell cultures were incubated with oligonucleotides for 5 days without media change. Subsequently, neuronal cultures were lysed and processed for qPCR assay with RealTime ready Cell lysis and RNA Virus Master kit (Roche). Liquid handling was performed using a semi-automated laboratory robotic system (Beckmancoulter). Samples were analyzed by a Lightcycler480 real-time PCR system (Roche).
  • Activity of the oligonucleotides was assessed by qPCR monitoring transcript abundance of UBE3A using the following primers and probes
  • UBE3a-Sense:
    Forward primer:
    (SEQ ID NO: 837)
    ATATGTGGAAGCCGGAATCT,
    Reverse primer:
    (SEQ ID NO: 838)
    TCCCAGAACTCCCTAATCAGAA,
    Internal probe labeled with dye FAM:
    (SEQ ID NO: 839)
    ATGACGGTGGCTATACCAGG
  • The RT-qPCR was multiplexed with PPIA (peptidylprolyl isomerase A) as housekeeping gene for normalization. PPIA primers and probe labeled with the dye VIC were purchased from Thermo Fisher Scientific (assay ID Hs99999904_m1). Each plate includes a non-targeting oligonucleotide (mock) as negative control (TTGaataagtggaTGT (SEQ ID NO: 846)) and a reference oligonucleotide CMP ID NO: 41_1, resulting in up-regulation of UBE3A mRNA.
  • Selectivity of oligonucleotides was verified by counter screening for SNORD115 transcript, which is located upstream of SNORD109B on chromosome 15. Expression of SNORD115 was monitored by qPCR using the following primers and probe
  • Forward primer:
    (SEQ ID NO: 840)
    GGGTCAATGATGAGAACCTTAT,
    Reverse primer
    (SEQ ID NO: 841)
    GGGCCTCAGCGTAATCCTATT,
    Internal probe labeled with the dye FAM:
    (SEQ ID NO: 842)
    TTCTGAAGAGAGGTGATGACTTAAAA
  • The RT-qPCR was multiplexed with PPIA (Thermo Fisher Scientific) upon oligonucleotide treatment.
  • The reduction of the SNHG14 transcript downstream of SNORD109B (also termed the UBE3A suppressor) was measured by RT-qPCR using the following primers and probe
  • Forward primer:
    (SEQ ID NO: 843)
    ATCCGAGGCATGAATCTCAC,
    Reverse primer:
    (SEQ ID NO: 844)
    CAGGCCAAAACCCTTGATAA,
    Internal probe labeled with dye FAM:
    (SEQ ID NO: 845)
    TTGCTGAGCATTTTTGCATC
  • The RT-qPCR was multiplexed with PPIA (Thermo Fisher Scientific).
  • Data are presented as average % expression relative to mock across all plates and normalized to the reference oligonucleotide to account for plate to plate variation.
  • Screening Oligonucleotides in Human Neuronal Cell Cultures—96 Well System
  • For screening, oligonucleotide stocks were pre-diluted to the indicated concentrations with water into 96 well microtiter plates (compound plate). The plate layout served as a treatment template. Two microliter oligonucleotide dilution from each well was transferred from the compound plate to a respective culture plate. All liquid handling was done under sterile conditions in a laminar flow using a semi-automated laboratory robotic system (Beckman Coulter). Neuronal cell cultures were incubated with oligonucleotides for 5 days without media change. Subsequently, neuronal cultures were lysed and RNA purified using RNA purification kit Pure Link Pro96 (12173011A) LifeTechnologies. Liquid handling was performed using a semi-automated laboratory robotic system (Beckmancoulter). qPCR analysis of Ube3a and Ube3a-ATS was carried out on a ViiA™ 7 Real-Time PCR System Thermo Fisher Scientific using the qScript™ XLT 1-Step RT-qPCR ToughMix Low ROX, from Quanta (95134-50).
  • The following primers and probes were used:
  • qPCR UBE3a-Sense:
    Forward primer:
    (SEQ ID NO: 697)
    ATATGTGGAAGCCGGAATCT,
    Reverse primer:
    (SEQ ID NO: 698)
    TCCCAGAACTCCCTAATCAGAA,
    Internal probe labeled with dye FAM:
    (SEQ ID NO: 699)
    ATGACGGTGGCTATACCAGG

    qPCR SNHG14 transcript downstream of SNORD109B (also termed the UBE3A suppressor): Commercially available primer and probe set from ThermoFisher: Hs01372957_m1. These primers amplifies a 87 bp exon-exon spanning sequence in the Genbank transcript AF400500.1
  • QPCR GAPDH Transcript:
  • Commercially available primer and probe set from Thermofisher: Gene Symbol: with following assay details: RefSeq: NM_002046.3, Probe Exon Location:3, Amplicon Size: 122 bp. Corresponding TaqMan Assay ID: Hs99999905_m1.
  • The RT-qPCR for both Ube3a and Ube3a-ATS was multiplexed with GAPDH as housekeeping gene for normalization. Each plate includes a non-targeting oligonucleotide (mock) as negative control (TTGaataagtggaTGT (SEQ ID NO: 846)) and a reference oligonucleotide CMP ID NO: 21_1, resulting in up-regulation of UBE3A mRNA. Moreover panel of oligos not targeting Ub3a or SNHG14 transcript downstream of SNORD109B (also termed the UBE3A suppressor) were included to monitor the assay noise and risk of detecting false positives. These were randomly distributed over the plates.
  • Control Oligonucleotides:
  • (SEQ ID NO: 819)
    CGAaccactgaaCAA
    (SEQ ID NO: 820)
    CGAaccactgaacAAA
    (SEQ ID NO: 821)
    CGAagtgcacaCG
    (SEQ ID NO: 822)
    GCGtaaagagaGGT
    (SEQ ID NO: 823)
    GAGAaggcacagaCGG
    (SEQ ID NO: 824)
    GCGaagtgcacaCGG
    (SEQ ID NO: 825)
    GAGaaggcacagaCGG
    (SEQ ID NO: 826)
    CGAaccactgAACA
    (SEQ ID NO: 827)
    GAAccactgaacAAA
    (SEQ ID NO: 828)
    caGCGtaaagagaGG
    (SEQ ID NO: 829)
    GCgtaaagagAGG
    (SEQ ID NO: 830)
    CGAaccactgaAC
    (SEQ ID NO: 831)
    CGAAccactgaaCAAA
    (SEQ ID NO: 832)
    AGCgaagtgcacaCGG
    (SEQ ID NO: 833)
    AGGtgaagcgaAGTG
    (SEQ ID NO: 834)
    TAGTaaactgagCCA
    (SEQ ID NO: 835)
    AGAaggcacagaCGG
    (SEQ ID NO: 836)
    CCGcagtatggaTCG
  • Example 1—Oligonucleotide Activity in Mouse Primary Neuronal Cell Cultures
  • Oligonucleotides targeting the part of SNHG14 long non-coding RNA which is antisense to the UBE3A pre-mRNA (position 55319 to 141053 of SEQ ID NO: 1) were tested for their ability to reduce the SNHG14 long non-coding RNA transcript preventing UBE3A expression (also termed UBE3A suppressor or UBE3A-SUP in the data table) and their ability to induce UBE3A mRNA re-expression in mouse primary cortical neuron cell cultures, obtained as described in the “Materials and methods” section above. The oligonucleotide concentration was 5 microM.
  • The oligonucleotides were screened according to the protocol for screening in mouse cortical neuron cell cultures described in the section “Materials and methods”. The results are shown in table 4.
  • TABLE 4
    Oligonucleotide activity in primary
    mouse neuronal cell cultures.
    CMP % of Mock % of Mock
    ID NO oligonucleotide UBE3A_SUP sd UBE3A sd
    95_1 CTCAtacttgctttaAT 3.6 0.1 154.1 15.1
    95_2 CTcatacttgctttaAT 15.9 2.6 119.8 12.4
    96_1 ACatctcatacttGCTT 4.0 0.5 149.9 11.5
    96_2 ACatctcatacttgcTT 9.3 3.9 139.9 36.4
    96_3 ACatctcatacttgCTT 3.1 0.2 143.2 3.9
    97_1 ACatctcatactTGCT 4.0 1.5 154.5 10.0
    97_2 ACatctcatacttgCT 6.1 1.7 141.1 14.1
    97_3 ACatctcatacttGCT 3.7 0.6 162.7 15.0
    97_4 ACATctcatacttgCT 5.2 0.4 156.7 24.4
    98_1 TAcatctcatactTGCT 5.0 0.9 159.0 15.6
    98_2 TAcatctcatacttgCT 15.5 5.3 130.4 3.4
    98_3 TACAtctcatacttgCT 4.7 0.4 140.3 38.2
    101_1 TACatctcatactTGC 2.6 0.5 152.6 10.2
    101_2 TAcatctcatacttGC 19.2 6.0 112.0 15.0
    101_3 TAcatctcatactTGC 3.5 0.4 117.2 13.7
    101_4 TACAtctcatacttGC 3.0 0.7 140.5 12.4
    100_1 CTAcatctcatactTGC 5.4 0.8 160.4 4.1
    100_2 CTacatctcatacttGC 9.6 3.7 159.2 14.5
    100_3 CTacatctcatactTGC 3.0 0.1 133.2 5.9
    99_2 CCtacatctcatacttGC 7.8 1.4 150.7 11.0
    99_3 CCtacatctcatactTGC 3.2 0.6 134.7 12.5
    99_4 CCtacatctcatacTTGC 2.7 0.2 145.2 4.7
    102_1 CCTAcatctcatactTG 5.8 1.7 127.0 24.5
    102_2 CCtacatctcatactTG 20.2 6.6 129.7 9.2
    102_4 CCTacatctcatacTTG 4.0 0.6 140.2 7.2
    102_3 CCTacatctcatactTG 3.9 1.0 133.3 10.0
    104_1 CCTacatctcataCTT 6.6 1.5 136.5 8.7
    104_3 CCtacatctcatACTT 3.5 0.4 131.4 6.0
    103_1 ACCtacatctcataCTT 5.8 1.4 130.8 0.7
    103_2 ACctacatctcatacTT 11.4 2.2 123.6 12.4
    103_3 ACctacatctcatACTT 5.8 0.8 132.2 4.5
    105_1 TACCtacatctcatacTT 5.2 0.8 152.3 7.2
    106_1 TTAcctacatctcataCTT 13.3 3.0 140.1 17.5
    106_2 TTacctacatctcatacTT 21.0 1.4 116.9 15.0
    107_1 ACCTacatctcataCT 6.2 0.9 119.2 3.4
    107_2 ACctacatctcataCT 14.3 7.4 142.9 13.7
    108_1 TACCtacatctcataCT 5.6 1.0 127.0 10.7
    108_2 TAcctacatctcataCT 21.4 12.5 117.1 8.5
    109_1 TTacctacatctcaTACT 4.4 0.4 138.9 1.2
    109_2 TTacctacatctcataCT 22.9 3.3 117.1 13.0
    110_1 TTAcctacatctcaTAC 8.7 2.1 133.2 5.1
    110_2 TTacctacatctcatAC 21.0 5.1 111.4 11.1
    111_1 GTtacctacatctCATA 8.0 2.4 143.8 14.8
    111_2 GTtacctacatctcaTA 19.0 2.3 115.4 4.1
    112_1 GTTacctacatctCAT 6.6 1.4 145.5 16.8
    112_2 GTtacctacatctcAT 15.8 4.5 120.3 8.1
    126_1 TCACtttccagatatCA 8.0 1.9 133.8 5.4
    126_3 TCactttccagatatCA 53.4 75.9 112.0 11.4
    128_1 ACATgtccctttataTT 16.3 2.5 114.7 11.1
    128_2 ACatgtccctttataTT 14.8 1.1 136.9 6.2
    129_1 ACAtgtccctttaTAT 11.8 1.9 135.0 14.3
    132_1 CTCAtccctccaagaAA 9.1 1.6 131.7 8.4
    132_2 CTcatccctccaagaAA 11.2 3.9 159.3 17.7
  • Example 2—Oligonucleotide Activity in Human Neuronal Cell Cultures
  • Oligonucleotides targeting human SNHG14 in the region downstream of SNORD109B corresponding to position 25278410 to 25419462 on chromosome 15 (SEQ ID NO: 1) were tested in patient derived human neuronal cell cultures (see protocol in “Materials and methods” section). The oligonucleotides ability to reduce the SNHG14 transcript in the region downstream of SNORD109B (also termed UBE3A suppressor or UBE3A-SUP in the data table), without affecting expression of SNORD115 was analyzed. Furthermore, the ability to induce UBE3A mRNA re-expression was analyzed.
  • The oligonucleotides were screened according to the protocol for screening oligonucleotides in human neuronal cell cultures described in the section “Materials and methods” above.
  • The results are shown in table 5. The expression of UBE3A mRNA has been measured for all compounds, whereas the knock-down of the UBE3A suppressor and the maintenance of SNORD1115 levels have not been analyzed for all compounds.
  • TABLE 5
    Oligonucleotide activity in patient derived human neuronal cell cultures.
    Start % of Mock % of Mock % of Mock
    SEQ ID CMP Oligo conc Oligo conc Oligo conc
    NO 1 ID NO Target 0.2 μM sd 1.0 μM sd 5.0 μM sd
    1678 10_1 UBE3A 107 14 88 10 151 8
    1679 12_2 UBE3A 100 9 87 14 158 16
    1687 20_1 UBE3A 87 7 102 22 213 44
    1712 21_1 UBE3A 127 23 166 6 178 13
    1712 21_1 UBE3A-SUP 81 3 82 8 72 12
    1712 21_1 SNORD115 115 6 142 24 169 26
    4167 22_1 UBE3A 87 5 90 8 146 20
    4170 27_1 UBE3A 94 16 106 11 170 10
    4171 29_2 UBE3A 86 13 100 12 194 35
    4172 30_1 UBE3A 96 6 121 12 209 27
    9210 35_1 UBE3A 88 5 112 23 195 27
    10838 37_1 UBE3A 77 7 85 9 169 24
    15565 38_2 UBE3A 93 11 108 6 167 34
    22209 42_1 UBE3A 125 16 143 14 180 17
    22209 42_1 UBE3A-SUP 108 14 98 15 85 18
    22209 42_1 SNORD115 101 14 93 25 127 21
    30449 43_1 UBE3A 99 5 95 13 115 8
    30451 44_1 UBE3A 99 15 80 20 141 17
    30451 44_2 UBE3A 98 31 104 16 119 7
    30697 46_1 UBE3A 91 8 87 5 167 20
    36066 49_1 UBE3A 95 6 111 10 155 29
    36066 49_1 UBE3A-SUP 76 7 84 24 110 31
    36066 49_1 SNORD115 99 14 111 20 94 6
    36068 50_1 UBE3A 109 15 105 11 92 14
    36068 50_1 UBE3A-SUP 122 24 93 28 73 7
    36068 50_1 SNORD115 120 15 113 12 99 6
    37206 51_1 UBE3A 114 16 101 7 101 3
    37206 51_1 UBE3A-SUP 128 21 67 9 84 13
    37206 51_1 SNORD115 140 26 110 9 100 11
    46130 52_1 UBE3A 139 3 160 1 236 36
    46130 52_1 UBE3A-SUP 135 16 133 26 160 32
    46130 52_1 SNORD115 104 8 119 14 100 8
    48145 59_1 UBE3A 179 3 122 17 115 NA
    48170 76_1 UBE3A 85 16 100 8 155 12
    48171 80_1 UBE3A 120 7 114 10 172 20
    48171 78_1 UBE3A 136 31 103 20 169 11
    48172 82_2 UBE3A 96 11 121 4 186 32
    48172 84_1 UBE3A 95 14 100 8 158 14
    49343 85_1 UBE3A 97 22 121 10 189 17
    49722 87_1 UBE3A 111 9 126 11 177 22
    52417 92_1 UBE3A 133 7 140 30 140 8
    52417 92_1 UBE3A-SUP 88 14 80 14 82 8
    52417 92_1 SNORD115 102 8 114 20 91 9
    52420 93_1 UBE3A 111 14 120 9 126 16
    52420 93_1 UBE3A-SUP 104 23 82 20 79 8
    52420 93_1 SNORD115 110 11 114 17 95 7
    53953 94_1 UBE3A 117 12 147 15 166 15
    53953 94_1 UBE3A-SUP 92 18 81 5 86 22
    53953 94_1 SNORD115 124 33 122 17 106 14
    60819 95_1 UBE3A 103 11 131 14 175 7
    60819 95_1 UBE3A-SUP 93 13 87 3 74 6
    60819 95_1 SNORD115 162 19 158 20 201 11
    60819 95_2 UBE3A 147 10 129 20 117 2
    60819 95_2 UBE3A-SUP 118 24 87 13 83 8
    60819 95_2 SNORD115 104 17 118 10 129 6
    60823 96_1 UBE3A 115 16 135 19 174 17
    60823 96_1 UBE3A-SUP 104 25 93 32 91 11
    60823 96_2 UBE3A 108 7 114 9 115 13
    60823 96_2 UBE3A-SUP 99 17 92 19 93 10
    60824 97_1 UBE3A 111 12 134 23 169 14
    60824 97_1 UBE3A-SUP 110 27 105 33 92 10
    60824 97_2 UBE3A 124 13 126 12 124 11
    60824 97_2 UBE3A-SUP 113 17 107 33 96 20
    60824 98_1 UBE3A 111 16 119 11 138 14
    60824 98_1 UBE3A-SUP 118 34 98 23 82 19
    60824 98_1 SNORD115 109 11 123 18 114 16
    60824 98_2 UBE3A 128 10 109 7 136 12
    60824 98_2 UBE3A-SUP 91 15 77 11 110 16
    60824 98_2 SNORD115 101 3 110 7 124 11
    60825 99_1 UBE3A 125 6 115 5 131 10
    60825 99_1 UBE3A-SUP 139 18 121 34 127 45
    60825 99_1 SNORD115 110 18 112 12 99 19
    60825 99_2 UBE3A 120 21 111 11 135 22
    60825 99_2 UBE3A-SUP 96 21 79 15 75 11
    60825 99_2 SNORD115 104 34 113 22 131 24
    60825 100_1 UBE3A 123 34 139 34 145 21
    60825 100_1 UBE3A-SUP 104 37 127 46 99 17
    60825 100_2 UBE3A 124 46 138 37 145 31
    60825 100_2 UBE3A-SUP 111 36 120 47 92 11
    60825 101_1 UBE3A 112 18 123 15 150 13
    60825 101_1 UBE3A-SUP 96 18 102 14 88 12
    60825 101_2 UBE3A 118 15 138 24 139 32
    60825 101_2 UBE3A-SUP 100 29 110 39 92 10
    60826 102_1 UBE3A 132 17 120 7 125 9
    60826 102_1 UBE3A-SUP 113 16 83 5 88 18
    60826 102_1 SNORD115 121 36 131 23 100 9
    60826 102_2 UBE3A 90 6 116 23 103 7
    60826 102_2 UBE3A-SUP 91 7 90 12 64 18
    60826 102_2 SNORD115 116 15 146 27 183 28
    60827 103_1 UBE3A 106 8 112 10 115 9
    60827 103_1 UBE3A-SUP 99 15 110 28 94 8
    60827 103_2 UBE3A 107 14 120 13 112 14
    60827 103_2 UBE3A-SUP 97 14 118 38 93 20
    60827 104_1 UBE3A 128 14 111 9 111 6
    60827 104_1 UBE3A-SUP 111 12 97 9 87 19
    60827 104_1 SNORD115 114 10 110 12 109 13
    60827 104_2 UBE3A 108 10 111 16 109 10
    60827 104_2 UBE3A-SUP 103 13 103 33 89 9
    60827 105_1 UBE3A 122 13 121 12 121 4
    60827 105_1 UBE3A-SUP 119 7 97 15 93 7
    60827 105_1 SNORD115 114 21 128 12 118 9
    60827 105_2 UBE3A 123 5 110 9 114 8
    60827 105_2 UBE3A-SUP 110 11 89 17 94 21
    60827 105_2 SNORD115 102 15 108 16 107 18
    60827 106_1 UBE3A 114 17 133 23 125 9
    60827 106_1 UBE3A-SUP 112 35 103 15 87 12
    60827 106_2 UBE3A 110 12 130 22 123 14
    60827 106_2 UBE3A-SUP 105 19 107 27 93 10
    60828 107_1 UBE3A 83 11 117 13 112 6
    60828 107_1 UBE3A-SUP 86 11 114 16 67 7
    60828 107_1 SNORD115 108 17 130 21 137 24
    60828 107_2 UBE3A 143 42 117 10 122 11
    60828 107_2 UBE3A-SUP 116 12 92 4 100 8
    60828 107_2 SNORD115 108 4 127 16 108 14
    60828 108_1 UBE3A 120 7 127 31 132 31
    60828 108_1 UBE3A-SUP 153 33 118 34 89 17
    60828 108_1 SNORD115 114 9 114 9 105 15
    60828 108_2 UBE3A 122 18 133 26 128 9
    60828 108_2 UBE3A-SUP 101 19 100 28 89 17
    60828 109_1 UBE3A 108 10 129 14 128 5
    60828 109_1 UBE3A-SUP 106 21 107 24 84 8
    60828 109_2 UBE3A 109 11 110 8 111 13
    60828 109_2 UBE3A-SUP 95 15 86 14 83 9
    60829 110_1 UBE3A 104 6 83 3 101 15
    60829 110_1 UBE3A-SUP 100 13 95 12 79 4
    60829 110_1 SNORD115 126 21 125 6 182 13
    60829 110_2 UBE3A 92 7 87 8 96 7
    60829 110_2 UBE3A-SUP 99 7 108 9 81 5
    60829 110_2 SNORD115 118 15 139 22 198 39
    60830 111_1 UBE3A 110 6 122 13 124 10
    60830 111_1 UBE3A-SUP 104 14 90 28 79 11
    60830 111_2 UBE3A 115 10 120 15 121 10
    60830 111_2 UBE3A-SUP 114 20 89 19 87 9
    60831 112_1 UBE3A 93 8 94 13 106 10
    60831 112_1 UBE3A-SUP 97 1 68 29 82 7
    60831 112_1 SNORD115 116 20 110 13 158 20
    60831 112_2 UBE3A 83 8 78 7 83 6
    60831 112_2 UBE3A-SUP 106 35 80 23 69 9
    60831 112_2 SNORD115 107 6 106 8 159 21
    62198 113_1 UBE3A 110 3 122 6 134 9
    62198 113_1 UBE3A-SUP 113 20 85 19 79 24
    62198 113_1 SNORD115 116 18 123 9 91 9
    62284 115_1 UBE3A 105 14 98 19 141 36
    62422 116_1 UBE3A 130 19 142 29 172 18
    62423 117_1 UBE3A 76 8 93 13 171 17
    62439 118_1 UBE3A 75 7 88 9 150 19
    66378 119_1 UBE3A 96 14 93 5 110 10
    77565 126_1 UBE3A 94 6 113 5 125 14
    77565 126_1 UBE3A-SUP 83 17 95 33 85 5
    77565 126_1 SNORD115 105 11 123 19 152 15
    77565 126_2 UBE3A 95 5 126 9 111 2
    77565 126_2 UBE3A-SUP 77 27 106 21 83 15
    77565 126_2 SNORD115 115 17 157 13 180 15
    92321 128_1 UBE3A 102 7 91 5 111 13
    92321 128_1 UBE3A-SUP 115 3 104 25 91 13
    92321 128_1 SNORD115 135 9 132 12 196 35
    92321 128_2 UBE3A 91 5 96 8 104 8
    92321 128_2 UBE3A-SUP 112 20 92 20 79 7
    92321 128_2 SNORD115 125 7 111 13 169 12
    92322 129_1 UBE3A 101 5 103 2 110 7
    92322 129_1 UBE3A-SUP 99 39 113 12 94 13
    92322 129_1 SNORD115 124 25 114 6 140 13
    92322 129_2 UBE3A 93 2 100 4 113 16
    92322 129_2 UBE3A-SUP 109 4 102 22 85 7
    92322 129_2 SNORD115 103 11 99 9 152 31
    97154 132_1 UBE3A 100 10 128 13 142 13
    97154 132_1 UBE3A-SUP 103 9 115 8 109 6
    97154 132_1 SNORD115 49 7 90 12 143 25
    97154 132_2 UBE3A 111 8 128 17 128 17
    97154 132_2 UBE3A-SUP 95 7 116 9 105 13
    97154 133_2 SNORD115 86 7 106 9 121 9
    97154 133_1 UBE3A 101 3 107 11 124 19
    97154 133_1 UBE3A-SUP 112 9 117 7 146 25
    97154 133_1 SNORD115 60 7 110 15 141 15
    97154 133_2 UBE3A 94 13 116 14 138 12
    97154 133_2 UBE3A-SUP 116 6 128 13 148 38
    97154 132_2 SNORD115 70 5 108 9 160 34
    106137 137_1 UBE3A 83 12 74 11 124 20
    109404 138_1 UBE3A 80 20 92 7 120 21
    110766 139_1 UBE3A 76 5 85 12 121 17
    114826 140_1 UBE3A 87 10 88 11 136 9
    118637 143_1 UBE3A 83 7 104 30 141 28
    118639 144_1 UBE3A 74 17 31 39 106 33
    124160 145_2 UBE3A 89 6 95 10 115 25
    125499 146_1 UBE3A 83 13 76 7 124 16
    125499 146_2 UBE3A 123 30 79 14 102 23
    125538 150_2 UBE3A 82 17 82 7 119 24
  • Of the 187 compounds tested approximately 90% showed re-expression of UBE3A when compared to the mock oligonucleotide at the 5 micro Molar concentration. The number of oligonucleotides capable of inducing re-expression of UBE3A is higher in the region between position 1 to 55318 of SEQ ID NO: 1 (non-overlapping region) then in the region complementary to UBE3A coding region (overlapping region. FIG. 2 plots the distribution of the oligonucleotides according to their position on chromosome 15 versus the UBE3A mRNA expression relative to the mock oligonucleotide.
  • For the oligonucleotides where SNORD115 has been tested there is no significant down regulation when compared to mock at 1 and 5 microM.
  • Example 3—Activity of Oligonucleotides Targeting the SNHG14 Transcript in the Region Downstream of SNORD109B and Upstream of the Region Antisense to the UBE3A Pre-mRNA
  • Oligonucleotides targeting position 4806-54939 of SEQ ID NO: 1 were tested in patient derived human neuronal cell cultures (see protocol in “Materials and methods” section). The oligonucleotides ability to reduce the SNHG14 transcript in the region downstream of SNORD109B (also termed UBE3A suppressor or UBE3A-SUP in the data table. Furthermore, the ability to induce UBE3A mRNA re-expression was analyzed.
  • The oligonucleotides were screened according to the protocol for screening oligonucleotides in human neuronal cell cultures described in the section “Materials and methods”—“Screening oligonucleotides in human neuronal cell cultures—96 well system”
  • The results are shown in table 6.
  • TABLE 6
    Oligonucleotide activity in patient derived human neuronal cell cultures.
    Start SEQ CMP ID Conc % of Mock % of Mock
    ID NO 1 NO μM UBE3A-SUP sd UBE3A sd
    4806 151_1 0.2 66 2 125 NA
    4806 151_1 1 53 10 NA NA
    4808 152_1 0.2 49 6 167 NA
    4808 152_1 1 33 4 289 NA
    4809 153_1 0.2 41 1 208 NA
    4809 153_1 1 29 10 NA NA
    4811 154_1 0.2 48 3 282 NA
    4811 154_1 1 37 5 331 NA
    4812 155_1 0.2 35 5 286 64
    4812 155_1 1 32 3 327 21
    4972 156_1 0.2 60 6 145 6
    4972 156_1 1 46 14 145 NA
    4973 157_1 0.2 75 9 128 6
    4973 157_1 1 59 NA 158 NA
    4979 158_1 0.2 46 9 131 NA
    4979 158_1 1 37 5 219 8
    5058 159_1 0.2 69 6 133 19
    5058 159_1 1 51 14 NA NA
    5071 160_1 0.2 55 8 98 NA
    5071 160_1 1 39 7 136 34
    5078 161_1 0.2 65 7 205 18
    5078 161_1 1 51 10 306 31
    5094 162_1 0.2 53 5 154 27
    5094 162_1 1 34 8 300 65
    5096 163_1 0.2 44 1 206 49
    5096 163_1 1 36 6 316 NA
    5100 164_1 0.2 34 3 220 NA
    5100 164_1 1 30 3 227 32
    5101 165_1 0.2 38 7 245 NA
    5101 165_1 1 36 4 246 55
    5218 166_1 0.2 45 4 240 NA
    5218 166_1 1 36 6 280 44
    5218 167_1 0.2 46 2 261 NA
    5218 167_1 1 31 4 346 30
    5224 168_1 0.2 39 3 377 40
    5224 168_1 1 33 5 338 65
    5224 169_1 0.2 37 4 313 NA
    5224 169_1 1 31 2 308 3
    5427 170_1 0.2 89 13 105 26
    5427 170_1 1 117 35 124 NA
    5434 171_1 0.2 51 5 164 10
    5434 171_1 1 33 6 213 46
    5785 172_1 0.2 46 5 210 NA
    5785 172_1 1 38 4 342 NA
    5786 173_1 0.2 54 4 292 61
    5786 173_1 1 39 6 552 NA
    6341 174_1 0.2 97 11 126 3
    6341 174_1 1 90 33 NA NA
    6694 175_1 0.2 44 4 226 NA
    6694 175_1 1 35 4 296 NA
    6695 176_1 0.2 32 7 297 87
    6695 176_1 1 29 4 263 9
    6958 177_1 0.2 58 7 244 76
    6958 177_1 1 47 NA NA NA
    7159 179_1 0.2 33 4 282 NA
    7159 179_1 1 29 5 289 7
    7159 178_1 0.2 43 5 248 NA
    7159 178_1 1 32 4 258 NA
    7720 180_1 0.2 75 6 144 36
    7720 180_1 1 54 7 233 26
    7724 181_1 0.2 72 6 177 20
    7724 181_1 1 45 19 224 62
    7725 182_1 0.2 65 5 139 37
    7725 182_1 1 47 4 208 76
    7725 183_1 0.2 103 13 140 2
    7725 183_1 1 74 6 NA NA
    7727 184_1 0.2 45 2 300 107
    7727 184_1 1 35 2 272 16
    8117 185_1 0.2 87 17 122 13
    8117 185_1 1 63 17 175 NA
    8118 186_1 0.2 40 5 368 105
    8118 186_1 1 33 5 NA NA
    8119 187_1 0.2 62 5 197 NA
    8119 187_1 1 43 13 517 143
    8120 188_1 0.2 96 10 136 41
    8120 188_1 1 79 22 146 19
    8571 189_1 0.2 53 11 204 NA
    8571 189_1 1 49 24 298 15
    8573 190_1 0.2 54 9 140 9
    8573 190_1 1 50 10 267 4
    8574 191_1 0.2 56 1 117 NA
    8574 191_1 1 57 13 199 NA
    8575 192_1 0.2 56 9 165 10
    8575 192_1 1 54 13 246 NA
    8576 193_1 0.2 56 6 185 7
    8576 193_1 1 52 8 330 35
    8585 194_1 0.2 47 2 302 NA
    8585 194_1 1 39 7 NA NA
    8819 195_1 0.2 62 10 155 10
    8819 195_1 1 41 3 192 7
    8820 196_1 0.2 55 12 237 69
    8820 196_1 1 40 3 278 26
    8887 197_1 0.2 69 15 301 59
    8887 197_1 1 58 7 383 92
    9150 198_1 0.2 49 6 NA NA
    9150 198_1 1 43 3 365 38
    9201 199_1 0.2 79 23 88 42
    9201 199_1 1 64 24 140 22
    9202 201_1 0.2 61 10 NA NA
    9202 201_1 1 45 8 343 27
    9202 200_1 0.2 47 3 287 76
    9202 200_1 1 41 4 281 NA
    9203 202_1 0.2 55 17 166 92
    9203 202_1 1 40 5 297 54
    9209 203_1 0.2 60 1 122 NA
    9209 203_1 1 40 14 204 8
    9210 204_1 0.2 43 2 216 NA
    9210 204_1 1 37 3 409 NA
    9210 205_1 0.2 45 8 187 NA
    9210 205_1 1 37 22 336 18
    9211 206_1 0.2 51 10 384 17
    9211 206_1 1 42 3 381 35
    9211 207_1 0.2 65 8 301 28
    9211 207_1 1 50 5 272 53
    9212 35_2 0.2 42 11 203 16
    9212 35_2 1 44 18 335 NA
    9212 208_1 0.2 64 5 147 58
    9212 208_1 1 50 6 260 73
    9213 209_1 0.2 57 7 NA NA
    9213 209_1 1 49 4 346 31
    9214 210_1 0.2 49 7 139 NA
    9214 210_1 1 45 7 223 59
    10832 211_1 0.2 70 6 147 10
    10832 211_1 1 56 9 200 38
    10837 212_1 0.2 59 9 146 46
    10837 212_1 1 41 6 226 47
    10838 213_1 0.2 50 8 247 69
    10838 213_1 1 44 12 307 NA
    10877 214_1 0.2 108 21 115 1
    10877 214_1 1 92 37 88 32
    11434 215_1 0.2 97 12 81 23
    11434 215_1 1 80 26 111 11
    11435 216_1 0.2 90 16 87 NA
    11435 216_1 1 82 29 82 21
    11436 217_1 0.2 87 6 83 11
    11436 217_1 1 68 26 123 NA
    11438 218_1 0.2 57 5 133 NA
    11438 218_1 1 44 16 188 NA
    11439 219_1 0.2 84 1 93 NA
    11439 219_1 1 66 22 113 29
    11464 220_1 0.2 67 9 209 51
    11464 220_1 1 41 6 256 33
    11507 221_1 0.2 59 6 237 NA
    11507 221_1 1 40 63 320 NA
    11508 222_1 0.2 53 7 195 NA
    11508 222_1 1 48 12 302 NA
    11511 223_1 0.2 41 3 210 6
    11511 223_1 1 37 9 273 NA
    11513 224_1 0.2 22 8 288 91
    11513 224_1 1 26 5 360 46
    11514 225_1 0.2 98 17 98 31
    11514 225_1 1 68 16 129 11
    11736 226_1 0.2 69 8 197 80
    11736 226_1 1 55 7 329 66
    12361 227_1 0.2 48 8 183 56
    12361 227_1 1 37 4 193 46
    12794 228_1 0.2 38 9 201 71
    12794 228_1 1 32 2 362 48
    12795 229_1 0.2 50 12 161 30
    12795 229_1 1 34 7 301 35
    12796 230_1 0.2 44 12 237 86
    12796 230_1 1 32 3 379 106
    12894 232_1 0.2 91 17 79 27
    12894 232_1 1 66 10 99 24
    12894 231_1 0.2 80 5 89 NA
    12894 231_1 1 57 14 164 31
    12895 234_1 0.2 88 11 75 32
    12895 234_1 1 68 19 91 24
    12895 233_1 0.2 57 5 199 37
    12895 233_1 1 38 7 249 57
    12896 235_1 0.2 72 3 176 9
    12896 235_1 1 45 3 251 42
    13223 236_1 0.2 40 3 267 66
    13223 236_1 1 31 3 270 23
    13224 238_1 0.2 33 3 265 NA
    13224 238_1 1 28 4 265 6
    13224 237_1 0.2 38 2 212 NA
    13224 237_1 1 31 1 254 31
    13225 239_1 0.2 42 5 317 113
    13225 239_1 1 29 7 215 26
    13226 240_1 0.2 38 7 223 NA
    13226 240_1 1 32 5 232 16
    15115 241_1 0.2 61 8 377 15
    15115 241_1 1 41 3 377 43
    15258 242_1 0.2 66 14 133 35
    15258 242_1 1 55 10 170 17
    15568 243_1 0.2 62 13 192 58
    15568 243_1 1 41 11 309 5
    15570 244_1 0.2 53 17 252 59
    15570 244_1 1 44 5 332 52
    15572 245_1 0.2 57 21 321 122
    15572 245_1 1 49 7 407 77
    15573 246_1 0.2 47 16 348 129
    15573 246_1 1 40 7 410 69
    15574 247_1 0.2 48 14 326 116
    15574 247_1 1 44 8 411 36
    15722 248_1 0.2 51 3 258 17
    15722 248_1 1 36 3 230 NA
    16597 249_1 0.2 66 19 111 39
    16597 249_1 1 54 14 174 44
    16603 250_1 0.2 67 26 89 31
    16603 250_1 1 56 6 172 32
    16730 251_1 0.2 36 5 354 41
    16730 251_1 1 31 2 326 75
    16849 252_1 0.2 74 17 188 81
    16849 252_1 1 48 17 282 1
    17089 253_1 0.2 70 17 98 37
    17089 253_1 1 62 19 153 13
    17401 254_1 0.2 42 6 209 83
    17401 254_1 1 29 3 327 49
    24290 255_1 0.2 106 13 105 36
    24290 255_1 1 109 21 136 NA
    24296 256_1 0.2 92 20 117 30
    24296 256_1 1 93 15 138 21
    24811 257_1 0.2 85 12 126 4
    24811 257_1 1 74 12 137 17
    25032 258_1 0.2 50 11 329 131
    25032 258_1 1 39 5 411 53
    25033 259_1 0.2 40 10 343 50
    25033 259_1 1 31 3 483 84
    25250 260_1 0.2 33 10 279 42
    25250 260_1 1 33 4 338 65
    25251 261_1 0.2 40 8 209 97
    25251 261_1 1 34 3 370 57
    25718 262_1 0.2 56 20 113 48
    25718 262_1 1 45 8 198 65
    25720 263_1 0.2 84 7 121 39
    25720 263_1 1 72 11 88 10
    25721 264_1 0.2 83 15 87 40
    25721 264_1 1 84 22 NA NA
    26331 265_1 0.2 93 5 88 38
    26331 265_1 1 81 8 NA NA
    27165 266_1 0.2 63 3 117 39
    27165 266_1 1 46 9 174 15
    27248 267_1 0.2 81 10 124 17
    27248 267_1 1 59 10 190 112
    29330 268_1 0.2 109 4 124 48
    29330 268_1 1 98 28 114 35
    29635 269_1 0.2 45 1 218 50
    29635 269_1 1 33 9 267 NA
    29635 270_1 0.2 55 5 225 41
    29635 270_1 1 45 8 NA NA
    29636 271_1 0.2 48 2 285 56
    29636 271_1 1 40 7 359 99
    29636 272_1 0.2 48 3 166 5
    29636 272_1 1 35 8 293 40
    29637 273_1 0.2 56 5 255 47
    29637 273_1 1 46 4 300 105
    29637 274_1 0.2 67 7 134 35
    29637 274_1 1 54 7 234 19
    29661 275_1 0.2 51 3 167 15
    29661 275_1 1 42 11 251 NA
    29661 276_1 0.2 54 5 127 17
    29661 276_1 1 39 8 229 NA
    29684 277_1 0.2 40 3 168 73
    29684 277_1 1 31 13 NA NA
    29684 278_1 0.2 46 7 179 2
    29684 278_1 1 36 8 NA NA
    30455 279_1 0.2 102 20 96 34
    30455 279_1 1 86 22 118 23
    30456 280_1 0.2 94 23 91 28
    30456 280_1 1 83 18 134 36
    30457 281_1 0.2 89 23 97 37
    30457 281_1 1 94 23 106 39
    30458 282_1 0.2 99 14 77 27
    30458 282_1 1 103 17 96 20
    30462 283_1 0.2 66 26 98 36
    30462 283_1 1 56 14 129 13
    30465 284_1 0.2 73 11 114 47
    30465 284_1 1 57 10 197 63
    30601 285_1 0.2 41 31 311 29
    30601 285_1 1 30 16 373 40
    30605 286_1 0.2 40 2 221 86
    30605 286_1 1 33 6 375 NA
    30609 287_1 0.2 43 3 267 65
    30609 287_1 1 37 5 332 27
    30610 288_1 0.2 46 6 253 79
    30610 288_1 1 38 3 338 NA
    30667 289_1 0.2 38 15 325 144
    30667 289_1 1 36 3 461 68
    30668 290_1 0.2 74 19 124 54
    30668 290_1 1 58 14 183 20
    30669 291_1 0.2 86 18 98 40
    30669 291_1 1 78 12 133 26
    30670 292_1 0.2 93 10 86 31
    30670 292_1 1 94 16 127 22
    30679 293_1 0.2 85 19 83 21
    30679 293_1 1 87 21 113 23
    30681 294_1 0.2 92 17 78 20
    30681 294_1 1 100 19 86 22
    30682 295_1 0.2 93 22 101 40
    30682 295_1 1 94 33 101 8
    30699 296_1 0.2 80 24 134 6
    30699 296_1 1 47 21 232 36
    30700 297_1 0.2 53 5 146 26
    30700 297_1 1 32 8 NA NA
    30700 298_1 0.2 47 4 221 NA
    30700 298_1 1 38 0 294 NA
    30701 299_1 0.2 49 4 140 NA
    30701 299_1 1 23 NA NA NA
    30701 300_1 0.2 50 9 163 19
    30701 300_1 1 39 11 346 11
    30702 301_1 0.2 66 9 116 36
    30702 301_1 1 44 14 230 51
    30711 302_1 0.2 41 14 288 120
    30711 302_1 1 40 5 422 132
    30714 303_1 0.2 45 9 355 94
    30714 303_1 1 31 5 355 8
    30715 305_1 0.2 39 4 292 56
    30715 305_1 1 34 12 253 5
    30715 304_1 0.2 50 13 263 87
    30715 304_1 1 43 7 285 12
    31630 306_1 0.2 92 32 134 48
    31630 306_1 1 85 25 177 26
    31632 307_1 0.2 94 24 92 32
    31632 307_1 1 86 17 109 33
    31633 308_1 0.2 92 18 78 13
    31633 308_1 1 102 23 98 7
    32755 310_1 0.2 47 12 220 40
    32755 310_1 1 40 16 285 NA
    32755 309_1 0.2 62 6 167 NA
    32755 309_1 1 40 10 225 NA
    32756 311_1 0.2 55 9 128 9
    32756 311_1 1 56 NA 224 NA
    33366 312_1 0.2 64 23 121 4
    33366 312_1 1 56 10 137 1
    33367 313_1 0.2 81 7 91 NA
    33367 313_1 1 79 22 115 12
    33368 314_1 0.2 70 4 103 NA
    33368 314_1 1 57 15 157 NA
    33369 315_1 0.2 73 12 87 20
    33369 315_1 1 67 19 155 NA
    33375 316_1 0.2 79 18 100 18
    33375 316_1 1 51 14 159 39
    33377 317_1 0.2 46 21 248 72
    33377 317_1 1 41 9 313 NA
    33378 318_1 0.2 38 17 273 63
    33378 318_1 1 36 7 321 1
    36606 319_1 0.2 79 10 154 21
    36606 319_1 1 48 9 233 65
    36607 320_1 0.2 60 9 157 18
    36607 320_1 1 49 9 206 25
    38092 321_1 0.2 51 10 221 59
    38092 321_1 1 41 5 328 39
    38297 322_1 0.2 43 9 298 31
    38297 322_1 1 34 6 365 91
    39173 323_1 0.2 98 8 119 27
    39173 323_1 1 82 20 177 21
    39174 324_1 0.2 89 8 139 24
    39174 324_1 1 84 23 192 15
    39175 325_1 0.2 93 18 167 13
    39175 325_1 1 68 17 203 33
    39176 326_1 0.2 79 12 185 83
    39176 326_1 1 55 17 374 107
    39228 327_1 0.2 75 12 151 29
    39228 327_1 1 57 8 207 32
    39230 328_1 0.2 65 11 176 19
    39230 328_1 1 52 19 357 NA
    39231 329_1 0.2 63 19 150 35
    39231 329_1 1 46 6 257 43
    39563 330_1 0.2 69 10 116 34
    39563 330_1 1 56 11 196 NA
    39808 331_1 0.2 40 8 201 17
    39808 331_1 1 25 5 300 NA
    39808 332_1 0.2 40 14 282 109
    39808 332_1 1 33 7 404 81
    39931 333_1 0.2 80 11 107 53
    39931 333_1 1 70 16 112 26
    41114 334_1 0.2 64 4 113 NA
    41114 334_1 1 28 NA 179 NA
    41444 335_1 0.2 57 17 165 39
    41444 335_1 1 46 4 290 40
    41445 336_1 0.2 51 2 134 NA
    41445 336_1 1 42 15 238 NA
    41446 337_1 0.2 63 1 108 NA
    41446 337_1 1 56 14 151 22
    41725 338_1 0.2 91 16 130 50
    41725 338_1 1 75 23 154 27
    41726 339_1 0.2 66 20 142 23
    41726 339_1 1 55 14 193 NA
    41728 340_1 0.2 60 16 137 23
    41728 340_1 1 51 13 233 NA
    42167 341_1 0.2 70 9 138 7
    42167 341_1 1 51 11 182 20
    42168 343_1 0.2 67 9 210 92
    42168 343_1 1 52 6 193 NA
    42168 342_1 0.2 51 6 183 NA
    42168 342_1 1 46 10 275 14
    42169 344_1 0.2 55 1 231 32
    42169 344_1 1 35 3 NA NA
    42169 345_1 0.2 55 7 164 41
    42169 345_1 1 45 5 284 27
    42287 346_1 0.2 66 7 144 32
    42287 346_1 1 53 5 279 34
    42289 347_1 0.2 75 20 125 10
    42289 347_1 1 68 7 241 69
    43452 348_1 0.2 62 12 231 92
    43452 348_1 1 48 23 257 72
    43453 349_1 0.2 52 11 142 41
    43453 349_1 1 44 23 257 34
    43562 350_1 0.2 50 13 148 35
    43562 350_1 1 36 10 NA NA
    43565 351_1 0.2 71 10 116 43
    43565 351_1 1 60 11 154 37
    43566 352_1 0.2 65 19 139 14
    43566 352_1 1 44 8 255 23
    43634 353_1 0.2 63 25 172 75
    43634 353_1 1 51 22 214 NA
    44180 355_1 0.2 60 6 165 8
    44180 355_1 1 57 25 145 NA
    44180 354_1 0.2 76 17 149 55
    44180 354_1 1 48 10 240 29
    44181 356_1 0.2 60 5 170 27
    44181 356_1 1 43 15 154 55
    44183 357_1 0.2 50 15 214 33
    44183 357_1 1 37 17 196 19
    44184 358_1 0.2 57 5 155 31
    44184 358_1 1 47 10 257 94
    44439 359_1 0.2 46 4 220 53
    44439 359_1 1 45 2 347 52
    44440 360_1 0.2 48 9 261 37
    44440 360_1 1 44 6 NA NA
    44440 361_1 0.2 43 5 218 46
    44440 361_1 1 29 3 291 19
    44441 362_1 0.2 50 5 192 60
    44441 362_1 1 45 7 290 58
    44441 363_1 0.2 45 10 185 51
    44441 363_1 1 43 10 247 NA
    44442 364_1 0.2 54 8 124 24
    44442 364_1 1 39 5 271 54
    44442 365_1 0.2 59 6 166 9
    44442 365_1 1 44 8 313 47
    44443 367_1 0.2 55 10 161 29
    44443 367_1 1 40 7 314 67
    44443 366_1 0.2 51 5 202 44
    44443 366_1 1 41 10 300 31
    44477 368_1 0.2 73 6 155 58
    44477 368_1 1 52 3 362 141
    44478 369_1 0.2 82 18 130 35
    44478 369_1 1 58 11 228 66
    44776 370_1 0.2 60 7 128 20
    44776 370_1 1 46 5 274 NA
    45216 371_1 0.2 50 10 149 33
    45216 371_1 1 41 8 260 59
    45217 372_1 0.2 59 7 132 45
    45217 372_1 1 39 4 270 12
    45217 373_1 0.2 47 3 167 52
    45217 373_1 1 38 4 330 62
    45218 374_1 0.2 51 9 189 27
    45218 374_1 1 42 9 359 93
    45246 375_1 0.2 61 8 175 29
    45246 375_1 1 50 7 257 NA
    45247 376_1 0.2 84 4 116 40
    45247 376_1 1 74 10 144 NA
    45248 378_1 0.2 61 10 226 2
    45248 378_1 1 50 5 367 141
    45248 377_1 0.2 74 11 138 29
    45248 377_1 1 62 4 251 NA
    45249 379_1 0.2 48 5 232 NA
    45249 379_1 1 50 NA 312 NA
    45249 380_1 0.2 54 4 203 16
    45249 380_1 1 53 1 353 12
    45250 381_1 0.2 48 6 230 25
    45250 381_1 1 40 7 387 79
    45250 382_1 0.2 60 7 153 30
    45250 382_1 1 46 3 288 43
    45258 383_1 0.2 46 4 211 NA
    45258 383_1 1 34 6 307 29
    45266 385_1 0.2 80 34 85 8
    45266 385_1 1 55 13 128 25
    45266 384_1 0.2 92 4 128 50
    45266 384_1 1 79 12 108 23
    45267 386_1 0.2 93 23 105 13
    45267 386_1 1 80 23 139 14
    45268 387_1 0.2 90 17 111 1
    45268 387_1 1 109 9 122 44
    45270 388_1 0.2 97 7 146 47
    45270 388_1 1 88 9 113 22
    45271 390_1 0.2 79 12 141 14
    45271 390_1 1 58 14 197 38
    45271 389_1 0.2 70 3 97 28
    45271 389_1 1 53 6 150 26
    45272 391_1 0.2 61 4 128 24
    45272 391_1 1 55 14 208 39
    45560 392_1 0.2 86 22 97 26
    45560 392_1 1 71 19 125 18
    45627 393_1 0.2 48 14 150 64
    45627 393_1 1 39 1 209 35
    45628 394_1 0.2 51 4 174 34
    45628 394_1 1 44 8 309 30
    45629 395_1 0.2 60 5 151 24
    45629 395_1 1 48 7 297 43
    45629 396_1 0.2 86 24 139 55
    45629 396_1 1 64 13 203 38
    45635 397_1 0.2 50 10 289 61
    45635 397_1 1 46 2 401 56
    45709 398_1 0.2 47 6 207 61
    45709 398_1 1 49 6 233 NA
    45709 399_1 0.2 56 6 206 13
    45709 399_1 1 45 4 287 93
    46215 400_1 0.2 78 14 122 13
    46215 400_1 1 60 9 114 19
    46256 401_1 0.2 62 7 164 56
    46256 401_1 1 45 5 213 20
    46257 404_1 0.2 44 4 207 44
    46257 404_1 1 41 3 288 45
    46257 402_1 0.2 48 5 197 57
    46257 402_1 1 41 1 300 11
    46257 403_1 0.2 51 4 265 50
    46257 403_1 1 44 5 382 NA
    46259 405_1 0.2 46 4 NA NA
    46259 405_1 1 39 10 359 10
    46260 406_1 0.2 52 9 153 63
    46260 406_1 1 48 7 262 71
    46263 407_1 0.2 52 9 148 9
    46263 407_1 1 41 5 262 45
    46264 408_1 0.2 51 17 269 72
    46264 408_1 1 42 8 280 55
    46392 409_1 0.2 38 10 359 91
    46392 409_1 1 38 8 NA NA
    46393 410_1 0.2 39 12 295 30
    46393 410_1 1 32 12 NA NA
    46420 411_1 0.2 75 10 69 3
    46420 411_1 1 86 3 101 21
    46505 412_1 0.2 65 11 97 7
    46505 412_1 1 53 5 226 59
    46505 413_1 0.2 74 16 124 19
    46505 413_1 1 69 13 117 11
    46506 414_1 0.2 75 7 149 17
    46506 414_1 1 71 10 169 118
    46507 415_1 0.2 86 31 119 36
    46507 415_1 1 66 17 129 28
    46508 416_1 0.2 86 22 87 22
    46508 416_1 1 67 10 142 16
    47364 417_1 0.2 49 2 166 22
    47364 417_1 1 47 13 295 NA
    47365 418_1 0.2 54 3 131 29
    47365 418_1 1 41 3 230 42
    48110 419_1 0.2 77 9 101 45
    48110 419_1 1 58 8 178 68
    48111 420_1 0.2 63 7 121 32
    48111 420_1 1 51 2 238 59
    48186 421_1 0.2 69 5 176 52
    48186 421_1 1 44 12 307 62
    48221 422_1 0.2 58 15 149 63
    48221 422_1 1 39 6 235 50
    48222 423_1 0.2 60 12 143 9
    48222 423_1 1 43 10 209 57
    49345 85_2 0.2 43 14 242 38
    49345 85_2 1 37 5 275 NA
    50282 424_1 0.2 75 20 138 19
    50282 424_1 1 56 9 226 62
    51241 426_1 0.2 61 6 144 NA
    51241 426_1 1 46 9 264 44
    51241 425_1 0.2 46 8 164 22
    51241 425_1 1 44 4 244 35
    51242 428_1 0.2 57 6 138 30
    51242 428_1 1 48 7 290 39
    51242 427_1 0.2 40 15 341 NA
    51242 427_1 1 30 8 286 63
    51244 429_1 0.2 46 5 184 25
    51244 429_1 1 44 6 283 4
    51245 430_1 0.2 47 7 203 9
    51245 430_1 1 37 5 271 29
    51358 431_1 0.2 51 7 265 10
    51358 431_1 1 40 4 363 70
    51358 432_1 0.2 60 4 202 51
    51358 432_1 1 37 7 275 NA
    51359 433_1 0.2 40 3 238 20
    51359 433_1 1 32 3 NA NA
    51359 434_1 0.2 39 6 424 83
    51359 434_1 1 35 6 360 NA
    51438 435_1 0.2 78 15 144 62
    51438 435_1 1 60 14 201 27
    51438 436_1 0.2 71 4 125 32
    51438 436_1 1 54 6 205 71
    51953 437_1 0.2 46 6 217 35
    51953 437_1 1 37 4 277 52
    52150 438_1 0.2 67 6 131 39
    52150 438_1 1 53 13 177 NA
    52549 439_1 0.2 56 5 162 31
    52549 439_1 1 50 10 215 39
    52550 440_1 0.2 69 13 137 40
    52550 440_1 1 50 5 156 53
    52551 441_1 0.2 66 3 132 8
    52551 441_1 1 49 5 169 27
    52579 442_1 0.2 38 7 280 60
    52579 442_1 1 37 5 257 51
    53012 443_1 0.2 79 10 197 61
    53012 443_1 1 65 7 212 36
    53013 445_1 0.2 64 6 211 13
    53013 445_1 1 56 4 264 42
    53013 444_1 0.2 68 11 137 33
    53013 444_1 1 58 9 198 35
    53014 446_1 0.2 59 6 125 NA
    53014 446_1 1 47 3 216 22
    53014 447_1 0.2 53 2 188 94
    53014 447_1 1 51 10 192 47
    54198 448_1 0.2 54 15 161 66
    54198 448_1 1 48 11 243 NA
    54199 449_1 0.2 63 12 166 20
    54199 449_1 1 45 8 185 41
    54232 450_1 0.2 84 17 112 67
    54232 450_1 1 83 8 157 15
    54233 451_1 0.2 67 14 118 44
    54233 451_1 1 51 8 192 34
    54235 452_1 0.2 50 3 162 NA
    54235 452_1 1 42 7 190 NA
    54236 453_1 0.2 47 21 234 17
    54236 453_1 1 42 5 295 NA
    54238 454_1 0.2 76 14 85 NA
    54238 454_1 1 48 12 162 NA
    54239 455_1 0.2 62 6 132 69
    54239 455_1 1 46 7 149 57
    54609 456_1 0.2 66 10 130 57
    54609 456_1 1 56 11 141 60
    54924 457_1 0.2 78 3 137 29
    54924 457_1 1 61 4 178 25
  • Example 4—Activity of Oligonucleotides Targeting the SNHG14 Transcript in the Region Antisense to the UBE3A Pre-mRNA
  • Oligonucleotides targeting position 55337-136214 of SEQ ID NO: 1 were tested in patient derived human neuronal cell cultures (see protocol in “Materials and methods” section). The oligonucleotides ability to reduce the SNHG14 transcript in the region downstream of SNORD109B (also termed UBE3A suppressor or UBE3A-SUP in the data table). Furthermore, the ability to induce UBE3A mRNA re-expression was analyzed.
  • The oligonucleotides were screened according to the protocol for screening oligonucleotides in human neuronal cell cultures described in the section “Materials and methods”—“Screening oligonucleotides in human neuronal cell cultures—96 well system”.
  • The results are shown in table 7.
  • TABLE 7
    Oligonucleotide activity in patient derived human neuronal cell cultures.
    Start SEQ CMP ID Conc % of Mock % of Mock
    ID NO 1 NO μM UBE3A-SUP sd UBE3A sd
    55337 458_1 0.2 64 0 177 6
    55337 458_1 1 50 10 233 9
    55338 459_1 0.2 48 1 186 6
    55338 459_1 1 44 9 213 NA
    59565 460_1 0.2 66 4 110 24
    59565 460_1 1 66 9 131 23
    59574 461_1 0.2 56 5 162 19
    59574 461_1 1 45 13 149 6
    59575 462_1 0.2 56 7 114 84
    59575 462_1 1 39 11 101 13
    59576 463_1 0.2 82 19 52 NA
    59576 463_1 1 65 15 95 18
    60012 464_1 0.2 47 5 129 71
    60012 464_1 1 41 3 160 64
    60298 465_1 0.2 49 7 206 95
    60298 465_1 1 37 9 222 44
    60448 466_1 0.2 47 7 130 NA
    60448 466_1 1 33 8 167 31
    60821 467_1 0.2 87 1 73 NA
    60821 467_1 1 62 18 101 3
    61925 468_1 0.2 108 19 105 19
    61925 468_1 1 95 17 101 19
    62287 469_1 0.2 62 8 180 57
    62287 469_1 1 48 5 196 38
    62422 470_1 0.2 71 2 130 20
    62422 470_1 1 57 9 116 18
    62443 471_1 0.2 51 2 NA NA
    62443 471_1 1 43 2 160 34
    64113 472_1 0.2 95 4 83 22
    64113 472_1 1 76 14 74 36
    64461 473_1 0.2 79 23 141 22
    64461 473_1 1 59 12 279 53
    64462 474_1 0.2 80 12 138 3
    64462 474_1 1 84 15 202 3
    65272 475_1 0.2 77 3 104 2
    65272 475_1 1 75 23 113 10
    66840 476_1 0.2 67 5 86 5
    66840 476_1 1 72 10 100 12
    67426 477_1 0.2 62 15 101 8
    67426 477_1 1 65 13 170 52
    68194 478_1 0.2 53 10 109 6
    68194 478_1 1 59 4 178 7
    68328 479_1 0.2 74 6 94 2
    68328 479_1 1 79 16 111 38
    68805 480_1 0.2 58 15 157 63
    68805 480_1 1 49 2 190 26
    68921 481_1 0.2 58 7 210 58
    68921 481_1 1 55 10 281 NA
    70133 482_1 0.2 50 9 149 6
    70133 482_1 1 54 8 247 41
    72377 483_1 0.2 44 2 143 NA
    72377 483_1 1 52 6 195 37
    72378 484_1 0.2 47 12 111 8
    72378 484_1 1 56 3 201 NA
    72826 485_1 0.2 54 12 116 0
    72826 485_1 1 64 13 172 1
    72861 486_1 0.2 52 9 93 6
    72861 486_1 1 54 6 167 16
    72887 487_1 0.2 55 3 128 5
    72887 487_1 1 59 4 193 24
    73474 488_1 0.2 55 10 132 20
    73474 488_1 1 55 5 202 56
    73992 489_1 0.2 60 7 146 17
    73992 489_1 1 67 7 197 31
    74791 490_1 0.2 42 5 167 65
    74791 490_1 1 46 6 277 19
    74851 491_1 0.2 69 14 78 1
    74851 491_1 1 73 6 114 11
    74853 492_1 0.2 64 6 84 1
    74853 492_1 1 68 5 136 25
    75840 493_1 0.2 40 10 90 6
    75840 493_1 1 61 8 155 32
    75841 494_1 0.2 65 10 131 30
    75841 494_1 1 57 4 119 16
    76238 495_1 0.2 70 9 109 41
    76238 495_1 1 50 8 156 22
    76254 496_1 0.2 67 13 134 34
    76254 496_1 1 55 7 201 NA
    76811 497_1 0.2 83 7 134 41
    76811 497_1 1 77 8 148 32
    77114 498_1 0.2 59 2 128 13
    77114 498_1 1 64 10 206 NA
    80468 499_1 0.2 55 2 105 34
    80468 499_1 1 61 6 151 42
    81047 500_1 0.2 103 17 80 6
    81047 500_1 1 143 25 122 7
    82233 501_1 0.2 57 NA 104 NA
    82233 501_1 1 61 3 199 39
    84166 502_1 0.2 49 6 89 0
    84166 502_1 1 57 5 115 NA
    85392 503_1 0.2 61 6 90 14
    85392 503_1 1 62 8 118 15
    86974 504_1 0.2 73 7 82 4
    86974 504_1 1 79 3 104 19
    87728 505_1 0.2 79 14 76 2
    87728 505_1 1 80 19 97 35
    87810 506_1 0.2 69 9 101 20
    87810 506_1 1 73 6 155 2
    88417 507_1 0.2 45 NA 116 3
    88417 507_1 1 61 14 168 6
    88991 508_1 0.2 51 6 113 20
    88991 508_1 1 59 2 154 31
    90228 509_1 0.2 65 6 76 10
    90228 509_1 1 62 7 118 4
    90474 510_1 0.2 71 7 83 14
    90474 510_1 1 81 3 125 NA
    91625 511_1 0.2 57 17 105 3
    91625 511_1 1 65 11 150 NA
    91885 512_1 0.2 57 5 105 1
    91885 512_1 1 66 7 155 30
    92976 513_1 0.2 67 6 136 44
    92976 513_1 1 68 11 138 38
    94304 514_1 0.2 81 11 110 7
    94304 514_1 1 87 6 153 28
    94528 515_1 0.2 48 5 128 6
    94528 515_1 1 55 3 191 25
    95653 516_1 0.2 57 3 108 7
    95653 516_1 1 62 3 131 16
    96751 517_1 0.2 63 9 90 19
    96751 517_1 1 62 4 106 NA
    97636 518_1 0.2 49 5 107 14
    97636 518_1 1 44 9 137 NA
    98480 519_1 0.2 55 1 106 NA
    98480 519_1 1 54 5 112 23
    98481 520_1 0.2 55 2 116 6
    98481 520_1 1 62 4 129 6
    99646 521_1 0.2 74 10 105 1
    99646 521_1 1 87 13 119 27
    100334 522_1 0.2 49 7 157 28
    100334 522_1 1 57 2 120 37
    101110 523_1 0.2 51 10 96 10
    101110 523_1 1 72 14 114 25
    101898 524_1 0.2 85 11 79 3
    101898 524_1 1 93 21 92 46
    102558 525_1 0.2 82 9 104 8
    102558 525_1 1 86 18 104 30
    103589 526_1 0.2 85 17 114 14
    103589 526_1 1 94 39 126 6
    104309 527_1 0.2 63 11 148 2
    104309 527_1 1 70 26 155 NA
    105686 528_1 0.2 66 11 91 24
    105686 528_1 1 66 14 140 36
    107972 529_1 0.2 84 15 109 15
    107972 529_1 1 94 14 127 24
    108257 530_1 0.2 63 7 114 19
    108257 530_1 1 67 12 141 40
    109407 531_1 0.2 84 24 87 16
    109407 531_1 1 82 11 127 26
    110210 532_1 0.2 72 12 91 14
    110210 532_1 1 80 14 122 40
    110768 533_1 0.2 67 8 126 16
    110768 533_1 1 87 21 176 45
    111811 534_1 0.2 77 2 98 17
    111811 534_1 1 74 6 143 14
    111812 535_1 0.2 64 4 97 0
    111812 535_1 1 77 3 136 37
    112149 536_1 0.2 73 2 63 2
    112149 536_1 1 77 18 127 36
    112150 537_1 0.2 76 6 78 8
    112150 537_1 1 90 29 91 11
    112945 538_1 0.2 69 4 121 2
    112945 538_1 1 83 14 102 39
    113533 539_1 0.2 95 17 85 2
    113533 539_1 1 91 27 87 17
    114274 540_1 0.2 89 11 103 17
    114274 540_1 1 87 26 132 20
    114495 541_1 0.2 76 5 88 1
    114495 541_1 1 83 15 120 6
    114831 542_1 0.2 59 3 76 4
    114831 542_1 1 74 3 104 4
    115355 543_1 0.2 66 8 91 9
    115355 543_1 1 74 16 110 NA
    116105 544_1 0.2 55 12 77 NA
    116105 544_1 1 74 6 110 8
    116106 545_1 0.2 58 18 96 9
    116106 545_1 1 66 8 130 10
    117096 546_1 0.2 69 9 118 20
    117096 546_1 1 65 4 146 NA
    117189 547_1 0.2 69 6 98 9
    117189 547_1 1 74 11 146 25
    117476 548_1 0.2 59 4 87 5
    117476 548_1 1 65 3 104 10
    118293 549_1 0.2 55 8 92 3
    118293 549_1 1 66 10 105 24
    118294 550_1 0.2 55 18 90 4
    118294 550_1 1 72 21 119 5
    118756 551_1 0.2 60 13 86 18
    118756 551_1 1 88 24 120 26
    119621 552_1 0.2 77 21 117 4
    119621 552_1 1 102 19 146 NA
    120655 553_1 0.2 55 9 124 19
    120655 553_1 1 57 7 185 14
    123733 554_1 0.2 74 6 87 14
    123733 554_1 1 77 4 127 4
    124163 555_1 0.2 89 12 117 46
    124163 555_1 1 67 20 152 13
    125512 556_1 0.2 70 5 114 26
    125512 556_1 1 69 11 119 47
    126882 557_1 0.2 78 15 106 8
    126882 557_1 1 84 10 113 33
    127105 558_1 0.2 71 7 91 13
    127105 558_1 1 68 5 108 28
    127809 559_1 0.2 59 4 74 NA
    127809 559_1 1 58 7 101 26
    129020 560_1 0.2 82 11 103 39
    129020 560_1 1 77 9 103 27
    129205 561_1 0.2 75 24 78 16
    129205 561_1 1 89 11 102 23
    129928 562_1 0.2 57 0 98 21
    129928 562_1 1 63 9 107 18
    130020 563_1 0.2 65 5 85 9
    130020 563_1 1 65 3 145 12
    130884 564_1 0.2 81 24 117 31
    130884 564_1 1 83 4 139 17
    130886 565_1 0.2 80 8 103 13
    130886 565_1 1 69 7 122 11
    131404 566_1 0.2 79 4 85 3
    131404 566_1 1 80 7 116 24
    132514 567_1 0.2 71 8 98 28
    132514 567_1 1 69 9 97 29
    133367 568_1 0.2 78 9 88 16
    133367 568_1 1 91 17 88 32
    136198 569_1 0.2 88 5 87 2
    136198 569_1 1 81 6 109 35
  • Example 5—Activity of Oligonucleotides Targeting the SNHG14 Transcript in the Region Downstream of SNORD109B and Upstream of the Region Antisense to the UBE3A Pre-mRNA
  • Oligonucleotides targeting position 5224-51257 of SEQ ID NO: 1 were tested in patient derived human neuronal cell cultures (see protocol in “Materials and methods” section). The oligonucleotides ability to reduce the SNHG14 transcript in the region downstream of SNORD109B (also termed UBE3A suppressor or UBE3A-SUP in the data table. Furthermore, the ability to induce UBE3A mRNA re-expression was analyzed.
  • The oligonucleotides were screened according to the protocol for screening oligonucleotides in human neuronal cell cultures described in the section “Materials and methods” “Screening oligonucleotides in human neuronal cell cultures—96 well system” with the following modifications:
  • UBE3a-Sense Primer
  • Using commercially available primers and probe from ThermoFisher: Hs00166580_m1 amplifying a 94 bp sequence in position 838 of refseq ID NM_000462.3.
  • Each plate include PBS controls (instead on a non-targeting ologinucleotide) and a positive control oligonucleotide CMP ID NO: 271_1, resulting in up-regulation of UBE3A mRNA. The additional control oligonucleotides were not included.
  • Data are presented as average % expression relative to PBS controls across all plates and normalized to the positive control oligonucleotide to manage plate to plate variation in efficacy levels. The results are shown in table 8.
  • TABLE 8
    Oligonucleotide activity in patient
    derived human neuronal cell cultures.
    Start SEQ CMP Conc % of Mock % of Mock
    ID NO 1 ID NO μM UBE3A-SUP sd UBE3A sd
    5224 169_2 7.5 μM 49 4 209 9
    5224 169_3 7.5 μM 47 5 282 5
    5224 169_4 7.5 μM 57 14 202 12
    5224 169_5 7.5 μM 84 36 148 4
    5224 169_6 7.5 μM 42 1 285 16
    5224 169_7 7.5 μM 52 6 233 27
    5224 169_8 7.5 μM 51 7 278 11
    5224 169_9 7.5 μM 51 4 228 20
    5224 169_10 7.5 μM 78 17 143 5
    5224 169_11 7.5 μM 74 15 146 2
    5224 169_12 7.5 μM 47 1 277 26
    5224 169_13 7.5 μM 56 23 244 42
    5224 169_14 7.5 μM 74 16 141 1
    5224 169_15 7.5 μM 95 32 122 13
    5224 169_16 7.5 μM 44 4 276 23
    5224 169_17 7.5 μM 85 5 118 5
    5224 169_18 7.5 μM 75 18 131 4
    5224 169_19 7.5 μM 95 18 126 11
    5224 169_20 7.5 μM 61 12 169 20
    5224 169_21 7.5 μM 79 18 156 3
    5224 169_22 7.5 μM 63 14 173 16
    5224 169_23 7.5 μM 43 2 233 27
    5224 169_24 7.5 μM 56 1 183 9
    5224 169_25 7.5 μM 48 0 220 24
    5224 169_26 7.5 μM 41 1 244 39
    5224 169_27 7.5 μM 55 16 260 42
    5224 169_28 7.5 μM 48 1 265 65
    5224 169_29 7.5 μM 56 2 197 18
    5224 169_30 7.5 μM 57 12 189 12
    5224 169_31 7.5 μM 53 4 196 9
    5224 169_32 7.5 μM 50 1 220 3
    5224 169_33 7.5 μM 64 19 227 8
    5224 169_34 7.5 μM 58 4 193 10
    5224 169_35 7.5 μM 45 2 229 3
    5224 169_36 7.5 μM 44 6 262 14
    5224 169_37 7.5 μM 55 2 180 21
    5224 169_38 7.5 μM 75 22 158 13
    5224 169_39 7.5 μM 76 15 159 17
    5224 169_40 7.5 μM 60 18 232 31
    5224 169_41 7.5 μM 46 3 230 10
    5224 169_42 7.5 μM 47 3 240 11
    5224 169_43 7.5 μM 48 9 273 30
    5224 169_44 7.5 μM 83 32 196 11
    5224 169_45 7.5 μM 69 4 185 20
    5224 169_46 7.5 μM 45 9 256 3
    5224 169_47 7.5 μM 41 2 304 4
    5224 169_48 7.5 μM 44 1 260 16
    5224 169_49 7.5 μM 38 1 245 32
    5224 169_50 7.5 μM 35 2 314 28
    5224 169_51 7.5 μM 41 5 281 5
    5224 169_52 7.5 μM 36 1 282 1
    5224 169_53 7.5 μM 38 7 301 7
    5224 169_54 7.5 μM 36 3 304 6
    5224 169_55 7.5 μM 52 5 246 23
    5224 169_56 7.5 μM 33 15 302 15
    5224 169_57 7.5 μM 34 16 273 16
    5784 570_1 7.5 μM 47 0 274 7
    5784 570_2 7.5 μM 47 8 232 8
    5784 570_3 7.5 μM 55 25 280 54
    5784 570_4 7.5 μM 61 11 235 54
    5784 570_5 7.5 μM 72 10 198 30
    5784 570_6 7.5 μM 66 8 244 50
    5784 570_7 7.5 μM 42 1 284 13
    5784 570_8 7.5 μM 43 6 257 11
    5784 570_9 7.5 μM 32 9 242 30
    5785 571_1 7.5 μM 40 1 269 35
    5785 571_2 7.5 μM 42 3 187 6
    5785 571_3 7.5 μM 46 6 242 8
    5785 571_4 7.5 μM 37 4 282 19
    5785 571_5 7.5 μM 48 16 296 2
    5785 571_6 7.5 μM 37 6 274 10
    5785 571_7 7.5 μM 39 1 260 8
    5785 571_8 7.5 μM 35 1 252 3
    5785 571_9 7.5 μM 30 5 297 10
    5786 572_1 7.5 μM 34 4 279 29
    5786 572_2 7.5 μM 63 10 152 4
    5786 572_3 7.5 μM 39 0 280 42
    5786 572_4 7.5 μM 40 1 283 14
    5786 572_5 7.5 μM 38 6 310 11
    5786 572_6 7.5 μM 33 1 316 18
    5786 572_7 7.5 μM 35 1 318 11
    5786 572_8 7.5 μM 47 9 310 19
    5786 572_9 7.5 μM 31 7 321 12
    8116 573_1 7.5 μM 39 8 316 28
    8116 573_2 7.5 μM 49 15 305 41
    8116 573_3 7.5 μM 46 13 308 3
    8116 573_4 7.5 μM 39 3 332 6
    8116 573_5 7.5 μM 34 6 278 12
    8116 573_6 7.5 μM 42 1 285 10
    8116 573_7 7.5 μM 38 0 289 33
    8116 573_8 7.5 μM 40 4 311 20
    8116 573_9 7.5 μM 57 9 315 5
    8117 574_1 7.5 μM 40 2 291 35
    8117 574_2 7.5 μM 42 3 343 18
    8117 574_3 7.5 μM 36 6 325 8
    8117 574_4 7.5 μM 38 1 279 15
    8117 574_5 7.5 μM 42 6 308 10
    8117 574_6 7.5 μM 47 8 340 11
    8117 574_7 7.5 μM 43 0 308 42
    8117 574_8 7.5 μM 44 6 268 10
    8117 574_9 7.5 μM 41 8 241 22
    8118 575_1 7.5 μM 47 0 198 28
    8118 575_2 7.5 μM 83 26 253 31
    8118 575_3 7.5 μM 48 4 348 5
    8118 575_4 7.5 μM 37 2 269 7
    8118 575_5 7.5 μM 43 6 258 17
    8118 575_6 7.5 μM 50 6 286 3
    8118 575_7 7.5 μM 37 2 331 30
    8118 575_8 7.5 μM 47 7 264 1
    8118 575_9 7.5 μM 64 23 243 3
    8119 576_1 7.5 μM 47 1 272 14
    8119 576_2 7.5 μM 109 31 119 3
    8119 576_3 7.5 μM 36 3 287 6
    8119 576_4 7.5 μM 35 3 285 23
    8119 576_5 7.5 μM 49 10 222 1
    8119 576_6 7.5 μM 79 12 132 10
    8119 576_7 7.5 μM 76 4 132 3
    8119 576_8 7.5 μM 62 1 147 5
    8119 576_9 7.5 μM 43 3 230 5
    8120 577_1 7.5 μM 57 3 158 15
    8120 577_2 7.5 μM 39 4 279 60
    8120 577_3 7.5 μM 38 1 290 68
    8120 577_4 7.5 μM 77 11 148 11
    8120 577_5 7.5 μM 31 6 272 36
    8120 577_6 7.5 μM 38 8 228 32
    8120 577_7 7.5 μM 40 8 246 39
    8120 577_8 7.5 μM 43 11 256 26
    8120 577_9 7.5 μM 85 32 109 6
    8584 578_1 7.5 μM 57 7 199 7
    8584 578_2 7.5 μM 40 5 263 3
    8584 578_3 7.5 μM 40 2 289 23
    8584 578_4 7.5 μM 43 8 199 16
    8584 578_5 7.5 μM 42 1 256 15
    8584 578_6 7.5 μM 42 6 241 10
    8584 578_7 7.5 μM 42 5 329 20
    8584 578_8 7.5 μM 49 7 271 13
    8584 578_9 7.5 μM 45 3 222 3
    8585 579_1 7.5 μM 45 0 208 8
    8585 579_2 7.5 μM 51 4 226 6
    8585 579_3 7.5 μM 54 5 178 8
    8585 579_4 7.5 μM 41 4 328 13
    8585 579_5 7.5 μM 50 5 272 3
    8585 579_6 7.5 μM 86 12 161 0
    8585 579_7 7.5 μM 72 5 155 15
    8585 579_8 7.5 μM 57 3 230 14
    8585 579_9 7.5 μM 83 0 123 1
    8586 580_1 7.5 μM 37 2 313 13
    8586 580_2 7.5 μM 43 1 266 3
    8586 580_3 7.5 μM 42 5 303 5
    8586 580_4 7.5 μM 57 4 225 26
    8586 580_5 7.5 μM 51 4 228 35
    8586 580_6 7.5 μM 44 4 253 15
    8586 580_7 7.5 μM 50 1 241 10
    8586 580_8 7.5 μM 44 0 227 26
    8586 580_9 7.5 μM 31 5 323 31
    8587 581_1 7.5 μM 50 6 223 30
    8587 581_2 7.5 μM 66 7 199 19
    8587 581_3 7.5 μM 56 8 197 9
    8587 581_4 7.5 μM 57 12 270 24
    8587 581_5 7.5 μM 51 12 259 12
    8587 581_6 7.5 μM 39 4 282 2
    8587 581_7 7.5 μM 38 11 263 5
    8587 581_8 7.5 μM 45 10 203 19
    8587 581_9 7.5 μM 43 2 234 10
    9209 582_1 7.5 μM 61 7 225 7
    9209 582_2 7.5 μM 46 9 341 36
    9209 582_3 7.5 μM 44 9 306 38
    9209 582_4 7.5 μM 43 1 249 5
    9209 582_5 7.5 μM 33 16 306 6
    9209 582_6 7.5 μM 37 8 329 19
    9209 582_7 7.5 μM 44 9 289 4
    9209 582_8 7.5 μM 39 3 314 20
    9209 582_9 7.5 μM 41 4 299 25
    9210 583_1 7.5 μM 43 5 319 25
    9210 583_2 7.5 μM 53 9 352 5
    9210 583_3 7.5 μM 42 2 362 42
    9210 583_4 7.5 μM 46 5 225 13
    9210 583_5 7.5 μM 39 6 343 21
    9210 583_6 7.5 μM 44 9 298 8
    9210 583_7 7.5 μM 37 5 332 9
    9210 583_8 7.5 μM 42 6 343 25
    9210 583_9 7.5 μM 36 2 341 9
    9211 584_1 7.5 μM 45 5 343 39
    9211 584_2 7.5 μM 42 2 298 22
    9211 584_3 7.5 μM 44 10 321 2
    9211 584_4 7.5 μM 50 1 299 5
    9211 584_5 7.5 μM 44 1 319 25
    9211 584_6 7.5 μM 50 6 323 13
    9211 584_7 7.5 μM 42 4 316 27
    9211 584_8 7.5 μM 53 3 217 11
    9212 208_2 7.5 μM 44 7 312 26
    9212 208_3 7.5 μM 38 2 331 21
    9212 208_4 7.5 μM 47 3 353 11
    9212 208_5 7.5 μM 54 11 348 14
    9212 208_6 7.5 μM 51 12 310 8
    9212 208_7 7.5 μM 60 9 224 11
    9213 209_2 7.5 μM 44 12 242 21
    9213 209_3 7.5 μM 37 12 335 12
    9213 209_4 7.5 μM 55 7 350 2
    9213 209_5 7.5 μM 47 7 337 19
    9213 209_6 7.5 μM 51 8 300 19
    9213 209_7 7.5 μM 47 15 342 23
    9213 209_8 7.5 μM 45 12 289 5
    9213 209_9 7.5 μM 41 1 368 37
    9213 209_10 7.5 μM 40 4 315 1
    11511 585_1 7.5 μM 41 7 350 12
    11511 585_2 7.5 μM 44 4 233 7
    11511 585_3 7.5 μM 40 8 310 31
    11511 585_4 7.5 μM 33 8 324 41
    11511 585_5 7.5 μM 29 3 314 23
    11511 585_6 7.5 μM 38 4 332 15
    11511 585_7 7.5 μM 30 2 315 15
    11511 585_8 7.5 μM 36 11 328 37
    11511 585_9 7.5 μM 39 5 303 49
    11512 586_1 7.5 μM 60 3 236 5
    11512 586_2 7.5 μM 40 9 282 53
    11512 586_3 7.5 μM 36 1 279 11
    11512 586_4 7.5 μM 34 3 288 21
    11512 586_5 7.5 μM 30 1 270 4
    11512 586_6 7.5 μM 29 5 269 24
    11512 586_7 7.5 μM 33 4 263 6
    11512 586_8 7.5 μM 32 4 270 4
    11512 586_9 7.5 μM 33 5 310 48
    11513 587_1 7.5 μM 45 2 237 34
    11513 587_2 7.5 μM 44 3 307 4
    11513 587_3 7.5 μM 37 1 285 24
    11513 587_4 7.5 μM 44 1 252 41
    11513 587_5 7.5 μM 51 7 220 29
    11513 587_6 7.5 μM 41 2 262 35
    11513 587_7 7.5 μM 39 7 280 21
    11513 587_8 7.5 μM 48 9 230 11
    11513 587_9 7.5 μM 41 5 270 9
    11514 588_1 7.5 μM 54 9 204 25
    11514 588_2 7.5 μM 98 5 143 4
    11514 588_3 7.5 μM 55 9 180 1
    11514 588_4 7.5 μM 113 24 109 17
    11514 588_5 7.5 μM 66 26 150 5
    11514 588_6 7.5 μM 74 1 131 1
    11514 588_7 7.5 μM 79 4 140 9
    11514 588_8 7.5 μM 49 2 235 2
    11514 588_9 7.5 μM 51 10 281 2
    11515 589_1 7.5 μM 61 2 154 9
    11515 589_2 7.5 μM 70 9 126 12
    11515 589_3 7.5 μM 53 3 212 32
    11515 589_4 7.5 μM 93 14 108 14
    11515 589_5 7.5 μM 69 11 191 7
    11515 589_6 7.5 μM 53 9 183 20
    11515 589_7 7.5 μM 45 8 257 4
    11515 589_8 7.5 μM 35 5 213 5
    11515 589_9 7.5 μM 41 2 290 22
    13223 236_2 7.5 μM 39 6 286 21
    13223 236_3 7.5 μM 32 10 256 29
    13223 236_4 7.5 μM 37 5 285 12
    13223 236_5 7.5 μM 33 8 280 19
    13223 236_6 7.5 μM 40 16 295 7
    13223 236_7 7.5 μM 45 10 254 50
    13223 236_8 7.5 μM 41 22 306 50
    13223 236_9 7.5 μM 32 11 292 47
    13223 236_10 7.5 μM 31 10 307 3
    13223 236_11 7.5 μM 52 32 198 29
    13223 236_12 7.5 μM 31 7 261 18
    13223 236_13 7.5 μM 34 3 279 32
    13223 236_14 7.5 μM 38 0 285 75
    13223 236_15 7.5 μM 40 17 307 53
    13223 236_16 7.5 μM 41 6 321 30
    13224 237_2 7.5 μM 49 18 251 38
    13224 237_3 7.5 μM 53 14 236 33
    13224 237_4 7.5 μM 39 0 283 26
    13224 237_5 7.5 μM 43 2 243 2
    13224 237_6 7.5 μM 39 10 265 48
    13224 237_7 7.5 μM 50 3 302 19
    13224 237_8 7.5 μM 46 7 327 43
    13224 237_9 7.5 μM 38 9 287 12
    13224 237_10 7.5 μM 35 6 248 35
    13224 237_11 7.5 μM 41 1 259 24
    13224 237_12 7.5 μM 33 6 303 35
    13224 237_13 7.5 μM 26 4 265 53
    13224 237_14 7.5 μM 30 8 321 15
    13224 237_15 7.5 μM 33 11 315 24
    13224 237_16 7.5 μM 36 11 292 19
    13225 239_2 7.5 μM 35 16 291 30
    13225 239_3 7.5 μM 40 15 311 42
    13225 239_4 7.5 μM 81 6 144 16
    13225 239_5 7.5 μM 90 16 127 11
    13225 239_6 7.5 μM 49 29 282 3
    13225 239_7 7.5 μM 35 4 296 23
    13225 239_8 7.5 μM 40 1 292 48
    13225 239_9 7.5 μM 36 1 318 44
    13225 239_10 7.5 μM 49 NA 304 NA
    13225 239_11 7.5 μM 45 NA 258 NA
    13225 239_12 7.5 μM 43 1 285 1
    13225 239_13 7.5 μM 31 1 308 31
    13225 239_14 7.5 μM 41 8 253 6
    13225 239_15 7.5 μM 28 3 291 16
    13225 239_16 7.5 μM 29 3 314 14
    13226 590_1 7.5 μM 34 1 283 18
    13226 590_2 7.5 μM 49 7 213 17
    13226 590_3 7.5 μM 40 1 274 51
    13226 590_4 7.5 μM 36 1 300 2
    13226 590_5 7.5 μM 37 3 280 36
    13226 590_6 7.5 μM 38 2 204 17
    13226 590_7 7.5 μM 38 5 245 16
    13226 590_8 7.5 μM 30 6 219 34
    13226 590_9 7.5 μM 33 1 269 2
    13226 590_10 7.5 μM 33 2 258 49
    13226 590_11 7.5 μM 48 17 297 31
    13226 590_12 7.5 μM 33 4 317 65
    13226 590_13 7.5 μM 35 7 337 43
    13226 590_14 7.5 μM 25 1 306 22
    13226 590_15 7.5 μM 30 5 299 2
    15113 591_1 7.5 μM 43 3 313 14
    15113 591_2 7.5 μM 52 2 295 24
    15114 592_1 7.5 μM 53 2 232 17
    15114 592_2 7.5 μM 39 1 309 23
    15114 592_3 7.5 μM 46 1 278 12
    15114 592_4 7.5 μM 36 1 328 13
    15114 592_5 7.5 μM 49 9 295 40
    15114 592_6 7.5 μM 46 3 297 10
    15114 592_7 7.5 μM 75 21 160 23
    15114 592_8 7.5 μM 41 10 325 23
    15114 592_9 7.5 μM 55 15 265 3
    15115 241_2 7.5 μM 66 18 168 2
    15115 241_3 7.5 μM 51 15 265 11
    15115 241_4 7.5 μM 49 4 239 7
    15115 241_5 7.5 μM 52 11 314 20
    15115 241_6 7.5 μM 41 13 307 7
    15115 241_7 7.5 μM 38 6 344 33
    15115 241_8 7.5 μM 39 10 329 9
    15115 241_9 7.5 μM 50 11 321 32
    15115 241_10 7.5 μM 48 9 316 1
    15563 593_1 7.5 μM 38 10 282 14
    15563 593_2 7.5 μM 31 5 279 16
    15563 593_3 7.5 μM 34 7 281 16
    15563 593_4 7.5 μM 32 16 318 2
    15563 594_1 7.5 μM 40 2 320 21
    15563 594_2 7.5 μM 54 7 237 14
    15563 594_3 7.5 μM 35 6 300 45
    15563 594_4 7.5 μM 37 7 254 6
    15564 596_1 7.5 μM 47 7 225 35
    15564 596_2 7.5 μM 49 2 184 14
    15564 596_3 7.5 μM 34 8 271 18
    15564 596_4 7.5 μM 45 8 277 29
    15564 595_1 7.5 μM 42 4 254 6
    15564 595_2 7.5 μM 36 9 277 35
    15564 595_3 7.5 μM 40 8 295 31
    15564 595_4 7.5 μM 45 5 173 20
    15566 597_1 7.5 μM 48 6 296 22
    15566 597_2 7.5 μM 44 12 293 8
    15566 597_3 7.5 μM 41 6 318 23
    15566 597_4 7.5 μM 60 9 340 72
    15567 38_3 7.5 μM 41 3 306 14
    15567 38_4 7.5 μM 45 1 303 48
    15567 38_5 7.5 μM 39 15 292 28
    15567 38_6 7.5 μM 46 12 261 40
    15567 598_1 7.5 μM 42 2 257 31
    15567 598_2 7.5 μM 41 12 272 46
    15567 598_3 7.5 μM 54 9 281 29
    15567 598_4 7.5 μM 45 8 307 6
    15568 599_1 7.5 μM 47 3 326 68
    15568 599_2 7.5 μM 60 14 307 30
    15568 599_3 7.5 μM 50 8 274 24
    15568 599_4 7.5 μM 45 6 250 12
    15568 600_1 7.5 μM 37 6 251 1
    15568 600_2 7.5 μM 45 11 267 15
    15568 600_3 7.5 μM 44 5 278 1
    15568 600_4 7.5 μM 41 10 265 5
    15569 601_1 7.5 μM 42 12 271 18
    15569 601_2 7.5 μM 38 6 269 24
    15569 601_3 7.5 μM 39 4 260 34
    15569 601_4 7.5 μM 56 8 146 1
    15570 244_2 7.5 μM 46 1 338 6
    15570 244_3 7.5 μM 47 0 275 47
    15570 244_4 7.5 μM 47 8 281 67
    15570 244_5 7.5 μM 41 8 258 52
    15570 39_2 7.5 μM 53 4 339 25
    15570 39_3 7.5 μM 65 5 200 17
    15570 39_4 7.5 μM 47 7 321 6
    15570 39_5 7.5 μM 46 3 289 20
    15571 602_1 7.5 μM 34 5 278 29
    15571 602_2 7.5 μM 39 8 254 37
    15571 602_3 7.5 μM 41 10 266 23
    15571 602_4 7.5 μM 42 8 256 40
    15571 40_2 7.5 μM 58 0 325 4
    15571 40_3 7.5 μM 58 2 326 35
    15571 40_4 7.5 μM 54 1 306 3
    15571 40_5 7.5 μM 44 2 322 4
    15571 40_6 7.5 μM 43 4 293 17
    15571 40_7 7.5 μM 53 7 343 20
    15571 40_8 7.5 μM 52 1 337 17
    15572 604_1 7.5 μM 58 1 289 3
    15572 604_2 7.5 μM 63 12 230 5
    15572 604_3 7.5 μM 57 3 306 23
    15572 604_4 7.5 μM 46 6 324 4
    15572 603_1 7.5 μM 60 7 339 31
    15572 603_2 7.5 μM 70 0 279 19
    15572 603_3 7.5 μM 59 9 290 48
    15572 603_4 7.5 μM 85 11 123 24
    15573 605_1 7.5 μM 56 5 288 3
    15573 605_2 7.5 μM 58 4 286 6
    15573 605_3 7.5 μM 59 3 261 9
    15573 605_4 7.5 μM 69 24 328 17
    15573 606_1 7.5 μM 50 4 282 19
    15573 606_2 7.5 μM 112 NA 133 NA
    15573 606_3 7.5 μM 55 22 254 43
    15573 606_4 7.5 μM 107 59 116 2
    15574 607_1 7.5 μM 56 2 337 31
    15574 607_2 7.5 μM 59 1 254 10
    15574 607_3 7.5 μM 53 0 295 26
    15574 607_4 7.5 μM 48 3 268 15
    25248 608_1 7.5 μM 86 7 189 5
    25248 608_2 7.5 μM 102 13 136 3
    25248 608_3 7.5 μM 54 17 280 12
    25248 608_4 7.5 μM 71 8 219 31
    25248 608_5 7.5 μM 59 20 179 16
    25248 608_6 7.5 μM 71 2 198 0
    25248 608_7 7.5 μM 47 3 230 21
    25248 608_8 7.5 μM 55 12 287 13
    25248 608_9 7.5 μM 66 19 297 18
    25249 609_1 7.5 μM 58 19 264 7
    25249 609_2 7.5 μM 88 6 156 5
    25249 609_3 7.5 μM 76 19 140 13
    25249 609_4 7.5 μM 50 15 185 6
    25249 609_5 7.5 μM 95 29 139 1
    25249 609_6 7.5 μM 86 15 126 7
    25249 609_7 7.5 μM 72 9 174 1
    25249 609_8 7.5 μM 64 3 189 18
    25249 609_9 7.5 μM 77 12 223 35
    25250 610_1 7.5 μM 55 17 233 7
    25250 610_2 7.5 μM 52 15 233 9
    25250 610_3 7.5 μM 77 5 151 11
    25250 610_4 7.5 μM 48 0 242 21
    25250 610_5 7.5 μM 59 8 234 0
    25250 610_6 7.5 μM 59 12 208 23
    25250 610_7 7.5 μM 69 7 216 5
    25250 610_8 7.5 μM 70 16 211 2
    25250 610_9 7.5 μM 77 22 157 19
    25251 611_1 7.5 μM 43 4 306 10
    25251 611_2 7.5 μM 43 1 300 36
    25251 611_3 7.5 μM 43 17 306 6
    25251 611_4 7.5 μM 40 1 320 37
    25251 611_5 7.5 μM 48 9 273 7
    25251 611_6 7.5 μM 51 2 302 26
    25251 611_7 7.5 μM 40 8 326 8
    25251 611_8 7.5 μM 55 10 330 17
    25251 611_9 7.5 μM 40 3 297 11
    25252 612_1 7.5 μM 58 9 219 5
    25252 612_2 7.5 μM 54 9 282 4
    25252 612_3 7.5 μM 56 13 265 35
    25252 612_4 7.5 μM 81 16 239 51
    25252 612_5 7.5 μM 57 2 234 25
    25252 612_6 7.5 μM 76 18 221 8
    25252 612_7 7.5 μM 45 7 285 11
    25252 612_8 7.5 μM 50 8 231 4
    25252 612_9 7.5 μM 51 3 305 17
    29636 271_1 7.5 μM 35 4 345 29
    29636 271_1 7.5 μM 32 6 383 31
    29636 271_1 7.5 μM 42 7 292 13
    29636 271_1 7.5 μM 40 1 309 41
    29636 271_1 7.5 μM 41 10 339 17
    29636 271_1 7.5 μM 35 8 306 40
    29636 271_1 7.5 μM 33 1 320 12
    29636 271_1 7.5 μM 43 1 347 7
    29636 271_1 7.5 μM 36 2 339 19
    29636 271_1 7.5 μM 36 1 315 5
    29636 271_1 7.5 μM 41 1 326 16
    29636 271_1 7.5 μM 38 2 344 1
    29636 271_1 7.5 μM 34 6 341 8
    29636 271_1 7.5 μM 42 9 320 1
    29636 271_1 7.5 μM 31 8 344 37
    29636 271_1 7.5 μM 44 2 335 11
    29636 271_1 7.5 μM 32 0 316 17
    29636 271_1 7.5 μM 43 11 323 2
    29636 271_1 7.5 μM 35 7 340 2
    29636 271_1 7.5 μM 43 1 340 8
    29636 271_1 7.5 μM 33 4 296 27
    29636 271_1 7.5 μM 38 5 334 4
    29636 271_1 7.5 μM 36 4 341 22
    29636 271_1 7.5 μM 48 4 334 3
    29636 271_1 7.5 μM 36 8 303 13
    29636 271_1 7.5 μM 36 0 343 7
    29636 271_1 7.5 μM 39 1 326 1
    29636 271_1 7.5 μM 38 2 346 14
    29636 271_1 7.5 μM 32 0 332 11
    29636 271_1 7.5 μM 39 4 330 23
    29636 271_1 7.5 μM 39 7 346 33
    29636 271_1 7.5 μM 40 1 329 14
    29636 271_1 7.5 μM 34 6 316 38
    29636 271_1 7.5 μM 33 4 317 14
    29636 271_1 7.5 μM 41 6 328 11
    29636 271_1 7.5 μM 45 2 345 3
    29636 271_1 7.5 μM 37 1 330 3
    29636 271_1 7.5 μM 45 7 322 18
    29636 271_1 7.5 μM 36 3 334 13
    29636 271_1 7.5 μM 33 8 333 3
    29636 271_1 7.5 μM 35 10 321 43
    29636 271_1 7.5 μM 41 3 323 18
    29636 271_1 7.5 μM 39 8 354 39
    29636 271_1 7.5 μM 35 2 327 23
    30599 613_1 7.5 μM 73 29 172 22
    30599 613_2 7.5 μM 87 40 114 9
    30599 613_3 7.5 μM 59 23 168 23
    30599 613_4 7.5 μM 43 15 281 31
    30599 613_5 7.5 μM 51 3 271 28
    30600 614_1 7.5 μM 56 11 179 22
    30600 614_2 7.5 μM 96 40 100 7
    30600 614_3 7.5 μM 41 7 246 27
    30600 614_4 7.5 μM 47 19 283 14
    30600 614_5 7.5 μM 52 21 209 16
    30600 615_1 7.5 μM 61 19 197 12
    30600 615_2 7.5 μM 45 11 287 25
    30600 615_3 7.5 μM 102 NA 115 NA
    30600 615_4 7.5 μM 72 NA 170 NA
    30600 615_5 7.5 μM 95 NA 138 NA
    30601 285_2 7.5 μM 83 NA 165 NA
    30601 285_3 7.5 μM 124 NA 111 NA
    30601 285_4 7.5 μM 69 NA 183 NA
    30601 285_5 7.5 μM 47 23 211 7
    30601 285_6 7.5 μM 46 12 183 6
    30601 617_1 7.5 μM 67 26 190 19
    30601 617_2 7.5 μM 74 35 137 6
    30601 617_3 7.5 μM 51 16 211 4
    30601 617_4 7.5 μM 65 22 142 11
    30601 617_5 7.5 μM 43 8 298 26
    30601 616_1 7.5 μM 50 22 181 12
    30601 616_2 7.5 μM 37 13 276 33
    30601 616_3 7.5 μM 38 16 264 9
    30601 616_4 7.5 μM 43 NA 304 NA
    30601 616_5 7.5 μM 50 NA 229 NA
    30602 619_1 7.5 μM 90 43 131 22
    30602 619_2 7.5 μM 78 40 138 2
    30602 619_3 7.5 μM 66 22 123 8
    30602 619_4 7.5 μM 100 43 96 5
    30602 619_5 7.5 μM 75 17 157 5
    30602 618_1 7.5 μM 46 16 226 12
    30602 618_2 7.5 μM 68 NA 151 NA
    30602 618_3 7.5 μM 52 4 207 18
    30602 618_4 7.5 μM 57 12 223 2
    30602 618_5 7.5 μM 54 2 211 3
    30603 620_1 7.5 μM 106 23 110 16
    30603 620_2 7.5 μM 48 10 243 18
    30603 620_3 7.5 μM 53 1 174 32
    30603 620_4 7.5 μM 81 0 138 15
    30603 620_5 7.5 μM 56 5 218 9
    30604 621_1 7.5 μM 39 4 304 10
    30604 621_2 7.5 μM 35 7 311 3
    30604 621_3 7.5 μM 67 18 142 8
    30604 621_4 7.5 μM 34 6 273 21
    30604 621_5 7.5 μM 36 5 266 18
    30605 622_1 7.5 μM 42 1 242 28
    30605 622_2 7.5 μM 31 10 300 8
    30605 622_3 7.5 μM 35 3 319 11
    30605 622_4 7.5 μM 37 4 281 5
    30605 622_5 7.5 μM 39 5 306 11
    30606 623_1 7.5 μM 47 3 287 1
    30606 623_2 7.5 μM 74 23 166 7
    30606 623_3 7.5 μM 82 1 149 8
    30606 623_4 7.5 μM 66 9 135 8
    30606 623_5 7.5 μM 78 7 128 12
    30608 624_1 7.5 μM 84 13 185 25
    30608 624_2 7.5 μM 35 2 245 9
    30608 624_3 7.5 μM 31 3 267 9
    30608 624_4 7.5 μM 39 16 257 13
    30608 624_5 7.5 μM 34 3 283 4
    30666 625_1 7.5 μM 45 5 286 39
    30666 625_2 7.5 μM 39 3 280 13
    30666 625_3 7.5 μM 40 10 258 9
    30666 625_4 7.5 μM 41 14 234 39
    30666 625_5 7.5 μM 42 5 293 26
    30666 625_6 7.5 μM 44 0 284 25
    30666 625_7 7.5 μM 46 3 271 4
    30666 625_8 7.5 μM 47 5 256 17
    30666 625_9 7.5 μM 40 7 302 2
    30667 626_1 7.5 μM 38 1 279 10
    30667 626_2 7.5 μM 39 21 329 22
    30667 626_3 7.5 μM 59 12 265 65
    30667 626_4 7.5 μM 39 5 318 25
    30667 626_5 7.5 μM 36 2 302 33
    30667 626_6 7.5 μM 36 6 273 34
    30667 626_7 7.5 μM 30 0 299 29
    30667 626_8 7.5 μM 35 4 277 43
    30667 626_9 7.5 μM 32 3 275 22
    30668 627_1 7.5 μM 71 3 131 11
    30668 627_2 7.5 μM 49 4 226 30
    30668 627_3 7.5 μM 64 5 147 8
    30668 627_4 7.5 μM 52 6 176 9
    30668 627_5 7.5 μM 78 14 108 3
    30668 627_6 7.5 μM 40 1 183 23
    30668 627_7 7.5 μM 85 8 116 2
    30668 627_8 7.5 μM 45 1 128 7
    30668 627_9 7.5 μM 42 5 215 36
    30669 628_1 7.5 μM 90 11 120 15
    30669 628_2 7.5 μM 73 12 124 4
    30669 628_3 7.5 μM 88 2 115 4
    30669 628_4 7.5 μM 54 4 190 18
    30669 628_5 7.5 μM 64 1 138 3
    30669 628_6 7.5 μM 62 4 138 11
    30669 628_7 7.5 μM 55 1 138 13
    30669 628_8 7.5 μM 62 1 140 5
    30669 628_9 7.5 μM 79 10 134 22
    30711 629_1 7.5 μM 42 1 252 47
    30711 629_2 7.5 μM 40 2 295 30
    30711 629_3 7.5 μM 46 1 302 78
    30711 629_4 7.5 μM 41 3 260 16
    30711 629_5 7.5 μM 41 1 284 3
    30711 629_6 7.5 μM 43 0 262 1
    30711 629_7 7.5 μM 43 3 278 65
    30711 629_8 7.5 μM 53 5 234 24
    30711 629_9 7.5 μM 37 4 289 1
    30711 629_10 7.5 μM 47 6 292 6
    30711 629_11 7.5 μM 50 5 224 20
    30712 630_1 7.5 μM 44 2 282 22
    30712 630_2 7.5 μM 45 6 297 23
    30712 630_3 7.5 μM 46 2 272 10
    30713 631_1 7.5 μM 45 2 294 10
    30713 631_2 7.5 μM 42 0 285 14
    30713 631_3 7.5 μM 38 3 319 21
    30713 631_4 7.5 μM 43 3 282 4
    30713 631_5 7.5 μM 54 2 173 17
    30713 631_6 7.5 μM 37 0 315 10
    30713 631_7 7.5 μM 40 4 317 2
    30713 631_8 7.5 μM 44 1 275 5
    30713 631_9 7.5 μM 47 2 233 8
    30713 631_10 7.5 μM 108 18 101 3
    30714 632_1 7.5 μM 48 4 210 4
    30714 632_2 7.5 μM 53 5 256 5
    30714 632_3 7.5 μM 60 5 224 19
    30714 632_4 7.5 μM 89 12 117 11
    30714 632_5 7.5 μM 39 6 312 6
    30714 632_6 7.5 μM 40 2 278 31
    30714 632_7 7.5 μM 86 1 160 21
    30714 632_8 7.5 μM 57 17 278 40
    30714 632_9 7.5 μM 51 7 236 13
    30715 304_2 7.5 μM 53 5 206 18
    30715 304_3 7.5 μM 70 11 142 24
    30715 304_4 7.5 μM 88 1 120 10
    30715 304_5 7.5 μM 82 15 123 7
    30715 304_6 7.5 μM 43 4 264 12
    30715 304_7 7.5 μM 41 5 266 49
    30715 304_8 7.5 μM 43 1 291 12
    30715 304_9 7.5 μM 36 3 285 18
    30715 304_10 7.5 μM 42 1 280 40
    33376 633_1 7.5 μM 53 1 234 50
    33376 633_2 7.5 μM 45 5 301 7
    33376 633_3 7.5 μM 53 7 263 17
    33376 633_4 7.5 μM 53 4 229 22
    33376 633_5 7.5 μM 43 3 264 36
    33376 633_6 7.5 μM 53 5 247 12
    33376 633_7 7.5 μM 49 6 289 6
    33376 633_8 7.5 μM 64 11 238 24
    33376 633_9 7.5 μM 63 2 249 28
    33377 634_1 7.5 μM 57 9 250 14
    33377 634_2 7.5 μM 53 10 265 3
    33377 634_3 7.5 μM 48 2 275 10
    33377 634_4 7.5 μM 39 6 287 12
    33377 634_5 7.5 μM 49 1 255 22
    33377 634_6 7.5 μM 51 2 291 15
    33377 634_7 7.5 μM 47 5 297 16
    33377 634_8 7.5 μM 42 9 311 14
    33377 634_9 7.5 μM 47 5 271 23
    33378 635_1 7.5 μM 56 11 257 3
    33378 635_2 7.5 μM 56 5 213 23
    33378 635_3 7.5 μM 61 8 215 8
    33378 635_4 7.5 μM 58 15 232 16
    33378 635_5 7.5 μM 48 3 316 20
    33378 635_6 7.5 μM 59 5 262 30
    33378 635_7 7.5 μM 55 7 287 15
    33378 635_8 7.5 μM 42 1 284 3
    33378 635_9 7.5 μM 40 0 277 23
    33379 636_1 7.5 μM 50 2 239 7
    33379 636_2 7.5 μM 74 16 204 10
    33379 636_3 7.5 μM 55 4 201 3
    33379 636_4 7.5 μM 54 2 238 7
    33379 636_5 7.5 μM 52 5 207 43
    33379 636_6 7.5 μM 47 3 249 6
    33379 636_7 7.5 μM 48 5 241 1
    33379 636_8 7.5 μM 37 7 304 12
    33379 636_9 7.5 μM 62 9 245 5
    33380 637_1 7.5 μM 39 1 219 25
    33380 637_2 7.5 μM 59 1 197 11
    33380 637_3 7.5 μM 56 1 250 19
    33380 637_4 7.5 μM 53 7 244 36
    33380 637_5 7.5 μM 73 13 297 34
    33380 637_6 7.5 μM 65 1 124 17
    33380 637_7 7.5 μM 74 5 133 5
    33380 637_8 7.5 μM 53 2 207 7
    33380 637_9 7.5 μM 54 15 226 26
    39806 638_1 7.5 μM 37 7 283 31
    39806 638_2 7.5 μM 49 11 291 30
    39806 638_3 7.5 μM 41 1 270 20
    39806 638_4 7.5 μM 42 13 267 9
    39806 638_5 7.5 μM 50 1 184 5
    39806 638_6 7.5 μM 38 1 276 15
    39806 638_7 7.5 μM 56 1 292 4
    39806 638_8 7.5 μM 41 4 267 11
    39806 638_9 7.5 μM 41 4 218 33
    39807 639_1 7.5 μM 48 15 293 30
    39807 639_2 7.5 μM 38 3 269 2
    39807 639_3 7.5 μM 72 5 167 3
    39807 639_4 7.5 μM 69 38 242 36
    39807 639_5 7.5 μM 47 6 303 36
    39807 639_6 7.5 μM 53 6 179 5
    39807 639_7 7.5 μM 51 3 189 8
    39807 639_8 7.5 μM 42 3 185 19
    39807 639_9 7.5 μM 45 3 202 15
    39808 640_1 7.5 μM 39 5 265 7
    39808 640_2 7.5 μM 37 4 272 56
    39808 640_3 7.5 μM 38 3 260 17
    39808 640_4 7.5 μM 33 4 255 2
    39808 640_5 7.5 μM 38 3 253 3
    39808 640_6 7.5 μM 40 8 216 10
    39808 640_7 7.5 μM 39 8 310 7
    39808 640_8 7.5 μM 41 6 282 21
    39808 640_9 7.5 μM 40 5 269 12
    44439 641_1 7.5 μM 35 6 336 32
    44439 641_2 7.5 μM 67 20 161 6
    44439 641_3 7.5 μM 34 9 317 30
    44439 641_4 7.5 μM 62 18 193 9
    44439 641_5 7.5 μM 34 4 280 3
    44439 641_6 7.5 μM 43 1 315 45
    44439 641_7 7.5 μM 45 17 307 53
    44439 641_8 7.5 μM 41 0 294 41
    44439 641_9 7.5 μM 37 2 334 43
    44440 361_2 7.5 μM 36 1 303 15
    44440 361_3 7.5 μM 32 3 315 12
    44440 361_4 7.5 μM 41 1 299 7
    44440 361_5 7.5 μM 40 5 295 6
    44440 361_6 7.5 μM 40 2 296 30
    44440 361_7 7.5 μM 39 1 300 55
    44440 361_8 7.5 μM 45 6 285 45
    44440 361_9 7.5 μM 44 6 321 26
    44440 361_10 7.5 μM 46 7 290 18
    44441 362_2 7.5 μM 50 4 277 4
    44441 362_3 7.5 μM 40 6 296 8
    44441 362_4 7.5 μM 37 5 340 18
    44441 362_5 7.5 μM 45 2 266 21
    44441 362_6 7.5 μM 39 7 263 0
    44441 362_7 7.5 μM 41 12 262 36
    44441 362_8 7.5 μM 35 13 313 6
    44441 362_9 7.5 μM 36 8 300 20
    44441 362_10 7.5 μM 48 10 293 1
    46391 642_1 7.5 μM 51 25 278 6
    46391 642_2 7.5 μM 46 2 303 4
    46391 642_3 7.5 μM 48 3 297 11
    46391 642_4 7.5 μM 45 11 320 37
    46391 642_5 7.5 μM 71 32 303 40
    46391 642_6 7.5 μM 47 15 298 16
    46391 642_7 7.5 μM 38 6 277 5
    46391 642_8 7.5 μM 38 3 280 20
    46391 642_9 7.5 μM 51 20 285 16
    46391 642_10 7.5 μM 32 7 293 20
    46391 642_11 7.5 μM 42 2 291 2
    46391 642_12 7.5 μM 40 3 317 19
    46391 642_13 7.5 μM 39 11 295 5
    46391 642_14 7.5 μM 52 20 295 16
    46391 642_15 7.5 μM 39 8 316 38
    46391 642_16 7.5 μM 35 2 294 30
    46391 642_17 7.5 μM 51 5 292 8
    46391 643_1 7.5 μM 39 4 276 16
    46392 644_1 7.5 μM 39 0 321 7
    46392 644_2 7.5 μM 46 4 308 4
    46392 644_3 7.5 μM 44 1 317 3
    46392 644_4 7.5 μM 38 6 315 11
    46392 645_1 7.5 μM 46 5 342 42
    46392 645_2 7.5 μM 37 5 292 25
    46392 645_3 7.5 μM 46 16 317 30
    46392 645_4 7.5 μM 47 8 381 102
    46392 645_5 7.5 μM 42 2 269 4
    46393 646_1 7.5 μM 49 4 295 2
    46393 646_2 7.5 μM 49 9 304 38
    46393 646_3 7.5 μM 44 6 298 50
    46393 646_4 7.5 μM 43 1 296 41
    46393 646_5 7.5 μM 35 1 260 3
    46393 646_6 7.5 μM 40 2 281 67
    46393 646_7 7.5 μM 38 1 278 44
    46393 646_8 7.5 μM 42 6 262 49
    46393 646_9 7.5 μM 38 3 289 24
    46393 646_10 7.5 μM 38 1 317 4
    46393 646_11 7.5 μM 42 1 320 34
    46393 646_12 7.5 μM 36 5 323 8
    46393 646_13 7.5 μM 41 3 262 27
    46393 646_14 7.5 μM 46 13 315 18
    46393 646_15 7.5 μM 42 4 340 27
    46393 646_16 7.5 μM 45 8 360 14
    46393 646_17 7.5 μM 44 1 303 3
    46393 646_18 7.5 μM 50 2 304 28
    46393 646_19 7.5 μM 54 10 217 25
    51241 425_2 7.5 μM 49 12 296 3
    51241 425_3 7.5 μM 48 6 297 10
    51241 425_4 7.5 μM 52 5 275 25
    51241 425_5 7.5 μM 40 6 284 29
    51241 425_6 7.5 μM 39 5 301 22
    51241 425_7 7.5 μM 39 4 263 13
    51241 425_8 7.5 μM 32 5 188 13
    51241 425_9 7.5 μM 42 5 286 2
    51241 425_10 7.5 μM 34 3 165 17
  • Example 6—Activity of Exon-Exon Spanning Oligonucleotides
  • Oligonucleotides designed to be complementary across exon-exon junctions of SNHG14-023 (ENST00000554726) were tested for their ability to reduce the SNHG14 transcript in the region downstream of SNORD109B (also termed UBE3A suppressor or UBE3A-SUP in the data table). Furthermore, the ability to induce UBE3A mRNA re-expression was analyzed. The oligonucleotides primarily span exon2 and exon3 (i.e. are complementary to a region in exon2 and a region in exon 3).
  • The oligonucleotides were screened according to the protocol for screening oligonucleotides in human neuronal cell cultures described in the section Example 5.
  • The results are shown in table 9.
  • TABLE 9
    Oligonucleotide activity in patient derived human neuronal cell cultures.
    CMP ID Conc % of Mock % of Mock
    NO μM UBE3A-SUP sd UBE3A sd
    674_1 7.5 μM 47 2 214 12
    675_1 7.5 μM 44 6 265 10
    676_1 7.5 μM 44 3 284 16
    677_1 7.5 μM 55 19 351 18
    678_1 7.5 μM 41 11 257 1
    656_1 7.5 μM 46 3 140 19
    657_1 7.5 μM 35 7 218 27
    658_1 7.5 μM 38 12 253 43
    659_1 7.5 μM 39 7 274 6
    660_1 7.5 μM 38 8 275 29
    661_1 7.5 μM 43 13 246 21
    662_1 7.5 μM 27 10 290 5
    663_1 7.5 μM 28 0 287 23
    664_1 7.5 μM 27 2 288 14
    665_1 7.5 μM 37 9 321 47
    666_1 7.5 μM 54 1 259 10
    667_1 7.5 μM 47 8 236 2
    647_1 7.5 μM 19 3 300 25
    648_1 7.5 μM 22 7 320 3
    649_1 7.5 μM 34 8 326 2
    650_1 7.5 μM 44 4 292 7
    651_1 7.5 μM 36 5 254 9
    652_1 7.5 μM 21 2 314 18
    653_1 7.5 μM 24 5 299 41
    654_1 7.5 μM 31 2 344 41
    655_1 7.5 μM 60 9 301 3
    668_1 7.5 μM 21 3 297 11
    669_1 7.5 μM 24 5 296 27
    670_1 7.5 μM 30 3 274 55
    671_1 7.5 μM 27 6 263 35
    672_1 7.5 μM 27 6 280 50
    673_1 7.5 μM 33 2 290 19
  • Example 7—Testing In Vitro Efficacy and Potency of Selected Oligonucleotides
  • Based on the screenings in examples 2 to 5 above 52 oligonucleotides were selected for potency and efficacy testing.
  • The oligonucleotides were screened in human AS patient derived cells as described in the Materials and Method section “Screening oligonucleotides in human neuronal cell cultures—96 well system” with the following modifications:
  • For UBE3a-Sense primer commercially available primers and probe from ThermoFisher: Hs00166580_m1 amplifying a 94 bp sequence in position 838 of refseq ID NM_000462.3 were used.
  • Each plate include PBS controls (instead on a non-targeting oligonucleotide) and the positive control oligonucleotides CMP ID NO: 186_1 and 39_1 identified in previous screens were included. The additional control oligonucleotides described in the materials and method section were not included. Oligonucleotide test concentrations were from 31.6 μM to 1 nM using a 10 point half-log dilution. All oligonucleotides were tested in 5 independent experiments in 5 different weeks. In the data QC process some plates were removed from the analysis if these were obvious outliers e.g. no PCR product detected. After this filtration there is a minimum of three independent experiments behind each the reported values.
  • The EC50 (UBE3A mRNA re-expression) and IC50 (reduction of the SNHG14 transcript in the region downstream of SNORD109B, also termed UBE3A suppressor or UBE3A-SUP in the data table) were determined after curve fitting using a 4 parameter sigmoidal dose-response model. Fitting was executed using the fit engine available inside the Biobook software by IDBS (XLfit). From the curve-fitting the maximum obtainable up-regulation of UBE3A (UBE3A Max Up) and the maximum obtainable knockdown of UBE3A-SUP (UBE3A-SUP max Kd) were determined. Both are shown as % of control (PBS treated cells). The results are shown in table 10, values are reported as geometric means of each biological replicate.
  • TABLE 10
    Oligonucleotide EC50 and IC 50 values and maximum
    UBE3A upregulation and UBE3A suppressor knock down.
    CMP EC50 IC50 UBE3A UBE3A-SUP
    ID NO ↑ UBE3A Sd ↓ UBE3A-SUP Sd Max Kd Sd max Kd Sd
    586_9 0.02 0.02 0.01 0.00 329.4 25.5 33.5 3.8
    585_1 0.03 0.01 0.03 0.02 301.6 18.3 31.0 5.3
    572_7 0.03 0.00 0.01 0.03 294.1 30.4 31.3 3.5
    591_1 0.03 0.02 0.01 0.00 387.3 46.0 41.4 2.8
    585_8 0.04 0.02 0.02 0.01 312.3 23.1 35.2 3.3
    626_7 0.04 0.02 0.02 0.00 362.5 44.6 38.7 3.3
    621_2 0.04 0.03 0.02 0.01 264.5 19.6 24.7 3.9
    624_3 0.04 0.03 0.04 0.03 288.1 19.2 29.7 5.2
    169_52 0.04 0.04 0.02 0.01 303.4 23.1 27.3 1.8
    624_5 0.04 0.07 0.01 0.01 249.2 16.3 16.4 1.4
    586_5 0.04 0.01 0.01 0.00 364.4 43.9 30.4 3.3
    626_8 0.04 0.03 0.01 0.01 338.7 24.0 39.1 2.6
    169_50 0.05 0.02 0.02 0.02 280.3 23.0 28.3 2.4
    572_6 0.05 0.01 0.01 0.02 298.5 22.4 36.3 4.0
    639_5 0.05 0.03 0.01 0.00 327.7 22.0 38.2 3.6
    592_2 0.05 0.03 0.02 0.05 364.9 27.1 36.4 3.6
    586_8 0.05 0.03 0.02 0.01 366.6 35.1 38.0 3.9
    625_6 0.06 0.03 0.01 0.00 335.5 34.7 32.5 1.9
    644_3 0.06 0.04 0.01 0.02 298.5 22.0 25.3 1.6
    586_4 0.06 0.03 0.01 0.01 354.3 31.5 33.0 2.3
    642_12 0.06 0.05 0.02 0.01 289.2 14.8 24.7 3.0
    572_5 0.07 0.09 0.02 0.00 312.7 25.9 31.5 3.0
    592_4 0.07 0.06 0.03 0.01 341.1 31.9 35.7 1.8
    622_3 0.07 0.04 0.02 0.01 300.9 21.0 27.6 3.6
    622_5 0.07 0.01 0.02 0.01 306.2 13.5 24.4 4.0
    616_4 0.07 0.04 0.03 0.02 293.8 17.9 29.1 5.0
    304_6 0.08 0.08 0.02 0.00 318.1 39.2 43.8 3.9
    638_8 0.08 0.01 0.01 0.01 354.8 30.6 42.4 4.1
    622_4 0.08 0.07 0.02 0.01 330.3 24.8 29.5 2.4
    642_13 0.08 0.07 0.04 0.03 268.4 21.0 26.8 2.5
    573_8 0.08 0.01 0.04 0.02 320.1 34.4 34.3 3.4
    241_9 0.09 0.04 0.04 0.03 352.6 26.4 34.1 2.3
    304_10 0.09 0.07 0.03 0.01 289.5 19.9 28.3 2.8
    636_8 0.10 0.08 0.03 0.04 330.8 34.1 53.9 13.4 
    598_4 0.11 0.06 0.03 0.04 295.0 15.1 41.3 2.2
    586_6 0.11 0.10 0.02 0.02 316.2 21.2 23.8 3.5
    621_1 0.11 0.21 0.02 0.01 311.9 19.2 27.5 5.2
    331_1 0.12 0.02 0.03 0.02 293.6 49.0 25.1 5.4
    626_9 0.13 0.12 0.02 0.03 302.2 32.6 34.4 2.2
    169_56 0.14 0.18 0.02 0.01 356.5 22.3 26.8 2.2
    631_6 0.14 0.30 0.04 0.00 292.9 25.1 33.5 4.9
    186_1 0.16 0.02 0.04 0.05 371.7 70.1 32.5 5.5
    611_7 0.16 0.15 0.02 0.01 369.2 29.3 37.2 3.9
    165_1 0.17 0.02 0.07 0.12 266.3 NA 26.7 NA
    646_16 0.18 0.15 0.03 0.02 306.0  9.0 30.6 2.9
    640_4 0.20 0.10 0.02 0.01 328.4 31.0 40.4 7.0
    631_1 0.22 0.07 0.07 0.02 324.6  1.6 47.5 8.1
    590_13 0.23 0.59 0.02 0.02 353.4 22.3 31.8 2.2
    172_1 0.24 0.10 0.11 0.14 254.2 NA 34.2 NA
    35_2 0.26 0.02 0.06 0.09 257.9 NA 22.3 NA
    425_5 0.26 0.14 0.08 0.08 317.3 33.9 32.9 2.4
    359_1 0.27 0.03 0.03 0.08 260.5 NA 31.3 NA
    209_1 0.28 0.08 0.03 0.03 339.9 30.6 48.2 11.6 
    123_1 0.28 0.13 0.26 0.08 235.9 NA 51.8 NA
    361_1 0.29 0.10 0.06 0.02 331.9 17.2 30.7 6.3
    602_1 0.31 0.33 0.15 0.20 340.3 21.7 42.2 5.0
    NA 0.44 0.12 0.15 0.18 251.3 NA 24.6 NA
    287_1 0.45 0.09 0.04 0.02 318.1 45.2 28.8 9.3
    303_1 0.46 0.05 0.09 0.15 259.9 NA 30.9 NA
    379_1 0.47 0.02 0.08 0.16 247.2 NA 22.5 NA
    405_1 0.48 0.42 0.04 0.01 323.0 56.2 32.5 11.9 
    39_1 0.51 0.20 0.06 0.06 341.2 30.3 40.4 4.7
    206_1 0.52 0.07 0.14 0.31 262.9 NA 30.5 NA
    155_1 0.53 0.10 NA 0.53 260.8 NA 26.7 NA
    362_1 0.57 0.25 0.09 0.02 328.1 57.3 27.4 8.6
    178_1 0.58 0.35 0.11 0.04 334.3 50.8 26.6 8.0
    48_1 0.59 0.02 0.07 0.56 262.7 NA 27.2 NA
    200_1 0.62 0.51 0.15 0.06 331.0 54.3 33.1 6.2
    361_5 0.67 0.18 0.07 0.00 307.1 22.9 32.1 4.5
    597_4 0.67 0.51 0.10 0.06 325.3 17.3 35.3 2.7
    85_1 0.68 0.06 0.28 0.41 255.5 NA 35.1 NA
    278_1 0.69 0.67 0.08 0.09 313.8 33.4 27.2 4.6
    271_1 0.69 0.00 0.03 0.65 247.3 NA 24.0 NA
    403_1 0.77 0.57 0.11 0.09 296.4 55.0 28.8 7.0
    204_1 0.78 0.59 0.05 0.05 316.1 35.5 36.3 7.9
    116_1 0.91 0.05 0.09 0.43 240.6 NA 31.6 NA
    124_1 0.92 0.29 0.55 0.94 190.0 NA 43.9 NA
    237_8 0.93 0.66 0.05 0.03 376.2 32.8 33.6 3.7
    378_1 0.95 0.64 0.13 0.09 317.7 30.1 48.5 6.1
    126_2 0.95 0.05 0.12 0.70 219.7 NA 45.0 NA
    373_1 1.03 0.63 0.13 0.08 321.7 38.6 27.5 4.8
    641_5 1.16 1.36 0.07 0.06 335.1 28.9 26.6 5.1
    207_1 1.18 0.58 0.18 0.06 318.5 42.9 44.0 7.2
    19_1 1.50 0.19 0.24 1.07 261.7 NA 28.4 NA
    175_1 1.51 0.42 0.17 0.11 333.5 23.8 29.2 5.2
    304_1 1.55 0.09 0.08 0.11 297.8 26.2 32.5 5.7
    399_1 1.86 2.50 0.44 0.26 340.1 52.2 39.6 4.3
    38_1 2.12 0.10 0.34 0.43 257.3 NA 45.1 NA
    222_1 2.29 0.75 0.28 0.12 298.2 34.9 26.8 5.6
    187_1 2.30 1.39 1.00 0.91 315.3 38.4 28.6 6.2
    272_1 2.32 1.39 0.24 0.16 330.4 41.2 37.1 6.1
    18_1 2.42 0.21 0.24 2.00 271.0 NA 29.3 NA
    118_1 2.78 0.30 0.31 0.07 205.4 NA 40.4 NA
    35_1 2.93 4.94 3.61 1.52 258.4 NA 48.2 NA
    233_1 3.14 1.68 0.35 0.16 330.3 20.1 29.3 5.2
    220_1 3.47 0.99 1.02 0.48 315.5 27.4 29.6 7.6
    33_1 3.97 0.41 1.07 NA 265.7 NA 32.2 NA
    109_1 4.06 1.45 1.33 0.67 231.7 44.7 39.6 3.9
    40_1 4.17 0.05 0.12 3.74 263.6 NA 38.3 NA
    115_1 4.98 0.15 0.25 NA 184.2 NA 47.0 NA
    161_1 6.55 3.20 1.25 1.24 294.0 24.8 32.1 7.4
    105_4 6.61 1.62 1.38 4.20 NA NA 50.6 NA
    19_2 6.66 1.17 3.17 1.52 201.7 NA 57.7 NA
    104_1 7.75 6.77 1.67 1.05 267.9 25.5 42.5 4.1
    18_2 20.00 1.67 3.50 NA 245.9 NA 46.4 NA
    108_1 20.00 0.61 1.27 NA 219.6 NA 51.2 NA
    129_2 20.00 0.08 1.10 NA 165.8 NA 56.5 NA
    141_1 20.00 0.03 0.15 NA 159.0 NA 64.1 NA
    142_1 20.00 1.04 1.12 NA 133.1 NA 57.6 NA
    145_1 20.00 1.30 1.81 NA 139.0 NA 56.9 NA

Claims (24)

1. An antisense oligonucleotide which comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 98% complementarity to position 25278410 to 25419462 on human chromosome 15.
2. The oligonucleotide of claim 1, wherein the contiguous nucleotide sequence is complementary to a region of the target nucleic acid of SEQ ID NO: 1 and/or 2.
3. The oligonucleotide of claim 1, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid, wherein the sub-sequence is selected from the group consisting of the regions indicated in table 1 or 2.
4. The oligonucleotide of claim 1, wherein the oligonucleotide comprises a sequence selected from the group consisting of SEQ ID NO: 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 1819, 20, 21, 22, 23, 23, 24, 25, 26, 26, 27, 28, 29, 30, 31, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 44, 45, 45, 46, 47, 48, 49, 50, 51, 52, 53, 53, 54, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 79, 80, 81, 8283, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 95, 96, 96, 96, 97, 98, 99, 100, 101, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817 and 818.
5. The oligonucleotide of claim 1, comprising one or more modified nucleosides.
6. The oligonucleotide of claim 5, wherein the one or more modified nucleosides is a 2′ sugar modified nucleoside.
7. The oligonucleotide of claim 6, wherein the one or more 2′ sugar modified nucleoside is independently selected from the group consisting of 2′-O-alkyl-RNA, 2′-O-methyl-RNA, 2′-alkoxy-RNA, 2′-O-methoxyethyl-RNA, 2′-amino-DNA, 2′-fluoro-DNA, arabino nucleic acid (ANA), 2′-fluoro-ANA and LNA nucleosides.
8. The oligonucleotide of claim 5, wherein the one or more modified nucleoside is a LNA nucleoside.
9. The oligonucleotide of claim 1, wherein the oligonucleotide comprises at least one modified internucleoside linkage.
10. The oligonucleotide of claim 9, wherein the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate internucleoside linkages.
11. The oligonucleotide of claim 1, wherein the oligonucleotide is capable of recruiting RNase H.
12. The oligonucleotide of claim 11, wherein the oligonucleotide is a gapmer.
13. The oligonucleotide of claim 11, wherein the oligonucleotide is a gapmer of formula 5′-F-G-F′-3′, where region F and F′ independently comprise 1-7 modified nucleosides and G is a region between 6 and 16 nucleosides which are capable of recruiting RNaseH.
14. The oligonucleotide of claim 1, wherein the oligonucleotide is selected from the group consisting of CMP ID NO: 4_1, 4_2, 5_1, 5_2, 6_1, 6_2, 7_1, 7_2, 8_1, 9_1, 10_1, 11_1, 11_2, 12_1, 12_2, 13_1, 13_2, 14_1, 15_1, 16_1, 17_1, 17_2, 18_1, 18_2, 19_1, 19_2, 20_1, 21_1, 22_1, 23_1, 23_2, 24_1, 25_1, 26_1, 26_2, 27_1, 28_1, 28_2, 29_1, 29_2, 30_1, 31_1, 31_2, 32_1, 33_1, 34_1, 34_2, 34_3, 34_4, 34_5, 34_6, 34_7, 35_1, 35_2, 36_1, 37_1, 38_1, 38_2, 38_3, 38_4, 38_5, 38_6, 39_1, 39_2, 39_3, 39_4, 39_5, 40_1, 40_2, 40_3, 40_4, 40_, 40_6, 40_7, 40_8, 41_1, 42_1, 43_1, 44_1, 44_2, 45_1, 45_2, 46_1, 47_1, 48_1, 48_2, 48_3, 48_4, 48_5, 48_6, 48_7, 49_1, 50_1, 51_1, 52_1, 53_1, 53_2, 54_1, 54_2, 54_3, 55_1, 55_2, 56_1, 57_1, 58_1, 58_2, 58_3, 59_1, 59_2, 60_1, 60_2, 60_3, 61_1, 62_1, 63_1, 64_1, 64_2, 65_1, 66_1, 67_1, 68_1, 69_1, 69_2, 69_3, 70_1, 70_2, 70_3, 71_1, 72_1, 72_2, 73_1, 73_2, 73_3, 74_1, 74_2, 75_1, 75_2, 76_1, 77_1, 77_2, 77_3, 78_1, 79_1, 79_2, 79_3, 80_1, 80_2, 80_3, 81_1, 82_1, 82_2, 83_1, 83_2, 84_1, 84_2, 85_1, 85_2, 86_1, 87_1, 88_1, 88_2, 89_1, 90_1, 91_1, 92_1, 93_1, 94_1, 95_1, 95_2, 96_1, 96_2, 96_3, 97_1, 97_2, 97_3, 97_4, 98_1, 98_2, 98_3, 99_1, 99_2, 99_3, 99_4, 100_1, 100_2, 100_3, 101_, 101_2, 101_3, 101_4, 102_1, 102_2, 102_3, 102_4, 103_1, 103_2, 103_3, 103_4, 104_1, 104_2, 104_3, 105_1, 105_2, 105_3, 105_4, 106_1, 106_2, 106_3, 106_4, 107_1, 107_2, 107_3, 107_4, 108_1, 108_2, 108_3, 108_4, 109_1, 109_2, 109_3, 109_4, 110_1, 110_2, 111_1, 111_, 111_3, 112_, 112_2, 113_1, 114_1, 115_1, 116_1, 117_1, 118_1, 119_1, 120_1, 120_2, 121_1, 122_1, 123_1, 124_1, 125_1, 126_1, 126_2, 127_1, 128_1, 128_2, 128_3, 128_4, 129_1, 129_2, 130_1, 131_1, 132_1, 132_2, 132_3, 133_1, 133_2, 133_3, 133_4, 134_1, 134_2, 135_1, 135_2, 136_1, 137_1, 138_1, 139_1, 140_1, 141_1, 142_1, 143_1, 144_1, 145_1, 145_2, 146_1, 146_2, 147_1, 148_1, 149_1, 150_1, 150_2, 151_1, 152_1, 153_1, 154_1, 155_1, 156_1, 157_1, 158_1, 159_1, 160_1, 161_1, 162_1, 163_1, 164_1, 165_1, 166_1, 167_1, 168_1, 169_1, 169_10, 169_11, 169_12, 169_13, 169_14, 169_15, 169_16, 169_17, 169_18, 169_19, 169_2, 169_20, 169_21, 169_22, 169_23, 169_24, 169_25, 169_26, 169_27, 169_28, 169_29, 169_3, 169_30, 169_31, 169_32, 169_33, 169_34, 169_35, 169_36, 169_37, 169_38, 169_39, 169_4, 169_40, 169_41, 169_42, 169_43, 169_44, 169_45, 169_46, 169_47, 169_48, 169_49, 169_5, 169_50, 169_51, 169_52, 169_53, 169_54, 169_55, 169_56, 169_57, 169_6, 169_7, 169_8, 169_9, 169_58, 169_59, 169_60, 169_61, 169_62, 170_1, 171_1, 172_1, 173_1, 174_1, 175_1, 176_1, 177_1, 178_1, 179_1, 180_1, 181_1, 182_1, 183_1, 184_1, 185_1, 186_1, 187_1, 188_1, 189_1, 190_1, 191_1, 192_1, 193_1, 194_1, 195_1, 196_1, 197_1, 198_1, 199_1, 200_1, 201_1, 202_1, 203_1, 204_1, 205_1, 206_1, 207_1, 208_1, 208_2, 208_3, 208_4, 208_5, 208_6, 208_7, 209_1, 209_10, 209_2, 209_3, 209_4, 209_5, 209_6, 209_7, 209_8, 209_9, 210_1, 211_1, 212_1, 213_1, 214_1, 215_1, 216_1, 217_1, 218_1, 219_1, 220_1, 221_1, 222_1, 223_1, 224_1, 225_1, 226_1, 227_1, 228_1, 229_1, 230_1, 231_1, 232_1, 233_1, 234_1, 235_1, 236_1, 236_10, 236_11, 236_12, 236_13, 236_14, 236_15, 236_16, 236_2, 236_3, 236_4, 236_5, 236_6, 236_7, 236_8, 236_9, 236_17, 236_18, 236_19, 236_20, 236_21, 237_1, 237_10, 237_11, 237_12, 237_13, 237_14, 237_15, 237_16, 237_2, 237_3, 237_4, 237_5, 237_6, 237_7, 237_8, 237_9, 237_17, 237_18, 237_19, 237_20, 237_21, 238_1, 239_1, 239_10, 239_11, 239_12, 239_13, 239_14, 239_15, 239_16, 239_2, 239_3, 239_4, 239_5, 239_6, 239_7, 239_8, 239_9, 239_17, 239_18, 239_19, 239_20, 239_21, 240_1, 241_1, 241_10, 241_2, 241_3, 241_4, 241_5, 241_6, 241_7, 241_8, 241_9, 241_11, 241_12, 241_13, 241_14, 241_15, 242_1, 243_1, 244_1, 244_2, 244_3, 244_4, 244_5, 245_1, 246_1, 247_1, 248_1, 249_1, 250_1, 251_1, 252_1, 253_1, 254_1, 255_1, 256_1, 257_1, 258_1, 259_1, 260_1, 261_1, 262_1, 263_1, 264_1, 265_1, 266_1, 267_1, 268_1, 269_1, 270_1, 271_1, 272_1, 273_1, 274_1, 275_1, 276_1, 277_1, 278_1, 279_1, 280_1, 281_1, 282_1, 283_1, 284_1, 285_1, 285_2, 285_3, 285_4, 285_5, 285_6, 285_7, 285_8, 285_9, 285_10, 285_11, 286_1, 287_1, 288_1, 289_1, 290_1, 291_1, 292_1, 293_1, 294_1, 295_1, 296_1, 297_1, 298_1, 299_1, 300_1, 301_1, 302_1, 303_1, 304_1, 304_10, 304_2, 304_3, 304_4, 304_5, 304_6, 304_7, 304_8, 304_9, 304_11, 304_12, 304_13, 304_14, 304_15, 305_1, 306_1, 307_1, 308_1, 309_1, 310_1, 311_1, 312_1, 313_1, 314_1, 315_1, 316_1, 317_1, 318_1, 319_1, 320_1, 321_1, 322_1, 323_1, 324_1, 325_1, 326_1, 327_1, 328_1, 329_1, 330_1, 331_1, 332_1, 333_1, 334_1, 335_1, 336_1, 337_1, 338_1, 339_1, 340_1, 341_1, 342_1, 343_1, 344_1, 345_1, 346_1, 347_1, 348_1, 349_1, 350_1, 351_1, 352_1, 353_1, 354_1, 355_1, 356_1, 357_1, 358_1, 359_1, 360_1, 361_1, 361_10, 361_2, 361_3, 361_4, 361_5, 361_6, 361_7, 361_8, 361_9, 362_1, 362_10, 362_2, 362_3, 362_4, 362_5, 362_6, 362_7, 362_8, 362_9, 363_1, 364_1, 365_1, 366_1, 367_1, 368_1, 369_1, 370_1, 371_1, 372_1, 373_1, 374_1, 375_1, 376_1, 377_1, 378_1, 379_1, 380_1, 381_1, 382_1, 383_1, 384_1, 385_1, 386_1, 387_1, 388_1, 389_1, 390_1, 391_1, 392_1, 393_1, 394_1, 395_1, 396_1, 397_1, 398_1, 399_1, 400_1, 401_1, 402_1, 403_1, 404_1, 405_1, 406_1, 407_1, 408_1, 409_1, 410_1, 411_1, 412_1, 413_1, 414_1, 415_1, 416_1, 417_1, 418_1, 419_1, 420_1, 421_1, 422_1, 423_1, 424_1, 425_1, 425_10, 425_2, 425_3, 425_4, 425_5, 425_6, 425_7, 425_8, 425_9, 426_1, 427_1, 428_1, 429_1, 430_1, 431_1, 432_1, 433_1, 434_1, 435_1, 436_1, 437_1, 438_1, 439_1, 440_1, 441_1, 442_1, 443_1, 444_1, 445_1, 446_1, 447_1, 448_1, 449_1, 450_1, 451_1, 452_1, 453_1, 454_1, 455_1, 456_1, 457_1, 458_1, 459_1, 460_1, 461_1, 462_1, 463_1, 464_1, 465_1, 466_1, 467_1, 468_1, 469_1, 470_1, 471_1, 472_1, 473_1, 474_1, 475_1, 476_1, 477_1, 478_1, 479_1, 480_1, 481_1, 482_1, 483_1, 484_1, 485_1, 486_1, 487_1, 488_1, 489_1, 490_1, 491_1, 492_1, 493_1, 494_1, 495_1, 496_1, 497_1, 498_1, 499_1, 500_1, 501_1, 502_1, 503_1, 504_1, 505_1, 506_1, 507_1, 508_1, 509_1, 510_1, 511_1, 512_1, 513_1, 514_1, 515_1, 516_1, 517_1, 518_1, 519_1, 520_1, 521_1, 522_1, 523_1, 524_1, 525_1, 526_1, 527_1, 528_1, 529_1, 530_1, 531_1, 532_1, 533_1, 534_1, 535_1, 536_1, 537_1, 538_1, 539_1, 540_1, 541_1, 542_1, 543_1, 544_1, 545_1, 546_1, 547_1, 548_1, 549_1, 550_1, 551_1, 552_1, 553_1, 554_1, 555_1, 556_1, 557_1, 558_1, 559_1, 560_1, 561_1, 562_1, 563_1, 564_1, 565_1, 566_1, 567_1, 568_1, 569_1, 570_1, 570_2, 570_3, 570_4, 570_5, 570_6, 570_7, 570_8, 570_9, 570_10, 570_11, 570_12, 570_13, 570_14, 571_1, 571_2, 571_3, 571_4, 571_5, 571_6, 571_7, 571_8, 571_9, 571_10, 571_11, 571_12, 571_13, 571_14, 572_1, 572_2, 572_3, 572_4, 572_5, 572_6, 572_7, 572_8, 572_9, 572_10, 572_11, 572_12, 572_13, 572_14, 573_1, 573_2, 573_3, 573_4, 573_5, 573_6, 573_7, 573_8, 573_9, 573_10, 573_11, 573_12, 573_13, 573_14, 574_1, 574_2, 574_3, 574_4, 574_5, 574_6, 574_7, 574_8, 574_9, 574_10, 574_11, 574_12, 574_13, 574_14, 575_1, 575_2, 575_3, 575_4, 575_5, 575_6, 575_7, 575_8, 575_9, 575_10, 575_11, 575_12, 575_13, 575_14, 576_1, 576_2, 576_3, 576_4, 576_5, 576_6, 576_7, 576_8, 576_9, 576_10, 576_11, 576_12, 576_13, 576_14, 577_1, 577_2, 577_3, 577_4, 577_5, 577_6, 577_7, 577_8, 577_9, 577_10, 577_11, 577_12, 577_13, 577_14, 578_1, 578_2, 578_3, 578_4, 578_5, 578_6, 578_7, 578_8, 578_9, 579_1, 579_2, 579_3, 579_4, 579_5, 579_6, 579_7, 579_8, 579_9, 580_1, 580_2, 580_3, 580_4, 580_5, 580_6, 580_7, 580_8, 580_9, 581_1, 581_2, 581_3, 581_4, 581_5, 581_6, 581_7, 581_8, 581_9, 582_1, 582_2, 582_3, 582_4, 582_5, 582_6, 582_7, 582_8, 582_9, 583_1, 583_2, 583_3, 583_4, 583_5, 583_6, 583_7, 583_8, 583_9, 584_1, 584_2, 584_3, 584_4, 584_5, 584_6, 584_7, 584_8, 585_1, 585_2, 585_3, 585_4, 585_5, 585_6, 585_7, 585_8, 585_9, 585_10, 585_11, 585_12, 585_13, 585_14, 586_1, 586_2, 586_3, 586_4, 586_5, 586_6, 586_7, 586_8, 586_9, 586_10, 586_11, 586_12, 586_13, 586_14, 587_1, 587_2, 587_3, 587_4, 587_5, 587_6, 587_7, 587_8, 587_9, 587_10, 587_11, 587_12, 587_13, 587_14, 588_1, 588_2, 588_3, 588_4, 588_5, 588_6, 588_7, 588_8, 588_9, 588_10, 588_11, 588_12, 588_13, 588_14, 589_1, 589_2, 589_3, 589_4, 589_5, 589_6, 589_7, 589_8, 589_9, 589_10, 589_11, 589_12, 589_13, 589_14, 590_1, 590_10, 590_11, 590_12, 590_13, 590_14, 590_15, 590_2, 590_3, 590_4, 590_5, 590_6, 590_7, 590_8, 590_9, 590_16, 590_17, 590_18, 590_19, 590_20, 591_1, 591_2, 592_1, 592_2, 592_3, 592_4, 592_5, 592_6, 592_7, 592_8, 592_9, 592_10, 592_11, 592_12, 592_13, 592_14, 593_1, 593_2, 593_3, 593_4, 594_1, 594_2, 594_3, 594_4, 595_1, 595_2, 595_3, 595_4, 596_1, 596_2, 596_3, 596_4, 597_1, 597_2, 597_3, 597_4, 598_1, 598_2, 598_3, 598_4, 599_1, 599_2, 599_3, 599_4, 600_1, 600_2, 600_3, 600_4, 601_1, 601_2, 601_3, 601_4, 602_1, 602_2, 602_3, 602_4, 603_1, 603_2, 603_3, 603_4, 604_1, 604_2, 604_3, 604_4, 605_1, 605_2, 605_3, 605_4, 606_1, 606_2, 606_3, 606_4, 607_1, 607_2, 607_3, 607_4, 608_1, 608_2, 608_3, 608_4, 608_5, 608_6, 608_7, 608_8, 608_9, 609_1, 609_2, 609_3, 609_4, 609_5, 609_6, 609_7, 609_8, 609_9, 610_1, 610_2, 610_3, 610_4, 610_5, 610_6, 610_7, 610_8, 610_9, 611_1, 611_2, 611_3, 611_4, 611_5, 611_6, 611_7, 611_8, 611_9, 612_1, 612_2, 612_3, 612_4, 612_5, 612_6, 612_7, 612_8, 612_9, 613_1, 613_2, 613_3, 613_4, 613_5, 613_6, 613_7, 613_8, 613_9, 613_10, 614_1, 614_2, 614_3, 614_4, 614_5, 614_6, 614_7, 614_8, 614_9, 614_10, 615_1, 615_2, 615_3, 615_4, 615_5, 615_6, 615_7, 615_8, 615_9, 615_10, 616_1, 616_2, 616_3, 616_4, 616_5, 616_6, 616_7, 616_8, 616_9, 616_10, 617_1, 617_2, 617_3, 617_4, 617_5, 617_6, 617_7, 617_8, 617_9, 617_10, 618_1, 618_2, 618_3, 618_4, 618_5, 618_6, 618_7, 618_8, 618_9, 618_10, 619_1, 619_2, 619_3, 619_4, 619_5, 619_6, 619_7, 619_8, 619_9, 619_10, 620_1, 620_2, 620_3, 620_4, 620_5, 620_6, 620_7, 620_8, 620_9, 620_10, 621_1, 621_2, 621_3, 621_4, 621_5, 621_6, 621_7, 621_8, 621_9, 621_10, 621_11, 622_1, 622_2, 622_3, 622_4, 622_5, 622_6, 622_7, 622_8, 622_9, 622_10, 623_1, 623_2, 623_3, 623_4, 623_5, 623_6, 623_7, 623_8, 623_9, 623_10, 624_1, 624_2, 624_3, 624_4, 624_5, 624_6, 624_7, 624_8, 624_9, 624_10, 625_1, 625_2, 625_3, 625_4, 625_5, 625_6, 625_7, 625_8, 625_9, 625_10, 625_11, 625_12, 625_13, 625_14, 626_1, 626_2, 626_3, 626_4, 626_5, 626_6, 626_7, 626_8, 626_9, 626_10, 626_11, 626_12, 626_13, 626_14, 627_1, 627_2, 627_3, 627_4, 627_5, 627_6, 627_7, 627_8, 627_9, 627_10, 627_11, 627_12, 627_13, 627_14, 628_1, 628_2, 628_3, 628_4, 628_5, 628_6, 628_7, 628_8, 628_9, 628_10, 628_11, 628_12, 628_13, 628_14, 629_1, 629_10, 629_11, 629_2, 629_3, 629_4, 629_5, 629_6, 629_7, 629_8, 629_9, 629_12, 629_13, 629_14, 629_15, 629_16, 630_1, 630_2, 630_3, 631_1, 631_10, 631_2, 631_3, 631_4, 631_5, 631_6, 631_7, 631_8, 631_9, 631_11, 631_12, 631_13, 631_14, 631_15, 632_1, 632_2, 632_3, 632_4, 632_5, 632_6, 632_7, 632_8, 632_9, 632_10, 632_11, 632_12, 632_13, 632_14, 633_1, 633_2, 633_3, 633_4, 633_5, 633_6, 633_7, 633_8, 633_9, 634_1, 634_2, 634_3, 634_4, 634_5, 634_6, 634_7, 634_8, 634_9, 635_1, 635_2, 635_3, 635_4, 635_5, 635_6, 635_7, 635_8, 635_9, 636_1, 636_2, 636_3, 636_4, 636_5, 636_6, 636_7, 636_8, 636_9, 637_1, 637_2, 637_3, 637_4, 637_5, 637_6, 637_7, 637_8, 637_9, 638_1, 638_2, 638_3, 638_4, 638_5, 638_6, 638_7, 638_8, 638_9, 638_10, 638_11, 638_12, 638_13, 638_14, 639_1, 639_2, 639_3, 639_4, 639_5, 639_6, 639_7, 639_8, 639_9, 639_10, 639_11, 639_12, 639_13, 639_14, 640_1, 640_2, 640_3, 640_4, 640_5, 640_6, 640_7, 640_8, 640_9, 640_10, 640_11, 640_12, 640_13, 640_14, 641_1, 641_2, 641_3, 641_4, 641_5, 641_6, 641_7, 641_8, 641_9, 642_1, 642_10, 642_11, 642_12, 642_13, 642_14, 642_15, 642_16, 642_17, 642_2, 642_3, 642_4, 642_5, 642_6, 642_7, 642_8, 642_9, 642_18, 642_19, 642_20, 642_21, 642_22, 643_1, 644_1, 644_2, 644_3, 644_4, 644_5, 644_6, 645_1, 645_2, 645_3, 645_4, 645_5, 645_6, 645_7, 645_8, 645_9, 645_10, 646_1, 646_10, 646_11, 646_12, 646_13, 646_14, 646_15, 646_16, 646_17, 646_18, 646_19, 646_2, 646_3, 646_4, 646_5, 646_6, 646_7, 646_8, 646_9, 646_20, 646_21, 646_22, 646_23, 646_24, 647_1, 648_1, 649_1, 650_1, 651_1, 652_1, 653_1, 654_1, 655_1, 656_1, 657_1, 658_1, 659_1, 660_1, 661_1, 662_1, 663_1, 664_1, 665_1, 666_1, 667_1, 668_1, 669_1, 670_1, 671_1, 672_1, 673_1, 674_1, 675_1, 676_1, 677_1, 678_1, 679_1, 679_2, 679_3, 679_4, 679_5, 680_1, 680_2, 680_3, 680_4, 680_5, 681_1, 681_2, 681_3, 681_4, 681_5, 682_1, 682_2, 682_3, 682_4, 682_5, 683_1, 683_2, 683_3, 683_4, 683_5, 684_1, 684_2, 684_3, 684_4, 684_5, 685_1, 685_2, 685_3, 685_4, 685_5, 686_1, 686_2, 686_3, 686_4, 686_5, 687_1, 687_2, 687_3, 687_4, 687_5, 688_1, 688_2, 688_3, 688_4, 688_5, 689_1, 689_2, 689_3, 689_4, 689_5, 690_1, 690_2, 690_3, 690_4, 690_5, 691_1, 691_2, 692_1, 692_2, 692_3, 692_4, 692_5, 693_1, 693_2, 693_3, 693_4, 693_5, 694_1, 694_2, 694_3, 694_4, 694_5, 695_1, 695_2, 695_3, 695_4, 695_5, 696_1, 696_2, 696_3, 696_4, 696_5, 697_1, 697_2, 697_3, 697_4, 697_5, 698_1, 698_2, 698_3, 698_4, 698_5, 699_1, 699_2, 699_3, 699_4, 699_5, 700_1, 700_2, 700_3, 700_4, 700_5, 701_1, 701_2, 701_3, 701_4, 701_5, 702_1, 702_2, 702_3, 702_4, 702_5, 703_1, 703_2, 703_3, 703_4, 703_5, 704_1, 704_2, 704_3, 704_4, 704_5, 705_1, 705_2, 705_3, 705_4, 705_5, 706_1, 706_2, 706_3, 706_4, 706_5, 707_1, 707_2, 707_3, 707_4, 707_5, 708_1, 708_2, 708_3, 708_4, 708_5, 709_1, 709_2, 709_3, 709_4, 709_5, 710_1, 710_2, 710_3, 710_4, 710_5, 711_1, 711_2, 711_3, 711_4, 711_5, 712_1, 712_2, 712_3, 712_4, 712_5, 713_1, 713_2, 713_3, 713_4, 713_5, 714_1, 714_2, 714_3, 714_4, 714_5, 715_1, 715_2, 715_3, 715_4, 715_5, 716_1, 716_2, 716_3, 716_4, 716_5, 717_1, 717_2, 717_3, 717_4, 717_5, 718_1, 718_2, 719_1, 719_2, 719_3, 719_4, 719_5, 720_1, 720_2, 720_3, 720_4, 720_5, 721_1, 721_2, 721_3, 721_4, 721_5, 722_1, 722_2, 722_3, 722_4, 722_5, 723_1, 723_2, 723_3, 723_4, 723_5, 724_1, 724_2, 724_3, 724_4, 724_5, 725_1, 725_2, 725_3, 725_4, 725_5, 726_1, 726_2, 726_3, 726_4, 726_5, 727_1, 727_2, 727_3, 727_4, 727_5, 728_1, 728_2, 728_3, 728_4, 728_5, 729_1, 729_2, 729_3, 729_4, 729_5, 730_1, 730_2, 730_3, 730_4, 730_5, 731_1, 731_2, 731_3, 731_4, 731_5, 732_1, 732_2, 732_3, 732_4, 732_5, 733_1, 733_2, 733_3, 733_4, 733_5, 734_1, 734_2, 734_3, 734_4, 734_5, 735_1, 735_2, 735_3, 735_4, 735_5, 736_1, 736_2, 736_3, 736_4, 736_5, 737_1, 737_2, 737_3, 737_4, 737_5, 738_1, 738_2, 738_3, 738_4, 738_5, 738_6, 739_1, 739_2, 739_3, 739_4, 739_5, 740_1, 740_2, 740_3, 740_4, 740_5, 741_1, 741_2, 741_3, 741_4, 741_5, 742_1, 742_2, 742_3, 743_1, 743_2, 743_3, 743_4, 743_5, 744_1, 744_2, 744_3, 744_4, 744_5, 745_1, 745_2, 745_3, 745_4, 745_5, 746_1, 746_2, 746_3, 747_1, 747_2, 747_3, 747_4, 747_5, 748_1, 748_2, 748_3, 748_4, 748_5, 749_1, 749_2, 749_3, 749_4, 749_5, 750_1, 750_2, 750_3, 750_4, 751_1, 751_2, 751_3, 751_4, 751_5, 752_1, 752_2, 752_3, 752_4, 752_5, 753_1, 753_2, 753_3, 753_4, 753_5, 754_1, 754_2, 754_3, 754_4, 754_5, 755_1, 755_2, 755_3, 755_4, 755_5, 756_1, 756_2, 756_3, 756_4, 756_5, 757_1, 757_2, 757_3, 757_4, 757_5, 758_1, 758_2, 758_3, 758_4, 758_5, 759_1, 759_2, 759_3, 759_4, 759_5, 760_1, 760_2, 760_3, 760_4, 760_5, 761_1, 761_2, 761_3, 761_4, 761_5, 762_1, 762_2, 762_3, 762_4, 762_5, 763_1, 763_2, 763_3, 763_4, 763_5, 764_1, 764_2, 764_3, 764_4, 764_5, 765_1, 765_2, 765_3, 765_4, 765_5, 766_1, 766_2, 766_3, 766_4, 766_5, 767_1, 767_2, 767_3, 767_4, 767_5, 768_1, 768_2, 768_3, 768_4, 768_5, 769_1, 769_2, 769_3, 769_4, 769_5, 770_1, 770_2, 770_3, 770_4, 770_5, 771_1, 771_2, 771_3, 771_4, 771_5, 772_1, 772_2, 772_3, 772_4, 772_5, 773_1, 773_2, 773_3, 773_4, 773_5, 774_1, 774_2, 774_3, 774_4, 774_5, 775_1, 775_2, 775_3, 775_4, 775_5, 776_1, 776_2, 776_3, 776_4, 776_5, 777_1, 777_2, 777_3, 777_4, 777_5, 778_1, 778_2, 778_3, 778_4, 778_5, 779_1, 779_2, 779_3, 779_4, 779_5, 780_1, 780_2, 780_3, 780_4, 780_5, 781_1, 782_1, 782_2, 782_3, 782_4, 782_5, 783_1, 783_2, 783_3, 783_4, 783_5, 784_1, 784_2, 784_3, 784_4, 784_5, 785_1, 786_1, 786_2, 786_3, 786_4, 786_5, 787_1, 787_2, 787_3, 787_4, 787_5, 788_1, 788_2, 788_3, 788_4, 788_5, 789_1, 789_2, 789_3, 789_4, 789_5, 790_1, 790_2, 790_3, 790_4, 790_5, 791_1, 791_2, 791_3, 791_4, 791_5, 792_1, 792_2, 792_3, 792_4, 792_5, 793_1, 793_2, 793_3, 793_4, 793_5, 794_1, 794_2, 794_3, 794_4, 794_5, 795_1, 795_2, 795_3, 795_4, 795_5, 796_1, 796_2, 796_3, 796_4, 796_5, 797_1, 797_2, 797_3, 797_4, 797_5, 798_1, 798_2, 798_3, 798_4, 798_5, 799_1, 799_2, 799_3, 799_4, 799_5, 800_1, 800_2, 800_3, 800_4, 800_5, 801_1, 801_2, 801_3, 801_4, 801_5, 802_1, 802_2, 802_3, 802_4, 802_5, 803_1, 803_2, 803_3, 803_4, 803_5, 804_1, 804_2, 804_3, 804_4, 804_5, 805_1, 805_2, 805_3, 805_4, 805_5, 806_1, 806_2, 806_3, 806_4, 806_5, 807_1, 807_2, 807_3, 807_4, 807_5, 808_1, 808_2, 808_3, 808_4, 808_5, 809_1, 809_2, 809_3, 809_4, 809_5, 810_1, 810_2, 810_3, 810_4, 810_5, 811_1, 811_2, 811_3, 811_4, 811_5, 812_1, 812_2, 812_3, 812_4, 812_5, 813_1, 813_2, 813_3, 813_4, 813_5, 814_1, 814_2, 814_3, 814_4, 814_5, 815_13, 815_2, 815_3, 815_4, 815_5, 816_1, 816_2, 816_3, 816_4, 816_5, 816_6, 817_1 and 818_1
15. A conjugate comprising the oligonucleotide of claim 1, and at least one conjugate moiety covalently attached to said oligonucleotide.
16. A pharmaceutical composition comprising the oligonucleotide of claim 1 and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
17. An in vivo or in vitro method for inducing UBE3A expression in a target cell where expression of paternal UBE3A is suppressed, said method comprising administering an oligonucleotide of claim 1 in an effective amount to said cell.
18. The method according to claim 17, wherein the expression of UBE3A is increased by at least 40% compared to a control.
19. The method according to claim 17, wherein the level of the SNHG14 transcript downstream of SNORD109B is reduced by at least 30% compared to a control.
20. The method according to claim 17, wherein the target cell is a neuronal cell.
21. The method according to claim 17, wherein the expression of SNORD115 is not significantly affected compared to a control.
22. A method for treating or preventing a disease comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide of claim 1 to a subject suffering from or susceptible to Angelman syndrome.
23. The oligonucleotide of claim 1 for use in the treatment or prevention of Angelman syndrome.
24. Use of the oligonucleotide of claim 1 for the preparation of a medicament for treatment or prevention of Angelman syndrome.
US15/351,113 2015-11-12 2016-11-14 Oligonucleotides for inducing paternal UBE3A expression Active 2037-02-21 US10494633B2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US16/388,714 US10739332B2 (en) 2015-11-12 2019-04-18 Oligonucleotides for inducing paternal UBE3A expression
US16/663,024 US10718753B2 (en) 2015-11-12 2019-10-24 Oligonucleotides for inducing paternal UBE3A expression
US16/933,445 US11320421B2 (en) 2015-11-12 2020-07-20 Oligonucleotides for inducing paternal UBE3A expression
US17/581,089 US11852627B2 (en) 2015-11-12 2022-01-21 Oligonucleotides for inducing paternal UBE3A expression
US18/172,707 US20230296587A1 (en) 2015-11-12 2023-02-22 Oligonucleotides for inducing paternal ube3a expression
US18/491,513 US20240085402A1 (en) 2015-11-12 2023-10-20 Oligonucleotides for inducing paternal ube3a expression

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15194367.7 2015-11-12
EP15194367 2015-11-12
EP15194367 2015-11-12
EP16189502 2016-09-19
EP16189502.4 2016-09-19
EP16189502 2016-09-19
PCT/EP2016/077383 WO2017081223A1 (en) 2015-11-12 2016-11-11 Oligonucleotides for inducing paternal ube3a expression

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/077383 Continuation WO2017081223A1 (en) 2015-11-12 2016-11-11 Oligonucleotides for inducing paternal ube3a expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/388,714 Continuation US10739332B2 (en) 2015-11-12 2019-04-18 Oligonucleotides for inducing paternal UBE3A expression

Publications (2)

Publication Number Publication Date
US20170191064A1 true US20170191064A1 (en) 2017-07-06
US10494633B2 US10494633B2 (en) 2019-12-03

Family

ID=57345910

Family Applications (9)

Application Number Title Priority Date Filing Date
US15/351,113 Active 2037-02-21 US10494633B2 (en) 2015-11-12 2016-11-14 Oligonucleotides for inducing paternal UBE3A expression
US15/977,970 Pending US20190154664A1 (en) 2015-11-12 2018-05-11 Methods for determining the efficacy profile of a drug candidate
US15/977,895 Pending US20190144824A1 (en) 2015-11-12 2018-05-11 Standardized neuronal cell assays from primate species
US16/388,714 Active US10739332B2 (en) 2015-11-12 2019-04-18 Oligonucleotides for inducing paternal UBE3A expression
US16/663,024 Active US10718753B2 (en) 2015-11-12 2019-10-24 Oligonucleotides for inducing paternal UBE3A expression
US16/933,445 Active US11320421B2 (en) 2015-11-12 2020-07-20 Oligonucleotides for inducing paternal UBE3A expression
US17/581,089 Active 2037-01-01 US11852627B2 (en) 2015-11-12 2022-01-21 Oligonucleotides for inducing paternal UBE3A expression
US18/172,707 Pending US20230296587A1 (en) 2015-11-12 2023-02-22 Oligonucleotides for inducing paternal ube3a expression
US18/491,513 Pending US20240085402A1 (en) 2015-11-12 2023-10-20 Oligonucleotides for inducing paternal ube3a expression

Family Applications After (8)

Application Number Title Priority Date Filing Date
US15/977,970 Pending US20190154664A1 (en) 2015-11-12 2018-05-11 Methods for determining the efficacy profile of a drug candidate
US15/977,895 Pending US20190144824A1 (en) 2015-11-12 2018-05-11 Standardized neuronal cell assays from primate species
US16/388,714 Active US10739332B2 (en) 2015-11-12 2019-04-18 Oligonucleotides for inducing paternal UBE3A expression
US16/663,024 Active US10718753B2 (en) 2015-11-12 2019-10-24 Oligonucleotides for inducing paternal UBE3A expression
US16/933,445 Active US11320421B2 (en) 2015-11-12 2020-07-20 Oligonucleotides for inducing paternal UBE3A expression
US17/581,089 Active 2037-01-01 US11852627B2 (en) 2015-11-12 2022-01-21 Oligonucleotides for inducing paternal UBE3A expression
US18/172,707 Pending US20230296587A1 (en) 2015-11-12 2023-02-22 Oligonucleotides for inducing paternal ube3a expression
US18/491,513 Pending US20240085402A1 (en) 2015-11-12 2023-10-20 Oligonucleotides for inducing paternal ube3a expression

Country Status (30)

Country Link
US (9) US10494633B2 (en)
EP (5) EP4220360A3 (en)
JP (6) JP6751142B2 (en)
KR (3) KR102482440B1 (en)
CN (5) CN116064540A (en)
AU (4) AU2016352836B2 (en)
BR (1) BR112018007633A2 (en)
CA (1) CA3004799A1 (en)
CL (3) CL2018001189A1 (en)
CO (1) CO2018004550A2 (en)
CR (3) CR20220077A (en)
DK (1) DK3374509T3 (en)
ES (1) ES2852998T3 (en)
HK (3) HK1253325A1 (en)
HR (1) HRP20210227T1 (en)
HU (1) HUE053197T2 (en)
IL (3) IL300119A (en)
LT (1) LT3374509T (en)
MX (4) MX2018004978A (en)
NZ (1) NZ741585A (en)
PE (2) PE20210451A1 (en)
PH (1) PH12018501005A1 (en)
PL (1) PL3374509T3 (en)
RS (1) RS61529B1 (en)
RU (1) RU2742007C2 (en)
SG (1) SG11201803951QA (en)
SI (1) SI3374509T1 (en)
UA (1) UA125963C2 (en)
WO (3) WO2017081223A1 (en)
ZA (1) ZA201802494B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10718753B2 (en) 2015-11-12 2020-07-21 Hoffman-La Roche Inc. Oligonucleotides for inducing paternal UBE3A expression
WO2020237130A1 (en) * 2019-05-22 2020-11-26 The University Of North Carolina At Chapel Hill Ube3a genes and expression cassettes and their use
US11149264B2 (en) 2018-02-12 2021-10-19 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
US11198869B2 (en) 2017-12-01 2021-12-14 The Texas A&M University System Angelman syndrome antisense treatment
EP3947684A4 (en) * 2019-03-29 2023-09-20 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating ube3a-ats

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616051T3 (en) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Method for the synthesis of modified nucleic acids in the phosphorus atom
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
JP5868324B2 (en) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan Asymmetric auxiliary group
SG10201700554VA (en) 2011-07-19 2017-03-30 Wave Life Sciences Pte Ltd Methods for the synthesis of functionalized nucleic acids
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
CA2878945A1 (en) 2012-07-13 2014-01-16 Wave Life Sciences Pte. Ltd. Chiral control
JPWO2015108048A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antitumor agent having antitumor activity
WO2015108047A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
KR20220106232A (en) 2014-01-16 2022-07-28 웨이브 라이프 사이언시스 리미티드 Chiral design
WO2016086104A1 (en) 2014-11-25 2016-06-02 Ionis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
CN108795935B (en) * 2018-05-23 2022-06-21 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) SiRNA of SjELAV-like 1 gene of schistosoma japonicum and application thereof
US20210332368A1 (en) * 2018-09-21 2021-10-28 University Of Connecticut Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
US20220091137A1 (en) * 2019-01-17 2022-03-24 Hoffmann-La Roche Inc. E3 ubiquitin ligase (ube3a) protein targets
JP2022534249A (en) 2019-05-28 2022-07-28 エフ.ホフマン-ラ ロシュ アーゲー Methods for generating monocyte progenitor cells
EP4162047A1 (en) * 2020-06-09 2023-04-12 Roche Innovation Center Copenhagen A/S Guanosine analogues for use in therapeutic polynucleotides
JPWO2022158487A1 (en) 2021-01-21 2022-07-28
WO2023217890A1 (en) 2022-05-10 2023-11-16 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting cfp-elk1 intergene region

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4373084A (en) 1981-07-07 1983-02-08 E. I. Du Pont De Nemours And Company Sulfur-modified polypropylene ether glycols, a method for preparing them, and polyurethanes prepared therefrom
DE69233046T2 (en) 1991-10-24 2004-03-04 Isis Pharmaceuticals, Inc., Carlsfeld DERIVATIZED OLIGONUCLEOTIDS WITH IMPROVED CAPACITY
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
US6617162B2 (en) 2001-12-18 2003-09-09 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor alpha expression
JP4236812B2 (en) 1997-09-12 2009-03-11 エクシコン エ/エス Oligonucleotide analogues
US6238921B1 (en) 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
CA2702148C (en) * 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
ES2234563T5 (en) 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited New nucleoside and oligonucleotide analogs
CA2372085C (en) 1999-05-04 2009-10-27 Exiqon A/S L-ribo-lna analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
CA2396460A1 (en) 1999-12-02 2001-06-07 Myriad Genetics, Inc. Protein-protein interactions
US6300132B1 (en) 1999-12-17 2001-10-09 Isis Pharmaceuticals, Inc. Antisense inhibition of telomeric repeat binding factor 2 expression
AU2001268163A1 (en) * 2000-06-01 2001-12-11 Genaissance Pharmaceuticals, Inc. Haplotypes of the ube3a gene
US20030087855A1 (en) 2001-09-13 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of protein kinase R expression
CA2790034A1 (en) * 2001-06-21 2003-01-03 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US20050124572A1 (en) * 2002-06-17 2005-06-09 Freier Susan M. Compositions and their uses directed to signal tranducers
CA2495398A1 (en) 2002-08-14 2004-02-26 Pharmacia Corporation Antisense modulation of nav1.3 expression
EP1575498A2 (en) * 2002-09-25 2005-09-21 Pharmacia Corporation Antisense modulation of microsomal prostaglandin e2 synthase expression
EP2752488B1 (en) 2002-11-18 2020-02-12 Roche Innovation Center Copenhagen A/S Antisense design
KR20060115351A (en) * 2003-08-29 2006-11-08 위스콘신 얼럼나이 리서어치 화운데이션 Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
EP1976567B1 (en) 2005-12-28 2020-05-13 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
DK2314594T3 (en) 2006-01-27 2014-10-27 Isis Pharmaceuticals Inc 6-modified bicyclic nucleic acid analogues
CA3044969A1 (en) 2006-05-05 2007-12-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
PE20090064A1 (en) 2007-03-26 2009-03-02 Novartis Ag DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2009090182A1 (en) 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
EP2285819B1 (en) 2008-04-04 2013-10-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
WO2010096496A2 (en) * 2009-02-17 2010-08-26 Memorial Sloan-Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
CN102762718B (en) * 2009-10-13 2015-06-17 干细胞技术公司 Manipulation of osmolality for differentiating stem cells
US8940708B2 (en) 2009-12-23 2015-01-27 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US8980860B2 (en) 2010-07-14 2015-03-17 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
AU2011282217B2 (en) 2010-07-19 2015-12-03 Ionis Pharmaceuticals, Inc. Modulation of dystrophia myotonica-protein kinase (DMPK) expression
KR20160033798A (en) * 2010-08-19 2016-03-28 에프. 호프만-라 로슈 아게 Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs)
US9714427B2 (en) 2010-11-11 2017-07-25 The University Of North Carolina At Chapel Hill Methods and compositions for unsilencing imprinted genes
AU2011329777B2 (en) 2010-11-17 2016-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
EP2694644B1 (en) * 2011-03-30 2018-01-24 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
JP2014514313A (en) 2011-04-20 2014-06-19 ロシュ グリクアート アクチェンゲゼルシャフト Methods and constructs for pH-dependent passage of the blood brain barrier
WO2013033230A1 (en) 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
SG11201401314PA (en) 2011-09-07 2014-09-26 Marina Biotech Inc Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
US9221864B2 (en) 2012-04-09 2015-12-29 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
DK3461895T3 (en) * 2012-06-25 2020-07-20 Ionis Pharmaceuticals Inc MODULATION OF UBE3A-ATS EXPRESSION
CN117126846A (en) 2012-11-15 2023-11-28 罗氏创新中心哥本哈根有限公司 Oligonucleotide conjugates
WO2014077693A1 (en) 2012-11-16 2014-05-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for reducing an effect of aging in a mammalian cell
WO2015143342A1 (en) * 2014-03-21 2015-09-24 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof
DK3374509T3 (en) 2015-11-12 2021-02-15 Hoffmann La Roche Oligonucleotides for inducing paternal UBE3A expression
BR112019027692A2 (en) 2017-06-28 2020-11-24 University Of South Florida ube3a gene modified for a genetic therapeutic approach to angelman syndrome
RU2020121752A (en) 2017-12-01 2021-12-30 ТЕХАССКАЯ УНИВЕРСИТЕТСКАЯ СИСТЕМА А энд М MEANS FOR THE TREATMENT OF ANGELMAN'S SYNDROME BASED ON ANTISENSE NUCLEIC ACID
BR112020010436A2 (en) 2018-01-26 2020-11-24 F. Hoffmann-La Roche Ag radiolabeled oligonucleotide, processes for preparing a radiolabeled oligonucleotide, use of radiolabeled oligonucleotide, method for determining biodistribution and pharmacokinetics and oligonucleotide
CN113728104B (en) 2019-03-29 2023-10-27 Ionis制药公司 Compounds and methods for modulating UBE3A-ATS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Angelman syndrome - Natural Living Center. Downloaded from http://www.naturallivingcenter.net/ns/DisplayMonograph.asp?StoreID=b571dewxvcs92jj200akhmccqa7w8v75&DocID=condition-angelman#PREVENTION on 2.11.2019. *
Angelman Syndrome Prevention ++ Cleveland Clinic. Downloaded from https://my.clevelandclinic.org/health/diseases/17978-angelman-syndrome/prevention on 2.11.2019 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10718753B2 (en) 2015-11-12 2020-07-21 Hoffman-La Roche Inc. Oligonucleotides for inducing paternal UBE3A expression
US10739332B2 (en) 2015-11-12 2020-08-11 Hoffmann-La Roche Inc. Oligonucleotides for inducing paternal UBE3A expression
US11320421B2 (en) 2015-11-12 2022-05-03 Hoffmann-La Roche Inc. Oligonucleotides for inducing paternal UBE3A expression
US11852627B2 (en) 2015-11-12 2023-12-26 Hoffmann-La Roche Inc. Oligonucleotides for inducing paternal UBE3A expression
US11198869B2 (en) 2017-12-01 2021-12-14 The Texas A&M University System Angelman syndrome antisense treatment
US11685920B2 (en) 2017-12-01 2023-06-27 The Texas A&M University System Angelman syndrome antisense treatment
US11739328B2 (en) 2017-12-01 2023-08-29 The Texas A&M University System Angleman syndrome antisense treatment
US11149264B2 (en) 2018-02-12 2021-10-19 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
US11332733B2 (en) 2018-02-12 2022-05-17 lonis Pharmaceuticals, Inc. Modified compounds and uses thereof
EP3947684A4 (en) * 2019-03-29 2023-09-20 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating ube3a-ats
WO2020237130A1 (en) * 2019-05-22 2020-11-26 The University Of North Carolina At Chapel Hill Ube3a genes and expression cassettes and their use
CN114127296A (en) * 2019-05-22 2022-03-01 北卡罗来纳大学查佩尔希尔分校 UBE3A gene and expression cassette and application thereof

Also Published As

Publication number Publication date
SI3374509T1 (en) 2021-04-30
CN108350431A (en) 2018-07-31
CN116064539A (en) 2023-05-05
WO2017081250A1 (en) 2017-05-18
WO2017081254A1 (en) 2017-05-18
EP4220360A3 (en) 2023-08-23
US10718753B2 (en) 2020-07-21
PE20210451A1 (en) 2021-03-08
KR20200137027A (en) 2020-12-08
WO2017081223A1 (en) 2017-05-18
RU2018119315A (en) 2019-12-13
ES2852998T3 (en) 2021-09-14
JP6751142B2 (en) 2020-09-02
BR112018007633A2 (en) 2018-11-06
HK1258309A1 (en) 2019-11-08
UA125963C2 (en) 2022-07-20
AU2016352836B2 (en) 2020-06-25
CR20200118A (en) 2021-04-21
US10739332B2 (en) 2020-08-11
ZA201802494B (en) 2024-01-31
HRP20210227T1 (en) 2021-03-19
US20230296587A1 (en) 2023-09-21
AU2022211910A1 (en) 2022-11-10
CN116064540A (en) 2023-05-05
LT3374509T (en) 2021-03-10
EP3374509A1 (en) 2018-09-19
US20190310244A1 (en) 2019-10-10
CN108350432A (en) 2018-07-31
CO2018004550A2 (en) 2018-11-22
CR20220077A (en) 2023-04-11
KR20180070611A (en) 2018-06-26
US11320421B2 (en) 2022-05-03
CL2018001189A1 (en) 2018-08-31
HK1258434A1 (en) 2019-11-08
US10494633B2 (en) 2019-12-03
PL3374509T3 (en) 2021-05-04
RU2742007C2 (en) 2021-02-01
IL258488A (en) 2018-05-31
PH12018501005A1 (en) 2019-01-28
US20220146496A1 (en) 2022-05-12
JP2019500851A (en) 2019-01-17
IL300119A (en) 2023-03-01
JP7066609B2 (en) 2022-05-13
MX2022016377A (en) 2023-01-30
US20240085402A1 (en) 2024-03-14
EP3374499A1 (en) 2018-09-19
KR102482440B1 (en) 2022-12-29
CL2020000889A1 (en) 2020-08-28
MX2022016381A (en) 2023-01-30
CA3004799A1 (en) 2017-05-18
NZ741585A (en) 2024-01-26
PE20181157A1 (en) 2018-07-19
JP2023052630A (en) 2023-04-11
CL2021002159A1 (en) 2022-03-11
CR20180264A (en) 2018-08-06
AU2023200410A1 (en) 2023-02-23
JP2021191262A (en) 2021-12-16
US11852627B2 (en) 2023-12-26
CN108291226B (en) 2022-11-04
US20200057052A1 (en) 2020-02-20
HK1253325A1 (en) 2019-06-14
AU2016352836A1 (en) 2018-04-26
JP7279000B2 (en) 2023-05-22
KR102185465B1 (en) 2020-12-03
EP3374509B1 (en) 2020-12-16
RS61529B1 (en) 2021-04-29
KR20230008233A (en) 2023-01-13
IL281211A (en) 2021-04-29
US20200348286A1 (en) 2020-11-05
HUE053197T2 (en) 2021-06-28
MX2018004978A (en) 2018-07-06
SG11201803951QA (en) 2018-06-28
IL258488B (en) 2021-03-25
US20190144824A1 (en) 2019-05-16
IL281211B1 (en) 2023-09-01
US20190154664A1 (en) 2019-05-23
AU2020203573A1 (en) 2020-06-18
RU2018119315A3 (en) 2020-03-26
AU2020203573B2 (en) 2022-07-07
MX2022016376A (en) 2023-01-30
EP3374498A1 (en) 2018-09-19
EP4220360A2 (en) 2023-08-02
IL281211B2 (en) 2024-01-01
EP3798307A1 (en) 2021-03-31
JP2018533954A (en) 2018-11-22
JP2021003113A (en) 2021-01-14
JP2018533362A (en) 2018-11-15
DK3374509T3 (en) 2021-02-15
CN108291226A (en) 2018-07-17

Similar Documents

Publication Publication Date Title
US11852627B2 (en) Oligonucleotides for inducing paternal UBE3A expression
CN106470688B (en) Oligomers and oligomer conjugates
US11732262B2 (en) Use of FUBP1 inhibitors for treating hepatitis B virus infection
JP2022141739A (en) Oligonucleotides for modulating tau expression
JP7281474B2 (en) Oligonucleotides for modulating TMEM106B expression
TW202020152A (en) Oligonucleotides for modulating rtel1 expression
US20190345496A1 (en) Antisense oligonucleotides for modulating relb expression
US20210371860A1 (en) Oligonucleotides for modulating myh7 expression
CN114901821A (en) Use of SEPT9 inhibitors for treating hepatitis B virus infection
US20200216845A1 (en) Antisense oligonucleotides for modulating rela expression
WO2023111210A1 (en) Combination of oligonucleotides for modulating rtel1 and fubp1
JP2021510295A (en) Oligonucleotides for regulating GSK3B expression
CN114829601A (en) Use of SBDS inhibitors for the treatment of hepatitis b virus infection
US20190338286A1 (en) Antisense oligonucleotides for modulating rel expression
JP2023506547A (en) Use of COPS3 inhibitors to treat hepatitis B virus infection
CN114867856A (en) Use of SARAF inhibitors for the treatment of hepatitis B virus infection

Legal Events

Date Code Title Description
AS Assignment

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COSTA, VERONICA;HOENER, MARIUS;JAGASIA, RAVI;AND OTHERS;REEL/FRAME:040326/0716

Effective date: 20161006

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:040326/0895

Effective date: 20161017

Owner name: HOFFMAN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:040327/0196

Effective date: 20161014

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COSTA, VERONICA;HOENER, MARIUS;JAGASIA, RAVI;AND OTHERS;REEL/FRAME:040327/0071

Effective date: 20151215

Owner name: ROCHE INNOVATION CENTER COPENHAGEN A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HEDTJAERN, MAJ;JENSEN, MADS AABOE;PEDERSEN, LYKKE;SIGNING DATES FROM 20160304 TO 20160817;REEL/FRAME:040327/0661

Owner name: ROCHE INNOVATION CENTER COPENHAGEN A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HEDTJAERN, MAJ;JENSEN, MADS AABOE;PEDERSEN, LYKKE;AND OTHERS;REEL/FRAME:040327/0770

Effective date: 20161005

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE INNOVATION CENTER COPENHAGEN A/S;REEL/FRAME:051882/0296

Effective date: 20200217

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

AS Assignment

Owner name: ROCHE INNOVATION CENTER COPENHAGEN A/S, DENMARK

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND INVENTOR'S EXECUTION DATE PREVIOUSLY RECORDED AT REEL: 040327 FRAME: 0661. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:HEDTJAERN, MAJ;JENSEN, MADS AABOE;PEDERSEN, LYKKE;SIGNING DATES FROM 20160329 TO 20160817;REEL/FRAME:066133/0358